<SEC-DOCUMENT>0001193125-14-201070.txt : 20140515
<SEC-HEADER>0001193125-14-201070.hdr.sgml : 20140515
<ACCEPTANCE-DATETIME>20140515152630
ACCESSION NUMBER:		0001193125-14-201070
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140515
DATE AS OF CHANGE:		20140515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CymaBay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001042074
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943103561
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55021
		FILM NUMBER:		14846674

	BUSINESS ADDRESS:	
		STREET 1:		7999 GATEWAY BLVD
		STREET 2:		SUITE 130
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560
		BUSINESS PHONE:		510-293-8800

	MAIL ADDRESS:	
		STREET 1:		7999 GATEWAY BLVD
		STREET 2:		SUITE 130
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX, INC.
		DATE OF NAME CHANGE:	20090721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX INC
		DATE OF NAME CHANGE:	19970710
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d705860d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;10-Q </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE TRANSITION PERIOD FROM <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> TO
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 000-55021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CymaBay Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-3103561</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>7999 Gateway Blvd, Suite 130<BR>Newark, CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94560</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) 293-8800 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the
Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2014, there were 10,064,826 shares of the registrant&#146;s Common Stock outstanding. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CYMABAY THERAPEUTICS,&nbsp;INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUARTERLY REPORT ON FORM&nbsp;10-Q </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PART&nbsp;I</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><A HREF="#tx705860_1">FINANCIAL INFORMATION </A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item&nbsp;1.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_2">Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_3">Condensed Balance Sheets &#151; March 31, 2014 (unaudited) and December&nbsp;31, 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_4">Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2014 and 2013 (unaudited)
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_5">Condensed Statements of Cash Flows for the three months ended March 31, 2014 and 2013 (unaudited)</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_6">Notes to Condensed Financial Statements (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 2.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 3.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_8">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 4.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_9">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PART&nbsp;II</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B><A HREF="#tx705860_10">OTHER INFORMATION </A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_11">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item&nbsp;1A.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_12">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 2.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_13">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item 6.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_14">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx705860_15"><B>Signatures</B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx705860_1"></A>PART&nbsp;I. FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_2"></A>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx705860_3"></A>CymaBay Therapeutics, Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility loan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility loan, less current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilites</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value: 100,000,000 shares authorized;10,064,495 and 9,455,064 shares issued and outstanding as of
March&nbsp;31, 2014 and December&nbsp;31, 2013, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(358,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(348,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx705860_4"></A>CymaBay Therapeutics, Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations and Comprehensive Loss </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share information) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss/income:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(985.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding used to calculate basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,873,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx705860_5"></A>CymaBay Therapeutics, Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Cash Flows </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-employee stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee and director stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premium on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest associated with debt discount accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sales of marketable securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock and warrants, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets in accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock warrants</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon cashless warrant exercise</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash issuance costs incurred in common stock financing</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx705860_6"></A>CymaBay Therapeutics,&nbsp;Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Description of Business </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc. (the &#147;Company&#148; or &#147;CymaBay&#148;) is a biopharmaceutical company focused on
developing therapies to treat metabolic and rare diseases with high unmet need. The Company&#146;s lead product candidate, arhalofenate, is being developed for the treatment of gout. The Company&#146;s second product candidate, MBX-8025, is being
considered for the treatment of certain orphan diseases. The Company was incorporated in Delaware in October 1988 as Transtech Corporation. The Company&#146;s headquarters and operations are located in Newark, California and it operates in one
segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company sold shares of its common stock and warrants to purchase shares of its common stock in a
private placement for aggregate gross proceeds of $26.8 million, and raised an additional $5.0 million in venture debt financing pursuant to a $10.0 million loan agreement which it entered into simultaneously with the private placement on
September&nbsp;30, 2013, resulting in aggregate net proceeds to the Company of $28.8 million after deducting placement agent fees and estimated offering expenses. At the same time the Company issued shares of its common stock in cancellation of
approximately $16.9 million of debt owed to the holder of that debt. On October&nbsp;31, 2013, the Company sold additional shares of its common stock and warrants to purchase shares of its common stock, which sales are also part of the private
placement, for net proceeds of $2.2 million after deducting placement agent fees and estimated offering expenses. Further, on November&nbsp;22, 2013, the Company entered into an agreement with investors to purchase shares of its common stock and
warrants to purchase shares of its common stock as part of the private placement for net proceeds of $2.7 million, which sales occurred on January&nbsp;29, 2014, after the listing of the Company&#146;s common stock on the over-the-counter market.
The Company refers to the private placement, the venture debt financing and the issuance of the Company&#146;s common stock in cancellation of the $16.9 million of debt as the 2013 financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses and negative cash flows from operations since its inception. During the three months ended
March&nbsp;31, 2014, the Company incurred a loss from operations of $10.1 million and used $5.0 million of cash in operations. At March&nbsp;31, 2014, the Company had an accumulated deficit of $358.9 million. CymaBay expects to incur increased
research and development expenses as it continues to study its product candidates in clinical trials. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim condensed financial statements are unaudited. These unaudited interim financial statements have been prepared in
accordance U.S. GAAP (&#147;GAAP&#148;) and following the requirements of the United States Securities and Exchange Commission (&#147;SEC&#148;) for interim reporting. As permitted under those rules, certain footnotes or other financial information
that are normally required by GAAP can be condensed or omitted. In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which
include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include
all disclosures required by GAAP and should be read in conjunction with the Company&#146;s financial statements and accompanying notes for the fiscal year ended December&nbsp;31, 2013, which is contained in the Company&#146;s Annual Report on Form
10-K as filed with the SEC on March&nbsp;31, 2014. The results for the three months ended March&nbsp;31, 2014, are not necessarily indicative of results to be expected for the year or for any other period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial
statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements and accompanying notes. Management bases its estimates on
historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that
falls within that range of reasonable estimates. Actual results could differ materially from those estimates. The Company believes significant judgment is involved in estimating stock-based compensation, accrued liabilities, and equity and liability
instrument valuations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company filed an amended and restated certificate of incorporation under which the Company&#146;s preferred stock and common
stock was reverse split on a 1-for-79.5 basis. The accompanying financial statements and notes to the financial statements, give retroactive effect to the reverse split for all periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s financial instruments consist of cash and cash equivalents, short-term marketable securities, accounts payable, accrued expenses, warrant liabilities and convertible notes. Fair value estimates of these instruments are made at a
specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value
hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and maximizes the use of unobservable inputs and is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement
date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or
indirectly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Inputs that are unobservable for the asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments such as cash and cash equivalents, accounts payable, convertible notes, and accrued expenses
approximate the related fair values due to the short-term maturities of these instruments. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt and asset backed securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketable securities consist of available-for-sale securities that are reported at fair value, with the
related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders&#146; equity. The Company values cash equivalents and marketable securities using quoted market prices or alternative pricing
sources and models utilizing observable market inputs and, as such, classifies cash equivalents and marketable securities within Level 1 or Level 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, the Company held a Level 3 liability associated with warrants, issued in connection with the Company&#146;s 2013
financing. The warrants are considered a liability and are valued using an option-pricing model, the inputs for which include exercise price of the warrants, market price of the underlying common shares, expected term, volatility based on a group of
the Company&#146;s peers and the risk-free rate corresponding to the expected term of the warrants. As of December&nbsp;31, 2013, the Company also held a Level 3 liability associated with a forward contract which arose in connection with the
Company&#146;s November&nbsp;22, 2013 execution of an equity purchase agreement with certain investors. The agreement required the Company to issue a fixed number of shares of common stock and warrants to purchase common stock at a predetermined
price of $3.0 million provided the Company completes the listing of its common stock on a public stock exchange. The forward contract&#146;s fair value was determined upon execution as the difference between the present value of the equity proceeds
to be received under the agreement less the fair value of the underlying securities. The forward contract liability is presented in the balance sheet as a component of accrued liabilities and is revalued at each reporting period until contract
settlement which occurred on January&nbsp;29, 2014. The fair value of the underlying common stock and warrants were valued using an option-pricing model, the inputs of which are similar to those used in the valuation of the Company&#146;s liability
classified warrants. Changes to any of the inputs to the option-pricing models used by the Company can have a significant impact to the estimated fair value of the warrants and forward contract liabilities.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth an activity summary which includes the changes in the fair value
of the Company&#146;s Level 3 financial instruments (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Forward</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Contract</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of financial instrument</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of financial instrument</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of March&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gains and losses from remeasurement of Level 3 financial liabilities are recorded through other expense,
net on the accompanying statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash, Cash Equivalents, and Marketable Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with a remaining maturity of 90 days or less at the time of purchase to be cash
equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and demand money market accounts. The Company invests excess cash in marketable securities with high credit ratings. These securities
consist primarily of corporate debt and asset-backed securities and are classified as &#147;available-for-sale.&#148; Management may liquidate any of these investments in order to meet the Company&#146;s liquidity needs in the next year.
Accordingly, any investments with contractual maturities greater than one year from the balance sheet date are classified as short-term in the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realized gains and losses from the sale of marketable securities, if any, are calculated using the specific identification method. Realized
gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the statements of operations. Unrealized holding gains and losses are reported in accumulated other comprehensive income (loss),
in the balance sheet. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary,
various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#146; financial condition, and the Company&#146;s intent and ability to hold the security for a period of time
sufficient to allow for an anticipated recovery in market value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to maintain compensating cash balances with financial institutions that provide the Company with its corporate credit
cards. As of March&nbsp;31, 2014 and December&nbsp;31, 2013, cash restricted under these arrangements was $100,000 and $155,000, respectively. These amounts are presented in other assets on the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash
equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the balance sheet. The Company invests cash that is not
required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its
credit risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation and amortization is calculated using the
straight-line method, and the cost is amortized over the estimated useful lives of the respective assets, generally three to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the non-cancelable term of the
related lease. Maintenance and repair costs are charged as expense in the statements of operations and comprehensive income (loss) as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company reviews long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized if the estimated undiscounted future
cash flow expected to result from the use and eventual disposition of an asset is less than the carrying amount. While the Company&#146;s current and historical operating losses and cash flows are indicators of impairment, the Company believes the
future cash flows to be received support the carrying value of its long-lived assets. Accordingly, the Company has not recognized any impairment losses as of March&nbsp;31, 2014 and December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Rent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records its costs under facility operating lease agreements as rent expense. Rent expense is recognized on a straight-line basis
over the non-cancelable term of the operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent in the balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Warrant Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants
issued to common stock holders and lenders by the Company in conjunction with the 2013 financing were classified as liabilities in the accompanying balance sheets, as the terms for redemption of the underlying security were outside the
Company&#146;s control. The warrants were recorded at fair value using either the Black-Scholes option pricing model, probability weighted expected return model or a binomial model, depending on the characteristics of the warrants. The fair value of
these warrants is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying condensed statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist
primarily of costs for research and development personnel, including: related stock-based compensation; contract research organizations and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site
fees; laboratory services; consultants; contract manufacturing services; non-clinical studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and
development activities. Research and development costs are expensed as incurred, including expenses that may or may not be reimbursed under research and development funding arrangements. Research and development expenses under collaboration
agreements approximate the revenue recognized under such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses related to clinical trials are based upon estimates of
the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (CROs) that conduct and manage clinical trials on behalf of the Company. Expenses related to clinical trials are
accrued based upon the level of activity incurred under each contract as indicated by such factors as progress made against specified milestones or targets in each period, patient enrollment levels, and other trial activities as reported by CROs.
Accordingly, the Company&#146;s clinical trial accrual is dependent upon the timely and accurate reporting of expenses by clinical research organizations and other third-party vendors.&nbsp;Payments made to third parties under these clinical trial
arrangements in advance of the receipt of the related services are recorded as prepaid assets, depending on the terms of the agreement, until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee and
director stock-based compensation is measured at the grant date, based on the fair-value based measurements of the stock awards, and the portion that is ultimately expected to vest is recognized as an expense over the related vesting periods, net of
estimated forfeitures. The Company calculates the fair-value based measurements of options using the Black-Scholes valuation model and the single-option approach and recognizes expense using the straight-line attribution method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity awards granted to non-employees are accounted for using the Black-Scholes valuation model to determine the fair value of such
instruments. The fair value of equity awards granted to non-employees are re-measured over the related vesting period and amortized to expense as earned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the
liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted
tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and
measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon
examination based on the technical merits of the position.The Company records interest related to income taxes, if any, as interest, and any penalties would be recorded as other expense in the statements of comprehensive income (loss). There was no
interest or penalties related to income taxes recorded during the three months ended March&nbsp;31, 2014 and 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous
statement. Accumulated other comprehensive income (loss) is disclosed in the statements of redeemable convertible preferred stock and stockholders&#146; equity (deficit), and is stated net of related tax effects, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Common Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss
per share of common stock is based on the weighted average number of shares of common stock outstanding equivalents during the period. Prior to the 2013 financing, in addition to common stock, the Company had preferred stock outstanding that
contractually entitled the holder to participate in dividends and earnings of the Company. Accordingly, the Company applied the two-class method for calculating net loss per share. Under this method, all undistributed earnings are allocated first to
the preferred stockholders based on their contractual right to dividends. This right is calculated on a pro rated basis for the portion of the period the preferred shares were outstanding. On September&nbsp;30, 2013, in connection with the 2013
financing, all outstanding shares of the Company&#146;s preferred stock were converted into shares of the Company&#146;s common stock. Accordingly, no preferred stock was outstanding during the three months ended March&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of common stock is calculated using the more dilutive of the two approaches: one, &#147;as-converted&#148; method,
under which the weighted average number of common stock shares outstanding during the period is adjusted to include the assumed conversion of redeemable convertible preferred stock at the beginning of the period, and the other, the
&#147;two-class&#148; method as described above. Under either approach, the weighted average number of shares outstanding is also adjusted to include the assumed exercises of stock options and warrants, if dilutive. For the three months ended
March&nbsp;31, 2014 and 2013, diluted net loss per share is the same as basic, as any adjustments would have been anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the total outstanding securities considered anti-dilutive and therefore
excluded from the computation of diluted net loss per share: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>(unaudited)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,848,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,755,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Certain Balance Sheet Items </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,054</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, the Company ceased use of a substantial portion of its leased facility in Hayward, California.
In connection with the closure of this facility, the Company disposed of certain fully depreciated leasehold improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued
liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued pre-clinical and clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forward contract</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Common Stock Warrants </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2014, in connection with the 2013 financing, the Company completed the sale of common stock for aggregate
proceeds of $3.0 million and as part of this transaction, the Company issued five-year warrants to purchase 120,800 shares of common stock at an exercise price of $5.75 per share. Due to certain provisions, the Company is required to account for the
warrants issued as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be
reclassified to stockholders&#146; equity, or expiration of the warrants. At issuance date, the fair value of the total warrant liability was estimated to be $0.4 million using a binomial lattice options-pricing model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Collaboration and License Agreements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August&nbsp;2006, CymaBay entered into a strategic alliance with Ortho-McNeil, Inc., a subsidiary of Johnson and Johnson.
As part of the alliance, Janssen Pharmaceutical NV, an affiliate of Ortho-McNeil, granted to CymaBay an exclusive worldwide, royalty-bearing license to MBX-8025 and certain other PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;compounds (the
&#147;PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products&#148;) with the right to grant sublicenses to third parties to make, use and sell such PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products. Under the terms of the
agreement, CymaBay has full control and responsibility over the research, development and registration of any PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products and is required to use diligent efforts to conduct all such activities.
Janssen has the sole responsibility for the preparation, filing, prosecution, maintenance of, and defense of the patents with respect to, the PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products. Janssen has a right of first negotiation
under the agreement to license a particular PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Product from CymaBay in the event that CymaBay elects to seek a third party corporate partner for the research, development, promotion, and/or
commercialization of such PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products. Under the terms of the agreement Janssen is entitled to receive up to an 8% royalty on net sales of
PPAR<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;Products. No payments were made and no royalties were received under this agreement during the three months ended March&nbsp;31, 2014 and 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2010, CymaBay entered into two development and license agreements with Janssen Pharmaceuticals, Inc. (Janssen), a subsidiary of
Johnson and Johnson, to further develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders and received a one-time nonrefundable technology access fee related to the agreements. CymaBay is also
eligible to receive up to $228 million in contingent payments if certain development and commercial events are achieved as well as royalties on worldwide net sales of products. No such payments have been made to date. Under the terms of the
agreements, Janssen has full control and responsibility over the research, development and registration of any products developed and/or discovered from the metabolic disease targets and is required to use diligent efforts to conduct all such
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 1998, the Company entered into a license agreement with DiaTex, Inc. (DiaTex) relating to products containing
halofenate, its enantiomers, derivatives, and analogs (the licensed products). The license agreement provides that DiaTex and the Company are joint owners of all of the patents and patent applications covering the licensed products and methods of
producing or using such compounds, as well as certain other know-how (the covered IP). As part of the license agreement, the Company received an exclusive worldwide license, including as to DiaTex, to use the covered IP to develop and commercialize
the licensed products. The Company also retained the right to sub-license the covered IP. The license agreement contains a $2,000 per month license fee as well as a requirement to make additional payments for development achievements and royalty
payments on any sales of licensed products. Pursuant to the license agreement, all of the Company&#146;s patents and patent applications related to arhalofenate, its use, and production are jointly owned with DiaTex. DiaTex is entitled to up to $0.8
million for the future development of arhalofenate, as well as a 2% royalty payment on net sales of products containing arhalofenate. No development payments were made in the three months ended March&nbsp;31, 2014 and 2013, and no royalties have
been paid to date. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Debt </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;20, 2006 the Company entered into a equity and loan facility with the Johnson and Johnson Development
Corporation (&#147;JJDC&#148;) pursuant to which the Company could drawn down up to an aggregate of $30 million in loans in the form of convertible preferred stock promissory notes. In March and September 2008, the Company issued notes in the
aggregate amount of $3.5 million and $10.5 million, respectively. The notes were due on March&nbsp;17 and September&nbsp;17, 2011, including interest that accrued at 7.57%&nbsp;per annum. In December 2010, the aggregate principal amount and all
accrued interest under the notes issued in March and September 2008 were converted into the Company&#146;s Series E-3 convertible preferred stock (Series E-3 Preferred) at $232.93&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and July 2009, the Company issued notes in the aggregate amount of $7.0 million and $6.7 million, respectively, which represented
the remaining amount available to the Company, in accordance with the terms of the equity and loan facility with JJDC. The notes were due in February 2012 and July 2012, including interest that accrued at 4.42%&nbsp;per annum and 4.960%&nbsp;per
annum, respectively. In January 2012, the Company amended the maturity dates of the outstanding $7.0 million and $6.7 million convertible promissory notes to extend the maturity date to March&nbsp;1, 2013, and interest rates were increased to 4.919%
and 5.46%&nbsp;per annum, respectively. In addition, the conversion price of the notes to convert into shares of the Company&#146;s Series C-1 Preferred Stock was decreased from $438.84 per share to $292.56 per share. All of these notes were further
amended in March 2013, to extend the maturity date on the notes to August&nbsp;1, 2013, and to make the notes subordinate to repayment of the Company&#146;s severance obligations to all employees until January&nbsp;1, 2014. On July&nbsp;31, 2013,
the maturity date was extended to December&nbsp;31, 2013. There are no financial covenants associated with the notes. For the three months ended March&nbsp;31, 2013, the Company recognized $0.2 million of interest expense related to the convertible
promissory notes. On September&nbsp;30, 2013, the outstanding principal and accrued interest of $16.9 million under the equity and loan facility with JJDC was extinguished in exchange for 624,944 shares of common stock as an integral part of the
2013 financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facility Loan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company entered into a facility loan agreement with Silicon Valley Bank and Oxford Finance for a total loan
amount of $10.0 million of which the first tranche of $5.0 million was drawn as part of&nbsp;the 2013 financing.&nbsp;The loan has a fixed interest rate of 8.75% payable twelve months interest only and thirty-six months amortization thereafter, with
a final interest payment of&nbsp;$0.3 million at the end of the loan period.&nbsp;Until positive Phase 2b data is achieved, the Company must be in compliance with one of two financial covenants at all times: (1)&nbsp;maintain 1.3 times cash to
outstanding debt or (2)&nbsp;maintain sufficient cash on hand to support eight months of operations based on a trailing average monthly cash burn. The first tranche loans under the term loan facility bear interest at a rate equal 8.75%&nbsp;per
annum. Loans under the second tranche will bear interest at a rate fixed at the time of borrowing equal to the greater of (i)&nbsp;8.75%&nbsp;per annum and (ii)&nbsp;the sum of the Wall Street Journal prime rate plus 4.25%&nbsp;per annum. We were
also required to pay a facility fee of 1.00% on the term loan facility commitment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the facility loan drawdown, the
Company&nbsp;issued&nbsp;warrants exercisable for a total of 121,739 shares of the Company&#146;s common stock to the lenders at an exercise price of $5.00 per share.&nbsp;As a result of this issuance, a warrant liability of $0.5 million was
recorded in the accompanying balance sheets which is required to be revalued at each balance sheet date. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leased office and laboratory space in a single building in Hayward, California. The facility lease, as amended
on July&nbsp;15, 2010, had a term of four years and expired on April&nbsp;30, 2014. On November&nbsp;8, 2013, the Company entered into a new lease commencing January&nbsp;16, 2014, and expiring on December&nbsp;31, 2018, for 8,894 square feet of
office space in Newark, California. Rent expense was $0.2 million and $0.1 million for the three months ended March&nbsp;31, 2014 and 2013, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Lease</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December&nbsp;31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and
provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. The Company&#146;s exposure under these agreements is unknown because it involves future claims that
may be made against the Company that may be, but have not yet been, made. To date, the Company has not paid any claims or been required to defend any action related to these indemnification obligations, and no amounts have been accrued in the
accompanying balance sheets related to these indemnification obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to indemnify its executive officers and
directors for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments the Company could be required
to make under this indemnification is unlimited; however, the Company maintains insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness
of the insurer to assume coverage, and subject to certain retention, loss limits, and other policy provisions, the Company believes the fair value of these indemnification obligations is not material. Accordingly, the Company has not recognized any
liabilities relating to these obligations as of March&nbsp;31, 2014 and December&nbsp;31, 2013. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive
litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stockholders&#146; Equity </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing in the 2013 financing on September&nbsp;30, 2013, all of the outstanding shares of redeemable convertible
preferred stock were converted into 2,793,281 shares of common stock, and the related carrying value of $320.0 million was reclassified to additional paid-in capital. As of March&nbsp;31, 2014, no shares of redeemable convertible preferred stock
were issued or outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was authorized to issue 100,000,000 shares of common stock with a par value of
$0.0001 per share as of March&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company sold 5,366,669 shares of common stock and 1,073,338
warrants to purchase shares of common stock in the 2013 financing for net proceeds to the Company of $22.8 million after deducting placement agent fees and estimated offering expenses. Also on that date, the Company issued 624,944 shares of common
stock in cancellation of approximately $16.9 million of debt owed to JJDC, the holder of that debt (Note 6). On October&nbsp;31, 2013, the Company sold an additional 664,300 shares of common stock and warrants to purchase 132,860 shares of common
stock, which sales were also part of the 2013 financing, for net proceeds to CymaBay of $2.2 million after deducting placement agent fees and estimated offering expenses. On November&nbsp;22, 2013, the Company entered into an agreement with
investors to purchase 604,000 shares of common stock and 120,800 warrants to purchase shares of common stock as part of the 2013 financing for net proceeds of $2.7 million, which sales were set to occur shortly after the listing of the
Company&#146;s common stock on the over-the-counter market. The Company began trading on the over-the-counter market on January&nbsp;24, 2014 enabling this portion of the 2013financing to be completed in late January 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014 and December&nbsp;31, 2013, the Company had reserved shares of authorized but unissued common stock as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,848,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity incentive plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total reserved shares of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,320,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock Plans and Stock-Based Compensation </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;30, 2013, the Company&#146;s stockholders approved the 2013 Equity Incentive Plan, or 2013 Plan, under which shares of the Company&#146;s common stock are reserved for issuance pursuant to stock awards, including, but not limited to,
incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and performance cash awards. In addition, the share reserve automatically increased by
472,753 shares on January&nbsp;1, 2014, and will continue to automatically increase on January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year, for a period of not more than ten years, in an amount equal to 5% of the total
number of shares of capital stock outstanding on December&nbsp;31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the preceding calendar year, unless the Board determines otherwise prior to December&nbsp;31<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of such calendar year. From plan inception through March&nbsp;31, 2014, the Company had issued options for an aggregate of 830,647&nbsp;shares of the Company&#146;s common stock under the 2013 Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee and
Director Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee and director stock-based compensation expense recorded was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;Months&nbsp;Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Related-Party Transactions </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company paid a former member of its Board of Directors, who is also a member of its Scientific and Clinical Advisory
Boards, a total of $45,000 in the year ended December&nbsp;31, 2013 and $15,000 for the three months ended March&nbsp;31, 2014, in monthly cash retainers. The Company also issued options to purchase shares of common stock and incentive awards to
this individual in his capacity as a member of its Scientific Advisory Board. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_7"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Operating results for the three months ended March&nbsp;31, 2014, are not necessarily indicative of results that may occur in future interim
periods or for the full fiscal year. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on Form&nbsp;10-Q contains statements indicating expectations about
future performance and other forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act, that involve risks and uncertainties. We usually use words such as &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;intend,&#148; or the negative of these terms or similar
expressions to identify these forward-looking statements. These statements appear throughout this Quarterly Report on Form&nbsp;10-Q and are statements regarding our current expectation, belief or intent, primarily with respect to our operations and
related industry developments. Examples of these statements include, but are not limited to, statements regarding the following: our business and scientific strategies; the progress of our and our collaborators&#146; product development programs,
including clinical testing, and the timing of results thereof; our corporate collaborations and revenues that may be received from our collaborations and the timing of those potential payments; our expectations with respect to regulatory submissions
and approvals;&nbsp;our drug discovery technologies; our research and development expenses; protection of our intellectual property; sufficiency of our cash and capital resources and the need for additional capital; and our operations and legal
risks. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including as a result of the risks and
uncertainties discussed under the heading &#147;Risk Factors&#148; in Item&nbsp;1A of Part&nbsp;II of this Quarterly Report on Form&nbsp;10-Q. Any forward-looking statement speaks only as of the date on which it is made, and we undertake no
obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible
for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in
any forward-looking statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to treat metabolic and rare diseases with high unmet
need. Our lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay has completed three Phase 2 studies of arhalofenate in gout patients in which it demonstrated a consistent pattern of reduction of flare incidence
and duration and lowering of serum uric acid (sUA). Gout flares are recurring and painful episodes of joint inflammation that are triggered by the presence of monosodium urate crystals that form as a result of elevated sUA levels. One additional
Phase 2b clinical study of 12 weeks duration is underway to confirm the safety and efficacy of a higher dose prior to initiating Phase 3 studies. Our second product candidate, MBX-8025, demonstrated favorable effects on cholesterol, triglycerides
and markers of liver health in a Phase 2 clinical trial in patients with mixed dyslipidemia. We are considering pursuing MBX-8025 in a number of orphan diseases in which these attributes would be beneficial, such as Homozygous Familial
Hypercholestorolemia (HoFH). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company. Under the JOBS Act emerging growth companies can delay adopting new or
revised accounting standards until such time of those standards apply to private companies. We have adopted this exemption from new or revised accounting standards, and therefore, we may not be subject to the same new or revised accounting standards
as other public companies that are not &#147;emerging growth companies&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, we effected a 1-for-79.5 reverse split of our preferred stock and common stock, which we refer to as the reverse
stock split, The discussion in this &#147;Management&#146;s Discussion and Analysis of Financial Conditions and Results of Operations&#148; gives retroactive effect to the reverse stock split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We base our estimates on historical experience and on various other factors that
we believe to be materially reasonable under the circumstances and review our estimates on an ongoing basis. Actual results may materially differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity within Note 2 to our audited
financial statements in our Annual Report on Form 10-K filed with the SEC on March&nbsp;31, 2014. There were no material changes to our critical accounting policies and estimates during the quarter ended March&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any income from operations. Since our date of incorporation through March&nbsp;31, 2014, we have an accumulated
deficit of $358.9 million, primarily as a result of expenditures for research and development and general and administrative expenses. While we may in the future generate revenue from a variety of sources, including license fees and milestone
payments in connection with strategic partnerships, our product candidates are at a mid-level stage of development and may never be successfully developed or commercialized. Accordingly, we expect to continue to incur substantial losses from
operations for the foreseeable future and there can be no assurance that we will ever generate significant revenue to achieve and sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Month Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Variance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>($ in thousands)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research&nbsp;&amp; Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting research and development is central to our business model. For the three months ended March&nbsp;31, 2014 and 2013, research and
development expenses were $2.6 million and $1.5 million, respectively. Research and development expenses are detailed in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B></B>(unaudited)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arhalofenate &#150; Phase 2b Randomized Study</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arhalofenate Gout &#150; Drug manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arhalofenate Gout &#150; Three Phase 2 Randomized Studies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MBX-8025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Project Costs</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal Research and Development Costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Research and Development</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our external research and development costs consist primarily of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of acquiring and manufacturing clinical trial and other materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other costs associated with development activities, including additional studies </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal
research and development costs consist primarily of salaries and related fringe benefits costs for our employees (such as workers compensation and health insurance premiums), stock-based compensation charges, travel costs, lab supplies and overhead
expenses. Internal costs generally benefit multiple projects and are not separately tracked per project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total project costs increased by
$1.1 million during the three months ended March&nbsp;31, 2014 as compared to the three months ended March&nbsp;31, 2013, due to the commencement of clinical trial activities for arhalofenate, our lead product candidate. Internal research and
development cost remained consistent at $1.1 million for the three months ended March&nbsp;31, 2014 and March&nbsp;31, 2013 as cost reductions from the closure of our research labs in mid 2013 were offset by consulting and stock compensation
expenses incurred in 2014 primarily to support the expansion of our clinical development activities for arhalofenate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to
continue to incur substantial expenses related to our development activities for the foreseeable future as we continue product development and initiate our next clinical study for arhalofenate. Since product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials, we expect that our research and development expenses will
increase in the future. In addition, if our product development efforts are successful, we expect to incur substantial costs to prepare for potential Phase 3 clinical trials and activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit services,
and other general operating expenses not otherwise included in research and development. For the three months ended March&nbsp;31, 2014 and 2013, general and administrative expenses were $2.5 million, and $0.9 million, respectively. The $1.6 million
increase for the three months ended March&nbsp;31, 2014 as compared to the three months ended March&nbsp;31, 2013 was due primarily to an increase in headcount related expenses, an increase in professional fees and compliance costs of $0.5 million
associated with operating as a public company, and an increase of $0.6 million for employee and director stock-based compensation expense. We anticipate general and administrative expenses will increase in future periods, reflecting an expanding
infrastructure and increased professional fees associated with being a public reporting company under the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expense, Net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net for the three months ended March&nbsp;31, 2014 was $4.8 million due to the remeasurement of our warrant
liabilities at fair value as of March&nbsp;31, 2014. We use a binomial lattice option pricing model to value our warrants and the valuation increase was due primarily to an increase in the value of our common stock from $5 at December&nbsp;31, 2013
to $8 at March&nbsp;31, 2014 which is an input to the valuation model. No warrants subject to liability accounting were outstanding during the three months ended March&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date,
we have funded our operations through the sale of equity securities, licensing fees, issuance of debt and collaborations with third parties. At March&nbsp;31, 2014, we had cash, cash equivalents and marketable securities of $28.5 million, primarily
as a result of the aggregate proceeds received in a series of equity and debt transactions initiated in 2013. Specifically, on September&nbsp;30, 2013, all of the shares of our outstanding redeemable convertible preferred stock converted to common
stock, we sold shares of our common stock and warrants to purchase shares of our common stock in a private placement for aggregate gross proceeds of $26.8 million, and raised an additional $5.0 million in venture debt financing pursuant to a $10.0
million loan agreement which we entered into simultaneously with the private placement, resulting in aggregate net proceeds to CymaBay of $28.8 million after deducting placement agent fees and offering expenses. At the same time we issued shares of
our common stock in cancellation of approximately $16.9 million of debt owed to the holder of that debt. On October&nbsp;31, 2013, we sold additional shares of our common stock and warrants to purchase shares of our common stock, which sales are
also part of the private placement, for net proceeds to CymaBay of $2.2 million after deducting placement agent fees and offering expenses. Further, on November&nbsp;22, 2013, we entered into an agreement with investors to purchase shares of our
common stock and warrants to purchase shares of our common stock as part of the 2013 financing for net proceeds of $2.7 million, which sales occurred on January&nbsp;29, 2014, shortly after the listing of our common stock on the over-the-counter
market. We refer to the private placement, the venture debt financing and the issuance of our common stock in cancellation of the $16.9 million of debt as the 2013 financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The venture debt financing referenced in the 2013 financing was provided to us pursuant to a term loan facility with Silicon Valley Bank and
Oxford Finance LLC, collectively referred to as the lenders, for an aggregate amount of $10 million, $5 million of which was made available to us as of September&nbsp;30, 2013, and the remaining $5 million, referred to as the second tranche, which
shall be made available to us upon the achievement of positive data and successful completion of all primary endpoints for either the 600mg or 800mg dose of arhalofenate in our planned Phase 2b study (the &#147;second draw milestone&#148;). The
second tranche shall be available to us until the earlier of June&nbsp;30, 2015, or the occurrence and continuation of an event of default (as described in the term loan facility). Each tranche matures 48 months following the funding date of such
tranche. The proceeds of the term loan facility may be used for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first tranche loans under the term loan
facility bear interest at a rate equal 8.75%&nbsp;per annum. Loans under the second tranche will bear interest at a rate fixed at the time of borrowing equal to the greater of (i)&nbsp;8.75%&nbsp;per annum and (ii)&nbsp;the sum of the Wall Street
Journal prime rate plus 4.25%&nbsp;per annum. We were also required to pay a facility fee of 1.00% on the term loan facility commitment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted to make voluntary prepayments of the term loans with a prepayment fee equal to 3% of the term loans prepaid. On each tranche,
we are required to make 12 monthly interest only payments after the funding date followed by a repayment schedule equal to 36 equal monthly payments of the outstanding principal of the outstanding term loans of each tranche. After the 36-month
amortization period of each tranche, the remaining balance of such tranche and a final payment equal to 6.50% of the original principal amount of the applicable tranche are payable on the maturity date of such tranche. We are required to make
mandatory prepayments of the outstanding term loans upon the acceleration by the lenders of such loans following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any all other obligations (each
as defined or described under the term loan facility) that are due and payable at the time of the prepayment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the term loan facility are secured, subject to customary permitted liens
and other agreed upon exceptions, (1)&nbsp;by a first priority pledge of all of the equity interests of each of our direct and indirect subsidiaries, and (2)&nbsp;a perfected first priority interest in all of our tangible and intangible assets,
including all of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan facility contains customary representations and warranties and customary
affirmative and negative covenants applicable to us and our subsidiaries, including, among other things, restrictions on dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness,
encumbrances, distributions, investments, transactions with affiliates and subordinated debt. Until the occurrence of the second draw milestone, the term loan facility contains financial covenants that require us to maintain a certain cash
liquidity. The term loan facility also contains performance covenants that require that (a)&nbsp;by no later than June&nbsp;30, 2014, shares of our common stock must be publicly traded on NASDAQ; (b)&nbsp;within one hundred twenty (120)&nbsp;days of
us becoming eligible to file a registration statement with the United States Securities and Exchange Commission on Form S-3, we must have access to an At The Market facility; and (c)&nbsp;by no later than March&nbsp;31, 2015, the lenders must have
received evidence of the occurrence of the second draw milestone; provided that our failure to comply with these performance covenants shall not be an event of default under the term loan facility so long as we deposit an amount equal to 100% of the
aggregate outstanding term loans in a segregated, blocked deposit account at Silicon Valley Bank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term loan facility also includes
customary events of default, including but not limited to the nonpayment of principal or interest, violations of covenants, material adverse change, attachment, levy, restraint on business, cross-defaults on our or any our subsidiary&#146;s material
indebtedness, bankruptcy, material judgments and misrepresentations. Upon an event of default, the lenders may, among other things, accelerate the loans and foreclose on the collateral. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of
the net cash flow activity for each of the periods indicated below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities</I>: Net cash used in operating activities for the three months ended March&nbsp;31,
2014 was $5.0 million and was primarily due to a net loss of $10.1 million which resulted from the planned commencement of clinical trial activities for arhaolfenate, our lead product candidate. This net loss was partially offset by a $4.8 million
noncash adjustment incurred to revalue our warrant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities:</I>&nbsp;Net cash provided by investing activities
was $0.5 million for the three months ended March&nbsp;31, 2014 and was primarily due to the sale of marketable securities. No investing activities occurred during the three months ended March&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities:</I> Cash provided by financing activities was $2.4 million for the three months ended March&nbsp;31, 2014, primarily
as a result of the consummation of an agreement with investors to purchase shares of our common stock and warrants to purchase shares of our common stock in January 2014 as part of the 2013 financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that cash and cash equivalents as of March&nbsp;31, 2014, including the funds raised in the 2013 financing, are sufficient
to sustain our operations through the second quarter of 2015. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates. We will continue to require additional
financing to develop our products and fund operating losses. We will seek funds through equity financings, debt, collaborative or other arrangements with corporate sources, or through other sources of financing, including a public offering. Adequate
additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If adequate funds
are not available to us, we may be required to close our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no significant changes to our aggregate contractual obligations as compared to the disclosures in our Annual Report on Form 10-K
for the year ended&nbsp;December&nbsp;31, 2013 as filed with the SEC on March&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities
often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities
involving non-exchange traded contracts. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_8"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quantitative and Qualitative Disclosures About Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This item is not applicable
to us as a smaller reporting company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_9"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Evaluation of Disclosure Controls and Procedures. </I>Based on the evaluation of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange Act), our chief
executive officer and chief financial officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Limitations on the Effectiveness of Controls. </I>A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to
provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our chief executive officer and chief financial officer have concluded, based on their evaluation as of the end of the
period covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Changes in Internal Controls. </I>There were no changes in our internal control over financial reporting that occurred during the quarter ended March&nbsp;31, 2014, that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx705860_10"></A>PART&nbsp;II. OTHER INFORMATION
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_11"></A>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Legal Proceedings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_12"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In evaluating our business, you should carefully consider the following risks, as well
as the other information contained in this Quarterly Report on Form&nbsp;10-Q. These risk factors could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on
Form&nbsp;10-Q and those we may make from time to time. If any of the following risks actually occurs, our business, financial condition and operating results could be harmed. The risks and uncertainties described below are not the only ones facing
us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. The risks facing our business have not changed substantively from those discussed in our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2013, except for those risk factors below designated by an asterisk (*). </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial
Condition and Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional capital in the future to sufficiently fund our operations and
research.* </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have consumed substantial amounts of capital to date as we continue our research and development activities,
including our Phase 2b study of arhalofenate. As of March&nbsp;31, 2014, we had cash and cash equivalents of approximately $22.3 million and marketable securities of $6.2 million. These funds were obtained through recent equity and debt financings
including approximately $28.8 million which we raised in aggregate net proceeds on September&nbsp;30, 2013 and $2.2 million of additional net proceeds which we raised on October&nbsp;31, 2013. On November&nbsp;22, 2013, we entered into an agreement
with investors to purchase shares of our common stock and warrants to purchase shares of our common stock as part of the 2013 financing for net proceeds of $2.7 million, which sales occurred on January&nbsp;29, 2014 after our listing of our common
stock on the over-the-counter market. After giving effect to these financings, we believe that our existing cash will allow us to continue operation through the second quarter of 2015. We currently believe that we will need to raise additional
capital to continue our operations beyond the second quarter of 2015. Our monthly spending levels vary based on new and ongoing development and corporate activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials,
is a time-consuming, expensive and uncertain process that takes years to complete. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance development of our
lead clinical product candidate, arhalofenate, for the prevention of gout flares and the treatment of hyperuricemia in patients with gout. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we do not successfully raise sufficient funds in financing our product development activities, particularly related to the
development of arhalofenate, it will be necessary to curtail our product development activities commensurate with the magnitude of the shortfall or our product development activities may cease altogether. To the extent that the costs of the our
ongoing Phase 2b study of arhalofenate in patients with gout exceed our current estimates and we are unable to raise sufficient additional capital to cover such additional costs, we will need to reduce operating expenses, enter into a collaboration
or other similar arrangement with respect to development and/or commercialization rights to arhalofenate, outlicense intellectual property rights to arhalofenate, sell assets or effect a combination of the above. No assurance can be given that we
will be able to effect any of such transactions on acceptable terms, if at all. Failure to progress the development of arhalofenate will have a negative effect on our business, future prospects and ability to obtain further financing on acceptable
terms (if at all). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the plan of operations outlined above, our future funding requirements and sources will depend on many factors,
including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress and cost of our clinical studies, including in particular the Phase 3 studies of arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need for additional or expanded clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress and cost of our Chemistry, Manufacturing and Control registration and validation program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, economic and other terms of any licensing, collaboration or other similar arrangement into which we may enter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of seeking and obtaining FDA and other regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of our other development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing products and market developments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects and on
our ability to develop our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception. We anticipate that we will
continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.* </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
biopharmaceutical company focused primarily on developing our lead product candidate, arhalofenate. We have incurred significant net losses in each year since our inception, including a net loss of approximately $10.1 million for the year ended
December&nbsp;31, 2013. As of March&nbsp;31, 2014, we had an accumulated deficit of $358.9 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have financed our
operations primarily through the sale of equity securities, licensing fees, issuance of debt and collaborations with third parties. We have devoted most of our financial resources to research and development, including our preclinical development
activities and clinical trials. We have not completed development of any product candidates. We expect to continue to incur significant and increasing losses and negative cash flows for the foreseeable future. The size of our losses will depend, in
part, on the rate of future expenditures and our ability to generate revenues. In particular, we expect to incur substantial and increased expenses as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the development of our lead product candidate, arhalofenate, for the prevention of flares and treatment of hyperuricemia in patients with gout; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek to obtain regulatory approvals for arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prepare for the potential commercialization of arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scale up manufacturing capabilities to commercialize arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">begin outsourcing of the commercial manufacturing of arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish an infrastructure for the sales, marketing and distribution of arhalofenate for any indications for which we receive regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand our research and development activities and advance our clinical programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and development efforts and seek to discover additional product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate that we will generate revenue from the sale of our products for the foreseeable future. Our ability to become profitable
depends upon our ability to generate significant continuing revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of additional sources of capital, which may not be
available to us on acceptable terms, or at all, the development of arhalofenate or future product candidates may be reduced in scope, delayed or terminated. If our product candidates or those of its collaborators fail in clinical studies or do not
gain regulatory approval, or if our future products, if any, do not achieve market acceptance, we may never become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we
do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital,
expand our business, diversify our product offerings or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to generate future revenues from
product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the
development, obtain the necessary regulatory approvals and commercialize our product candidates. We do not anticipate generating revenues from sales of our product candidates for the foreseeable future, if ever. Our ability to generate future
revenues from product sales depends heavily on our success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining favorable results for and advancing the development of arhalofenate, including successfully initiating and completing our Phase 2b and Phase 3 clinical development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining United States (U.S.) and foreign regulatory approvals for arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing arhalofenate, either on our own or with a partner, including building a sales force and collaborating with third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving broad market acceptance of arhalofenate in the medical community and by third-party payors and patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating a pipeline of product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting preclinical testing and clinical
trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data required to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely
increase if we do not obtain favorable results or if development of our product candidates is delayed. In particular, we would likely incur higher costs than we currently anticipate if development of our product candidates is delayed because we are
required by the U.S. FDA to perform studies or trials in addition to those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or
amount of any increase in our anticipated development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates, if approved, may not achieve commercial
success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Even if one or more of our product candidates is approved for commercial sale, we
anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved product candidates, or that we will achieve or maintain profitability
even if we do generate sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations
or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate
substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We do not
have any committed external source of funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional funds to support our operations, we may sell additional equity or
debt securities, enter into collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and will impose limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds
through collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams,
research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of
operations could be materially adversely affected and we may not be able to meet our debt service obligations. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or
terminate our product development or commercialization efforts, or grant others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth
companies will make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company. Under the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We elected to avail ourselves of this exemption from new
or revised accounting standards and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not &#147;emerging growth companies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various
reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of
holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation in the assessment of our internal control over financial
reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit
and the financial statements (auditor discussion and analysis). If we do, the information that we provide stockholders may be different than what is available with respect to other public companies. We cannot predict if investors will find our
common stock less attractive because we will rely on these exemptions. If investors find our common stock less attractive as a result of our status as an emerging growth company, there may be less liquidity for our common stock and our stock price
may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;the end of the fiscal year in which the
market value of our common stock that is held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter, (ii)&nbsp;the end of the fiscal year in which we have total annual gross revenues of $1 billion or more during such
fiscal year, (iii)&nbsp;the date on which we issue more than $1 billion in non-convertible debt in a three-year period or (iv)&nbsp;the end of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant
to an effective registration statement filed under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Clinical Development and Regulatory Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on the success of our lead product candidate, arhalofenate, which is still under clinical development, and may not obtain
regulatory approval or be successfully commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not marketed, distributed or sold any products. The success of our
business depends upon our ability to develop and commercialize our lead product candidate, arhalofenate, which has completed eight Phase 1 and seven Phase 2 clinical trials, including three Phase 2 studies in gout. We are conducting a Phase 2b
clinical trial for arhalofenate in preventing flares and reducing serum uric acid in gout patients prior to initiation of a Phase 3 program. There is no guarantee that our clinical trials will be completed or, if completed, will be successful. For
example, the 800 mg dose of arhalofenate to be used in our Phase 2b gout trial is higher than doses of arhalofenate previously administered in our gout and T2DM programs, and may demonstrate unacceptable toxicities or lack of efficacy. The success
of arhalofenate will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment and completion of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from the FDA and regulatory authorities outside the U.S. for our product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of the product, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by patients, the medical community and third-party payors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of the product following approval; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining, maintaining, enforcing and defending intellectual property rights and claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize arhalofenate, which would materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have never obtained regulatory approval for a drug and we may be unable to obtain, or may be delayed in obtaining, regulatory
approval for arhalofenate.* </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never obtained regulatory approval for a drug. In the U.S. it is possible that the FDA may
refuse to accept our New Drug Application (NDA) for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval of arhalofenate. If the FDA does not accept or approve our NDA, it may
require that we conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other FDA required studies, approval of any NDA or
application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to
approve our NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not know when we might commence our Phase 3 study of arhalofenate or achieve FDA approval of
arhalofenate. We currently do not have the capital necessary to conduct or complete Phase 3 studies of arhalofenate and we may not be able to raise sufficient funds necessary to conduct this study. We believe that our existing cash will be
sufficient to enable us to complete our Phase 2b study, which we anticipate completing in the second quarter of 2015. We currently believe that we will need to raise additional capital to continue our operations beyond the second quarter of 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining, or an inability to obtain, regulatory approvals would prevent us from commercializing arhalofenate, generating
revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for arhalofenate, which would have a material adverse effect on our business and could potentially cause us to
cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on the successful completion of clinical trials for our product candidates, including arhalofenate. The
positive clinical results obtained for our product candidates in prior clinical studies may not be repeated in future clinical studies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of our product candidates, including arhalofenate, we must conduct additional clinical trials
to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical
trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have
nonetheless failed to obtain marketing approval for their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed three Phase 2 clinical studies of arhalofenate in
gout. In addition, six clinical studies with MBX-8025 and five clinical studies with MBX-2982 have been completed. However, we have never conducted a Phase 3 clinical trial. The positive results we have seen to date in our Phase 2 clinical trials of
arhalofenate for gout do not ensure that later clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed
satisfactorily through preclinical studies and initial clinical testing. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in Phase 3
clinical development, even after seeing promising results in earlier clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience a number of unforeseen events
during clinical trials for our product candidates, including arhalofenate, that could delay or prevent the commencement and/or completion of our clinical trials, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical study protocol may require one or more amendments delaying study completion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate or subjects may drop
out of these clinical trials at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical investigators or study subjects fail to comply with clinical study protocols; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trial conduct and data analysis errors may occur, including, but not limited to, data entry and/or labeling errors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of clinical trials of our product candidates may be greater than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase in connection with our ongoing activities, particularly if we commence a Phase 3
clinical trial with arhalofenate and undertake additional clinical trials of our other product candidates MBX-8025 and MBX-2982. Before we commence a Phase 3 clinical trial for arhalofenate, we will need to raise substantial additional capital. We
also will need to raise substantial additional capital in the future to complete the development and commercialization of MBX-8025 and MBX-2982, for which we currently have no planned clinical trials. Because successful development of our product
candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative or inconclusive results of our future clinical trials of arhalofenate, or any other clinical trial we conduct, could cause the FDA to
require that we repeat or conduct additional clinical studies. Despite the results reported in earlier clinical trials for arhalofenate, we do not know whether any clinical trials we may conduct will demonstrate adequate efficacy and safety to
result in regulatory approval to market our product candidates, including arhalofenate. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates, including arhalofenate,
may be adversely impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have never conducted a clinical trial of arhalofenate as a monotherapy for the treatment of gout
flares without the use of colchicine. If arhalofenate does not demonstrate efficacy in the treatment of such flares in our Phase&nbsp;2b clinical trial, our ability to successfully develop and commercialize arhalofenate may be adversely affected.*
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously conducted a clinical trial of arhalofenate for the purpose of measuring its effect on flare reduction and
control without the use of colchicine.&nbsp;We are conducting a Phase&nbsp;2b clinical trial to investigate the potential benefit of arhalofenate monotherapy with regard to flare prevention and serum uric acid (sUA) lowering. In addition, our
Phase&nbsp;2b study will investigate the benefits of two doses of arhalofenate monotherapy, including a higher dose than we studied in previous gout studies, without colchicine. If we do not obtain favorable efficacy and safety results in the
Phase&nbsp;2b trial, our ability to successfully develop and market arhalofenate could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical
trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may
experience delays in clinical trials at any stage of development and testing of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule,
if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Events which may result in delays or unsuccessful completion of clinical trials, including our future clinical trials for
arhalofenate, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to raise funding necessary to initiate or continue a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining regulatory approval to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement with the FDA on final trial design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining required institutional review board (IRB) approval at each site; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in recruiting suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in having subjects complete participation in a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays caused by subjects dropping out of a trial due to side effects or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays caused by clinical sites dropping out of a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">time required to add new clinical sites; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If initiation or completion of any of our clinical trials for our product candidates, including arhalofenate, are delayed for any of the above
reasons, our development costs may increase, the approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may bring products to market
before us. Any of these events could impair our ability to generate revenues from product sales and impair our ability to generate regulatory and commercialization milestones and royalties, all of which could have a material adverse effect on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory
approval or limit the scope of any approved label or market acceptance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arhalofenate has been studied in a total of 15 clinical
trials with nearly a thousand subjects. The emergence of adverse events (AEs) caused by arhalofenate in future studies could cause us, other reviewing entities, clinical study sites or regulatory authorities to interrupt, delay or halt clinical
studies and could result in the denial of regulatory approval. There is also a risk that our other product candidates may induce AEs, many of which may be unknown at this time. If an unacceptable frequency and/or severity of AEs are reported in our
clinical trials for our product candidates, our ability to obtain regulatory approval for product candidates, including arhalofenate, may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if any of our approved products cause serious or unexpected side effects after receiving market approval, a number of potentially
significant negative consequences could result, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a modified risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications that could diminish the usage of the product or otherwise limit the commercial success of the affected
product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered or to conduct additional clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may choose to discontinue sale of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, health care
payors and the medical community, the revenues that it generates from its sales will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if arhalofenate or any other
product candidates receive regulatory approval, the products may not gain market acceptance among physicians, patients, health care payors and the medical community. Coverage and reimbursement of our product candidates by third-party payors,
including government payors, generally is also necessary for commercial success. The degree of market acceptance of any of our approved products will depend upon a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety, as demonstrated in clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk/benefit profile of our products such as arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by physicians, other health care providers and patients as a safe and effective treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including its use outside the approved indications; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or our partners&#146; sales, marketing and distribution efforts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate sufficient revenue from these products and we may not become or remain profitable.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Potential conflicts of interest arising from relationships and any related compensation with respect to clinical studies could
adversely affect the process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal investigators for our clinical studies may serve as scientific advisors or consultants to
us from time to time and receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable
clinical study site may be questioned or jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to costly claims related to its clinical studies and may
not be able to obtain adequate insurance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we conduct clinical studies in humans, we face the risk that the use of
arhalofenate or future product candidates, will result in adverse side effects. We cannot predict the possible harms or side effects that may result from our clinical studies. Although we have clinical study liability insurance, our insurance may be
insufficient to cover any such events. There is also a risk that we may not be able to continue to obtain clinical study coverage on acceptable terms. In addition, we may not have sufficient resources to pay for any liabilities resulting from a
claim excluded from, or beyond the limit of, our insurance coverage. There is also a risk that third parties that we have agreed to indemnify could incur liability. Any litigation arising from our clinical studies, even if we are ultimately
successful, would consume substantial amounts of our financial and managerial resources and may create adverse publicity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>After the
completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize arhalofenate and we cannot, therefore, predict the timing of any future revenue from arhalofenate. Regulatory approval of an NDA
is not guaranteed, and the approval process is expensive, uncertain and lengthy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates,
including arhalofenate until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to
obtain regulatory approval for arhalofenate. Additional delays may result if arhalofenate is brought before an FDA advisory committee, which could recommend restrictions on approval or recommend non-approval of the product candidate. In addition, we
may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review
process. As a result, we cannot predict when, if at all, we will receive any future revenue from commercialization of any of our product candidates, including arhalofenate. The FDA has substantial discretion in the drug approval process, including
the ability to delay, limit or deny approval of a product candidate for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe and effective for any indication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may not find the data from nonclinical studies and clinical studies sufficient or may differ in the interpretation of the data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional nonclinical or clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority might not approve our third party manufacturers&#146; processes or facilities for clinical or commercial product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority may change its approval policies or adopt new regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authority may not accept clinical data from studies that are conducted in countries where the standard of care is potentially different from that in the U.S.; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of clinical studies may not meet the level of statistical significance required by the FDA or foreign regulatory authorities for approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the data collection from clinical studies of our product candidates may not be sufficient to support the submission of a NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, events raising questions about the safety of certain marketed pharmaceuticals may
result in increased caution by the FDA and other regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for arhalofenate and our other product candidates, we will still face extensive regulatory
requirements and our products may face future development and regulatory difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in
the U.S., the FDA may still impose significant restrictions on the indicated uses or marketing of our product candidates, including arhalofenate, or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance. For example, the labeling ultimately approved for our product candidates, including arhalofenate, may include restrictions on use due to the specific patient population and manner of use in which the drug was evaluated and the safety
and efficacy data obtained in those evaluations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arhalofenate and our other product candidates will also be subject to additional ongoing
FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor
and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling
or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Furthermore, promotional materials must be approved by the
FDA prior to use for any drug receiving accelerated approval, the pathway we are pursuing for arhalofenate in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices (cGMP), and
adherence to commitments made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or AEs of unanticipated severity or frequency, or problems with the facility where the product is
manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we, or our third party contractors, fail to comply with applicable regulatory requirements following approval of our product candidate, a
regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue an untitled or warning letter asserting violation of the law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve a pending NDA or supplements to an NDA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall and/or seize product. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could
require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize arhalofenate and our other product candidates and
inhibit our ability to generate revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for arhalofenate or any of our other products in the U.S.,
we may never obtain approval for or commercialize arhalofenate or any of our other products outside of the U.S., which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements on a
country-by-country basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and
additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we
do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international
markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and payors will be subject to applicable anti-kickback,
fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health care providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain
marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and
relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state health care laws and regulations, include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal health care anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal health care programs such as Medicare and Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme
to defraud any health care benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
health care benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements under the PPACA require manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to physician
payments and other transfers of value and physician ownership and investment interests; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental
third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and
regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion
from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in
compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize
our product candidates and affect the prices we may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S. and some foreign jurisdictions, there have been a number
of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably
sell any products for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 (Medicare Modernization Act) changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average
sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could
decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in
setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the Health Care Reform Law was enacted to broaden access to health insurance,
reduce or constrain the growth of health care spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose
additional health policy reforms. The Health Care Reform Law revises the definition of &#147;average manufacturer price&#148; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the new law imposes a
significant annual fee on companies that manufacture or import branded prescription drug products. New provisions affecting compliance have also been enacted, which may affect our business practices with health care practitioners. We will not know
the full effects of the Health Care Reform Law until applicable federal and state agencies issue regulations or guidance under the new law. Although it is too early to determine the effect of the Health Care Reform Law, the new law appears likely to
continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to
produce commercial supplies of any approved product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and we do not expect to own or operate,
facilities for product manufacturing, storage and distribution, or testing. In the past we have relied on third-party manufacturers for supply of our preclinical and clinical drug supplies. We expect that in the future we will continue to rely on
such manufacturers for drug supplies that will be used in clinical trials of our product candidates, including arhalofenate, and for commercialization of any of our product candidates that receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture the product candidates must be approved by the FDA pursuant to inspections
that will be conducted only after we submit an NDA to the FDA, if at all. We do not control the manufacturing process of our product candidates and are completely dependent on our contract manufacturing partners for compliance with the FDA&#146;s
requirements for manufacture of finished pharmaceutical products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA&#146;s strict regulatory requirements of safety, purity and
potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no direct control over the ability of the contract manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product
candidates. No assurance can be given that our manufacturers can continue to make clinical and commercial supplies of arhalofenate, or future product candidates, at an appropriate scale and cost to make it commercially feasible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not have the capability to package and distribute finished products to pharmacies and other customers. Prior to commercial
launch, we will enter into agreements with one or more pharmaceutical product packager/distributor to ensure proper supply chain management once we are authorized to make commercial sales of our product candidates. If we receive marketing approval
from the FDA, we intend to sell pharmaceutical product packaged and distributed by such suppliers. Although we have entered into agreements with our current contract manufacturers and packager/distributor for clinical trial material, we may be
unable to maintain an agreement on commercially reasonable terms, which could have a material adverse impact upon our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on limited sources of supply for the drug substance for our lead product candidate, arhalofenate, and any disruption in the chain of supply may cause delay in developing and commercializing arhalofenate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently transferring the drug substance manufacturing process to our selected contractor that will produce the supplies needed to meet
clinical development, registration and forecasted commercial demand. It is our expectation that only one supplier of drug substance and one supplier of drug product will be qualified by the FDA. If supply from an approved vendor is interrupted,
there could be a significant disruption in commercial supply of arhalofenate. An alternative vendor would need to be qualified through an NDA supplement which would be expensive and could result in further delay. The FDA or other regulatory agencies
outside of the U.S. may also require additional studies if a new drug substance or drug product supplier is relied upon for commercial production. These factors could cause the delay of clinical trials, regulatory submissions, required approvals or
commercialization of arhalofenate, and cause us to incur additional costs. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredient on a timely basis and at commercially reasonable prices,
and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our supply chain for arhalofenate may be delayed, which could inhibit our ability to generate revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing issues may arise that could increase product and regulatory approval costs or
delay commercialization of arhalofenate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are modifying the drug substance production process for arhalofenate at the selected
commercial manufacturer to cost effectively remove impurities. As the modified process is scaled up it may reveal previously unknown impurities which could require resolution in order to proceed with our planned clinical trials and obtain regulatory
approval for the commercial marketing of arhalofenate. In the future, we may identify impurities, which could result in increased scrutiny by the regulatory agencies, delays in the clinical program and regulatory approval for arhalofenate, increases
in our operating expenses, or failure to obtain or maintain approval for arhalofenate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third-party manufacturers entails
risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to meet our product specifications and quality requirements consistently; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a delay or inability to procure or expand sufficient manufacturing capacity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and product quality issues related to scale-up of manufacturing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs and validation of new equipment and facilities required for scale-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a failure to comply with cGMP and similar foreign standards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reliance on a limited number of sources, and in some cases, single sources for key materials, such that if we are unable to secure a sufficient supply of these key materials, we will be unable to manufacture and
sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of qualified backup suppliers for those materials that are currently purchased from a sole or single source supplier; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">carrier disruptions or increased costs that are beyond our control; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure to deliver our products under specified storage conditions and in a timely manner. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical study delays, failure to obtain regulatory approval or impact our ability to successfully
commercialize our products. Some of these events could be the basis for FDA or other regulatory authorities&#146; action, including injunction, recall, seizure, or total or partial suspension of production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory
manner, it may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on contract service providers (CSPs) including clinical research organizations, clinical
trial sites, central laboratories and other service providers to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have
relied and plan to continue to rely upon CSPs to monitor and manage data for our ongoing clinical programs for arhalofenate and our other product candidates, as well as the execution of nonclinical studies. We control only certain aspects of our
CSPs&#146; activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CSPs does not relieve us of our
regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CSPs are required to comply with the FDA&#146;s guidance, which follows the International
Conference on Harmonization Good Clinical Practice (ICH GCP), which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces the ICH GCP through periodic inspections of trial
sponsors, principal investigators and clinical trial sites. If we or our CSPs fail to comply with the ICH GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical
trials before approving our marketing applications. For example, upon inspection, the FDA may determine that our Phase 3 clinical trial for arhalofenate, does not comply with the ICH GCP. In addition, our Phase 3 clinical trials for arhalofenate
will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of arhalofenate. Accordingly, if our CSPs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required
to repeat these Phase 3 clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CSPs are not our employees, and we cannot
control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CSPs may also have relationships with other entities, including our competitors, for whom they may also be conducting clinical
studies, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CSPs, which may reduce our trade secret protection and
allow our potential competitors to access and exploit our proprietary technology. If our CSPs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data
they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval
for, or successfully commercialize arhalofenate or our other product candidates. As a result, our financial results and the commercial prospects for arhalofenate and any other product candidates that we develop would be harmed, our costs could
increase, and our ability to generate revenues could be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of arhalofenate and our other product candidates will depend upon the acceptance of these products by the medical
community, including physicians, patients and health care payors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates, including arhalofenate,
receive marketing approval, they may nonetheless not gain sufficient market acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not
generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates, including arhalofenate, will depend on a number of factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstration of clinical safety and efficacy in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk/benefit profile of our products such as arhalofenate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative convenience, ease of administration and acceptance by physicians, patients and health care payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including its use outside the approved indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the FDA and other regulatory authorities approved label for the relevant product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product by physicians, other health care providers and patients as a safe and effective treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or any future collaborators&#146; sales and marketing strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain formulary approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain sufficient third-party coverage or reimbursement, which may vary from country to country; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or any future collaborators&#146; sales, marketing and distribution efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates, including arhalofenate, is approved but does not achieve an adequate level of acceptance by physicians,
patients and health care payors, we may not generate sufficient revenue and we may not become or remain profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and
maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, including arhalofenate, we must build our sales, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. We may enter into strategic partnerships with third parties to commercialize our product candidates, including arhalofenate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a strategic partnership for the commercialization of arhalofenate, we may be forced
to delay the potential commercialization of arhalofenate, or reduce the scope of our sales or marketing activities for arhalofenate. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain
additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring arhalofenate to market or generate product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not
be able to generate sufficient product revenue and may not become profitable. We will be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party
to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks involved with both establishing our own sales and marketing
capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product
candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our
investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain approval to
commercialize any products outside of the U.S., a variety of risks associated with international operations could materially adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are approved for commercialization, we intend to enter into agreements with third parties to market those product
candidates outside the U.S., including for arhalofenate. We expect that we will be subject to additional risks related to international operations, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign taxes, including withholding of payroll taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism, pandemics, or natural disasters including earthquakes, typhoons, volcanic eruptions, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both
the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe to be very challenging. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors develop and market products that are more effective, safer or less expensive than arhalofenate, our commercial
opportunities will be negatively impacted. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive, and we face significant competition
from other pharmaceutical, biopharmaceutical and biotechnology companies and possibly from academic institutions, government agencies and private and public research institutions that are researching, developing and marketing products designed to
address the treatment of gout. Our competitors may have significantly greater financial, manufacturing, marketing and drug development resources. Large pharmaceutical companies, in particular, have extensive experience in the clinical testing of,
obtaining regulatory approvals for, and marketing of, drugs. New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These developments may render our product candidates obsolete or noncompetitive. Compared to us, potential competitors may have
substantially greater: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">research and development resources, including personnel and technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience in pharmaceutical development and commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to negotiate competitive pricing and reimbursement with third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience and expertise in exploitation of intellectual property rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">capital resources. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these factors, our competitors may obtain regulatory approval of their products
more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The competitors may also develop products that are more effective, better
tolerated, more useful and less costly than our products and they may also be more successful in manufacturing and marketing their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Formulary approval and reimbursement may not be available for arhalofenate and our other product candidates, which could make it
difficult for us to sell our products profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining formulary approval can be an expensive and time consuming process. We
cannot be certain if and when we will obtain formulary approval to allow us to promote our product candidates, including arhalofenate, into our target markets. Failure to obtain timely formulary approval will limit our commercial success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, market acceptance and sales of arhalofenate, or any other product candidates that we develop, will depend in part on the extent
to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A prevailing trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and
these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.
Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. We cannot be sure that reimbursement will be available for arhalofenate, or any other product candidates. Also, reimbursement amounts may
reduce the demand for, or the price of, our products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize arhalofenate, or any other product candidates that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been a number of legislative and regulatory proposals to change the health care system in the U.S. and in some foreign
jurisdictions that could affect our ability to sell any future products profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future products, following approval. The availability of generic treatments
may also substantially reduce the likelihood of reimbursement for any future products, including arhalofenate. The application of user fees to generic drug products will likely expedite the approval of additional generic drug treatments. We expect
to experience pricing pressures in connection with the sale of arhalofenate and any other product candidate that we develop, due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional
legislative changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there may be significant delays in obtaining reimbursement for approved products, and coverage may be
more limited than the purposes for which the product is approved by the FDA or health authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of
the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for products may be reduced
by mandatory discounts or rebates required by government health care programs or private payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the U.S.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
are unable to promptly obtain coverage and profitable payment rates from both government funded and private payors for any of our product candidates, including arhalofenate, it could have a material adverse effect on our operating results, our
ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory
approval for arhalofenate, we will be subject to ongoing FDA and other regulatory obligations and continued regulatory review, which may result in significant additional expense and limit our ability to commercialize arhalofenate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we or potential collaboration partners receive for arhalofenate or future product candidates, may also be subject
to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing studies. In addition, even if approved, the labeling, packaging, adverse event reporting, storage, advertising,
promotion and recordkeeping for any product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, may result in
restrictions on the marketing of the product, and could include withdrawal of the product from the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory policies may change
and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we might not be permitted to market arhalofenate or future products, if any, and we may not achieve or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities
and may be required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure
related to the testing of our product candidates in human clinical studies, and will face an even greater risk if we sell our product candidates commercially. An individual may bring a liability claim against us if one of our product candidates
causes, or merely appears to have caused, an injury. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment to our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical study participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenues. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do carry product liability insurance for our clinical studies. Further,
we intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability insurance on commercially
reasonable terms and with insurance coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals. A successful
product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business
depends primarily upon our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on product candidates for specific indications. As a result, we may forego or delay
pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential. We may focus our efforts and resources on product candidates that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable
rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to
compete effectively in our market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements
to protect the intellectual property related to our products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications
that we own, co-own or in-license may fail to result in issued patents with claims that cover the products in the U.S. or in other countries. If this were to occur, early generic competition could be expected against arhalofenate and other product
candidates in development. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing based on a pending patent
application. Even if patents do successfully issue, third parties may challenge their validity, enforceability, scope or ownership, which may result in such patents, or our rights to such patents, being narrowed or invalidated. Furthermore, even if
they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold or license with respect to arhalofenate fail to
issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us and threaten our ability to commercialize our products. We cannot offer any assurances about which, if any, patents will issue
or whether any issued patents will be found invalid or unenforceable, will be challenged by third parties or will adequately protect our products and product candidates. Further, if we encounter delays in development or regulatory approvals, the
period of time during which we could market arhalofenate under patent protection could be reduced. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we
cannot be certain that we or our licensors were the first to file any patent application related to arhalofenate or our other product candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the
U.S. can be provoked by a third party or instituted by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. An unfavorable outcome could require us to cease using the related
technology or to attempt to license it from the prevailing party, which may not be available on commercially reasonable terms or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and
confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and other elements of our drug discovery and development processes that involve proprietary know-how, information
or technology that is not covered by patents. Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or
technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that such agreements provide adequate protection and will not be breached, that our trade secrets and other
confidential proprietary information will not otherwise be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent
material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a
competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect patents and other proprietary rights to the same extent or in the same manner as
the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property abroad. We may also fail to pursue or obtain patents and other intellectual property protection relating to our products
and product candidates in all foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our
development and commercialization efforts or otherwise affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding
infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and
pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party re-examination proceedings before the U.S. Patent and Trademark Office (U.S. PTO) and its foreign counterparts. Numerous U.S. and foreign
issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are
issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of
third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of arhalofenate and/or our other product candidates. Because patent applications can
take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our
technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party
patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and
commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that
we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary
information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay
royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially
reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to
obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot
provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay
royalties and/or other forms of compensation to third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We license certain key intellectual property from third parties, and the loss of our
license rights could have a materially adverse effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of technology licenses that are
important to our business and expect to enter into additional licenses in the future. For example, we rely on an exclusive license to certain patents, proprietary technology and know-how from DiaTex, which include arhalofenate. During the term of
the exclusive license with DiaTex we may perform research and development of compounds and products for the treatment of human disease based on the patents, proprietary technology and know-how from DiaTex. If we fail to comply with our obligations
under our agreement with DiaTex, including our obligations to pay royalty payments during the development and commercialization of arhalofenate, or our other license agreements, or if we are subject to a bankruptcy, the licensor may have the right
to terminate the license, in which event we would not be able to develop or market products covered by the license, including in the case of the DiaTex license, arhalofenate, which would have a materially adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property
rights, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, the
patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court
may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result
in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also
cause the third party to bring counter-claims against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, misappropriation of
our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Our business could be harmed if in a litigation if the prevailing party does not offer us a license on commercially
reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the
lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within
prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and patent
applications covering our product candidates, we may lose our rights and our competitors might be able to enter the market, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on principal members of our executive team listed under &#147;Business &#151;Executive Officers of Registrant&#148; of
our Annual Report on Form 10-K as filed with the SEC on March&nbsp;31, 2014. While we have entered into employment agreements or offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our
employees are &#147;at will&#148; employees. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. Recruiting and retaining other qualified employees for our business, including scientific and technical
personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. We also experience competition from universities and research institutions for the hiring of
scientific and clinical personnel. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. In addition, failure of any of our clinical studies may make it more challenging to recruit and retain qualified personnel. If we are unable to successfully recruit key employees or
replace the loss of services of any executive or key employee, it may adversely affect the progress of our research, development and commercialization objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to
assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that
may limit their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, we had 14 full-time employees. As our company matures, we expect to expand our employee base to
increase our managerial, clinical, scientific and engineering, operational, sales, and marketing teams. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate
and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth
activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity
among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage
our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize
arhalofenate and our other product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Owning Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile, and our stockholders&#146; investment in our stock could decline in value. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently quoted over-the-counter and is not listed on any exchange. Currently, there is no an active trading market for
our common stock and an active trading market for our common stock may not develop. You may not be able to sell your shares quickly or at the market price if trading in our common stock is not active. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock, if one develops, is likely to be volatile. Our stock price could be subject to wide fluctuations in
response to a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results or delays in preclinical testing or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain additional funding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay in filing an IND or NDA for any of our future product candidates an any adverse development or perceived adverse development with respect to the FDA&#146;s review of that IND or NDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to maintain our existing collaborations or enter into new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our collaboration partners to elect to develop or commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our licensors and collaboration partners to prosecute, maintain or enforce our intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to successfully develop and commercialize our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain adequate product supply for our future product candidates or the inability to do so at acceptable prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products, services or technologies by our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed financial projections we may provide to the public; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the estimates and projections of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our collaboration partners or our competitors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant lawsuits, including patent or stockholder litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders in the future; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in
general have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common
stock, regardless of our actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors and principal stockholders own a
significant percentage of our stock and will be able to exert significant control over matters submitted to our stockholders for approval. * </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, together
beneficially own shares representing approximately 39.6% of our common stock. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to influence all matters requiring
stockholder approval. For example, these stockholders, acting together, may be able to influence elections of directors, amendments to our organizational documents, or approval of any merger, sale of assets, or other major corporate action. This may
prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have recently become a public company and we will incur significant increased costs as a result of operating as a public company, and
our management will be required to devote substantial new time to compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We became a public company in October
2013, and as a result, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange
Commission, or the SEC, and any stock market upon which we may list, have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are
significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Recent legislation
permits smaller &#147;emerging growth companies&#148; to implement many of these requirements over a longer period and up to five years from the pricing of their public offerings. We intend to take advantage of this new legislation but cannot
guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government
intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our
management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our
current levels of such coverage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market by our existing
stockholders could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public
market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales
may have on the prevailing market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase
common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. * </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise
additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine
from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing
stockholders, and new investors could gain rights superior to our existing stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our equity incentive plans, our management is authorized to grant stock options and
other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under our equity incentive plans as of March&nbsp;31, 2014 was 143,251 shares. We have submitted a proposal for approval at our
annual meeting of stockholder in June 2014 to increase the aggregate number of shares reserved under our equity incentive plan by an additional 500,000 shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common
stock, which may never occur, will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. In addition, our ability to pay cash dividends is currently prohibited without the prior consent of the
lender pursuant to the terms of our loan and security agreement with Silicon Valley Bank and Oxford. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to
securities litigation, which is expensive and could divert management attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price may be volatile, and in the past,
companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in
substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our amended
and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more
difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management team. In addition, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advance notice requirements for nominations for election to
our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our
board of directors, they would apply even if the offer may be considered beneficial by some stockholders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_13"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">On November&nbsp;22, 2013, we entered into an agreement with two investors to purchase 604,000 shares of our common stock, and warrants to purchase 120,800 shares of our common stock. The shares and related warrants
were sold for an aggregate offering price of $3.0 million, which sales occurred on January&nbsp;29, 2014, shortly after the listing of our common stock on the over-the-counter market on January&nbsp;24, 2014. The shares and warrants were sold to the
investors in reliance on Rule 506 of Regulation D, in that all of the investors represented that they were &#147;accredited investors&#148; as that term is defined in Regulation D. Wells Fargo Securities and Trout Capital LLC acted as placement
agents with respect to these shares and related warrants issued in the transaction, and received an aggregate placement agent commission of $298,980 in the first quarter of 2014 in cash. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">From January&nbsp;1, 2014, to March&nbsp;31, 2014, we issued options to purchase an aggregate of 342,950 shares of common stock to 21 of our employees, directors and consultant at a weighted average exercise price of
$5.02, in reliance on Section&nbsp;4(2) and Rule 701 under the Securities Act. In addition, from January&nbsp;1, 2014 to March&nbsp;31, 2014, we issued incentive awards which may be settled at our sole discretion in cash or the right to purchase an
aggregate of 6,486 shares of common stock to one of our employees at a weighted average exercise price of $5.00, in reliance on Section&nbsp;4(2) and Rule 701 under the Securities Act. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx705860_14"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the Exhibit&nbsp;Index which follows the signature page&nbsp;of this Quarterly Report on
Form&nbsp;10-Q, which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx705860_15"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CYMABAY THERAPEUTICS,&nbsp;INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Harold Van Wart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: May 15, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Financial and Accounting Officer)</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: May 15, 2014</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman"><B>Description&nbsp;of&nbsp;Document</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation (Filed with the SEC as Exhibit 3.1 to our Amendment No. 2 to Registration Statement on Form 10, filed with the SEC on October 17, 2013, SEC File No. 000-55021).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws. (Filed with the SEC as Exhibit 3.2 to our Amendment No. 2 to Registration Statement on Form 10, filed with the SEC on October 17, 2013, SEC File No. 000-55021).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits 3.1 and 3.2.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement (Filed with the SEC as Exhibit 4.2 to our Amendment No. 2 to Registration Statement on Form 10, filed with the SEC on October 17, 2013, SEC File No. 000-55021).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2013 Financing Warrant (Filed with the SEC as Exhibit 4,3 to our Amendment No. 2 to Registration Statement on Form 10, filed with the SEC on October 17, 2013, SEC File No. 000-55021).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Registration Rights Agreement. (Filed with the SEC as Exhibit 4.4 to our Form 10-K, filed with the SEC on March 31, 2014, SEC File No. 000-55021).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated February 28, 2014, between CymaBay Therapeutics, Inc. and Pol Boudes. (Filed with the SEC as Exhibit 10.27 to our Registration Statement on Form S-1, filed with the SEC on April 8, 2014, SEC File No.
333-195127).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement, dated February 17, 2014, between CymaBay Therapeutics, Inc. and INC Research, LLC. (Filed with the SEC as Exhibit 10.28 to our Registration Statement on Form S-1, filed with the SEC on April 8, 2014, SEC
File No. <FONT STYLE="white-space:nowrap">333-195127).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Employee Director Compensation Policy. (Filed with the SEC as Exhibit 10.29 to our Registration Statement on Form S-1, filed with the SEC on April 8, 2014, SEC File No. 333-195127).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer pursuant to Rule 13-a-14(a) or Rule 15(d)-14(a) of the Exchange Act</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 13a-14(b) or 15d-14(b) of the Exchange Act</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Schema Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Labels Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document*</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit have been omitted pursuant to a request for confidential treatment, which portions were omitted and filed separately with the Securities and Exchange Commission. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d705860dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Harold Van Wart,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Form&nbsp;10-Q of CymaBay Therapeutics,&nbsp;Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for
the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of
the registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May 15, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Harold Van Wart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d705860dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Sujal Shah, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Form&nbsp;10-Q of CymaBay Therapeutics,&nbsp;Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for
the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of
the registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May 15, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d705860dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the requirement set forth in Rule&nbsp;13a-14(b)&nbsp;of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Harold Van
Wart, Chief Executive Officer of CymaBay Therapeutics,&nbsp;Inc. (the &#147;Company&#148;), and Sujal Shah, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form&nbsp;10-Q for the period ended March&nbsp;31, 2014, to which this Certification is attached as Exhibit&nbsp;32.1 (the &#147;Periodic Report&#148;), fully complies with the
requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Exchange Act, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Witness Whereof, the undersigned have set their hands hereto as of May 15, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harold Van Wart</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Harold Van Wart</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Sujal Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certification accompanies the Form&nbsp;10-Q to which it relates, is not deemed filed with the Securities
and Exchange Commission and is not to be incorporated by reference into any filing of CymaBay Therapeutics,&nbsp;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the
date of the Form&nbsp;10-Q), irrespective of any general incorporation language contained in such filing. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>cyma-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:cyma="http://imetrix.edgar-online.com/20140331" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="cyma-20140331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20090228_0_926396x1224360" unitRef="pure" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_3001_5">0.04420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE98833---1410-Q0002_STD_0_20090228_0_927592x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_5001_6">438.84</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20120131_0_926396x1224360_931308x954129" unitRef="pure" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_3003_5">0.04919</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20120131_0_926396x1224362_931308x954129" unitRef="pure" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_4003_4">0.05460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE98833---1410-Q0002_STD_0_20120131_0_927592x930400_931308x954129" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_5003_6">292.56</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20131031_0" unitRef="shares" decimals="INF" id="id_3866818_8ADE482C-7669-4EA7-8087-7558DDECB6E3_1_0">664300</us-gaap:CommonStockSharesIssued>
  <cyma:WarrantsToPurchaseOfCommonStockShares contextRef="eol_PE98833---1410-Q0002_STD_0_20131031_0" unitRef="shares" decimals="INF" id="id_3866818_8ADE482C-7669-4EA7-8087-7558DDECB6E3_1_1">132860</cyma:WarrantsToPurchaseOfCommonStockShares>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20131122_0" unitRef="shares" decimals="INF" id="id_3866818_3734A139-92EB-411E-B6A3-1849902C8A9E_1_0">604000</us-gaap:CommonStockSharesIssued>
  <cyma:WarrantsToPurchaseOfCommonStockShares contextRef="eol_PE98833---1410-Q0002_STD_0_20131122_0" unitRef="shares" decimals="INF" id="id_3866818_3734A139-92EB-411E-B6A3-1849902C8A9E_1_1">120800</cyma:WarrantsToPurchaseOfCommonStockShares>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20140430_0" unitRef="shares" decimals="INF" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_2_5">10064826</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20080331_0_926396x1224358" unitRef="pure" decimals="INF" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_1002_3">0.0757</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <cyma:LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones contextRef="eol_PE98833---1410-Q0002_STD_0_19980630_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1003_2">800000</cyma:LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones>
  <cyma:MonthlyLicenseFees contextRef="eol_PE98833---1410-Q0002_STD_0_19980630_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1003_1">2000</cyma:MonthlyLicenseFees>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE98833---1410-Q0002_STD_0_20060620_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_1_0">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20090731_0_926396x1224362" unitRef="pure" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_4002_4">0.04960</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE98833---1410-Q0002_STD_0_20090731_0_927592x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_5002_6">438.84</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20080930_0_926396x1224359" unitRef="pure" decimals="INF" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_1003_3">0.0757</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE98833---1410-Q0002_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1002_28">5567000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3866818_CC7F32B1-D5A8-466D-90A5-3670F0404BBF_1001_0">5366669</us-gaap:CommonStockSharesIssued>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_C34E107E-7E31-485B-B4DB-A1E53F2F9538_1001_2">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <cyma:WarrantsToPurchaseOfCommonStockShares contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_3866818_CC7F32B1-D5A8-466D-90A5-3670F0404BBF_1001_1">1073338</cyma:WarrantsToPurchaseOfCommonStockShares>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_923791x1126038" unitRef="shares" decimals="INF" id="id_3866818_494E6032-0A7A-49BB-8A78-4E91529DAD90_1001_0">121739</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_923791x1126038" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_3866818_494E6032-0A7A-49BB-8A78-4E91529DAD90_1001_1">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_923791x1126038" unitRef="iso4217_USD" decimals="-5" id="id_3866818_494E6032-0A7A-49BB-8A78-4E91529DAD90_1001_2">500000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_924791x995488_926396x1202104_928628x1008215" unitRef="pure" decimals="INF" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_3001_2">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_926396x1202104" unitRef="iso4217_USD" decimals="-5" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_4001_0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_926396x1202104" unitRef="iso4217_USD" decimals="-5" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_4001_4">300000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_926396x1202104_928628x1104289" unitRef="pure" decimals="INF" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_5001_6">0.0875</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <cyma:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage contextRef="eol_PE98833---1410-Q0002_STD_0_20130930_0_930809x1165861" unitRef="pure" decimals="2" id="id_3866818_24BDCFE2-44EF-49C0-8F8C-E23D1DBAEBD9_3001_2">0.05</cyma:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_34">10064495</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_33">10064495</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_1_2">2898534</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_29">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_27">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_32">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_31">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_26">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_28">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_25" />
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_15">2368000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_2">209000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_1_5">1054000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_1_4">215000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LinesOfCreditCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_17">410000</us-gaap:LinesOfCreditCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_35">370276000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_6">1063000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_14">1069000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_1_2">501000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_4">222000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_19">15521000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_36">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_1_0">419000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_38">11376000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_21">200000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_5">228000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:LongTermLineOfCredit contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_20">4099000</us-gaap:LongTermLineOfCredit>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_16">11638000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_37">-358904000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_DBB49C2B-CE41-4256-A1DA-187BB2E6AD6E_2001_4">400000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_30">1000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_39">31196000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CapitalLeaseObligations contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_35C5F8A9-FFF0-4E4F-82F8-881D32251BB2_1_0">0</us-gaap:CapitalLeaseObligations>
  <us-gaap:Liabilities contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_22">19820000</us-gaap:Liabilities>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_3">216000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_18">36000</us-gaap:InterestPayableCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_4_4">11638000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_23" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_AD17E569-1438-45CF-8FF6-7C770D65BEEE_1001_1">188000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_3">6191000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_8">30933000</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_10">203000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_6">1876000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_7DCB11C6-0596-4096-AC20-B434751C0FD5_1_0">100000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:Assets contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_11">31196000</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_4_2">27928000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_2">22342000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_4">168000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_1_4">1114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_7">266000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_5">90000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_1_9">60000</us-gaap:PropertyPlantAndEquipmentNet>
  <cyma:AccruedExpensesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_1_1">1233000</cyma:AccruedExpensesCurrent>
  <cyma:ShortTermInvestmentContractualMaturity contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" id="id_3866818_891F9E13-50B2-4702-BC5A-B631249ECAA1_1001_0">P1Y</cyma:ShortTermInvestmentContractualMaturity>
  <cyma:IndemnificationLiability contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-6" id="id_3866818_0AE90520-51A0-4070-8EDA-F19AB98D0881_1001_0">0</cyma:IndemnificationLiability>
  <cyma:PurchasedCommonStockAndCommonStockWarrantsCarryingValue contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_76E08FD4-9183-4D1B-8173-44EB9A02195F_1001_0">3000000</cyma:PurchasedCommonStockAndCommonStockWarrantsCarryingValue>
  <cyma:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_921954x1211839" unitRef="iso4217_USD" decimals="-6" id="id_3866818_6E4043B8-6992-4A00-875B-A897A8EFE859_2001_2">228000000</cyma:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_923791x1144362" unitRef="shares" decimals="INF" id="id_3866818_DBB49C2B-CE41-4256-A1DA-187BB2E6AD6E_3001_0">120800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_923791x1144362" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_3866818_DBB49C2B-CE41-4256-A1DA-187BB2E6AD6E_3001_2">5.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x1256770" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_1004_1">6191000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x1256770_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_1002_1">6191000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x932359" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_2004_0">21737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x932359_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_2001_0">21737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x1038552" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_3004_3">11638000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x1038552_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_3003_3">11638000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x925633_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_1001_4">11638000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_1_2">21737000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x925851" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_2_2">6191000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_EA515A85-A5FF-456F-89EF-CDD251D77002_3_4">11638000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x929831_932336x929612" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_1002_4" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x1125873" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_1001_0">556000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x923325" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_2001_3">349000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x932226" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_3001_2">42000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x964907" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_4001_1">166000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_930809x1165861" unitRef="shares" decimals="INF" id="id_3866818_24BDCFE2-44EF-49C0-8F8C-E23D1DBAEBD9_3002_3">830647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_932040x974512" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_1001_1">1050047</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_932040x980834" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_2001_0">1848487</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_932980x932774" unitRef="shares" decimals="INF" id="id_3866818_1441BEF6-6CE9-4DA4-90B6-419B077B66A7_1001_0">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE98833---1410-Q0002_STD_0_20140331_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_1441BEF6-6CE9-4DA4-90B6-419B077B66A7_1001_1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE98833---1410-Q0002_STD_0_20101231_0_927592x929729" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_2004_4">232.93</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE98833---1410-Q0002_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2001_27">7726000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_34">9455064</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_33">9455064</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_2_2">2320021</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_29">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_27">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_32">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_31">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_26">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_28">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_25" />
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_15">2251000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_2_5">3295000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_2_4">80000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LinesOfCreditCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_17">38000</us-gaap:LinesOfCreditCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_35">367435000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_14">697000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_2_2">782000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_19">9488000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_36">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_2_0">518000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_38">18596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_21">9000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermLineOfCredit contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_20">4407000</us-gaap:LongTermLineOfCredit>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_16">6466000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_37">-348842000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:CommonStockValue contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_30">1000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_39">32500000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Liabilities contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_22">13904000</us-gaap:Liabilities>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_18">36000</us-gaap:InterestPayableCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_23" />
  <us-gaap:MarketableSecuritiesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_3">6843000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_8">32239000</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_10">258000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_6">364000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_7DCB11C6-0596-4096-AC20-B434751C0FD5_2_0">155000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:Assets contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_11">32500000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_2">24401000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_4">110000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_2_4">3298000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_7">453000</us-gaap:OtherAssetsCurrent>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_5">68000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_CA1FA77D-AED6-4524-8E73-C1B6E31730AA_2_9">3000</us-gaap:PropertyPlantAndEquipmentNet>
  <cyma:AccruedExpensesCurrent contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_2_1">418000</cyma:AccruedExpensesCurrent>
  <cyma:AccruedLiabilityOfDerivativeInInstruments contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_54BD5F74-A0D5-4C9F-9E52-60B5F51AC9B1_2_3">453000</cyma:AccruedLiabilityOfDerivativeInInstruments>
  <cyma:IndemnificationLiability contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-6" id="id_3866818_0AE90520-51A0-4070-8EDA-F19AB98D0881_1002_0">0</cyma:IndemnificationLiability>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_927111x925633_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_2001_0">6466000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_929790x929831_932336x929612" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_2002_0">453000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x1125873" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_1002_0">556000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x923325" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_2002_3">2534000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x932226" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_3002_2">42000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x964907" unitRef="iso4217_USD" decimals="-3" id="id_3866818_4489E825-57B0-439A-90AA-2159CD7FA3F9_4002_1">166000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_932040x974512" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_1002_1">577294</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE98833---1410-Q0002_STD_0_20131231_0_932040x980834" unitRef="shares" decimals="INF" id="id_3866818_050C574D-DE33-435E-986E-DBD664B9D4F4_2002_0">1742727</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE98833---1410-Q0002_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_3866818_07A4FC1B-BAF9-4905-B2E9-42F9DE9B8F8F_1_0">2793281</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockAmountIssued1 contextRef="eol_PE98833---1410-Q0002_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_07A4FC1B-BAF9-4905-B2E9-42F9DE9B8F8F_1_1">320000000</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_28_20090228_0_926396x1224360" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_1001_2">2012-02-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE98833---1410-Q0002_STD_28_20090228_0_926396x1224360" unitRef="iso4217_USD" decimals="-5" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_1001_0">7000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE98833---1410-Q0002_STD_3_20131108_0_926744x929485" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1003_3">2018-12-31</us-gaap:LeaseExpirationDate1>
  <cyma:AreaOfOfficeSpace contextRef="eol_PE98833---1410-Q0002_STD_3_20131108_0_926744x929485" unitRef="sqft" decimals="0" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1003_4">8894</cyma:AreaOfOfficeSpace>
  <cyma:LeaseStartDate contextRef="eol_PE98833---1410-Q0002_STD_3_20131108_0_926744x929485" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1003_2">2014-01-16</cyma:LeaseStartDate>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE98833---1410-Q0002_STD_3_20131122_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_3734A139-92EB-411E-B6A3-1849902C8A9E_2_2">2700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="shares" decimals="INF" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_7_9">624944</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="pure" decimals="5" id="id_3866818_A857E677-FAAB-460F-9656-49CF85870E2D_1_0">0.01258</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_C34E107E-7E31-485B-B4DB-A1E53F2F9538_1_0">26800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_7_8">16900000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:ProceedsFromLinesOfCredit contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_C34E107E-7E31-485B-B4DB-A1E53F2F9538_1_1">5000000</us-gaap:ProceedsFromLinesOfCredit>
  <cyma:StockIssuedDuringPeriodAmountForCancellationOfDebt contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_C34E107E-7E31-485B-B4DB-A1E53F2F9538_1_6">16900000</cyma:StockIssuedDuringPeriodAmountForCancellationOfDebt>
  <cyma:ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_C34E107E-7E31-485B-B4DB-A1E53F2F9538_1_3">28800000</cyma:ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0_924420x1116164_924791x1056074_926396x1202104_928628x1008215" unitRef="pure" decimals="4" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_1001_7">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0_926396x1202104" unitRef="pure" decimals="4" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_2001_8">0.0100</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <us-gaap:DebtInstrumentCovenantDescription contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0_926396x1202104" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_2001_5">Until positive  Phase 2b data is achieved, the Company must be in compliance with one of two  financial covenants at all times (1) maintain 1.3 times cash to outstanding  debt or (2) maintain sufficient cash on hand to support eight months of  operations based on a trailing average monthly cash burn.</us-gaap:DebtInstrumentCovenantDescription>
  <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0_926396x1202104" unitRef="iso4217_USD" decimals="-5" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_2001_1">5000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
  <cyma:AmortizationPeriod contextRef="eol_PE98833---1410-Q0002_STD_3_20130930_0_926396x1202104" id="id_3866818_5AE80BE3-8E23-430A-B60A-0C7B86359504_2001_3">P36M</cyma:AmortizationPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_30_20080930_0_926396x1224359" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_3_2">2011-09-17</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE98833---1410-Q0002_STD_30_20080930_0_926396x1224359" unitRef="iso4217_USD" decimals="-5" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_3_1">10500000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE98833---1410-Q0002_STD_30_20130930_0" unitRef="shares" decimals="INF" id="id_3866818_CC7F32B1-D5A8-466D-90A5-3670F0404BBF_1_3">624944</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="eol_PE98833---1410-Q0002_STD_30_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_CC7F32B1-D5A8-466D-90A5-3670F0404BBF_1_4">16900000</us-gaap:ExtinguishmentOfDebtAmount>
  <cyma:NetProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE98833---1410-Q0002_STD_30_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_CC7F32B1-D5A8-466D-90A5-3670F0404BBF_1_2">22800000</cyma:NetProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE98833---1410-Q0002_STD_30_20130930_0_926437x923140_930809x1165861" id="id_3866818_24BDCFE2-44EF-49C0-8F8C-E23D1DBAEBD9_1001_1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <cyma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease contextRef="eol_PE98833---1410-Q0002_STD_30_20130930_0_930809x1165861" unitRef="shares" decimals="INF" id="id_3866818_24BDCFE2-44EF-49C0-8F8C-E23D1DBAEBD9_2001_0">472753</cyma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20120131_0_926396x1224360_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_1003_2">2013-03-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20120131_0_926396x1224362_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_2003_3">2013-03-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20130731_0_926396x1224360_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_1005_2">2013-12-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20130731_0_926396x1224362_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_2005_3">2013-12-31</us-gaap:DebtInstrumentMaturityDate>
  <cyma:NetProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE98833---1410-Q0002_STD_31_20131031_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_8ADE482C-7669-4EA7-8087-7558DDECB6E3_2_2">2200000</cyma:NetProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20080331_0_926396x1224358" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_2_2">2011-03-17</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE98833---1410-Q0002_STD_31_20080331_0_926396x1224358" unitRef="iso4217_USD" decimals="-5" id="id_3866818_DEC55016-68D7-42C3-85D1-7AADDCBFCEFB_2_1">3500000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20090731_0_926396x1224362" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_2002_3">2012-07-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE98833---1410-Q0002_STD_31_20090731_0_926396x1224362" unitRef="iso4217_USD" decimals="-5" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_2002_1">6700000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20130331_0_926396x1224360_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_1004_2">2013-08-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE98833---1410-Q0002_STD_31_20130331_0_926396x1224362_931308x954129" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_2004_3">2013-08-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:SponsorFees contextRef="eol_PE98833---1410-Q0002_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_82CA1F0E-478F-41F6-A8D7-ECDEDB7238B5_2_0">45000</us-gaap:SponsorFees>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE98833---1410-Q0002_STD_365_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_724A0AAE-34E1-4715-9AB1-454AFBD650C6_2_0">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_18">-2159000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_16">-985.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_2_3">786956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_15">-5737000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_11">-5737000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_8">-2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_6">1000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_13">55000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_4">-2415000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_12">-20000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_11">-9000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_9">-2628000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_7">-10000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:IncreaseDecreaseInContractReceivablesNet contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_10">11000</us-gaap:IncreaseDecreaseInContractReceivablesNet>
  <us-gaap:PaymentsForRoyalties contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_2_4">0</us-gaap:PaymentsForRoyalties>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_2">925000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_10">3109000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_5">18000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_26">-2159000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_2_0">100000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_15">228000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_7">212000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_14">20000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_1">1490000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_3">26000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_FF6984E4-1568-4E87-8AC3-12C08D8CCFC6_2_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_2_16">204000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_E1111E87-7DD2-4D0D-9FEA-C9F5D7F13700_6_7">200000</us-gaap:InterestExpenseDebt>
  <us-gaap:OperatingExpenses contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_3">2415000</us-gaap:OperatingExpenses>
  <cyma:ShareBasedCompensationExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_2_2">18000</cyma:ShareBasedCompensationExpense>
  <cyma:DevelopmentPayment contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_2_3">0</cyma:DevelopmentPayment>
  <cyma:WeightedAverageNumberOfBasicAndDilutedSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0" unitRef="shares" decimals="0" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_2_17">5824</cyma:WeightedAverageNumberOfBasicAndDilutedSharesOutstanding>
  <us-gaap:ProceedsFromRoyaltiesReceived contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_921954x1264243" unitRef="iso4217_USD" decimals="0" id="id_3866818_C343AD4A-138E-4069-B12D-0CAA3A42E5FC_2_2">0</us-gaap:ProceedsFromRoyaltiesReceived>
  <cyma:PaymentsMadeUnderLicenseAgreement contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_921954x1264243" unitRef="iso4217_USD" decimals="0" id="id_3866818_C343AD4A-138E-4069-B12D-0CAA3A42E5FC_2_1">0</cyma:PaymentsMadeUnderLicenseAgreement>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_1002_1">12000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_2002_0">6000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x929614" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_1002_0">28210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x930643" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_2002_1">97687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x932152" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_3002_2">661059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dei:TradingSymbol contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_1_0">CYMA</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_1_1">CymaBay Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_702A8B96-F633-489E-9FDA-F5D0E14DDF97_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_1_4">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_702A8B96-F633-489E-9FDA-F5D0E14DDF97_1_3">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_702A8B96-F633-489E-9FDA-F5D0E14DDF97_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_702A8B96-F633-489E-9FDA-F5D0E14DDF97_1_2">2014-03-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_1_2">0001042074</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1BBA9CCB-412B-4DE4-80E2-527235572308_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_702A8B96-F633-489E-9FDA-F5D0E14DDF97_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1DF80F73-8CB0-473B-8A8C-C18DE0FC8148_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;9. Stock Plans and Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Stock Plans&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;30, 2013, the Company&amp;#x2019;s stockholders
 approved the 2013 Equity Incentive Plan, or 2013 Plan, under which
 shares of the Company&amp;#x2019;s common stock are reserved for
 issuance pursuant to stock awards, including, but not limited to,
 incentive stock options, nonstatutory stock options, stock
 appreciation rights, restricted stock awards, restricted stock unit
 awards, performance stock awards, and performance cash awards. In
 addition, the share reserve automatically increased by 472,753
 shares on January&amp;#xA0;1, 2014, and will continue to automatically
 increase on January&amp;#xA0;1&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt; of each year, for a
 period of not more than ten years, in an amount equal to 5% of the
 total number of shares of capital stock outstanding on
 December&amp;#xA0;31&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt; of the preceding
 calendar year, unless the Board determines otherwise prior to
 December&amp;#xA0;31&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;st&lt;/sup&gt; of such calendar
 year. From plan inception through March&amp;#xA0;31, 2014, the Company
 had issued options for an aggregate of 830,647&amp;#xA0;shares of the
 Company&amp;#x2019;s common stock under the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Stock-Based Compensation Expense&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Employee and Director Expense&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Employee and director stock-based compensation expense recorded was
 as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;568&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;714&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_B9893D18-AF7B-4F94-B4DF-107E5FE0C4D2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Employee and director stock-based compensation is measured at the
 grant date, based on the fair-value based measurements of the stock
 awards, and the portion that is ultimately expected to vest is
 recognized as an expense over the related vesting periods, net of
 estimated forfeitures. The Company calculates the fair-value based
 measurements of options using the Black-Scholes valuation model and
 the single-option approach and recognizes expense using the
 straight-line attribution method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Equity awards granted to non-employees are accounted for using the
 Black-Scholes valuation model to determine the fair value of such
 instruments. The fair value of equity awards granted to
 non-employees are re-measured over the related vesting period and
 amortized to expense as earned.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_D514503E-344C-470A-BFA7-26F1F8C169A8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company leased office and laboratory space in a single building
 in Hayward, California. The facility lease, as amended on
 July&amp;#xA0;15, 2010, had a term of four years and expired on
 April&amp;#xA0;30, 2014. On November&amp;#xA0;8, 2013, the Company entered
 into a new lease commencing January&amp;#xA0;16, 2014, and expiring on
 December&amp;#xA0;31, 2018, for 8,894 square feet of office space in
 Newark, California. Rent expense was $0.2 million and $0.1 million
 for the three months ended March&amp;#xA0;31, 2014 and 2013,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future minimum lease payments are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Payments&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Year ending December&amp;#xA0;31:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;222&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total future minimum payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,063&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Indemnification&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In the normal course of business, the Company enters into contracts
 and agreements that contain a variety of representations and
 warranties and provide for general indemnification, including
 indemnification associated with product liability or infringement
 of intellectual property rights. The Company&amp;#x2019;s exposure under
 these agreements is unknown because it involves future claims that
 may be made against the Company that may be, but have not yet been,
 made. To date, the Company has not paid any claims or been required
 to defend any action related to these indemnification obligations,
 and no amounts have been accrued in the accompanying balance sheets
 related to these indemnification obligations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has agreed to indemnify its executive officers and
 directors for losses and costs incurred in connection with certain
 events or occurrences, including advancing money to cover certain
 costs, subject to certain limitations. The maximum potential amount
 of future payments the Company could be required to make under this
 indemnification is unlimited; however, the Company maintains
 insurance policies that may limit its exposure and may enable it to
 recover a portion of any future amounts paid. Assuming the
 applicability of coverage, the willingness of the insurer to assume
 coverage, and subject to certain retention, loss limits, and other
 policy provisions, the Company believes the fair value of these
 indemnification obligations is not material. Accordingly, the
 Company has not recognized any liabilities relating to these
 obligations as of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013.
 No assurances can be given that the covering insurers will not
 attempt to dispute the validity, applicability, or amount of
 coverage without expensive litigation against these insurers, in
 which case the Company may incur substantial liabilities as a
 result of these indemnification obligations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_674279EF-3653-4B3A-A572-AB894FDE78EE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future minimum lease payments are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Payments&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Year ending December&amp;#xA0;31:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;216&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;222&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total future minimum payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,063&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_F94400F0-2065-4E79-BA97-FF316F59E9E5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s financial instruments consist of cash and cash
 equivalents, short-term marketable securities, accounts payable,
 accrued expenses, warrant liabilities and convertible notes. Fair
 value estimates of these instruments are made at a specific point
 in time, based on relevant market information. These estimates may
 be subjective in nature and involve uncertainties and matters of
 significant judgment and therefore cannot be determined with
 precision.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants at the
 measurement date. Assets and liabilities that are measured at fair
 value are reported using a three-level fair value hierarchy that
 prioritizes the inputs used to measure fair value. This hierarchy
 maximizes the use of observable inputs and maximizes the use of
 unobservable inputs and is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 1&amp;#x2014;Quoted prices in active markets for identical assets
 or liabilities that the Company has the ability to access at the
 measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 2&amp;#x2014;Inputs other than quoted prices in active markets
 that are observable for the asset or liability, either directly or
 indirectly.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 3&amp;#x2014;Inputs that are unobservable for the asset or
 liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The carrying amounts of financial instruments such as cash and cash
 equivalents, accounts payable, convertible notes, and accrued
 expenses approximate the related fair values due to the short-term
 maturities of these instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Marketable securities consist of available-for-sale securities that
 are reported at fair value, with the related unrealized gains and
 losses included in accumulated other comprehensive income (loss), a
 component of stockholders&amp;#x2019; equity. The Company values cash
 equivalents and marketable securities using quoted market prices or
 alternative pricing sources and models utilizing observable market
 inputs and, as such, classifies cash equivalents and marketable
 securities within Level 1 or Level 2.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014, the Company held a Level 3 liability
 associated with warrants, issued in connection with the
 Company&amp;#x2019;s 2013 financing. The warrants are considered a
 liability and are valued using an option-pricing model, the inputs
 for which include exercise price of the warrants, market price of
 the underlying common shares, expected term, volatility based on a
 group of the Company&amp;#x2019;s peers and the risk-free rate
 corresponding to the expected term of the warrants. As of
 December&amp;#xA0;31, 2013, the Company also held a Level 3 liability
 associated with a forward contract which arose in connection with
 the Company&amp;#x2019;s November&amp;#xA0;22, 2013 execution of an equity
 purchase agreement with certain investors. The agreement required
 the Company to issue a fixed number of shares of common stock and
 warrants to purchase common stock at a predetermined price of $3.0
 million provided the Company completes the listing of its common
 stock on a public stock exchange. The forward contract&amp;#x2019;s fair
 value was determined upon execution as the difference between the
 present value of the equity proceeds to be received under the
 agreement less the fair value of the underlying securities. The
 forward contract liability is presented in the balance sheet as a
 component of accrued liabilities and is revalued at each reporting
 period until contract settlement which occurred on January&amp;#xA0;29,
 2014. The fair value of the underlying common stock and warrants
 were valued using an option-pricing model, the inputs of which are
 similar to those used in the valuation of the Company&amp;#x2019;s
 liability classified warrants. Changes to any of the inputs to the
 option-pricing models used by the Company can have a significant
 impact to the estimated fair value of the warrants and forward
 contract liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The gains and losses from remeasurement of Level 3 financial
 liabilities are recorded through other expense, net on the
 accompanying statements of operations and comprehensive loss.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1_1">P4Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_A07DD36A-C048-42C5-86BE-4D9EFD341BE9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;As of March&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt and asset backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total assets measured at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total liabilities measured at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_DD403CCC-B893-4861-9A82-D4F1C317BB35_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Comprehensive Loss&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss includes net loss and net unrealized gains and
 losses on marketable securities, which are presented in a single
 continuous statement. Accumulated other comprehensive income (loss)
 is disclosed in the statements of redeemable convertible preferred
 stock and stockholders&amp;#x2019; equity (deficit), and is stated net
 of related tax effects, if any.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_3CC6F4DC-FE8F-4DBB-B92E-F1CA52BF8B73_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain compensating cash balances with
 financial institutions that provide the Company with its corporate
 credit cards. As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013,
 cash restricted under these arrangements was $100,000 and $155,000,
 respectively. These amounts are presented in other assets on the
 accompanying balance sheets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:LiquidityDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_00EA2C17-B359-498D-850E-022633111D1E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has incurred net operating losses and negative cash
 flows from operations since its inception. During the three months
 ended March&amp;#xA0;31, 2014, the Company incurred a loss from
 operations of $10.1 million and used $5.0 million of cash in
 operations. At March&amp;#xA0;31, 2014, the Company had an accumulated
 deficit of $358.9 million. CymaBay expects to incur increased
 research and development expenses as it continues to study its
 product candidates in clinical trials.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_32A45512-9E6A-4C4A-9754-1C438D685446_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Office and computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Purchased software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,054&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_C25E0271-1241-4BF7-A3CC-40EE6E1201AF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months
 Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;(unaudited)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants for common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,848,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;906,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Redeemable convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;661,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,755,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;786,956&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_A9B8BF09-E16A-4245-AA0C-B7E3B5E4283D_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Debt&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On June&amp;#xA0;20, 2006 the Company entered into a equity and loan
 facility with the Johnson and Johnson Development Corporation
 (&amp;#x201C;JJDC&amp;#x201D;) pursuant to which the Company could drawn down
 up to an aggregate of $30 million in loans in the form of
 convertible preferred stock promissory notes. In March and
 September 2008, the Company issued notes in the aggregate amount of
 $3.5 million and $10.5 million, respectively. The notes were due on
 March&amp;#xA0;17 and September&amp;#xA0;17, 2011, including interest that
 accrued at 7.57%&amp;#xA0;per annum. In December 2010, the aggregate
 principal amount and all accrued interest under the notes issued in
 March and September 2008 were converted into the Company&amp;#x2019;s
 Series E-3 convertible preferred stock (Series E-3 Preferred) at
 $232.93&amp;#xA0;per share.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In February and July 2009, the Company issued notes in the
 aggregate amount of $7.0 million and $6.7 million, respectively,
 which represented the remaining amount available to the Company, in
 accordance with the terms of the equity and loan facility with
 JJDC. The notes were due in February 2012 and July 2012, including
 interest that accrued at 4.42%&amp;#xA0;per annum and 4.960%&amp;#xA0;per
 annum, respectively. In January 2012, the Company amended the
 maturity dates of the outstanding $7.0 million and $6.7 million
 convertible promissory notes to extend the maturity date to
 March&amp;#xA0;1, 2013, and interest rates were increased to 4.919% and
 5.46%&amp;#xA0;per annum, respectively. In addition, the conversion
 price of the notes to convert into shares of the Company&amp;#x2019;s
 Series C-1 Preferred Stock was decreased from $438.84 per share to
 $292.56 per share. All of these notes were further amended in March
 2013, to extend the maturity date on the notes to August&amp;#xA0;1,
 2013, and to make the notes subordinate to repayment of the
 Company&amp;#x2019;s severance obligations to all employees until
 January&amp;#xA0;1, 2014. On July&amp;#xA0;31, 2013, the maturity date was
 extended to December&amp;#xA0;31, 2013. There are no financial
 covenants associated with the notes. For the three months ended
 March&amp;#xA0;31, 2013, the Company recognized $0.2 million of
 interest expense related to the convertible promissory notes. On
 September&amp;#xA0;30, 2013, the outstanding principal and accrued
 interest of $16.9 million under the equity and loan facility with
 JJDC was extinguished in exchange for 624,944 shares of common
 stock as an integral part of the 2013 financing.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Facility Loan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On September&amp;#xA0;30, 2013, the Company entered into a facility
 loan agreement with Silicon Valley Bank and Oxford Finance for a
 total loan amount of $10.0 million of which the first tranche of
 $5.0 million was drawn as part of&amp;#xA0;the 2013 financing.&amp;#xA0;The
 loan has a fixed interest rate of 8.75% payable twelve months
 interest only and thirty-six months amortization thereafter, with a
 final interest payment of&amp;#xA0;$0.3 million at the end of the loan
 period.&amp;#xA0;Until positive Phase 2b data is achieved, the Company
 must be in compliance with one of two financial covenants at all
 times: (1)&amp;#xA0;maintain 1.3 times cash to outstanding debt or
 (2)&amp;#xA0;maintain sufficient cash on hand to support eight months
 of operations based on a trailing average monthly cash burn. The
 first tranche loans under the term loan facility bear interest at a
 rate equal 8.75%&amp;#xA0;per annum. Loans under the second tranche
 will bear interest at a rate fixed at the time of borrowing equal
 to the greater of (i)&amp;#xA0;8.75%&amp;#xA0;per annum and (ii)&amp;#xA0;the
 sum of the Wall Street Journal prime rate plus 4.25%&amp;#xA0;per
 annum. We were also required to pay a facility fee of 1.00% on the
 term loan facility commitment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At the time of the facility loan drawdown, the
 Company&amp;#xA0;issued&amp;#xA0;warrants exercisable for a total of
 121,739 shares of the Company&amp;#x2019;s common stock to the lenders
 at an exercise price of $5.00 per share.&amp;#xA0;As a result of this
 issuance, a warrant liability of $0.5 million was recorded in the
 accompanying balance sheets which is required to be revalued at
 each balance sheet date.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_80481DCF-145F-479D-A1E6-BB5C77749DA5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;3. Certain Balance Sheet Items&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Office and computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Purchased software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,298&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,054&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,295&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In March 2014, the Company ceased use of a substantial portion of
 its leased facility in Hayward, California. In connection with the
 closure of this facility, the Company disposed of certain fully
 depreciated leasehold improvements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;518&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued pre-clinical and clinical trial expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forward contract&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;215&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_A40FBE15-F31B-43CF-9237-DF851DFE218F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;518&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued pre-clinical and clinical trial expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,233&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forward contract&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;215&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total accrued liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,251&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_2E1E58A5-8DB0-4C43-86A9-2538C3667F16_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;8. Stockholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Upon the closing&amp;#xA0;in the 2013 financing on September&amp;#xA0;30,
 2013, all of the outstanding shares of redeemable convertible
 preferred stock were converted into 2,793,281 shares of common
 stock, and the related carrying value of $320.0 million was
 reclassified to additional paid-in capital. As of March&amp;#xA0;31,
 2014, no shares of redeemable convertible preferred stock were
 issued or outstanding.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The Company was authorized to issue 100,000,000 shares of common
 stock with a par value of $0.0001 per share as of March&amp;#xA0;31,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;30, 2013, the Company sold 5,366,669 shares of
 common stock and 1,073,338 warrants to purchase shares of common
 stock in the 2013 financing for net proceeds to the Company of
 $22.8 million after deducting placement agent fees and estimated
 offering expenses. Also on that date, the Company issued 624,944
 shares of common stock in cancellation of approximately $16.9
 million of debt owed to JJDC, the holder of that debt (Note 6). On
 October&amp;#xA0;31, 2013, the Company sold an additional 664,300
 shares of common stock and warrants to purchase 132,860 shares of
 common stock, which sales were also part of the 2013 financing, for
 net proceeds to CymaBay of $2.2 million after deducting placement
 agent fees and estimated offering expenses. On November&amp;#xA0;22,
 2013, the Company entered into an agreement with investors to
 purchase 604,000 shares of common stock and 120,800 warrants to
 purchase shares of common stock as part of the 2013 financing for
 net proceeds of $2.7 million, which sales were set to occur shortly
 after the listing of the Company&amp;#x2019;s common stock on the
 over-the-counter market. The Company began trading on the
 over-the-counter market on January&amp;#xA0;24, 2014 enabling this
 portion of the 2013financing to be completed in late January
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013, the Company
 had reserved shares of authorized but unissued common stock as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,848,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,742,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity incentive plans&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,050,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;577,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total reserved shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,898,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,320,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_E7E31545-94B3-4EB2-9B70-27D7A16D49FA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment is stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization is
 calculated using the straight-line method, and the cost is
 amortized over the estimated useful lives of the respective assets,
 generally three to seven years. Leasehold improvements are
 amortized over the shorter of the useful lives or the
 non-cancelable term of the related lease. Maintenance and repair
 costs are charged as expense in the statements of operations and
 comprehensive income (loss) as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_249B1780-1833-438E-AC40-6806FF592B45_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Cash, Cash Equivalents, and Marketable Securities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with a
 remaining maturity of 90 days or less at the time of purchase to be
 cash equivalents. Cash and cash equivalents consist of deposits
 with commercial banks in checking, interest-bearing, and demand
 money market accounts. The Company invests excess cash in
 marketable securities with high credit ratings. These securities
 consist primarily of corporate debt and asset-backed securities and
 are classified as &amp;#x201C;available-for-sale.&amp;#x201D; Management may
 liquidate any of these investments in order to meet the
 Company&amp;#x2019;s liquidity needs in the next year. Accordingly, any
 investments with contractual maturities greater than one year from
 the balance sheet date are classified as short-term in the balance
 sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Realized gains and losses from the sale of marketable securities,
 if any, are calculated using the specific identification method.
 Realized gains and losses and declines in value judged to be
 other-than-temporary are included in interest income or expense in
 the statements of operations. Unrealized holding gains and losses
 are reported in accumulated other comprehensive income (loss), in
 the balance sheet. To date, the Company has not recorded any
 impairment charges on its marketable securities related to
 other-than-temporary declines in market value. In determining
 whether a decline in market value is other-than-temporary, various
 factors are considered, including the cause, duration of time and
 severity of the impairment, any adverse changes in the
 investees&amp;#x2019; financial condition, and the Company&amp;#x2019;s
 intent and ability to hold the security for a period of time
 sufficient to allow for an anticipated recovery in market
 value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_18">-5011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_16">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1_5">2014-04-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_C385A08B-24F0-4ED1-91D2-6BE40D1B44DA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses consist of costs incurred in
 identifying, developing, and testing product candidates. These
 expenses consist primarily of costs for research and development
 personnel, including: related stock-based compensation; contract
 research organizations and other third parties that assist in
 managing, monitoring, and analyzing clinical trials; investigator
 and site fees; laboratory services; consultants; contract
 manufacturing services; non-clinical studies, including materials;
 and allocated expenses, such as depreciation of assets, and
 facilities and information technology that support research and
 development activities. Research and development costs are expensed
 as incurred, including expenses that may or may not be reimbursed
 under research and development funding arrangements. Research and
 development expenses under collaboration agreements approximate the
 revenue recognized under such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The expenses related to clinical trials are based upon estimates of
 the services received and efforts expended pursuant to contracts
 with multiple research institutions and clinical research
 organizations (CROs) that conduct and manage clinical trials on
 behalf of the Company. Expenses related to clinical trials are
 accrued based upon the level of activity incurred under each
 contract as indicated by such factors as progress made against
 specified milestones or targets in each period, patient enrollment
 levels, and other trial activities as reported by CROs.
 Accordingly, the Company&amp;#x2019;s clinical trial accrual is
 dependent upon the timely and accurate reporting of expenses by
 clinical research organizations and other third-party
 vendors.&amp;#xA0;Payments made to third parties under these clinical
 trial arrangements in advance of the receipt of the related
 services are recorded as prepaid assets, depending on the terms of
 the agreement, until the services are rendered.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_57460F31-37BE-4985-B5C2-C24FF1315136_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying interim condensed financial statements are
 unaudited. These unaudited interim financial statements have been
 prepared in accordance U.S. GAAP (&amp;#x201C;GAAP&amp;#x201D;) and following
 the requirements of the United States Securities and Exchange
 Commission (&amp;#x201C;SEC&amp;#x201D;) for interim reporting. As permitted
 under those rules, certain footnotes or other financial information
 that are normally required by GAAP can be condensed or omitted. In
 management&amp;#x2019;s opinion, the unaudited interim financial
 statements have been prepared on the same basis as the audited
 financial statements and include all adjustments, which include
 only normal recurring adjustments, necessary for the fair
 presentation of the Company&amp;#x2019;s financial position and its
 results of operations and comprehensive loss and its cash flows for
 periods presented. These statements do not include all disclosures
 required by GAAP and should be read in conjunction with the
 Company&amp;#x2019;s financial statements and accompanying notes for the
 fiscal year ended December&amp;#xA0;31, 2013, which is contained in the
 Company&amp;#x2019;s Annual Report on Form 10-K as filed with the SEC on
 March&amp;#xA0;31, 2014. The results for the three months ended
 March&amp;#xA0;31, 2014, are not necessarily indicative of results to
 be expected for the year or for any other period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:LeasePolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_D526D921-4C9F-4D83-8FF4-6749CD7D03C5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Deferred Rent&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company records its costs under facility operating lease
 agreements as rent expense. Rent expense is recognized on a
 straight-line basis over the non-cancelable term of the operating
 lease. The difference between the actual amounts paid and amounts
 recorded as rent expense is recorded to deferred rent in the
 balance sheet.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_B3384125-8AD0-4B2C-BCAF-DA523544F2EB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Cash, cash equivalents, and marketable securities consist of
 financial instruments that potentially subject the Company to a
 concentration of credit risk to the extent of the fair value
 recorded in the balance sheet. The Company invests cash that is not
 required for immediate operating needs primarily in highly liquid
 instruments that bear minimal risk. The Company has established
 guidelines relating to the quality, diversification, and maturities
 of securities to enable the Company to manage its credit risk.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_3E844A1D-9905-4B69-B861-AA1D470336CB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;10. Related-Party Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company paid a former member of its Board of Directors, who is
 also a member of its Scientific and Clinical Advisory Boards, a
 total of $45,000 in the year ended December&amp;#xA0;31, 2013 and
 $15,000 for the three months ended March&amp;#xA0;31, 2014, in monthly
 cash retainers. The Company also issued options to purchase shares
 of common stock and incentive awards to this individual in his
 capacity as a member of its Scientific Advisory Board.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_AD1E1435-49BE-471A-8984-6EFC8D2E02DE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying interim condensed financial statements are
 unaudited. These unaudited interim financial statements have been
 prepared in accordance U.S. GAAP (&amp;#x201C;GAAP&amp;#x201D;) and following
 the requirements of the United States Securities and Exchange
 Commission (&amp;#x201C;SEC&amp;#x201D;) for interim reporting. As permitted
 under those rules, certain footnotes or other financial information
 that are normally required by GAAP can be condensed or omitted. In
 management&amp;#x2019;s opinion, the unaudited interim financial
 statements have been prepared on the same basis as the audited
 financial statements and include all adjustments, which include
 only normal recurring adjustments, necessary for the fair
 presentation of the Company&amp;#x2019;s financial position and its
 results of operations and comprehensive loss and its cash flows for
 periods presented. These statements do not include all disclosures
 required by GAAP and should be read in conjunction with the
 Company&amp;#x2019;s financial statements and accompanying notes for the
 fiscal year ended December&amp;#xA0;31, 2013, which is contained in the
 Company&amp;#x2019;s Annual Report on Form 10-K as filed with the SEC on
 March&amp;#xA0;31, 2014. The results for the three months ended
 March&amp;#xA0;31, 2014, are not necessarily indicative of results to
 be expected for the year or for any other period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The financial statements have been prepared in accordance with
 GAAP, which requires management to make estimates and assumptions
 that affect the amounts and disclosures reported in the financial
 statements and accompanying notes. Management bases its estimates
 on historical experience and on assumptions believed to be
 reasonable under the circumstances. The estimation process often
 may yield a range of potentially reasonable estimates of the
 ultimate future outcomes, and management must select an amount that
 falls within that range of reasonable estimates. Actual results
 could differ materially from those estimates. The Company believes
 significant judgment is involved in estimating stock-based
 compensation, accrued liabilities, and equity and liability
 instrument valuations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On September&amp;#xA0;30, 2013, the Company filed an amended and
 restated certificate of incorporation under which the
 Company&amp;#x2019;s preferred stock and common stock was reverse split
 on a 1-for-79.5 basis. The accompanying financial statements and
 notes to the financial statements, give retroactive effect to the
 reverse split for all periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s financial instruments consist of cash and cash
 equivalents, short-term marketable securities, accounts payable,
 accrued expenses, warrant liabilities and convertible notes. Fair
 value estimates of these instruments are made at a specific point
 in time, based on relevant market information. These estimates may
 be subjective in nature and involve uncertainties and matters of
 significant judgment and therefore cannot be determined with
 precision.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants at the
 measurement date. Assets and liabilities that are measured at fair
 value are reported using a three-level fair value hierarchy that
 prioritizes the inputs used to measure fair value. This hierarchy
 maximizes the use of observable inputs and maximizes the use of
 unobservable inputs and is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 1&amp;#x2014;Quoted prices in active markets for identical assets
 or liabilities that the Company has the ability to access at the
 measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 2&amp;#x2014;Inputs other than quoted prices in active markets
 that are observable for the asset or liability, either directly or
 indirectly.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Level 3&amp;#x2014;Inputs that are unobservable for the asset or
 liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The carrying amounts of financial instruments such as cash and cash
 equivalents, accounts payable, convertible notes, and accrued
 expenses approximate the related fair values due to the short-term
 maturities of these instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;As of March&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 39.5pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt and asset backed securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total assets measured at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total liabilities measured at fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Marketable securities consist of available-for-sale securities that
 are reported at fair value, with the related unrealized gains and
 losses included in accumulated other comprehensive income (loss), a
 component of stockholders&amp;#x2019; equity. The Company values cash
 equivalents and marketable securities using quoted market prices or
 alternative pricing sources and models utilizing observable market
 inputs and, as such, classifies cash equivalents and marketable
 securities within Level 1 or Level 2.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014, the Company held a Level 3 liability
 associated with warrants, issued in connection with the
 Company&amp;#x2019;s 2013 financing. The warrants are considered a
 liability and are valued using an option-pricing model, the inputs
 for which include exercise price of the warrants, market price of
 the underlying common shares, expected term, volatility based on a
 group of the Company&amp;#x2019;s peers and the risk-free rate
 corresponding to the expected term of the warrants. As of
 December&amp;#xA0;31, 2013, the Company also held a Level 3 liability
 associated with a forward contract which arose in connection with
 the Company&amp;#x2019;s November&amp;#xA0;22, 2013 execution of an equity
 purchase agreement with certain investors. The agreement required
 the Company to issue a fixed number of shares of common stock and
 warrants to purchase common stock at a predetermined price of $3.0
 million provided the Company completes the listing of its common
 stock on a public stock exchange. The forward contract&amp;#x2019;s fair
 value was determined upon execution as the difference between the
 present value of the equity proceeds to be received under the
 agreement less the fair value of the underlying securities. The
 forward contract liability is presented in the balance sheet as a
 component of accrued liabilities and is revalued at each reporting
 period until contract settlement which occurred on January&amp;#xA0;29,
 2014. The fair value of the underlying common stock and warrants
 were valued using an option-pricing model, the inputs of which are
 similar to those used in the valuation of the Company&amp;#x2019;s
 liability classified warrants. Changes to any of the inputs to the
 option-pricing models used by the Company can have a significant
 impact to the estimated fair value of the warrants and forward
 contract liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth an activity summary which includes
 the changes in the fair value of&amp;#xA0;the Company&apos;s&amp;#xA0;Level 3
 financial instruments (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Forward&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Contract&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance as of December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Issuance of financial instrument&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;443&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Settlement of financial instrument&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(443&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance as of March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The gains and losses from remeasurement of Level 3 financial
 liabilities are recorded through other expense, net on the
 accompanying statements of operations and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Cash, Cash Equivalents, and Marketable Securities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with a
 remaining maturity of 90 days or less at the time of purchase to be
 cash equivalents. Cash and cash equivalents consist of deposits
 with commercial banks in checking, interest-bearing, and demand
 money market accounts. The Company invests excess cash in
 marketable securities with high credit ratings. These securities
 consist primarily of corporate debt and asset-backed securities and
 are classified as &amp;#x201C;available-for-sale.&amp;#x201D; Management may
 liquidate any of these investments in order to meet the
 Company&amp;#x2019;s liquidity needs in the next year. Accordingly, any
 investments with contractual maturities greater than one year from
 the balance sheet date are classified as short-term in the balance
 sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Realized gains and losses from the sale of marketable securities,
 if any, are calculated using the specific identification method.
 Realized gains and losses and declines in value judged to be
 other-than-temporary are included in interest income or expense in
 the statements of operations. Unrealized holding gains and losses
 are reported in accumulated other comprehensive income (loss), in
 the balance sheet. To date, the Company has not recorded any
 impairment charges on its marketable securities related to
 other-than-temporary declines in market value. In determining
 whether a decline in market value is other-than-temporary, various
 factors are considered, including the cause, duration of time and
 severity of the impairment, any adverse changes in the
 investees&amp;#x2019; financial condition, and the Company&amp;#x2019;s
 intent and ability to hold the security for a period of time
 sufficient to allow for an anticipated recovery in market
 value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company is required to maintain compensating cash balances with
 financial institutions that provide the Company with its corporate
 credit cards. As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013,
 cash restricted under these arrangements was $100,000 and $155,000,
 respectively. These amounts are presented in other assets on the
 accompanying balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Cash, cash equivalents, and marketable securities consist of
 financial instruments that potentially subject the Company to a
 concentration of credit risk to the extent of the fair value
 recorded in the balance sheet. The Company invests cash that is not
 required for immediate operating needs primarily in highly liquid
 instruments that bear minimal risk. The Company has established
 guidelines relating to the quality, diversification, and maturities
 of securities to enable the Company to manage its credit risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment is stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization is
 calculated using the straight-line method, and the cost is
 amortized over the estimated useful lives of the respective assets,
 generally three to seven years. Leasehold improvements are
 amortized over the shorter of the useful lives or the
 non-cancelable term of the related lease. Maintenance and repair
 costs are charged as expense in the statements of operations and
 comprehensive income (loss) as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company reviews long-lived assets for impairment whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. An
 impairment loss is recognized if the estimated undiscounted future
 cash flow expected to result from the use and eventual disposition
 of an asset is less than the carrying amount. While the
 Company&amp;#x2019;s current and historical operating losses and cash
 flows are indicators of impairment, the Company believes the future
 cash flows to be received support the carrying value of its
 long-lived assets. Accordingly, the Company has not recognized any
 impairment losses as of March&amp;#xA0;31, 2014 and December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Deferred Rent&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company records its costs under facility operating lease
 agreements as rent expense. Rent expense is recognized on a
 straight-line basis over the non-cancelable term of the operating
 lease. The difference between the actual amounts paid and amounts
 recorded as rent expense is recorded to deferred rent in the
 balance sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Common Stock Warrant Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Warrants issued to common stock holders and lenders by the Company
 in conjunction with the 2013 financing were classified as
 liabilities in the accompanying balance sheets, as the terms for
 redemption of the underlying security were outside the
 Company&amp;#x2019;s control. The warrants were recorded at fair value
 using either the Black-Scholes option pricing model, probability
 weighted expected return model or a binomial model, depending on
 the characteristics of the warrants. The fair value of these
 warrants is re-measured at each financial reporting period with any
 changes in fair value being recognized as a component of other
 income (expense) in the accompanying condensed statements of
 operations and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses consist of costs incurred in
 identifying, developing, and testing product candidates. These
 expenses consist primarily of costs for research and development
 personnel, including: related stock-based compensation; contract
 research organizations and other third parties that assist in
 managing, monitoring, and analyzing clinical trials; investigator
 and site fees; laboratory services; consultants; contract
 manufacturing services; non-clinical studies, including materials;
 and allocated expenses, such as depreciation of assets, and
 facilities and information technology that support research and
 development activities. Research and development costs are expensed
 as incurred, including expenses that may or may not be reimbursed
 under research and development funding arrangements. Research and
 development expenses under collaboration agreements approximate the
 revenue recognized under such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The expenses related to clinical trials are based upon estimates of
 the services received and efforts expended pursuant to contracts
 with multiple research institutions and clinical research
 organizations (CROs) that conduct and manage clinical trials on
 behalf of the Company. Expenses related to clinical trials are
 accrued based upon the level of activity incurred under each
 contract as indicated by such factors as progress made against
 specified milestones or targets in each period, patient enrollment
 levels, and other trial activities as reported by CROs.
 Accordingly, the Company&amp;#x2019;s clinical trial accrual is
 dependent upon the timely and accurate reporting of expenses by
 clinical research organizations and other third-party
 vendors.&amp;#xA0;Payments made to third parties under these clinical
 trial arrangements in advance of the receipt of the related
 services are recorded as prepaid assets, depending on the terms of
 the agreement, until the services are rendered.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Employee and director stock-based compensation is measured at the
 grant date, based on the fair-value based measurements of the stock
 awards, and the portion that is ultimately expected to vest is
 recognized as an expense over the related vesting periods, net of
 estimated forfeitures. The Company calculates the fair-value based
 measurements of options using the Black-Scholes valuation model and
 the single-option approach and recognizes expense using the
 straight-line attribution method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Equity awards granted to non-employees are accounted for using the
 Black-Scholes valuation model to determine the fair value of such
 instruments. The fair value of equity awards granted to
 non-employees are re-measured over the related vesting period and
 amortized to expense as earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on differences between the financial reporting and
 the tax bases of assets and liabilities and are measured using
 enacted tax rates and laws that will be in effect when the
 differences are expected to reverse. A valuation allowance is
 recorded when it is more likely than not that all or part of a
 deferred tax asset will not be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The accounting guidance for uncertainty in income taxes prescribes
 a recognition threshold and measurement attribute criteria for the
 financial recognition and measurement of tax positions taken or
 expected to be taken in a tax return. For those benefits to be
 recognized, a tax position must be more likely than not to be
 sustained upon examination based on the technical merits of the
 position.The Company records interest related to income taxes, if
 any, as interest, and any penalties would be recorded as other
 expense in the statements of comprehensive income (loss). There was
 no interest or penalties related to income taxes recorded during
 the three months ended March&amp;#xA0;31, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Comprehensive Loss&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss includes net loss and net unrealized gains and
 losses on marketable securities, which are presented in a single
 continuous statement. Accumulated other comprehensive income (loss)
 is disclosed in the statements of redeemable convertible preferred
 stock and stockholders&amp;#x2019; equity (deficit), and is stated net
 of related tax effects, if any.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share of common stock is based on the weighted
 average number of shares of common stock outstanding equivalents
 during the period. Prior to the 2013 financing, in addition to
 common stock, the Company had preferred stock outstanding that
 contractually entitled the holder to participate in dividends and
 earnings of the Company. Accordingly, the Company applied the
 two-class method for calculating net loss per share. Under this
 method, all undistributed earnings are allocated first to the
 preferred stockholders based on their contractual right to
 dividends. This right is calculated on a pro rated basis for the
 portion of the period the preferred shares were outstanding. On
 September&amp;#xA0;30, 2013, in connection with the 2013 financing, all
 outstanding shares of the Company&amp;#x2019;s preferred stock were
 converted into shares of the Company&amp;#x2019;s common stock.
 Accordingly, no preferred stock was outstanding during the three
 months ended March&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Diluted net loss per share of common stock is calculated using the
 more dilutive of the two approaches: one,
 &amp;#x201C;as-converted&amp;#x201D; method, under which the weighted average
 number of common stock shares outstanding during the period is
 adjusted to include the assumed conversion of redeemable
 convertible preferred stock at the beginning of the period, and the
 other, the &amp;#x201C;two-class&amp;#x201D; method as described above. Under
 either approach, the weighted average number of shares outstanding
 is also adjusted to include the assumed exercises of stock options
 and warrants, if dilutive. For the three months ended
 March&amp;#xA0;31, 2014 and 2013, diluted net loss per share is the
 same as basic, as any adjustments would have been
 anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months
 Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;(unaudited)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants for common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,848,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;906,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Redeemable convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;661,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,755,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;786,956&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_1_3">2755283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_7B13DF84-8DDE-4D9B-B031-B63403B9F0C8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company reviews long-lived assets for impairment whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. An
 impairment loss is recognized if the estimated undiscounted future
 cash flow expected to result from the use and eventual disposition
 of an asset is less than the carrying amount. While the
 Company&amp;#x2019;s current and historical operating losses and cash
 flows are indicators of impairment, the Company believes the future
 cash flows to be received support the carrying value of its
 long-lived assets. Accordingly, the Company has not recognized any
 impairment losses as of March&amp;#xA0;31, 2014 and December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_BE67F045-2BC3-41C8-A755-F6A341043668_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Employee and director stock-based compensation expense recorded was
 as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;568&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;714&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_2C1909C6-7331-447F-B171-8FF60AA83B79_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The financial statements have been prepared in accordance with
 GAAP, which requires management to make estimates and assumptions
 that affect the amounts and disclosures reported in the financial
 statements and accompanying notes. Management bases its estimates
 on historical experience and on assumptions believed to be
 reasonable under the circumstances. The estimation process often
 may yield a range of potentially reasonable estimates of the
 ultimate future outcomes, and management must select an amount that
 falls within that range of reasonable estimates. Actual results
 could differ materially from those estimates. The Company believes
 significant judgment is involved in estimating stock-based
 compensation, accrued liabilities, and equity and liability
 instrument valuations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_A48CD121-2C3A-4E75-8D1C-6E9CC02DE888_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;1. Organization and Description of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 CymaBay Therapeutics, Inc. (the &amp;#x201C;Company&amp;#x201D; or
 &amp;#x201C;CymaBay&amp;#x201D;) is a biopharmaceutical company focused on
 developing therapies to treat metabolic and rare diseases with high
 unmet need. The Company&amp;#x2019;s lead product candidate,
 arhalofenate, is being developed for the treatment of gout. The
 Company&amp;#x2019;s second product candidate, MBX-8025, is being
 considered for the treatment of certain orphan diseases. The
 Company was incorporated in Delaware in October 1988 as Transtech
 Corporation. The Company&amp;#x2019;s headquarters and operations are
 located in Newark, California and it operates in one segment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;30, 2013, the Company sold shares of its common
 stock and warrants to purchase shares of its common stock in a
 private placement for aggregate gross proceeds of $26.8 million,
 and raised an additional $5.0 million in venture debt financing
 pursuant to a $10.0 million loan agreement which it entered into
 simultaneously with the private placement on September&amp;#xA0;30,
 2013, resulting in aggregate net proceeds to the Company of $28.8
 million after deducting placement agent fees and estimated offering
 expenses. At the same time the Company issued shares of its common
 stock in cancellation of approximately $16.9 million of debt owed
 to the holder of that debt. On October&amp;#xA0;31, 2013, the Company
 sold additional shares of its common stock and warrants to purchase
 shares of its common stock, which sales are also part of the
 private placement, for net proceeds of $2.2 million after deducting
 placement agent fees and estimated offering expenses. Further, on
 November&amp;#xA0;22, 2013, the Company entered into an agreement with
 investors to purchase shares of its common stock and warrants to
 purchase shares of its common stock as part of the private
 placement for net proceeds of $2.7 million, which sales occurred on
 January&amp;#xA0;29, 2014, after the listing of the Company&amp;#x2019;s
 common stock on the over-the-counter market. The Company refers to
 the private placement, the venture debt financing and the issuance
 of&amp;#xA0;the Company&apos;s&amp;#xA0;common stock in cancellation of the
 $16.9 million of debt as the 2013 financing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has incurred net operating losses and negative cash
 flows from operations since its inception. During the three months
 ended March&amp;#xA0;31, 2014, the Company incurred a loss from
 operations of $10.1 million and used $5.0 million of cash in
 operations. At March&amp;#xA0;31, 2014, the Company had an accumulated
 deficit of $358.9 million. CymaBay expects to incur increased
 research and development expenses as it continues to study its
 product candidates in clinical trials.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_6E31D4CC-2459-4838-9969-E76DEDDB8169_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share of common stock is based on the weighted
 average number of shares of common stock outstanding equivalents
 during the period. Prior to the 2013 financing, in addition to
 common stock, the Company had preferred stock outstanding that
 contractually entitled the holder to participate in dividends and
 earnings of the Company. Accordingly, the Company applied the
 two-class method for calculating net loss per share. Under this
 method, all undistributed earnings are allocated first to the
 preferred stockholders based on their contractual right to
 dividends. This right is calculated on a pro rated basis for the
 portion of the period the preferred shares were outstanding. On
 September&amp;#xA0;30, 2013, in connection with the 2013 financing, all
 outstanding shares of the Company&amp;#x2019;s preferred stock were
 converted into shares of the Company&amp;#x2019;s common stock.
 Accordingly, no preferred stock was outstanding during the three
 months ended March&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Diluted net loss per share of common stock is calculated using the
 more dilutive of the two approaches: one,
 &amp;#x201C;as-converted&amp;#x201D; method, under which the weighted average
 number of common stock shares outstanding during the period is
 adjusted to include the assumed conversion of redeemable
 convertible preferred stock at the beginning of the period, and the
 other, the &amp;#x201C;two-class&amp;#x201D; method as described above. Under
 either approach, the weighted average number of shares outstanding
 is also adjusted to include the assumed exercises of stock options
 and warrants, if dilutive. For the three months ended
 March&amp;#xA0;31, 2014 and 2013, diluted net loss per share is the
 same as basic, as any adjustments would have been
 anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months
 Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;(unaudited)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants for common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,848,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;906,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Redeemable convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;661,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,755,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;786,956&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_A4A750A2-417D-497B-861D-B70FB785C6FD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company utilizes the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on differences between the financial reporting and
 the tax bases of assets and liabilities and are measured using
 enacted tax rates and laws that will be in effect when the
 differences are expected to reverse. A valuation allowance is
 recorded when it is more likely than not that all or part of a
 deferred tax asset will not be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The accounting guidance for uncertainty in income taxes prescribes
 a recognition threshold and measurement attribute criteria for the
 financial recognition and measurement of tax positions taken or
 expected to be taken in a tax return. For those benefits to be
 recognized, a tax position must be more likely than not to be
 sustained upon examination based on the technical merits of the
 position.The Company records interest related to income taxes, if
 any, as interest, and any penalties would be recorded as other
 expense in the statements of comprehensive income (loss). There was
 no interest or penalties related to income taxes recorded during
 the three months ended March&amp;#xA0;31, 2014 and 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_15">-10061000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_11">-10062000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_8">-4775000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_6">12000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_13">211000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_13">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_4">-5115000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_12">1512000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:InterestPaid contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_30">109000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_11">22000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:NetIncomeLoss contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_9">-10062000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_7">-49000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_14">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:IncreaseDecreaseInContractReceivablesNet contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_10">58000</us-gaap:IncreaseDecreaseInContractReceivablesNet>
  <us-gaap:PaymentsForRoyalties contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1_4">0</us-gaap:PaymentsForRoyalties>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_20">32000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_8">4784000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_24">2402000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_4">2000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:SponsorFees contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_82CA1F0E-478F-41F6-A8D7-ECDEDB7238B5_1_0">15000</us-gaap:SponsorFees>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_2">2500000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_25">2402000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_5">714000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_26">-2059000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-5" id="id_3866818_7939CD88-5560-4A73-9693-2812E7A35F9F_1_0">200000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_15">830000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_7">184000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_14">372000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_22">550000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_1">2615000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_17">3000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_724A0AAE-34E1-4715-9AB1-454AFBD650C6_1_0">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_3">3000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_21">582000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_FF6984E4-1568-4E87-8AC3-12C08D8CCFC6_1_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_16">26000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:OperatingExpenses contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_3">5115000</us-gaap:OperatingExpenses>
  <cyma:ReservedSharesOfCommonStockForIssuanceTableTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_1B68879E-A28D-49A9-A27E-94FA783133AC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013, the Company
 had reserved shares of authorized but unissued common stock as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,848,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,742,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equity incentive plans&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,050,047&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;577,294&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total reserved shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,898,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,320,021&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</cyma:ReservedSharesOfCommonStockForIssuanceTableTextBlock>
  <cyma:ReverseStockSplitPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_48098E20-A264-4A0C-B598-E080978AB040_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On September&amp;#xA0;30, 2013, the Company filed an amended and
 restated certificates of incorporation under which the
 Company&amp;#x2019;s preferred stock and common stock was reverse split
 on a 1-for-79.5 basis. The accompanying financial statements and
 notes to the financial statements, give retroactive effect to the
 reverse split for all periods presented.&lt;/p&gt;
 &lt;/div&gt;</cyma:ReverseStockSplitPolicyTextBlock>
  <cyma:ShareBasedCompensationExpense contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_1_2">714000</cyma:ShareBasedCompensationExpense>
  <cyma:DevelopmentPayment contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1_3">0</cyma:DevelopmentPayment>
  <cyma:AmortizationOfPremiumOnMarketableSecurities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_6">71000</cyma:AmortizationOfPremiumOnMarketableSecurities>
  <cyma:LicenseAgreementDate contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1_0">1998-06-30</cyma:LicenseAgreementDate>
  <cyma:CashEquivalentMaturityDescription contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_60F60CAD-B28D-457E-9621-1BE53414F621_1_0">90 days or less</cyma:CashEquivalentMaturityDescription>
  <cyma:ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_42449116-896E-45E8-9C1F-CBCA6DF3E4C1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table sets forth an activity summary which includes
 the changes in the fair value of&amp;#xA0;the Company&apos;s&amp;#xA0;Level 3
 financial instruments (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Forward&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Contract&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance as of December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Issuance of financial instrument&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;443&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Settlement of financial instrument&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(443&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance as of March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</cyma:ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock>
  <cyma:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="pure" decimals="2" id="id_3866818_0F4ACE9A-B6D5-4455-9739-C59749B17A4D_1_5">0.02</cyma:RoyaltyPercentageBasedOnNetSales>
  <cyma:WeightedAverageNumberOfBasicAndDilutedSharesOutstanding contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_3866818_E002FCFA-DC3F-4FC1-93AD-620E044FB476_1_17">9873687</cyma:WeightedAverageNumberOfBasicAndDilutedSharesOutstanding>
  <cyma:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_F57CCB3D-0F2B-43C7-A231-3A8F9D63D332_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2014, in connection with the 2013 financing, the Company
 completed the sale of common stock for aggregate proceeds of $3.0
 million and as part of this transaction, the Company issued
 five-year warrants to purchase 120,800 shares of common stock at an
 exercise price of $5.75 per share. Due to certain provisions, the
 Company is required to account for the warrants issued as a
 liability at fair value. In addition, the estimated liability
 related to the warrants is required to be revalued at each
 reporting period until the earlier of the exercise of the warrants,
 at which time the liability will be reclassified to
 stockholders&amp;#x2019; equity, or expiration of the warrants. At
 issuance date, the fair value of the total warrant liability was
 estimated to be $0.4 million using a binomial lattice
 options-pricing model.&lt;/p&gt;
 &lt;/div&gt;</cyma:StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock>
  <cyma:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_BA6C2A99-BAFA-4F22-B6C5-29749643DA03_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;5. Collaboration and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In August&amp;#xA0;2006, CymaBay entered into a strategic alliance with
 Ortho-McNeil, Inc., a subsidiary of Johnson and Johnson. As part of
 the alliance, Janssen Pharmaceutical NV, an affiliate of
 Ortho-McNeil, granted to CymaBay an exclusive worldwide,
 royalty-bearing license to MBX-8025 and certain other
 PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;compounds (the
 &amp;#x201C;PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products&amp;#x201D;) with the right
 to grant sublicenses to third parties to make, use and sell such
 PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products. Under
 the terms of the agreement, CymaBay has full control and
 responsibility over the research, development and registration of
 any PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products
 and is required to use diligent efforts to conduct all such
 activities. Janssen has the sole responsibility for the
 preparation, filing, prosecution, maintenance of, and defense of
 the patents with respect to, the PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products. Janssen has a right
 of first negotiation under the agreement to license a particular
 PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Product from
 CymaBay in the event that CymaBay elects to seek a third party
 corporate partner for the research, development, promotion, and/or
 commercialization of such PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products. Under the terms of
 the agreement Janssen is entitled to receive up to an 8% royalty on
 net sales of PPAR&lt;font style="FONT-FAMILY: SYMBOL"&gt;d&lt;/font&gt;&amp;#xA0;Products. No payments were made
 and no royalties were received under this agreement during the
 three months ended March&amp;#xA0;31, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In June&amp;#xA0;2010, CymaBay entered into two development and license
 agreements with Janssen Pharmaceuticals, Inc. (Janssen), a
 subsidiary of Johnson and Johnson, to further develop and discover
 undisclosed metabolic disease target agonists for the treatment of
 T2DM and other disorders and received a one-time nonrefundable
 technology access fee related to the agreements. CymaBay is also
 eligible to receive up to $228 million in contingent payments if
 certain development and commercial events are achieved as well as
 royalties on worldwide net sales of products. No such payments have
 been made to date. Under the terms of the agreements, Janssen has
 full control and responsibility over the research, development and
 registration of any products developed and/or discovered from the
 metabolic disease targets and is required to use diligent efforts
 to conduct all such activities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In June 1998, the Company entered into a license agreement with
 DiaTex, Inc. (DiaTex) relating to products containing halofenate,
 its enantiomers, derivatives, and analogs (the licensed products).
 The license agreement provides that DiaTex and the Company are
 joint owners of all of the patents and patent applications covering
 the licensed products and methods of producing or using such
 compounds, as well as certain other know-how (the covered IP). As
 part of the license agreement, the Company received an exclusive
 worldwide license, including as to DiaTex, to use the covered IP to
 develop and commercialize the licensed products. The Company also
 retained the right to sub-license the covered IP. The license
 agreement contains a $2,000 per month license fee as well as a
 requirement to make additional payments for development
 achievements and royalty payments on any sales of licensed
 products. Pursuant to the license agreement, all of the
 Company&amp;#x2019;s patents and patent applications related to
 arhalofenate, its use, and production are jointly owned with
 DiaTex. DiaTex is entitled to up to $0.8 million for the future
 development of arhalofenate, as well as a 2% royalty payment on net
 sales of products containing arhalofenate. No development payments
 were made in the three months ended March&amp;#xA0;31, 2014 and 2013,
 and no royalties have been paid to date.&lt;/p&gt;
 &lt;/div&gt;</cyma:CollaborationAndLicenseAgreementsDisclosureTextBlock>
  <cyma:CommonStockWarrantLiabilityPolicyTextBlock contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" id="id_3866818_20AC5BC4-4452-4686-8E4F-33259F2FC886_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Common Stock Warrant Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Warrants issued to common stock holders and lenders by the Company
 in conjunction with the 2013 financing were classified as
 liabilities in the accompanying balance sheets, as the terms for
 redemption of the underlying security were outside the
 Company&amp;#x2019;s control. The warrants were recorded at fair value
 using either the Black-Scholes option pricing model, probability
 weighted expected return model or a binomial model, depending on
 the characteristics of the warrants. The fair value of these
 warrants is re-measured at each financial reporting period with any
 changes in fair value being recognized as a component of other
 income (expense) in the accompanying condensed statements of
 operations and comprehensive loss.&lt;/p&gt;
 &lt;/div&gt;</cyma:CommonStockWarrantLiabilityPolicyTextBlock>
  <cyma:CashlessExerciseOfCommonStockForWarrantsLiability contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_33">55000</cyma:CashlessExerciseOfCommonStockForWarrantsLiability>
  <cyma:IssuanceOfCommonStockWarrantsToInvestors contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_32">443000</cyma:IssuanceOfCommonStockWarrantsToInvestors>
  <cyma:FixedAssetsInAccruedExpenses contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_31">28000</cyma:FixedAssetsInAccruedExpenses>
  <cyma:NoncashIssuanceCostsIncurredInCommonStockFinancing contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_3866818_14E82886-DDAB-4BE9-BF9D-3D14477EE75B_1_34">453000</cyma:NoncashIssuanceCostsIncurredInCommonStockFinancing>
  <cyma:LicenseAgreementDate contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1211839" id="id_3866818_6E4043B8-6992-4A00-875B-A897A8EFE859_1001_0">2010-06-30</cyma:LicenseAgreementDate>
  <cyma:NumberOfDevelopmentAndLicenseAgreements contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1211839" unitRef="Agreement" decimals="0" id="id_3866818_6E4043B8-6992-4A00-875B-A897A8EFE859_1001_1">2</cyma:NumberOfDevelopmentAndLicenseAgreements>
  <us-gaap:ProceedsFromRoyaltiesReceived contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243" unitRef="iso4217_USD" decimals="0" id="id_3866818_C343AD4A-138E-4069-B12D-0CAA3A42E5FC_1_2">0</us-gaap:ProceedsFromRoyaltiesReceived>
  <cyma:PaymentsMadeUnderLicenseAgreement contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243" unitRef="iso4217_USD" decimals="0" id="id_3866818_C343AD4A-138E-4069-B12D-0CAA3A42E5FC_1_1">0</cyma:PaymentsMadeUnderLicenseAgreement>
  <cyma:CollaborativeArrangementDateOfAgreement contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243" id="id_3866818_95D12E39-C9B9-4F3B-822F-9FE8E20194AF_1001_0">2006-08-31</cyma:CollaborativeArrangementDateOfAgreement>
  <cyma:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243_926437x923140" unitRef="pure" decimals="2" id="id_3866818_C343AD4A-138E-4069-B12D-0CAA3A42E5FC_1001_0">0.08</cyma:RoyaltyPercentageBasedOnNetSales>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_923791x1144362" unitRef="iso4217_USD" decimals="-5" id="id_3866818_DBB49C2B-CE41-4256-A1DA-187BB2E6AD6E_1001_1">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <cyma:ClassOfWarrantOrRightTerm contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_923791x1144362" id="id_3866818_DBB49C2B-CE41-4256-A1DA-187BB2E6AD6E_1001_3">P5Y</cyma:ClassOfWarrantOrRightTerm>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_926437x923140" id="id_3866818_EAA02049-4C87-43AA-AEF4-FC0B71E0AA79_1001_1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_926437x932953" id="id_3866818_EAA02049-4C87-43AA-AEF4-FC0B71E0AA79_2001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_1001_1">568000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_3866818_390B96BE-1F84-4751-A08A-0E48F0496C80_2001_0">146000</us-gaap:ShareBasedCompensation>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927111x925633_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_1_1">443000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927111x925633_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_1_3">55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927111x925633_929790x929831" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_1_2">-4784000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927592x929614" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_1001_0">1848487</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_927592x930643" unitRef="shares" decimals="INF" id="id_3866818_CD8E0B9E-EC25-480A-9223-868C209B41CA_2001_1">906796</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_929790x929831_932336x929612" unitRef="iso4217_USD" xsi:nil="true" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_2_1" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_929790x929831_932336x929612" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_2_3">443000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE98833---1410-Q0002_STD_90_20140331_0_929790x929831_932336x929612" unitRef="iso4217_USD" decimals="-3" id="id_3866818_1FDECC0C-6262-468A-8908-D9175B09C209_2_2">10000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_929790x929831_932336x929612">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_927111x925633_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_923791x1144362">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cyma:WarrantsOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cyma:OrthoMcneilIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1264243">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cyma:OrthoMcneilIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0_921954x1211839">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cyma:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x932152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0_921954x1264243">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cyma:OrthoMcneilIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20130331_0_926396x1224362_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20130331_0_926396x1224360_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20090731_0_926396x1224362">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-07-01</startDate>
      <endDate>2009-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20080331_0_926396x1224358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FirstIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-03-01</startDate>
      <endDate>2008-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20131031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20130731_0_926396x1224362_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20130731_0_926396x1224360_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20120131_0_926396x1224362_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_31_20120131_0_926396x1224360_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_30_20130930_0_930809x1165861">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cyma:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_30_20130930_0_926437x923140_930809x1165861">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cyma:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_30_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_30_20080930_0_926396x1224359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:SecondIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-09-01</startDate>
      <endDate>2008-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_3_20130930_0_926396x1202104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FacilityLoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-28</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_3_20130930_0_924420x1116164_924791x1056074_926396x1202104_928628x1008215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cyma:WallStreetJournalPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FacilityLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cyma:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">cyma:ScenarioTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-28</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_3_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-09-28</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_3_20131122_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-11-20</startDate>
      <endDate>2013-11-22</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_3_20131108_0_926744x929485">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-11-06</startDate>
      <endDate>2013-11-08</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_28_20090228_0_926396x1224360">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-02-01</startDate>
      <endDate>2009-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_932040x980834">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cyma:CommonStockWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_932040x974512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cyma:EquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x964907">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cyma:PurchasedSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_929865x1125873">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cyma:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_929790x929831_932336x929612">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0_927111x925633_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20101231_0_927592x929729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_932040x980834">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cyma:CommonStockWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_932040x974512">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cyma:EquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_930809x1165861">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cyma:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x964907">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cyma:PurchasedSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929865x1125873">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cyma:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x929831_932336x929612">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x925633_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x1038552_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cyma:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_927111x1038552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cyma:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x932359_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x932359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x1256770_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cyma:CorporateDebtAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_926956x1256770">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cyma:CorporateDebtAndAssetBackedSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_923791x1144362">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cyma:WarrantsOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0_921954x1211839">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cyma:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0_930809x1165861">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cyma:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0_926396x1202104_928628x1104289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FacilityLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cyma:FirstTrancheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0_926396x1202104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FacilityLoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0_924791x995488_926396x1202104_928628x1008215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FacilityLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">cyma:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">cyma:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0_923791x1126038">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cyma:WarrantsTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20080930_0_926396x1224359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:SecondIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-09-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20090731_0_927592x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-07-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20090731_0_926396x1224362">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-07-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20060620_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2006-06-20</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_19980630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>1998-06-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20080331_0_926396x1224358">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FirstIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-03-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20140430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2014-04-30</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131122_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2013-11-22</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20131031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20120131_0_927592x930400_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20120131_0_926396x1224362_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:FourthIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20120131_0_926396x1224360_931308x954129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cyma:AsAmendedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20090228_0_927592x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-02-28</instant>
    </period>
  </context>
  <context id="eol_PE98833---1410-Q0002_STD_0_20090228_0_926396x1224360">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cyma:ThirdIssuanceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-02-28</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_Warrant">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>cyma:Warrant</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Agreement">
    <measure>cyma:Agreement</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cyma-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:cyma="http://imetrix.edgar-online.com/20140331"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://imetrix.edgar-online.com/20140331"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>106 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>107 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" id="Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock">
        <link:definition>109 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock">
        <link:definition>110 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
        <link:definition>111 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>112 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>114 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>115 - Disclosure - Stock Plans and Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>116 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
        <link:definition>117 - Disclosure - Organization and Description of Business (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>118 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables">
        <link:definition>119 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>120 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>121 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>122 - Disclosure - Stock Plans and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" id="DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
        <link:definition>123 - Disclosure - Organization and Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>124 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis">
        <link:definition>125 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability">
        <link:definition>126 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Warrant Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1">
        <link:definition>127 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare" id="DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare">
        <link:definition>128 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment" id="DisclosureCertainBalanceSheetItemsPropertyAndEquipment">
        <link:definition>129 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities" id="DisclosureCertainBalanceSheetItemsAccruedLiabilities">
        <link:definition>130 - Disclosure - Certain Balance Sheet Items - Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation" id="DisclosureCommonStockWarrantsAdditionalInformation">
        <link:definition>131 - Disclosure - Common Stock Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
        <link:definition>132 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation" id="DisclosureDebtAdditionalInformation">
        <link:definition>133 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>134 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments">
        <link:definition>135 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation" id="DisclosureStockholdersEquityAdditionalInformation">
        <link:definition>136 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock" id="DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock">
        <link:definition>137 - Disclosure - Stockholders' Equity - Reserved Shares of Authorized but Unissued Common Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation" id="DisclosureStockPlansAndStockBasedCompensationAdditionalInformation">
        <link:definition>138 - Disclosure - Stock Plans and Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense" id="DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense">
        <link:definition>139 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>140 - Disclosure - Related-Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="cyma-20140331_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="cyma-20140331_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="cyma-20140331_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="cyma-20140331_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedExpensesCurrent" id="cyma_AccruedExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedLiabilityOfDerivativeInInstruments" id="cyma_AccruedLiabilityOfDerivativeInInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmortizationOfPremiumOnMarketableSecurities" id="cyma_AmortizationOfPremiumOnMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmortizationPeriod" id="cyma_AmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AreaOfOfficeSpace" id="cyma_AreaOfOfficeSpace" type="num:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AsAmendedMember" id="cyma_AsAmendedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashEquivalentMaturityDescription" id="cyma_CashEquivalentMaturityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashlessExerciseOfCommonStockForWarrantsLiability" id="cyma_CashlessExerciseOfCommonStockForWarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightTerm" id="cyma_ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsDisclosureTextBlock" id="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationsAndLicenseAgreementsLineItems" id="cyma_CollaborationsAndLicenseAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationsAndLicenseAgreementsTable" id="cyma_CollaborationsAndLicenseAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CollaborativeArrangementDateOfAgreement" id="cyma_CollaborativeArrangementDateOfAgreement" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockWarrantLiabilityPolicyTextBlock" id="cyma_CommonStockWarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockWarrantMember" id="cyma_CommonStockWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentPaymentsReceivableBasedOnDevelopmentEvents" id="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CorporateDebtAndAssetBackedSecuritiesMember" id="cyma_CorporateDebtAndAssetBackedSecuritiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentFairValueCarryingValueAbstract" id="cyma_DebtInstrumentFairValueCarryingValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentPayment" id="cyma_DevelopmentPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="cyma_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanMember" id="cyma_EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanTwoThousandAndThirteenMember" id="cyma_EquityIncentivePlanTwoThousandAndThirteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FacilityLoanAgreementMember" id="cyma_FacilityLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstIssuanceMember" id="cyma_FirstIssuanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstTrancheMember" id="cyma_FirstTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FixedAssetsInAccruedExpenses" id="cyma_FixedAssetsInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FourthIssuanceMember" id="cyma_FourthIssuanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IndemnificationLiability" id="cyma_IndemnificationLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockWarrantsToInvestors" id="cyma_IssuanceOfCommonStockWarrantsToInvestors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JanssenPharmaceuticalsIncMember" id="cyma_JanssenPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseStartDate" id="cyma_LeaseStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDate" id="cyma_LicenseAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" id="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MonthlyLicenseFees" id="cyma_MonthlyLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromIssuanceOfPrivatePlacement" id="cyma_NetProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashIssuanceCostsIncurredInCommonStockFinancing" id="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfDevelopmentAndLicenseAgreements" id="cyma_NumberOfDevelopmentAndLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeAndComputerEquipmentMember" id="cyma_OfficeAndComputerEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrthoMcneilIncMember" id="cyma_OrthoMcneilIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsMadeUnderLicenseAgreement" id="cyma_PaymentsMadeUnderLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" id="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchasedCommonStockAndCommonStockWarrantsCarryingValue" id="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchasedSoftwareMember" id="cyma_PurchasedSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReservedSharesOfCommonStockForIssuanceTableTextBlock" id="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseStockSplitPolicyTextBlock" id="cyma_ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyPercentageBasedOnNetSales" id="cyma_RoyaltyPercentageBasedOnNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioOneMember" id="cyma_ScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioTwoMember" id="cyma_ScenarioTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" id="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondIssuanceMember" id="cyma_SecondIssuanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondTrancheMember" id="cyma_SecondTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" id="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" id="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationExpense" id="cyma_ShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShortTermInvestmentContractualMaturity" id="cyma_ShortTermInvestmentContractualMaturity" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" id="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodAmountForCancellationOfDebt" id="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdIssuanceMember" id="cyma_ThirdIssuanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WallStreetJournalPrimeRateMember" id="cyma_WallStreetJournalPrimeRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantLiabilityMember" id="cyma_WarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsOneMember" id="cyma_WarrantsOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsToPurchaseOfCommonStockShares" id="cyma_WarrantsToPurchaseOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsTwoMember" id="cyma_WarrantsTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" id="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cyma-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsPropertyAndEquipment" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommonStockWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLineOfCredit" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationOfPremiumOnMarketableSecurities" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cyma_AmortizationOfPremiumOnMarketableSecurities" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractReceivablesNet" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedExpensesCurrent" xlink:label="cyma_AccruedExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedLiabilityOfDerivativeInInstruments" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cyma_AccruedExpensesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cyma_AccruedLiabilityOfDerivativeInInstruments" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cyma-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsPropertyAndEquipment" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommonStockWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CorporateDebtAndAssetBackedSecuritiesMember" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantLiabilityMember" xlink:label="cyma_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="cyma_CorporateDebtAndAssetBackedSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="cyma_WarrantLiabilityMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForwardContractsMember" xlink:label="us-gaap_ForwardContractsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="us-gaap_WarrantsNotSettleableInCashMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ForwardContractsMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="100.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantsNotSettleableInCashMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OfficeAndComputerEquipmentMember" xlink:label="cyma_OfficeAndComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PurchasedSoftwareMember" xlink:label="cyma_PurchasedSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cyma_OfficeAndComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cyma_PurchasedSoftwareMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ClassOfWarrantOrRightTerm" xlink:label="cyma_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsOneMember" xlink:label="cyma_WarrantsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cyma_WarrantsOneMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="cyma_ClassOfWarrantOrRightTerm" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsTable" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborativeArrangementDateOfAgreement" xlink:label="cyma_CollaborativeArrangementDateOfAgreement"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DevelopmentPayment" xlink:label="cyma_DevelopmentPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_JanssenPharmaceuticalsIncMember" xlink:label="cyma_JanssenPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAgreementDate" xlink:label="cyma_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_MonthlyLicenseFees" xlink:label="cyma_MonthlyLicenseFees"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NumberOfDevelopmentAndLicenseAgreements" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OrthoMcneilIncMember" xlink:label="cyma_OrthoMcneilIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PaymentsMadeUnderLicenseAgreement" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_RoyaltyPercentageBasedOnNetSales" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_CollaborationsAndLicenseAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_CollaborativeArrangementDateOfAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_RoyaltyPercentageBasedOnNetSales" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_PaymentsMadeUnderLicenseAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_LicenseAgreementDate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_NumberOfDevelopmentAndLicenseAgreements" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_MonthlyLicenseFees" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_DevelopmentPayment" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cyma_OrthoMcneilIncMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="cyma_JanssenPharmaceuticalsIncMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationPeriod" xlink:label="cyma_AmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AsAmendedMember" xlink:label="cyma_AsAmendedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FacilityLoanAgreementMember" xlink:label="cyma_FacilityLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstIssuanceMember" xlink:label="cyma_FirstIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstTrancheMember" xlink:label="cyma_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FourthIssuanceMember" xlink:label="cyma_FourthIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioOneMember" xlink:label="cyma_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioTwoMember" xlink:label="cyma_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondIssuanceMember" xlink:label="cyma_SecondIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondTrancheMember" xlink:label="cyma_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ThirdIssuanceMember" xlink:label="cyma_ThirdIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WallStreetJournalPrimeRateMember" xlink:label="cyma_WallStreetJournalPrimeRateMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsTwoMember" xlink:label="cyma_WarrantsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cyma_WarrantsTwoMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cyma_WallStreetJournalPrimeRateMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cyma_AmortizationPeriod" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FirstIssuanceMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_SecondIssuanceMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_ThirdIssuanceMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FourthIssuanceMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FacilityLoanAgreementMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementScenarioAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cyma_AsAmendedMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cyma_SecondTrancheMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cyma_FirstTrancheMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cyma_ScenarioOneMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cyma_ScenarioTwoMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AreaOfOfficeSpace" xlink:label="cyma_AreaOfOfficeSpace"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_IndemnificationLiability" xlink:label="cyma_IndemnificationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LeaseStartDate" xlink:label="cyma_LeaseStartDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementAxis" xlink:label="us-gaap_PartiesToContractualArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementMember" xlink:label="us-gaap_PartiesToContractualArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementMember" xlink:label="us-gaap_PartiesToContractualArrangementMember_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_LeaseStartDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_AreaOfOfficeSpace" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_CapitalLeaseObligations" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_IndemnificationLiability" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PartiesToContractualArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PartiesToContractualArrangementAxis" xlink:to="us-gaap_PartiesToContractualArrangementMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PartiesToContractualArrangementAxis" xlink:to="us-gaap_PartiesToContractualArrangementMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PartiesToContractualArrangementMember" xlink:to="us-gaap_LeaseAgreementsMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsToPurchaseOfCommonStockShares" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cyma_WarrantsToPurchaseOfCommonStockShares" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cyma_NetProceedsFromIssuanceOfPrivatePlacement" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CommonStockWarrantMember" xlink:label="cyma_CommonStockWarrantMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanMember" xlink:label="cyma_EquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cyma_CommonStockWarrantMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cyma_EquityIncentivePlanMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cyma_EquityIncentivePlanTwoThousandAndThirteenMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationExpense" xlink:label="cyma_ShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="cyma_ShareBasedCompensationExpense" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cyma-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3866818_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3866818_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3866818_933775_1_1">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3866818_933775_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_3866818_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_3866818_938700_2_1">Contract receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" id="id_3866818_935707_1_1">Accretion Amortization Of Discounts And Premiums Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" id="id_3866818_935707_14_1">Non-cash interest associated with debt discount accretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedExpensesCurrent" xlink:label="cyma_AccruedExpensesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AccruedExpensesCurrent_lbl" xml:lang="en-US" id="id_3866818_961402_3_1">Accrued Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AccruedExpensesCurrent_lbl" xml:lang="en-US" id="id_3866818_961402_1_1">Accrued Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AccruedExpensesCurrent_lbl" xml:lang="en-US" id="id_3866818_961402_2_1">Accrued pre-clinical and clinical trial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AccruedExpensesCurrent" xlink:to="cyma_AccruedExpensesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_933113_1_1">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_933113_2_1">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_933113_6_1">Total accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedLiabilityOfDerivativeInInstruments" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments_lbl" xml:lang="en-US" id="id_3866818_1053590_3_1">Accrued Liability Of Derivative In Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments_lbl" xml:lang="en-US" id="id_3866818_1053590_1_1">Accrued Liability Of Derivative In Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments_lbl" xml:lang="en-US" id="id_3866818_1053590_2_1">Forward contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AccruedLiabilityOfDerivativeInInstruments" xlink:to="cyma_AccruedLiabilityOfDerivativeInInstruments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_3866818_933907_1_1">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_3866818_933907_2_1">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3866818_933479_1_1">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3866818_933479_14_1">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3866818_934223_1_1">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3866818_934223_2_1">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3866818_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3866818_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_929248_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3866818_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3866818_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationOfPremiumOnMarketableSecurities" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities_lbl" xml:lang="en-US" id="id_3866818_1011798_3_1">Amortization Of Premium On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities_lbl" xml:lang="en-US" id="id_3866818_1011798_1_1">Amortization Of Premium On Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities_lbl" xml:lang="en-US" id="id_3866818_1011798_2_1">Amortization of premium on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AmortizationOfPremiumOnMarketableSecurities" xlink:to="cyma_AmortizationOfPremiumOnMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationPeriod" xlink:label="cyma_AmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AmortizationPeriod_lbl" xml:lang="en-US" id="id_3866818_1166343_3_1">Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AmortizationPeriod_lbl" xml:lang="en-US" id="id_3866818_1166343_1_1">Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AmortizationPeriod_lbl" xml:lang="en-US" id="id_3866818_1166343_2_1">Facility loan, interest amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AmortizationPeriod" xlink:to="cyma_AmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_3866818_931668_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_3866818_931668_2_1">Anti-dilutive securities excluded from the computation of diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_3866818_923482_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_3866818_923482_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AreaOfOfficeSpace" xlink:label="cyma_AreaOfOfficeSpace"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_3866818_970529_3_1">Area Of Office Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_3866818_970529_1_1">Area Of Office Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_3866818_970529_2_1">Area of office space</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AreaOfOfficeSpace" xlink:to="cyma_AreaOfOfficeSpace_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AsAmendedMember" xlink:label="cyma_AsAmendedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_AsAmendedMember_lbl" xml:lang="en-US" id="id_3866818_954129_3_1">As Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_AsAmendedMember_lbl" xml:lang="en-US" id="id_3866818_954129_1_1">As Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_AsAmendedMember_lbl" xml:lang="en-US" id="id_3866818_954129_2_1">As Amended [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_AsAmendedMember" xlink:to="cyma_AsAmendedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_3866818_939751_1_1">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_3866818_939751_2_1">Impairment losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3866818_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3866818_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3866818_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3866818_928450_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3866818_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3866818_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3866818_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3866818_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_3866818_938194_1_1">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_3866818_938194_2_1">Total assets measured at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_930060_1_1">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_930060_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_3866818_932588_1_1">Business Combinations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_3866818_932588_2_1">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="id_3866818_936003_1_1">Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="id_3866818_936003_2_1">Accrued in the balance sheets related to indemnification obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3866818_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3866818_938283_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3866818_938283_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3866818_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3866818_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3866818_938600_6_1">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_928679_1_1">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_928679_2_1">Cash, Cash Equivalents, and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_3866818_925153_1_1">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_3866818_925153_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CashEquivalentMaturityDescription" xlink:label="cyma_CashEquivalentMaturityDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CashEquivalentMaturityDescription_lbl" xml:lang="en-US" id="id_3866818_1099979_3_1">Cash Equivalent Maturity Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CashEquivalentMaturityDescription_lbl" xml:lang="en-US" id="id_3866818_1099979_1_1">Cash Equivalent Maturity Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CashEquivalentMaturityDescription_lbl" xml:lang="en-US" id="id_3866818_1099979_2_1">Cash and cash equivalents, maturity description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CashEquivalentMaturityDescription" xlink:to="cyma_CashEquivalentMaturityDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CashlessExerciseOfCommonStockForWarrantsLiability" xlink:label="cyma_CashlessExerciseOfCommonStockForWarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CashlessExerciseOfCommonStockForWarrantsLiability_lbl" xml:lang="en-US" id="id_3866818_1256940_3_1">Cashless Exercise of Common Stock For Warrants Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CashlessExerciseOfCommonStockForWarrantsLiability_lbl" xml:lang="en-US" id="id_3866818_1256940_1_1">Cashless Exercise Of Common Stock For Warrants Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CashlessExerciseOfCommonStockForWarrantsLiability_lbl" xml:lang="en-US" id="id_3866818_1256940_2_1">Issuance of common stock upon cashless warrant exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CashlessExerciseOfCommonStockForWarrantsLiability" xlink:to="cyma_CashlessExerciseOfCommonStockForWarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3866818_932584_1_1">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3866818_932584_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_3866818_925604_1_1">Class Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_3866818_925604_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_3866818_923791_1_1">Class Of Warrant Or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_3866818_923791_2_1">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_3866818_928960_1_1">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_3866818_928960_2_1">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_3866818_932954_1_1">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_3866818_932954_2_1">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_3866818_932954_12_1">Exercise price of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_3866818_931483_1_1">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_3866818_931483_2_1">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="id_3866818_927527_1_1">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="id_3866818_927527_2_1">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_3866818_925087_1_1">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_3866818_925087_2_1">Issued warrants to purchase common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_3866818_928347_1_1">Class Of Warrant Or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_3866818_928347_2_1">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ClassOfWarrantOrRightTerm" xlink:label="cyma_ClassOfWarrantOrRightTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_3866818_1121574_3_1">Class Of Warrant Or Right Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_3866818_1121574_1_1">Class Of Warrant Or Right Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" id="id_3866818_1121574_2_1">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ClassOfWarrantOrRightTerm" xlink:to="cyma_ClassOfWarrantOrRightTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1218875_3_1">Collaboration And License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1218875_1_1">Collaboration And License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1218875_2_1">Collaboration and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems_lbl" xml:lang="en-US" id="id_3866818_1256936_3_1">Collaborations And License Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems_lbl" xml:lang="en-US" id="id_3866818_1256936_1_1">Collaborations And License Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems_lbl" xml:lang="en-US" id="id_3866818_1256936_2_1">Collaborations And License Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_CollaborationsAndLicenseAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsTable" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable_lbl" xml:lang="en-US" id="id_3866818_1234497_3_1">Collaborations And License Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable_lbl" xml:lang="en-US" id="id_3866818_1234497_1_1">Collaborations And License Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable_lbl" xml:lang="en-US" id="id_3866818_1234497_2_1">Collaborations And License Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="cyma_CollaborationsAndLicenseAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborativeArrangementDateOfAgreement" xlink:label="cyma_CollaborativeArrangementDateOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CollaborativeArrangementDateOfAgreement_lbl" xml:lang="en-US" id="id_3866818_1102949_3_1">Collaborative Arrangement Date Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CollaborativeArrangementDateOfAgreement_lbl" xml:lang="en-US" id="id_3866818_1102949_1_1">Collaborative Arrangement Date Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CollaborativeArrangementDateOfAgreement_lbl" xml:lang="en-US" id="id_3866818_1102949_2_1">Entered into a collaboration agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CollaborativeArrangementDateOfAgreement" xlink:to="cyma_CollaborativeArrangementDateOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_3866818_936604_1_1">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_3866818_936604_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3866818_930041_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3866818_930041_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_923990_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_923990_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3866818_925879_1_1">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3866818_925879_2_1">Total reserved shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3866818_930643_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3866818_930643_2_1">Common stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3866818_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3866818_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3866818_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3866818_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_925763_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_925763_2_1">Common stock shares sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_925763_12_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3866818_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3866818_935685_2_1">Common stock, $0.0001 par value: 100,000,000 shares authorized;10,064,495 and 9,455,064 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CommonStockWarrantLiabilityPolicyTextBlock" xlink:label="cyma_CommonStockWarrantLiabilityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CommonStockWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_1222154_3_1">Common Stock Warrant Liability Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CommonStockWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_1222154_1_1">Common Stock Warrant Liability Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CommonStockWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_1222154_2_1">Common Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CommonStockWarrantLiabilityPolicyTextBlock" xlink:to="cyma_CommonStockWarrantLiabilityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CommonStockWarrantMember" xlink:label="cyma_CommonStockWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CommonStockWarrantMember_lbl" xml:lang="en-US" id="id_3866818_980834_3_1">Common Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CommonStockWarrantMember_lbl" xml:lang="en-US" id="id_3866818_980834_1_1">Common Stock Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CommonStockWarrantMember_lbl" xml:lang="en-US" id="id_3866818_980834_2_1">Outstanding common stock warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CommonStockWarrantMember" xlink:to="cyma_CommonStockWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3866818_933343_1_1">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3866818_933343_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_925034_1_1">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_925034_2_1">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_3866818_930739_1_1">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_3866818_930739_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_3866818_1056049_3_1">Contingent Payments Receivable Based On Development Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_3866818_1056049_1_1">Contingent Payments Receivable Based On Development Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_3866818_1056049_2_1">Contingent payment eligible to receive on development and commercial events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:to="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" id="id_3866818_936092_1_1">Conversion Of Stock Amount Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" id="id_3866818_936092_2_1">Conversion of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_3866818_929557_1_1">Conversion Of Stock Shares Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_3866818_929557_2_1">Issuance of common stock upon conversion of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CorporateDebtAndAssetBackedSecuritiesMember" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember_lbl" xml:lang="en-US" id="id_3866818_1256770_3_1">Corporate Debt And Asset Backed Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember_lbl" xml:lang="en-US" id="id_3866818_1256770_1_1">Corporate Debt And Asset Backed Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember_lbl" xml:lang="en-US" id="id_3866818_1256770_2_1">Corporate debt and asset backed securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_CorporateDebtAndAssetBackedSecuritiesMember" xlink:to="cyma_CorporateDebtAndAssetBackedSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_3866818_924420_1_1">Credit Facility [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="id_3866818_924420_2_1">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_3866818_924655_1_1">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="id_3866818_924655_2_1">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3866818_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3866818_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_3866818_930446_1_1">Debt Conversion Converted Instrument Shares Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_3866818_930446_2_1">Loan facility extinguished in exchange of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_3866818_928741_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_3866818_928741_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_925940_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_925940_2_1">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_3866818_926396_1_1">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_3866818_926396_2_1">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_3866818_928734_1_1">Debt Instrument Basis Spread On Variable Rate 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_3866818_928734_2_1">Facility loan, prime rate plus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3866818_925437_1_1">Debt Instrument Convertible Conversion Price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3866818_925437_2_1">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xml:lang="en-US" id="id_3866818_930717_1_1">Debt Instrument Covenant Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xml:lang="en-US" id="id_3866818_930717_2_1">Facility loan, financial covenants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="cyma_DebtInstrumentFairValueCarryingValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_DebtInstrumentFairValueCarryingValueAbstract_lbl" xml:lang="en-US" id="id_3866818_1238100_3_1">Debt Instrument Fair Value Carrying Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_DebtInstrumentFairValueCarryingValueAbstract_lbl" xml:lang="en-US" id="id_3866818_1238100_1_1">Debt Instrument Fair Value Carrying Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_DebtInstrumentFairValueCarryingValueAbstract_lbl" xml:lang="en-US" id="id_3866818_1238100_2_1">Debt Instrument Fair Value Carrying Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="cyma_DebtInstrumentFairValueCarryingValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_3866818_924352_1_1">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_3866818_924352_2_1">Facility loan, fixed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_3866818_924921_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_3866818_924921_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_3866818_926342_1_1">Debt Instrument Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_3866818_926342_2_1">Maturity date of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_3866818_931220_1_1">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_3866818_931220_2_1">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" id="id_3866818_936031_1_1">Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" id="id_3866818_936031_2_1">Facility loan, final interest payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_3866818_924143_1_1">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_3866818_924143_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3866818_939791_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3866818_939791_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3866818_935603_1_1">Derivative Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3866818_935603_2_1">Fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3866818_935603_12_1">Long term warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DevelopmentPayment" xlink:label="cyma_DevelopmentPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_DevelopmentPayment_lbl" xml:lang="en-US" id="id_3866818_995474_3_1">Development Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_DevelopmentPayment_lbl" xml:lang="en-US" id="id_3866818_995474_1_1">Development Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_DevelopmentPayment_lbl" xml:lang="en-US" id="id_3866818_995474_2_1">Development payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_DevelopmentPayment" xlink:to="cyma_DevelopmentPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3866818_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3866818_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_3866818_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_3866818_923166_2_1">Stock Plans and Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DocumentAndEntityInformationAbstract" xlink:label="cyma_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3866818_951207_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3866818_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3866818_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="cyma_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3866818_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3866818_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3866818_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3866818_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3866818_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3866818_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3866818_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3866818_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_3866818_929815_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_3866818_929815_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3866818_929231_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3866818_929231_2_1">Basic and diluted net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_931897_2_1">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_934475_1_1">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_934475_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3866818_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3866818_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3866818_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3866818_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_3866818_921970_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_3866818_921970_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3866818_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3866818_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3866818_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3866818_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3866818_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3866818_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3866818_927325_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3866818_927325_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanMember" xlink:label="cyma_EquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3866818_974512_3_1">Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3866818_974512_1_1">Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3866818_974512_2_1">Equity incentive plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_EquityIncentivePlanMember" xlink:to="cyma_EquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember_lbl" xml:lang="en-US" id="id_3866818_1165861_3_1">Equity Incentive Plan Two Thousand And Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember_lbl" xml:lang="en-US" id="id_3866818_1165861_1_1">Equity Incentive Plan Two Thousand And Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember_lbl" xml:lang="en-US" id="id_3866818_1165861_2_1">2013 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:to="cyma_EquityIncentivePlanTwoThousandAndThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" id="id_3866818_937935_1_1">Extinguishment Of Debt Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" id="id_3866818_937935_2_1">Amount of debt cancelled upon issuance of common stock shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" id="id_3866818_937935_12_1">Loan facility, outstanding principal and accrued interest settled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FacilityLoanAgreementMember" xlink:label="cyma_FacilityLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_FacilityLoanAgreementMember_lbl" xml:lang="en-US" id="id_3866818_1202104_3_1">Facility Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_FacilityLoanAgreementMember_lbl" xml:lang="en-US" id="id_3866818_1202104_1_1">Facility Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_FacilityLoanAgreementMember_lbl" xml:lang="en-US" id="id_3866818_1202104_2_1">Facility Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_FacilityLoanAgreementMember" xlink:to="cyma_FacilityLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_3866818_937097_1_1">Fair Value Adjustment Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_3866818_937097_2_1">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_3866818_928161_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_3866818_928161_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_3866818_932133_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_3866818_932133_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_3866818_932752_1_1">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_3866818_932752_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_3866818_926956_1_1">Fair Value By Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_3866818_926956_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3866818_929790_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3866818_929790_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="id_3866818_927111_1_1">Fair Value By Liability Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="id_3866818_927111_2_1">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_3866818_932057_1_1">Fair Value By Shareholders Equity Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_3866818_932057_2_1">Fair Value by Shareholders' Equity Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3866818_930808_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3866818_930808_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3866818_925736_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3866818_925736_2_1">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3866818_925851_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3866818_925851_2_1">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3866818_929831_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3866818_929831_2_1">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="id_3866818_930594_1_1">Fair Value Instruments Classified In Shareholders Equity Measured On Recurring Basis Unobservable Input Reconciliation Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="id_3866818_930594_2_1">Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_3866818_926700_1_1">Fair Value Instruments Classified In Shareholders Equity Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_3866818_926700_2_1">Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_3866818_927627_1_1">Fair Value Instruments Classified In Shareholders Equity Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_3866818_927627_2_1">Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="id_3866818_927500_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="id_3866818_927500_2_1">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_924053_1_1">Fair Value Measurement Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_924053_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3866818_930398_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3866818_930398_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues_lbl" xml:lang="en-US" id="id_3866818_933740_1_1">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues_lbl" xml:lang="en-US" id="id_3866818_933740_2_1">Issuance of financial instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_lbl" xml:lang="en-US" id="id_3866818_939609_1_1">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_lbl" xml:lang="en-US" id="id_3866818_939609_14_1">Settlement of financial instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_lbl" xml:lang="en-US" id="id_3866818_936357_1_1">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Value Of Instruments Classified In Shareholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_lbl" xml:lang="en-US" id="id_3866818_936357_4_1">Balance as of March 31, 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_lbl" xml:lang="en-US" id="id_3866818_936357_5_1">Balance as of December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstIssuanceMember" xlink:label="cyma_FirstIssuanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_FirstIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224358_3_1">First Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_FirstIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224358_1_1">First Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_FirstIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224358_2_1">First Issuance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_FirstIssuanceMember" xlink:to="cyma_FirstIssuanceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstTrancheMember" xlink:label="cyma_FirstTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_FirstTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1104289_3_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_FirstTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1104289_1_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_FirstTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1104289_2_1">First Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_FirstTrancheMember" xlink:to="cyma_FirstTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FixedAssetsInAccruedExpenses" xlink:label="cyma_FixedAssetsInAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_FixedAssetsInAccruedExpenses_lbl" xml:lang="en-US" id="id_3866818_1264226_3_1">Fixed Assets in Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_FixedAssetsInAccruedExpenses_lbl" xml:lang="en-US" id="id_3866818_1264226_1_1">Fixed Assets In Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_FixedAssetsInAccruedExpenses_lbl" xml:lang="en-US" id="id_3866818_1264226_2_1">Fixed assets in accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_FixedAssetsInAccruedExpenses" xlink:to="cyma_FixedAssetsInAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForwardContractsMember" xlink:label="us-gaap_ForwardContractsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractsMember_lbl" xml:lang="en-US" id="id_3866818_929612_1_1">Forward Contracts [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractsMember_lbl" xml:lang="en-US" id="id_3866818_929612_2_1">Forward Contract [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractsMember" xlink:to="us-gaap_ForwardContractsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FourthIssuanceMember" xlink:label="cyma_FourthIssuanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_FourthIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224362_3_1">Fourth Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_FourthIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224362_1_1">Fourth Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_FourthIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224362_2_1">Fourth Issuance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_FourthIssuanceMember" xlink:to="cyma_FourthIssuanceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3866818_932226_1_1">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3866818_932226_2_1">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3866818_937408_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3866818_937408_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3866818_925832_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3866818_925832_2_1">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_931752_1_1">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_931752_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3866818_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3866818_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3866818_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3866818_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3866818_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3866818_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_932576_1_1">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_932576_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_3866818_938987_1_1">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_3866818_938987_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_3866818_935362_1_1">Increase Decrease In Accrued Interest Receivable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US" id="id_3866818_935362_14_1">Accrued interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_3866818_938916_1_1">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_3866818_938916_2_1">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet_lbl" xml:lang="en-US" id="id_3866818_936458_1_1">Increase Decrease In Contract Receivables Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet_lbl" xml:lang="en-US" id="id_3866818_936458_14_1">Contract receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:to="us-gaap_IncreaseDecreaseInContractReceivablesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" id="id_3866818_939891_1_1">Increase Decrease In Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" id="id_3866818_939891_14_1">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" id="id_3866818_940674_1_1">Increase Decrease In Interest Payable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" id="id_3866818_940674_2_1">Accrued interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3866818_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3866818_924543_2_1">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_3866818_934505_1_1">Increase Decrease In Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_3866818_934505_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_3866818_939677_1_1">Increase Decrease In Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_3866818_939677_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_3866818_934983_1_1">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_3866818_934983_14_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_IndemnificationLiability" xlink:label="cyma_IndemnificationLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_IndemnificationLiability_lbl" xml:lang="en-US" id="id_3866818_1113562_3_1">Indemnification Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_IndemnificationLiability_lbl" xml:lang="en-US" id="id_3866818_1113562_1_1">Indemnification Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_IndemnificationLiability_lbl" xml:lang="en-US" id="id_3866818_1113562_2_1">Indemnification liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_IndemnificationLiability" xlink:to="cyma_IndemnificationLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_3866818_938923_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_3866818_938923_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="id_3866818_940678_1_1">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="id_3866818_940678_2_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_3866818_935259_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_3866818_935259_2_1">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_3866818_936371_1_1">Interest Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_3866818_936371_2_1">Accrued interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_3866818_940810_1_1">Interest Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" id="id_3866818_940810_2_1">Accrued interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_3866818_934440_1_1">Investment Income Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_3866818_934440_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3866818_932040_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3866818_932040_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3866818_932609_1_1">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3866818_932609_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_IssuanceOfCommonStockWarrantsToInvestors" xlink:label="cyma_IssuanceOfCommonStockWarrantsToInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_IssuanceOfCommonStockWarrantsToInvestors_lbl" xml:lang="en-US" id="id_3866818_1257136_3_1">Issuance of common stock warrants to investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_IssuanceOfCommonStockWarrantsToInvestors_lbl" xml:lang="en-US" id="id_3866818_1257136_1_1">Issuance Of Common Stock Warrants To Investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_IssuanceOfCommonStockWarrantsToInvestors_lbl" xml:lang="en-US" id="id_3866818_1257136_2_1">Issuance of common stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_IssuanceOfCommonStockWarrantsToInvestors" xlink:to="cyma_IssuanceOfCommonStockWarrantsToInvestors_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_3866818_937119_1_1">Issuance Of Stock And Warrants For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_3866818_937119_2_1">Non-employee stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_JanssenPharmaceuticalsIncMember" xlink:label="cyma_JanssenPharmaceuticalsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_JanssenPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_3866818_1211839_3_1">Janssen Pharmaceuticals, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_JanssenPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_3866818_1211839_1_1">Janssen Pharmaceuticals Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_JanssenPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_3866818_1211839_2_1">Janssen Pharmaceuticals, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_JanssenPharmaceuticalsIncMember" xlink:to="cyma_JanssenPharmaceuticalsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US" id="id_3866818_929485_1_1">Lease Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US" id="id_3866818_929485_2_1">New Lease Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_3866818_929765_1_1">Lease Expiration Date 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_3866818_929765_2_1">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3866818_923325_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3866818_923325_2_1">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_930516_1_1">Lease Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_930516_2_1">Deferred Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="us-gaap_LeasePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LeaseStartDate" xlink:label="cyma_LeaseStartDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_LeaseStartDate_lbl" xml:lang="en-US" id="id_3866818_1220916_3_1">Lease start date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_LeaseStartDate_lbl" xml:lang="en-US" id="id_3866818_1220916_1_1">Lease Start Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_LeaseStartDate_lbl" xml:lang="en-US" id="id_3866818_1220916_2_1">Lease start date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_LeaseStartDate" xlink:to="cyma_LeaseStartDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_3866818_921954_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_3866818_921954_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_3866818_924755_1_1">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_3866818_924755_2_1">Operating leases term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3866818_936129_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3866818_936129_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3866818_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3866818_935778_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3866818_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3866818_924388_2_1">Liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3866818_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3866818_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_3866818_936528_1_1">Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_3866818_936528_2_1">Total liabilities measured at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAgreementDate" xlink:label="cyma_LicenseAgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_3866818_1080434_3_1">License Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_3866818_1080434_1_1">License Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_3866818_1080434_2_1">License agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_LicenseAgreementDate" xlink:to="cyma_LicenseAgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones_lbl" xml:lang="en-US" id="id_3866818_1066074_3_1">License And Collaboration Agreements Potential Payments For Development Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones_lbl" xml:lang="en-US" id="id_3866818_1066074_1_1">License And Collaboration Agreements Potential Payments For Development Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones_lbl" xml:lang="en-US" id="id_3866818_1066074_2_1">Potential future development payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" xlink:to="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US" id="id_3866818_930353_1_1">Line Of Credit Facility Commitment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US" id="id_3866818_930353_2_1">Facility fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_3866818_935023_1_1">Line Of Credit Facility Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_3866818_935023_2_1">Maximum borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_3866818_935023_12_1">Venture debt financing loan agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US" id="id_3866818_933702_1_1">Lines Of Credit Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US" id="id_3866818_933702_2_1">Facility loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_925371_1_1">Liquidity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_925371_2_1">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="id_3866818_932276_1_1">Long Term Debt Percentage Bearing Fixed Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="id_3866818_932276_2_1">Facility loan, fixed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3866818_931308_1_1">Longterm Debt Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3866818_931308_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3866818_925976_1_1">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3866818_925976_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US" id="id_3866818_935143_1_1">Long Term Line Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US" id="id_3866818_935143_2_1">Facility loan, less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_3866818_924082_1_1">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_3866818_924082_2_1">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_3866818_923738_1_1">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_3866818_923738_2_1">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_3866818_928628_1_1">Major Types Of Debt And Equity Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" id="id_3866818_928628_2_1">Major Types of Debt and Equity Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_3866818_928856_1_1">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" id="id_3866818_928856_2_1">Major Types of Debt and Equity Securities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_3866818_936967_1_1">Marketable Securities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" id="id_3866818_936967_2_1">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3866818_923140_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3866818_923140_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3866818_932953_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3866818_932953_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_3866818_932359_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_3866818_932359_2_1">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_MonthlyLicenseFees" xlink:label="cyma_MonthlyLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_MonthlyLicenseFees_lbl" xml:lang="en-US" id="id_3866818_1224350_3_1">Monthly License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_MonthlyLicenseFees_lbl" xml:lang="en-US" id="id_3866818_1224350_1_1">Monthly License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_MonthlyLicenseFees_lbl" xml:lang="en-US" id="id_3866818_1224350_2_1">Monthly license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_MonthlyLicenseFees" xlink:to="cyma_MonthlyLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3866818_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3866818_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_924600_2_1">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3866818_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3866818_939292_6_1">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_924425_2_1">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3866818_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3866818_928832_2_1">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3866818_928832_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3866818_930909_2_1">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_935636_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_935636_6_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_935636_12_1">Net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_3866818_933727_1_1">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_3866818_933727_6_1">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_977748_3_1">Net Proceeds From Issuance Of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_977748_1_1">Net Proceeds From Issuance Of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_977748_2_1">Net proceeds from issuance of 2013 financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_977748_12_1">Net proceeds from issuance of private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_NetProceedsFromIssuanceOfPrivatePlacement" xlink:to="cyma_NetProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing" xlink:label="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing_lbl" xml:lang="en-US" id="id_3866818_1264228_3_1">Noncash Issuance Costs Incurred in Common Stock Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing_lbl" xml:lang="en-US" id="id_3866818_1264228_1_1">Noncash Issuance Costs Incurred In Common Stock Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing_lbl" xml:lang="en-US" id="id_3866818_1264228_2_1">Noncash issuance costs incurred in common stock financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing" xlink:to="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_3866818_927496_1_1">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_3866818_927496_2_1">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NumberOfDevelopmentAndLicenseAgreements" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements_lbl" xml:lang="en-US" id="id_3866818_1264241_3_1">Number Of Development And License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements_lbl" xml:lang="en-US" id="id_3866818_1264241_1_1">Number Of Development And License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements_lbl" xml:lang="en-US" id="id_3866818_1264241_2_1">Number of development and license agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_NumberOfDevelopmentAndLicenseAgreements" xlink:to="cyma_NumberOfDevelopmentAndLicenseAgreements_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OfficeAndComputerEquipmentMember" xlink:label="cyma_OfficeAndComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" id="id_3866818_1125873_3_1">Office and Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" id="id_3866818_1125873_1_1">Office And Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" id="id_3866818_1125873_2_1">Office and computer equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_OfficeAndComputerEquipmentMember" xlink:to="cyma_OfficeAndComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3866818_940683_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3866818_940683_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3866818_927909_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3866818_927909_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3866818_934856_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3866818_933732_1_1">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3866818_933732_6_1">Total future minimum payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3866818_936689_1_1">Operating Leases Future Minimum Payments Due Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3866818_936689_2_1">2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_3866818_935061_1_1">Operating Leases Future Minimum Payments Due In Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_3866818_935061_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3866818_934077_1_1">Operating Leases Future Minimum Payments Due In Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3866818_934077_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3866818_936161_1_1">Operating Leases Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3866818_936161_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3866818_933250_1_1">Operating Leases Future Minimum Payments Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3866818_933250_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_3866818_938759_1_1">Operating Leases Rent Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_3866818_938759_2_1">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3866818_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3866818_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_931858_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_931858_2_1">Organization and Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OrthoMcneilIncMember" xlink:label="cyma_OrthoMcneilIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_OrthoMcneilIncMember_lbl" xml:lang="en-US" id="id_3866818_1264243_3_1">Ortho McNeil Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_OrthoMcneilIncMember_lbl" xml:lang="en-US" id="id_3866818_1264243_1_1">Ortho Mcneil Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_OrthoMcneilIncMember_lbl" xml:lang="en-US" id="id_3866818_1264243_2_1">Ortho-McNeil Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_OrthoMcneilIncMember" xlink:to="cyma_OrthoMcneilIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_933626_1_1">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3866818_933626_2_1">Other accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3866818_939944_1_1">Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3866818_939944_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_3866818_937594_1_1">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_3866818_937594_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_3866818_934765_1_1">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_3866818_934765_2_1">Unrealized gain on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3866818_935817_1_1">Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3866818_935817_6_1">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3866818_927247_1_1">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3866818_927247_2_1">Other comprehensive loss/income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3866818_934563_1_1">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3866818_934563_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_3866818_934087_1_1">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_3866818_934087_2_1">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementAxis" xlink:label="us-gaap_PartiesToContractualArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartiesToContractualArrangementAxis_lbl" xml:lang="en-US" id="id_3866818_926744_1_1">Parties To Contractual Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartiesToContractualArrangementAxis_lbl" xml:lang="en-US" id="id_3866818_926744_2_1">Parties to Contractual Arrangement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartiesToContractualArrangementAxis" xlink:to="us-gaap_PartiesToContractualArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementMember" xlink:label="us-gaap_PartiesToContractualArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartiesToContractualArrangementMember_lbl" xml:lang="en-US" id="id_3866818_925015_1_1">Parties To Contractual Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartiesToContractualArrangementMember_lbl" xml:lang="en-US" id="id_3866818_925015_2_1">Parties to Contractual Arrangement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartiesToContractualArrangementMember" xlink:to="us-gaap_PartiesToContractualArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US" id="id_3866818_936463_1_1">Payments For Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US" id="id_3866818_936463_2_1">Royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PaymentsMadeUnderLicenseAgreement" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_3866818_1031819_3_1">Payments Made Under License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_3866818_1031819_1_1">Payments Made Under License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_3866818_1031819_2_1">Payments made under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_PaymentsMadeUnderLicenseAgreement" xlink:to="cyma_PaymentsMadeUnderLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3866818_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3866818_936514_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_3866818_930809_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_3866818_930809_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_3866818_931386_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_3866818_931386_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3866818_932596_1_1">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3866818_932596_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3866818_929540_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3866818_929540_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_932934_1_1">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_932934_2_1">Convertible preferred stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_3866818_932934_12_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_926142_1_1">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_926142_32_1">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_926142_2_1">Convertible preferred stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_926142_12_1">Preferred stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_3866818_933055_1_1">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_3866818_933055_2_1">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_3866818_937707_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_3866818_937707_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_3866818_940825_1_1">Proceeds From Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_3866818_940825_2_1">Notes issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_937835_1_1">Proceeds From Issuance Of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_937835_2_1">Gross proceeds from issuance of common stock and warrants in a private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="id_3866818_937835_12_1">Net proceeds from issuance of 2013 financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" xlink:label="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses_lbl" xml:lang="en-US" id="id_3866818_1254843_3_1">Proceeds from Issuance of Private Placement Net Of Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses_lbl" xml:lang="en-US" id="id_3866818_1254843_1_1">Proceeds From Issuance Of Private Placement Net Of Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses_lbl" xml:lang="en-US" id="id_3866818_1254843_2_1">Net proceeds after deducting placement agent fees and estimated offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" xlink:to="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_3866818_937117_1_1">Proceeds From Issuance Or Sale Of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_3866818_937117_2_1">Proceeds from issuance of common stock and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_3866818_937117_12_1">Proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="id_3866818_939713_1_1">Proceeds From Lines Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US" id="id_3866818_939713_2_1">Additional proceeds from venture debt financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" id="id_3866818_939728_1_1">Proceeds From Long Term Lines Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" id="id_3866818_939728_2_1">Facility loan, drawn</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US" id="id_3866818_939597_1_1">Proceeds From Royalties Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US" id="id_3866818_939597_2_1">Royalties received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" id="id_3866818_940305_1_1">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" id="id_3866818_940305_2_1">Proceeds from sales of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3866818_928864_1_1">Property Plant And Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3866818_928864_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3866818_929865_1_1">Property Plant And Equipment By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3866818_929865_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3866818_938855_1_1">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3866818_938855_2_1">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3866818_925379_1_1">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3866818_925379_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3866818_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3866818_940861_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3866818_940861_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_928618_1_1">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_928618_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3866818_925467_1_1">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3866818_925467_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3866818_930445_1_1">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3866818_930445_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3866818_928464_1_1">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3866818_928464_2_1">Property and equipment, estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue" xlink:label="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue_lbl" xml:lang="en-US" id="id_3866818_1264300_3_1">Purchased common stock and common stock warrants carrying value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue_lbl" xml:lang="en-US" id="id_3866818_1264300_1_1">Purchased Common Stock And Common Stock Warrants Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue_lbl" xml:lang="en-US" id="id_3866818_1264300_2_1">Predetermined price of common stock purchased for warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue" xlink:to="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PurchasedSoftwareMember" xlink:label="cyma_PurchasedSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_PurchasedSoftwareMember_lbl" xml:lang="en-US" id="id_3866818_964907_3_1">Purchased Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_PurchasedSoftwareMember_lbl" xml:lang="en-US" id="id_3866818_964907_1_1">Purchased Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_PurchasedSoftwareMember_lbl" xml:lang="en-US" id="id_3866818_964907_2_1">Purchased software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_PurchasedSoftwareMember" xlink:to="cyma_PurchasedSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3866818_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3866818_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3866818_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3866818_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_932152_1_1">Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_932152_2_1">Redeemable convertible preferred stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_3866818_928760_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_3866818_928760_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_930751_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_930751_2_1">Related-Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3866818_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3866818_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3866818_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3866818_928963_2_1">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3866818_929876_1_1">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3866818_929876_2_1">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:label="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_959447_3_1">Reserved Shares Of Common Stock For Issuance Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_959447_1_1">Reserved Shares Of Common Stock For Issuance Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_959447_2_1">Reserved Shares of Authorized but Unissued Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:to="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_3866818_938076_1_1">Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_3866818_938076_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3866818_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3866818_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ReverseStockSplitPolicyTextBlock" xlink:label="cyma_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_979089_3_1">Reverse Stock Split Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_979089_1_1">Reverse Stock Split Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_3866818_979089_2_1">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ReverseStockSplitPolicyTextBlock" xlink:to="cyma_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_RoyaltyPercentageBasedOnNetSales" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3866818_1130424_3_1">Royalty Percentage Based On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3866818_1130424_1_1">Royalty Percentage Based On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3866818_1130424_2_1">Percentage of royalty received on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_RoyaltyPercentageBasedOnNetSales" xlink:to="cyma_RoyaltyPercentageBasedOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioOneMember" xlink:label="cyma_ScenarioOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3866818_995488_3_1">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3866818_995488_1_1">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3866818_995488_2_1">Scenario one, conversion basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ScenarioOneMember" xlink:to="cyma_ScenarioOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioTwoMember" xlink:label="cyma_ScenarioTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3866818_1056074_3_1">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3866818_1056074_1_1">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3866818_1056074_2_1">Scenario two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ScenarioTwoMember" xlink:to="cyma_ScenarioTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_3866818_930891_1_1">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_3866818_930891_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_926939_1_1">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_926939_2_1">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_3866818_928220_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_3866818_928220_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3866818_925701_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3866818_925701_2_1">Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" xlink:label="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_1118807_3_1">Schedule Of Changes In Fair Value Of Financial Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_1118807_1_1">Schedule Of Changes In Fair Value Of Financial Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_1118807_2_1">Schedule of Changes in Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" xlink:to="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3866818_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3866818_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_3866818_931816_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_3866818_931816_2_1">Summary of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_924987_1_1">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_924987_2_1">Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_924008_1_1">Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3866818_924008_2_1">Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3866818_931140_1_1">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3866818_931140_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3866818_930578_1_1">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3866818_930578_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_3866818_929898_1_1">Schedule Of Stock By Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_3866818_929898_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondIssuanceMember" xlink:label="cyma_SecondIssuanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_SecondIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224359_3_1">Second Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_SecondIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224359_1_1">Second Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_SecondIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224359_2_1">Second Issuance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_SecondIssuanceMember" xlink:to="cyma_SecondIssuanceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondTrancheMember" xlink:label="cyma_SecondTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_SecondTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1008215_3_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_SecondTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1008215_1_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_SecondTrancheMember_lbl" xml:lang="en-US" id="id_3866818_1008215_2_1">Second Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_SecondTrancheMember" xlink:to="cyma_SecondTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_932774_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_932774_2_1">Series B-1 Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_930400_1_1">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_930400_2_1">Series C-1 Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_929729_1_1">Series E Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US" id="id_3866818_929729_2_1">Series E-1 Preferred [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3866818_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3866818_938471_2_1">Employee and director stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3866818_938471_12_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_3866818_926550_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_3866818_926550_2_1">Share based compensation arrangement by share based payment award, expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_lbl" xml:lang="en-US" id="id_3866818_1203643_3_1">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Reserved Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_lbl" xml:lang="en-US" id="id_3866818_1203643_1_1">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Reserved Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_lbl" xml:lang="en-US" id="id_3866818_1203643_2_1">Share based compensation arrangement percentage increase in share reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3866818_926498_1_1">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3866818_926498_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3866818_1013381_3_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3866818_1013381_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3866818_1013381_2_1">Increased in shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3866818_924337_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3866818_924337_2_1">Share based compensation arrangement number of issued options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationExpense" xlink:label="cyma_ShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3866818_993959_3_1">Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3866818_993959_1_1">Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3866818_993959_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ShareBasedCompensationExpense" xlink:to="cyma_ShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3866818_923943_1_1">Share Based Compensation Option And Incentive Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3866818_923943_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_3866818_932336_1_1">Shareholders Equity Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_3866818_932336_2_1">Shareholders' Equity Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_ShareholdersEquityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShortTermInvestmentContractualMaturity" xlink:label="cyma_ShortTermInvestmentContractualMaturity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ShortTermInvestmentContractualMaturity_lbl" xml:lang="en-US" id="id_3866818_1067068_3_1">Short Term Investment Contractual Maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ShortTermInvestmentContractualMaturity_lbl" xml:lang="en-US" id="id_3866818_1067068_1_1">Short Term Investment Contractual Maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ShortTermInvestmentContractualMaturity_lbl" xml:lang="en-US" id="id_3866818_1067068_2_1">Short-term contractual maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ShortTermInvestmentContractualMaturity" xlink:to="cyma_ShortTermInvestmentContractualMaturity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_3866818_931089_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_3866818_931089_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SponsorFees" xlink:label="us-gaap_SponsorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SponsorFees_lbl" xml:lang="en-US" id="id_3866818_937280_1_1">Sponsor Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SponsorFees_lbl" xml:lang="en-US" id="id_3866818_937280_2_1">Advisory fee paid to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SponsorFees" xlink:to="us-gaap_SponsorFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3866818_932980_1_1">Statement Class Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3866818_932980_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3866818_927592_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3866818_927592_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3866818_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3866818_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3866818_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3866818_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_3866818_924791_1_1">Statement Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_3866818_924791_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3866818_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3866818_925186_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_3866818_934503_1_1">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="id_3866818_934503_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_927127_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_927127_2_1">Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_3866818_931725_1_1">Stockholders Equity Note Stock Split Conversion Ratio 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_3866818_931725_2_1">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" xlink:label="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1194197_3_1">Stockholders Equity Note Warrants Or Rights Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1194197_1_1">Stockholders Equity Note Warrants Or Rights Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3866818_1194197_2_1">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" xlink:to="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt" xlink:label="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt_lbl" xml:lang="en-US" id="id_3866818_1201602_3_1">Stock Issued During Period Amount For Cancellation Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt_lbl" xml:lang="en-US" id="id_3866818_1201602_1_1">Stock Issued During Period Amount For Cancellation Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt_lbl" xml:lang="en-US" id="id_3866818_1201602_2_1">Issued shares of common stock in cancellation of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt" xlink:to="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_3866818_926294_1_1">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_3866818_926294_2_1">Certain Balance Sheet Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_3866818_930441_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_3866818_930441_2_1">Supplemental disclosure of cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_3866818_938443_1_1">Temporary Equity Accretion To Redemption Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_3866818_938443_14_1">Accretion to redemption value of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3866818_931202_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3866818_931202_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ThirdIssuanceMember" xlink:label="cyma_ThirdIssuanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_ThirdIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224360_3_1">Third Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_ThirdIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224360_1_1">Third Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_ThirdIssuanceMember_lbl" xml:lang="en-US" id="id_3866818_1224360_2_1">Third Issuance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_ThirdIssuanceMember" xlink:to="cyma_ThirdIssuanceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3866818_921927_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3866818_921927_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_3866818_940382_1_1">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_3866818_940382_2_1">Interest or penalties related to income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_3866818_931855_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_3866818_931855_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WallStreetJournalPrimeRateMember" xlink:label="cyma_WallStreetJournalPrimeRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" id="id_3866818_1116164_3_1">Wall Street Journal Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" id="id_3866818_1116164_1_1">Wall Street Journal Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" id="id_3866818_1116164_2_1">Wall Street Journal Prime Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WallStreetJournalPrimeRateMember" xlink:to="cyma_WallStreetJournalPrimeRateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantLiabilityMember" xlink:label="cyma_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_3866818_1038552_3_1">Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_3866818_1038552_1_1">Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_3866818_1038552_2_1">Warrant liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WarrantLiabilityMember" xlink:to="cyma_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_3866818_929614_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_3866818_929614_2_1">Warrants for common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_3866818_935273_1_1">Warrants And Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_3866818_935273_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="us-gaap_WarrantsNotSettleableInCashMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashMember_lbl" xml:lang="en-US" id="id_3866818_925633_1_1">Warrants Not Settleable In Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashMember_lbl" xml:lang="en-US" id="id_3866818_925633_2_1">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashMember" xlink:to="us-gaap_WarrantsNotSettleableInCashMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsOneMember" xlink:label="cyma_WarrantsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WarrantsOneMember_lbl" xml:lang="en-US" id="id_3866818_1144362_3_1">Warrants One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WarrantsOneMember_lbl" xml:lang="en-US" id="id_3866818_1144362_1_1">Warrants One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WarrantsOneMember_lbl" xml:lang="en-US" id="id_3866818_1144362_2_1">Warrants, Exercise price of $5.75 per share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WarrantsOneMember" xlink:to="cyma_WarrantsOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsToPurchaseOfCommonStockShares" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US" id="id_3866818_1027820_3_1">Warrants To Purchase Of Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US" id="id_3866818_1027820_1_1">Warrants To Purchase Of Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US" id="id_3866818_1027820_2_1">Warrants to purchase shares of common stock in 2013 financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WarrantsToPurchaseOfCommonStockShares" xlink:to="cyma_WarrantsToPurchaseOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsTwoMember" xlink:label="cyma_WarrantsTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WarrantsTwoMember_lbl" xml:lang="en-US" id="id_3866818_1126038_3_1">Warrants Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WarrantsTwoMember_lbl" xml:lang="en-US" id="id_3866818_1126038_1_1">Warrants Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WarrantsTwoMember_lbl" xml:lang="en-US" id="id_3866818_1126038_2_1">Warrants, Exercise price of $5.00 per share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WarrantsTwoMember" xlink:to="cyma_WarrantsTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" xlink:label="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_1179026_3_1">Weighted Average Number Of Basic And Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_1179026_1_1">Weighted Average Number Of Basic And Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_3866818_1179026_2_1">Weighted average common shares outstanding used to calculate basic and diluted net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" xlink:to="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cyma-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-05-15T18:28:56Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DocumentandEntityInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfIncome" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsPropertyAndEquipment" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCertainBalanceSheetItemsAccruedLiabilities" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommonStockWarrantsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureDebtAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="cyma-20140331.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DocumentAndEntityInformationAbstract" xlink:label="cyma_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLineOfCredit" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" xlink:label="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationOfPremiumOnMarketableSecurities" xlink:label="cyma_AmortizationOfPremiumOnMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CashlessExerciseOfCommonStockForWarrantsLiability" xlink:label="cyma_CashlessExerciseOfCommonStockForWarrantsLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FixedAssetsInAccruedExpenses" xlink:label="cyma_FixedAssetsInAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInContractReceivablesNet" xlink:label="us-gaap_IncreaseDecreaseInContractReceivablesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_IssuanceOfCommonStockWarrantsToInvestors" xlink:label="cyma_IssuanceOfCommonStockWarrantsToInvestors"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing" xlink:label="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cyma_AmortizationOfPremiumOnMarketableSecurities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractReceivablesNet" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.2100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.2200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="cyma_FixedAssetsInAccruedExpenses" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="cyma_IssuanceOfCommonStockWarrantsToInvestors" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="cyma_CashlessExerciseOfCommonStockForWarrantsLiability" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" xlink:label="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt" xlink:label="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cyma_NetProceedsFromIssuanceOfPrivatePlacement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CashEquivalentMaturityDescription" xlink:label="cyma_CashEquivalentMaturityDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue" xlink:label="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShortTermInvestmentContractualMaturity" xlink:label="cyma_ShortTermInvestmentContractualMaturity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_CashEquivalentMaturityDescription" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_ShortTermInvestmentContractualMaturity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CorporateDebtAndAssetBackedSecuritiesMember" xlink:label="cyma_CorporateDebtAndAssetBackedSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DebtInstrumentFairValueCarryingValueAbstract" xlink:label="cyma_DebtInstrumentFairValueCarryingValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantLiabilityMember" xlink:label="cyma_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="cyma_CorporateDebtAndAssetBackedSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="cyma_WarrantLiabilityMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForwardContractsMember" xlink:label="us-gaap_ForwardContractsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="us-gaap_WarrantsNotSettleableInCashMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ForwardContractsMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantsNotSettleableInCashMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OfficeAndComputerEquipmentMember" xlink:label="cyma_OfficeAndComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PurchasedSoftwareMember" xlink:label="cyma_PurchasedSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cyma_OfficeAndComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cyma_PurchasedSoftwareMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedExpensesCurrent" xlink:label="cyma_AccruedExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AccruedLiabilityOfDerivativeInInstruments" xlink:label="cyma_AccruedLiabilityOfDerivativeInInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="cyma_AccruedExpensesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="cyma_AccruedLiabilityOfDerivativeInInstruments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ClassOfWarrantOrRightTerm" xlink:label="cyma_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsOneMember" xlink:label="cyma_WarrantsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cyma_WarrantsOneMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="cyma_ClassOfWarrantOrRightTerm" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:label="cyma_CollaborationsAndLicenseAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationsAndLicenseAgreementsTable" xlink:label="cyma_CollaborationsAndLicenseAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborativeArrangementDateOfAgreement" xlink:label="cyma_CollaborativeArrangementDateOfAgreement"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_DevelopmentPayment" xlink:label="cyma_DevelopmentPayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_JanssenPharmaceuticalsIncMember" xlink:label="cyma_JanssenPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAgreementDate" xlink:label="cyma_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" xlink:label="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_MonthlyLicenseFees" xlink:label="cyma_MonthlyLicenseFees"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NumberOfDevelopmentAndLicenseAgreements" xlink:label="cyma_NumberOfDevelopmentAndLicenseAgreements"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_OrthoMcneilIncMember" xlink:label="cyma_OrthoMcneilIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_PaymentsMadeUnderLicenseAgreement" xlink:label="cyma_PaymentsMadeUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_RoyaltyPercentageBasedOnNetSales" xlink:label="cyma_RoyaltyPercentageBasedOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="cyma_CollaborationsAndLicenseAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_CollaborativeArrangementDateOfAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_RoyaltyPercentageBasedOnNetSales" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_PaymentsMadeUnderLicenseAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_LicenseAgreementDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_NumberOfDevelopmentAndLicenseAgreements" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_MonthlyLicenseFees" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="cyma_DevelopmentPayment" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyma_CollaborationsAndLicenseAgreementsTable" xlink:to="cyma_CollaborationsAndLicenseAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cyma_OrthoMcneilIncMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="cyma_JanssenPharmaceuticalsIncMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AmortizationPeriod" xlink:label="cyma_AmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AsAmendedMember" xlink:label="cyma_AsAmendedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FacilityLoanAgreementMember" xlink:label="cyma_FacilityLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstIssuanceMember" xlink:label="cyma_FirstIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FirstTrancheMember" xlink:label="cyma_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_FourthIssuanceMember" xlink:label="cyma_FourthIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioOneMember" xlink:label="cyma_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScenarioTwoMember" xlink:label="cyma_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondIssuanceMember" xlink:label="cyma_SecondIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_SecondTrancheMember" xlink:label="cyma_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ThirdIssuanceMember" xlink:label="cyma_ThirdIssuanceMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WallStreetJournalPrimeRateMember" xlink:label="cyma_WallStreetJournalPrimeRateMember"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsTwoMember" xlink:label="cyma_WarrantsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cyma_WarrantsTwoMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cyma_WallStreetJournalPrimeRateMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cyma_AmortizationPeriod" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FirstIssuanceMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_SecondIssuanceMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_ThirdIssuanceMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FourthIssuanceMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cyma_FacilityLoanAgreementMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementScenarioAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cyma_AsAmendedMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cyma_SecondTrancheMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="cyma_FirstTrancheMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cyma_ScenarioOneMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="cyma_ScenarioTwoMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_AreaOfOfficeSpace" xlink:label="cyma_AreaOfOfficeSpace"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_IndemnificationLiability" xlink:label="cyma_IndemnificationLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_LeaseStartDate" xlink:label="cyma_LeaseStartDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementAxis" xlink:label="us-gaap_PartiesToContractualArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PartiesToContractualArrangementMember" xlink:label="us-gaap_PartiesToContractualArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_LeaseStartDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_AreaOfOfficeSpace" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_CapitalLeaseObligations" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="cyma_IndemnificationLiability" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PartiesToContractualArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartiesToContractualArrangementAxis" xlink:to="us-gaap_PartiesToContractualArrangementMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PartiesToContractualArrangementMember" xlink:to="us-gaap_LeaseAgreementsMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_NetProceedsFromIssuanceOfPrivatePlacement" xlink:label="cyma_NetProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_WarrantsToPurchaseOfCommonStockShares" xlink:label="cyma_WarrantsToPurchaseOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cyma_WarrantsToPurchaseOfCommonStockShares" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cyma_NetProceedsFromIssuanceOfPrivatePlacement" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CommonStockWarrantMember" xlink:label="cyma_CommonStockWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanMember" xlink:label="cyma_EquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cyma_CommonStockWarrantMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cyma_EquityIncentivePlanMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="cyma_EquityIncentivePlanTwoThousandAndThirteenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" xlink:label="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cyma_EquityIncentivePlanTwoThousandAndThirteenMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ShareBasedCompensationExpense" xlink:label="cyma_ShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="cyma_ShareBasedCompensationExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SponsorFees" xlink:label="us-gaap_SponsorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_SponsorFees" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CommonStockWarrantLiabilityPolicyTextBlock" xlink:label="cyma_CommonStockWarrantLiabilityPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ReverseStockSplitPolicyTextBlock" xlink:label="cyma_ReverseStockSplitPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_ReverseStockSplitPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_CommonStockWarrantLiabilityPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" xlink:label="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" xlink:label="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="cyma-20140331.xsd#cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:label="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SponsorFees', window );">Advisory fee paid to related party</a></td>
        <td class="nump">$ 15,000<span></span></td>
        <td class="nump">$ 45,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SponsorFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fees paid to advisors who provide certain management support and administrative oversight services including the organization and sale of stock, investment funds, limited partnerships and mutual funds.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SponsorFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"4*VK8[`$``-X8```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4%/VS`8AN](^P^1KU/C
MVAZ,34TY;.P(2+`?X,5?FZB);=D&VG^/DP)"J"NJ5FGO)5$:^WN?^O`<WLPN
MUGU7/%"(K;,5$^64%61K9UJ[K-CONU^3<U;$I*W1G;-4L0U%=C'_=#*[VWB*
M1=YM8\6:E/QWSF/=4*]CZ3S9_&;A0J]3?@Q+[G6]TDOB<CH]X[6SB6R:I&$&
MF\]^TD+?=ZFX7.>?MR2!NLB*']N%0U;%M/==6^N42?F#->]2)L\)9=XYKHE-
MZ^/GC,'XSH3AS=\#GO==YZ,)K:'B1H=TI?N,P=<=?W1A]<>Y5;E_R`Y*MUBT
M-1E7W_?Y!,KH`VD3&Z+4=^5X+WO=VA?N/?GCXLC'FS@RR/#_QL$'<D@0#@7"
M\06$XQ2$XPR$XRL(QSD(QS<0#C%%`4$QJD!1JD!QJD"1JD"QJD#1JD#QJD`1
MJT`QJT0QJT0QJT0QJT0QJT0QJT0QJT0QJT0QJT0QJT0QJT(QJT(QJT(QJT(Q
MJT(QJT(QJT(QJT(QJT(QJ_I?9DVY/28^7O]=9>.8#^K+F#8=Q2-7#MNA'R4W
M.I"Y32'W[$<'>#M['T=NH6^"\S'W\8$./X67PGW8/?%Y$(74TFOEOJNZ?DW,
M7?[A@>^Z<QJ^%A@R.[+Y^'5B_@0``/__`P!02P,$%``&``@````A`+55,"/U
M````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DIC
MV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=
MWFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&
MOQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:
M0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]
MSCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`:799%/P!``#G
M%P``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````O)C=:N,P$(7O%_8=C.XWRLRX
MZ0]U>K,4>MN?!Q"V$H<FMI&T;?/V%:$X#;1G>V'F)B"92!_C.>=(OKYYVVV+
M%Q_BIN\J0[.Y*7Q7]\VF6U?FZ?'VSX4I8G)=X[9]YRNS]]'<+'__NK[W6Y?R
MGV*[&6*15^EB9=J4ABMK8]WZG8NS?O!=?K+JP\ZE/`QK.[CZV:V]Y?E\8</G
M-<SR9,WBKJE,N&M(3/&X'_+6_U^\7ZTVM?_;U_]VODM?[&%?^_`<6^]37M2%
MM4^5&:>B/3PAF65F8[_!R?70Q;E`.+Q0QN$%PI%+91RY1#A,RCA,"$=*91PI
M$4[)4^+$U@7?/*20G2/FA3_4=3*-:,ZGA!DU?009ISYD?HY@)JW,N//W,(Q@
M2%OC!#7..2)4'9#GJ#JL;3D,+:><U')BVF]SX![5=!BC<DRZ_0\Z%QJ>=N/"
MOB7UTL#:L'88,`P#T;8\@9XGVG$@,`_*23TOY=.Q/XKZ,+2'7]@Q9\J^>P9]
M1IN&(`YKWQ(8WA)8^Y;`\)8@VD8LV(DG5=-/0@J>($C[!$'P!"':.270=;1C
M"J:4]IN"+XJT2T.P-JR=X`P3G+43G&&"B[;G"/0<T8Y/@?&I'5<XK93/.3#)
M25M5!%5%VJHBJ"K6;F.&;2S:IT"!O2/:LI)15_;D\_SR'0``__\#`%!+`P04
M``8`"````"$`W+=!^K$#``";#```#P```'AL+W=O<FMB;V]K+GAM;)27;T_;
M,!#&WT_:=XCR?DN3M.6/*`@*TY"F@58V7EHF<5N+Q,YLE\(^_<ZN2,]Q&]%7
MQ4G]].ZYWYW-V<5K744O3&DNQ21.OP[BB(E"EEPL)O'OAV]?CN-(&RI*6DG!
M)O$;T_'%^>=/9VNIGI^D?(Y`0.A)O#2F.4T272Q93?57V3`!;^92U=3`4BT2
MW2A&2[UDS-15D@T&XZ2F7,0;A5/U$0TYG_."7<MB53-A-B**5=1`^'K)&QV?
MG\UYQ?YL,HIHT_RD-<3]6L511;6Y*;EAY20>P5*NF?=`K9JK%:_@[4D^R./D
MO$WR7D4EF]-591X@O7=U\"L;9MG8?M-:\8>SM=YNLLOH]9&+4J[M5\':MW:5
M0P!K]^J1EV8)[P>#0?OL.^.+I7E_"/()TG<.PN^XSTBX]-X=(5`I<B,,-V_D
M5FS<YQ)*:%V_A<S2.%*G'/Y0MV5J`\<J4RE*)C0KR16MJ"@8F=E]&NT?0A:M
M0/91`7)/%8-*MV'D2,4YO3N,F:$&_!9&$SDG=PU3U""5(5(9[H_%5YE2O23?
MD`JXWF8TZJK<J045_)\#S)E[S72A>&.!(]C8(7;6(8%3FJWJFJHWF\6,+P0'
MBJDPY+(HY$IX*64HFJ-N-%.F#+2,7QYR"QYY-<+N'@<:LJXA]IF1Q3-YI$I!
M(-YN[.I)N+NJZ).$.E@#+&T_H"&!&7*Y4`RY.L2VIH.NSC5[\M(>H[33'6#6
M-3<;$.QO`J@&)A1,*@[S:(O5\`C+!'BZG)>R*F$ZD)N_*^@2O!E&70M"&E"Y
M,>P>^D*[O-WZBMINF<H:ZYQ@G8#+7W9<L1(Z`GKT`=S7M'#C"TF,<)>E!T()
M(+9]-L)4I@=BZ0EA+M-#P"0/%`>$V4QWPKFWT`3K8$K3`-,=E88XGBJ/EA%&
M%,9S9QKV%]PS!].;!?3VSQ`PMBU7AEV&13>BWBGB"6&;LY#E7B'8VT8TPAV5
M!3#WSS6H42N4>68'2/<+P=ZMD&?V@4C#WJV0E]I!2-\KI#/"<R,+D=X_LV'^
M8QT\-[(`:1@RX=PFER5<:&`4(YT<#P]8="":RKX)CK'.8=$.1%ATA.P(;W^?
M5NB^(<@U0P&-O8`"JFUB^WL>!S3V`@JH[A?"[3'&?9:'5-NST3\G4*(H,WN+
MVSH40KU#YQ?33+W`H3'#.ICI/&3:G=7[CAZ<6(Z9AD6G9/TC#?=]CJ&&14=H
M[R'F?,*98:AS!W7B.A`NL`6M"KA9VP][-76D)N__5YS_!P``__\#`%!+`P04
M``8`"````"$`8R@)*4D$``"9#P``&````'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;)2776^C.A"&[U<Z_P%QGX#)!Q`E62VI>LY*N])J=<[N-0$G006,,&G:
M?W_&'@>PV5)ZTR;QZ^&9#X^9[>>7(K>>:<TS5NYL,G=MBY8)2[/RO+/_^_=Q
M%M@6;^(RC7-6TIW]2KG]>?_7I^V-U4_\0FEC@862[^Q+TU0;Q^')A18QG[.*
MEK!R8G41-_"U/CN\JFF<RDU%[GBNNW:*."MMM+"II]A@IU.6T`>67`M:-FBD
MIGG<`#^_9!6_6RN2*>:*N'ZZ5K.$%168.&9YUKQ*H[95))NOYY+5\3$'OU_(
M,D[NMN67@?DB2VK&V:F9@SD'08<^AT[H@*7]-LW``Q%VJZ:GG?V%;`Z>:SO[
MK0S0KXS>>.^SQ2_L]G>=I=^RDD*T(4\B`T?&GH3T:RI^@LW.8/>CS,"/VDKI
M*;[FS4]V^X=FYTL#Z5Z!1\*Q3?KZ0'D"$04S<V\E+"4L!P#X:Q69*`V(2/PB
M_]^RM+GL[,5ZOO+=!0&Y=:2\><R$2=M*KKQAQ6\4$64*C7C*R`+HU;HWU8B#
M0-*_A[B)]]N:W2PH&G@DKV)1@F0#AN^.(4;KZEN>@HO"R!=A1=H")SBDYWGO
MNUOG&2*:*$F$$M^V6@G1%8>[0B0"Z%I$\-M$7$`&_QS[.Y'89!`9SXN&$L\@
M&BK\3J(Q0NCZC.-L0@P5T`N%O]"?'*%DV9.L=,5A3*&A@9'I:$*\L\'O-DO^
M4G]PA))`9ME;$Y.KOTR685<&&A14_70H(3:@C*=&*%DCU,KMGBKK\X#+2[D<
M>MUFC6G]$28A-IC61J!0@DPK,@A4?]E;]I8U*#@PTP,EQ`:4;T"A!*%F?Z#2
MUM_&$A=;KVV,U[L0&_4>&%@H@=IIZZY+$J9P3*%%+/P(FA`;$0L--)1@[9#N
M^".5MMANU'@(]*KIL9)JG2@PJCE2&D2:D<`XH0=]W>M!ZV!&[Q]/(L'VW&\-
M@=E1E495U]+WS20J@2+O@JESB;8[N;@(-FF-JS,LLQ0IC>(B\.YD*`ZZPEM[
M78'J;*+M]MC$?;F$[O).[+!9:XQFQR=C#1V+34F4&POB=J6J0XH>;$"^?V,2
M[-P:I%%9D=*,!1*M*,7*7W0-2&<4+;G'^$X`L8%#B-K^$!BU%8GW,3C+8SUD
M5*+C&9>!R/.$$`YOA<"\%0AJ5#]I6X;*\'VQ\[-S4P?\T,5`AC=#T"5&'1+4
MO`%V7WP?[$-7`\&VKA5==_04&&KPC6,F3J_1=P[*BE*,%)UQ-TS,ZO"2"+J3
MIQA1$\HWC!E,@H,&HPG"8#5WN\K0,@MSC'8RIK48N4N_-WKO7@BI-'@VP\!?
MK,TB$$.4.$0H605>UP"0$2<DG"`*6I_I@>8YMQ)V%=,/`??;7W$RBV`RDV.,
MTR[`8%3%9_H]KL]9R:V<GF"K._?A_-8X6N&7AE7R#?[(&AB)Y,<+C,`4!@YW
M#N(38\W]BY@9VJ%Z_S\```#__P,`4$L#!!0`!@`(````(0"%1\I7Y`,``#`.
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)27VXZ;,!"&[ROU'9#O
M&P*!'%!(M0&VK=1*5=7#-0$G00L886>S^_8=8TXV6<CNQ28,'[_G'QM[LOW\
MDJ7:,RYI0G(7&;,YTG`>D3C)3R[Z\_OQTQIIE(5Y'*8DQRYZQ11]WGW\L+V2
M\HF>,68:*.3416?&"D?7:73&64AGI,`YW#F2,@L97)8GG18E#N/JH2S5S?E\
MJ6=ADB.AX)3W:)#C,8FP3Z)+AG,F1$J<A@SRI^>DH(U:%MTCEX7ETZ7X%)&L
M`(E#DB;LM1)%6A8YWTXY*<-#"KY?#"N,&NWJ8B"?)5%)*#FR&<CI(M&AYXV^
MT4%IMXT3<,#+KI7XZ*('PPD,$^F[;56@OPF^TMYWC9[)]4N9Q-^3'$.U89[X
M#!P(>>+HMYB'X&%]\/1C-0,_2RW&Q_"2LE_D^A4GIS.#Z;;!$3?FQ*\^IA%4
M%&1FILV5(I)"`O!?RQ*^-*`BX4OU>4UB=G;18CFS5_.%`;AVP)0])EP2:=&%
M,I+]$Y!12PD1LQ990/;U??/=(E8M`I^=B+FV#7OYCE0@Z<H/?#9^C-F]*KHH
M3E5K/V3A;EN2JP8+&.S3(N2O@^&`<E-D49*V[&]5'<K-11ZXBHM62(."4E@J
MSSO+M+?Z,TQO5#/[(6/(A-<0?"ZYK"\"8D9X(&@"W3CFQFI5=/#4&H.9ZQN[
MO6J:_#G,\V]&WC>!WD#M,%5NWI!8F3+B#Q%S+2.!0,!6KW#+EI$,P1*\WQ"'
M)4-JP%,#OAH(1$#.;74[-UC9]^?&82DW->"I`5\-!"(@Y];55JH;K.K[<^,P
M;!32?&Q:S]7,[P4#&;1SIBQU;Y+P)XE@C)#\+=_CC\,N@E77YFXMYHH_P:RK
MUQC.//B3`:\/&#<`7P`C%0K&",D=["GWSQZ'57?*)K,73#\W:Z&\N-Z046;8
MGR2",4)RR/N5W@X\OE%Q6'6XD*=G+YB^0R5[;Y+P)XE`$+;8[(VEW8TAN=N\
MQQV'57?=]B[>/L$TXZYLY>WTQ/T1]_XD$4AC+*SE&]X,Z&GNG[J*5MUURL)=
M#8VD[TTC_C02U,BRFK_U^JU3U.`G;F]U\OY@`;;'5VGUE&JU.]9JJUS:15:5
M@;K%U`HC=?"GD6`4D98I-+*2SPE_XMB6M]'N:*S]"4CLHP-_XN:HOY'G>>,M
MBM=MY-U2$LY$8RV:O0R7)^SA-*5:1"Z\:>8O4!MM&_H'B[=`2GQO.-":W8B;
MSOX6[YD.G.!#WC<=.,@AKK<#0+]>A"?\(RQ/24ZU%!\AM?EL!8=?*3I^<<%(
M4;6J!\*@4Z^^GN&7&8:><#X#^$@(:R[X`.UOO=U_````__\#`%!+`P04``8`
M"````"$`HM[B!0,,``""7```&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6R<W%USHD@7!_#[I^KY#I;WJX+&J#69K55>1$$0>=%+QYC$VAA3ZDQVO_UV
MVV#H`^&/,Q<3<_AQ:+`/KQV^_?G/_K7V:WL\[0YO#W6ET:K7MF^;P^/N[?FA
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MZ]D_?(RWN^>7,_NZ[]@:\14;//ZK;4\;MD59FH9HQN;PRAK`_J_M=[QKL"VR
M_N?R\V/W>'YYJ+>[C;O[5EMAO/9C>SH;.YZR7MO\/)T/^U@@A3?JFD1-DG18
MZY/I=XV.>G??NR4+6]ZE*>QGFD6]N2G=)`G[>4U2>3WNDYG9SV3FW]@8K+(N
MJ\%^)DG47N->:?7;]]6W:#])HK`-_YFE=W?7Z?9N2*.DWPS_D.91&[?G::?M
M81_2/'<W?SD*ZR"BMWUN8;5]>YIT$ZN9K=.Y?:W4=.OP#\E:_<87KJ8;AW](
MT]S><]5TX_#"2]-4KL6FJ.O+;D);G]??OQT/'S6V[V6;Z/2^YGMR9<`SISL(
M4<[77<97>PQ6Y3S+7SS-)1G;&9S8;N[7]W:O_:WYB^V:-HD9YHW:[\AF5&3N
M9*/EC2(+/15\)\2;9]"`20-C&K!H8$(#4QJP18#UW>M&4/ND\4YJTJ;-:,"E
M`8\&YC3@T\""!@(:"&D@$@'V?Z;QY-N)Z4Q+&EB59VFR3G?M>:RH<CVOS0YP
MQ8>FM*/QN6A'(\T<"B-_#_=R%QE5,%K>W*MR&CU/B#`*1+\O9S&%D;<]:?`X
M;]J]KIS'*C(]V4P*3+\EFVF1(35F%QE2\4Z1(04Q*S*D/6Z1(>OEY0W]LN9Y
MTNZ3U?(+3(\L:E%@^L0$>4.;$^9)KCE1WJA]TC/B"F99P:S*C52[[$CV&[7+
MY^*UF^[[AB)P?PV,:$"C`9T&#!HP12!;3.T>Z73C(D,VJU5D2.%.*IAI!6,7
M&'IH=(H,V0',B@Q9+[>"\2J8>07C%QFR#1<53%#!A!5,E#>=%MG9Q!7,LH)9
ME1NIG-BIW6^4$Y]+*B<1R)03#6@TH-.`00.F"'P6[9@&+!J8T,`T#7R>6[3[
MY#AIIR;=.3@T,*,!-PV4I/4JF'D%XZ<F;=XB#90L/*A@P@HF2DVZ\#@-?"Z\
MTR)'LF61(1M]560^SZ:D/LJN#:0^6GZ:QK74-T4@TS=I0*,!G08,&C!%(-,W
M:<"B@0D-3&G`I@&'!F8TX-*`1P-S&O!I8$$#`0V$-!#10$P#RS20[2?D)&U5
M;J0^P.Z:2'V`7RSB4W8^E]071"#3%VA`HP&=!@P:,$4@TQ=HP**!"0U,:<"F
M`8<&9C3@TH!'`W,:\&E@00,!#80T$-%`3`-+&EBE@6SG^#Q1DKYX=BTE??'E
MQ<\UZQB92\E.BYRI#(5A^Y_KY>;GHB_7[",H-"AT*`PH3"C&4%A03*"80F%#
MX4`Q@\*%PH-B#H4/Q0**`(H0B@B*&(HE%*LR(14B?RZ3O5U77HA</]39==VU
MR#HM<CDP%*9WN6>GD'/A4=E$34PL*6$="B.[@#99N@EG'T-A03&!8@J%#84#
MQ0P*%PH/BCD4/A0+*`(H0B@B(8H[9@QG7T*Q*A-2T;&G+3<4'=>TZ,C=H:$P
M):4S@D*#0H?"@,*$8@R%!<4$BBD4=BHN#Q\:Y&S"R4Y56G3R+#N9["'==-KG
M7I0D]Z"80^&G@C>_VR!M6*13OVQ#`$4(101%#,42BE69D.I.84\#;BB\"Z>5
M1^XV#1-45GJ8:)CHF!B8F)B,,;$PF6`RQ<1.R-WE;(*=]"MD\SL$]%KD:G1&
M0+]+*L&5@=)MDT5X!'1Z),.<@';[\X['Y<K#)T!1R:V5!0&Y-@0$Y-H0$I!K
M0Y2`DGX:8[+$9%5*Y'+D#_>JGWSRL0GT0$A/,(<)*EG-$28:)CHF!B8F)F-,
M+$PFF$PQL5/2O=3C/1])D?W7UO\@-P2=F^>8R7-TV+B>["):^66XZ1R9RQ)Z
M0,5DGA*Q;IU&7UZNDELW/S?'73_[KY>;8Y'.\75+`TS"E(B6LI%/7;"%HG2.
MKY<;8[),B5@N&V34R:YNOY-;WU4Z1^%RY7T!?UAXP[Y`/%N4KD05LE<=\D%(
M;(=1NB^`1,-9=$P,3$Q,Q@D1US!JFQSK+&ERAQ[()N63I])DM4^2V\GDDJWI
M8#+#Q,7$PV2.B8_)`I,`DQ"3"),8DR4FJU(BER1_X'A#28KGD]F2[)$;,$-%
MF)(^-,)$NQ)^:</&F<J#3?3KY"^O;0Q,3$S&F%B83#"98F)CXF`RP\3%Q,-D
MCHF/R0*3`),0DPB3&),E)JM2(E<G*R*I.JL].^-#8G,GT:2"A@GJB'NXW49/
M.LZ3ZZ/135J[ZB^K4\?$P,3$9(R)A<D$DRDF-B8.)C-,7$P\3.:8^)@L,`DP
M"3&),(DQ66*R*B5R`?/GY-G#:\4"%H_7LX?9CD+.U8;\+S)8E8L3]:[:Z7?(
M+8D1%%HB2H[5.B8&)B8F8TPL3":83#&Q,7$PF6'B8N)A,L?$QV2!28!)B$F$
M28S)$I-5*9$+E8]KR!9J^3-210R#D`N4E-\P027%-<)$PT3'Q,#$Q&2,B87)
M!),I)C8F#B8S3%Q,/$SFF/B8+#`),`DQB:Z$7WZ1&VWQ=>*7IW=+3%:E1"Y.
M/M(A6YP5CZ)B@(1<I&1=ADK9*`HQI@@3#1,=$P,3$Y,Q)A8F$TRFF-B8.)C,
M,'$Q\3"98^)CLL`DP"3$)"H@'86,F8L+$*F!)2:K4B(7*Q\AD2U6<"05`RKD
M(B4/WX9*V:B+I$@AT7`6'1,#$Q.3,286)A-,IIC8F#B8S#!Q,?$PF6/B8[+`
M),`DQ"2Z$G$CDUS%Q=?))<=2V+57I5GD\N0#*;+ER8^E2IM=2X(Z%0,PY#JE
M(Y24LE$:29U"HN$L.B8&)B8F8TPL3":83#&Q,7$PF6'B8N)A,L?$QV2!28!)
MB$E40#IT)$I<@'('4]C!5Z59I&I5;QO,=.%D,%-N]$2"RBY+,=$PT3$Q,#$Q
M&6-B83+!9(J)C8F#R0P3%Q,/DSDF/B8+3`),0DPB3.*45![`L$SG*!S`<#EJ
MK4J)7+&WC7=2"\8[J?2):H)**U;D*2$:SJ)C8F!B8C+&Q,)D@LD4$QL3!Y,9
M)BXF'B9S3'Q,%I@$F(281)C$F"PQ6:5$U'V'O9GJZP%3<L6R<UKIC+C\1)B_
MUX<^7*5C/8<)*BG'$28:)CHF!B8F)F-,+$PFF$PQL3%Q,)EAXF+B83+'Q,=D
M@4F`28A)E!)12*T&_1OQ.`5?'R^7F*Q*B5R@MXU1XF_,RA4H'?V0H-("A>.8
M-)Q%Q\3`Q$R(^$K8T/)[.NYOC)-8F$PPF6)B8^)@,L/$Q<3#9(Z)C\D"DP"3
M$),(DQB3)2:K4B)7**NC6PZAG)/+5)7<&!OR5]<Q5%JAD&@XBXZ)@8EY)04/
MS,;7B5_>Y+,PF6`RQ<3&Q,%DAHF+B8?)'!,?DP4F`28A)A$F,29+3%:E1"Y.
M.@8)G-\6C#U2Z=`&_M)'5)R0:#B+GI#^991BJT':8>`,)LE`;M>-<08+DPDF
M4TQL3!Q,9IBXF'B8S#'Q,5E@$F`28A)A$F.RQ(2_FOGKXA"E*5Z]+-ZINM\>
MG[>C[>OKJ;8Y_.2O5;YGO?T:%:]\MI4!>_LF>Y43B<?*@+U/,Q\?JH-AMR`^
M4@>CHKBF#MC[<_)Y='7`7J.3CQOJ@+U-A\6;UP:Q-T"_KY^WSOKXO'L[U5ZW
M3VQ56@W^9N&C>(>T^.5\>.<O]JG].)S9NY\O'U_8N[ZW[)6K[$^LZ[6GP^&<
M_L(7\)&^/?S[?P```/__`P!02P,$%``&``@````A`/1Q*IBH!```2A0``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULG%A=CZ,V%'VOU/^`>-_PE9`/
M)5D-6-.NU$I5U=T^$^(D:`!'F)G,_/M><PV#3=:$ODPF^'!RSO6UC^7MU_<B
MM]YHQ3-6[FQOYMH6+5-VS,KSSO[^S_.7E6WQ.BF/2<Y*NK,_*+>_[G_]97MC
MU0N_4%I;P%#RG7VIZ^O&<7AZH47"9^Q*2Q@YL:I(:OA:G1U^K6AR;%XJ<L=W
MW=`IDJRTD6%3/<+!3J<LI82EKP4M:R2I:)[4H)]?LBMOV8KT$;HBJ5Y>KU]2
M5ER!XI#E6?W1D-I6D6Z^G4M6)8<<?+][\R1MN9LO`_HB2RO&V:F>`9V#0H>>
MU\[:`:;]]IB!`U%VJZ*GG?WD;8COV\Y^VQ3H1T9OO/>_Q2_L]EN5'?_(2@K5
MAGD2,W!@[$5`OQW%(WC9&;S]W,S`7Y5UI*?D-:__9K??:7:^U##="W`DC&V.
M'X3R%"H*-#-_(9A2EH,`^&L5F6@-J$CRWGS>LF-]V=E!.%LLW<`#N'6@O'[.
M!*5MI:^\9L6_"/(D%9+XDB0`]7+<GTPRER3PV9&,*7#035,<DM3)?ENQFP4=
M!WKY-1']ZVV`L*T*>NCJ]+,R07T$R9-@V=E+VX(*<)C;MWT0AEOG#>8CE9AH
MB/%41-PB1/$%+<$'30D=T-N)AC+V1=^?PE:;``MM+6N$#X"[$^MK0H:(I08A
M0T@0+CL:12U,=E^M*'$`[6M6+5X"7$]D$*XZ_J8\$6)@UCHC"Q41CR*(":&X
M@)^9[D*\M+.A5IW"(%RK&B/$S,.F;=R9JU4ZEN,]#LTE,2$4#[!0^Q[,,R#`
MFO:EJVE'S`([?K%>:CT?XSCHZ_SKVDT(17LX1;L`Z]JUU18AQJ`M'D401*P:
M_Y!GG^51I,.^T"_[8PM`O*1;T%HC0HS)PBB"(`*[;P46?F9"G`-Z&Z6Y=P18
M%Q]HO8.8.;:].A8;QD@[=J^GE+*OIR@68%WQ7%45(>:^8L,8:<=&%7NP+3Y>
MY`:M:];65R1!IAX9AQ`C1"FZ)S*KUR>/-7OSUMAV+T%&*YB8!@@QLJA61,;U
MK)A;WL-$5/9Z?3^,)$ANF*MU^+EC-)$62X#1`/[0?8AJ0(3;XP8P"E4#GY&.
MD>NU>2G..`/QAD'2O3F^"L#:!-D"K:\"_:3@(>C^TC4-DFYP7+:(LEZU'^Q\
M#$"UZOH109S3P>/]*9>-,PHA1A:U<42N3;>":0A-T*7]\,SFC89J/`XA1HAJ
M1>3;="N8BLJL#`YNG@S7[N2F=5W<`GH%T;9G8H2H1D3N33>"::D866GK-O),
MD2K;:Q1"C"RJ%1&(TZU@C(ZTEREKI951"/%,$,6*/RFQ&[2^5^FS(4&8$7,W
M6&B[02P!AMV`&"&J@?^5US[FK-I6^@%;@G#3U8ZN<3?XN5GH:\,(44V`$+VA
MYK`AFA,;;EL&R;'2=$82)(_X/IZ0M2F+)<@X(_AC]R%H!J]N\':BH-69QC3/
MN96R5W$MX\-!N7O:71D]-3=&VO/(V\!=@K@,Z@;@)N>:G.F?277.2F[E]`24
M[FP)1:KP+@B_U.S:W(D<6`UW.,V_%[BSHW`;X<X`?&*L;K^('^AN`??_`0``
M__\#`%!+`P04``8`"````"$`-CN4O?P"``"["```&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6R45LENVS`0O1?H/Q"\1ZLE+[`<)`W2!FB!HNARIB7*
M(B*)`DG'R=]W2-JT+,>)<M'Z^-Z\F1%'R^OGID9/5$C&VPR'7H`1;7->L':3
MX3^_[Z]F&$E%VH+4O*49?J$27Z\^?UKNN'B4%:4*`4,K,UPIU2U\7^85;8CT
M>$=;>%-RT1`%MV+CRTY04IA%3>U'09#Z#6$MM@P+,8:#ER7+Z1W/MPUME241
MM"8*XI<5Z^2!K<G'T#5$/&Z[JYPW'5"L6<W4BR'%J,D7#YN6"[*NP?=S."'Y
M@=O<G-$W+!=<\E)Y0.?;0,\]S_VY#TRK9<'`@4X[$K3,\$VXN`U#[*^6)D%_
M&=W)WC62%=]]%:SXSEH*V88ZZ0JL.7_4T(="/X+%_MGJ>U.!GP(5M"3;6OWB
MNV^4;2H%Y4[`D3:V*%[NJ,PAHT#C18EFRGD-`<`1-4RW!F2$/)OSCA6JRG"<
M>LDTB$.`HS65ZIYI2HSRK52\^6=!QI$CB?8D<-Z3A(DWB9+I;`2+;R,R!N^(
M(JNEX#L$70.:LB.Z!\,%,!^<V3B<UTM6P:,FN=$L&9YB!"XDU.=I%2?3I?\$
M.<WWF%N+@:/#A`[A0S0N)`BC']+K23XH:[!6UDG7H=S:!WV9Z'69^",R&@Q5
MZP4?)S/':Y4M9M+#)`YQ8A`@XPUJ<(;!E4M;G,P=KU6VF)E)?#0)8'<('.)$
M&;IMO+(&#Y33(Z]5MIC4*$]`]I)P>BJLVRR&S_#MVNI%PP"./6,#L)@128?F
M'&]=@]\KM\6,4-938/")O>]=+QIZ/S:R]6XQ-OEA%,PN)7]^&L#;2=?@@?!9
MOUF,[;?85/W8%R?]%D*-^][?EC;H@78:NTZVIO>@B6FYQ)M>^,9@''Q$V6Y.
M)U]9.ADJ6U"_XG$ZE+<SQ&ZQ#14;^H76M40YW^KY$$+4[JF;73>1F3[N!8R.
MCFSH#R(VK)6HIB4L#<`J1L(.'WNC>&<V\#57,#3,904_"12VP<`#<,FY.MSH
M\>9^.U;_`0``__\#`%!+`P04``8`"````"$`]$+]YAH#```/"0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6R45MMNHS`0?5]I_\'R>\,MD(N25(6J
MNY5VI=5J+\\.F&`5,+*=IOW['=L)`;?-MB\AV&<.9\X,'E;73TV-'JF0C+=K
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M`OP0J*`EV=?J)S]\I6Q7*:AV#`GIO);%\RV5.1@*-),PUDPYKT$`_**&Z<X`
M0\B3N1Y8H:HUCI))//.C`.!H2Z6Z8YH2HWPO%6_^6E!PI+(DX9$$KD>2(/PP
M270D@>N9))S'09S\7XIGTS(NW1)%-BO!#P@Z#X3+CN@^#I;`K.V)P.37[0%?
M=,R-#C*A@)90TL=-%"<K[Q'JD!\QJ<7,,.HQX1B1O8*8]Q`/]/4BP;>/B]1!
M8Y'AK*<W>:06,C.UTHEE@X61`'#FXP)T$+@Y<"`)'`$6,AU`XC$BNX082022
MH<3+!=3@-89LS\4)_?&34XN9F_).@\5X-QONQL$;=8,W9*CI?<VE@UQMKF\6
MDQAM01A%CCB[/3U*?T-<,A9WV3`-=D4Y_9Q:C'UJ[#N2L^'N;'Z.'1417I>A
M89<U:;"KR7$BM1@H5E]HM\%."/T63^-S_$B7'H:#4^*R+@UV=4W'%4HMQGH5
M!JZFX>[\W)<C28N/2-)@5Y+ST-1B;+^'47+N&G-6P(S2%,?M,#Z7UZJR`\@>
MK0T5.YK1NI8HYWL]7$)HQ7[5SKTT6,+Y`P/'6<]@'IIUK]^`>=21'?U.Q(ZU
M$M6T!$I_,H,V%W:BV1O%.W/@;;F"263^5O#A0>%D\R<`+CE7IQL],_M/F<T_
M````__\#`%!+`P04``8`"````"$`C0K+0^`#``#,#@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6R<5TUOVS@0O1?8_R#H'LN4+'_!=E$KR&Z!%BB*
MW?8L2[1-1!(%D8Z3?[]#CB*+M$/;O426^.;E\0TYY"P^OY:%]T(;P7BU],E@
MZ'NTRGC.JMW2_^_?IX>I[PF95GE:\(HN_3<J_,^KOSXMCKQY%GM*I0<,E5CZ
M>RGK>1"(;$_+5`QX32L8V?*F3"6\-KM`U`U-<QU4%D$X'(Z#,F65CPSSYA8.
MOMVRC#[R[%#22B))0XM4@GZQ9[5X9RNS6^C*M'D^U`\9+VN@V+""R3=-ZGME
M-O^ZJWB3;@J8]RL9I=D[MWXYHR]9UG#!MW(`=`$*/9_S+)@%P+1:Y`QFH&SW
M&KI=^E_(/"%3/U@MM$&_&#V*WF]/[/GQ[X;EWUA%P6W(D\K`AO-G!?V:JT\0
M')Q%/^D,_&B\G&[30R%_\N,_E.WV$M(=PXS4Q.;YVR,5&3@*-(,P5DP9+T``
M_/5*II8&.)*^ZN>1Y7*_]*/Q()X,(P)P;T.%?&**TO>R@Y"\_(T@TE(A2=B2
MP+,E(>'=)%%+`L\323B-23R^+B7`:6F7'E.9KA8-/WJP]$"XJ%.UD,D<F)4]
M$9A\V1[P1<5\44$Z%-`"<OJRBN+A(GB!/&0M9HV8B>]UF-!$)!<0TPX2@+Y.
M)/AVOT@59(H,)QV]GL<:(1.=*S6QI/?!$`#.W"]`!8&;/0>B:&8I0,RHAXE-
M1.)"&!J!I*_1G4$%7OHPW2X[44S,_[Q&S%3GEQ`R,H>3_G`4SCY('6R2OJK;
MUI<*,M6%Q/)EC9BQ5O=`AK$MSQ@'?:=XP[6QJ<_MF@*;NB)[22%DI&6-K3V1
M]`>CSDY##VR8^_U209:NV-IM:\1`TKJ,GQS1NR%Q(0R-ZFR\NV:HH&N[`3$N
MC2Z$H7%F:G3G58%M_^S=@!A,;!R/N^RA=Q^-&IH(%-:^<6Y1&FVK.JT:K&`M
MR&69$V+J^[/#`.NXN\X1!#EUNB"F3E6F>POPBH]8U-VUCB`(TTO&=GH_'#9U
MJ5I]NRZL[*8NJXJMB:O\X])S0DQ]8']?WVW%F*BH:SNW!3GSBSR7(:9.Z]"X
MDM_ST^+\+%-7/I@$YG=DU<;DHU%3U5U'!;EP5L16Q5VWH,N6M-E]/S,NU6U3
MWQ\='02K_I7=ZSH:6ITNB*G3.CZN9!<KOKE+[-H,#83*+EY5HI%UR5+]Q6DX
MC*/3)D-AV#S@M;BDS8XFM"B$E_&#:@Q".,N[K]BTK,D<[H[0+%C?$VAF]/>@
M&X!>HDYW]'O:[%@EO()N@7(XF,!Z;+`;P1?):WU9W7`)783^N8>ND<*M=#@`
M\)9S^?ZB^IVN#UW]#P``__\#`%!+`P04``8`"````"$`S/&/4&X#``"N"P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R4EEUOVC`4AN\G[3]$N2_Y
M3@`1JD+5;=(F3=,^KDUBP&H21[8I[;_?.3&D<=A<JDJ4)*_?/#ZOL<_B]KFN
MG"<J).--[@83WW5H4_"2-;O<_?7SX6;J.E*1IB05;VCNOE#IWBX_?E@<N7B4
M>TJ5`PZ-S-V]4NW<\V2QIS61$][2!IYLN:B)@DNQ\V0K*"F[077EA;Z?>C5A
MC:L=YN(:#[[=LH+>\^)0TT9I$T$KHH!?[EDKSVYU<8U=3<3CH;TI>-V"Q895
M3+UTIJY3%_,ONX8+LJE@WL]!3(JS=W=Q85^S0G#)MVH"=IX&O9SSS)MYX+1<
ME`QF@&5W!-WF[ETP7P>1ZRT778%^,WJ4@^^.W//C)\'*KZRA4&W("1/8</Z(
MTB\EWH+!WL7HARZ![\(IZ98<*O6#'S]3MMLKB#N!&>'$YN7+/94%5!1L)F&"
M3@6O```^G9KATH"*D.?N_Y&5:I^[43I),C\*0.YLJ%0/#"U=ISA(Q>L_6A2<
MK+1)>#*)@/[T/+S6Q--`W?SNB2++A>!'!Q8-O%*V!)=@,`=CG%@,2!JCG^K_
M9@I31),[=,G=S'5@N(1XGI91'"^\)RAI<=*L+C6!J5B?%9@$X/6,,/$AX[^+
M?D9!,:)@",BVTC?`NV<+1^^]5&2O$H,$*C0D.5?+3H2#(/`!0!0G)L)*:^*!
M9J18VQ0&(YB\GQ$'Y2X4HB]2%*<C1JU)NWC#+$G":60JUD-%-DUGR:N%@0@+
M;(AH+Q^*QVB9^>*5UL#K>_QQ^6P*@RTUV:Z+&`>]%;'6V!AM"H,1?FC#^EW'
MB(/&=7S-1_]6M$9''$QC^!M5>CU4A-,P\/LD#$(\^`;;BCUA%(_)IKVO)M,:
M6_5L"H-M9K)=5ST<]%;"6F-CM"D,Q@".J&$!KX/L1HTK.<[X)-(AS_PTFXT4
M:U.1I8-%8$+BACU(&2$C`+>G'>AMWMQK9J.X3R);+:T2DQ,W^!$G'G)O<.IC
MP;YO!UIDY;1)3$[<X]_/J4\&>$N_^5WNW=`<X?JU<FJ)7A=I&OC):R@:4[='
MNGVHJ=C1-:TJZ13\@*U/"`=#?[=OR^Y"/(E']U?8KN%]KW\`W5)+=O0;$3O6
M2*>B6[#T)QG$)'2_I2\4;[NF9<,5]$G=USWTQ11.>G\"XBWGZGR!+^@[[>5?
M````__\#`%!+`P04``8`"````"$`9S&60*\"``!=!P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6R45<MNVS`0O!?H/Q"\1Y1,.W[`<I`T2!N@!8JB
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M2[&U@]_(UGK[V<CBJVP%A`UC\@-8:_W@H?>%OP7%Y%GU73^`[P85HF2;QOW0
MVR]"5K6#:4_`D/>U*/:WPG((%&B2T<0S<=V``/A$2OJ3`8&P7?^]E86K<TPO
MD\DTI1G`T5I8=R<])49\8YU6?P(H.U`%DM&!!+X/)-DD&8\FT]D9+"0HZ@W>
M,L=62Z.W"`X-]+0=\T<P6P"S=T8AGZ`C>GW-*GCT)->>)<=3C*#<PG@>5Y1.
ME^01,N4'S$W`P&?$9!%!0$V4!#*&DEX.^=C9@WUG'[J7<A-N#-N,7FY#W]/&
M@W,,W%$\I;/(&SH'S'B`F43$$X,`&1H\9OZV45\$LQFP4SJ/_$%!P)RA`$[=
M^Q7XHI,,QNF)@H`9*J#C5\9\^53#V^X]^+3WO[D&]P$S[/U*_G!.W^_>%_TO
M_X`Y0X%_+[SPU+V=@2\ZS>`T_X`9*J!C&F<43F%8<V$+*&$J\4DTC45<;_P*
MR^#QC7?C=KT>]0LR_@';K6.5^,9,)5N+&E%":9I,8?XF[,=PX737[YBU=K#7
M^I\UO,8$/*EI`N!2:W>\\!LXOAA7?P$``/__`P!02P,$%``&``@````A`/R9
M=(G"`@``@@<``!D```!X;"]W;W)K<VAE971S+W-H965T,S0N>&ULG%7+;MLP
M$+P7Z#\0O$<ORT]8#N(&:0,T0%'T<:8I2B(BB@))Q\G?=TG*LFPG@=.+96EG
M9W9VJ=7R^EG4Z(DIS663X3B(,&(-E3EOR@S__G5W-<-(&]+DI)8-R_`+T_AZ
M]?G3<B?5HZX8,P@8&IWARIAV$8::5DP0'<B6-1`II!+$P*TJ0]TJ1G*7).HP
MB:))*`AOL&=8J$LX9%%PRFXEW0K6&$^B6$T,U*\KWNH]FZ"7T`FB'K?M%96B
M!8H-K[EY<:08";JX+QNIR*8&W\]Q2NB>V]V<T0M.E=2R,`'0A;[0<\_S<!X"
MTVJ9<W!@VXX4*S)\$R_6<QRNEJX_?SC;Z<%_I"NY^ZIX_ITW#)H-8[(#V$CY
M:*'WN7T$R>%9]IT;P`^%<E:0;6U^RMTWQLO*P+3'8,CZ6N0OMTQ3:"C0!,G8
M,E%90P'PBP2W)P,:0I[==<=S4V5X-`G&TV@4`QQMF#9WW%)B1+?:2/'7@^*.
MRI,D'0E<.Y(XN90D]`4Y?[?$D-52R1V",P.2NB7V!,8+(+;&TC>-@2.;<V.3
M7"J@-0SC:96.9LOP"3I(.\S:8Z88]9BD1X0@WE<`JJ<5C&!`K[=V7X%-.JX@
MF?;TKLBUATS=7(=ZH__1LTDPM*&;-#T1])AT@!GWB"/'`!DZ?M^I!6<X<5U.
MHOA4U(=G+AS/#D,X$H2!7BYHP0/!@P??5A].NWKFKSN<?$30@@>"DY[2"_IP
M)Q@?HD<.X9Q=[M""!X*G!\>'.\'DC5-K%_O@O7E_AA8\$#Q,R3OTX;W@(7KD
M</X100NV@H.7;QR?]-5CNI,3349]V,OZ7>AWA6"J9%]876M$Y=;NN1CFWS_U
M*W@-*SAQ;UL?@!78DI(]$%7R1J.:%9`:!5,X0\HO47]C9.M>YHTTL/S<WPJ^
M=0QV310`N)#2[&_LFNZ_GJM_````__\#`%!+`P04``8`"````"$`JCL9+M\%
M``"^'0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R<F5NOJC@4Q]\G
MF>]`>-\@5\6H)P>YG60FF4SF\LS&JF0+&&!?SK>?50I(JW;I^+#9PJ]_Z+^K
MBU6[^O95G)0/4C=Y5:Y50YNI"BFS:I>7A[7Z]U_1RT)5FC8M=^FI*LE:_4D:
M]=OFUU]6GU7]UAP):150*)NU>FS;\U+7F^Q(BK31JC,IX<J^JHNTA:_U06_.
M-4EW7:/BI)NSF:L7:5ZJ3&%9/Z)1[?=Y1H(J>R](V3*1FIS2%IZ_.>;G9E`K
MLD?DBK1^>S^_9%5Q!HG7_)2W/SM152FRY8]#6=7IZPGZ_678:39H=U^NY(L\
MJZNFVK<:R.GL0:_[[.F>#DJ;U2Z''E#;E9KLU^IW8YD8GJIO5IU!_^3DLYG\
MKS3'ZC.N\]UO>4G`;1@G.@*O5?5&T1\[>@H:ZU>MHVX$_JB5'=FG[Z?VS^HS
M(?GAV,)P.]`CVK'E[F=`F@P<!1G-=*A25IW@`>"O4N0T-,"1]*L[?N:[]KA6
M+5=SYC/+`%QY)4T;Y5125;+WIJV*?QED]%),Q.Q%X-B+&.;3(E8O`L>+B+EP
M#,=]XE'L7@6.H\K#_8`>=V;`<6RL/?T(;J\"QT'%T6S3F2^>\73>J\!Q4'G>
M4YCE78?@>!%YM$,Z"Y4N\H*T33>KNOI48#I#,#3GE"8'8PG*0\BQ`!F#\%X,
M0O!1D>]4I=."\&I@XGQL;,M;Z1\0[%G/^(P!"T;&]&R>V0X,C6TJ'`PGIHT<
MOE$X,$.CB)V`O^.=;'O&-XH'9FB43$[HX,UH$,P#T2`+9O;M.3GX01OQ?E@+
MH:_^-6-Z+O^4VUO,G&>"6\R"9\);C*`3/<#$-QC^3LD-XO(PG+&0&Z;&R@VE
M,*0S;D@-_M8^8R!9C,,N1,H6)0*4"%$B0HD8)1(9P;D(W9VZ2.>O??>5,80G
M;;168:A&IVS;%-QDC,Q-E`A0(D2)B!%NEU3,N6>9"V'<8U0CD1&<F^"<Z"8^
MV6DCT4U+<),Q\!RCXV)LHD2`$B%*1(Q8=&Y:II@4T?:)C."<A!?FU$GY[*:P
MZ*"8+ADC<Q`E`I0(42)"B7@@Z&M0<#BY?8US#MZ04^?HC,9CD#82'10BS&>,
MS$&4"%`B1(D()>*!N.7@[6N<@W0]-*EIY+%'8=XY5W@S^@R1&8<2`4J$*!&A
M1,P(EBR-6?_A4U$B9S@CO6>,I+!@I%#.^`R1&8D2`4J$*!&A1,P(K\N31O@B
M)*/D[F7./@/JQ,<#L:-Y`VU;=+"'V`B[,QN&F!_>+4<XE@L?H1(/.,1U;4L4
M"3GBIDB$(S&'0#BZMNT)22GA&,]V'*#&'O%NT@I],JT?2XP&J^OY6D><X#W4
MSQMSMA`-V?+$;&Y9UJ6L[9<J[$Z]"-0IKC`T(2X2X4C<(Y)9E$@1WE1:KS]O
M*JOR>5,%/WR#09+GW.)(,"+T76!J\(O4]",4K2%/FYKP3-%X_6X=%N-((D5X
M>VD=_[R]K/KG[#7$BM*0+1&ZB-SV2)\L3-NS+U.KCUE4)$1%(OQ)8AQ)I`AO
M*H34_S"5MA+3JY`9?8-!TI@=$!J0AJLM/.XSYJ[>X(&^&W#A>,]'!*.1OBL8
MXT@B17BS:<7_?`2S=0(7P;8P&7WZTR:,"'O)FIJ0E+?\93!:M%:V%NG<#WL)
MR7!&.!+C2")%>#_I"F#BI[PX-=AZ@?/1$5XK?@])>KG%D0!'0AR)<"3&D42*
M\';2Y<#C=K+%`R2]<1ENV\+/";XQK#`ND%"T;'$DP)$01R(<B7$DD2*\G71Q
M\+B=;"DQC<ZKM9/!&&EPHDB`JX0X$N%(W"-]$3>4&GSF2:0ZO)]TH?"XGVQ9
MP?EYM0!@C-1/%`E@%XNF7HE*B",1CL0]<G<A)95@5K+M,K9I49#Z0+;D=&J4
MK'JG6V$F+-'&LVR;SC>6L)$`/^P+YP-C"7L%<%X?+\#NV3D]D-_3^I"7C7(B
M>Y"<:7-XM=1L_XU]::MS]W/^:]7"OEGW[Q'V20EL4<PT@/=5U0Y?Z`W&G=?-
M?P```/__`P!02P,$%``&``@````A``AL7A'>`@``^0@``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&ULE)9=;]HP&(7O)^T_6+YOOD,`$:H"ZE9IDZ9I
M']<F<8A%$D>V*>V_W^N8CQBZM`B))/#XY+SO<>S,[E_J"CU3(1EO4NP['D:T
MR7C.FDV*?_]ZO!MC)!5I<E+QAJ;XE4I\/__\:;;G8BM+2A4"A4:FN%2JG;JN
MS$I:$^GPEC;P3\%%311<BHTK6T%)W@VJ*S?PO)%;$]9@HS`5']'@1<$RNN+9
MKJ:-,B*"5D2!?UFR5A[5ZNPC<C41VUU[E_&Z!8DUJYAZ[40QJK/ITZ;A@JPK
MJ/O%CTAVU.XNKN1KE@DN>:$<D'.-T>N:)^[$!:7Y+&=0@6X[$K1(\8,_74ZP
M.Y]U_?G#Z%[VSI$L^?Z+8/DWUE!H-L2D`UASOM7H4ZY_@L'NU>C'+H`?`N6T
M(+M*_>3[KY1M2@5IQU"0KFN:OZZHS*"A(.,$L5;*>`4&X!O53,\,:`AYZ8Y[
MEJLRQ>'(B1,O]`%':RK5(].2&&4[J7C]UT#^0<J(!`<1.!Y$_.!FD?`@`L>S
M2#"._7CTOA77E-5U:444F<\$WR.8>6!<MD3/8W\*RKH]T7_;`WW18Q[TH&XH
MT!(B?9Y'L3]SGR&'[,`LKIG`)I9O$.,3XH*_DTGH6]_DV]D=S6D84L+H;"ZZ
M-&>8J,?$ISMW)2Z'",L;W.CCWC2<8M`^>0M&D7WGA6%&75N#\60<AQ?$TB)"
M6$^"<WV6-RBP[TV'&\(3--P_/<CV&,47T2T,,]2_(<+R").M[W'8FX;?R]8P
M0]Z&",O;Z!9O&K;[=IVM84RV_CB"3V*GO[2()`J2X$Q8WI);O&G8]A;%H7WG
MA6&&^C9$6-[TWME;5(8SU?![F1IFR-L087F;W.)-PW;?KC,US"%3+_:\Z)R8
M64OZ1)PDP>3\0!MK9O<RZW)+-O0[$1O62%31`AY9STE@Q@JS=YD+Q=MN_5US
M!7M.=UK"*P:%Q=ES`"XX5\<+O3N>7EKF_P```/__`P!02P,$%``&``@````A
M``2400B`!0``XA8``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R4F-N.
MHS@0AN]7VG=`W'?`YI`0)1D-M'IWI!UIM=K#-4V<!'6`".C#O/V6*7?L,E$&
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MA@3]6XKWSOC?Z4[-^V]MN?^CK`5D&^HD*_#<-"]2^FTO?X*'O='33T,%_FR=
MO3CDK^?^K^;]=U$>3SV4.X(1R8&M]S\>15=`1B',@D<R4M&<`0#^.E4IIP9D
M)/\8/M_+?7_:ND&\B)9^P$#N/(NN?RIE2-<I7KN^J?Y#$5.A,`A70>!3!6%\
M=I!`!8%/'82O(A;%/T?Q<%A#EA[S/M]MVN;=@:D'X-TEEQ.9K2'R[;1`/J3V
MJQ0/C\"(.ZCEVX['&^\-TE\H28J2I>MH"55D-Q2KJ\0#K"L;I,MDDZ4+8`+<
M9Y0/68S+:_AA&"E*ED.)Y+@RXP<"``DQ`>YW+,4`:(X\L3I&26A((JK([BD(
M&@29CB;%6Q=&>2U*X-..4Y2LL*@\"#EMSTA[&/KLVDZP8$U,QY)B"TN'Q5*A
M)!ZP8I98S1EI7H7!;:AX#I046U!6+E*4A`,4B_7D'9`STLITGDF>8(%,SY,4
M6TAZI)@GE"!2HOM$(K/1P"5`<K^;[`-2;`&%U]0C$$JP<&RUM&PBPV;D#6+]
M,&%*YC!)L<5D+:X4)=@ICVTDLS6,=(()$@/_F9ZG06U!6=VF2H.9"OPDT#UC
M]:B`\T"["D6;9^5HP\03;)]DJ,&$Q?:L(JT:FC))9YT\K1CZ,&&R5E>J-*J(
MONY7)0M#J.9(/TVQI,U.QT)3)EBZ!CC=&6I4%1E+K#)G5,`C7Z>3HLTR=H:V
M#)U?G3W4@14::N#O56,MC$R%N2VA>+,,7AZTK$496A:>*HUR"C^V,INI=C4)
M$SU'*=<LCV=CD[<WO%1ID(L'AF^JF88Q5#N/]+@HV"RG9V.K-S8U54_4J(2Q
M.-"37)&9@C@TC(Z2S;)\-O;\4-NV(C-=/32V/L5E-AO4E&J6Z;.QZX?6Y$Z5
M!B=0,%J7INT;K02*SW+]04U=/[2Z395&%3&*N)X^F"PB2,*5+C(EFV7Z?&SZ
MH5Y06$2E0;+03^SU2-M#7S]/P:013[98CK9M6FRH1ZS`4//I_);-92H$-FMH
M"C7+]_G8]T,=6$&9OL^2%1]A$4&0^'K14#3ITM/SA9YNYBNR>DXY:HBICV;9
M70T%G.7\\HT4G!\&KS<=^QBM-`20GB*SNQ**9VT`\F4Q!(C[[VQ\O!$8)S]5
M8M00S%$>[VHHJ+4A2-#DYV^UXXTATC-)@:(&5\"(\'8C19NU(_#QCA#9WJLT
M:";!TN>C%P&JB)=AH&-0.&MCF'@;,-X@HI$7DRW`GH%FHY[!!$U>2DQ?NX.:
M;@^1-E$LI=)@WAZ":&7ZQB#)+`GL$,81AN+-VB."\1YA'*,5'FK4[L6"4555
M$"581<9QF*))3S=<;UI1X;[0/E9&MC$K#5YH!#<.Y%1PXT".5XIX65:)]B@R
M<3YW3M&\RNM"#F__UU_Q*C-EZW2XR;1^S^"*<_C=NS;`#>,E/XKO>7LLZ\XY
MBP.$]!=+,*P6[RCQ2]]<AKNLYZ:'N\7AWQ/<)0NXM/(7(#XT3?_Y1=Z"7F^G
M=_\#``#__P,`4$L#!!0`!@`(````(0#>:`D0Y`(``'4)```8````>&PO=V]R
M:W-H965T<R]S:&5E=#,N>&ULE)9;;]HP&(;O)^T_1+YO#I"$!A&JAJ[;I$V:
MIAVN3>(0JTD<V::T_WZ?;0K84`9<D!B_?GF^0^S,[EZZUGLF7%#6YRCR0^21
MOF05[5<Y^OWK\>86>4+BOL(MZTF.7HE`=_./'V8;QI]$0XCTP*$7.6JD'*9!
M(,J&=%CX;"`]S-2,=UC"D*\",7""*[VH:X-1&*9!AVF/C,.47^+!ZIJ6Y(&5
MZX[TTIAPTF()_**A@WASZ\I+[#K,G];#3<FZ`2R6M*7R59LBKRNG7U<]XWC9
M0MPO48S+-V\].++O:,F98+7TP2XPH,<Q9T$6@--\5E&(0*7=XZ3.T7TT740A
M"N8SG:`_E&S$P;TG&K;YS&GUC?8$L@UU4A58,O:DI%\K]1,L#HY6/^H*_.!>
M16J\;N5/MOE"Z*J14.X$(E*!3:O7!R)*R"C8^*-$.96L!0#X]CJJ6@,R@E_T
M=4,KV>1HG/K))!Q'(/>61,A'JBR15ZZ%9-U?(XJV5L9DM#6!Z]8D&EUM,MZ:
MP'5O,KI-HB3]/TI@PM)9>L`2SV><;3QH/0`7`U:-'$W!6:5G#$D^G1[(BUIS
MKQ;II:`64-/G>1K.@F<H0[F5%,>2D:U8G%#<[B0!X.T8(6W7,ZI%$`OR]HS1
MSEZ'41A)?"!);,7BG,)"A/\Y1#R?/B7.$7COT9SD%$:2Z=Q&GVYBA^O=:0L*
M(KL<2HD=J+']KX61I`8J-!];LC@KL>#@Z;D<3HD=."<EA9'$&LYIQL7I.0LG
MO09'B1T<IW,*(SF-<WK.PIE<@Z/$#DYJUZ4PDG?[Z=UI"TJ=B0=[Q?DF5V('
M:N)`&8G=3V[ISFLLO.P:/"5V\/:[C]D>C&2'E\9QYE1Y<2C)XB0)TWU;6FQP
MQ%V1.ZUVZ#(G>5O-63Q+<YK/')SF2!CPBGS'?$5[X;6DAMTI]"?P['!S;)J!
M9(/>^I=,PG&G;QMXO2%P+H0^B&O&Y-M`'<R[%Z;Y/P```/__`P!02P,$%``&
M``@````A`!("Z#981P``F-\``!0```!X;"]S:&%R9613=')I;F=S+GAM;+2=
MVVX<5Y:F[P>8=P@8*E@&2(HGG<HN-VC*ZI;;LEB2W)["8"Z"F4$R2\G,K(Q,
M2>RK>HBY:6`&T+/H4>I)YOO7VGO'CD,F*:,&F*ZQF!'[L([_.NP=W_W+Q^MI
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MO%XMR]'J?W6'_;K[AS34VYM%U?WQZX/]W3]W_W@"`<9&A.?3\K+[Z]<7Y;3N
M#91F.:N6D[E(-RZ>E:O-SSV?U*-R6ORE*I?%<XA>]^89(EJ:)KP>9AL>X,\'
MW3'?+DN)6_'FYOI\/NW^^O7I7UZ>=/\89.!U=3D1Q9&,7\KKWK:^/KVY+G\H
M;XJW5]6R7%3KU614[R`YH[T-`YXB9$L(\`+!^5C\>W73?>[K_?W]@_WCP_W'
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MI:EQ?*0GRL_+D::_*:;SLF?PXP2)-1L6TJ9IG&M`'EJS[10FT)$5IG-]I^,$
MWC*F3[[E`:GI9"4.UB[9""7:B3L>6.'7GS]]_M2EHFGXU7PZQI]_;0*QNNEQ
M"^&\J)"\,7[=#,*]_3U9-;BW+%"B=?7'XF!_AS_I_XK:S46Y7EW-EY/_K,;?
M%K-Y_.NDKJ42$K_Y-GMB]F?;=-OFTV(>'>\</WUH$SW=.7[X4'_9OHBBQ`9=
M%*C_Z"JY>QL`LU-=GZ.``00<[:#*,E*KR?MJVI.\D_$8L9_/T$8I]>YD5HS*
MQ03M[)(?,5Q?KZ>8;<CA*HY=7E97&`&&QG*,YGTOE;\UKBXFHTE/>5UTC'X=
M[G:7T!,RV_%=WMQL],_P%\"I"N]93K_9Y`3>K-BWX9-7%_C`&7YC`LG.YK51
M;PLXZ@ED$L3N[GI/]H3SKF^XX-[UZ3O+]L:5!Q<<5.#690\^/KSFP4>W+C@Z
M]\0Q4Y17>))2<N[&AV$SR?UYCD>_D_>O/HZJQ<I!1C$N5^67`((<FO<`05@@
M:">ZU9YI>UW5(%?T709I7*'-<_.(73[_:S5CLU-[K!Q?3V:&(J7^W2==G^1E
MH4TV=?<Y(]#%<GY=A&>A8_<9]Q!N!(K[81/?]#;Q(N*+87.1?@X##,\2?AR$
M`K]4*[QHW5N?O"A*#E)<S0O\0W6]L'^93Y`MU=^(\`2E1O,90>-JHO]&3G*'
MTEU0G*XH5ZOEY'SM6(PI1@Y+<^/4?==)QH.9+&KI#YPV/=K].B/.G,I+%9?$
MEP5[N;X+_AN:9YC\;;T8(N,/93T9N01.IFOY`N"8$;Q`C-*NY5:[V_VMFEQ>
MZ8T2XI:7(K-[3O?!F587:\%S$;&<CLSE%.>_?][&]K=MPJFP]?/I_,-&Y6^4
MDK!W\GX07)^,_[JN`ZXQR4)X`'-50Q?^*AH9E+>-B75)YYJ1>_Q^5B$8^!F3
M4RE]>:V(Z#_M#UWJ_C*?[2+3T_E-12P@[+,+S2"CY`L7[:-L4*L?XXMF6B;,
MNIHOOWB4DVQYTBA6?SU98S3N**?:@E$I(5U0^UP$8!L?)JLKK-[YJA@3Q@N1
M%V54Z2XM3J]*D"6(I+@H)P'V:4$?;L/A_F*M-SU@,$G/4&V/1]+_6SG;7=\+
MS$MM%K?A?O>9LS6F'@::^UH,AD*]5Y;S456-Z\),=4W$:"_?R4:D?3#5^\D8
M@I_?0(;;UQG`$-YCRUY:"Y.GM[@;CD03('DU6@<6U6;;Q;/T]&A>]^/?P65?
M.#[;NB2].*YP"9!8[#8>2OKM/[9$W*>;0G,\0'%.RF8VDRN5^%M:JLNDK>^3
M!-O\YIOU8C$U$(ISEQ)@G]?+2B_8HB\P96QE8^+09K;(G4=XT`/][OJ>3S["
M_"#]TH.0&`B6H^=77VSB9N1D=X*-+ZP7&`KMQ`+2J*O5QVHY(M'2'09C8;MN
MRP?;LDA6B8RV<"6AZ`[T:GE9SH)1-1%\5M6CY<31`;3]85U/9N1\NN\!*&2%
MQ.RS^93`!FW;G",]V"M^[T2;\WS%?0*7XA]__S_RVV3(_O'W_UO`6OW!<X/\
MX1LTJ"B+\\E\@9^]+D>6*$2"Y!=XI[A0)A260_P`*K4E!7C$@>P)][5"35;%
MM1)-VJE1:8F'EQ1*@6JWSE?X=Q)D/(?#J\9[RDS&Y-T__OY?-9F&<HQ7F(_7
M(UG-V7@"AJYVBG)Y10+^HIK9OUCO>:4UA.6P-@FLMFH+L3`,QER"&/ISD`8C
MP3<TR\L?_L?ND_W#ASNBB,_`HS7&3NF"P2E&H$!#6DN(!WW"=ENSXE7D,$;S
M);D3<U6(WK-J6B+!9EI>X4P5D!\\??)$<3L9X5F]J@#RI^$=4&EK2"/6%<3Z
MV[I<HJ8>M#38&X)58*Y1G.V7BKE(?IZ"#MG';%(:BR:K@#-@$&NBPD&2\%+D
MZV6(7Y%`);*QS,'G3Z%$<+1C1`_"5=2D7F)6`O)/2.1L--^2FD7P8-O>D8&!
M5R0E5T#M*=)IW!4SRLO+976IOU\N%:`A-^[=F/O>X:.])\7U9#J%=,@/#%^6
M,`?#Q8!-2N/>P[W]^)A(\)Z]RV0:CD@602N52UIIU65Q[X"447I+&3G6LB0V
MX.7BP]4$QD%9_F%R@QTE830A,T(=J2)//+UQ;9"\]G>&E@T2FAP-(TCJ19*T
M]1FZE#8N36PT2G;_WN&3A@Y%><&2V)O42R,U]`1ML_:+"D$0K00^J%Y)Z2\(
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M!K1+CP_K%%36CQ0UCXID['JF_VTS74'`@0`$8DINFSA5R8!@/F8RRTKY)M@9
M0H[,0X&9J*S)1^@_#$SM%<\H4$%]+6IUA44M*-RID@WL1?O)CXVNDG(?MYU/
M6E7IR89.-DH<E=T^B`)B=LYP3<L'\)BCQA2"@P#,YFV=_0K<(E7)4N`AF6T3
M'SU\TIBTO2("-MG4$11`D6SY^E\+./!6U7`N+]EAJ0A>!H""P*XA/(/4J_68
MH(P1>QC*'/QH2JZ/E`DPB>1TW>/TF_4U`GRC);^97,ZH6F*I5\4`D.UBW<.]
MXO>_K)21!:)GVO6,3#I.NSN#I!#R.B:5D%A\,KD6!4*Y-H@P^Z.TZ]EXW!F&
M>#TKUU0Q`N(DGDM_2*,,OGM%(@H@6,V@)R5-H4`Y7U:Q'%N`^NO>F[WB7T].
MSHK[8&K]AP%J:>W%?$JX%:5YJ8"1;`>[LYU*PG^=:4G4I5EKC=-'JRR!9)+Y
MXT>">^4H4/1KM%]Y2<WQYL=3FT(`*%*`M7DA'#F%]=62.II&7D,8P>(Y.UZN
M"9IVBHA7+^;SU6RN>1G'BS4-!;(0D;=QL*+A3/TL4]QSV(K%_[9U9`0B97S0
MD+Z$/5H)L(DSX(6V;K!UOD`(!<I$@]_/B&"!#84H]P>GW9H%5D>#UI$&.(.2
M3==CN6=2X$UR+GJ,^/-\QF9]U^Q9)D_,;+TPHY16U]*8&!Q8.@EA26(\Y$D:
M2B]B>4@2([UUE&<BDME*_2K);VII,K8F)P:RE7%0<(^5A?:>5I`-L&4T4I]I
MQ9B4XWS5(D63,-`R3%P;'FL%-4T.`'Q8C8TR34#U_KJ>@25AAJ7?Q%($=F&A
MYG^QG%0(R^;66"U-=D%,)/0FG!LUX;C=CQ7+9/J/$J\486`PB+]M0=WY3V;X
M^FGAG2+"/L^18LJ[N_\N:;D@"QORAGH1U=(C'3OOOCSR)2[R+M[)M4:AKDO)
M!'F:$-(2E<DW8F3CJ)ANJ.K>@!7%28P$,%3_5B#N>NKL[=GN7U%RAOPQ(/=>
M-N(M.QQDQZU&SC@K38]4#])19YHM[W-=OF,3<7Z33K)$:R^C2#=E20@G".U%
M;G+5ZUCK;\N>K%G#S\%%#\O0'LR+MD8%`<R;]*-9$^R]`N%1R9<7%,&7$QH,
M6`PRR8_Y>L^KZ80:F@4=+O,U57!5?*)=Q>9-EM2\D6W&`"6(QF$RJ83%9>CI
M''@I,WA3W$PJ-*@D%I5IAUT+;#`./!C6,LZ0K5@Q#E,2^BD@*R[6%I^2V<`@
MR*)KY8V%+:[7M.;4U514%B`Q(COMZ9&;>B(&)V;<2,L0Z`B;2U/C3$8K:4^4
M4C`NBQ]/%!$R):&DK]N0EGN9[&71(I@"A-M(61,&-ZCBK^NQI1J4;"&FF$]%
M:U86QI"QW52E8-<AZ9AEWIT4,ERA(RC^)JVC36YMX;FJ>88O^NCG-=Q>HD5O
M+-?\9D&_31>$O-H0G(M%<;-N58SV;K[$(6@H-X\95]E0N`I>PG^<39/B"8+E
M&81L2'.;BW:9T?B."*BSS<AD6:9EV$*MQ9M`%P>[F(_=QT_W'EJ)+$AIR_YN
MU#`WS*BV%C/TU$YQ*5-&W70YM^P^\A\TW%]J+\@,&5ZW[Z&ZA'ZNLLQ_J!M'
M5'J>W,B+Q,E!`Q=X8`1KUMNPW]P%6,$B<L/Y8H[]1Y;1WY&K6ZYVD?!K!'V@
M@<X$L-7TU8AD3)1@+3O5)"5+;;ZL>FPDWBMLOUYI3CJDG4-X)#+?@+S*=2GX
M@H+'YL(1A@0T*/511F;'C)]9M"6FX+U`O.^#)V`"RHM],GO%Z,V$,E&8NGI]
M_E?LASC+@.1<E1'3PH.:(J<!1ZJ9T'YA1*AEN&50Q_4V>T&&YXP%8F3?FFI<
MB<CFOLW-(.7D\K6X08EP"F$P%%S)YP?,1]N%HV6B:ZRY&;</#5I14R,/F_B9
MD5?@"E!2DZ*D6_E6&35"Q]#G=U/<1X.KCVB1#4F2W"-^_D7U=H%99(!K*DX@
M0M$7A$MJ+U)9,TEGK$JB)YMQ&8>1"2"J)7C`II;FH,;GU>J#8HW`*>4_*!HL
M&!P:N\^\QD[##+-D8TR(`+_Z0XT'<0[+R4?8'MZ`4J3WFEJGI,C#!NBB^@7(
MEA43<N\B+]4T?_9J0J:?R)O5:E0H@/^DR@SKM<?);$'O6ZK(APFS`21GL*P9
MYKHDUY?>7R."2/K\O*Z6UGH:1Y3,##ZZG@T_S"1"=19X]5MF?[9]'?SC[__[
MSVN\KBH`R(K%Q<%T.>$=1)/TQR\+)1@/D>R&B8G`VGXT^\J,&,NM3Q1:D2D>
M"?AMY%U7PGV!ARSPA9/4\1Y$GQ5_NV7)QADQ-:/,9B'<*2HR>0C\V"KYR"&[
M$S1577]ZT],]7]E1L[(T78L5FR?LC?@6RHTPCS<F>0$)(@7#1KM>DU*'OELL
MMAR:P<G0^TJHV[6R#A`B<HAF.D\^&P.QF.:I&VW!W."'@AMLN08LHX?L0Z:Z
MM^G/`SVK)V8S7[8S6UW)R`J.W9^"5`__^7#XST?=/\O[?/YD[K;[$T=)JIMH
MDBY`OCV_>Z_["F(RM--8RPK%%6FWF\?S<O0.==S<GNY=:$$/APU:=PW]1M"[
MO0<C^NWR$J4(&LKWY62J*,!@E7+]V<+=0+9L:\OL`@F409>9B%*V;K=L!4ON
MJ=20B3!4C-C>H;FVN*_$P#=(NN4+X!V>']DTA!AZ9P%'H3?:`Y9HP,RW!AW+
MP%!P[T-D<;\13%/T6FY4L2?E%-<.>!",D*DU0#^GY!<APWQ<$8]P*H6.-?V8
MF:XP6'`MB`H[(GK`#*#74R1!!RJ^:*TB/*XWJ(OL73"W/2T=U,AVKOG*H[A@
M%C/GSLI:[4BQA*2*LM7%6`+"1$9@<\ZDDXVWH#*.8YDXDT;@`SJ3`Q93*#R`
M\3$Y=:6Q-==N9,&UR.[;">25V0Y5RY`9BRT5[B(##HUPEI@SYW7\U8+BJ=GS
M&)98VQZ^QK+<K%90;Z<@TD,H[#"#]Y\!?4J5<->+.%8.XQ=5+&^;VDSJ=[L7
MJ@RHD@XMJ>K4"S+`$J!@H5OSQ2$C!2U%BD8,Y90T0=0&J]W=F<^EL"53*$T7
MCM(X14LJTX:B;^-ZOR@'W<@ZFIRP7J%1#VU3R2VK.<NJQ-1NJL^Y>C=/I:1>
MOD]H9J()"RZLL6>VML,!,AJA[7)+$Y9(GM83V>ZM6@!CQ(>667'=L+KA+?'C
MWE%6/B=)XNUD^:H8BDXFI:?UUZPH9^G./.HUX5FLS]5UXG%PC`5\^UV^>&C8
M`&'U9F1KM!:CAO#\J`5XSL,211&DZ\]L3WE>U[@H:)%+L1D!"A'G`*P\!FER
M1PUCK)U)`S:0(XZ6:57C'X=WEIDA@'!8&UH7`I?S<);-3J'*FG9<1,1%>10A
MD\)8!/&*Q"V&J$J@6"HXA$B>@!"-;F2?D&3EC6C!L&RMOX;M-#Q!1$2-;.]M
MT6)549V+#]C!+S=YS!#U$_]-,#(EV6SF0^I*1)+(IIU;M!PY$@R$R5&DU4WC
ME)JE4>:SF!01(A10^M:W%:RNS09>'[#.(9BBOU)D"!,J:*;\BC,EZL_2:!.R
M[>3ZPG`QEB?8[=$ST4QL[>I%DA[\:L\EOI5L-O4L2X):V,DH6!X69A&4$F_D
M>_$.=+AX&XP[%-<B#]$MX.H)^^=/V595U(Z^=3@@N&]"'<Y<]L\0_.:)ERXH
M?.XVNOOGGV/,W_WA--CR[M_CL5"4")[V/4GW^1=9!^30?KK/N]Q(<1LF=I^Y
M?[#?_=,W`R?B&D5DI7>9^_[#A]UQ[Q\?]R*&-@E>;@]?)#XZC]`"MY8U5BJC
MR6BPQ#[;HXX)[SFR5O55:.(*R$`_H4?)(9P+7<&>JU%,:+4H@YY-29AY;BVN
M]73@E"*;&N@HM?V((\8N8/K!0E(F]A^CAJ:,VR6CJ)!T.;05LB72H6J+)`:?
M<OR?A)3[;Z\46[A`N8!C)Q1-@3CDV11RFC%YNL\)HQO/3&1Y!FO)8HO)+V,:
M\$#=)"?F27O1\KL_R9#'>&=,;9DC;*&!$WI>J]N6M,AY.7MGNLRU!Z-WK`V,
M&SJ&=\^IW=E?-#H':?3_D:AN`DEQ!I]1N^F/5/&=4Z_A$!5Y$UL62N!H,QB=
M5"0WTEA#*2T3%/<%")G3A\2(-^XR;0<`PE@JPT&>F'?OAJ,<BNB$HT8CB5Z*
M/!2YJHFV'PSNJ<,V*T(IH^I\%5QMO("!0O7..Y_9I64$9<:O.6N>&_[@:20;
M8KP:9Y,-G54?5X7*A"K62"^@P/1&0JFB1S.^$2M"4]5T@AQ)J>A<9&W*5V+'
MU0)J9<=0U*']H84;E'3T("1&84:++"EBEKGS6D^97N?'E/IF0;[`0FOX-,A]
M9$V06#L57^(AH!CUV/M^['Y4>";/2B[*LM)\?#6G]7CS$EQHU2L#==B.@9]"
MY2I9'5,FLSDT?I4SB@37"]IZ<7E:2AZR1W70'ZG5*>8,5DJCVAHWV*0]>D/@
MBI_D4M@.6_L65/.E'"XCHE1?DB(89%3Q=JYCBU00M+ZHF,IMSDC8@V+=]II\
M85HG2TM%X]F7EQ`+\LI4#+*,EZ<,;!0<)-^X:DCN(SCEK8<D0G01X@-G<96\
M+#$M]HK(F;\AS#HT!;$GZJ\T_05X11V,)CW!%E<D&9Q]FD3;'Y4@P1V2?S(M
M[`UI-.,J`:E5:0N&6,\*ACDU7/NH"E@QL0-Z7"EILU46IO''J*:?LG9_DM'>
MM%^21)RA>?T:`DLO2S!<C+QUR+M0B+I8&+>=Q-76ZPN=JM8`""_^AD,@X#9&
MX_]YA4%L$6]9LNQ&BY@#NDLQ=3+2._(@V]R<Q0X8+J4J9-EP8M8MCSJ$$V=0
MVLQ\L#+!S32$4>5KLK(H6"#2R@\6+[;DT\R;AX:AQ[X(3H$<\QB7<&)([64;
MIA@]^^B-#),<HRJV89LI9L-J&[+T;B86BU[05.@W!8@[]PYT-I\_Z/5TI-Z\
MG-Z-'0\H[L)C1P@#O1W"A`0G@B;^M\!+RPCW\3E`=01_&S$]=9?XFFQ)ES_B
M6=ABEN5SN1M6W`P-M!GC)?7(EZR3(1006SR2[,D3MQ<:?3<+E81HX[@TR:K$
MEW\U"-@DU)#?!LO%T]%@121AG#2Q013=@@5QE`9,`#-C'1Z,<!!I=/?:(`7F
MZL*SV$L0-GZN1B4=HJ8]KEBRD3:HD>U$E(`O$T)O#N;BQVF'D&\QBVC&QG?.
M80ZEQ;`XY$RYDBKZK,B<O-J0P1OHQL$8-:9D=L/U3<TP9I(S.O<4^BP_.RAL
M.WAHO/64),>>DJD-G0WHID[@A>M"<F<$AL2Z;#BF2M/OMI\UP;!_1]QU7'A7
MM`Q>O;&>6HE>1>5T(!:ZR[BY?&%1@#_\">M^L9Z"SP!*4=X:O?7J!`B?HQ$4
M0-7ZZ%U?T%O6?V9`">/RLTXXF3'&"9#-LO*L^Y:!Z0TJL90@W^TU^`IG=LP5
M3;%"@Z5-X^/1B7)0JJ;Z^U(6%>;SK%DSX(#"?CL)Z<[-/+-AM#MB#QM'!KII
M-@SXQ6L+@K[\P=KI>Z+T(GE!+?CG^>QR]V<KO9]8F;IKB]YF*DN2:5+1P<@]
M:Y?P5/7Z8!!=5:-[E?N?R?D6X@%H`T7.G.QY.(S7;LUBQ=9W%UH#I">=ZF,D
M<)A3N%WVXAP+M/:N5W./4C/<"3BGV:GU8B)K\J"T-TG80*>:H\G&X$+"H61^
M#3U<9ISL3&:3L=;-`SKGXR=T-08"8BRQW0JZ,U!J&X7(<N,BKJ0])!+YT\`.
M]XK?KG3L7#\%.VG@PE@9T$76'#?8V)^6[.(=J"HDQ4H:DK31XWGL_M+,W;UC
M1-L)TII#K.AL>P<.P34'#.])2"?XR39HYQ7<[B?>=+!K/+;P!0BA)_;/X@T0
MKY'([4(N`(T"L0U74L<6X%&OB&14EX8WY\H@N"0,/@4]5@33_$O<S^0/#$&6
ML&4AO4<Z6<$M-J:S!G=G&U+@X&C)9$0V*"EJ*Y@:H([69#Z[L_JX7L_D$'-$
M"MH6!QU\EZ[(L)K?WEBY(63\BHVYO/``I/="'%*'D6NZYT)QU!9/9H?R&D=`
MVPE85@5^Z3<\MPMVGI%NIPKR'%;8VQ9XAQ<3M$!3J9QX-XKJ*.$Z$I1`OYG<
M>+DM0`%RKLJ%ZY8,$$9?S97,G$^=FRD5;*\T3,+N-&EC+^^&3A'-^0/'+]_M
MOAE!*SE,RUP#9+VT&^J*.,#S&*-\B/=Y)/M&H^!Z27RA&J0,MXX=SS@K@`B%
M]\$*4%^@*.!@Q99(&3$-?GMD6JJUQ!WX?K)5.WU0G?B$B]IN7O^W(D:#97OE
M#$^[D4/)'$LVA1\-SM0-?G6J*8[HH^,,*IN:R%K,1Z;H-5+)P8"4)X38Q9>G
M*%]7V9FA9SB,</]/\>.&B_A:+V07!D4;(R.5,H%NKZ+K5]@2,BNJ^8)9?3[[
M;UD`BG?*QR$?G=/<(*:WUM48J-),TJ!NMN_3R??C$8'8E)TT;+Y*`MU:Q73*
MV2R+,QW,]T<>GQJZLVK@P!4GWVI3F$:*)FED+FE-1_SA)?,X`^D9H*:[4"<>
M$F^!!,Y6_:-LW[JN;;^8D8F:RD4'LW[<EG9C/0V=$U??\I[=F,'Y.(D_$Y%<
MQ2N2$?BV`.[I@#AW7@(PE^_5G6:+%2!0%V"V<N9>*XE!,A@:-T^;68^GO'0<
MC'5GU&'-TB2*V]_Z0LD&^"'QR`QZ7T.S50NUPQ!'1K[!X*\L)\\>LJ92^#ZZ
MFLVG\TL93V*"Z,\3K;M<9!?AYARYM`VL;A!M6*A!VBB,^0[C1GQVX3@(G<&Y
M936Y/E_3YPW^M_-1&Q>F;B=1-P_YMRPQ3>S#CJB7.3^5.DK%7J1K@4KX86<S
MTFJ1Y@!?[KY]!&=$/%C>C_K1HD91H]3+KT7^^RD_BP.\T\*KVR'^2:8T2H]6
MX$5JL8@^;F"8DO$RR%"+>D(Z`Q\U*.1K=+9]0L&^4:A6WD;#I44E<K=U[O[I
MZU?U-\XT1K<+(/2>*9E2[ZV3BW(.YQ5W0F`FW1\&1+N7;!UK<3NP@2+88+O/
M-*.,_,I49DR#!K%4/LR#G2`NYCOB_N6I8VAAAZ6,9U),RRZJ##^'@10SO&7;
MJF#HA.>F(2J59^PD67>X0?"G-"HTQ[C8-)[)V\$`87\$]F9X\*FE7&V=J+9H
M%&R5]#HNVS13D%!8FGF`,B+P9J3LH4"+RDI!+87NP);NEK4&DR%12JE08F(M
M@`>5(XWI:"D-%$P*P>2)?QO8GVU#)G=7)O=&MS&,(>3>YT]GY8T[1J,C+&U;
M9E<85H7?3U.9^+>T5X2U=NT1.,GEQF2>&_O2/X/S"/;7E*?!1]97X2#7`EJY
MO0Y><=`6ADMJKVL`U2(APB5]\P2^C!!G]+KPUG#M[@\$`6,+U^(-7=WGOO!F
M+GB9(R&MYY+V=RY1@'_9N0'](,BSZZ&7:TE6K&VLA[?[@+9T^['XJ%<E=K)[
M,?<6SR\A,!(+RQ[#1?G"&`J$T%E82IWWD!5FIG@E:K-Y3\$*2W(SHQU"1]B"
M5;/.A@M`ZQI),Z01@]TFC>3H^M;=.<!5,X8$6KMJ`V!1Q@L#CF?CWO4X_:$!
M'YNY5].,?DZ8,=A5=MB,WH[7XG6!6<VJQWJR<&B)[I$AIC0V(BR052B`>,&N
M>H.<1`5"G$@@/PM1-7-NWQ%#Q<*+!Q09"$;"S=AE9U.<W.UGE"F\XQJ750/2
M;^&[6YV4VV.=46`0'\`B1T-Z"O7"JW!ORX_]&ZG?PMS@04)#JL$]M9[%8,;K
MANX9C)82"DM-^;@KC:O"'>J,L)B>J=(H$W'A%P[S2$!1MOXXMMEJ>)1(C;DV
MM4=_FK!;-Q+Y^1!3S70BJ@E>HOQI&@U@*AKR6?JM-9^L-G,F6Q""O1FN2S+$
M$#+HCH6YJ2B`WP]<J*.<F!R4G_-2-LYT(U^I1L[5/)P"P_M82<^5QBI1EKD,
MN0O+!=AX5/-%/QT5FD[>R<M@1SB)1$+.,3BK0(P7X6H5%0*[)*;3FH?T!LN-
MM=2>3(CO037$3N7F;46F)"15[7(GQ)?]`@-4Q#4VX];M"K!S$2@J=;!W_&*Y
M8%$\LY><`L$?<?TG#HJZH4"X24^7F9:FLJ&Z`\BEP):8^X,CG+=5WT"+U.S6
M_RY79R]XS,T1,P$,NPO@G`3JA5)0Z(U1)^;&L-^M.?PT*8\,L\+>KM>$K=;?
MZ>CR8TDMQ#F<I%B;M+C`#M300:+)@XN,^]D3+Z(.NL<5$()2\A'1_+/BG!$`
M_]@'T#SL7DAI/GP(7>C2K_PP6$I(.6Z*E@.":9WM(!R>P^OV#=:AR=ZLW5)Y
M!I66FJ5*,-.\&]9M,F/R/EY;!&<4NO7&$S,;2C?U!%F$:];Y,X<`NLZB_83G
MK&-WGGRH_44RIW]L.Y6`51JL$\;3X5)^UJ+.6"R)B:%[1(N[N:M$!?A$94.D
M=V];,"SJ-QOZX'V6*5=V^S6]1DI+$83,GPKRP5G=QYR0U%KI'`4$P139<ITT
MB&UB*NKH9A`<XH+88\PO4%/L*,YP"_#`4I9JK.[RYP>[OS9Q`GSC#=C2$Z2P
MR52RG)9BI2Q;O#7WU@[N_")=;1D@`[-TRBG)HL.KO>),A_UD)T3G=J)303=H
MVOL6]$B^RG8%0+?C(!+!1AO5\POSW:C'F(J(0R@1N$P/L:-)9Y'FD,F'-01$
MYH0HE"H)!?H1H^3X,>/)M$CD,0.;@Q[%XIQ,]TE6'^:[EK8-Q40SS['T*._0
MY\V@NV?Y"A5)$KF]S]8EU9#;\Y3+Q62)90NT[9`G"&6+TU;8\\R5HK*EJI]Z
M/1%!%DF^U'[@/^+BV2!*JW9\RDM0SO`%O\O+B:\1K$>+C'VF?\1^:9@FF<6.
MQA0S"2DE1^S:M<'[ZA`..-H[Z=*5(5$KE\?:YPE+"1RTX+1#H9!G]T-^;`E7
MD;[+,/!V+IP=@<!X]\;&IN>KRC3C]IL_>C;@V=!%V+;1(>7.N-;@='/`8XU#
M932Z3B36LTF$%U7]1YA,!*>VQ)K[R,@S*O)7/Z)#5X6@PJ;>F2WN;K$<.;G2
M01`J"X'M?5,A*^EWXTB=S$O;)3N:!PS*Y0MV-H9%V55&<.BN=AH99XS6Q;DF
MFB:E3<1ISMS-#B1(RMSL7[F:<8!M@-]S0HRHOZ'&$4,U'V4+=:*09@31]G7=
MWVTTB$>KS$@%2VB%%#=AL6AA_B3R.V(WQ6"W78IFAE!*1MRQ6>Q8K6AHER=!
M%OS)9`0IM0;BR>9.I(";FBMBU#&VF];5]6%O&;-W3N!*]Q)IMI5]TB=7JZR)
M!8&-%ZVVYK#]\':X.8#68(D58:P^-J!1D53.GSO@1*HV;[IW,_=;(^9+B@%;
MOI46+ISK[O3^.EXIUOL<U&]^^,#-:ZY'W3%.<Z\>D@W=9U[?"<QTWSKUP*7]
M_:KB!:VJ/5C8NG/X%"9P?R^I(&4=3G"I9P[D_`^O\ILXWD#ST.FR^5+C([K,
M[[Z6L[P1J6DQ,M'@:N]H]AH)N^482*NWKTNC5^J*Q#:Q21<A3&.:L_OP6;BI
MEG(-E_F@I#WXQ@6;U(!(.MF('*73?_>H/=PJU)W-#B]W__BSM?AG+;ZM^HRV
M$9J-C%?=M^\?[.P_/.[]]6CG\&GOO,>+<`>6?2&P#>1&:DJPQBDQ@Q:#-9_\
MD[Z"1S(485T:_FBH%%D(_6_EC5)5^37$UMP+@WLX(;N[W)(I<9SV>KP7AA6Q
MFA"MAWZ=1!U^M&8I"\KS!JV>FS[IWRDD"!-/0LC8W%GTXE@2K4V9V_@,X`/@
M&>H;)H_Q'Y[!#@%J3YB:][D9VVX(A`NJ)';93.0ONFLS5O?L_OY*]E5Y$&7[
M>V^'T_=]XG2'"?;,$M=%M(+=A][JQ,(/0.!W6^Y"/\9LA%`I[^[H+0U)#;>Y
M!EF](^@4*YE@(6\G#NFHJ0/>FE#(A"FWS<+)S8W+H.CFFNG\)*OI(!6"D)4R
ML87>?%F#"N=\UI;<T(9R`9S;M0,7<$AY>$O*I*,[!X?[.T^:KY!)RO.%45XE
M+18A!2A6%HV'N-'T\4.ER!VZZ5Y5N=^D(FSAO=VR4W<7!2HC(`2:Z7$D0DGC
M%">D)8;%"R^DK"*X@2=3]X@I=HP.?98F11\SD;I,<FH!";.)*=D,K96<*X=G
ME0C,''6P+8=0-0R!(&%=ZK%,!((T^2P@GE6$P_$>ZV9I,==)+JHYZ\(ZAY,&
M.R$1-R'`DO/L3$7(H9QF^*Z%UUJTE(9@\0U'28$0&7659FHHR#J@"9^N.T[W
MV7JPD'740%EB903"\>6NQ$-QK%4K>M;OM%VOQI_\S,NJP9RD$G17F1]*3UME
M[CN]AMJ>K"_)&W(',]_"Q1_<7)?Z4*E21I(]B^6\@8UO@.I[`MSC;HE9Z\QY
MQ:'3^>[+T2_5A-8/\OI[<-)\$4>DPOVU/\VOP#)$O:PH_#<\R+730G$;=4=6
MA'K>K#@C^LR^@/#+?RB^T*6%=.<IY0!7VY-G19>X"=-(4*I]\^[#?#D=?R!'
MP8F`^0W)R)MX.`[6.GEA9?SP@*TV^C'/3IZ=G;P>?_XD*X4NDNB(7W0(/X"9
M5"OG/`D?<C#J2*Q2;L!K>[CI,)N9%RQ3WM7B-S<2'L)KD8O;`[E!5UT@G3EB
MN*098!2]:4'*LS)GI(+:WM4YZTYG/K61040+.=1P15)6Y/&VC]1%9"5NK84+
M_I5(23HEB]U9E8U,0)-;+FV%2&!BM]K'3@8(C0?TSH*XPU#E)T6\EX0@WN0$
M%);9:2TYI4S4:>W+X@YW9E+K#V95$8T;>SOL$EJSYQ>2(S4O77A5T^V0LEBR
M^,8V341=%+OKUK*SR_;R*#I8D@?Z>Q:)&[?GH#`S/1[FBTF)+[+F4=[(`UD2
M;3WEW$)[%H^J(@MQIAI$[2F*P;&5\1>[7M)$J:XJ/LO#KU&BY%#C&1S-0^M\
M\A]LT1JY6FPVLEVS>'E(B/0`9RLGY\=,XV=7V.COD\C$522$?82<HMJLK=>%
M=@;S=+/BR1^BABI9IER?L(")>)M(2,HO2D2&A@3+B'EW!QPFE^1Z;D4'C%F<
M*'8;&2IH^/)%B263H<'TOX#0>E;)GO*YT(9/N3U5MBCOGI-`)IE()MZ%<=@>
M@A9D;(O[X6?EQV\WNXCS'%-@WQ^("W!M4$<\"2'/E@KP8_K)585OR(#MK07:
MFV*099KL%`5&%6Q]ZN7MX;.7-JA;3=Y5E4<G_,R(Q+XFI<AV[0P?)7)2"JB*
M.OKSIC5`CR(M<#2L:X&3Q#4D(&I"3/O0XGYI7P-DKVW1NG=XF#Y$HHRY0#C6
M0CJ59(C:0;3Z70XUJA#/.U@2><1M>GY$@BP>Q@QKV\@=\IO\3EN2L5#F+4R$
M3:'2&IH<3VRQ$4JYW>0C%%%:_C_:_+CP*$!(2K`5L-JDB+^DG-`F(7)Q^"?X
MBBX0"OK'%WR>/FE#:OB<0YJ>PKF^/9N4!$91O?Q?W[C\";$A5(D`DA_JK?IS
MZYM(:(:\#784TPE3D'Y]-(?X@G]("[@9F:[,`"#".E26<8GX1L4#E=L=E"19
MUP.JL2B%AP?PI=EX\@VG(8B23/[5;B"=?\#BF]6TS'[;T6D9[O2\\J*;L,$#
MZ`1FP#;:+*%9FLWF.6P;V)>LQW$5CGI-E!-&8K^J5+A:1,5RP_!N-O^P2T;2
M8504G!=G;+\##GN4:/,U*+G(2@#6@WN1D"J2A<YD+0I&1E;SGT(IHF*S##T0
M+(#MNM%^CA79LSW&.=\2(Y2#IN+O%7D-GJ`@()!S50%SMF;=Q/H@:HKR[AW:
MU[`54E*)Y,Z7.)+L9$9M=4-8`&D(CMW8I>`Q#BS)$D6_*3/>,G9NTKS+SZRV
MX^7F#4/SM$9'MSQ`"O)TJ4=5FX^K3.*,:"`6`;8&HGEU*6"Q32*:^8+.Q\A0
M/!CI.A:T20%@4@F*F5**<-&\LY^(W#1>59,<E3@:(:QK7$9T=^'@5$XRMM%>
M2XL1APV@"43O`9NH_.:4@E')1S0WD<^8N->@GH`2OZ@R(2*WD%+C?*RY4EH@
MY],UL\_XT-/0WZ!F^MCAYF3T(QTU[0_PJL%.^A[0_B/3LZA0'?LMX58[&QNP
M[W[%M&03>@T$GDS;G,4XS>[[U@<]?OKIF7_1(^^O;FIT<1UD8G3Y^K+\0%,8
M\M0`UR8SA3S<.VH^3`9GM$9K)Y8R($E\:E4I)*L-#GV\6-9>7QO1$829/@]B
M:1P[-V][3I5>$:KCZ4)2R%X3T-&4S=K\0)BFY_:WAREI(4+JLSSI+P,GYWTE
M7N_51:PH5SC)?_"XO:K/GPX>VS>=^/Q78W=3$Y'WCH5$)L[L\=[#QW_X_$E&
MC0NIU]>VV5@T8(>"TNU=D$()MS^'_6C]LBB6/$7'TUQ-$!8(XL?.H,LF:OH&
M`W-\*$^*Y6;J#7X27_SC[M%6-M[/GCN+-?QOE.ZZ=WATN/?TR'=M=<R>EKW@
M,QG5.;E@A$#[^VF-"8/?3]L>\,[\?IS=]F?\?K27?:8KQ+W@%%U<XX)/<*U8
MT1J(Q(#F_J-(]O?A%E8Y3#T1:.0]*:0MP_=Y4D*DE:[8KL122/>(SCDS=9([
M>)?H@G`<YL0YX$MJ=Y"XX[WCPUSB;(CCO:>/]O._=G4`A@"QC1^:M\T&OL)G
MQS-$A70[E*QGRL[D%==[VYC1$:FV)1"E[6H&3Y2WIM)O427C%^7$Z:0-ZCH)
MS2-0B79,A7J\Q-8/GO[!J/!P[_C1+42(,,()X)IBW02HY<B2<R*"<XW!@RII
M%=LZ0X*JG.X>J-IYX:VZ7L3PRR'C>BV\N'=\Q!<5CYODNK9Q[_#IX=[#1\T?
M09,)9@#R,D&*@7!D6S((</:(C6TA,G:OM;^80TW?.A3)&<`@5_,DN`]U4$\F
M"%+@,*$!!^>Y>;%;;2S1.B=CJ(^X"9[SEFQ<TU&^)LR81IG$Z/IW]*P72,8B
M_TY/3RRM7](%R64@&MSF+=,^(@I!*&!"<U!30%DQ#HBT<]%NVNX7]$J(W(WI
M@#"Q#59Y]</DHG!928YCKVB&!C5$VZ.V]69SAY3>S'4S<R[R*L%/I;GE.EM?
MQFQ<S.T&+5*=J&GM]Y`@>/&F5$NI/#H\WGEZ?)R:?;JE)L7.1@A2RH+QS5<M
M);F1272$??=@]?UW#^K)]]_I_U;?/X]GVW\&C'1_!'PE3($`X'"#'F2,Z4"P
M!+FZ'U[5);AO2,7"#7TZ9,IU<S]P29U9EU<?03_C\"$1@T+*6EI#B@_CW\DQ
M&N<?=^4/#18+#7N4Z>BW,BB3?SW6C(7A,V!XH,_G3V)RAT"?/[WECS:M,B;Q
MXMW$:!E+C?Z$(MX?%/YXBHJ`EM8OB[Z:7F?`$,[9%)\4+-6%>O(Q/I/W`TC2
M,;OZSF6XA%S3DA%H9+LQ"Y\_H0!'20%`#=H%;D:KTG_:VD.+Z.=/OYHU\#YN
M5D@-!9-W>"X(7UI;6$A6M=7-/E1T;EYUI!)L5M_1)72:B83EH.ZOS!PIC4?3
MV_T#[KU,-TL=L&[[@>9'+G'"<N4:-@;^*VEP_S!_)[L@RUY"?#AM8*8T'EZU
M@^R1KBPM.YN=>G&1)VZD426@B)VXQBSX8\-RZ#1\Q+DM1R(F(60X-Z)<)##=
M*)PDW:X82O(!/PBS)23H/1PT.6G!V)\[0U*5H/!A'QN1Y(;*)NG_@3']%NC`
M<TN5LE\\R-(_9NA30E?)`5ECEF%UUOL32-I=B0GF_8E^TN-T`48)^DT.Y0TI
M7/+L/W$IO"01^\<!"]O8@O(9X.#P88X(N,!$/8MR#)[E:"K5R*[T*%H:)258
M]<'>_OX?%"YH\@&R(G=\IE`9AY[1.G&9C_O7`&ETXXTB,<5A+:'^_,E!\>=/
MJ9`=:L^FP@KEH]71\@X/=AX?/<TLKJ;)W;$6R/*]33#0/%Y.(2G84/NG8:"I
M_7_^="(;`Y[6M3),:Q4(K5-^GK1%++J3+(EGG7@*"Y!B,G,><H]V8@''H76J
M.<`Z*"3P[?O)@LGLY%G1]5X-O_7><,P//0*3Y('&T"?DS[G2KM<0DC]\TGWX
M;EF"Q]Y[XG)QARG?-CSS1B-9R=1:EA_I7_#Q<C0.BH?S$.?KB5_MR!\'>Z,T
M=B-V0LWPBS4%R(]H.-PZ>&A^$^]IWZ%U68>)%VB6WU)EI`.]6&L'[YV@;-/D
M<.FW>95_%YK(_E8W/*L^^'Y!/U3K"(N1@Q"F``FIZC/$L:?%;&+]SLP]N,=D
M4HPG.T^>@C[T07LV+;O`!@(EZTBZ_G?L.]?@R`FWT)M$AC\TG_W57)+?+TI8
MY4%JSU8\]T_RV15P6#CK-FNREMH.B_+.,;+OICX;;ZZV!L$N2#H+.=/NW_]"
M-55N693-R=KO=#6@$S*(<9W!W_=TZ`6>Z-J__2OXWYWT18Q"]#E8>$_&U8QM
MO'BK91"5W%0Y`#]C\1@>4M\[%E-22C94%O!0=C=D:9=T5B39X']*!(1(1"\&
MTZHTB/Y)QDKU"9.A<%,;T[6VT`[-6S_U`HF0$LV-H=SDA<H3UNZJ9<EM@B_]
M[B/>P-JR7LNTDS'++(*EEI'^>;U&#)*/AV+9]K&3ZYD*$[K3P.X<Y7XHYGBO
M3R(B.2Y>-"%-Z+BP'):NL\"<>M4YW"D@F<;\+=0AD3W$D>[U"K,`,)MQ&/(&
MO3KG(V/ZAL>8ZMY;S[2VF294JH?#;4XZO6]SHSEZ%ZXTGM=:&N"F^L:MS8U?
MIX`"@T^LB:UVN,%W7E)HZ>:!&,_S.GPD3`NU29KXQ]1UF[OYDAE[VIMQB]F1
M*97";?5QW?2NJKCF7^-@>6Z40FW9OYFEVQYD6'2(+LBEWUA"ML-NRH,(BA);
M;:ZQ,F4-%F1KP%&Z1X$;L*A`YS+K5Q9(RT$#1#6F2RJ<QQ%L+MW<8M_ML]]#
MU_64;QNL7'E<,.V#:EBI1;RN,Y!>8ATD+1H&HWL4*<\_(W0Y\RW3$*4:,8X4
MT^<M50,QR;8E5.-O"\IN;)7X(Q?5B-SU,DIBN8<%/>CR[HT<VQB!#4&9I/O2
M`Q("JN"C,9!%($6$H<<E7$#`MB2;86M1S"39JOB!2$56+<B.@HTR!&0C<7^F
MKU>8F4>YJ"/EU6S!3,:\?L(%#C.YO:+5#;"#RAP6$=)P2Z8.!=J^X+4>]P*E
M[9V3JQLZ-,];=^FE;DMQ[U9E$SNDUO$.(`A@F5*VI=1KSI5H`;*<B*@8$:)X
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M4>*TXG)-:^S2[B!%&VP,/G=N%U1;`;^A=DX>KUY:8Z#?N6[T@!K[^P=-*#FL
MU+TEO=K`?U$_+I76RG'Q<.?HT:.=1X_R"+BU*EE%SJT\/MHY.GH2<1]>@6Z8
M<!YG`[NEEIJN(YGRT&KLP[AZ!S\CY:N2$!P>9K5WRY?1I:">*9F>Q9003OD"
M[('^ES#%06C3F`TX\%86-R.JH)XH6V&Z@RE39:9M:P.C;\F_FJ@!#.BV-M?*
M6NVXHE\D1HZIG1OF9T]V?7`LHZ*63^MZ[IJH]2@E=O\7T$#QB"88F/=JM)J?
M5WP/,ICMH_9RC758Z$P7'CTZWCG:<DH!-J9\2,Z\@Z/#G2>/]C<P,18#O=^C
MR?ML3CU[(-GE<&S5,^YF>?U_#G,A6/_3;6V*60P4+94H%YLM7>W\1D`AR)PV
MC_:/MRFLJ48X'#)(VPV*CHG83#^#L"WR.<VR:JTGPS.6Z.9AUFW(%4:"NI2/
M5I[95"O[=%NF:186M53=U`,(@5'GLQJ<A[+;BG1QG[ZLX]`U&@^.`D-%0DD+
M?+>_*;U+20DJ'):4<,QHV$7GY3.H&(U&2#L+&MI!"]8:#@FAAPIOXJ`V7L\$
M#OJ"#>BG+2O*WZCTO51S9\/#S*PKG%O3"6N?DVS1$-Z&+$,O`0#IDB],NMAU
M\`$J`%J$4<$_F+M9+SW@Q\$&UIBOI3NT(97B3.,9&>S?=[C<+.OK>75AWB,>
MIBM>AS#SE)O>Z^*-K@WP5'S,EFPY7_8T8)[?L:)L)^U-+E7KPAH,8I^N[-<Z
MUA80E]MQ\3M*7P!@Q8O$"5'.<.O_(^]L=ZLXDC!\*R,4R:QD@XWY$-&"9&P<
M6;+AR(;-#[0_')O`2L;V<B"0*!>3:\F5[?-6=<_TU$S/.3YB\R=2$BF>_CK=
MU55O?;9)-/\_U[O2A:Q632A/I9$MJCTY24.1D:M<1>"<+2Y5%2O44+<D7(*W
MDT;'W;#/B5J\6THV$O`!+_-:E9<SM32^]EN:X?H:@)62%MQX8I$/9#U:$:K^
M.EAW_P.7`#D,\U/=.2PP_!Z*19ZI@H^R"_,7<<KRJ_EB_*/%^V0YYO?0KES>
M(Z&I*[0E52V"JW$Q4N0"!0WO/P)S/MAN[VC!9I*VXYC3E!39MBA\@X*`JC@Z
M9H]/;3EE05'Z9\9_YK\)ESVY]?C.]H-;=Y_^\XP"J\9@/[Q]<FM+?_FXSQS>
MZ)4<8PVFTN:8U5_JZ\\49>(7V!C6_*X-^^GI/,73C<RUM?DM9VJ^?KCXWNRX
M3VYQ[,;A;CT5#+%D/J5`NO@&A0*@_/T:$9M5OD`+A..C#JH=QPT7EB!UIRW6
MJ-,+;2W>4L;3+7+/[F@A',?KB4@*:*T3*'73O]49:,]T&7D.!9D'N6-5QK;L
MI_+YDCP8&6,H@'BE/.*V4!TJ#W_]^(5,#;JG2D%_VTWT(/1R[PA&49D*R5%Q
MC[>6B,E&^L.%P3HR!`))R">V:>A,5/\._$AH#FB)&`%")A[>?_3G'QU6T#DA
M[Z\QV`QQ5C;6)=U(DB2A%SA`$;1Q(AXZ(J!S>5V_'5V01Z\*Z1Y>IC/X_E*-
MLP'5;^1(O>YDD)'D2AY(4W1;L+/(I6)E/O[\XPC^^)Z'19\K6BXN/X&)C1EA
M+;\VKS!$I:3M`?S)L&/8<@)O$.":\<H24[SJ#C"9X'7T9'60')7?9I9%VB\C
M1)#W&\;XY;VT?G>0GX;V)_8(F%X5,@RVFZL,[)R3#*Z(7QN000H?]7?W[3VK
MK%"+(8">V<$>KW0[GHW*"UBFMPA=B!(7N]F,FX-./^D-3)/.*7^!PK^E+\5_
M5+@3</U%M@`!@`[3NN27M'`_.-XSW$<2(,@4:0,8=`@C@`ID3:GO8'_3!AI`
MKZR*5K!GE8><`7!DSY2W(JYZ>Y:,W8,Z,H?V'"@KB<2Z!,@D;D:UTTQ&^G%I
M#8)0YIJ1W\!?EP(HL!JVIXA*=Q[1A3V5S`0A@7U#.=H)93%L#V*ZV0PU#I$P
MQ^J*&Q>6U6QM0!`;CQX35*!B0^ED>TZ=+M3'5BDSBRL+EPI$]Q/#S=<6/NU:
M\423U!7(YN.5)?02&>/52>V8]:5<D$A3QDC'&>A_@B.*-1Z<XDEZS)@M.BF>
M7);9_+-%(33Y])K;K^2&F`].D=<R,!]Y48E]V>N)3`,(XGI0H6^=RF$*NY!1
M_0@?/Y9EG`&7,(PSG$&2Q\^T8Y$*RH%W@4=Z?Q$2+N9@U?OM;AV`QM-[;7&D
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M/]WHUB`G-47`F#Q,LZ:X\3B.7VQC?Q(EWBMNP&RTK4DJ=O_7:"N/(.Q,C:XK
MQ;ZZN.V<W\(@.CG!8.<6;LV!F[DZ<-O;:[877V'/)JZM&EN#.^;CEUW%B.H%
M-L"D@'KW\E57%R+V*:_6`IFP\@TAMV3JBAQG<6:&#I.R<94SN9H4\FB5F=EG
M["*15#-P(G$:B9B)-HYD>R2J-FB&KIW+Q2J$!/(45#KOP$WLOA9>*8_?3V0R
MYA%E8EYE)5%\D,!8&AHI%#NL;9E:&O\,Y\WF(2TT?BX>)APGA0,%*C&&PC#P
M_Z:RT=E;"(X01LKUO^/H['8/%15FA=CT1N13ROA"L-\</#2+>'(W^OK-L(DH
MXX5J*?3`2O/F4*]RFGS_=]R"'[W2%6;$'&WQYL@4FT%++D'W9KR*-<R;6M/=
MMNJ(<4LMBY`"V-M/@^?<:T,<<JTNFJWJ%/%[\[MNZ;(+]-[W%HS>?6?T;_:;
MMA?,VGUGUN6/9V5:KN+5/'>&?+\6A.L;V"UUO1F'%\,Q:@=>$GV!CYO="T@'
M_0ADBX@Q*!<!X`109UV75S_)P&F!20>7(&:!>9X^)CO`())50#RC`(^Y<M\<
M4T-+Y?F_8%P;W(&,F%%'8>#9N%9%,OWF9F+*;>_'BYBFA,[2>VBUC;K101=P
MID2%6^U1QF5D'%Z;?98"+-<-$6/SYV[+5W5MGO@I3I-[6A>)+NNR7M11^UP\
M`1S7M;;MYN;X]Z-3G.[H#;7UKCT:[W>S7?P_*&75$Y`&2+DL+RY=50#16$KE
M[WFNMC[+2M\DUS<MLYU$=;*`#M(RER[I*\%M&J;!P7@JZ=I['&8/)M;.B=_S
M`0W,#1G9R%IK?+Q4(=XJ34SIOQODG:80XCYI+Q+:O6X%>;^3PA+WYV67E,#N
M*$BNJ'=;7?=L4/BVVG2\`FZUN6G=8JMZ-YAHQUQ+N`(%IC=PQ%30$GM-#4W'
M;PIX%GKS9F7,;D)#+#K+'X#DL15I6\"A/!3)]`_%5428'L_1A!:./(Q(3(;(
MP%@MEZQCJ1'`G"_&.O8<%55S7XWK`Z%0:/6PDAZ69NM'JI1W+2YV..-4Z[QS
MT@;B2&L/QIGJ[A+U)U<_5+,+R**@PDYQ2;VIYU8N^S#5U]G)(3X`U@DD#.=4
MK`7!9#K+5"`2:V4J5P9S4C2.1=O$R?-,G8:OR++8RK1(S.I$OUKA006LQ3:S
M-A(\!4F/%7R)G<J*)BE>/#8Y[M?OB9_+.IJ*=+A3);[GIIJE2$^]L]NK.)IW
M.HZ?[7FHDN<Y]:+=K-C8URIIE#<_MJ@O5VK``D20"Z3->N5%\;1,_NX7G[.W
MISP1B8A\G.WO&1RJ(!VF8X@+%Y)5*FS&2M1!87%L75"Q"91P]"%L\'$G]A0Q
MN#*;/*``BD+IB0X!AWV53]01MJ4+ZXT*<S9W?N7VK<RXC@5\K4R"K)(6<+HU
M"F[&"4Z(0Y`5O%<8HH8/2,3+(VT^KHS4+S%1&XD:(]@B+05O.!*4E*?9NA>G
M(>QL!TPL[UQM<!2"W']SP-#V[4$:\7J+HZF-08038[BQ=#`&Z%&IQ@L'>645
M0Q<V*[9U:._=)_F,G/^%@^SGO&#E17?EC*N;Y/L@+["RI:O;`$L])>@!7PT1
MO?QJ^9B4]6(.KGHWWZ"E1U<6?&T)8UG4,\NB/I;%N=;-;G"G\$Z*J,S:N@SP
M[""-U/?"W'3_,8MM_';46@JU+F3=F)VV/28E6*NJ[E=3P)-=3GGA<5BX7-YT
M,W'&[W;>.8&6^+DND%Y6^5S)2::B6&P#RY%>GYH<$/8E'CM23X,?.(5SP@\]
M5]&(.%-HHXQ#,T]BQ\=W^YM;#MR#&;NN;3],I0KBES"H7`KR>Z>A*W)\I!,[
M1T=ESE@UECC-VFN$#_Y5TD0LCA2Q!^C\BRI"J"`$,I]?Q;^4`-A>KAY$U^6O
M+`<1=R[L-41:5D2HM@;6Q6]9.GH.R("0^\`\=CZ\4N2S;/()\;?ZQ2`887?2
M`[LR3#`_GRK,C?GY%-KH3ML69U=YW?R_/P\<0N:J;A&291I.H?1CH:B<SA&W
MZB5WD,O(?ETH/Q_5:$QYN3^NO/B/()"!8CIC\-V_,W5^56"LT0Y!J6*I9:Y\
M7&76C[D1"LKIE5U(J7SP6O-R]-.CBYR^..9!/\FZ)9$1%701D4PZY!<J\J,>
M^I4I[_&DZZW5\MUL,$4V+2P)TL!?4"_P`M_EK5O\9F4\@4+\,<9U<$)QFE-"
MR#M_&JT".2[$IWH4HG6XRL+,ECRY<^P^L5W+L5AX=DVVX=5]@2JS?#^W*P[6
M<VP/_,[3?7?:6E#F2DHN9NZ'/7"KO3%X'(_5?UI<2%(BGBVE1%0H><6HDO;B
MQ#6]+'!022*9VV.TJ%CA9';'WPMT@B>V*2+5YGY)%&3JH4[V_V-1I4O<5CNS
M-#]J<YI?8[?3#R)-S'630DKA0<KK=>"T(ZM9JN=`,'_9+MD-FAU$'WK4A/6&
M5:1\`,@Q$?;I+[DPI7SJF5;B`=A\TA,@*@Z@6Y=9\]*Z$"SZE3(.L=\VD^C>
M)H)AS"U':*61N[AXO^CYA9B5!F/[?$G^<[*UX53;)PV_E5T5L+JU.2X;;T`[
MI6-E0;13>R=J5N$VD)F+^XNB)NRL1F@(/[F_Y"J5#UX@#]^[2\N\G7D"@V<F
M35&0WX<1.DAH(QZ(&,'I1QYFD1&H--S4[NL/O/3]$:BN]J?G!(.DQU2(EJQU
MJ8="KV[T:8-E`:H>T@R/S[$5UXJY[G[IW?G\T]/_`0``__\#`%!+`P04``8`
M"````"$`=[NA2"\+```F7P``#0```'AL+W-T>6QE<RYX;6SD7&UOXM@5_EZI
M_\'RM-6NU`0P)D`V9#60N!UI.EWMI&JE;E498Q)O_$)M,Y/LJO^]YUR_G0O8
MO@X7[H<NV@D8[CG/><[+?;5OOG\)?.V+&R=>%,[TP65?U]S0B59>^#C3__9@
M74QT+4GM<&7[4>C.]%<WT;^__>UO;I+TU7<_/[ENJH&(,)GI3VFZN>[U$N?)
M#>SD,MJX(7RSCN+`3N%C_-A+-K%KKQ)L%/@]H]^_Z@6V%^J9A.O`$1$2V/'S
M=G/A1,'&3KVEYWOI*Y.E:X%S_>$QC&)[Z0/4EX%I.X5L]F%/?.`Y<91$Z_02
MQ/6B]=ISW'V4T]ZT!Y)N;\)M8`5IHCG1-DQGNE%>TK)O/JQF^I6N928OHA6`
M^,-_ME'ZW>^R/^_^^.Y=_]_??O?/']W5OW[Z9O^[G[[5>X4:(A-\T"SSLM\H
M%K[.)/=R"VYOUE%(#!D#3<C6]7,8?0TM_`Z"`<S#G]W>)+]H7VP?K@P0GA/Y
M4:REX&6PCUT)[<#-?K&P?6\9>_BSM1UX_FMVV<`++##RWP4>N`DO]C(-Y]6S
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MN&"C\'P4M+BZMQ;W3"]!)HJB1JAE+<8G$'H_GR[D(UU,I[*%&A:\)`M]/\*7
M9*$6_+>0QFG>#YJR0);RM-3#67/_<CR=3B>#J\ED,C6'`]-D)"_SB/;"E?OB
MXD1:&DW["$:`8#J<3*\,`-(W)TS561$,`<!X-)J,!E/#A/]9)3P]`MF<CG35
M7B4(%'F5(%#D539QZTFH_'FFP!J6XEPE"!1YE2!0Y-6QY`H,BWR*O4H0*/(J
M0:#(JVSL+C%786U8L5<)`D5>)0@4>57:X#.OP%/E7B4(%'F5(#BW5XMIU>+^
MWF*+3_LCL_KQ,9O)P=QQ&<4KV%@K=HL&.'O,KMW>^.XZA5EB[#T^X=\TVL"_
MRRA-81OJ]F;EV8]1:/OPME>T*/XVM(2-.MB3F^GID^<\@S)NF2/#FZDXE8:R
M$IDXPC?'9G]LCHRK;!(E277@KKQML&]=J?M@K`"-R&V[X83#L%22AT.U%ME#
M+^3N$VS!7,T\+=@`8J(("<$6,FRLUN5%;20MQ&PD#01M)"U$;834.91<!9.K
M:`M[Q+L.MJQ)OY\M@8KJ:19(@!^(F,,@2)M]/EN;'&"TM4U76Z&^[.7&W,`7
M&[$>L+2EQ;Z=+0T.6-G20M1&/FX*[W+"R^4$+,\'D.SPS?W\;3!`4=:PP+-3
M!//ZA%LSV>:,<+D[;&ZK>&(U2.C6714V[-"T;X,,)5TL*8"UMFER8MY?0_?O
MN+[_&3OD?ZS+,0`L==W>O*S)T0XX;X-G'_#D"+Z%]>3\;=;?9Q^`X[I&1FTC
MS=YL_-=/VV#IQA8[A,-4L*NX;EU]FK.!2O7YO>\]AH'+%NOT3,P/<92Z3LH.
M";%U]CH\PQH\@UR0")YC])LU^H$G83Z.T0^+00>="+PHU0_!):Q?9CS@<:@\
MJ,$%-*B;\,A$`%/^`@$X004"/+Z5<P#AJ0(!3*4*!!"@%0*`TQ`5Q^3!@%0S
MB(%*)>@_E4JH,865G,H36EE7?D%_@Y465WZ/HIG46PCTBF;XT`#@*)5U)595
MB2%NATRK*(`/#118T.O*Z?(&=35?&2&DZ`*&BA$H`TV,R(M*4G-!9P6@F9&Y
MQ'$("0HL1:HA`!PE$(@C!HKZWP'%H*@'IM&@J`NF$+@^^(PY03W!]9"*,``>
M)5E1C1,&7(]Q1AH(!%45DD2#H:I$4@RJ:F3E"D-5B2005%5(Z@E5)9)B4%4C
MB2M4E4@"`1A14B&I)U252(I!58VL7#%452()!%45DGAB>.(2V:/+IMDB*ET_
M';]I_51[6;<NI`[J)DW@]Z)Y-GO*9H[@"S:7(E-IO&'.+M9.M:<H]GZ!22;>
M..?`8JH;ZWBC9>HY],K7V-X\N"\P%<WVG5[6]6N]@*18W]@-1AYA+:9*/RRN
MZUH7Y=+Y.0++\42T6LXF]:T+\SN1P2]NMT9(*PA<W%&-`;G.,4@/`4DI@IFK
MFB;H))5CH*Z"#E.L5EC`'!:?EFK6&JM4.9*1+WC#96X`PQ>J$RA''$*Z3U$D
M<1XEIOT$EN-<MIORIGU%Z.>["9,80`99U>8"")?RFB)HGJ\@LKZT;HN2\C3<
MG6XU2;?8`FEKJM"JAF<A:+>_U^UJ>+]#EH'@C5Y3]W]JW*TI3KJC#E@.=XI\
M_+^!679FI.,0AB3(FQS?D"\=")%D>I=PX9*H)8=JZ^(YXEHZT"Q,#G)5$\[-
M$$2B68C!-\2OT;#SUE2W:O&T9CQPL<Y'5K7*X:$@@C599@]!NJ<WI;),+'5N
MP1V7)K]4O95,-,?WG2UH:!TH)K:=(JD6(7PAA:]C$9Z_F'>;BI-^K+E:\5U-
M;1V@?(F/6-@C7H1'+-*!OJ&`GM.O,GFL'0\#J4T)(^3PMZ0P)5**8X]8#,)-
M&ZDS%9H-;R$'"!'#4^N>+M5T\'\[TU<ZV39@U"/F9<$:W,7GM?5`VECLV!RH
M34II"#OQ)7MMOU4Y._ZH8$V2;9_`A@DY?LX?/B^W5S1\)A`\P[#_>^U">^]@
MH2L'\EA3EEO/AQM+<=\$M[Z<;0+W3\VSB_EF19.L<NB+L4IEP6"YJZQR6&C@
M=BC!!>.@KK)`?=9C#L%:(@M.YG>6!5O4N2S<K*YPF1!N77%!DUP6S_U(D'OS
MD!_9L8X*%YHL@HO*JOP(S!$;X6$^G655?@3'45E@<E=<E1\!(9%E@I*NLBH_
M@A>H+`BWKK)*/YHX+JJX'PER?W70CWRLXAZL""XJJ_(C'ZM#P5BELBH_\K&*
M)G?%5?D1I!*^3/BBJZS*CWR=,`7K!+6Q\B//_4B0^]V*RD>\(1CQF93*=_".
M<(0+'R(<95(JK_%1/A2,\DQ*Y2\^ODW!^,ZD5)X"><0B$[X0MZCTT9!GUQ1D
M=VZOBJK+!PSV,R(PX)ETSM:'IQ!'^`QC=L8`QS?$(!P'"4EZ<IUG;0&WC)6"
M^'S`;E1$T/W+QK=#.XWB5PW/%93B>*>/!,7]*8I*CG@)!GP4`?1G>.(S/$Q:
M`UXRAO@8QCWE+F+*7.#IP4/&7<1`ZPP-'W\XK^TB!EIG8OBBBN,G$3$?PLVV
M]!!?2['K%A'QT0N?W14?.3S#N'`K(NF3NTUCNXP_/J4,06(^X8V&I0R^1&3/
MYRONBLS'GY_@OL*"1#QS07('Q]`BP/^Z30F-[+1_U>_B/$U$R(.7POW@11+S
M.`"6D(@(SOJ4(G8JBJ",O]MQB-G"I>Y.C-985)V<@M'_ZJ6ZZ93QGN(ST=GM
MJ.5\`.A=N6M[ZZ</Y9<SO7K_%_:D!0BF_%<_>%^BE(F8Z=7[C_@("\ABV&*!
M<O,Q@<<BP%]M&WLS_=?[^7AZ=V\9%Y/^?')A#MW1Q70TO[L8F8OYW9TU[1O]
MQ7^!,GR`_#4\@?R(![2S!\G#V:F!>9WX\!CW.#<V!_^YNC;3R8<,/KMO'6##
M#FQA1"\I'W!_^S\```#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3
M````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQ
MFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5
M]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[
M=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+
MRSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW
M&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\
MRM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NU
MG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(
M/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA
M_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"
M?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3
MXX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,G
MO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q
M)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)
MYQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?V
MW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV
M:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3
MJ[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3
M<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>"
M.S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8
MQ,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2
MVVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#
M!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M
M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8
MG,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z
M+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0
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MT#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?
M*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-
M`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2B
MS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9
M_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPO
MN-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^
ME!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$
M%``&``@````A`),RQZ:%`@``'@8``!D```!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULE)1=;]HP%(;O)^T_6+YOG(0$*")4+56W2ILT3?NX-LY)8C6.(]N4
M]M_O.(8(2C>QFP3'KQ_>\^7ES8MJR3,8*W57T"2**8%.Z%)V=4%__GBXFE-B
M'>]*WNH."OH*EMZL/GY8[K1YL@V`(TCH;$$;Y_H%8U8TH+B-=`\=[E3:*.YP
M:6IF>P.\'`ZIEJ5Q/&6*RXX&PL)<PM!5)07<:[%5T+D`,=!RA_YM(WM[H"EQ
M"4YQ\[3MKX16/2(VLI7N=8!2HL3BL>ZTX9L6XWY),BX.[&%QAE=2&&UUY2+$
ML6#T/.9K=LV0M%J6$B/P:2<&JH+>)HMU1MEJ.>3GEX2=/?I-;*-WGXPLO\@.
M,-E8)E^`C=9/7OI8^D]XF)V=?A@*\,V0$BJ^;=UWO?L,LFX<5CO'@'Q<B_+U
M'JS`A"(F2G-/$KI%`_@D2OK.P(3PE^&]DZ5K"CJ91ODLGB0H)QNP[D%Z)"5B
M:YU6OX,HV:,")-U#\+V')'F4I?EL_C^4R9Z"[P-E>C&%A;B&--USQU=+HW<$
M6P^=VY[[1DX62#[D)T0S9NQO"<-,><BMIQ1T1@GFPF*1GU?9=+IDSU@9L=?<
M!0T^1TURJEB?*R;Q]:AAZ'BTC:D\MOU^.0_NO-B[\^7U=N_"AV,KZ?@W@V+]
MCF(^2DZ<8-(N=^+%V$)'.4AG^<@-YH(F.]*\4:S_I3CQAI#+O7EQ03'PL3[9
M=/;&6]#,APHG>1S'I_LXR9X1]K.3_>`KS&EH0`6FAC6TK25";_T,)L@=OX[7
MPVTZ3/BX@>/9\QJ^<E/+SI(6*CP:1S.<1Q,&/"R<[H?VWFB'@SG\;/`>!FR`
M.$)QI;4[+/P5,M[LJS\```#__P,`4$L#!!0`!@`(````(0!-1\45'0,``"(*
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)1676^;,!1]G[3_8/F]
M$!)"VBBD:E)UF[1)T[2/9P<,6,48V4[3_OM=VPD!TI#T)<'<X\.YYUY\6=R_
M\A*]4*F8J&(<>".,:)6(E%5YC/_\?KJYQ4AI4J6D%!6-\1M5^'[Y^=-B)^2S
M*BC5"!@J%>-"ZWKN^RHI*"?*$S6M()()R8F&I<Q]54M*4KN)E_YX-(I\3EB%
M'<-<7L,ALHPE]%$D6TXK[4@D+8D&_:I@M3JP\>0:.D[D\[:^202O@6+#2J;?
M+"E&/)E_RRLAR::$O%^#D"0';KLXH><LD4*)3'M`YSNAISG?^7<^,"T7*8,,
MC.U(TBS&#\%\'0387RZL07\9W:G6-5*%V'V1+/W.*@IN0YU,!39"/!OHM]3<
M@LW^R>XG6X&?$J4T(]M2_Q*[KY3EA89R3R$CD]@\?7ND*@%'@<8;3PU3(DH0
M`+^(,],:X`AYM?\[ENHBQI/(F\Y&DP#@:$.5?F*&$J-DJ[3@_QS(9M20C/<D
M$U"_CX^O)?&=()O?(]%DN9!BAZ!IX)&J)J8%@SD0'Q)S,II4SV4**1J2!\-B
MN2`)!>5Y6891L/!?P-)DCUDYS`RC!M-#K`\(4PF0UVB$Q/L:)U#"]\T_2#*;
MNI+&LYZB=R!=Q/H4,1LWD(Y&\*ZO,3S;(`>-9A.T0LN2,#KR6VM7#A.V,--&
M@46LAQ`=C4#2UCCLGP''&`QHRA5&D^Z35PYS:PL^"\)N=-V.!K=-L",)++I>
MD@%?DN0PX1E)[>@Y2=%')!EP7U+/AY7#@!N-D_T*#B$Z=L';T[;+O*V7N\QL
MNM1E#C.D<0C1T6AF7NM$&>XR`^[[U^\RAW$E#<*H:237_>WH,=91=/<110;<
M5]2KU\IAAMP:0G2T!7"0M>VZKJ1VUZ6:[D%#,@<A79V]03%<5IC%IR[VZ[H'
MN>-C&AU/"%?83C@X'HM.EAO5;I1Q*G.ZIF6I4"*V9@P'\/XW=]TGPLI\(M@A
MWP1@0M<DIS^(S%FE4$DSV#KR9G!*2#?CW4*+VDZ2C=`PF^UE`=]B%";?R`-P
M)H0^+,SL:K[NEO\!``#__P,`4$L#!!0`!@`(````(0`J]*0J%@,``$L)```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)Q676^;,!1]G[3_8/F]?),O
MA51-JFZ5-FF:]O'L@`&K@)'M-.V_WS4.!$A&N[U@#.<>SCW7]F5]^U(6Z)D*
MR7@58==R,*)5S!-691'^^>/A9H&15*1*2,$K&N%7*O'MYN.']9&+)YE3JA`P
M5#+"N5+URK9EG-.22(O7M((W*1<E43`5F2UK04G2!)6%[3G.S"X)J[!A6(GW
M</`T93&]Y_&AI)4R)((61(%^F;-:MFQE_!ZZDHBG0WT3\[(&BCTKF'IM2#$J
MX]5C5G%!]@7D_>(&)&ZYF\D%?<EBP25/E05TMA%ZF?/27MK`M%DG##+0MB-!
MTPC?N:O=$MN;=>//+T:/LG>/9,Z/GP1+OK"*@ME0)EV`/>=/&OJ8Z$<0;%]$
M/S0%^"900E-R*-1W?OQ,698KJ'8(">F\5LGK/94Q&`HTEA=JII@7(`"NJ&1Z
M98`AY*49CRQ1>83]F17.'=\%.-I3J1Z8IL0H/DC%R]\&Y)ZH#(EW(H'Q1.*&
M5N"%\\6_L/@G%AA;%N^]4FR35N/2/5%DLQ;\B&#E@7!9$[V.W140:WL"2,PD
MTQGV-[_`*$URIUDB/,<(PB74^'D3A,':?H;"Q"?,UF#@VF&\93C$[%J,KB@(
M[%2"<7V5UXO7BM%@+4874ZO;F@?#+\]'7[Z"Z1`#*6!27TIKV+0D'00KIY=[
M$(YRWQI,T,.,$+LIQ$`CD(PU^K!SIC7JH`B##UU]@G#6>6"<-)B9J?#<FX?^
M$+`S`+AV).<D!A)AC8TEZG4W+5$'C26."KDUF,!H="SG_/TFA=WI_=L*9Y<*
MWS91!XT5+H8>;0WFND=&HT&8%!:^,PO.20Y,A`W7-W':/`T>2O,#;R3-8*:D
M32$&VG3_O'*P3&O406_M$X.9TCB%&&A<_H]&'33T,0B7(Q\-IJ\QF#E###0]
MS=/'G)>J46F:FCFN2RHRNJ-%(5',#[IAN;`+NZ==+[WSFG;8O8!>5I.,?B4B
M8Y5$!4TAU+'FL`V$Z89FHGC=-(,]5]#%FML<?EHHG)^.!>"4<]5.].G<_09M
M_@```/__`P!02P,$%``&``@````A`,>*A=6.`P``60P``!@```!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6R4EUUOFS`4AN\G[3\@WS=@\M5&(55#U:W2)DW[
MO';`2:P"9K;3M/]^QY@0;$)';\+7RWL>'_N8D^7M2YYYSU1(QHL(X5&`/%HD
M/&7%+D*_?CY<72-/*E*D).,%C=`KE>AV]?'#\LC%D]Q3JCQP*&2$]DJ5"]^7
MR9[F1(YX20MXLN4B)PHNQ<Z7I:`DK5[*,S\,@IF?$U8@X[`00SSX=LL2>L^3
M0TX+94P$S8@"?KEGI3RYY<D0NYR(IT-YE?"\!(L-RYAZK4R1ER>+QUW!!=ED
M,.X7/"')R;NZZ-CG+!%<\JT:@9UO0+MCOO%O?'!:+5,&(]!I]P3=1N@.+V(\
M0?YJ627H-Z-'V3KWY)X?/PF6?F$%A6S#/"FR^4$SFBB:PLPA3\_(AO,G_>HC
MW`H@B*P$.HC\>PIS%^HH?A.F?7X*^5!-VS?AI71+#IGZSH^?*=OM%42:0AIT
M-A;IZSV5"4P#Q!J%4^V:\`PLX-?+F5Y/D$;R8NA8JO81&L]&TWDPQB#W-E2J
M!Z8MD9<<I.+Y'R/"M94Q"6L3.![-\_#])N/:!(ZU"0Y'>!+,_@_BFT%5^;HG
MBJR6@A\]6*V`+4NBUSY>@._EI$`VM/9.BR,TAVF+D(29>5X%2_\9<I_4BK51
MP&^CP+8B/BGT]`%#`P*9&0ZBQ1I$SY8F6YL;[;BA$[>K&#<*"P2RT`;1RV4,
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M`4R5U)IV'AV);@"US:S:&C$TR)/K\%Q)IDY,XV8:D9R*'8UIEDDOX0?=B&%X
MM;G;=)9UR]<\@!ZM)#OZE8@=*Z27T2V\&HSF\$D0ILLS%XJ759NSX0JZL^IT
M#RT\A;8A&(%XR[DZ7>BFI/E3L/H'``#__P,`4$L#!!0`!@`(````(0`-(ADG
M+@,``.0*```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)16VVZC,!!]
M7VG_`?F]@,,E:112M:JZN]*NM%KMY=D!$ZP"1K;3M'^_8YM`@"9-7D)(SIPS
M9V9\6=V]5J7S0H5DO$X0=GWDT#KE&:NW"?KS^^EF@1RI2)V1DM<T06]4HKOU
MYT^K/1?/LJ!4.<!0RP052C5+SY-I02LB7=[0&O[)N:B(@E>Q]60C*,E,4%5Z
M,]^/O8JP&EF&I;B$@^<Y2^DC3W<5K94E$;0D"O*7!6OD@:U*+Z&KB'C>-3<I
MKQJ@V+"2J3=#BIPJ77[;UER030F^7W%(T@.W>9G05RP57/)<N4#GV42GGF^]
M6P^8UJN,@0-==D?0/$'W>/F`8^2M5Z9`?QG=RZ/OCBSX_HM@V7=64Z@V]$EW
M8,/YLX9^R_1/$.Q-HI],!WX*)Z,YV97J%]]_I6Q;*&AW!(ZTL67V]DAE"A4%
M&G<6:::4EY``?#H5TZ,!%2&OYKEGF2H2%,1N-/<##'!G0Z5Z8IH2.>E.*E[]
MLR#<4EF264L"SY8$1VXXB^:+"U@\FY$Q^$@46:\$WSLP-:`I&Z)G$"^!63N+
MH3[O.P-+.N9>!YE00$MHQ\LZ"/#*>X$2IBWF88KI$1Z(=QF`ZCB#X,,,=-`P
M@]E\E,`[D`XQ2"`8)G#>N@8G"+B/K,\Z7E.>!XL)CS!1AQ@H`V1L?7YRK`[%
MUT$P0$?L01!T_#8#B[D@`U`[SN"\=PT>>P]'RA:S,$,1AW'<_3TP'E\CJ\%#
M61S[':\U;#&AD0W#OAP#U?DUJAH\5NTGV*I:3&Q5YXN^%@-9?0H<+;'S-=;@
ML6S/:V4MQIJ]B4[,UNTUJAH\5`V"GM>J6HPUBW$<++H6#-QB6+N7VS7HL7(_
M-%:Y!5TPSOB=[>SC%66B/EI2+>B2)$8[VOF&8[M/#7>4<<=;4#O?T8GYQE?M
M9`8]+/UT7;6@@>M^%0P;#Z`K&J_18_6>N6V\!;63COM%/Q2^:A/3Y_9$>%)O
M"VJ%3VXH<.>XQO)T(YNN,D.9H+,%M_<4>XPW9$M_$+%EM71*FL.IY+MZXH6]
MI=@7Q1MS6&ZX@MN%^5K`;9+"6>Z[`,XY5X<7?0_J[J?K_P```/__`P!02P,$
M%``&``@````A`(*JO@W*`P``^`T``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C,N>&ULG)==;YLP%(;O)^T_(.X+&/+11$FF$N@V:9.F:1_7!)S$*F!D.TW[
M[W>,@6+3DG2Y"`$>O_@]YQB?K#X]%;GUB!DGM%S;R/%L"Y<IS4AY6-N_?]W?
MW-H6%TF9)3DM\=I^QMS^M/GX876F[($?,186*)1\;1^%J):NR],C+A+NT`J7
M<&=/69$(.&4'EU<,)UD]J,A=W_-F;I&0TE8*2W:-!MWO28HCFIX*7`HEPG">
M")@_/Y**MVI%>HU<D;"'4W63TJ("B1W)B7BN16VK2)=?#R5ER2X'WT]HDJ2M
M=GTRD"](RBBG>^&`G*LF.O2\<!<N*&U6&0$',NP6P_NU?8>6,4*VNUG5`?I#
M\)GW?EO\2,^?&<F^D1)#M"%/,@,[2A\D^C63EV"P.QA]7V?@![,RO$].N?A)
MSU\P.1P%I'L*CJ2Q9?8<89Y"1$'&\:=2*:4Y3`"^K8+(TH"()$_U\4PR<5S;
MP<R9SKT``6[M,!?W1$K:5GKB@A9_%50[ZD3\1@2.C0B:.A-_.K]]CTK0J,"Q
M59DX:.+-WC&32:,!QU;#?[<=,%['!(ZMR.QJ.ZX*<)VO*!')9L7HV8)%`"'D
M52*7%%J"LDQ4`.E68>U2]U;F(&52Y$ZJK.VY;<%P#N7VN`F\VY7[""62-DRH
M&/CN&'\QT9GM4`?I1-02LF;DH^.A;.`MND$NV.R\0B'TO;Y>C*TE"4M+[8-"
M=4&?_[Q[4#V9[2N,3D1#8N[K2#Q$_)=8:H:@)J\W)&%(;B_^"+T$JIY_J!@H
MTRY'4WURVXM$=)&(QPC-'TSD>G\27ML0O&[N`?+TV8>*F=05BN#5,U_T/_&-
MD8IMR[]H&O&(+A+Q&*&YA>77=]LNQ?$RE8-,U\::"14#\^@B8[C8*N*V6;F>
M_.B1BRYJQ&.$YG/V/S[E(-.GD:U0,6,^AT2``L/ID#&B%8\1FE-X(?8S.IY)
M"9L.C?=CJ)@QAT,B0,;\HR%C$/$8H3F4#5MO^QAW*&'3X4R/?JB8,8>*F*DU
M_%JI7I2(-8GIM%_MFKO%>]Q)V'1G[`^A8L;<M83<0\TUV-Y[<QW'+:&/UCPA
MV-W[*;ON-5./,MV][$IJ]VB@,7L-HMXTIK^QF_&HN.Y0M@17%R6TP<.\F?MB
M`XTZ4SIJ;QDX:V^^G;KN$:_E3C7:JG$K,#O@+<YS;J7T))MH']9"=[5K\.]\
MV;L8U[=H"2T47'>[&]!W5\D!?T_8@93<RO$>)#UG#N]SICIW=2)H5;>+.RJ@
MXZY_'N$?%H8FS',`WE,JVA/Y@.X_V^8?````__\#`%!+`P04``8`"````"$`
MY*Q;*RP&``!2&```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RL65V/
MZC80?:_4_Q#E_1*2``L1<+5`W%ZIE:KJMGW.!@/1DA@EV67WWW<F_H@_<EFV
MZDNWG,P<S_&,/;;O\NM;>?9>:=T4K%KYX6CL>[3*V;ZHCBO_K^_DR]SWFC:K
M]MF9573EO]/&_[K^^:?EE=7/S8G2U@.&JEGYI[:])$'0Y"=:9LV(76@%7PZL
M+K,6?M;'H+G4--MW3N4YB,;C65!F1>5SAJ2^AX,=#D5.=RQ_*6G5<I*:GK,6
MXF].Q:61;&5^#UV9U<\OER\Y*R]`\52<B_:](_6],D^^'2M69T]GT/T63K)<
M<G<_'/JRR&O6L$,[`KJ`!^IJ7@2+`)C6RWT!"G#:O9H>5OYCF)`H]H/ULIN@
MOPMZ;;3_]YH3N_Y2%_O?BHK";$.>,`-/C#VCZ;<]0N`<.-ZDR\`?M;>GA^SE
MW/[)KK_2XGAJ(=U34(3"DOW[CC8YS"C0C*(I,N7L#`'`?[VRP-*`&<G>NK_7
M8M^>5GX\&TT?QG$(YMX3;5I2(*7OY2]-R\I_N%$HJ#A))$C@[P#)#<=8.$Z4
MXV+T$(X7\0,,?L,/OG91PU\Q8#2[Z0!?.P?X*QQN#A3P6>HF?9>UV7I9LZL'
ME0SST%PR7!=A`EQRMGFH:OY_-/TP[TCRB"PK_\'W8&8;J)G7=32)E\$KY#D7
M-AO7)C0MMM("DXJT.QM(;8!H0`"*E"Q(W/\@"UE0E@QH(P%-IZ5!6DB7G0VD
M-D`TP-``M61KB&$Y#2\$F0ET@I(W,C$Q8]P(&]@Q5;JFILE6F2@=#I(Z"-$1
M0PHL!UL*KNE/5AFR0)W"?*FXW3+C1O$M<<I$B7.0U$&(CACB0(@N[G9^T+C3
M(,?><"1>&*KL?"@CZ;9SD-1!B(X8(<-*UT/&53^+1_T>=??"1R)3#D<F4*A:
MDF96>2DC)<=!4@<A.F+(@8U'EW,[`VALALP1*^0'*V1EI$)VD-1!B(X8(>-Q
MQ=EWNPS<CA[]S.@Y,HG4+K5UD)V#I`Y"=,0(%2I3#_5V?&ALQB<0WF!Q6]\Z
MR,Y!4@<A.F+$%T*MW1]@9VU&*"%^G.A"[*&^C,-X8=;$3EC%L,ZT8I^;5FEO
M)4N']/0`F6*PHPT71GLJ\N<-@Y'`9B`+,31>T8YY6X2=4HZX"06D:U10'_V`
M1FX5P?1K&JV92`4]6,D1B3&BJ1$[GJ9Q0`N<U908WA\-,0*"U=7'-!V;\[[%
M1H&U"(6MK`;T*2L9>=H[2H@8D"D&F][]8GB+-,2(KAGQ<],XM-KU-A0^D(A;
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M0EVK,A<BG@&TR/];XL1!0F^.`H)95JLDFCK74VX5Z5;ZGB$T"B[0I;A"=Q\6
M5@N^#X]GUFV9A&*PNS8H+/M;\_*=77YT:-`:;<=B9EI`>J9[2-/GG(RDU5RE
M-74A(B$WTQ&>.K1,WZ[1SMJ*'`G@(@S3J-(03:UM8RL<P4I6W\Z%4A<B!F34
M:(3G"2URK-'Y`M^J/GO=[9@L5?RP8EY5IE;M;(4C6/6JE*.$4M>*&)"I"D\7
MEJIPTCW!?5J6.*AHZP_>$S%9EBS['-1;20T[%TI=")\K!3TX<EG\^9&_A)6T
M/M(M/9\;+V<O^+0(77.]5#!_]]P\)'";`P(;GR=P=1K`(WPH[6X]MD<4P9=.
MOO,EEH^KUA>X:B1XD7#'V84A?!D:!UYJ'P='@<"&[#<8UL`(&PBJ>_"U8GJ<
M`/_0A\TD@=<2-]3--($GB0%\EL#='O!`C0`ONI?L2'_/ZF-1-=Z9'B`MXZY%
MU_Q-F/]HQ<[VQ%IXRX7,P1,FO-U3N&:.1[#D#HRU\@<.H/XU8/TO````__\#
M`%!+`P04``8`"````"$`480.N>4"``!;"```&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6R45EUOFS`4?9^T_V#YO9BO-$T44J6KNE7:I&G:Q[,#)E@%
MC&RG:?_][L6$0I-U]`7"Y?B<>^ZU+UE=/U4E>13:2%4G-/!\2D2=JDS6NX3^
M^GEW<46)L;S.>*EJD=!G8>CU^N.'U4'I!U,(80DPU":AA;7-DC&3%J+BQE.-
MJ.%-KG3%+3SJ'3.-%CQK%U4E"WW_DE5<UM0Q+/44#I7G,A6W*MU7HK:.1(N2
M6\C?%+(Q1[8JG4)7<?VP;RY2535`L96EM,\M*255NKS?U4KS;0F^GX*8IT?N
M]N&$OI*I5D;EU@,ZYA(]];Q@"P9,ZU4FP0&6G6B1)W03+&^"@++UJBW0;RD.
M9O";F$(=/FN9?96U@&I#G[`#6Z4>$'J?80@6LY/5=VT'OFN2B9SO2_M#';X(
MN2LLM'L&CM#8,GN^%2:%B@*-%\Z0*54E)`!74DG<&E`1_M3>#S*S14+#V(O#
MV?PJ`#S9"F/O)')2DNZ-5=4?AVHM]2QAQP+WCB6Z]&9S/YI`PEQ&K<%;;OEZ
MI=6!P*X!2=-PW(/!$HC/.P(KB-T@.*%S2B!7`VUX7(?1;,4>H71IA[EQ&+CV
MF*!',!#ME4%MNC*"41EKBZG<N,!0)CPO$[U'!L$)A6N??!A=]KQ.V6'B`>:E
M!".#`)EN$,'0`[`UD'XA=M(.-$$:-M5T:02WTGUQNPB<DT$R\[X.(Y>78RD\
M&F$,-7I[)^&JL687&74TNCJO"3MP:`\U8W_A`<7;JKANK-I%QJJ+\ZHXS2<?
M%02/I;I(U$Z:X4%8O(<7P6/>+C)J5NR?MQ``:N@!*Q?%T.ZWZ]8N&ZL>0Z/*
MQ?\XZC";3V2#8.;]7Q@7OA+N0F/AUX??C7(WZ2JA=^*3*$M#4K7',1W"[.JC
M_2=D$V)K7L?CY<9]6EC_!D9[PW?B&]<[61M2BAPX?6\.=K3[.+@'JQK('>:[
MLC#3VY\%?,0%S"\?O>=*V>,#*+/^;\'Z+P```/__`P!02P,$%``&``@````A
M`.?/OX>H`@``(0<``!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULE%5;
M;YLP&'V?M/]@^;T82$A2%%*EJ[I5VJ1IVN79,0:L8HQLIVG__3[C!$&3KNR%
MR\?Q.=^=]<VSK-$3UT:H)L-1$&+$&Z9RT909_O7S_FJ%D;&TR6FM&I[A%V[P
MS>;CA_5!Z4=3<6X1,#0FPY6U;4J(8167U`2JY0U\*926U,*K+HEI-:=Y=TC6
M)`[#!9%4--@SI'H*ARH*P?B=8GO)&^M)-*^I!?]-)5IS8I-L"IVD^G'?7C$E
M6Z#8B5K8EXX4(\G2A[)1FNYJB/LYFE-VXNY>SNBE8%H95=@`Z(AW]#SF:W)-
M@&FSS@5$X-*.-"\RO(W2VQ4FFW67G]^"'\S@&9E*'3YKD7\5#8=D0YE<`79*
M/3KH0^Y,<)B<G;[O"O!=HYP7=%_;'^KPA8NRLE#M!`)R<:7YRQTW#!(*-$&<
M.":F:G``KD@*UQF0$/K<W0\BMU6&9TFP2I+Y8K4$FATW]EXX3HS8WE@E_WA4
M=.3R+/&1!>XGED60+,-9!*+OD!#O41?@';5TL];J@*!I0-*TU+5@E`+QY8@@
M%(?=.G"&EQB!KP:J\+2)9^&:/$'JV!%SZS%P[3%1CR`@VBN#VG1E!W;*+K?.
ME5MO&,K$EV5F_R/CP%"<@?-QO.QYO;+'S`>8I$>,`@3(]``=&&H`8?5Y.\^M
M!TV0AGZ8+NW`G72?W*,%YF3@S!ME7(REW&C,PU7@^OK?S>0.CF6/EE%19V^4
M%9IP&*&3C5>1&[]W9-W!L>S1,I:=7:ZI6^B#<9D>K3LXECU:QK+S5[)^)?F)
ME5R7_!.O:X.8VKMU$\,,]M9^$VYC-R:O[?-TVVU(TG^`#=72DG^CNA2-034O
M@#+L*J?]CO,O5K7@.6P896$U=8\5_(HXC&$80+X+I>SI!81)_W/;_`4``/__
M`P!02P,$%``&``@````A``C&WB%\`@``+@8``!@```!X;"]W;W)K<VAE971S
M+W-H965T.2YX;6R45%UOFS`4?9^T_V#YO1B<KQ:%5.FJ;I56:9KV\>R8"UC%
M&-E.T_[[7>,4)6FU92^`S?$Y]]P/+Z^?=4N>P#IENH)F24H)=-*4JJL+^O/'
MW<4E)<Z+KA2MZ:"@+^#H]>KCA^7.V$?7`'B"#)TK:.-]GS/F9`-:N,3TT.&?
MRE@M/"YMS5QO093#(=TRGJ9SIH7J:&3([3D<IJJ4A%LCMQHZ'TDLM,)C_*Y1
MO7MET_(<.BWLX[:_D$;W2+%1K?(O`RDE6N;W=6>LV+3H^SF;"OG*/2S>T&LE
MK7&F\@G2L1CH6\]7[(HATVI9*G00TDXL5`5=9_G-G++5<LC/+P4[=_!-7&-V
MGZTJOZH.,-E8IE"`C3&/`7I?ABT\S-Z<OAL*\,V2$BJQ;?UWL_L"JFX\5GN&
MAH*OO'RY!2<QH4B3\%E@DJ;%`/!)M`J=@0D1S\-[ITK?%)1/DFR:SA%--N#\
MG0J,E,BM\T;_CIALSQ0Y^)X#WWN.R3R9+=))]F\2%N,9[-T*+U9+:W8$6P8E
M72]"`V8Y$K_O!XT$[#J`"[J@!&-U6(.G%>?S)7O"Q,D]YB9B\#EBLA'!4'14
M1K7SE0,X*(?,AE!NXL:A#']?9O(_,@%<4'R.P7.^&'FC<L1,#S"S$7%D$"'G
M&PQ@K`':.I`^S6T$G2&-376^=``/TF-R]SLX)0?!7+[O<GXL%0:#3S%'?^^D
M<.I8<[]S5%%^=:(9YS,VL`9;PR=H6T>DV8;9X]B2X^YX+:QYZ)K3_6F^'JX+
M-O[`<>U%#0_"UJISI(4**=-D@<FP<>#CPIL>(\>I-1XG=?AL\%X&[,HT07!E
MC']=H#`;;_K5'P```/__`P!02P,$%``&``@````A`&$MBF#%"@``US(``!@`
M``!X;"]W;W)K<VAE971S+W-H965T."YX;6RL6]MNXS@2?5]@_\'P^\269#N)
MD630T5W8!1:+F=EGMZ,D1MM68+MO?S]5(HN7*EFR&_LRZ1Q5G2(/BV21PSS\
M_F.W'7VK#\=-LW\<!S?3\:C>KYN7S?[M<?SG']EO=^/1\;3:OZRVS;Y^'/^L
MC^/?G_[YCX?OS>'+\;VN3R-@V!\?Q^^GT\=R,CFNW^O=ZGC3?-1[^/+:'':K
M$_QZ>)L</P[UZJ5UVFTGX72ZF.Q6F_U8,2P/EW`TKZ^;=9TTZZ^[>G]2)(=Z
MNSI!^X_OFX\CL>W6E]#M5H<O7S]^6S>[#Z#XO-EN3C];TO%HMUZ6;_OFL/J\
MA7[_"&:K-7&WOPCZW69]:([-Z^D&Z":JH;+/]Y/["3`]/;QLH`<H^^A0OSZ.
M/P7+*EJ,)T\/K4!_;>KO1^??H^-[\ST_;%[^M=G7H#:,$X[`YZ;Y@J;E"T+@
M/!'>63L"_SF,7NK7U=?MZ;_-]Z+>O+V?8+CGT"/LV/+E9U(?UZ`HT-R$<V1:
M-UMH`/QWM-M@:H`BJQ^/XQ`";UY.[X_C:'$SOYU&`9B//M?'4[9!RO%H_?5X
M:G;_4T:!IE(DD2:9&9+YS6TPO8]N@:/'#[ZVP>&G#AXL+G)<:$?XJ1T7-\%L
MNL`V]\2[U6Z0_-KMLG;>:S_X>5T[`QC/MH?XCPM:.E&CTPYVLCJMGAX.S?<1
MS"#0__BQPOD8+)&+AEEUU@S\N7&'`4>63TCS.`898$B/D*S?GL+I_&'R#1)L
MK6V>I4W@6\1D@=F$M`D'4@YD',@Y4'"@Y$#E`!.0Q6@#J?O_T`9I4!OJU3,!
MCEA,"+(@EX0#*0<R#N0<*#A0<J!R`$\(F(9"B!G,B.ZU@'("O6#6>SFQ\#OZ
MK&U@WIC$86D3&Q,CAD!2@60"R052"*042.4BGB:P)`E-<'V\<N(@#<P]4-X(
M(&>.,HKZ5#(F1B6!I`+)!)(+I!!(*9#*13R50!!/I?Z,0>M6#.K$LT(B6!\=
M>6[])(J-$;DE`DD%D@DD%T@AD%(@E8MX?8<]Y(J^H[7?=X7,8%%V^G['^FZ,
M3-\%D@HD$T@ND$(@I4`J%_'Z#CN!UW>UK=S@MMV?`NCHRZ"066C6SU@@B4!2
M@60"R052"*042.4B7I^Q\G6WTOZ.HK7?48VH"@BWOU@@B4!2@60"R052"*04
M2.4B7D=A-E[14;3V.ZH1536V'36(3?4@NO=3/5%&$:20,Q^FOE%JC&@^9(:;
MD%P@A?%RJ5G\TA@14>42>0IA)>5)Y.3_Z7VS_O+<0!^@[NC(D0C*)UU4(8LO
M74L,D*.=A6SCI7C:*KS7Q5DP8\)9`^I>9ID)RB546$=5]@61SUQ:`Z*I/!I?
M.2S&+I]%@:K=8/\D[F>"7(FTE9LZ'1(IJQEL^4Z"L1HUU?1@11$S&3&74$&.
M,^-82JCR''UEL#J[0AE5S'G*:`A6,-O!@,V@&&L1S#J8_L:J0ZPNJQG;F5/-
M%05MULWGK/S+]/?0W>-$K-RVB"0O+.0TDH<O!\)70^%]_;$4O$)_53E""&KT
M<Z"@$*0SRH8!2[!86V$B&"NA26*MB#[54(0+R+>G8"'$UBV"8NT\<2Z)"PF5
M`[$J<CD7RU<6R\<KE%75IJ>LAOS,#OV%*`ZTU4!F&RNKK()T&L\8;Z9YA[)8
M\!:V012JU-"94-50*%]7+$U=77]M%T(6M@LIB"4R6_=C/`VAXT`B&RO2(-6.
M.I&C&=N(,R(&0?L261`7Y&A+K%)#X4SMB_.([8L5^9P+YBN.!;&K>,?^#E=)
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M8U=>V.+ZB`N@,Z<UY-_4!6R5CZT5S<-$0JF$,@GE$BHD5$JH\B`_@?!TX"K4
MO[2%^C#ARJ`@)@,KWF+M"%96!N-(4"JM,@GE$BHD5$JH\B!?!M@'/!F<>32@
M"'JRQ%"0>W<)A29:.5`BH51"F81R"142*B54>9#??2R:K\@"-&=]UI#=^F-<
M)]#*0HF$4@EE$LHE5$BHE%#E07Z?KRO:8;L5?=:07<-BLH*NV^U'7&EJJX$[
M36M%\R.S]`3E%NJ)6%@N:Q5.V20MK1715Y8>(%\_K(+=G'&FS.45*6[G/)4T
MY,IJ(-M\62MIKO.7G=:`^I=1?!LLMU!/L,)RG;G_M`84K++,0DRL8UTQ!Q8=
M7?:ZR["&;$?BT$`]'4FTU<#]I[6BWF26GJ#<0CT1"^)RKD0E5%DN(1;6L5>(
MI<I>;^O6$*25F:9AR,K`&!*IS4V0T5AU9%V7E:PXE15=\`1LZF4Z%A9_YV/E
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M@JPL?2FABJ"6WE<&#SBN,K^6G/J8Y-1R>#``#=DRP7(HUE8#=[)DY<UC7@RD
M%%'__Y!H(18-W4H8-[NTR$5#6\&/\U;%14TJ69/".=LZ*J(YUR1_K/AICX_5
M91=E\/1:9+>"O.PV4(\,B>:".I>F12JAC"`WNR^A+\C1TI<2PK?D;:HYV:W>
MAJOGPKOZ\%;']79['*V;K_CN&RX1GAX,K!ZE/X?1$B]7H!_BRPR^M%L4^P(/
MV3^U*<_P9WC@WNXF'`^!J"L"A.Z*_&FV_`2=ZV@2M*BK0<_S)3SJZ[!?+.'!
M6P=^NX1'81UXB"WM:FH2+I8I'*BE#YS/EWCZEE^2\!9\NN+`"11\NK[`D0Y\
MVG%G(L+1"WRZOB3W2WA$)>,7]TMX`27Q))@N4WC/([_`RZ`E/OZ17Y(@`)^N
MP857,N#3?IF8)L.?%7RLWNI_KPYOF_UQM*U?(?VF[6/"@_K#!/7+25]Q?VY.
M\`<%L/7`<W;X`Y(:GM)-\:;WM6E.]`LT:F+^).7I;P```/__`P!02P,$%``&
M``@````A`(Q7Y<8V&@``W:4``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX
M;6RLW5MSVSB6P/'WK=KOX/+[Q-9==B69ZDB\WUFSN\]N1TE<'<<IVST]\^T7
M$`&!.'^:LCRIK=I,_W@(4C@$1!Q)]/N__^O^^]D_=X]/=P\_/IQ/WEV>G^U^
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MJ"34$AH);0\N5'H..5*7]*_(D6Y&Y\CV[B<++FE3D1`;87?92@@DA!(B";&$
M1$(J(9.02R@DE!(J";6$1D+;`R\A:J+X%0G1S:BWG_Z@F5SY&?AD8M3(/(RL
MA1^R.80<L@0)("$D@L20!))",D@.*2`EI(+4D`;2]L5+FIJJ?T72=#-JLE27
MQB$AG.JZH-E8U@XAAZQ!`D@(B2`Q)(&DD`R20PI(":D@-:2!M'WQLJ;N=[RL
M#=_FV;<A';U/CNW43YW,U+U(+UUR!!V"[&Y;2``)(1$DAB20%))!<D@!*2$5
MI(8TD+8O7B[4/<X)N=#1?BXZ$;E8BMGL$'3(!22`A)`($D,22`K)(#FD@)20
M"E)#&DC;%R\7ZE;+RX6^;UNH&X@3[]MT,WZ2.IFK._#>@%F))!V"#DF"!)`0
M$D%B2`))(1DDAQ20$E)!:D@#:?OB)4G-_UZ2QB<O'>WGHA,Q8-8B%X>@0RX@
M`22$1)`8DD!22`;)(06DA%20&M)`VKYXN5#O`%XN]("9+MZIR>[$(:,;\M/4
MB1@RXD9N<P@ZI`D20$)(!(DA"22%9)`<4D!*2`6I(0VD[8N7)ET#\/(T/F;V
MX7XV#,V[BHU>1FY(6U)`"DD1*28EI)24D7)202I)%:DF-:36(S\7>D':+PX<
MR46W?E6WQO82_Z3+,FJP^#/8[%+,8"[*[K@E!:20%)%B4D)*21DI)Q6DDE21
M:E)#:CWRTZ.7IR>DIUO->NGIR)^Y9A.9GD.42P\HT"LBE6K5EHT*21$I)B6D
ME)21<E)!*DD5J28UI-8C/SUZ)7I">KJ%JVK/]M\G79#DZ)$U&A=E=]R2`E)(
MBD@Q*2&EI(R4DPI22:I(-:DAM1[YZ=%+SGYZWGQ#H(O`XH[`D!A8,SFPNAU[
M0V;K=K3)#$@A*2+%I(24DC)23BI():DBU:2&U'KD9TXO4']-YKJEKC?F.A*9
M$Z7LC?[`R9_LMJ2`%)(B4DQ*2"DI(^6D@E22*E)-:DBM1W[F]'*VG[DC-Q3=
MZM=+3T<B/;*>,SE$V5&T)06DD!218E)"2DD9*2<5I))4D6I20VH]\M.C%[(G
MI*=;]WKI.2R%>]6#F2SQZ$^\Y.@!!8P*21$I)B6DE)21<E)!*DD5J28UI-8C
M/SUZ;7M">KJEL)>>CL3HD<4=_3&@3`\H8%1(BD@Q*2&EI(R4DPI22:I(-:DA
MM1[YZ=%KVA/2TRV!O?0<5L7]T2/K/9-#E)O<0`&C0E)$BDD)*25EI)Q4D$I2
M1:I)#:GUR$O/5!86ND^ZW^GO78R_#>WW]&L,AN;N9GU#VI("4DB*2#$I(:6D
MC)23"E))JD@UJ2&U'OEI.:W&,&6-P5*OWD/:D@)22(I(,2DAI:2,E),*4DFJ
M2#6I(;4>^;G02_C^#-8;(L_?[F[_^/2@BJ8J`P/C9::^]-%]%63:%0+Z$YNE
M[OM8^Y*<H_Y<)XJF6Q,U5?.;^S1B+NI'@8NR,V)(BD@Q*2&EI(R4DPI22:I(
M-:DAM8;4[;9ZV7XB9>GA;8ED16)J2-U?]_(A"T8V2LVL+FJ&W)KJAO=)TUQ4
M-P+3UJQ75G+-VW1'CD:.&+NV>E%SL2I/7)1M/G7-6\H<]=J2KS%W;?6BYF(U
M6;@HVWSIFK=4.>JU)8]8N[9Z47.Q0&I<E&V^=<TK\J\F62D9&/[JNY.'\<]R
MR-20NLEW%\1<+@MLE+K7=%'R!6X'H^;B'C:P45?[[Z)-)ZN9B`A-A'YG>OEH
MD6UG])SBP;;D.24V2DV@[HAS<7N7VJC1\\I>=5[Y8%ORO`H;-7I>I8T:/:_J
M5>=5#T;)\VILU(LY;(^=DW\9ZYK-?_[NUE5^O'>WCO1TW,NKF.XV^MO%NDKH
M]3*O;A,U/U2!`[.C'I^]YL5E$]KFU4AS4;+YR$:-GD3LHNSLD-B3F._'TW)R
M)>;\U.XS>OS,1HT>/[=1KA,*>_S13BC=CB.=4-FHT9.H793MA,:>Q$N=T-I]
M7NH$_WK41:K^]7AD6NUJ6MZ%UY$ZJCW%S?1`(SVPM5'+PXX!*;3DFH\<C30?
MVRC7?$)*+;GF,T<CS><VRC5?D$I+KOG*T4CSM8URS3>DUM*^>3^ONI35S^O;
M;KZZ@IB7;D/>N^A"W`QOIEV4_N?EB6!KHG0UPT7)&3BP42_.P*$]VNB[0F2C
M1L\IMD<;/:?$1G7G-#03F0X8/:7L5:>4VRBO+=E-A8WR)A3YQE[:**\M.4-7
M-FJTJVH3-9Z^QD:9]*VNIN)=H[5'>^F<_`M;)6;TPO['P\^7EH=JCCK<'^IF
M1#FE(V\B.U#O`I6]M9V:J'5O(@.%-LI-!9&CD>9C&^6:3TBI)==\YFBD^=Q&
MN>8+4FG)-5\Y&FF^ME&N^8;46AJ8R'15\3^?R+K:I#>1=>3=,,EEV$:O^?5E
MHFZ(W`S%"\!$>>^X<H`&IJUCMU!#;<DC1J\ZK]A&C9Y7\JKS2@?;DN>5V:C1
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MC5S>@KWI6^NSKMK>OPTSY'\;8"$*\!L798L,6U)`"DD1*28EI)24D7)202I)
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ML^N,.=J2`E)(BD@Q*2&E'OFO65=O3GC-IMCCOL'U2?]*2;]`=Y>W<31RE[<U
M47H6<TN!A?C,/7!1=HH)7?.6(E+L=NPW+SX]3UR4;2OUVO(Z2\^&7F?UQNWK
MO^FS;\4?PY9Z?>BH=_I81I@H7</I]:$H3`4NRK[(T#5O*2+%;L=^\V(MG;@H
MVU;JM>7WH:PTC`\R=3,@)SQ+:I+KO6;YP;&-4L//1;'_3/->E%R.!K8M\^')
M?"FNHM`$'/E6A&W&+6MB1[VSE,=/3)1:\^I'!,T7XHXU/79X/P%R,7PD`5ST
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M-&^C8AOE=DQ(J:6!JU>O2?K=<V00ZW!QP]J1OLWKS5+BQG`S/T394]^2`E)(
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M\M.C5W[]D35^1[$P"\5>&=&0&#UBW;-Q42X]75O>Z`&%W#$BQ:2$E)(R4DXJ
M2"6I(M6DAM1ZY*='KT9/2(]9O/;3TY$8/7)MO#A$N?2``D:%I(@4DQ)22LI(
M.:D@E:2*5),:4NN1GQZ]LNVG1[\OO>V.HELC]U<LBX[$P!)EAXV+<ID[[&@I
M8%1(BD@Q*2&EI(R4DPI22:I(-:DAM1[YF=-KUW[FCLQ[9JW='U@=B8$E:C2;
MQ2'*YF)+"D@A*2+%I(24DC)23BI():DBU:2&U'KDIT>OG?OI>?O`ZE;AWL#J
M2`PL6:I9'*)<YD`!HT)21(I)"2DE9:2<5)!*4D6J20VI]<C/W&DEB@5+%(;$
MP)(E"A?ETM.UI7:T%#`J)$6DF)204E)&RDD%J215I)K4D%J/_/3H.L&O&5A=
MQ<$;6!V)@26K%XM#E$W3EA200E)$BDD)*25EI)Q4D$I21:I)#:GUR,O<4E8O
MQM^Q]N%^B<*0^M#1=OR&M"4%I)`4D6)20DI)&2DG%:225)%J4D-J/?)S(>L1
M1W+!FL.R(W^26\MRD8NR&=N2`E)(BD@Q*2&EI(R4DPI22:I(-:DAM1[YZ3FM
MYK!DS<&0/Y.M94G(1;GT=&VI'2T%C`I)$2DF):24E)%R4D$J216I)C6DUB,_
M/:?5'):L.1@2HT>6A%R4S<66%)!"4D2*20DI)66DG%202E)%JDD-J?7(3X]>
M^/^26X1E5T+HWR(8$@-+5HM<E,M<UY8WL$`A=XQ(,2DAI:2,E),*4DFJ2#6I
M(;4>^9F3Y8@C;TNL.2P[$@-+5HM<E$O/84=+`:-"4D2*20DI)66DG%202E)%
MJDD-J?7(3X^L.;S]4XPEZQ&&Q,B2Y2(79?.T)06DD!218E)"2DD9*2<5I))4
MD6I20VH]\E.G5_YR3GS;!U#+KHC@38J'ND+O4]^U+"69'7LSX)84D$)21(I)
M"2DE9:2<5)!*4D6J20VI]<A/W6D%B24+$H;$I"CK12[*C2P6)!@5DB)23$I(
M*2DCY:2"5)(J4DUJ2*U'?GI^64%BR8*$(3$GRE*2BW*90XTB8%1(BD@Q*2&E
MI(R4DPI22:I(-:DAM1YYF5N=5I#8A_L%"4,B/;)>Y*(.Z2$%I)`4D6)20DI)
M&2DG%:225)%J4D-J/?+3<UJ-8L4:A2%_WKN2-0H7Y=)S*&Y8"A@5DB)23$I(
M*2DCY:2"5)(J4DUJ2*U'?GIDC>+-GW"L6+XPY`\L^0R[C8NR:=J2`E)(BD@Q
M*2&EI(R4DPI22:I(-:DAM1[YF3NM?+%B^<)0OQ!+VI("4DB*2#$I(:6DC)23
M"E))JD@UJ2&U'OFY^&6UBA5K%8;$*))5)A?E1A$*$P&C0E)$BDD)*25EI)Q4
MD$I21:I)#:GUR,_<:;4*_=AZ\;4]0^+M29:27)1+#VL5C`I)$2DF):24E)%R
M4D$J216I)C6DUB,_/;)6,5Y*6K$>84B,'EE*<E$N/5U;:D=+`:-"4D2*20DI
M)66DG%202E)%JDD-J?7(3X^L1QQ)#VL.JX[$Z)'E(A=E<[$E!:20%)%B4D)*
M21DI)Q6DDE21:E)#:CWRTR-K#F^O]*U8CS`D1I8L%[DHE[JN+6]D@4+N&)%B
M4D)*21DI)Q6DDE21:E)#:CWR4_?+ZA$KUB,,B<S)2I*+<IEC/8)1(2DBQ:2$
ME)(R4DXJ2"6I(M6DAM1ZY&5N?5H]8A_NUR,,]>_+25M20`I)$2DF):24E)%R
M4D$J216I)C6DUB,_%Z<5']8L/A@20T66[ES48:B0`E)(BD@Q*2&EI(R4DPI2
M2:I(-:DAM1[YZ1DJ/DP6K_CC4&L6&PRIW]K;'&Q(6U)`"DD1*28EI)24D7)2
M02I)%:DF-:36(S\MIU46UJPL6.I]Q8NT)06DD!218E)"2CWR7[-<P8_?R:ZY
M3+?D?GJ[<=3[0*WWF^/]#Y^W)LI_CLV5*#\'+LI>WB$I(L6DA)0:&OBK1FNY
M0M8WD6:0OOZA-?M6Q-N<64OW.^Q`HQW617D/K9E>BH)P8(ZHHER''7:T%#$J
M)B6DU-!0A\DUZ]LZC$O9M:%^AQUHM,.Z*/7X7OU$E.GE1"Q_`].R"K`=$_)@
MD:.1@\6N+7,P40I)7(`]6.I:5N2/R]-6F&NN,"WUYR(3I=[NW<^;.2[-TE3]
M<XA2?>?_->G`-*^>"F9?34B*2#$I(:6&NL=_^3TC%W='9BPNX-:&_!<H"XLV
M2@4?NF'"SC)MN4<*!'9'\V"(]5S]GUACA";FR*-B;$NCIQ"[*)N)Q%)W"M/U
M=")FB?38"?A=+A=E1[J<*Z]U1]XS^*>78H1L3-211\2X*/MZ`]M\]P3YJ\OE
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M4IW!?EK%EHG:LK^RY):5VD=]'67HW-0^ZIL00UO4*U6?M`]MF:DML\$M<[5E
M_RA`G,%";=EWO=RR5/NH[TT/'&>I]E%?V1W:HOI:?2-T:(OJ:_6%PZ$MJJ_5
M=]V&MJB^5M^E&MBR4/NH'^P-;5'[J!^$#6Q9JKY6/T\:VJ+Z6OTR9FB+ZFOU
MHXRA+:JOU>\!!K8LU#[JX1%#6]0^ZKD%0UM47ZN?S`]M47VM?I(]M$7UM?HU
M\-`6U=?JUZ8#6Z:J#[JW?IGMF3HW]:CZ@7UFZMS4XQF'MJAS4Y6`H2WJW+KW
M`1Q'G5NW_I!;)NHXD\'C3-1QNK4K]E''F0SVP40=1SU8;N#<)NK:40^2'-JB
MKAWUU^$'MJA=!O=0.PS&3U0_3P:OM8FZUKH%$EZ+NFZZ;SACB\K-9"@WV_7J
M6B_$>,:_3:Y_&[P&]>$'XC^I@P_&Z\MB(/ZW^?5O:N+F@3^I+`XF45_'0_%Z
MQAARE;^A%[:=7U[K9_SRR.H!OM?Z\;S<HJI6JIN&SFJ[7J@M0^>U72^O=:F!
MK:FB@=IG:,NGN;I.U*/.N,^GN;I2U%.V!K8LU*6BGN(TM$7E2CTDB%O4WSR_
MUG_M>VC+[%K_/6QN47_9^CH9W*+^`O6U_OO2W$?]I6AUG*$MZGG6U_IIU=Q'
M/8KZ6C]H6FVY.%S'3Q_?_[SYNBMN'K_>_7@Z^[[[HM[&+_>E\\>[K_H^J/N/
M9_/7`7]_>'Y^N%>WX^=GWW8WGW>/.D#=P'UY>'BV_Z$/\-?#XQ_[6X6/_R\`
M````__\#`%!+`P04``8`"````"$`$ZC^/:0"``#M!@``&````'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;)1576^;,!1]G[3_8/F]&$C2)BBD2A9EJ[1*T[2/
M9\<8L(HQLIVD_?>[Q@F%)JVR%X0OQ^><>Z]]F=\_RPKMN39"U2F.@A`C7C.5
MB;I(\>]?FYLI1L;2.J.5JGF*7[C!]XO/G^8'I9],R;E%P%";%)?6-@DAAI5<
M4A.HAM?P)5=:4@M+71#3:$ZS=I.L2!R&MT1246//D.AK.%2>"\;7BNTDKZTG
MT;RB%OR;4C3FQ";9-722ZJ==<\.4;(!B*RIA7UI2C"1+'HI::;JM(._G:$S9
MB;M=G-%+P;0R*K<!T!%O]#SG&9D18%K,,P$9N+(CS?,4+Z-D-<5D,6_K\T?P
M@^F](U.JPU<MLN^BYE!L:)-KP%:I)P=]R%P(-I.SW9NV`3\TRGA.=Y7]J0[?
MN"A*"]V>0$(NKR1[67/#H*!`$\03Q\14!0;@B:1P)P,*0I]3'(.PR&R9XM%M
M,+D+1Q'`T98;NQ&.$B.V,U;)OQX4M:8\5VMM32U=S+4Z(&@WH$U#W>&)$B`^
M>?(,G<OW3(([1[)T+"F^PPCT#11VOXBBZ9SLH1KLB%EY##Q?,1V"@)O.$MCH
M6[I<GI.R`SME5RYG9>4#?9GXLLSH?V0<&.K=-Q_-.EZO[#'C'F;2(08)`N3Z
M!!T8F@-IO=;MK+8>=(4T')3KI1VXE>Z*>XS`T7\U$X>7L[P=2K4G:P9I?-Q/
MMVNH>8ST.QK%T65-.(']])SF.)P%0/&QJMLW5#U&AJKOG"0WG]_>H3'L_%C3
M[1IJ'B-#S=&;3/UX\7=8<EWP+[RJ#&)JYT9'#)>OBW93;1F[^_$V/DZ6[;0C
MW0>8-@TM^"/5A:@-JG@.E&%P!VW7?E[YA54-.(>9HRS,F?:UA-\*A_L7!@#.
ME;*G!0B3[D>U^`<``/__`P!02P,$%``&``@````A``H7>;[W!0``+!H``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<65V/JS80?:_4_X!X3\`&DLTJ
MR=6%U;97:J6JZL<S2YP$;0@1L%__OF./^?"0`.G+[F9]/!S/C,\QSOK;9W:R
MWD51IOEY8[.Y:UOBG.2[]'S8V'__]3Q[L*VRBL^[^)2?Q<;^$J7];?OS3^N/
MO'@MCT)4%D0XEQO[6%671\<IDZ/(XG*>7\091O9YD<45?"P.3GDI1+Q3D[*3
MPUUWX61Q>K8QPF,Q)4:^WZ>)>,J3MTR<*PQ2B%-<`?_RF%[*.EJ63`F7Q<7K
MVV66Y-D%0KRDI[3Z4D%M*TL>?QS.>1&_G&#=G\R/DSJV^M`+GZ5)D9?YOII#
M.`>)]M>\<E8.1-JN=RFL0*;=*L1^8W]GCY&WM)WM6B7HGU1\E)V_K?*8?_Q2
MI+O?TK.`;$.=9`5>\OQ50G_LY+]@LM.;_:PJ\$=A[<0^?CM5?^8?OXKT<*R@
MW`&L2"[L<??U),H$,@IAYCR0D9+\!`3@IY6ELC4@(_&G^OV1[JKCQO86\V#I
M>@S@UHLHJ^=4AK2MY*VL\NQ?!#$="H-P'<0#]GJ<3PWB("&UOJ>XBK?K(O^P
MH&G@D>4EEBW('B%PO3"DT2SUUDIAB3+(=QE%Q8)%E%">]^V*K9UWR&BB(2%"
MEK;50`@BJA&R$,"NH0CKIA0]J.#UW->,Y"23$5\21E<@)B+J(Y:\@1@<(75=
MCL/<)!@ZH).*51M6)31$B-^!!,V#%2(:0AC4(,AT:A*\L6'=394>*#6$/*@J
MSQCH$`%$!H`O^$/#W.`%C=_E)3MOO*QR$DF=UX3'U"$$2#1+H*D;0A@4%R;%
MX:I*L)FZE4^H(<17J2.TH^X87S03#3ZP>^Y/F9Q$>)&$A`A!7K2:]=BU=!KD
MI-<1)1FOIYQ$R+5KQWHB!,DM&4EIU!UE-SIM]7^8R4F$&140A-3,FI+A_JP'
M1_/&0,ON3YR:1?BUR\?,:0P2]%>$H#'*W&;4*"HC_C"\!12:D"*/#35FH3:!
MOWR@!=7CU_>OR4W*<Z?C1KBAF'=5%\2K6;7.&(*N/QSKRH8@)C\IT=/YH:!#
M]$:W/+(70U:+OG3864#J'9G#K/57DY;4Y^FT)-HLJ4>D*V2(P3Z;<<(Z,H;;
M=C!)$3<8J24JN)$KTD>A/)X!<>RS&0M8CU9M`S*9O.T$D]==%L#Z'N"1(H4:
M4R>K4R7=7UTCF`6M5)N\B!6,Y*OO`7[;';KU:Z&7Z?`ZYQQ-JSM\,UO$`T98
M]<7?)T4*65??'[RV2II5=YC?.FDP8@`CM/K*[[=5T,FJU5WU#G&L2#UO8V.)
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M,4D2XYA(LF\@S&WU3'<C@K0B<K<C>+K>)N"F(LIWK*XB3N.H9IEVPCKO`,A1
M@^I$^E36(P.P7-YZ;?6(H4RD>,58J&^$*G1]RN/<HP>(R``$P:+M:*/2'O&5
MB13E+.(O])P9JM"WA`5K/0@Q>=[E+]X5?V'47S0(M;O7J%$S/+I;/.D4D[U9
MH6D'MD<EW8$R9'.2(AL]TB$FJ(TGQ7TZ-;0"XTC#6HG0U&J_D$=`WR=9C=03
M;U7=+"FQDXFMA[9B<J2VXB%(VS)90=2,CE?VBJ/(O3_L*'`A+XMG4FSWGTXC
M@O`ZT0]Z:<3AH1+CI3U>:F>B.(A(G$ZEE>1O\D*>P3U#\U_\LB"$+PO4S;K3
M#,!=_24^B-_CXI">2^LD]C#5G2^AQ@7>]N.'*K^H2^67O();>O7G$;Z5$7`'
M[LX!O,_SJOX@K[&;[WFV_P$``/__`P!02P,$%``&``@````A`*WX/WI!!```
M/1,``!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULG%A=C]HX%'U?:?]#
ME/<2;`\P(*#J=#3=2ENIJG;;YY`8B":)H]@,,_]^KWTS(7%H;/9EF,"YG\?W
MV/'ZXVN1!R^\EIDH-R&93,.`EXE(L_*P"?_]Y^G#?1A(%9=IG(N2;\(W+L./
MVS__6)]%_2R/G*L`/)1R$QZ5JE91)),C+V(Y$14OX9>]J(M8P6-]B&15\S@U
M1D4>T>ET'A5Q5H;H857[^!#[?9;P1Y&<"EXJ=%+S/%:0OSQFE7SW5B0^[HJX
M?CY5'Q)15.!BE^69>C-.PZ!(5E\/I:CC70YUOY*[.'GW;1X&[HLLJ844>S4!
M=Q$F.JQY&2TC\+1=IQE4H-L>U'R_"3^1U0.C8;1=FP;]S/A9=OX/Y%&<O]19
M^G=6<N@V\*09V`GQK*%?4_T5&$<#ZR?#P/<Z2/D^/N7JASC_Q;/#40'=,ZA(
M%[9*WQZY3*"CX&9"9]I3(G)(`/X&1::7!G0D?C6?YRQ5QTW(YI/98LH(P(,=
ME^HITR[#(#E))8I?""*-*W1"&R?PV3@AU-=)A`F9^AYC%6_7M3@'L&@@I*QB
MO03)"ASKPN;0GNN%047:YI,V,J:`EL#&RY;1Z3IZ@0XF#>8!,8LP:#&T1400
MO,T`HMH9,&<&VJB?`5VT[DV2#PA9&%Z[\=@PWMUOJ7RO6!L!:9UJ&"560,3<
M=3"S%M&K&"#=BL=[K<&;$(II^TAF=J\1<V^8H(LEO;\>%ZKTCZO!=ER[8L3,
M35Q"YNPW<>>WQ-7@?EQ&+RL'J46,1Z=A^74KUJO;S;4V<G&-&(\,]`[0F:]Q
MKC6X7SN9V3U'C+/GRUOB:G`_+J.L74/8<\1X5$Q@>+LE^S7=6+FZWH!\DK!T
M;;SO!,5J?,@:$':>D@6["$YONHD6G@[ENGZWH!DKFX,[BX,&Y%/__U(YXB-S
M#<@G"<!T.^$@0:/['1@J'4$0DC`GR\MT]#FX2>KT3FY%9O2BW;C^&Y!/V9;>
M>0X`BMKX%D.\E8]8TN?H/>J98P`0Y!X`2_,\!V`H?HS.[0%`D`\)E@!ZDH`J
MYR#!6PJI)87C)!BT:P`:D),$>I,`&G0_-!L>J%`E/9I/KTB@>]\U5JXMH`'Y
M)&%)H*/Y*'WC$T`1Y%(?"MEU=<]O`(R5S<'E1-4<:K5K.,1TCH,7H>I)H'ZQ
ML)/PX`"E<'P`C&N_)"PI='"`ZN;@`$%.#F[2/SK4/T:7EO@T()_>7U%`C]ZC
MN#EZ[ZV`U%)`1^]1U/J]O^RNS>I#$/9^Y,"OCSOVVG,?@8R5-0#,?M5I0!XD
M,$L!_78`8^42H0;DDX2EA.,DP!6&?1`9O@`T('S;NT8"WF+@6W[!ZP/_S/-<
M!HDXZ1L*`F]K[;=X>_(`MR?F\B1J?X#+BRH^\&]Q?<A*&>1\#Z;3R0+DH<;K
M#WQ0HC*OX3NAX-K"_'N$:RH.MP33"8#W0JCW!WW!TEY\;?\#``#__P,`4$L#
M!!0`!@`(````(0!1,'`L_`8``+H=```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;*R9VXZ;2!"&[U?:=["XCPWXC&Q'L<U1N])JE=V]9C"VT=C&`B:3
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M&1#9!U5^7%M?'"]Q;6NT6;4"_5ODK[7R]Z`^EZ]A51S^*&XYJ`WS1&;@J2R?
MB6E\(`B<1\@[:&?@KVIPR(_IRZ7YNWR-\N)T;F"ZIY`12<P[_-CG=0:*0IBA
M.R61LO("`X#_!]>"E`8HDGYOCZ_%H3G#7\NANY@ZTQG8#Y[RN@D*$M,:9"]U
M4U[_8U8L%HWBLBAP9%'&L^%T;H\=$J3'<<P<X<@<9\K5>QPGS!&._(K.^SQA
M0&W&<&2>[FRXF$XGL\6\?[`SYCD7GN\<+"RV]I)P_.!@E\P3CA\<K`.E1&>6
MU!2=M/[ACFAIM)6V3YMTLZK*UP$L7YC[^IZ2S<#Q2%A>8W1Z1-6]5710;23*
M%Q)F;8%X4$XUK)1O&W<Z78V^075GS&:+;1S=8L<M2"F3L'L3^"8(3!":(#)!
M;()$`2.016@#%?\KM"%AB#8\JRT'BEB&$-R"N^Q-X)L@,$%H@L@$L0D2!6A"
MP`K^%4*0,&L+_E>*9*9GOF4VL)J$D5%'.V$BU$'$1R1`)$0D0B1&)%&))A+L
M5K]")!(&%B-,A1``+R5J-.Y329@(E1#Q$0D0"1&)$(D1252BJ02[L*92][V,
M;RO$NA6#)[&E9`Q[IB+/7"^BG3#B;GM$?$0"1$)$(D1B1!*5:+G#/4;+G>RU
M[G0(]A_<;4D@719*)K"!*[(L#%F$D9`%$1^1`)$0D0B1&)%$)9HL<-?09.DO
M"6*MYT[)Q!$;[`Z1/2(^(@$B(2(1(C$BB4JT1&&Y?B!18JTG2HDQR4MCDH61
MF&1$?$0"1$)$(D1B1!*5:+G#@M5R)[4_AS[RP[5/`NFR4*++,K,-6821D`41
M'Y$`D1"1")$8D40EFBRDY=)TZ2_^UES/GB$C?=19D>NL+;`2^4M'CGR,`HQ"
MC"*,8HP2#>DRD!8,MZ%#TK0_4(0V;W"_Y%EL'8HF$NTPVF/D8Q1@%&(4811C
ME&A(3Y\T7FKZ#W*F?9J6,T/T,9#TSCO20I"5(M$>(Q^C`*,0HPBC&*-$0WK.
MI)'Z0,ZT[X)X<IX9D@GN'('D?=`9&UODGEF-H;CDW=(V=@Q?6O$K!C(\1Z%$
M,A:Z8B1C22O7-L852RL>/I'A`>GZD19+U8\^N;5+ICD7V?.VA.1@*734TAB>
MT-AS&VW4-%D94F452`X?);EWJ)6[I,]_MC/1]V!?&O#\`H:4(@TEZKE8)&.U
M#YNV,]8O%DL#?K%$1D9B0BEH8G:(!F\[A&K$W-B&&5)5$Z@GD3UYH4-V9JA<
MI1B-_=N75CR;@"%-NO=<,>*Q)F(IQ1@E6GB]\D@GIU;>`[%HXZ>5&$/0*<F<
M9ZX^@SN'64%/(:PZJDY8<65\[D@+T5E,X)_QB!`P&WA]UQ,\Y)%ZAQ!)*SZ$
MF",VA/G$G;O&$))'0]!%)UVE*OK/+7?:FVIS09$+=PNALCLS5M/.88ZPGPBK
MCKD05EP(GSFZDW93<.RI;4\,(0(>'/:/MX.'W*IW")&TXD.(]2%,YW-W:>Q,
M"?=Z:P3Z5)`F5YV*!_5/>V)-<XI@1^&#W#D"]6BPYU8SX>AC%'`DPX<2]82/
MN)4,'V.4<-2&UY4A?:ZJS,\5*>V6-<$8@OH2%>+.C%G<.=3*5:TZBI3%6B@:
M,L3N7(OE8CHV@@<\^(,-XSU#B%@L$)+/?\P1&\(8/K6XQDT@>30$;2[(SM8[
M%U_+^UO]@7*K:\/HMSJ&U.J52,X/5IY;R;1]C`*.E.J5J"=\Q*UD^!@C\L&&
MW&_IZ*EB]`,,?2U^S:M3OLLOEWJ0E2_DXPJHOED)3+_\;)<>/-/!Y)G<L3WR
MF--U!CX6P1,`/@-?D;ZT72V*!0X=]EL7OCIU\;$'+R<[XD\@?N>0)AZ\I\,.
MVZD'[[`Z^,R#ES@=?.[!.X\.OO#@?0#FT'][I+O&9Z!/]D@7C,]`<PD^7:.%
M3A!\NLY`:P4^79E`"P0^=/\2JL.7LWMZRO],JU-QJP>7_`B3;[?]=$6_O=$?
M#5LW3V4#G\S:)72&;Z0Y/'/9Y'W&L2P;_@,2&8FOKIO_`0``__\#`%!+`P04
M``8`"````"$`@U1K"7X"```P!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6R45,MNVS`0O!?H/Q"\1[04VTH$RX'3P&V`%BB*/LXTM9*(B*)`TJ^_
M[U*T53L.6O<BB=1P9G=VE[.'G6K(!HR5NLUI'(TH@5;H0K953G]\7][<46(=
M;PO>Z!9RN@=+'^;OW\VVVKS8&L`19&AM3FOGNHPQ*VI0W$:Z@Q;_E-HH[G!I
M*F8[`[SH#ZF&):/1E"DN6QH8,G,-ARY+*>!)B[6"U@42`PUW&+^M96>/;$I<
M0Z>X>5EW-T*K#BE6LI%NWY-2HD3V7+7:\%6#>>_B,1='[GYQ0:^D,-KJTD5(
MQT*@ESG?LWN&3/-9(3$#;SLQ4.9T$6>/4\KFL]Z?GQ*V]N2;V%IO/QI9?)8M
MH-E8)E^`E=8O'OI<^"T\S"Y.+_L"?#6D@)*O&_=-;S^!K&J'U9Y@0CZOK-@_
M@15H*-)$R<0S"=U@`/@D2OK.0$/XKG]O9>'JG-Z.H^1N$D^FB"<KL&XI/2<E
M8FV=5K\"*CYP!9;DP(+O(\LTFJ2CV_C?)"Q$U"?XQ!V?SXS>$FP:E+0=]RT8
M9TC\=D:8BL<N/#BG*248J\4J;.9).IZQ#5HG#IC'@,'G@(D'!$/101G5KE?V
M8*_LO?6A/(:-4YGD;9G;_Y'Q8"S.2?!).AEX@W+`C$\P?Q!G"2+D^@0]&&N`
M:0V^77H;0%=(8U-=+^W!O?1@[F$'Y^0DF.G@PUF6TW.I?C3&6)>_=Y(_=:YY
MV#FK:)J^T@P3&AI8@:G@`S2-)4*O_?0EV)+#[G`Q+!+?-:_WQ]FBOS#8\`,'
MMN,5?.&FDJTE#91(.8I2-,.$D0\+ISN,'*=6.YS4_K/&FQFP*T<1@DNMW7&!
MPFRXZ^>_`0``__\#`%!+`P04``8`"````"$`_D@(:ND$``"(%@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6R4F-MNJS@4AN]'FG=`W#<<$G)2DJTF
M'*4]TF@TAVM*G`05<`2T:=]^EC&PL4.]FES4B?NM'_-[V>"U^?&19]H[*:N4
M%EO=FIBZ1HJ$'M/BO-7_^=M_6NI:5<?%,<YH0;;Z)ZGT'[O??]O<:/E:70BI
M-5`HJJU^J>OKVC"JY$+RN)K0*RG@/R=:YG$-/\NS45U+$A^;H#PS;-.<&WF<
M%CI76)??T:"G4YH0ER9O.2EJ+E*2+*YA_-4EO5:=6IY\1RZ/R]>WZU-"\RM(
MO*196G\VHKJ6)^OH7-`R?LG@OC^L69QTVLV/._D\34I:T5,]`3F##_3^GE?&
MR@"EW>:8PATPV[62G+;ZL[6.+%LW=IO&H']3<JL&W[7J0F]!F1Y_I@4!MV&>
MV`R\4/K*T.C(NB#8N(OVFQGXL]2.Y!2_9?5?]!:2]'RI8;H=N"-V8^OCITNJ
M!!P%F8GM,*6$9C``^*OE*4L-<"3^:-I;>JPO6WTZGS@+<VH!KKV0JO93)JEK
MR5M5T_P_#EFM%!>Q6Q%H6Q'+?EADVHI`^TO$7CJ6,W]@*+-6!=I>Y=OW`7?<
MF`%M'SQY>`CS5@7:3F4Z65CF:KKXOJ6+5@3:3N1Q2V&1-_<#;2?R^$A6K0BT
MG0C,LSHS#)YE3=*Z<1WO-B6]:;`30!Y5UYCM*]8:!%FV3B'G>6[U^?M5^D+>
M,I%GIK+5P1H(KV#-O>_LU71CO,,Z25IF/\;,1.;0,6Q9,&&WZQ@*.V*0US%=
MD-]U_`JRQ)"@([J0D'?P1<0N'`TZ#+"J]PN<'OHUOJH[6QC,;.DNL^<=H#WP
M:2Z.[3#&+$3&'6.6(N.-,9*./\*(*L$]L;!%)+Q';&DLT0BR6O4R@L&PVPP-
M9@DY@U6J-IH%0>(.?34E7_><@6VH]UY*I`-*N"CAH82/$@%*A"@1J0C!;S#D
M<;]9T%:'6>V]G)IF/Y_-TMUS9LEW@X7)/B)Q$(CY<@1Q.0)_^PM)D^:AA(\2
M`4J$*!&I",%P2&;9<+;CJA.<!<F&2YO:GC,PCJ^\.G!BWDR)T]@M38F+:G@H
MX:-$@!(A2D0J0O`;GOJ/^\V"9+^E?6_/&97?G.!^6]QOV7!4Q,-%?%0D0(D0
M):+A0&"Y-Y]^10N6PXN`;#F^A[,@V7+Y'8(S*LLYP2VWEZ-["BKBH82/$@%*
MA"@1J0C!<'9X''F+4^\I+$@V7'HAVW-&93A*N)QHIP1.H_#ITZ9Y5'@B,39I
M/GJ9`"5"E(A4A&`XO"H_;C@+D@V7'F=[SJ@,YT2[J<Q7(WZZJ(B'$CY*!"@1
MHD2D(@3#+7A$#AU7IW9#RU;++X0MI/(:1UP<\7#$;Q$^JT_PK)BSA2(NDT"$
M[+G-5HK(A/BU(B4BFLY.08-]!3&=GYG$MT+IQ+&W.*0T'45<7,7#$;]%6M,=
MTV+/:-'/0&1LRV$+3F1"_%*1$A$]9V>E[WO.3U9#SYT[RSFCM!Q%7*B9L=U+
MH>+AB-\B_%3P-'66*W-V9VB`"X62T&RYG-VO&%;H^WK0W'9>R.,UD9R49W(@
M659I"7UC1;H9O"OWO7T!\;FI'TK]>VL-]0LXZDO]KK6&$L5]OV^MH0X!_48?
M`'7`:WPF?\3E.2TJ+2,G&((Y856JDE<2^8^:7IO*S0NMH0+8?+U`Q9=`X<*<
M`'RBM.Y^L`OT->3=_P```/__`P!02P,$%``&``@````A`.]G4W\?!@``DA@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK)E;CZ,V%,??*_4[(-XW
M!')'25:3<%<K5=6V?68(2="$$`%S^_8]O@'V89C,MB^;S2_'?]M_'YN#9_W]
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M7OTR._R675-P&]:)K,!C43R1T/!`$#0V4&N/KL`?I79(C_'SI?ZS>`W2['2N
M8;EG,",R,?OP[J15`HZ"S,B:$:6DN,``X%\MSTAJ@"/Q&_U\S0[U>:-/YJ/9
M8CPQ(5Q[3*O:RXBDKB7/55WD_[`@DTLQ$8N+P&>/R$##"6\X;1N.IM9LL:2]
M#S2$L=%APR?O<3Y:SF;3^7(!:*#AG#>$_!=#O:_'%6\(G[SA;&1.QW-BTT!_
M)JPH,Y@L+7=XL$>#K1!=<">NX^VZ+%XUV$6P!M4M)GO2M(FL6&K6>[/X'ZT]
M+#I1>2`R&WVA:["L%23LR]9:F6OC!9(LX3$['*-$[$4$R2@BZZC`58&G`E\%
M@0I"%40=8(`MC3>0>?^'-T2&>"-FM1.@8Y9LU5Y$B":."EP5>"KP51"H(%1!
MU`&2$;"CD!$32);^\T#D!&D%.[^;$_.Y/-$=CX&-TR3.3`[9-R&-&8BXB'B(
M^(@$B(2(1%TB>0*G"_*$G)%?W#A$!O8>.-\88*TLV8(="YH,N=2$-"XAXB+B
M(>(C$B`2(A)UB>02&()<LF:CK_M$A*A/8GX[1J:0AJUS"\6Y?1,DFCF(N(AX
MB/B(!(B$B$1=(MD"#PQDBSD;D<?,\)XB#64;&)E:S?&R1\1!Q$7$0\1')$`D
M1"3J$FG.\'"0YCP\41(M3Y035F^0I\,>$0<1%Q$/$1^1`)$0D:A+I(F2*KC[
M2!V>*(F6)\I)9Z(-:5/=G*SD0\)A01-(H<Y^F,A!;A,D]H.'B(](@$B(2,0(
MG("@+-D!M8UD!ZLP:*[7YRQYVA4P7G@$]]@T@4J"U1=$1':)DXY+#6D-P"ZQ
M(`L^6I?&8\6E)JAQ"1$?D0"1$)&(D1Z72.WUWVVB*K)/`G6,:E%K`G:*1\%S
MGI9S8W.JN-0&-#:UR@+Y+1KH+&BU>&=*XH9M@%".6F5`4LJ9I**[?PO2<,4U
M5A.RA:(IN!=1W0W6XQIK*&_#L5+HNEP+HL1L/(Q\C`*,0HPBCOK2C)1X7W"&
M5810GHAQ[DBI0K8B''_-#EHHJ;$707`H-$$]7G$I*6JZ4-.,14U,FH?F5"DA
M/=Z7U2T$4%_^72,*>J/4$84\BH](&4_TV7CD3"7U97<]?NIT-%F5"CVWR\20
M!>8U*[!02VO1#G*V"4+6.6V44'<YFI`#^F4[FR_E-?-$$Z@+/Q;V1=1@]T$;
M);H/Y>Y-I>B+1(N/>I=7@-2NW17H>0[!Z[AX$)FLU)6L9@B"Q`#W/(J\QG\\
M?T=$T9L<>LBX&'D"M?)^BP;D`Q'5RH<810)1>=D9&+WDS,_E)E%1#E>.ND>(
MI3Y>]G!ZD896-ZHG.;G6)V<(B^([=J'VY8F^/CE#[AE1P+7,P1&%/$J<:LH&
MBCX;D+Q0I.;NIK"Z4#^*&ZQ`;XG536U6NDNIS9"4V@T:R#T';B?IXBV;/>%B
MY`G43>U[Y`/1L)4/,2)7I'00G=1F5Y[L!BQ/RU.Z3R^72DN*9W*="0?'=MU@
M=M>ZF]KP>@L[6^4S&][O>OC<AG<@S)VE#55S#U_94"?V<'-LNU#BX%^@6+))
M/81_<4P3?J'7J,IHX<;X@3X=%+XC-\D]2CO+AML@W,-N8L.5".8/4_L![(8?
MC*8'N!&^Q:?T][@\9==*NZ1'L'A,"_^2W2FS+S7/SL>BAKM@FJAGN/M/X15O
M3&X*CD51BR^D@^:O"=M_`0``__\#`%!+`P04``8`"````"$`Q*[X`NH&```U
M'@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLF5MSHS84Q]\[T^_`
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M'\A]661UU53'=@+N+#I0'/.]=6^!I\WJ4$`$1':CSH]K\\'V$L<VK<VJ$^CO
M(G]KI/\;S:EZ"^OB\%MQR4%MF"<R`X]5]4Q,XP-!T-A"K8-N!OZHC4-^3%_.
M[9_56Y073Z<6IGL.$9'`O,./?=YDH"BXF3ASXBFKSC``^-<H"Y(:H$CZO?M]
M*P[M:6VZB\E\.75M,#<>\Z8-"N+2-+*7IJW*?ZA1%Y%PXC`G\#O@9*2ARQK.
M1$/;G=BSZ8)T/M(.GG:CAE_6H3.?.'=S>_Y1RP5K"?G/6GZNQWO6#GYYN_O/
MC-2&&:4"DZEEXHW%:-$)ZN9[G[;I9E57;P8L(IB"YIJ2)6E[Q"N?:2J3F/OW
MIA[FG'AY(&[6YM(T8%8;R-?7C;.8KZQ7R+&,V6RQC:U:[+@%22CB=J\#7P>!
M#D(=1#J(=9!(P`)9A#:0>/^'-L0-T89'M>5`$DL3@EOP)GL=^#H(=!#J(-)!
MK(-$`HH0L*"0$"XDR_!VP'."M(*%K^3$0@UTRVQ@W8C$T=)F)TR$&(CXB`2(
MA(A$B,2()#)1-('-!6E"ML@;%PYQ`VL/E!<"X)5#C=PQE82)4`D1'Y$`D1"1
M")$8D40FBDH@B*+2>,80ZTX,'L26$A?V1TF>I9I$.V'$F^T1\1$)$`D1B1")
M$4EDHL0.+X4;8B?6:NR4:+'?:;$+(Q$[(CXB`2(A(A$B,2*)3)38X4V@Q$Y>
M*PMWL@2Q;EP@Q).J"R4SV'^DG+C7=!%&0A=$?$0"1$)$(D1B1!*9*+J0`EE^
MW8ZO!V*MQDZ)FA/+J1:[,!*Q(^(C$B`2(A(A$B.2R$2)'1;Q#;$3:S5V2F:0
M0OV\+_420AB)V!'Q$0D0"1&)$(D1262BQ$Y*JQN"[\S5Z!E2TW[I:%/?6XGX
M,?(Q"C`*,8HPBC%*%*3*0$HM.?]IN=GM"^-+P:9%&KPH>6!;AF8]VF&TQ\C'
M*,`HQ"C"*,8H49`:/BFPY/`_B)G68TK,#-%#%ZF1=Z1V("NE1WN,?(P"C$*,
M(HQBC!(%J3&3"NJ&F&G!!?[Z>6:H#W!G"]3O!;:KO0/VS,I5=PQ773)^;\5[
M##`*,8HPBC%*&*+3HRI#JB99&6DQM*<B>]Y6L-%!W@]DB0MG+';RHK67(AA#
MLF`"C0I&K1S8QOHM=JJ]7GQ;6/6"(11BJPBC&*.$H2'!2*GUWP4C7K2]E2%9
M,(%Z*08RC%K!6:@[\D[MF9Y<PJ#72GCF*"3G!KJ$1SJ+F%7?F9;)<6_`/2>]
M9T!J]I':319S(,O@>XE(,UKJ*6G&D*R:0".![&UJI:[+J?8F]WLK'DV`48A1
MA%&,4<(0"(24(=7;#<K08D]1AB'X$>MHJ:7&SF9&4"\)HX$,&[*::2<@G_ER
M[2X/[9EVS`[8<T>NF5%?X:=&%`U:Z2.*U1%IXTD^&H^:J:2BE.?CY_9)6I<J
MTT21`R]0,0-+_?.#S=K!/BR,D'3[WHHGJ\^02[;JU\U\H9W<`MX$ML[W'8?<
M:K3[J+?BW<=J][96*":\Q7N]JS-`ZEIY!C[8*V@9K$A-$6PH?(`[6Z"1^/?<
M:B$:^A@%'/7NPQZ-N(^X5>\^QBCA".\59$4IROQ4;G9>U%<21_(6XNBOEQVS
M<F0KG)S<%V1RGVGZBO69%=M#EGI?`>]K?`_A5J,CBCXUHE@=D:TMH(1W]=Z`
ME!1VR/E!3F%]HKY5U_>*+>DUV+G19HIX7IMR:C,K0)+@J#SE5G=]:F,4<"2E
M=H]&W$?<JG<?8T1ND?K14\7HK1"])2CS^BG?Y>=S8V35"[GQ@8UCLQ*87D=M
M[:E'3GVPMM$3N*F"`]'`DYD'GPT'^-R#3VH#?.'!YZ8!OO3@<\L`O_/@4\0`
MO_?@F(XYG!8\4K\//9G!DZ&Q[NVYY],*0HL;BC5H,Q0'5#_P9"@2N-1[Z(X]
MFJ\MD7!@7%L'+@&'N.O!9VL<Q\,,_'>.+-$#7-I=TZ?\][1^*BZ-<<Z/,,73
M[CQ>TVL_^D?+5L=CU<)U7;=03G`]F\,!=#J!-#]65<O_@)XM<>&[^1<``/__
M`P!02P,$%``&``@````A`%&61*$)!@```Q@``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C`N>&ULK)C;CJ,X$(;O5]IW0-Q/.`1R0$E&G7#6KK1:S>Y>TX0D
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MQ#3:$P2#-33:;V?@KTK99X?D^=S\7;Z&67X\-3#=-D1$`G/V[VY6IY!1D)F8
MK1MI>08'X'^ER$EI0$:2M_;ZFN^;TUJ=SB;V7)\:8*X\9G7CYT125=+GNBF+
M_ZB109SB(F8G`M<;(B,#I]U`N'8#S?[A(^.L;AQ<NW&&.5G8MC5;S,'MD9%P
MMXT7KFRD,3$L?4;"'1DWZ\;-^;C[/(5UUCX/KNQY=WJZ[$;"E8V\RU,#:HA.
M*2DF.EVCOFJT)-H*<Y,FV:RJ\E6!90N37E\3L@D8#E%EM473Q*OMHV*#`B$J
M#T1FK4+BH(YJ6"$O&W.Q7&DO4-5I9[/%-H9HL6,6I.Z(K"L#3P:^#`(9A#*(
M9!`/@`9IX;F!4O^*W!`9DAL6U9:!0;*D1#`+-L25@2<#7P:!#$(91#*(!T!(
M!"S=KT@$D8&]9U@D]DR,?-O9P%+BE62+)CMNPK.#B(>(CTB`2(A(A$@\)$*2
M8)_ZBB01&5B,,!4\`>92%U.PI4;3L2QQ$YXE1#Q$?$0"1$)$(D3B(1&R!#LP
MRI)I3_C&?/>.0X3:/+'XMI18L(GUF9O)6PPW8L-<1#Q$?$0"1$)$(D3B(1'2
M`J\>E!;#GI`7W>VW/-MXR4`Q#918)M]O=HBXB'B(^(@$B(2(1(C$0R+$#&\+
M(>;Q0(FU&&A':,=#7A<[1%Q$/$1\1`)$0D0B1.(A$0*%9?H3@1)K,=".#`+E
MI"]U8RJ];UUJ-(42ZM>#+NTD'C=BZ\'GVHP$G/1"Z&DA%^J-3%UR*>)&3#OF
MVD"$I$%+)"2--B;MBFA.>?JT+2$J>'/?J)HI-""T+2$B8BX[,L@E)[WC*#J7
M&IE+VMKHAB5NR!Z_SP+SN2PC`2<C#PJY4-M#Z<94?%#$[S/9F,O*&23MG)#"
M&ZF"CICEJC47D\70(%L]&HG"[:PL>%D.:D_:B[W>B@7C]_(,!3WJM=`$A4S+
MXMM>A%'<:Z%DD29PV`A_DBS:,\)KFOFY-3H$VT`?\\P4YV_'K*#NN16*QNVM
MF+S'$"U!8V'!O[DH[G<VYO`5B,0#IC3J0MA;,1<BACH7YI8Y-R47XL]<$-8X
MZ7*$I/_2(F]5I,*EG:PI=%$S:2WMV$"8N+&YH%H0&$N$UPTTK78[,'1;URTI
M$3X3AT[H8_&`68VZ$/96S(5(=,&>S\VEM"?%;-1''HA30?K:GZA_V@;#(YA'
M6X,BV%$8VO5H)`<NLYKQ@1Y&/D.]?-"C$?F06?7R$48Q0ZV\F!G2RPXS\VM%
M2CMB(6$=$C<,:19W!K4RAU9H3;N=E;$8Y+"3[]Y9B^7"GDKB/A/_9,.XQX40
MNQ`QU+DPA7-#4WH)Q)^Y(,X%::#'YN)'>?VH*QB^ZF@?+DP&14+U<C127BXY
MB(,>PQQF'B&?60VK]Q[YD`WLY2.,R.ECZ\2@>NEI(CWK*;+JF.VR\[E6TO*9
MG!1"UC<KCODQYD.[GB6^)<>;I*YD;CIP8G"#3QWX2L;\P7(>P%%\8VLY\,%X
M@]L.?#'=X#,'OBHP=Q<.]+.8APL'.D_,W:4#C1OFX=*!/@MS:&L<TK3@.]!^
M.*3?@#L:SQ(<P5Z38_9G4AWS2ZV<LP,D7F\[V(H>XM(?35>SCV4#AZ]M^9[@
ML#V#+QJ=?!@?RK)A/\@#^/']YG\```#__P,`4$L#!!0`!@`(````(0")TH9.
MN`H``&<R```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*Q;VV[CR!%]
M#Y!_$/2^DDCJ2MA>C'DG$B!8[";/LDS;PDBB(<IS^?M4LZOZ5A0I3_*RVCFL
M.M5U6-U=W<.Y^_W'\3#Z5IV;?7VZ'WN3V7A4G7;U\_[T>C_^Z\_TM_5XU%RV
MI^?MH3Y5]^.?53/^_>'O?[O[7I^_-F]5=1D!PZFY'[]=+N_A=-KLWJKCMIG4
M[]4)GKS4Y^/V`G\\OTZ;]W.U?6Z=CH>I/YLMI\?M_C26#.'Y%H[ZY66_J^)Z
M]W&L3A=)<JX.VPN,OWG;OS?$=MS=0G?<GK]^O/^VJX_O0/&T/^PO/UO2\>BX
M"XO74WW>/AT@[Q_>?+LC[O8/C/ZXWYWKIGZY3(!N*@?*<]Y,-U-@>KA[WD,&
M0O;1N7JY'W_QPC)8C*</=ZU`_]Y7WQOC_T?-6_T].^^?_[$_5:`VO"?Q!I[J
M^JLP+9X%!,Y3YIVV;^!?Y]%S];+].%S^J+_GU?[U[0*O>P$9B<3"YY]QU>Q`
M4:"9^.TP=O4!!@#_'1WWHC1`D>V/^[$/@??/E[?[<;"<+%:SP`/ST5/57-*]
MH!R/=A_-I3[^1QIY8E"*)$`2^$42;[)>+.;+]>IVDCF2P"^2^!-_O?`62S&2
MGNCPM$T!?M%Q-?'FLR&W);K!+\6[.>$5^L+OKR<,4[`=-_S2`"8K;[8)A&@]
M^6[0#W[1#QAZ[#THJC:0^!^*-)3J5-9)6W;Q]K)]N#O7WT<PEZ$2FO>M6!F\
M4!!2P<D!J!*\5H%0-8+EBZ"Y'X-^4%P-3)MO#_"N[Z;?H-1W://(;3S;(B(+
M48R"-G:!Q`52%\A<('>!P@5*`YB"+$H;F$3_#VT$C="&LGHDP!#+$8(LR"5V
M@<0%4A?(7"!W@<(%2@.PA("%@`DQAZKN7I6H)H07K#]F3<R6=J*/:`,5KPK'
M*9M(F2@Q&)(P)&5(QI"<(05#2A.Q-(%UC6DB5NI/3AQ!`W,/E%<">"M7)6D4
M]*FD3)1*#$D8DC(D8TC.D((AI8E8*H$@EDK]%2.L6S$HB4>)S&%A4O+XL[5=
M1)$R(K>8(0E#4H9D#,D94C"D-!$K=]B)K-SETCH1VT&_#,+1ED$B<U^M(1%#
M8H8D#$D9DC$D9TC!D-)$K)QA![!R[D]46-N)(B+[$;$%1`R)&9(P)&5(QI"<
M(05#2A.Q$H6Y^(E$A;6=*"*RAVL358@N=2_8V*4>2R/H0+41=.BV4:*,:#ZD
MBIN0C"&Y\C*IG?B%,B*BTB2R%()^QE+(*/_+VW[W];&&*0U;;T>)!-!!R+Y"
MD-C"(6((IQ`]<"Z<-/(WLC>9>7-',_6<$DL5+2$90W+EU78\,R^P60OUG#A*
MD\.22S1?EEX=ND#G3,*TYK8R!!G2:*A/&[2:PUYGK+).<Y9H*THFU?0$91S*
MR7&N5J^"0Z7E:"LC^C.S1QU01K9SL*72H!X]A&`VZP0]9]I$9`45K:QX(75:
MS5?VBT_0*O#:>ELLG!T]Q>>^N;&Q6)F.1:GD&C(&Z88O!L*70^%M_45;^`G]
M91=IZ2\AW^QR?,\IL$@T06*RP\OJTU]9D28).@9BV?CVX"V9V.@"7<IUXDR'
M)^*<0\5`K))<KL6RE17=Y2>4E<THA*`1/GH(V97MV]48D=5`92/76M$GZ(AE
M/'=X4WP\5,6,-]<#HDR*_E#E4"A;5]&/FKK^TM[CR:[6DEM"3B$[JWY$C@.%
MC/2ZUTG0$0LYF#N[;TK$X-E7R(PX)T<=JT#(G\L=<1$X.V))/M>"V8J++MA4
M?&"-EDVS):V$8(NCDHC$<0H6!'%?=#W=F*R6RC'A4$J0IL\XE!.DN0H.E02U
M7+8,HC'^A`RRC[9D0,B>T,Z[B3QIY9M6;/N(T<HS)S32RS[(\]P^*"7F@8U)
MQ:>7E?-@!4$R6.!OG(-;.13,UA:2M;05D]I?BGO0T>T-I2=8G+Y)0LZD=J\A
MR'&@&)%>3[0$'6%2ZRKV/;9'H:,UVY;.RI+I06C=6<2B.Z+3HI3$=2VB+;YH
M\S]1V'@J,'<J"5GS6T%:F8XJ1BL])Q.HZ'9AT%!*D#F_%;T6BSD6Y*BY2H(Z
MYK=HWTT9?FUCP4.`J0Y"\#+54A<X;RSRI-'0K$<J2%51>6Z'F"`7[NQ+IQ=.
M*=3`,J`&I!6^)7IA1W>JO!P*;E6F:#YZ7\F?]3O,]\YS)A0CG:=:&GM=0,BL
M6`T9VK)#.ED9ZRZ'4H*,BN503I#F*CA4$L0KUA=''UZQG[ZG;'E:?73F_MI9
MQ1[1JO>F4MM0T<0<2CB4<BCC4,ZA@D.E!=GU)`X+IF#]G8S8-9S]!"'[TM)S
M>KE(6VD9)!<X$I1PJY1#&8=R#A4<*BW(ED$T[:8,QDHWH`BV^\;JYDO(O+_D
M4,RAA$,IAS(.Y1PJ.%1:D)V^Z*'-]`=R%N;.ZH&0[@0BZ+5;*PW%'$HXE'(H
MXU#.H8)#I079.8MV^Q,Y"W,G9X3TDA:)[DQ8P8_>C?B**:T&[C612_[]>WL_
MF&IZFC*9AGHBYII+6_DS9Y(6VHKH2TT/D*V?:(I-_8PI<WN#ZF.';DX?A$Q9
M%:2'SULGY+I^ZZD-*+^4XNM@F89Z@N6:Z\IEJ#:@8*5F9F**MM84<V`"8A=L
MJH:03B02G=,-Q2BM!JY#D0NL*)M4TQ.4::A7.HQHW)`2O89*S<7$$FWM)\22
M7;!Y[/01@H&H:>K[3E<8D9756O+)C%R6%6M`D8NNEMS],<7GHK-1(V(5GMTT
MHKS3RAU188]HX;FGU:$1V8N!Z(/-5]*>5A<36.@&*AD;:+.2L<V&]D!)X?ON
M]2G,<MQ=M!43+-965*,)0K`QM->G?N#TXRGYP/:EXC/FC*QZ;[UR;47Q"X3P
MUFO.=<?$KH6W=`_<XT"_VJVYO8D19$\%Y^HS(BNKR-E4T%:4;8(0_<W`S'F-
M*3X?J'M-W/-*<FU%X0L[_&KMY%4.A;?%=@\7`V(+<T=L"8D^5)66[SL%&(%8
M-Y0V6>DE,T%(]'F*WIL[$SO5CH:5^RXSLH*Q:"[7*M=66G(Y>JKOA9-=22ZW
MU;<X([CKBK=HORJXO<D(Y$G#W`$(LLO>O7@DJX&R1WI]:$W0$7)MNP//N5Y+
M\?E0V2OBWG>@K/0[D!"&7SL;6SD4W:YZ]V@T4/7\/"3N`F$B0"M)`XPTU)-9
M3%;ZLBKA4$J0IL\TU$.?DY6F+SA4$M32V\J(`\[_7IR"Q5DF).0L$TX-10$Z
M]I\UR,J:QVXSD*`5;HI^L&2+!@:#G^O+04;!>H>4DU7OD`IG2/["V3I*HKDV
M)/M=B2-7W[NZ[=Y,'-G<ER4AJ[H5U"-6C%S09]&T2#B4$F16]RWT.3EJ^H)#
MXNMN/3>E8O)K;?G9[+$ZOU91=3@THUW](;[$;DM$P?B9N.^%7X`)\G">P!59
M*&Z?NI[X\*1M^YA/`$_:@X;S!#Y'_]+I`4&Z8P!15VP(T,D_!_[V.LH)_#@/
MX:._CB06(7P0UX$O0_AHC..QOP@362E.!#BAA^+\W>6S!)\N-CB#@D_7D]A?
M@4_[#2Z+LP*?KB?Q.H1/J7C\?!W"=U`<CS=ALNG`\TT('P)UV'NS4'Q5PY_`
M)S.A^$8&GDS5<.$S__?M:_7/[?EU?VI&A^H%BF_6;OQG^0\%Y!\N>-_]5%_@
M`W]81^&C;O@''15\3#<3QX^7NK[0'T0`]4]$'OX+``#__P,`4$L#!!0`!@`(
M````(0#5Y+QC0A(``")J```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;*R=6V\;R[&%WP/D/PAZCR4.;Y)@.R`YTS<DP,%!DO,L2[1%;$D41'I[[W^?
M:O9MJE9[)/(8`>+MKZMKNE=?9DV3''_\^Q]/CV>_KU]WF^WSI_/1A\OSL_7S
MW?9^\_SMT_F__Z7^=G5^MMO?/M_?/FZ?UY_._USOSO_^^:]_^?AC^_K;[F&]
MWI]1AN?=I_.'_?[EYN)B=_>P?KK=?=B^K)^IY.OV]>EV3W]]_7:Q>WE=W]X?
M*CT]7C27E[.+I]O-\WG(<//ZGAS;KU\W=^MV>_?]:?V\#TE>UX^W>VK_[F'S
MLDO9GN[>D^[I]O6W[R]_N]L^O5"*+YO'S?[/0]+SLZ>[&_OM>?MZ^^61^OW'
M:')[EW(?_@+IGS9WK]O=]NO^`Z6["`W%/E]?7%]0IL\?[S?4`R_[V>OZZZ?S
MQ>C&737G%Y\_'@3ZSV;]8]?[[[/=P_:'?MW<_V/SO":U:9S\"'S9;G_SH?;>
M(ZI\`;75803^Y_7L?OWU]OOC_G^W/\QZ\^UA3\,]I1[YCMW<_]FN=W>D**7Y
MT$Q]IKOM(S6`_O_L:>.G!BER^\?ASQ^;^_W#I_/Q[,-T?CD>4?C9E_5NKS8^
MY?G9W??=?OOT?R%H%%.%)$U,0G]6D@Q4',>*]&>L./LP::;SJ\/5!RI.8D7Z
M,UV1+CY0@3ISZ"?]&2LT\_==:A9KSG/-=[:1EMCADO3G^]IX'2O0GZF-),Q`
MIT8T7<+H^7D31F:X<1=A^`^SJ;W=WW[^^+K]<49+E`9X]W+K%_SHQJ=-\RA<
M/<^LGTTLFE$^R\*G^71.4M&<V=%J^/US,[_Z>/$[S>"[&+/$F!&/6*4(/UU]
MVE:"3@(E@9;`2&`E<#UP0;)D;6AF_0IM?!JO3>K5,H&>6$*(%)&JM!)T$B@)
MM`1&`BN!ZP$F!,W&7R&$3T/[3&^2C$;7O.?+&$-K)\^D*0]9Y9"L#I`.B`*B
M@1@@%HCK$R82;4F_0B2?AA8C#446H)E+E4+0>$BE'))5`M(!44`T$`/$`G%]
MPE2B?1A4&E_Y>U3<\-Z]Y?A,!Z%2!Y>!3&@7R]*-FK&8/3DH56N!=$`4$`W$
M`+%`7)\P7>AN`[KX^_F1^[!/(V;/J)EQ"98A:'#VY)"L$I`.B`*B@1@@%HCK
M$Z82W6"82G6WDVY*/IK/D$#&=*/MS1`ASRH'Y;X#Z8`H(!J(`6*!N#YA?:?%
MSOKN[]1S\FQ'SQ&?B,L2B%@X<SYK5CDHRP*D`Z*`:"`&B`7B^H3)0F,)LIRP
M<'P:6#C2P82@P8630[)*0#H@"H@&8H!8(*Y/F$K>VC&9AE?.(9S/D8C$VA$*
MK4I4[C^B#I%"I!$91!:18XC+X*V>M+M3@D=NLZ-@&>DNG;JYC$@L(G'C7I6H
M5+%%U"%2B#0B@\@B<@QQ?;P#E/J<L)J\?8'E-+[D.\HR1@VNIQ)3!`O)J5I"
M'48I1!J10601.8:X8-X.]@5[8UT%]TCY4M.7HV@H:>F6>Y*4:E6B4L4648=(
M(=*(#"*+R#'$9?!^KR^#OSDUTQ-N3J/@')E"`;&5U5R)R;2*%2FJ*)0K)M1A
ME$*D$1E$%I%CB"ODG9]4Z)25%1RDGY&]Z=+(E16BAE=6CDGJM+X]M&S9R@*D
M,$HC,H@L(L<0%\R;P+Y@;ZRLX!G9O(DVDJ\L(=5JE*.*#(`ZC%*(-"*#R")R
M#'$9O!_LRW#ZR@K.DBD4$%M9H[%\8AKEJ*(0H`ZC%"*-R""RB!Q#7"%O#:5"
MISU2CH++9!)EX]E?;Q.^WE:Q(MM\<L6D6H=1"I%&9!!91(XA+I'WA7V)WEA+
MP48R&0(2,T6>S(QR5.ISBZA#I!!I1`:11>088C(TQYG@0S@WP1$)&>0#9(G*
M,B#J$"E$&I%!9!$YAK@,T@0/SX8&O6Y$0@;YP%BBB@PA5V^==!BE$&E$!I%%
MY!CB,DBO^X8,V=*FWBR;@(0,\I&H1*6*+:(.D4*D$1E$%I%CB,L@':R_P9RV
M?3;H;B/B$DWE/;A$%8E"+C93`"FLJ!$91!:18XA+5'.WHTL:_2,?&QLTMQ$)
M@>0MN$05@=#<8I1"I!$91!:18X@+Y$UB__[BY]!H^F%._(U5%>QE_U;CCX+)
MA$[*,](*48NH0Z00:40&D47D&.+=]WZQW_TW^ASL)>MS0'P6S&`GR5%E%@#J
M&D`*D49D$%E$CB$N@S>%?1G"+#A^E01S2?KT+-=,G*0LFQ`U^(A38HI@N5I"
M'48I1!J10601.8:X8-*YOC%OT)TV`?%#.2G5JD2E/K>(.D0*D49D$%E$CB$N
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M642.(2Z8MZ]'K"PTP..`Q,H24JU*5.I@BZA#I!!I1`:11>08XC)X%]J7P>_(
MISU6CH.A99M/]KC]V22/HV)%6H!%HEPQH0ZC%"*-R""RB!Q#7*)?Y)?'-;\\
M%X=2RQ@UO+3`'+>E6A$,HA1&:40&D47D&.*"'>>7?5?#AY"IZ<N(Q-(24JU*
M5*K8(NH0*40:D4%D$3F&N`PUOWSBTD++[+7QC]_L6U1S>;97HHI$N6)"'48I
M1!J10601.8:81+[UL/OXSYJ.O&L=\AS\<G^?$<_ERQCE1XPVN?#U5[D7E9BD
M3HNH0Z00:40&D47D&.*"20,][`<GV2>GWBPC\F.211C)[P"O2E2JV"+J$"E$
M&I%!9!$YAK@,TA:?^"A*AU=RZXG(#T%/'W&JL2I119^0BRHFU&&40J01&406
MD6.(ZU/SRZ>LJ^R6>V+(C_27DQ`UO*YR3%*G+=42ZA`I1!J10601.8:X8-Z9
M]FW0&^LJ&-F^U9E$;\O6E91J5:)2GUM$'2*%2",RB"PBQQ"709IBOZY.>LZ:
MH%^.B*^L*WF"4:**0B$76UF`%%;4B`PBB\@QQ!6J^>535E8VR_V5)4\P)B%J
M>&7EF"(8H*YD2E$*D49D$%E$CB$NF'3/;ZRL;))3.Y>3Z&/YRA)2K4I4JM@B
MZA`I1!J10601.8:X#-(3GWK'0K,\"4BL*WE^4:**/KEB0AU&*40:D4%D$3F&
MN#[>E?8W8*_/*>O*YY%.\$H\E"\G(6IX7>68I$Y;JB74(5*(-"*#R")R##'!
MIM(Z#Z^K0S@_48Z(.T$IU:I$I3ZWB#I$"I%&9!!91(XA+H,TQ'[>G';H[C_*
M$,^A$8FE)9\92E21*.3JW[(P2B'2B`PBB\@QQ"6JF>43)4*_/,VVMW\CDX_J
M):I(E"LFU&&40J01&406D6.(2_2+_/*TZI?%0_DR1@WN/B4FJ=,BZA`I1!J1
M0601.8:X8,?YY2GZY8C$[B.D6I6H(D,VV@EU&*40:40&D47D&.(RU/SR:4<\
M4S3,$8G=1YQJK$I4TJ-%U"%2B#0B@\@B<@QQB;P7E3?VDQXIIL'5]A^Z(A(*
MR8?U$E44"KG8_@Q(846-R""RB!Q#7"'ID$^T/M-LG7L[\;7X$'T9HX8WG^BX
MRR\WVE(M:=@A4H@T(H/((G(,<<&DEW[#^J!EG@;$-Q\IU:I$I3ZWB#I$"I%&
M9!!91(XA+D/-,I^X^637G'JZG`;$E]:U?%HO4:EBBZA#I!!I1`:11>088A+-
MCC/)AW!NDB.BH\C4P16B%E&'2"'2B`PBB\@QQ/M<<\3>'1YYICY#.QR1F!/R
M2;Q$)<E:1!TBA4@C,H@L(L<0UZ=FAT]XTIQE+]S?;L5C]S)&#6ZW):8(%I)3
MM80ZC%*(-"*#R")R#''!I#D>WFYGV0.GIB\C$MNMD&I5HE+%%E&'2"'2B`PB
MB\@QQ&60EM??ID\R,C-TPQ&)E26.+58EJB@4<O6-#$8I1!J10601.8:X0C4W
M?,K*RE:XO[+$4_=R%J*&5U:.*8(!ZDJF%*40:40&D47D&.*"26_\QLI"`SP+
M2*PL(=6J1*4.MH@Z1`J11F00642.(2Y#S0"?=D`QRQXX]709D5A:\H"B1*6*
M+:(.D4*D$1E$%I%CB$LD+:_??$ZYJ:,7G@4D])$/XB6JZ),K)M1AE$*D$1E$
M%I%CB.LCO?`;*PG][BSZW;[1`]1B5(=((=*(#"*+R#'$^CP_SMP>PKFYC4@,
MO3Q@*%%IG%M$'2*%2",RB"PBQQ"7H>9WW_6CECDZW(CHD_74UQ6B%E&'2"'2
MB`PBB\@QQ+LO[>SPS)]GUYHZN$RH-_,1M8@Z1`J11F00642.(=[GXQSI'!UI
M0N&5B_X==JN">JYC+,Z2VACEOU!).W#X#M'H6D1U)2JIK!!I1`:11>0B(FM%
MZ;DR-9,:%\/^87/WVW)+S:9Y7YDE8WH?8'A+X!P-:D)]P6(4DP(%"U'^9Q-9
M,'H'*?]A=A?34U01+%=,2&.40601N8AJ@GD[*(\GCQ<LF,K^T:3_39W_-*DO
M6$9%BA$*%J+H1Q2'US->CL130!<S4T`21N'%=$$#%S,E5[R8>"BS)2!=S)7,
MA/CL.\[/SM'/)M3?BV(43=H\@2JJ12-,_B]'-9?BN*J+Z>FKJZDW"I%&9!!9
M1"XB>F\/*",M;F7]T0\7\P)$&SN/B'=0GKVD*+)F68:*6#%7[W0A5;P^S+K1
MU83^)SR@BC'^%^L_3ZY3IL$FF!*51L(F%)K07#4CL4NXMQK`)Z.WI_V5_8;D
MP<VR)1R0_TUV[F]S*5;(:AXKOC$_<U3J;Q<KTL]U_=J[OIS-K\53B4JY:2O,
M+8#AU"EJL`6F1*466-&"^4P.N4N5?M8`KKCWRWW%PP<9AQ_`'7'S":Z;#41$
M?.Z+?7$UCU&D],_%:F,43>(D0Y<0TV\B;+!*46_,_O<TPI2FID;8A,+LG\U&
MEU/A*MQ;+6"#<77<T\$AG#\=1$3;4FKDJJ`AB5/4+%?L$*F$2GI=T$!ZDZ)*
M>HO()71(SY6A<?[_3],KGT4(%A#]DJ0(%J/HGCXP)U.N<M?K(HJ;0S.?3ILK
ML?.H5.UGB_-@YG2*&FR"25&E"98W87XUNYZ*_<FE6C]K`===/JG([>%?VY>?
M>=/>O9'>U@["!\1F:D:#PL>HWHTPIJ>?0:=!5`GU9^I[TIM4L>2RB/SKYWV'
M0NN#8N%U\N$%X$_KUV_KU?KQ<7=VM_WN7Q5_[>\8&8?WV"_GES?^(9D:#27T
MBGMZ?L22Q:RY6=!Q+I;0QQ8W_A.!6LF82L;5D@F5U+(M9M.;!?6REFU*=0ZZ
MRE;/9E1R6$E0,J>2@X.#DBLJ.8@-)==4<GBX$"6+Z9PTJ*E#GY3?^`^A*ZV>
MTG7H<]E:"5V'/HZLE,QH?.A#NUH)C4^U!8O)]<V"OK14J4,E_KN!E9(I78>^
M+E<KH>O0D6&MA$:[>IW%=$PMJ(X"E?CO!]6RT3R@K\S42FBTZ9LBM1(:[>IU
M%A-J`7T=NU*'2OPW^FLEU`+ZDGNMA%I0S;:8S.@ZU3&E$O_]YEHVFB'TE=]:
M"<V0:K;%F.8;'==7ZE")_U%=K82RA8\"Q>Q=CFD>5+,M)I?4G_K<H1D2/B^2
MV28T0\(GW5!",Z2:;3$>47^JHT`E_I?MM?Y0-OJQ=ZV$QK2:;3&>T'6JHT`E
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M"]IY#BVZR,-'_T+/R^VW]3]O7[]MGG=GC^NO9,LN#P^ZK^'?^`E_V4='^V6[
MIW^;YV!N'^C?8EK3>?.E?^GNU^UVG_Y"8ESD?]WI\W\%````__\#`%!+`P04
M``8`"````"$`JS8$.EL/``!(4```&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6RLG-M.(TD2AN]7VG=`W`]0/H$M8`2NL\_6[.ZUVYC&:L#(=A_F[3>R
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M`O3?]>KGSOKWV>YE\S/9KI^&Z_<519ORI#+P9;/YIJ39DT+4^!):QT4&IMNS
MI]7SXOOK?K[YF:[67U_VE.XV/9%ZL-[3G^%JMZ2(DIF+1EM96FY>R0'Z_]G;
M6I4&163QJ_CY<_VT?[D[;W8NVM=7S8#D9U]6NWV\5B;/SY;?=_O-V_]*4:!-
ME48:V@C]K#'B:=C4#5NFH;<C<JGPEG[JCH+F1>.F';0[REU/3QW=DGZRBZ<U
MO-8-:<!P0V]'7:VGG^RB/W@!Y;Q,@4J^SL%IO@55]JS(>[T+..+J'[JS[L5U
M<-5M7OL#&%".2C>M$/K[XM`%](_/]47!+OLZ$O7+LIJ+P1$N]HO[V^WFYQG-
M.!28W<="S5]!+R`C/"S*"JD&RJ%Q0@-$67E09N[.R7T:`CL:W#_N&S?![>4/
M&I!+K7E$C5#T6:%&GS(;2A!)$$N02)!*D$F02S"08"C!2(*Q!!,)IA+,))A;
MX)+24^6(:O:?R)$RHW+$T7UD8"7-35F?%=PDE""2()8@D2"5(),@EV`@P5""
MD01C"2823"6823"W@),0FA+^B80H,[2,6(,F"+IN!AZUAD9F-;+:KJ1?2:HL
M`8F`Q$`2("F0#$@.9`!D"&0$9`QD`F0*9`9D;A,G:30M_Q-)4V9HLJ32J!+2
MN&FX*7DL14U?UBI)E34@$9`82`(D!9(!R8$,@`R!C(",@4R`3(',@,QMXF2-
MUEHG:_7;-5Z&E+I(#@?UL22M8F]8K"E]("&0"$@,)`&2`LF`Y$`&0(9`1D#&
M0"9`ID!F0.8V<0)/FY=/!%ZIW<!K4NY_U6+>!Q("B8#$0!(@*9`,2`YD`&0(
M9`1D#&0"9`ID!F1N$R?PM(ER`E_NR"[4KG/_LEY^>]R4QXR:D="DG5>Y'U-&
MW'QH4AYMBGQ4Q,QD05.L/V$I:M`FO9KN@M:5.]U%E8B'70PD`9("R8#D0`9`
MAD!&0,9`)D"F0&9`YB6A<R,]J9,UFNK_?M:4$3=KFE"Q6.&7VV8M4@7"NV],
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M&]H5&R]E_P-6>?L?LLH$8<3]>X,P-@T]3DQ8Y75B:E0<A!D[<2@(<VYS*`AN
M/5+_3CWZ)U%U'RAF48UHIF47^P9Y(A"RJE,UC!#%C(SYQ""/^915QGR&*&=D
MS`\,\I@?LLJ8'R$:,S+F)P9YS$]99<S/$,T9%>;=O*HK&+R?_.1N6)W69;HU
M<E;-MMC8]G7#AJ.2`S%D\\[B*N??B%4')^"8>_.OG*SR^I1R;UZ?,E:5/M7-
M1&68_(OYX"27AJQR'D^&:<0J9T*1Z_F858XMF9@)J[RAFFJ5NOTVLZWT:\8J
MG;[K;D/L,>;<VR&?W,)6]U2^POYC\T$KX]%[]_*ZB[KF6>M1O6%!Q>Y,9!6R
MGE!&*^2&-Y6M"%',R$P%B4$>\RFKC/D,4<[(F!\8Y#$_9)4Q/T(T9F3,3PSR
MF)^RRIB?(9HSJIG(U`V7+]\G'>O5>TMR(BN1LV&2)ZT^M_,?$5GEK+AR($1:
MU:":LH:+&`QQK2U9<@FKO'ZEK/+ZE9WD5UYK2_HU8)77KR&KW*E*'(=&[%>Y
MT0F"3E/$:LQVG.>3/DU8Y?5IRBJO3[.C/LW9SB&?W,F,?'**^\CN2\G%MK]$
MSJ15(:O.9%1"]1:^FNW,!B-"%#,RPSXQR&,^994QGR'*&1GS`X,\YH>L,N9'
MB,:,C/F)01[S4U89\S-$<T8UDY:ZI/S[DY:^ZK37*(V<A;DMCD']H%0=VWUI
ME;/LXJRE5>ZX$",QYAX=6[+F$E8YWDM5RBK'EO0K8Y77KYQ5CBW9XX!57K^&
M6N7?[HQ856YW:F>MNKA+GR8G^33EWHYLP<H>@X,^S;FW0W%R9RV*D[>Z3]R"
M*3-B-BN1,YM5R#-@0_4!$#6;F5U&A"AF9.:#Q""/^915QGR&*&=DS`\,\I@?
MLLJ8'R$:,S+F)P9YS$]99<S/$,T9U<QF5%TU^>:/YIS^61=EITBX\;9Q(RZW
M']7X(I7W/6"CX=U[B"A"%"-*$*6(,D0YH@&B(:(1HC&B":(IHAFBN8/<@:MN
M*N6RU&A?T%;@LQ];TI>B]M)4(GK'V&0W:(LW$_HT!ZGL6N\KAX@B1#&B!%&*
M*$.4(QH@&B(:(1HCFB":(IHAFCO(R9RZ1X#,!>WB.L>_9RQ:NK.L1BV3O#ZB
M$%&$*$:4($H198AR1`-$0T0C1&-$$T131#-$<P>Y::'=AY.6([E0<I$+C:RW
M^QN`0D01HAA1@BA%E"'*'>0^L[Q9//+,>(6HCMPJ#&8AZQMD31YR3Q1J59/F
M*W.";HMW$".CXL4A-N89)8A2T]`V+]X0S(R*;>6.+3=8Z@))SKAZW)[^H01U
M92#K1B,[AA6RW,<8EBKW@PEM<?:.=(^DXH>,V0G38X(H-0TM)]KBN)`9%9O/
M'5MN#.DH[<3P2,$IN1AD&M$FT:H;^=Y80ZN<O33&KTXE3R<1V]+WPZV.J*)8
M"]348ER2G25LQNS<4H.LAK+_3*N:0?%.6:LM-EGYL>[=!*BK`KN(CR2@O%FP
MKU9I0Z]RTJ2!;YZV(]\TT"KUIH91R9B$1L6U$[%Y]3&>'_<M>8L7<Q-*W6'#
M":O,5)PR,N\!9AJI<C6VY#5[;AI:*NM1W/BJX]DGXJM/<V;Y?J1;G"*^S@-V
MY+6`5JG]H7'=<JK\Z+A1F?@ZY\?6]8W8U<6ZS;%JUF;L:@:4\;,X5=`1'[C)
M:WOLF#)W`ZQ.AW:`_]*;[NHZ14XL)1)U+:+3YX;.$V'<M7E3?I%NV'1JK2/6
MNYC-N\DWH2C2FK#*F$\19?4]BLDKYX:'>G2#K\YS=O"/S![E\<^9/4I$8XHK
MLD\'?94+-<Q\I:Q5YAHOXH8&Q8R,^011RL@TS!#EC`I;;ACJSEZ?WPG@N4NM
MY*HLJ7Q,*#IB0>]KE<J<46$-:EL4-Z.2BTO$/1Z\3HJYMR.K6]D;^<1Y36L;
M2@<R5CD#"N=@;?Z0$TYZU.?[G"J54\1I=UJ%&7?SH9%=O099889DL,I,EQ&B
MF)%5O8A21L96ABAGA-5+&XFZ\'SZWJ"P4\3'/'E#+B>/6N6]`C(:+IX0480H
M1I0@2A%EB')$`T1#1"-$8T031%-$,T1S![EU+D]OJL[_TA606O3$<JB1>P74
M%9O_OE&9S)6VK%NA"%4QH@11BBA#E",:(!HB&B$:(YH@FB*:(9H[R,V<.KC9
MZZ@U0_F75+5_D)DJD7T%I%46"A%%B&)$":(4488H1S1`-$0T0C1&-$$T131#
M-'>0FQ;:!#EI.9(+)1<+A$9F9]9O`@H118AB1`FB%%&&*'>0^\R?.Q"J^QKY
MS!J95:O/*O^63JO<*Z"N.,I'1L533(PH090BRA#E&I476&YDU'GFP"`]_;ZG
MJ4]%U@F/D1TPK3H2L%*EMDS5EHZ^0<']F'>DS9/*!*QJR"A!58HH0Y1K5!<P
M=>KY^P'39R<[8!K9`:N0"07^O4>S5-%>J/AK[*M`'.<B(^#`Q!I9-YJ)09[.
M4F-+=R:.;9D1<&>YL4S(K3YUWK&#>60N*H]']E%+;;G44+7GH@IY'B34#95O
M5IF)&XC(J/AI8D0)HA11ABC7J/3>C8PZ"WPB,N71P8F,1NX#BFN)?E.K*&95
M&&I*K%)Q&")NJ,]4-RWZ3YSA8JTY<LO"EKPNI$;%+F2,2A?H;W,#,4ODQQQP
M0JYV@9\(>2%W%T:-U.UZ%<S&E1@A?6[H'`;A,&54_+P1FR\_7]:]ZEQWQ45'
MS*UH.:X\@'0FK/)ZD!H5>Y`)#ZX[,N4Y-SKD@!OQ^D/:)S_SW5)61"(T<FM?
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M:=:TH8U63VU]T!I]#]A#K2WJOK9WZKQ6K[JNL]_J/=`E,W;\V*(O(*OC[=Z\
MB*EXN(?@IO=`V^L:2_2*^O@2OA(VFCWUIC2^0N\X][+:5\)FFT)5YT'8[-`K
MQ30A?`N;USVUP:_IAUY1NW%\);SNS6KY38_^+ASU*66PC@]O>O2WUJB?WO1F
M=9P^#D$QJ4LA?9*!8E+WRF/0I0@7ISSQY(^-*ZJ'\JO@JI?H>]P^%E]7H\7V
MZ_I]=_:Z>J;RORHV%-ORF^#*7_;Z;VZ^;/;T#6ZT>:#OPZ)O[%O1MU=<J4^7
M/6\V>_Z%'O"R^@[`^_\#``#__P,`4$L#!!0`!@`(````(0#CC)Q1704``.03
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*Q8VXZC1A!]CY1_0+RO
M,1=[;&1[Y0LD*VVD*-HDSPQNVVB`MH`9S_Q]JN@+?7&\9)6783BN.EVGJ[JK
MZ=7G]ZITWDC3%K1>N_YDZCJDSNFQJ,]K]\]OZ:>%Z[1=5A^SDM9D[7Z0UOV\
M^?FGU8TV+^V%D,X!AKI=NY>NN\:>U^874F7MA%Y)#;^<:%-E';PV9Z^]-B0[
M]DY5Z073Z=RKLJ)V&4/<C.&@IU.1DP/-7RM2=XRD(6760?SMI;BV@JW*Q]!5
M6?/R>OV4T^H*%,]%670?/:GK5'G\Y5S3)GLN0?>['V6YX.Y?+/JJR!O:TE,W
M`3J/!6IK7GI+#Y@VJV,!"G#:G8:<UN[6CU-_X7J;53]!?Q7DUBK_.^V%WGYI
MBN/7HB8PVY`GS,`SI2]H^N6($#A[EG?:9^#WQCF24_9:=G_0VZ^D.%\Z2/<,
M%*&P^/AQ(&T.,PHTDV"&3#DM(0#XZU0%E@;,2/;>/V_%L;NLW7`^F3U-0Q_,
MG6?2=FF!E*Z3O[8=K?YF1CZG8B0!)X&G()E-HF#VM.A9'GB&W#.2GL$X1PBN
MCQN>?,CY)%C,_-D<XWXPXIP[PI,[/A[18Q/6S_\AZ[+-JJ$W!XH:IJ2]9KA$
M_!C(Q,2SH64J_BT3D`(DV2++VGUR'9CD%LKG;1,LGE;>&Z0\YS8[V\;7+?;"
M`O.+M`<32$P@50`/%$E9D,/_01:RH"P1T$X`BDY#@[`0+@<32$P@50!-`U25
MJ2&$E75_38A,H!-4OYJ)*-)CW'$;V#QENF:ZR5Z:2!T6DEA(JB*:%%@8IA1<
MWO^QRI`%ZA3F2\8=+!9ZY#MF%#X2)TVD.`M)+"15$4T<"%'%/<X/&O<:Q-@[
MAD20V4%59"R>O302;@<+22PD51$M9%CI:LALU4^>P/YQ].BG1\^0*)!K9&\A
M!PM)+"15$2U4V%344!_'A\9Z?!QA.SUN*GL+.5A(8B&IBFCQX1%$V4`?QX?&
M>GP<84VMCT\B0SWXX5*O\@,S"B%A2M$82R&11J)H4LD-B*9BJ:M0"J*[%/G+
MCL(PL-?>41?"=L^:`'+HXCBBB)/($+<MCAD%\%#$&3.02",I3G*;XGQ86^-S
MU%OK.@0$13!$-)OJ.=D+*YAD:66+&ZQ$X(D-I1JD9<K'EC>ZX'IK0PSKF6'`
M^O34-]K#7OB`W2,=C`:-!RMSWTHX5XA5\K;QS=TZ%6/!YCJP*-6N2\=..5XZ
MZZO0+L1$[[!U0(F&D9!NMCUN`$?=^^'P8PEG[@_$/90(9I\S&]6:\M\#=9=7
M:T/7B7UTO$[6=6&$02=OQ#+%<[-4N8^6/&7:N4YI)9@3GS.S?`:^09SRW_UQ
M^<26.EXG:\":3@8-^33;)L:!>])W\BFM!IV<F><S"/0)3#GQR'QB'U9T_M#N
MBN<E8WOET+"2C0:P%S[?23-G'GID(IAYF@.#.!7$,$LCEBWV=D7^G28"7SNB
MB_CL)*"EF4%@)/*SYU;XE70W`%[`W'$N'1/A.$"I@'IZ?2%BUU<B_['$\:.#
MNCXYI/<3ZW.(606JE;IG<(V<2RMQ>Q_F5DNV#T_GH5G0?+!Q&Q0,]FA>OM$K
M++J[QP4UT\AB]"8&:9F6T,-,<RMU2[8@O,+`$1D]RS2[DF"?Q!5ISF1/RK)U
M<OJ*UPW0AC<K";.[D,,BAI,55**)+V,XE-@XW)UL^]P;]CN\4[ECOPMB^"2T
M>79A#!]8-KZ-XBV[FS$'B&+X:+$==K,8O@SNX/,8CN&`>Y(([EBNV9G\EC7G
MHFZ=DIQ@4J;]AT+#;FG82\<3_DP[N%WI<W^!VS0"Y^WI!-;HB=).O.``\GYN
M\P\```#__P,`4$L#!!0`!@`(````(0"5<^;X,@$``$`"```1``@!9&]C4')O
M<',O8V]R92YX;6P@H@0!**```0``````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````"<D4%/PR`8AN\F_H>&>TO9G#K2LD3-3BXQ<4;C#>';1BR4`-KVW\NZ
MKL[HR2-Y7QZ>[Z-8M+I*/L%Y59L2D2Q'"1A12V6V)7I:+]-KE/C`C>15;:!$
M'7BT8.=GA;!4U`X>7&W!!04^B23CJ;`EVH5@*<9>[$!SG\6&B>&F=IJ'>'1;
M;+EXYUO`DSR_Q!H"ESQPO`>F=B2B`2G%B+0?KNH!4F"H0(,)'I.,X.]N`*?]
MGQ?ZY*2I5>ALG&G0/65+<0C'=NO56&R:)FNFO4;T)_AE=?_8CYHJL]^5`,3V
M^ZFX#ZNXRHT">=.Q]LU5B?>[`O_."BEZ.RH<\``RB>_1@]TQ>9[>WJV7B$UR
M<I'FLY3,UF1.)W.:7[T6^-@:[K,1J`>!?Q./`-9[__QS]@4``/__`P!02P,$
M%``&``@````A`*33>K8#`P``=PH``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($
M`2B@``$`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````G%;!3N,P$+VO
MM/\0Y0XIE$4+2H-*"P*)%14I<+1<9]I8.';6=BO*US-.MB5=G"!Z2^QYXS<S
M;\:.+UX+$:Q`&Z[D(#PZ[(4!2*8R+A>#\'%Z??`[#(RE,J-"21B$:S#A1?+S
M1SS1J@1M.9@`74@S"'-KR_,H,BR'@II#W):X,U>ZH!9_]2)2\SEG,%9L68"T
MT7&O=QK!JP690790;AV&M<?SE=W7:::8XV>>INL2"2?QL"P%9]1BE,D?SK0R
M:FZ#JU<&(HZ:FS&R2X$M-;?KI!='S=\X953`"!TG<RH,Q-''0GP#U"5M0KDV
M2;RRYRM@5NG`\#=,VW$8S*@!1V<0KJCF5%JDY<SJG^I;E,;JY%GI%Y,#6!-'
M:%`O5I]-V^8W/TGZ9Y4%?NU:.@\U$]S8Y3CE5H"YGT^HMA[*_;,FYXI%S;@F
MM*DB06V0*VDQ7^16UM7FJLE\&\-(8:&E@8Q<4D$E`Y)^"O-+8X)T07[A/[74
M@M.8(6I.[E&HU'X+,J(F)]=>R+U>4,G?*BU5P8_!,,U+IRWB#SQ=%@75:\<E
MY0O)L0NP_F3(F%K*%F+86Y3+W4R16XQJ1Q6-=!4%GI]:Q5[(,]4:#VBS%(+.
M%&;$$7;5N\.FQ+*0X4*CIK<NG3K_U1IF+2Q547!;)]IYP@I;;`*<(#@7O*XJ
M@KD2&8X<<O5WB;)IMR,3E(FI.%:X2VPA=TCAA3R`P*IG3LYK,L4$&,I<C'XB
MW64\\I[074<_9M1>2#*EWF,PP/:L$B_$DU;T/L/^;C=OS:X_D.Z$'?O/Z13^
M/IC^'N><[('YM0?FU(OI$L!$?QLR9'X(:N93_Y-AEG'7`BV0KD'@%\$8)\'6
M*Q6-B2_)V#\\NM7L/Z8;TZ(;-_IV)TN#J3<#OJYY``-ZA6,F;8>T=DX'LU:,
M7]&MPZR*J4EMYX;_[TZ_X_+%/)93-<;)N'FT["[&:8X7:H;7^6;_8R&^P?>*
M%L[)**<XU[.-S><-]\1ZJM^1R=')8:_?P]=38RV./EZ,R3L```#__P,`4$L!
M`BT`%``&``@````A`)0K:MCL`0``WA@``!,``````````````````````%M#
M;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``
M"P`````````````````E!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`
M:799%/P!``#G%P``&@````````````````!+!P``>&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`W+=!^K$#``";#```#P``````
M``````````"'"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`&,H
M"2E)!```F0\``!@`````````````````90X``'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+`0(M`!0`!@`(````(0"%1\I7Y`,``#`.```9````````````
M`````.02``!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!`BT`%``&``@`
M```A`*+>X@4##```@EP``!D`````````````````_Q8``'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`]'$JF*@$``!*%```&0``
M```````````````Y(P``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M
M`!0`!@`(````(0`V.Y2]_`(``+L(```9`````````````````!@H``!X;"]W
M;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@````A`/1"_>8:`P``
M#PD``!D`````````````````2RL``'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"+0`4``8`"````"$`C0K+0^`#``#,#@``&0````````````````"<
M+@``>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0#,
M\8]0;@,``*X+```9`````````````````+,R``!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L!`BT`%``&``@````A`&<QED"O`@``70<``!D`````````
M````````6#8``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`
M"````"$`_)ETB<("``""!P``&0`````````````````^.0``>&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0"J.QDNWP4``+X=```9
M`````````````````#<\``!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!
M`BT`%``&``@````A``AL7A'>`@``^0@``!D`````````````````34(``'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`!)1!"(`%
M``#B%@``&`````````````````!B10``>&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L!`BT`%``&``@````A`-YH"1#D`@``=0D``!@`````````````````
M&$L``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0`2
M`N@V6$<``)C?```4`````````````````#).``!X;"]S:&%R9613=')I;F=S
M+GAM;%!+`0(M`!0`!@`(````(0!WNZ%(+PL``"9?```-````````````````
M`+R5``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL`
M`!,`````````````````%J$``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4
M``8`"````"$`DS+'IH4"```>!@``&0````````````````#;IP``>&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0!-1\45'0,``"(*
M```9`````````````````)>J``!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L!`BT`%``&``@````A`"KTI"H6`P``2PD``!D`````````````````ZZT`
M`'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"+0`4``8`"````"$`QXJ%
MU8X#``!9#```&``````````````````XL0``>&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L!`BT`%``&``@````A``TB&2<N`P``Y`H``!D`````````````
M````_+0``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"```
M`"$`@JJ^#<H#``#X#0``&0````````````````!AN```>&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0#DK%LK+`8``%(8```9````
M`````````````&*\``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`
M%``&``@````A`%&$#KGE`@``6P@``!D`````````````````Q<(``'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`Y\^_AZ@"```A
M!P``&0````````````````#AQ0``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+`0(M`!0`!@`(````(0`(QMXA?`(``"X&```8`````````````````,#(
M``!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`82V*
M8,4*``#7,@``&`````````````````!RRP``>&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L!`BT`%``&``@````A`(Q7Y<8V&@``W:4``!@`````````````
M````;=8``'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````
M(0`3J/X]I`(``.T&```8`````````````````-GP``!X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`"A=YOO<%```L&@``&```````
M``````````"S\P``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&
M``@````A`*WX/WI!!```/1,``!D`````````````````X/D``'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`43!P+/P&``"Z'0``
M&0````````````````!8_@``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M`0(M`!0`!@`(````(0"#5&L)?@(``#`&```9`````````````````(L%`0!X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A`/Y("&KI
M!```B!8``!D`````````````````0`@!`'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"+0`4``8`"````"$`[V=3?Q\&``"2&```&0``````````````
M``!@#0$`>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````
M(0#$KO@"Z@8``#4>```9`````````````````+83`0!X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L!`BT`%``&``@````A`%&61*$)!@```Q@``!D`````
M````````````UQH!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4
M``8`"````"$`B=*&3K@*``!G,@``&0`````````````````7(0$`>&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#5Y+QC0A(``")J
M```9``````````````````8L`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`*LV!#I;#P``2%```!D`````````````````?SX!
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`XXR<
M45T%``#D$P``&0`````````````````13@$`>&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+`0(M`!0`!@`(````(0"5<^;X,@$``$`"```1````````````
M`````*53`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0"DTWJV
M`P,``'<*```0``````````````````Y6`0!D;V-0<F]P<R]A<'`N>&UL4$L%
3!@`````P`#```@T``$=:`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-14-201070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-14-201070-xbrl.zip
M4$L#!!0````(`%%[KT1;];:-8)@``,%:!0`1`!P`8WEM82TR,#$T,#,S,2YX
M;6Q55`D``^H4=5/J%'53=7@+``$$)0X```0Y`0``U%U;;]M(EGY?8/^#U@^+
M76#+KCNKC$X&O`X")+'7R?3T[(M!2W1,M"QZ2"JQY]?O*4JR*8J2*4JDZ6[`
ML<4B5=^I<Z\ZA[_]Y?%^.OH9I5F<S#Z<D%-\,HIFXV02SWY\.)EG*,S&<7PR
MRO)P-@FGR2SZ</(492=_^?CO__;;?R`TNKH:><EL%DVGT=/HCW$TC=(PCT:?
M9N:.<007Q_/[:);_S^@FS*+)*)F-_G"N/H_H*1F-[O+\X?SL[->O7Z=I.ED]
MYG2<W)^-$%I]Q>^+V9V/1O*4P@Q+EZZ2^6QR/I*EC]PT"G,8/IK`/,Y'%!..
ML$!$?"?JG*IS(?^O/#IY>$KC'W?YZ+_&_PV#823<P497IU>G)6#_.?J6S#(8
M??\0SIY&]G0ZNC)W9:.K*(O2G]'D=/G0QYMT.@*:SK(/)R5XYN/3)/UQ!E_!
MSN(E=4X6(\_-U>F.\=-X]J<AW_-X\\':^%^L&$VTUF?%U=70.$LX)=:NR2Q&
M/#\[B^N>#$/)V1]?/G\;WT7W(:HB`$[Y$88/SW?>AME-<=_RPIFA*L($,;*Z
M91*]?%$QHRP:G_Y(?I[!A9KAXZ?[\'E\?!_E:?QX&DU^A"E*9H`X*MC&+#=F
M+W?!U^=/#U%6.['B2LU7F=E,\O7)+6D@SA87UX;&M4/E8FB\&IKE#VD]8'/%
M3(-4$`-SY^E3_3W+BW6$FJ<IB/"V^Y97S8UT_<;H<7Q7?Y.Y4O--\>QGE.7U
MMRRNU=PTF]_7,^,D3\_,BIS!B"B-Q\\W@!2^?D\R0Y7[YGFZE>OU&5P]`7D=
MC0J)G9YG!5]?1;>C0GS.S5,_G&3Q_</4,'GQ69B.TV0:-1/4XHZ[-+K]<&)8
M%ZTX\_0QF[20X^8JXFP!:REXYUYTDQMMG!9J^-,LCU)8F"M0CM]R^#&YC-(Q
M7`A_1*-Q`E<?\RLSYRB97E_Z6BG&$$*$$XS^%V-,K[]]]Z[QM:$AIE3!KYI*
MIN4CH90S">9C/HL7CWB8IS"=232.[\,I2."GK\')*)Y\.(DGUTQ)J8BZ]@G\
MYRL+69Y'$?>PAW3@V\C5@?"L@#`+XVL&NN=:G'S$IYASBG\[VQ_;+IJX"?!J
MFL<WTVCQJ[$VE\!)$6E-$DMH^J@9YKA,D:6JO?[;-^_Z(4JOL[L0)GP4&@E#
M(WGRD3-UJO@V$NV`V@_7$*,0R`;77&M&&%:/6G!"=4<\Q%8\I(D^-@]U32':
M/86XH1`O*"2X'*Z4E0A4DK*M].E6YIB1.:KIJ9`'RQQXE_?)[%N>C/_\5DSR
M4Y;-P67>CSJ,8$.=$@6:(5:VYW-%761)J1'W;0LI;`@@A/(\WW6DSZ[-@S]*
MR4&:7N!NF?<"G+%]YW\/TS2<Y=GWY'*>CN_`3%W<;MPU+)SDY"-A5!DY:`ZA
MF_4$#=`")[,8MPG32%/?01RX&3G29H@HKL%.N<K6_G(]C?P,8#T[Q6G6DV*%
M6ZPGQ"/G_BR/\Z>-`1?SO(B,(5K>$R['($0MX!+'L;7K&J04?@`O`_OZ%`EJ
M428$_,#JFAI+1R`$`48'O=0,0$]NHS).<,6\";6G00,Y%0(3B:3R+,2IRY`2
M'D&6;7N>ZP2N'SC7Q'PO*PR:):SV]JS@E\^@KV=99,\F;C*=AC=)6F09[!]I
M%)G'9)=)#O_$X?0R?"H^")+4BWY&T^3!_/DEGL*7)+/]Y`+B`(5EA5%*%JU,
M)R0VR(0#;KN^MD$B/($X%P)I"T3%%=KBVB&6S3U#)G9-3SZ";.!G\3@>W!(-
MOP#PN^G3\ME!U!TM\`&D`$U!7PBQ.>=U.?D<SXSF2*-)G`?A.)Z"E'T)'^/[
M^;V3I&GR"R3+#1_@2OZTIZ1(+&G;E6\F($;[,XR7"]\&4F^QIE7C$W?D!=.E
M%\SU@+W@$DG>(M:D[R#6!%.CC;I8-S7[QDY-30T[AJEY=L'"[,[H7OC'_^<\
M_AE.C8JU<Q>\EB<0O]_#Z7S?N)(M#&\#=<(VO0[N*ZJ41)YG@]?A^!HY@?80
M\PCGEN7[EEC:6ZI./@HAK76/L@F<3ISG!0?L[66YKA4PZA#D"5LA+B6(`;8%
M8@`L`$'CCA,8O(4&%4S"?[JA`]V]X:A!W=QPN(S[!%L^LGQ&$%?"00[W'&03
M7["`!EHPM4!."Q?S8-O174#1^=J;F`*T,&/J@"!Q&F;9Q>WRSHNTV%;Z.K^_
MB=*+VV_1>)[&>1QE;CB=1A/GR0_'=^MCVU$%="*S-'F$H$MBIO8F$M?<AQLI
MPK9E(W"@'*1L"\CE:R*H]FQ/XV<!(<!ZK"P?AV)N0$+_$51KG$6%P7F^F"VO
MMN2E[52K6MOE]Y7)2`\@(G":.%W3J"TP5ZUN"HHXCW]&G^/PQ@@JD/QK,EML
M$!V=K9IKH.94`0TD*OKG%50]I7!?J,$--;067*D7-P13@CG\J215CX!$42+V
M]$J$[2OL^."+^)0ASK`);.`'=BU'2?!R!'P#6Q()O!)EB<.]DNY-5H5&K?BG
M$6GX2C5U%OT`$>-D$H^7\?'W*+W/'-!H"3C!RX\2)[H,XY8^3;^DXJM`<1L7
M-8=;X:ED]L,,-D][X3LG"E.@<Q`_1I,R?QZ%5,^2![]3M6\\T(AFJ]VXJN3M
MA[;D(!6N@V-.T)@S*-$L6Z1CC(+_421DG*>7(4N"V[_"%)XW3B/X\--LX7VL
MSJL<KMN8B:^`B%(H2780<=/N4>YX;N!#?,G]`#2\BY$*E(N`H![Q'-MW/%U6
M7F+I7G5(A%>"CT/RO-6HJZ$7:I/`MBP/V;XG$1>4`\-9#+G$;%"`/X5M^YI<
M,[Y,]'(M=@0@6].\QPFSN@;)&H&LB[)*@T!IQWDX7>>`($F#>0X<:VXN#JSU
M@QP+[`J+>\CSF=$BPD=:21]YCB<E=[3'`WY=\#]H*"48K\7=#-(Z12[3Z#8"
M9VCR'MB;:E``+]!?F?OK0.UY?I>D\;^&QN'4JG-%=B-X19"'"I65\@:[-AT;
M`+T,TXMTX;(6&210Y\6]!P-NESMM2@!2&#4P;[7HMX':Q=SODQ!4;A*B&:[7
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M@E>9Y2AH*[R5WT7I$.1(0,@F`HLC&YOM<U<'2/N"(HD=$0ABN]H!*3)I`J#5
M.A?MA+"98,I6R9?A*@MPUCC9S!I59UX1APE<@94W)R9BB$B7OOOPX#%@;V9A
M:LEU!J^??RM=.$@-*(U42]9&!6XH/E.<D<&`T&Q^#Y:/B]R!U%4]5C/Y6L,.
M.NPVRK*")\S!F,%JI6*?@-39]BT06AKX()FGP[7P1C=3VL["/R.KZNMWX-II
MX'(A**GHZ]V6J&3."P-F$HYI=!?-LO@GT&.<W$>?DRS[&N47M]_#Q^'!9G*1
ML:_U4)I`6J>'?_\P39ZBZ"HJ'O`>?!%LK/2Z<GL5Q3KH(N"Z2Z:3*,V,@Y8_
M`9FF<Y-JNC2N''AU>9[&-_/<J,KOB=EG!"JDR70*0U:9_`'R!@2BA+"*@3\.
MVAK_]1C[RSU0A2X/?FXXKPUVDILK4I"UX9H($P53U=)$K)#5[^^5MU4'N/9&
M66"]KBWJIKX.;G7"`@*XQ1&+8R;2CV\)C8=+)%M?X%T8UM%>17D(I)CX83J#
MB]E:R'L;CX>XL`QB-<2$TI4:E]>Q='E:ICGPFI/=CL.U2QWD^IP@3H5$-O%L
M1)3E.-27MB=]<_BU</CX(<=C2DGI#K*.1UG=Y0F.VD1ZS:'2$FA@]TV#-T"$
MX+TR0K3<YKW6XJ@>)BXB]4*!7]Q,XQ]%!JHS"[19>\&$*P)E:Q0$`4;<YV"`
M:*"04L1CE`H"C+MPV-;.#-?.>NN"#F_MJ-GITHI6,T7/4VZ;1[Y+HP$[$<SD
M`&4[)^(%VCIM5M[EX%,JX%FS=>SU4]_*QD$8IX7F\N)L/$VR^7%W\5Z!Z=N"
M"%L)9(L@`)@25EG[`7(]#\34@Z4VU3'&LFPZ$KM!;)J6."_6O2@QFQGFB&;C
MH\OQ<?:VV,;>5D..[I]1F\NI.;VN6CG[M3S\)4S_C(K0L'2">ZAR"CI*$KWN
M.NP`4,D-95F4#Q>;44%8LTKRISSGNCVFXOJ0PW."37A>2<_737UC]_PAC"?^
MHSDO.%S#84(S54G(U$Z]&I)E>1J/(6JI+['JS\>S/-<AQ)4("PTX,?RP78J1
MPQFW!'%QX(GKTI'K<BBV&T.=\`UO`0FI<]07LZU#\"[LO#D48.E*1FCK_+LO
M8>S#:3<I,,;7]TE:U"^N]M&NHG$$-X!5^1H-=TO;.'2;IU^V`JBJV"UG&?Z:
M)EF?HMKP^$;AO1)>T;6[,&PUF(-=4`O86,IMQK)V&9\K#YX7?+#HQ,E'C6NC
MK(W)-V15X.WAP=2F-T\S-H7YEZI%EKO;2\]AN%MT15.>I:>Z8^)K=3!)6A07
M?2KZ2R[[#.1I.,[GX?1+F!O'O74>K]HJ2I-`^X0A@1V*N(4I<EQAZGT8H5S[
MKFV3YR+72_*/YS*5)G,L@?HTFT3WL_@V'A<YKE4@W5TZ4F[6(]B^Q@+\-5@<
M4)W8PL"1GHT"HFU'*P\K]0)UM5K;YEV"MJJ#GI02LT7$__S7:O^A'[]@,Y]N
M21^KP.-($\40]XB#%$B@J4URM(TIT>*EU)^MCJT?`JY$GN?,1[X*KU\46%'%
M=#$K-=7Q?[;WZ:^U0<(?"26`<TN#O%>81/JF:Y6CD-0:Y,'&P"26<)"MM&4K
M/_"5T(NM![K:2'PA5ANH!Y7*'UCR_4*W944SK[2<:78VO-%V#7LNE%]T*#L2
MXM[+Y%^E6:LR^>8D-`>]3LOUEH>7R1\Y6C.EJ%J84E0A(<KJ+G@#C<6-?=U(
M<S4,W[K%#7]J2^-'3842I%,JT`%203.ZWHCHR+"I67R3+P-#9@T.=VGQ+28[
MI0(YB`I=;,N8?ET0?3X2S)006W3C,=`SPP/LT(V:'DCPP@Y:L0YU`5OVZ#J,
M(,\#OD2AN6J<E;_'^=W?9LF-J;\U[LRGV<.\<&^2F>D?43C'5\9:FRI_\'7B
MK'C"Q>U+^X2LL%3@2IL.`$4MV!$.)JP(#8(F&3L"G4G@^:Z+722I!`=0*AOH
MC!7R-`$_$(.1QOKYL/$FG=^&=EUKMEYTV<*E'HXZ[\5Z4P.ZK>GN2'/UHZH.
MWV%_9WJJ1-9KXR4P:?Z29*N!W+VQWU11F5:?U:W]+M+9!J&2PO3%$LIB'6:W
M5ST)174OL7E^NTL"0&3(J.@./UV>0&)<#Q,_HY2VLQ.-\*_"X,H&UF#@2U@7
MJSOX?'6P1;9G_]9=ABX>BA.*R_1"L6-6I&K:DFQ;@Z5FB:>F39:*%NF*8<E+
M?6N/3H,WZ<IC+`GF8%<L+LC^J;MF/7J>&X$*"+A*)#RP34_?)%)8,=X-B59Q
M.%$<_N^$1,=I>6.(`80P2MJR]B<&X9PX?B"1='V-N&=ST%".1)QH!UN6(Z5M
MO?1$Q7B5'F^`IZ<6.%L)T*X/3'."'*,E3E>O&\*$KC5:!U_U""\8:M16O,CC
MF;I=1D\U._P%0QT<R:$+ZG3757RQGV2=?+0LNF[4C]%5O'W!%ML`?L1F0;1H
M[*<YL(BL;_W62U^_KC&R)AC?HJU?6^#-[&&1RP&[BVF]OGO[MGX=+_Q@VOIU
MC7-`;?VZEN7!M?7;!-QA-SLZX+9^/1-B<&W]NA;RMVKKMW-=CU+Z1+MLZ_?*
M]`\_0$D7;?VHJ&W]LT<'F#[;UQU"E6894G-Z%L(\427*T-O7'4*91N=1B_=^
MJ77[U7/WNCYD`GR2C7VE?IK7]8"N:%XG+?"\U]F[2?.ZH_1MZV,%@4VEMJKR
MVV_;MAZD$3Q*2]$ZW=VH;=N[,%#:1,!JZS;O&_0FZT-(Y>H5FRTA==N;K`?6
M-CNT9'W5WT-OLCYXP_0F4T*_H]YD/5#%]";3FXY)@R8^1^B_U0<^TW_+5)V\
M6?^M/I0]J#W)*SO3;]A^JP]I+MIO@8&KG$?8M_W6@:VH^D#ZMJVH^D!H6E'1
MZ@OW]FM%U;Y?4Q]*R*0P6;53W-9^34?I2=2'VFG7D^AX+7IZR5-MMN@Y7D.:
M/H0+3(/BZ]U->FE(TP,VPW^4LDJ?\6X;TO0A5Z:T1*A-KZS[AC0]H#/MHV6U
M1T+?_6@:XVS9CZ8(Q(@0%=^D\WXT?7`GJ;/6=?UH.GG7?`_6&J0/0H:*S_6F
MC5IZ0%W4!536]&T:M?2P4<&+C0J%VY[D/;A12P\+:MXE([9V->NT44L/Z(1Q
M:VI=S_X:M?0`4U??M=!GGY8>TI7$O$IAL8[-VK14=LR>+FY?.D]_FI7*B8:'
ME;T(Y'Y0CM_0I3G:]@U=:/.&+BOF?A>E9>SEU&[_);"K$^\;V;XA5,"^L^7;
MNS+P*,M7B$75,`]A];KPX?JL3J2#JDZL$*"'ZL3"P%#!VK<?[)0`W9<GTB&5
M)U;A=U^>2`\M3^SIZ'M/M7,%.81E47V\-]SW3:%N2^<6.2J+4XL>LW1N52=T
M<;MQ3G6/`BEJL8(B6#/<IES"LGD`L11R[$`CD#V!'&I*Q6B@/5\[*E#!HFDT
MM8#::NUH]2X$KZ"U[TW&Y'AHFW<;;(BX2-[5'*;?A6-7-=RJZ:07YGMP.U6&
M`36F\$O1PXEIT\&+<B8W$ZX^N-G$5Q:R/`\\*P][2`>^C2#.$J#_B.E<4GK5
M-*$(4T35MJ*V\HPW#,`XBB99D";WI=(W<_NQH+58V.;P@9NMS9*0K9@J&ZCF
MQ0P0=\?IXGPN4&</!EZP+R%X"=KBW#C37-6TQ=0,[)92R/AJB-L60UIJ!BM&
MJ&_93`2Z:(M9M%2"IRH$*\I*`EHWTW*&((W"B]N+6X@UHV\/X3Y*>!>*%P7T
MS]O\E1V"Q@C-L6!E#%3]S$NH"M#?\C#-]Y.T3A9F(6<<88*(7$Y^?8+;!6ME
M-BYN+XMD1P2NR3C:[SS["A2E+94ELQBW"=-(4]]!'.0+.=)FB"BN071=96M_
MN1-@[1"H[5@V5>:+BEV*H8G)5CJII9$\R$0VTBM6T2J:<LWYNCYM#N>UTX5?
MDSQ:V-F':5QZ[I61[L.)\0"N2ID4F\Q@*V'YTK)08)MB88D#X'LA36>+0$'8
MBGWJ+5\B=HI-(+OK].!N-'V(Q0$^A,NX3[#E(\MG!(&.`&^">PZRB2]8`(Z$
M8&KI-4EU!+GP'\W1CWF<W9EK)O]YDR\\CQY!-Y0#<WJT>*/YVM':K0"VK_1:
M3<3P%M=$3;N<B+7IE_NG&Z9?B+PW-RFIRRB-D\F"&A`TN(8AIM/"9"\(-3SL
MLKS&+5&56Y0W$HGBZ+FI-3#A^7+?8WBD,;Z84F72M$>W*YXH$IG?'L`3FES,
M?@_3V*0^K]HXHPN:@,_#.<6/(..22&[^+!I(8_!Q+/[BGV-*L/GS_]F[TN;&
MC23[?2+\'RKD\80=(<@`"(!@]WHBP`.>GNUNM;OEV?5^F2B")1%C$*!Q2.*_
MW\RL`@F`ATB*HJBV(AQM$4>A\JBL(U^]<AW3A;NZ:QKVAE[$6DX">0-7[PY:
MFCLP<=:M(YL__*/WVEW7:=D=6U></FWJ2"S37C=#6:^#Y6UA94OT>4`)E06X
M#I0.SAK`7_QFYP'C7'E5]1Q>'Y3.<&7'VMPWMJ5DFZE:;D7,X[POLB`-B4#J
M0(K86UC[[.^_QGD8L6F2A9CI8^P3,OTS<\A&/.<LS!@/QJ&X%:-SEH\%PQTK
M/)ZQ29'E;"A8B#),8'1!"TQW83YF22Q8<LWRNX2QZQ`D#D+:0B>EAP)SQJ.(
MY>$$0LOWQ@]LPL,8<=+,N&BIRP'/QBQ/6%(!NH.!(4PG*?O>K+R3%3A#"6EH
M@B^!4L?P`KZ<%=-IDN9,(."<34#5XPQKQA)Y_A\>#CM$9B]\B;,\Y2%NHV`<
M1DGHI?1&-)/E#HLTOEA/3;-DV@U=;@7O_\BN=WV3V#[D;N\M#W;&JP2KSH6K
M.VNIYWIN_X=^Y%/+^5#.>)?J=_BUIA8NK2+A75T0TR*B]'W(D\H)L*'I'<UH
M/]-"TV:Y]CG_>SO92TJZ_9:9GFPJK#]F+MSKM?V6V36TONVY,`5T^IACL;66
MT]9]W=*M;M=7AWL><"Y\D.G/&KEW&`!N)[NUS_R'&CD,`0\^TSV6U)7C9E3(
MVEJ:%=R?PX=Y+X=-WLO%0N?.`5QO1'"KU<9$M&$M4X#N0_%9\NM],O3?&@2?
MAQ"T=C;7GJ2A\Q-M)$/0+0PW<"P-$[>?<6^<_-"[.$AQ\;(OY/_WUO`1:%5+
M_(_5-MMV:WXLV#'5\P0]M$%\?[BDNY0R`:V"@MW[CFT9YG)_O6URI.RR6YH.
M_QF[=]E/+*=Y"#G-1=+D!.1LZ>VGLZ<]MV<C.70B<A[*GO;<GCO*^60]KY39
MT/<^%L_U^@/+-7M:VW$ZFC7PVIJKHR9LV^W#&!3QSRKW8AZ@XSV8H2&XMY8,
M;;M[\J\NIA"M9YQ";)3KJ:80A,QI/6H&<1B#=E:VW+W;JJG:JJGI[;UBT@%M
MNDZTI\J/F`IPY6Q*EQ['K!!VE_WY8!V/M1A(N,_>P:Z0\U`=C[482.PGYY=I
M$F=)BDO_.PCFV(_<G0D=BV?X^D"SVBZ,H@W?T3R,18->?]#OMLV6VU6[,ZWZ
MYLQ*?5?LPWPWF?(PI85'&"O?'%>FMFEYNN<--$S5@&"&K74\F+I:MN7YW;YC
MZSWGW^5VB\W5KHN&V_EX-H8V>AN.\)S/7S-<NKB4B[7QC1?DX>V.G`H=O>*;
M3TC>3>P#!(*MF7%[D1IK,8HOI&0,Q1Q,X,6C?A@5^2[$H%O(OX89=47/`X7Z
M/=_3^KT6.+/?,[1.R^MKCJD/=,ORNU;;4?0O6L>U+W2GLC2S6:"&C\=Y.,(;
MX6V%$F!PCTQ(8B1C]V1:Y"K/V2Q[UT6K=3K:<K&N[P[T;F<`;=JT-<O5/:UC
MFC#2<%S<9-&UC)XB/FB[>#ADI4T<0LPE2'"33VQW>K3'MYEM/<4&3[&;9[UM
MD&$I7BPHT^;+!5=)!3.LP##D;:>H`&.5`G:4:\5>X(])G)0A1A:EDMTGJ`.*
MF\O[@M>*T-PC7!X]+Q_:G?#M:((Z3>*D=75O2EA?\(+>`_6SZ$)V)&8X7H_8
MP@U0#8FWD:7AT'4O>+_3YI>C&=="+[:,NK@KJOZ0;>O<(Z=H55.UUXUFK8OQ
MD-!JZ_'REOF=-L$?3P48M3L/:&"33!NZL1-T[0X:W#'=]7W4,OVNY-*NI-,O
MK_$`3^+O@%$?N,<D+";9(@*>8@!#3K]E#I(]9'O(_Y%T+.5!Q4FR$_5\7=&R
M;/+\U=(TUI9DVB?SD_1S,N/1DT[JEJ>PNF]YO4$'82%(D6#9,(5MMSI:S^ZT
MK4[7:'M67P;UZMK1BCK7I?I9Q!#P(^20'TW".,SRE.@33G?P!<&\8]8[K0>$
MJ$M\)2;3).7I3,+-Y\WC*ODL1G`/_Z9]X-[H/X5L#2>H!73KEJ'70_H>HFUS
MON8)MFH;F8CKJT\KJ[X-G=9C<]A'$QI/;UE>K]E%J#7#5-IYE'V&]U2+>=)0
MON>^*7-Q-..*X>HJ$;8<P^U%?'J\_LLN`31;#-T>)$0]W;`.(Q?3,!MBUBJ]
MA3FKYRR<HBTM2:[_D"FK8BR1.`J>!MC@^^)61`E1$9RN51'J2,=]UTD<U\O0
M3/4\?-[-"=H9$S]U%HEM!*F+_FL,+R0W,1['=L7ONS#$N0[S3,Y@X,(G$<OQ
M')1RK-:]/"KU?:?C6@-+,VS'U2Q,B[E>#[$6/=WMN[V>OR*Q\@C1'HH!#?;D
M$YV2T!D;U@-Q8%F4C2%]MQSWX_OLK=*@#H5UO1GREBJ^9ERR^V:NHP4V;.)K
MU\[JV[0V(`R?(7"W.GJWXW0'FN&[EH9\NYJGNYZF#RS7UZV.TW-U.<NJL@IN
MK'Y%S$I`5W//TYLBMQ:D>LO5K<CR/[0'1XP\N;6FA'HVTH"/.,YU^R3>"DJ/
M+?M?:'^V:Y;\"'N*M!YD,U]5D"LG>Z=Y_]TQC8YMW1NF8YG6%C1GRQKIM2Q0
M@.5I1LL=:);N0/`US+ZF]SROY5GFP/9[TK'7@&N69*EN1%4+*1_X2/P:C_!X
MEP!=W[M)Q8[XOV>2VUAX_8/"/.&B`)(^Z@;2N=EN:S^>P*TB6,E?U9A2;+-*
M\$3RNAUG/_J^[2*V8J-R=A;W.9$+J!V[8TK6R-UYNK;",93$AJ9K&OJ3(AE.
M0I,MW:G%D4,B0E2;ZK0=M_TGT*1IV+NSZVVER9)KT7$,W>X\B2I'(GQSE7+L
MOK_,)L-DAP-!I3JL<ES2G.1TNUZGUT/2'Q/^Z</DS]4'IF:;;;-EV_"/KBA.
M>K]]\/[KQZ6*+.HW`''SV6=Q0ROV<?Z13W8>"S^RFN#./>@3NWS&KL8P*)H*
M4'Z0G3.8D%W(RJ^JY4(&#SK,$>VIC_C.8[]UE6_KIN="T-=\!PD(77"GCH\,
MT79?'QA6O^]WVK+RU^"(0M:S5I.FDOTP$FF/Y^(F27<@_#V(CJVSOW^!!@,5
M8)\%[F['4;+:E%]5<:V."P'Z24!(63_,`A[])GCJPY6=)X6/U+4$\UJROFNJ
MM%SGJ]GT8!Z]945IE5S[I5Y1K,=R[6228``#_YW`TP>IYIP!K45(_[75:CIR
M3V"J-D(Z]/O_%L=V99P]Z+JA6Z;>MJJ^VZC6HM:*@'_A*0=6]Y85!_?5RAU0
MFZJUKME)FSQ'PX/H\8NQJME5JM18-8;;48(LX)?7U7&O.KZUEV1YMK2=,[L"
MD;I1$OQ^,,OT?5?WV]#U]Y!VN-WJ:J[G]K2>X?8'NM]S#4MUE'^+\K>C\/9O
M-_E;$`1_35F6SR+QT]D'[_//[SYJW<NKJ\L/;Y@^S=\R__+CE?;EW?\-WC!C
M<<'W/KQ[_]L;=D5D)!_%'?N<3'C\EJDBKBX_P?/N-#^K?&>(?W<N&"$T&7(<
M9PR92.BW1OIA517B.S_22_37]`A5=E;4N%+=YZG16W8U^-\K[=W'_N#CU1MF
M?5=6\3)F7\0T%[BP\C<^F;[]]M[3W[;T<X8CS!H?C;H-USMO,ZCJ`B,+Y?#I
M-$UP/05?P%>9XNJ'<0EX*]+>H/CGR"U#M^6O`J?S[&X<!F,H1(Y8B=AFW6<#
M`NC*KS-XFJ6*I9A=)RD4$98\S-,BQ;]R(JF13^,&:!@IA>5QO^=L6.0L3G(6
MA9,0,?]Y<HYES*LL7TP(B`!OQO`OC&6+',<DC7OT4RFBS)RPE(YA/<=*JG/`
M&G59NH&C=RQ%W9^*%.2:D$3U-]'KJW>)0$?>O`"E8QGJH'II1-)MJ2W&088)
MU!'"4C1#@6D1?\2&,V:US?.VW:J8(V;_Y''!T]G"00SR#TM6XRZ,Y&@]C`N!
M^JZ5+A4J,0HKBT+7SXJY\U<<W;6_>\O^-?A\]:[GO=>\]^]^_O@&RI^2\V8Y
M-2!X$W^ATP@>C-D,^H9S=`;&X<M3R:``-]',DP14D(]YS'(1TY/D#B`$XW(*
M)OXH>(0BV-\I-X1"\B2'BS$M/N+5A9L&DB^[](7*HFJ"%NB+H-FP#B<M&A5=
M3>#WX&,!`BE&/%4:*.)(9!D]U4W`*V`:F(MT@K1!+$%$\%V880$A:"I/GKJR
M60&F*6L('\,Z7C"<(+(I!`)J<I*M*Q^G27$S9A\PY5JM2^EQE=``!8WYB-H\
M$DS)IBAM#Q:]N4G%#8Y<X/LN1#3':B_*JX4:*.?A8"-#U3R\8?RZ.%H(7]D/
MKNOTF,IS/'_G%^+?Y6GT%"OZ(;@LQ,]:'</GJF.M:J.R:F1O3;*6!56]"I7^
MPG1P.H*[=YSZ/O2Y*$KN,O9]B!Z<%!D4F/WP9G^93+Q0K;5>T>S<BY?*IR->
M5S77AU74O?S<'WS6>I?OWWN?OL`[`<C$IYDX8TAXF4UY`(&&5O3Q]Q2[%_7[
M+ASEXY_.VLYW9XQ'X4W\TQGVH"(]8T-45(I/56N95G^,RO?=EAR6D%3YJ/[,
MK2IXF.30N<R_Z:Q_Y5#7G^W3/];UE.YCU[.-HM!WZ][T@/"--W9Z%ST*W`@N
M.$T_:8:VJW$JQ*+T#\0KN/@-DS\Q:H2WW2K^]2E;U5<UXS*P?$M@!IT9TYQE
M212.SG:TRMPDRQWRJP$.;`!SHP%P^'-8E9^^P*U7'WM\1%TWZ#`:@XXM!@G-
M$<DF\WU?Q!SFV3"W_6'#2/0()GUX@`CCE!M090(#E6][O<'`]]=8N9SA-#6[
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M";[P"3K%X&`HIF['[;3ZAJMY?KNK67['PJ.H?`V/I[+]@=ZS^N9)0$Y."U^R
M%LVQ8SXKS-A$<'2C$9X8)#.A-X@9Q9.)Q/GBY!Y,>U[S,-5ND8Y!75?O2FX9
ME9&>PR`J,`7*5".,D@J"#\%WBR@/)_"-:$99M4"B+QCRN<!M*&"QY1+S:WR1
M?$MN51HVE<Y.[V#*7>;Z$:8A<J@.E($W)O3,=9)>BQ`/L<XN$#@[/V,IX%%0
M8#G92AFAD*:499JYR/"CE%^/..CW2S!.(B@&WY;JG20C03-<*(5T`R]$0I,%
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M&%%F$.CO9(4)J8.F@Z:X##!SJF`UJM1&A!8][4H,F7ON=BR6_5%@)+@6U+&4
MNB^5#<6`37GZ>UVMR.TR;_UWH-"_ZA<FFX111-$?J@(7C/("%(+?0W%SS'V7
M1^E)&ZP!0U$II"?J,#/L1R$J1+,3Z0_\`GM<AJN[DV*B3#55HU'9#9P^=&8;
MC3P>.^.XC\3.N+MC9]JO`)9]TZV;$]=$[M3H0_[LF>NG!@N4D]RCJ_U%+]?B
M3AKL8[!#7-47+H?A)T]-/?ES+RV1VMIHP3DJZ"5@`=P36"8^[>;ZH+'MX[?(
M1R:+3;WS$JQ^0C9V7IZ-C1>!?CGIEMU^>58W3P`'\J):MOL";7P"??9+2NV^
M8E5.)^9N@55AU_5%JFEU'OD58EB,<]UIO;;H5ZB!_-6`&APU"X/D(Y,XO`Z#
M4\REOY-9[Q@WV./V]B+-*'DXQ&2ER+(5N8E,)B8"=3H'[0U%?'/)4YC)]#?>
MYY2DN>5I*/(9%ILBXW(&#W&97I:IQ#N.9[H3U3MM^)>''%*JX$8AJ,.Z%BO\
M!I0HJ=UD/,L2)"?`O:MA/L8"1T6`!`B2B'V&_`QA?(T9$JHRE`&5`[%$%(D@
MQ]WQ\,Y4I/"H9#>HY=/K^Z?%_902C7+O]#>4!<=4Z$(?B`2(?X<($[.A"'@!
M=\,</G>;1+<@LXK-0<3#B50>%#+A,W@8_C?"HCCF>FNF(!W+AR3#PYC?"MK_
M/Q,Y7!3Q.94R$E#U1"$=J@6,>4:/X_%*C$`"\ON@&GP;3/5'$<I$%*6CKT4L
MGP.;$^N#2@[#32EPTPK)$**"M/.Y\I$X410$F:PN?8A+EGP62E?$G#G5$%?K
MACR2K!!C(7()F-C^JR>2'[IJ*)T<@R0HZSX#=T`_$@%QS*G46UHVCQ+B(C?]
M1TF6J882(`(*6P+2!I$"H='%0MJ'/!]*P48(A8A;">U(61+0\Z#6*DT(XZ-;
M+G.+DR06,T9-')$`BS+H>^<L*X;_@8_0$_*>I!916B>!)_Q>#C22')/XN`>"
M#"];FO+X>9*LZI<0@Z(1NG[I@/B="?]=S+D)"#G3M#NU,<5P\I:-DSL0.*U[
M_`1JBK65KT.3E10J""P(1;9H452*,HEJVJAMO"5BRI^%N<11(*`%5<3GR!\0
M#C^E!"R='=O8!?.RK)@L("!\.H4OSR/2M50WOU'M%/E&X&$,PB7LB"J-*D@P
MQ!43038I7\(ZKC!-*L@"&#/1=:1T"K-$%!E0R%3BW2CP9I+II:JXH8A"<5L!
M#RU`)M0(5YBCT@S1-,1+`@TW!4\`103(+("I^]EYG9EB'I6JP"C$`U1.`Z$0
M0&I,YI^O?HZ3OC8ED]?FPUL74-9'J5WRCHP%'(,VNX%VJ7!=J`32.M9!F223
M]#!0<S1LGN.Q/A0VPVQ:Y!+#@Z.D$9CZO&YY(@M2Q"R$YRHM2BTX*<KT.@8&
MU,"-ZN,6?4(V]PQJT-BA(M40DN6(1@.8R6B!?H(D+M0PJ[K%\$1^G151/K?O
M;D%V&>BS&TZG@=L,QF)41.+R6N;9/\@9#"4?*P=I]21'C3QPYHJ..3TT[L=I
M6V:[,_"UEF.W-*O;\C3/;IN:UW4[EM\?M-W!X.BXGU=@PBLPX168\`I,>`4F
MO,2UN5=@PE>0[7@%)GP]S?45F/":OGP%)OPI6_8K,.'K;]FOP(2];/R2TIBO
MP(33B;FOP(178,(K,.%1'`B/7_ZN+Z?[/$S_A<F;#XL-WW)KK?SWX*OF?L>R
M=-W7-5-W;,T:M#M:U^NT-=]O&8YO=P:=@7T2NV51,^Q?95[+#V/,AD*`>K?8
M94TF.AWLQEI$PO6\\I4MXFC0+,QRR>B?R1WY^`>4A)G66^2MI_3N.$ESC7:[
M3GCZNU`K\_.#S\[+;>V8UZ13D"F]K[+X:B\H/*50'?7\$F6MXUN1YB&6&B<Y
M<A6@[J$,F54L^0RR:OYI(0;F+20J(L<-P%,18%Z*39.0LLN8Q@"%5E@=4A&)
M6ZR(E`:!'XAVP>P5Y:JSZB<G'/GVAZ+,I&+6#8J,>5ZF@15L@Q6QRK#.!9M@
MXB_-9!8O@\!#"3/X\'^*T0T=1ZIX(E)QC6<TP#U,=<+'YIO])6`%7J?C-3`5
M>R(@!G^1]0TS1(-09;E,"8O[8,SC&SIH(1`R2WJW2./+<UN_^<O\S((LPRW&
MJ82>8!87_"2[ICSZ`J+S/;%AA+DL]`<%#R'5A.#<4_!N*&*2@$<3="'G-R(I
MLM+*Y3[C^<<6)5.*%$JG_$XTDY]7J):AR.\0E*)*F7)P5/P8>5Y)'E(ARR!@
M#:7VA=IB7W5WT@0Y;(6`Y+KJ[))[`=$#<%,21'"Y-UJ+D`:UFFX?AR+%K/:L
MQ`C1N19A3H0:$A\P+7+D[%"@"?G12A'H[V"^>4$H"P(UYB44$OV5#/$`%0EU
MD&5*_UY^%$HHXM6/AUDEO_B(A.*NHT[KN[4G(;PGE1J+:&F]_:5(4/7D9!F1
M"LA&+QU`0F["$2(H`@2QD)VAI(I#S0W=1%>1^RF?0\A&$""68[T7G9"*S*J*
MWDF;$EA$'BSSQV:E??.7A>=7?&-]DSQG(J32)=0I0H`>Q?+R]RGIIK5"-W-Q
M:XVA*3`4,1?Y1.(ZCB$"Z*@);5?"E1"AM7((00?<\&SS^&%I=+#<XTOTD1HR
MX/MJT"#I@NZI+ZXQT"Q"&'0^\O@E>=Q3.52A2):K$<K*@</_LW=MO6TC2?<]
M@/\#L<@`#D`*O(M,@`5TQ4Z0V023V6^P3PM::MG$4*3`BQ//K_^JJILWF99E
M61=*YL/.QI)(=E=755>S3Y_3$H/_UE1256LS[][S`_Q>`?=1$J_^0Y'Y:].&
MF%.X?60._*L:+PMC!@LAQ%(1:$C`"@60D",`.7P01B1;9OPJ'NZ(Q8S9G<`?
MP6^C)9.N\=(/,D&%\`=1R`B\5)-+JY:D@HNH3DHEAO.Q"XG)ILE.?(84Z2>?
MHWD6HO#R`G"&D!B6Z7/\=1)E\2POT9!>"6Z30@S^3?PH9;3RVU':R><PHHA!
MIY<1'9LD4-")%F]H+Q9_98MQ-,"R8N;!K"<R;$O\<;`)+;>&&&8!\N"(+%BF
M,K3[&N):U/Z(1^.R50W8U`V25*0])5)0>,O=)K\E^3[%RYQ1157-JCROQ(P[
M5U%1A8+/3,E]@OQ`KA1-HCKEP#D1$HC(C6="0&R6PQTK?:LZ(*^%J#`*J:S$
MQ^326B3#)5<XX"!CR1*L([R4-[M8K&!O;N,H6VW4!UPQ@0[F<>XG?RD+I-.)
M800H)F/DR8DXL$#DRMK#U_O2XWYPM8$K:(VFR`N2Z"4>X:%]D9:I.#@@C.W%
M$27J=?\0UFSL_V,J)5WGC<Q1U#D45V0>+)8A"]QY56!^#2*-ZSI8!D:Q`#"7
MOZH"X:L`_(C[-O;,_PG=;)3.JPDY5@\[)'B#HDWUW^'"%K)N9558..![HZ?B
M7"<(EL11B?D:@GJY"EA.]A?XG+P-#SBDN=H;YBBNYH<'-%;930!+:/Y)OI@3
ME%EK@[;VHJ&ZE$'VITJ3LQ5IB>6C(>KAN;^`A1Z"SXNE5KZJHW,A-61Q3F$'
MO9PQ-B>355:4I5@=^ELQ7H4BX".D<C4TRQ1-'>7Q7_?/RHHQR=M7GE.H'4W(
M@;.UV3!_);+^`L1'#+-(4##6).@8YQ+<5X6<(]10?E"V!DK(-!!^2X$C</SS
M1KU)W97YEI?91`WX1)K*O;3P4717MD,VQ6?DT4WS(:P;`R_FJ2@BVL?2D/<%
M^>&&E%=+\L5</*\DL!%Y+?D(!D$!F>?U>23<I*GE8L5\\U"/(N@G'5+QJN]R
ML#R`[SG$GERT9-]\9.)RR@KGN7N1DZPY&#KA[M7`CH#;DRTWBAHTKT`7*)")
M"^%R/0P&S">58B52<0&_8*T4$H6YGB8O6L5R0G"DYAFF=K`(%6ZK;*<L+D^D
MK16]V,IM4.Y;OUJOOY'_`NF*,7QS#^T:H,/P,VG)5]ZH\%:\U8?$BCS(PG?V
M)??M&NYH[#B*9=FJ8@[ZAN+:KJ'HCJ9/^@/#FKK3_VG_T_[QSV_F?\N^[M;H
M)Y']N>7X:[1!./]2#K2PYOQK^#NF;#QU,83''@CD/U#[X[%A#Y21:CJ*J8\L
MQ;&'$\4<NY/IV#"UX<1M%<B_M9!Z5W\=I-YV7PZIWR"MN:_/NT<?]=$=\/X?
MFKD1>;]Q`;^V8]GZ4Q!-J(?U[/J2IQ6)[$G#?Y+^_'7\Q[\^2H;;LQJVA<<L
MF<7^ZIFC^RUSF>?.Q_!=D+WZQEGT67^#?=ZSN&C+^XRE9-D$*BJ/G@//&I7W
M&QW^SS?1LW"^(Q3O^,=;=$WN&_VMKFV)2&%3.[;K_-J%CXU1K@QHFW*?+>PL
MU69+M3R`SNU(P>9D.8KB%:I2((+KAL.[^%[_C3?[B\TK+YF/FD2?&9XN;`YS
M5L.6-5<[ITYW?G*I?G)I9P`NYU1/9[_.?IW]SM=^E[[^YZ?R.,[Y$6R=;V_O
M5LL&K3^;=\(7".TWSNF*VR/9Y@V^8FB_U^E]V>U.P+_=\[*=!3L+=A8\=PM>
MUDO?/]?.-3^TNA[NRIK.LN=FV5<4C)HFV\:!"\;..&^HFKZ<-U>=_3K[=?8[
M7_N]C3?/U2,^9_CZN2L*.\N>FV5;7E%VQGE#Y?8EO?;J+-A9L+/@N5OP-92M
MKS_77#\R/:H>3/^5R)@.2MXZ'L,WH]%(&3JNH9B.K2GNP-&5L3G51H;6'PZ-
M=I"WU@PC?8F2MG&UCAY1"N0L0PFQ%-`G))$*?VPF[(K"IWA9"\J-.EL)$EB$
MMP%G!D+MO0QY,@L&!-)CW)[V"^Z"#*!<MZ]D\:@3*B!Y#5M2`ZOD;W#/!8LY
MET[)-O(,:YATC72C,S_](.?T*?0PLM75._XXH0KK_9388L%FQ#Q%4IQ;ZA-N
M%59KP>@E=RAG"/\W*<G`?F=)&OM(M-3\/;_EO@(4@M.>FN.1,ITX4\4<#X?*
MT-4G"H3GP-*'4V?8-UH1H*59)#1(RZ*S2DM'[#Q5Y5DN&DLA`1["I4>)`DXP
M`"4Y756=,]%/,\XH0MR0N:9UE6&&Z*<X)Y,X1H(1"L_U4^1DG.>L7#MJF2(!
M$+4S+FU?,"8A#U:%MH/(F]YKJBKC9(KW?:]9%OZ!=T$R,<Z%'#SDE,DY5^2C
M;,,3B``0-I.OU%6=MXK05\3:&MV*#]^C#&N#\NB^HE)5)P-]I/45F!Y=Q72=
ML>)8ZD11==V&*S1MK+5+*71=HKJ0E"8"G9S2I2H]';);SK(HZ!L7)")*3#X5
M,AV8=V:,7!S_L>*4V^,L%B+(G.@8]:;3.V1X8B%R^6S%15BTT.-3)SX9YX+R
MV4B6IJD]K>!*PV83T=-[JZ<6G^9LZ$0*75X.H9=NR8KHS8G4NIQ#X49BQN*,
M;9;3<_/G]:31P](;HI0T\?$E7`<<-7GAOS&2YLQYQ#%\.#5ZCN>XHQ41(Y5,
MJ0FJ4(OYG-->)6DV)RGQJW>%Y/T,;N#/B=H<<UC@A\1CG*(0\U:1MRE>ZI'U
M+4;SI0_?(+A3"$8,1&KTWN/+T`>F96FZXD[L@6*.S('B]BU3T4:FX8QMQS)-
M^]CQM6EZR2U#H\ERL^2DKX6\-Z?*QMBX)F]\NW*\??MUW$%]\^7<09IV.AJ=
MPS_[['ETUBVWF0^B6GH^SN)KU>?+FGF0*U[0G<:";[\].GMG.33+R/ZIE7:Z
MX@C=W#-[S-E[UNYQ>YV%7@:%%)M_:('K;.C'_I]WZ<B%KXL%TC/GU*%9BARD
M>9FWTROOU[R@WW&WTK(.K"&[+\]N:_\N"^7^35"3PRP3+=(?7KPC[N9HKM&P
M_VZ?B4>WOJ.7GL"G61SZA<+;PO^)_SX^\=EK_<`\L!YT6_S]T/V\K$Q.3-RX
MO8;,]3$J9^PNL'M"YS9,]VUXMRY;AGEZ!S\GU-CE@+SWY81ORVJ77I\0-'ZW
MC!T<#R;[ZC)6UK0#)[Y]&.D4IC%DW6T!DOB<BA[$4U5P37-&DLI<:(B(.I<H
MN/2W5S"[7W)H76NR:NT<6Q\N,:2N,::L@YBD*Z_:6BATY5577C6\ZVS$9Y!\
M6.MGAEWIW-3+++1V-(=Q^MKJG":$2SK?<<PIX9+L]N)S,<_C`Y_2!QR$J3_W
M@PP!I]^+\PZ3GURX?!I'RQ%MNU(M_W4Q\>+0#V^3;RS^CDJ\>\<?CG1KHNI]
M3=%T4U/,X;2O#(S12#'5R<2>:'#E8'IL_*'Z#+RW!!<*:-\=`G8)A$OG[J,L
M35*/*T:79TJNWM6DMF$<E'P@<OGIF"VB&.6EA8P\88`YZ'M6C@IB'.E*`2HF
MT"ZX`]=*[O"-+\0W.ITVXMN`%=D;`5I_$'[^MQP_/T'\/-W_9E\KZ;.W[.LQ
M<IN'X-#HTFX`VH?%/'F'CX_*W/G5[\GSYQ9%A;965&PA*[I><30,V#K@\Q6;
M[0<:L?:^D1$<JPF4K708>0D5)!T3?JTECX_-DAW3D4WGK(0)]]%QW9%U[<!O
MF2YKSVI4\7,IHM.2YP?3<55;[KNG!EX>O]M]V3YTC%]ZTO_]&=*($\P`G4+>
M2:+)MG&_^L!XOTM[*7\Y^XV=_=JP7[MY6MAZU(+S0<GH<M^R9-TY\&[@^1NJ
M[]BRVX;S5.>4GR]I\Z^SX'YS](MH!?>U'5K?;AVSF_2`G$@#=^@,IZJK3#3D
M;-%-2QD,U)$R[$^,H34Q(>N.G]TS77KQK1\J,`=]U.@EG?B`C^I'FM,P%RJ)
M_S?[J)5_+[RE'SQ\W##%T<M4NR>A&6@`RK>KC?N2E:;83[0$S:;XX9R%Z4?S
MEYU:]C64/F<A*QU)5Y&#2+5K%$3TSI'8M])(\G+:/-R?#2(/F606WHR4BCCE
M&%[Z.;H+$X&$S?\]KO`,Y<KVX$%P_76Y0!E]^OQY/"K_'G_Z(*VR.,E0$@D>
MSSD(JZV;15DPE^:Q]R.$6/J!]\M6^%-D3;J]C9%)BG&FI)*6R0^I[4E.+[B(
MXB7\YNK=IJ4ALAXM_22)X@>8=E*6]*1?0\[B)"@4O[-52NP9:$1GC5(J23+<
MG8X$61)^5[:/\YWQ)KPW>E:-5@J)IHI/Y,=\:>*F/V"4I'D&G44CK.T<:7VZ
M5='"ZC?$.Z7)@C(2M^A]&O(D)7:Y*^)7BS/.E-_O6?U?RJMQD]T+PVQ)QLC9
M0_"&JESOXQ721L$C_!4JP/+^$E(Z"(K[%\\MF.1R@W'K^47/ZKTA>W,#B`',
M_;4R!*57N9\2&JT890`FBK%QU*\KO_N6?_=!(KN\UPV]YQIU<Q#FX#'Y56.:
MT0\7W#`<4W839U[,@_5S%CR@G=QG_1('_+%G2N_[%6(S\DN[UV]V2Z3UXZ$:
MLY*^#Q\;,Z0\1!_+7>#>\P-Z*U,?+9D/-C+[Q7/B\RNR"_C(LJ"U6DM']60$
M-\!\TA@E?L4^X!-ZU4B:7HD&N$DM'JK18/9,O2D:Z&9FS[75^K?8(_Q^/8IA
ML#Y[8=&6^A!Y2TY=QX=FZ:4X)S](G'=-F*$*L-DX4(]R7#VGX2B`[S&.OJD_
M#+YK2"R"#I*3I^9VBKW"U@7Q'-X:3**YOXAT:?5,N\EX#<9!D$M*;H:MXAU(
M>&\@J<Q8;H:B#Z*//`E01!:FVIP.1HI6AKGTG5(`TE?.6=X-@B"]-PVGYY@E
MR(@;Y[WNZCW++C_N20/(;_S)2<T'%UG,N2S%Z/IB+H&[<(-N&@G.?%EV=Y#=
M9DE:'97B-@2D0J;1OUCEFB1#1)`?\F'%,/4>:&KF3>7[!8_,)"4PB<<4C=$-
ME+R"#!%G6^@E6ZZ"Z('!W2&P_0"#C_OTNK>8/5YZ!)5O"E[1AMZ"_>%FW!C<
MCY[F):58QZ/V,7:U9$TEO[]G(>W[>>#Q>%J'S<NL(J;T:10_(H_DU)&/?;_>
MYCQ<8S:+;D/B5WZO]O0*%V0UDPBJQ9)<.*JX=G-LHM6J54:E(6JU(=5<4)ER
M<:[EF:O:#B*RM$L*R<K4NTUJI=B`D8%G97YRQ_V8_9S=(?DK[:_:NBF[IED)
M0K[C>E60-"/G)S7H-H9VKKPX]T+J4SZ$X>V&.;4R/ZY^?JH7\L7?Q01;+NN?
M7G$U3=?J`18%T]RH7\#$K5H:/.MG3RP0<C>Y>L?=QH-2@E@!>*Q]AR_!RZ7_
M@Y3!'J2A%W*>[J\_P5OFTI1&F[N.![?@^%%^H[(4@8JX1K):K@L6?HSS-"8I
M#`4JJ*N,K)3+:;4`_Q"^5G:PR>F*+_^@O$A-01I;#ZD\V-JDAXUQ>GWK%[CW
M`R]K?K#@OD)#6T9>&#P(F*L?IP\P0#_S?%,]/<A1L-X"KI*Y!=$LV+Z@O%>9
MO<OF0O(QRC(@Y2$-CQ.Q)19O,%/YT;S2R_]@[I964>(3#O<;TO1(^@UF8@_I
MJ[W9G0^SP+SF`UB7P`0DW5!=A<C<P"^+MBCD$_2/2CZN9N,4IP\<:_3%C]*U
M5CG_5C!D:]`;^@%GU`57J^:Y.2RLI0CKJVN]Z>HD0Q8MGXA1\?((QY#/C$FV
M@L4H9&1\`5F.$S2XPO=[0U,_&A)]"UP8*UB<"V_%T,)8<MKN+`YI#J)!JOHB
M7W&6Z17+V+7$>L.\N!Q4M`O<A=P*<C'8C#RK<?'U9>WF"4Q"V#W^;"S'P1$:
M[L_OSAU9^`@:&7L/!4+,,=WT<(I%^@'$LX<D9/";:[]B[*=:1TY^[5=_RDN,
M)%OFWO@G%A#?4\@4J?0Y`AOB3!!C2ZB!JR!+H'C4K>9RNB?]R7A5Y05)5&-8
MA\BHY"1IP:AO6D]5?RGYPQN&`B<I/R4%@Y,OY0;U@:$TE[>36HT)#5]^R(VU
M&]B*K_+*OW_D""CVD\4S/Z%,12DW!^QCXM1T3>X;[A;U<PU%E?M)@&53C+&$
MGA;FSV)ER8Z96:T4RV4#!YA?X:%9((H!GW)G@F^"9@RJ6NG'NE`VW;#RIH12
M/19C\;P0DKC:R!4OII$UCOX;+-+N46AESE?]#%)@_4HJ4[?ANW[B->C:T11(
M2`'-F%XPY(_YCD\I+TSV_@+544U'&X^F<)4U5<R^.U8&VL16AD-KU._W37<\
M:(<6"Q3X(RB0,:<+VTAD'.E7*%;:ILO247-WU-PG?O;9(_Q?AF.OIHJ.FKL[
M#G+^QT%.U,V.FGM?<=M1<V\:];/&%'?4W,="\;:Y?Y=U3J2CYCZ>1[>^HY>>
MP#MJ[K/R]XZ:NZ/FOESO[JBYW_"IFGTYX=NRVJ77)QTU=XM.19W"-!TU=T?-
M_1K_Z:BY'YNDH^9^>X5"5UYUY55'S7W;47.OUU>GKZW.:4*XI#/2QYP2+LEN
MSYPM/Q@:4-\`M"L.XB)`HWXZ8<9/;64)(4X]//F$J/$4,>B(^RZ/YJ2)%(@C
M7CFZU@^E?WD//[QX+DLC&(A%%(>^1T?29E$8XADU!)J*,T1P$P'0S#&KQ9WJ
M;9K[R2HB0/D"VL?1C(LL"!!'7ZQ7X.N@\0WN!D#R,6T^$,<@<P`NGIX3R,9&
M8&,':SPJK'$#B?>^/C_9H]\PFNCDH,8.WG@ZZUX@O/'D'>Z`CON*X-,!'3O(
MX]%>F>15'^(=69B\XBWZ\9&.IG9J),'1,(]:MVFT@U/#RDN9!7[HSP1A0O%'
M&N-Z49`VG!^&1I-UXS2\DZ=$Q9U'$+0_UZ_B:,$2Y-N!&%BP,_1_2]7>FO?W
MG0XL^1(D<!3C:SXZ3QU[L^.>WNB(X$\S05@MV/XYYPGB*V<PPVG""\YO5M"U
MG6$@Y^KR3@LT<\YIP_-RL!R=_=J`A6E+YB9@<<%D6MG"VRV)!ZW'O>BR81]X
M.7C&MM&M`Z^/+FU>N"1`1V?!_<X-V\@MO(#BZTG=>IZ\OY2Y^P]\[OZU%4QU
M.IQHEC(UM*%B&J.IXNI&7QE/'4L;3R>ZYAQ=C[X#IG3`E`Z8TJK=WPZ8LGO?
MSMYM.F!*!TQI;P1WP)0M5V#G_"ZZ`Z9TP)2]N7G;G+H#IK3)]SM@2FO"H@.F
MG)WW=\"4#IC2`5,Z8$H'3.F`*1TPI0-6=/;K@"D=,.4$V?X<;-,!4]XPK**S
MX'[GAFV`*5O#2]9@*2C\ATPE+$XFI!O\[RAE#5)W^T*EZ!-M8CD#2W'&0U4Q
M1Z:A./;`573+<$:&;?>GFMT*P3JG)U6-4RYUW4\2MQ2-1+DG=6K1NO^LA+HX
M#IT?WI;^Q344UP1R446S62KXJI`@+R30:YJMI:QDS.:,+0D)4Q'`OD)Q]UR)
MG2M+DL:G^$FN.*S+?=>0=4=[4F):B*#?E6K;,R^.20#R'G4=23G2T-6Z3#!<
M';-9X"6)O_"Y%&0N0T\RU?Y<0:U;;^5#Q=*3!O3@QR@(;@531C7RYWK<V-\K
MKGN);$%QU7XOH0'Z6?<6_'L-3O4B3>P]>Z.ZP1O_J-`FH:"GEZ5W44SJZC`@
M9!AXGBJK_']/RXQSZ624?*X,.@RYJFJE`BF*0F\:Q990+[U$G3M!^B@+BDQ;
MMNV*EBO<IB;:BB&BR6K?D`W#D0J!6)30%8HP3]NV.3&@GFS(4GQ+/V-LGN2Z
ML'G+N#BWKO><4J8:9:ZE.4Q!LY3DZP-OQK7#O5O\+[[CYV2-2>HO,92O4*D9
M8H9TBL4N&`0CR@!3&O.X.&O=)B*>A#0]=F.M9V6_9HC-#`)/\(1)W@JZ\Y.>
M'3Q([S6[Y\+U%2ERKD3]@_OGY\_C$7\T3_\\#6*;\%?7.$=*]H<>#"B.ZBR-
MUG%&3PTHRJ&7R<BV3=E0U:<[@B9K'%+-T&7'5I]T"UEHXB9>`%^7$LM".;UA
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M`]UAH-L;P1T&>LN7_><,>QA52[I\!;+3:^O38D(=TY%-I[_5Y1>$@=#DOJG+
M??W`';^L#6/^#AU6>9CX_'N&+Q#"<W1ZU5)EU7QS3F_U^[+N=KJ7;Q2]TMFO
M#>B?]I8T'`_4\%JK^OIJMVP?G(^,GRX[KG-X>>!+,)2APS2J=ZBA-XMYZ2RX
MWSEE&]30MNB?.F@HE]_[!A5[.@CGDUR![QO,E+.'O6.&)OV)H5FFI;CFT%#,
MR5!7W&%?5?3^N#_0[+'I3@>MP`S5=`D+JY#MVX,3:A9/E/P$VD*;M%X*`Y>D
MLA2L:?)>O=NLRMN3QIN^EF@/<.8%,R'QFR5\;Q"WD&(/YP(E\$,F+5EZ%\U+
M]`^VAE\L;H<[R?=B.[3<7,X2ML@"*8#%9))O,4+1L4*UKWN$B"0L37!?^9:%
M+/:"X`%^$C.&.X\)NV>A],"\..E)7QKENR2/,#T-3:!=VAPDP-;:$8L-U#`*
M%0Y*H$TS^/VR;&10RH;UI-\\'\(&MT49F2!F*\_'G62T`S5#FD$Y=8M#E>0[
MZ3F6@\:0MQ?NCB--MJ>->+H%](C=P15H$EA\1TLF74.T)Q_P9O!!AC"FQ[NL
MCY/'MEF@GCM&7G('/\;_PPL@AV);#Y0X=-,=:GU'532\V#2<B3(8F:IB.ZH]
MG5JN/C2M5B0.-`<JU25W4L4J/`)^HXUV<IKO#(:G1-6W)Z=4`01$V84S"N$'
M[R"L(=`"'[HU%P`-[IX<V'6%:+TE>#RF`HAC[!^!35Q5FGL/%$`\#Z7DWQ#L
M!`$KD!D$&Z"\`L9CI?%ZW)QTZ'[MJRJK&"2T*/%33"[4(%R>L'B&A_/_O[TO
M;6X;2=+^WA'Z#PQ';X0=0:AQD02[>SJ"YZYGV\?:[IUW/SD@$I0P!@$.#MF<
M7__F40440)"B#DJ@Q-BC98D$JC*S\JK,)R_<\%M"M417WNP;E<CX5'^2I-H%
M:`KZ#3Y_#AN@TP6!C;>6E1&@.+%4(BF75S`%\-C.<%>T-!^KB)8%FY.<S;PF
MI&%K!L?23UMXG,-+?FBB?I0.-V]K%8-&C/U@S?%6O(IB+*2@VB52RJ@)M0MW
M]@TCL^)EO`G2+T7Y)&B%HK9D])M[[?JDP;1%%&M8MW)>_'D,$N.&[B67Y"Q=
MK&Y@SN/[N78,N4CJJI`$(#'=VR,OEYZ7"HU96]G"CT,9":F@1JB]$+0%J>]S
M;#*'IP&1@C6R!]>P(7:R*3<#-@NA0P)<QI[+938N+`DL$3ZQM8BC)3P$7W/!
MF'^@\7&9O*L-<I$YT$C!B]6)KYW]Q%]L2`W+)P\<6#1DEW#\N%(+#0$\#7?,
MU@3XBSRK%4XTI?X"2=QF*M1:=C"_0)D9J&;,\\)/[`NPC3_?N0P^6PB9X1&C
MN?[SG]G\DJOTZ-Q'V#*J(<>`Y$L4]7A-RP%;%F1S+B22YU9:/%`JA=T4O-UF
M.<];?X6Q7"-Z!;BUZEK%N0%3'8D*9]5QXD7N,K[M8ATE&8-S'M440H+F`X<B
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M`V/FP_5?B3=_&W[@LQ)>#M#3SH$[[^3!9:'/7_*3R#:-WM>_/H]?H42!20N2
MO[W2K`TOS[`GCNDX76T\'@PU>SCI:\-I?ZQ98\.V>[W)I-<9@I=G.*_^T#JZ
M8<"K"RKLOZ4R*29NC'*??/3BSYC;'+J)/P-RCOT@HTZ%!]S_5UC,5\Z@JJ0P
M-P-E>.AT-!UHXY$UU>SIR-#ZUF"L=4U]HMOV=&CWL+G&Z`(EC'/=+,APPW;*
M>Z?X:/)CY?/Q&X,P&@_ELO?Z5G\T=ARMT^GJFCWH65J_V[<TTS',26]@=:9]
M1*WMO/H#'Z+IMF8IW*Q;67GMG\#YP&HOW!OHB2"BD&7"QH"%_Z&V,K*<SD!W
MAIII3V$KDS%PPQB;6G<XL?6Q,;3M<3/2%I(FHFXUITIKHL)3-2?:**UWKJQ7
M5I6K#CX'S3*P93,K?)$U>?#B`;DWGWI<7PV1/]:V8R?!G!Q8Z73#`S9>5'&Y
M\96HL.,M*X5'P)E.<!1YH!BW7W.+3-<CX*(G%62\WW+7E0(G\?0HOG1#D65A
MKX0=CO3*C^=4H8XJF1H8T%$E/XA"#O#5:=\0N/A@=W,:P!^"];^1"F7`LN0W
M823]2S>EZG;\-,1/'E7[_]:"T`"#C0B,$M[\^#/\)1(I"W!X>U):/[P_0X.?
M44M`\7E*E<CW)BF0!IQ-Q07`=`^O1BP`+>2,Z"89TP8;BF1/RADK+*OF-)#P
M%<2<=Q']P#N`:TO^;.K-KL(HB"[73+DD6Z%S5^(I9<0*^7-S8W&^74B++(Y8
M+`5=A8BJ.\WEC%:PQ#:,F/Z#SM\%^IO^\B*+^1E9B#'4-I%K+3)NWZ/RHDLQ
MDKZTS,IN\I?S@ZE`F[A+R3W9>9&HK37"D8HQFY9YY*!<AN0X\S.8*?E7&Q((
M87R>;[;PB:NR3SSC(YEAKZ7,/(KV&W;L6(9QYYY_38XY".4"I"H5J3KTUE?`
MLLQE[TZ>ASP#`3%#ZJ\"K^`DA!JIGV;%Z<X7)C^"[GM)![P>??J0O&&Q0;<5
M%1E^DXZ\M[$SZ@F[\*[<8%'I*SG/C<`-E$$A%N@/"HVH805EBHX>'X]UH8U9
M*CR7=B`IP8=A[O.)OEBSU.2108*:&40HP:AF#DX_Q6*H3T2L"5]:^@$V`H4B
M`8NA$.<9\%7"WVZ#8DS)Q_;"&&1;Z&5:K4B]"2U*4(W%V<8EY($>+`])C8%L
M*?&PO36GC``IL(XXO0VZ"@4$EI03#R."@'/U&%!2(H=?+GJ`<L&]P`AP0S)V
MVP8-;0-^#\[K'*A[7EPO?737?+R)R-0"J!H3YASG<N1+\1#PIA050Z'P_)I"
MVCS?#8=CE5;2WQ2YB>/#L;2,;9'CF`.?Y\J;"54T*%$Z73F'N8IIPT)3/R@?
M3GYZ2*'E/I'2'CYCV<E$[SFA5GS,`,(R^4,'RG)W>G97GUJ&9O6&$\WN.QUM
MV!F9V@C\SJEA&1W#>O26^FZ-FTE40:9_1.$,TP+JMSFN)9H"3-S2P47YHLR1
MOR0E2L9:R0<H&2-6@'FMMDS/YK_(GU/[[2OW&BR+YZ$6)E&/\Q02'`$Z.G^=
M?SYO_>=@\+'U6DW'XF_4_.L;.N'YF`QQ'&),?L=%<@M_]U=(Z_J<D@7[7,H"
M@\[GY`AG89<^8766W_QY,BJ_&/U=N<M<0U%__0JS1&FJ."GI5034B;,`/;69
M%Z>@PN$!40I^#>ML5E(%M13/C#:%KBP<XQ!_B3=Y8HNDD(E,X+9S/Z'D&SZ4
MEX')*^G^$E'*&AIC`4KRT&7>=@ZBPJKA8<%!H9L2=TE^@T^6@]03/Q+]SUIA
M(D^4LI=TA^+._YF)]+5L&!5_1KL?!FM!!E298%?)R5._$GIXUX#IO`5?1X(Q
MI0O%E7(0=_:3%LNDVQ)YN\OW)O`0<%EJ[ALK"4],=,JO\<7'`ML619LL&^5$
MKJDX0PIAYA$YOBIMYL7D'5I*10HH/+F*LF#.[K)+YPJ$XI]9.*-]D,^UX\)A
M*X=*:H+E=I'?]BY@6?`5NC]@GV]7/ZC@*6?-X"CPZ=^QJ$$8HM/PB8X9RMD4
M!``4H?;?*&(+\'[F^<9:<%+9P=O2KLH75)*+4D3X:AP"P_0JX2UL?T);G,4T
M%S6,A(4/AZPGY`Q^/N6:+]CAGN&YDB\D6L'/G.A<"PW`8K&/E=[/Z-9DL@YD
MEL<=LSONFX9FC_I3S1X[EN9,I[;6[=G]T;@WUJW1HU\^ZS5F>2RA2SXUKU9%
MO3EE?S!A[4$Q--L2$<*OI?*!TTB%%!B0*$$J^NQ%4'M.NRTN@1(U5D7M1LI=
M+4IA!9[7?.PHY\C70=$$E73@/N8^@A]X:,POO/0[6@JR!7P+Z2[ILKC%;BY7
MSN`O2*D5CG!<LVKZ&SCH<\E(^E"N0,KW27L<I+I#42GBB*AK@U7])S_Y-J++
M:?SIH4[/T+(<VS`[FC,8ZYH]-$?:<#28:N-!Q[0ZMCTU)\-&)$]+M$`18%JT
MD!@-.TU<95*MAFB+Q$#=!6&11RWY*AAOQQD?+'+%5A'>=_GDB279Q3]!LY?N
M*_$6BR/\,JUD40,*CD"9`=E!\94#W\!1X2LM]2"4K]7SF]*:,@O:+"W1IQM3
MU4<@AW6YA!5@4%UH#RXL*#*Z\+92%0O=[U4(@/4@+;P*)3<,ME->#M[7PGH0
M#0,6BT^XA`=Y?+5*\:]`P,!M_0OT`>@SB')]O*C,[\PEH]*BX@.HI'`+OD^(
M&UZ5]B+K0YJSH/A>EX3;3WKU7H6"^(^83_@"T7_BDGN5'!!*SIHXMCTPQEJ_
MKW=`173[VM#I&MH`?F?WX$O=43-4A*&CN2'Z:$2@EDJAABD)56S9&.%!62+B
M"_FO*',H2,,(T>WA'V,X3)2:0S\V$G6:B#7D5K[QF6ZTJ1@$!7DD4U6#^;6?
MX(T!/1+U$49XU#^"<#EVA[![Q)G?RZ,6R>R?#?[J=I=VNT.+5^KX00+?(2T2
M>^2:QY6"+MJJ!'I;<>RS";[%9W4#=:CH?G1Q6("`VO(Y_WGMSRDSB.J'*V<1
M%`4+=Y-=M"V3<[_\UMYGMX(>Z8/'A.HI3"MNMZ\,0GVP@:9C8V+8%ASU/N:Y
M>L9`<_H..-23Z<@9FQ/='$\:<=[-\];G;+G$@!O8HQ"I55"I)<GT-,?_E)P[
M)>=.R;E3<NZ4G#LEYQX^.?>HUO:OA+8PD;?Q#31:N^W*-JN",@(/P*,BI5`<
MH411CQS???.4<@11XY\MV1W-5?)B(>-RF6VB&I'BD);JEU-UX65U6G_"SM7B
M?ZP!X%Q=OB[2A^C+8J713$P_C'U/]CFAWBI6#:0)?.]:J?0&!9%$'-_FM\^M
MF1_/LB5B*\]$@99\(>H/PMU,4/NE'EN5=6OM>PC$VJ(K:FHE49(7RCO4\@YQ
MW+$R@\I<%AD$X82*C37<>0JE:'T`_0Z1>>!1V84@-W&!:HZ"@/L0?(%TFR^E
M[O78T4`I0G%(*8^".I,3BGDU%*Q>U.VC^5:^7D;W)*+B0Q+%+\6:>MD%Z(?7
M47#-,B!)B>59147:V4^EFK1VW=B/=MY>*#H-Y=_6I?0)Y79$G?TMCNM-N-C.
M4^-BU]18<M$YM=RV/J^`$D_K^=\&BYIM%@DRVTN.K[&C@F'9$0>=TE0DQ=C9
MP$U'>`;YK++^VF$UJQ#JPD51<;$2*BQ#*B9(/]8G;LN@5J1>_[S#CMSY9J"P
MS4\X^TDX!R+U5O>Y=NL2K22$_W'D<BNI)S1II-2[Y<MB&PG>SZ;3]+2&<HJY
MU/^5&.K3?*MOBV1F`VWG#7Z?FHE5JW[5WC]X4BG?K31HU3<VY;U[K96[QC]B
MJY-4<D6)J4!J4]6>$-MB,H"PC%/VZ;D/IFI9J`NIV`:Z:US9!L:C:*!:13X5
MJ*'1`(*V19D='($8#,VU2QUWU&VCA&/23R]>R5UYX..)/#VW(K5"ERP:1S=D
M`.#@BN`OWQ@\(<7&3KH.J+4?HB\&SG)$'6&A*%25K4+"]>7P9N9CY-J0(M!I
M?M.`1G#N+6BQ(B;T1,B-MP(SCXWV]R)PX5I/-.VB20?+U-!=I@0JJ@G,JBVH
M.2JW@ZW7\$GOAY_R0]\4407\.\0>GX"J?;'YG0KH4O`NHDSV<N6N>?ZRXLE4
MW>V*KDIL<R^2>OG=HW@*U?/ARTCR9.OE$OR0C',2U'V&F0*LO"M9\J*F'`66
MOT'H`0M5V$MM<=P7Z'+\HG%A:''%`[XA1*@0Q*REJP24B/!,_MMC/OCA*L.+
MWX3=0O%2Y1$H[\"^_$'D\_WPE_D3,HX6H@NL!J1S+Y[)\KWY44J+U'^<<P;W
M1]^^+?*2_1];K?J?1%*CT);V;_^312G-7*;:1PHQZ-"S`'!,R0T1-*2<^(RF
M-=YD=+4%D<2OZ&\##5ET:M=)48-(9*HD>LL\E86Q<'+^M9MH:I9+D8WM1[+=
M\GQZ^IQN2[!/)"9=+O_=)-I8-;3)MULZ#-4-8\6#W')#]/H7ZA<58X-DW`L:
MH-Z%D%TC._V'#>]@T^*W98R,+L.9TC!4:9;(B^H+%0;&)_.D0UJX*J3)\D[U
M.L?A'@1_8/S_?1AX_P$`??-^`P"Z_=L/`+">;@#`Z=6GL0=UW[T_G+MA[\1S
MWSGKI!(Q-A[HO0X[L*HM[S3)9"OA?VO]X^WXRW_]VK+ZYYW:^LMD%ONK&^Y;
M&R8RNR<`2"_T067C*/9LOL`]/_"PAX;O&?,$Q1(HG?;H.O"HD8'?J2!9V)3\
M^*#O=QUK;;1[UE$!O=>M8[_-5[ZX28PB,J`P\2%7>*)4DRG5\`/TO*9DC+:@
M][4VT/L>58G>P)[3L3D,2GJW;?0/C)!^DI.3G+Q$)/WG,UGD1+\3_4[T.U[Z
M/??XGR<#\3WS1MD`7X'=S9<-'F_<38/CGZ,ESM,YMX]$FQ>88FB^U)F]=M]T
M3K[R2YV9=*+@B8(G"AX[!9]7TO<?E;KR=:/]X9-;<Z+LL5'V'@ZC8;2[UH$=
MQA-Q7I`W_7PR5R?ZG>AWHM_QTN]E9)[5KJ8C3#^?G,(398^-L@WW*$_$>4'N
M]G-*>YTH>*+@B8+'3L&RAOV%FFKK5O687=/O;H`#;VW.`2\A43-\0PG[H>1B
MMPL$/-D!G153EO/IRO`,,0M:G>9\R\G*C#R^7$6A`!8G/"$<QNO%Y5&_#%=5
M1LRZYI[LS3[P';#I#',A,`0DT`9#"?#0Q"#UXI#1]_#WA*\59?%,XJQ$<R^`
MQZ00I]`41J7E/A_T6P!1M&GJ>#9#<'<YB3S9G'I?7N_93]4Y\T!9T;B'T`6B
MGZTA7?P[>U`KL[$9WDWTII5PQX`V$8Z"E`",`L`'ATLR@#/#3X;>?NB3!#4M
M<`00317%1CZR,L&:A+``:*$Z?O@`"5<.BQ(*`&E-R@3)05M!/CECB)D2S&C+
M^^'%,S^1X#0"*K38FRJ`Q8@T@N4*"!5!PFP14G6[`']$V(%VZSI">'I:=HXX
MA+NYC*-LM1.8=.4A6)`<E8V0\]H"<2NQGX'.9`SO6T4\R"V'_U=>7MW+.<L!
M?'<78*<J#(3.?0N)(+!SA.(NIA$RL=TX(K2%JGP(:M;N_WUT75FD:0J`<N#9
M+,M'DH9"\\##<MSP?'8)+TSB\/)@@TBBD!>?DNBJY04A64FV<6?^#]AFF$G<
M<.9W'2XY/".78Q7+O/PY1*<"K:M`.^4"^+-UKL-#EGX0"!A&FJY=6AFJY,!+
M!=A.X"=RHB$/>,$WH8ZB=Q'.VPJ,KS\3OY&(3$R&*M/*?"CA$7VGF;#YDGF2
M9\X-`6I3/ZOE+`?E%<\2XBE0#@ELTF,0=P46J@"K/%,FTK0"A,HIC[B0SU..
M9J&B::-\_LORJ<`^*5ASM3,R"#F^:@UKP!LENE'L"04%O*;)F3ET])G$!!;S
M%?/5)%Z:!D)NZ>!$,S'K$ZC[=S?,W'BMG(<^(JL5.+<[:;&!GB]E%,75NX,V
MQ7?(TTWVT`>!=6-617C<"6=*$/):`E7N4GDE)9_;XKFBP$8DM20CA*.[4->3
M`PK6K5S`7EVLRZ<(]DE(LJX*R(;N`?P]QRC,\=_F-20N3!:ADY-XG?VT*6`H
MA+?P!F["Z#2?&J-S-V2O1&EO2>^.H;+01H3%)-M$X/R7+'(B=/!,\%J"Z:J4
M+[9<DJ55E/R6%'\3)NMLV_"=U_3H*$N`=<F;>T"0'24`4*][/P"@WAT`@'I/
M!X5S\%<?/11.E7![0CJ(>BMZY,4=<Y4'^<;>F!2LM!]V`T<O#0='/RF5YSVM
MX!QZKR/I6#^VB!WUA?-0.-\NN9K;8]8[)2WODV*]<XN.W>WN]=7#-5,?=H=V
MQSKL_HZM4MG:*>!ODR0C"=\"J/GH@GU+^[K)?_O`_'^09;\$5(7CMPV[CPXG
M`C`VO&_AT5,>EW;/L9M_8!YBJZ\-_:X;??-R#,+G(OWW7$S"ZT[G((QOC&#?
MP^;=6[*/J7+H^13Z/I3HO2RJ';]'<IMH=1?><U-KH^\1^!U+G>EM2?*<BYJ?
MFX%Y3D5MCVEBGA/=FE@,B/>A>4F>+,BC69,XW*>8\0-60];8J(-#2X4%5!&(
M(TZI&B2.LLLK4<,G1J3@1.143&<^^ZD\QD\9WK?//.,GGK<W<I.K=@O_?VM2
M&A\#BU7J*S^7(5R+Y'J#IN_EE6P)33:\`AL0K(&QL*VY*$EBMG`1U1F.1%R"
MQ%#Q`D^MH5J'OMZ:NVN:(1X4HZ)HGAU-8I6%1G+D:[6&\9S)*0?SE,H;E>+4
MN4>3L*DPA(JGHN42:^0@$+UPPV]T(S^[\F;?8'UMGAT..]`N/#>FW]!87-@`
M54(M5;QR.?JG7"/*%$BP*`EW14OS>=YL77DHK0EIV)K%WMS'^:]84Y/D0[7S
MCY[]E&]K%?M+'MU,!5OUL,#:!BRP*.>B:L2B'@5<O,)TCW[;+.8]+_X\_DV=
MZ\OC`YGS^/ZBB(7*XPI)\,7X.9[3YLF98+6%<OPXE)&0"JA$P43H_4AI\C2.
MP$6=`40*UL@>'B);$3M9L(*S<I5129>QAQ-R>:X7\))G6:/Z.ONIID2*=[5!
M+F5F9+FR"AY"7VQ(H>RGC1KJDL+FD?<!G;;ZV9=(62Q)7//<\)D;S$2I-==5
MT1/D3$J>&T>37[$R:NFE5]'\?.<R^&S-`C_DRA@NB,$!DLJH9[((&G(,2+Y$
M48_7M!RU#%R>6UGO'>4VA`\?K72+Q3AO_564FV,I.&ZMNM:S2@7[[4O/\W64
M9`S.>41R5BE<!C'#<9FY?11R#G_U8SI\H!QC+"@"4F.19+UVD?7T-,N]EI`J
M^85>N^;AB6_#O#:2B_R^7WFT2U=^J?H=+!.L>TD;_AS[448ERW`HH[A:$MT6
MS)1"-7,SM/[S+"[*[-`NL`)+<,2NL")4,9=3A?0!3LBD$;SEFJM<37A>N=*_
MR$S.L/Y8C+$.Y[LJ^U#>Q(A39>@A"@^+&K-@S4-`97FDV`7N(%O`0?'%R'87
MR\OR>:$AS^!$MB'W82OK@M!GHG3UB=V93T#&V*?:;#3"#796J'*5JZ')^N`(
M6Y=*M^70<JPF12,MCF4B2[G+"6L_S=B]I.&'HHBY=&3)[G"]LC#(:+'9J,_<
M>"XKUK=E4TB8=M2R2Q<H+FB?5Q-CC7A,D^.%#03U\;.AZVT,4/"Y/QN=#OZC
M3>X8ZFQL.`G6TLV0PQ#Q6);JAEFQ"836>D^\I,^>W-&.0JQ9*?3&B#GPR4^^
M-4Q,.2:H^J[M';U$A5N[(9^R"I3%,T+M!'\*UG*T<[41@$N_*[22+BC0JNC!
M2$4X5RY;)3D2MJFNO+S>*:;-TA)]LF_T%'$Z:?8L^.9SGT;'LWD&\6(WL'!Y
MX6VEF(.T<84`Z+VWT'`M@3RXG?)RT+KBO/J+P(?%XA,NX4$>&T*RF4H7RK_`
MAZ2IK7,?S4KNX4A&I85_CHT42N-;U/)"8F&%]DMRH5E7%!1_XH/S,4:2BWXD
MC%%7^0U=<XY,:9&>7"0*$SEWU)PPBQ+P`SBD+#PT^#)$@CAGG*6=+/<2&QC^
M+8:CCW?]&5Y!^K?.`88#A'E0C5PB=GL+_P%7PU\6CT-G\9JUME*)#^[.(D,\
MDNM\H*NBIX7^1>5]Z85P,/!@T]QL%"=TAT**9,#$_.E!S$Q^"'A%,38=R3GR
M]4N@6(9[@,2<:V4=LE,EC$)MAF<[8'%6VK&DAQG@>\_!MI%GQ'<'(7HP*VZX
M03H(KX\<5PJD"A=]IX,NW+X=WC4^#'Y!S25/?([>%BXZYL"B\%+[DUI_>&IZ
MPPZ4JA5C[]KWOD,$CFL.:,W"[K-JSO<%@4"(+CA\'T4O)4E1G.T+/!R4_/!C
M.(#`UI`G9\]1=7KY_'`Z4:5IS%*J)"*\NZ8HZ`(L3X8R+QQBE$+PIL)R1(22
MP/[>++H,2<S]1?6<P1H22MN@Q<E`=^>II04ZX47+883G+PO2(E;&&?"D=W#/
MF%B`1U%NR:?N-&[>XXE,L`K1T^6&(J`I[?.\]8\KGPW#MCP(";,(,:Y\;/.C
MF>R%751B:-&0C#M(1&A,I,9`"YOHE/A(-4478/&\:]%TMTF,C>:U)%MA]%O>
M4-X^Q#FV#>&IY&NV!;F"81MAKMSEW3SG,VHHLQZR5<EYZE:E#8TS]A8>==5]
M:I[!+NL7E(-$Q$AH#CA^6;@SCJ`5V49K<J:T2)($T'D0-N.<=EM8D-*Q%UW)
M9<M\X2:8GY"&;X=-R]>!\LQV[<O61M"6R#+*"`HD=R[=AXP;$HLD3GD/<M5\
M`1*!@R(821_*LQ9EO_JIPROJN_Q,?9<2FWA;\\-3"]\_9#.CZ.@'$I?Z1@7L
M`V?YO)!^+K=44FR!<=(_L[",`U!I^.>FTU*:N'+;Y4MIV1HYMV7',<HB&5V2
MG;FW7*F]IIL=P6M^>Y2EB4A*;#4JF!:/@@H\`7V[$-*T'.:QI^OYE`C`!0P#
M=_9-^SP#\J&3R(NK--:"ZWE1=-9_]_`8PK-S\QI[8&U"_G2+<F07?A@M,9H5
M3P!OW6,T@$@F3M%SA-/FQ=@?/LO]Y**AMK9MF!3)]T(4X-V:BO5'S<Q%,)VW
M-<NL'5]CD2PH/H[RF@L//ZT:,1"I<E\U95%(F-AI%0K@3:U48!82_SHO.\3H
M8C3\EO,3$!M-M##(UUX0<8`VX?TVS?LMK7>NK%?PIW21R"9+1AF<SA=W'FNZ
M*10/R&\-4X]A#.`LS+,9)@%!GC'5+R_WT'^NOJARM9<([SO>LM(SZKU/$(<B
M4)+HO^9Q&6DZC<$ZBIQG!$225V2<$>2G1_&E&XJ0EV4L$L?>C^=@VN(<T0>]
M.Y_N6^AJ,W0O:=^@7'UT524-X`_!FF!K\,:`/-@TAF.6_"9R0OXENJEHZN'3
MX$O#`?8\^"M89<RA1O&ZA7`WB)=#2T:7'`]R:?WP_@PO%K*8M:+\/-EX^=XD
M!=(@IDEQU8`Q`:]&+``S\3-7:BID3)O`=%H$%*'D!]#9YYA<!*?"B<D!$T+@
MVI(_FWJSJS`*HLLU4TZZT2I/*3U1R)_H*2>HAZU"6H348K%TN5N(J+K37,YH
M!1A7@5`IX57L^<N++.9GL%NV3>1H3C>%,DK&N;S,RF[RE_.#J;>;N$N9%L7%
M6\%1^4&1FC!B,<9:F:<J5WX&,R7_:D,N7+]<><5FB[NWJNP3S_A(,N2("$^3
M`I%'RG`1?%'DN4#4`9$W05N]`I9E+M\BR?.05SHLX:CXJ\`K.%FZR"`+(A<F
M/X)&IJ0#7H\^?4C>L-B@84)%QGE/RF%6=T:V^L*[<H-%!1OC/#<"-U"&KQ<(
MAD2A$>'"4$$1P90(R(5<&[-4H"D_4]`JW"+I0&`9)#7Y#20FE2,0H003#7/$
MS\$[7]0GXDX;`;L@2@<5&HIL&&:NN)Z!O`;V$,#;`6*1H(?@7`5"+]-J13I?
M:%'<HW*V.1X0%\JP/"0U7IAO"Y@KOER)=$PSO`Q(.-6)`@)+RHF'-X^!0)M"
M&!8\9(6O`T3-!?>"7)VJ9.RV#1K:!OP>G-<Y(A(5L?%'=\W'FXA,2775F*AW
M6/*E>`AX4^JE%EZYSZ]EBR$G'^%PK-)*+I)NB,7Q*=68$<<]#M"$\E:]3,7W
MSL]AKF+:`MRF=#CYZ2%=83^QZT41F3:D`S-2['S#/*[)<A5$:X\3:7,?6`-G
M<:N3@MZZZJJS4;BDH)-K)G(4,GD[I0F?G'ZO%"3FT0*]"W4,HB0D1:*>3@(]
MB&^G4'FB4H8SHR8%KSV9SZ\X_&$>U><I!JGGKJ4C2.HB$56-*&(*%$\4+R#&
M@M56ZLGR.X>D=H_H_51VR1%9HEQ1E".V`KV(PR\VV$0;U#F>)D(Z,L>N<`#R
MW199^_SY&ZD6-X7C>Y&I=4#-,-`31N=BWK,@,5O14_2$;/*Y%M5]XF)2W>MN
M:E(>1T"*U6!ZH0DJWUC6A:W>EG6*NYCR2M5X]@;9DQ6`^3T0WE$*=N)]C!N'
M3Z[)WG*,_,7]T;AX43V7#,B9(];)*B`6=X&EA@*$Q*?[$]H6'C3<&-:<L=TC
M%<=WAGG^#SXBKT`H-U4NFB;[GH/6Y1JP2$\FI?QD76JC./+X*GQ$4H0TF^\4
M")6YE-%I0/45NJP7X2$QJ2CZJOM=Q!G?_2#`Z`+])5C<C*^.Q#%2URN#F.+J
MA2JXSEL#Y7Q1F129?[^45:5G^J2T0:Z1&=\\NA\%G8SA#8>K`>69T.N@G1(1
MJ^3F!><A$9<$OAR<,T5BL1Z"2$W*+Q2(D^1QRR06R3$5"\U`V7.%I#03PI+"
MW^@JF@(&I3E`V@?P^&*?0G!Z#\N%*J_%PZJ/0&L.;)/W;R!P[C<O9$A=59(N
M//$7]!Y94"GU>-Z:TAL1VN_""[V%GR9YR6EAVMOB2_(]$%0E)!WUDB:^G\"'
M7!52TH6SRD)<<E@H,T!>]A(+&J6/@DD=\;[SV@L46>RJ!%(J4R#P7U!"8]WF
M$(@_+C,R:S`&H1MP^7F4`7\NRDZRS%;NO)[?<1M/%BTF>$TR6,6"\03F[]ZR
M^F(I<\KG2$5%Y0Y+".VNP%!1]+OK.O"VUWZ'N2M1*/0G4*9AYFRTD3_.40O)
M1:7?(#'Q'[LAN:-P2PEY`:I9KBMTA;,IPG4_S*(L*42,;HWWKZY&CRK!^_@9
M_+.H2"M++%ZE>$M:(+P2#$SJX\_P3+8#9Q)AEE*1NW'!6Z_!>O@S/WW3E@"I
MH@(II")=>IT0;U`?;/WH8.(!?&+!?`_L1'%L?02JRAL]!`!NF'Q"-.O/"DE<
M8=X/E[D!4PS4+^E5>=^$2A#+12Z]FZ&.\?8L=3D7H)1CHI_`:64*$LF+/F]]
MA/_$LD"P?!/8YCS%7-C`B`2\>$^U`F)>R%_-0@1VOM+-@N$H')<T$`C*+**$
MS(P)%:X<QR7,?:Q0#N?RH*)OCXU%&VFYK>49$/\%/K\&=?#W2*/[3>GBHL66
MP2G7:5;YI#JY%*>*TCCPL:@.1S@!\V)M%'CE.?B%'R<2M?;LIRJAY.VMRGD_
M+G7^4'\R\R`G!QHGO`2D/_F)6M/'R-)Q1+[L7!0,%(Z)S!`(`HJ(BGXL5L;"
ME=_'"D:>MSY@8O2SMTJK12JZA"JOQYO?D"X@#^H714@*@=Z:*ZS*&*Z/Y0K5
M("E,+"2\^4&J*&^D*L'2;[P(W0EEK<I9(H-^]M->)KTAZ8.Q'V1"Q^^ADNJJ
M16F_,=:2P)/0C`EBP^G*\RU>\BOVIK6+(($;\Q(MYU>I(T^>*\ZDLKU5M:#4
M@>B+Y5JPM%C)^'I&"4'G(M;Y/\&WS9TVFCD@"O:R)67O0BJ2YF-26-Q"V,HV
MM\"/IPIR[](/0Y&/+EZ=)^G.1!,3ZRF5.+EVJJ$,7]YQE(+M.M&UU$RH%KFN
M0=*^74NY&NM1D(I]#QHN<!-UY'2&))\\(I-UXOY1&4*QR&5$ABIU/O#93S=Z
MP6U^4+W8^HE,X+E+2@&ATINU.:.Y%AL2/244*A"^^(7GA;3BU-?R5;Z8,'D#
M#OR*:B61/S14LJ2;-]IWQ0@0E712O.%01)0($7V-LO*478A5EN9WS]LY>L+]
MOB7NMW-[W&_KZ7"_#_[JHT=ZW@IJW-T):OR%5.L[4JUX48#*M1(.G3"T[XLK
MO9L%FX;LQ(`'9L!N8.\<T^O!2-[\#5N/+F-W1O!\<OVYAU-A5)R*&P_4IL=1
MP[#76>AF<Q\\GC<;[D<S.-9<)+^\")[R-4K4=U]*/CHXJ=%V;*=M.[V]OGXX
MD.%'W[CIM,V[(PX_3RSZW4(_*F5V.<0^.GGOZ]UVK__4,Q8>?]N]=O?09_RY
M*_U/-UQU/8$%>!&#"IIWFKI=HZUW^D]_G(X)?/7YX%2?Z-<$G._=9F%OK@6/
MAYQ];Y>UW>MTVJ;S-!-TCHA0/:?;[G<.[.0]-_W\G$">3Q1\6!V]`9/]R]R_
MQG_^_DN6:)>NN_KULY\/1Q[D):\?P7S,?"_YXOU(AP%XQW_`]UN_R^\,X$/R
MOJY`:9Z(J[II'"U'Q17=A\5$5+1\]&*JK!HPO`T6I\#S/WF+O[WRHN#KQTG?
M<2Q+TS3#-G3M?X!0YM?/7\9?^_I7=&%URS*^ZJ]:6>CSE_CZ^14B<"*V6?*W
M5V_?3U^U_/G?7OGSKY;3[3J&\W4T=B;ZL#_1)B.SH]F./M#ZIFEI3M<9F7I_
M:!NCP5?CJ_7J#Q/4-&CI@C8/LL\RZ0I$I`_QF"!SW.##`I&1"!B)<9&(_.N<
M^'>F5(42O:%AC:>.K3GC\42SQ_VA-M0M0QMV+?C*L#_51\Y7_.(?*"I"4F[(
M<9Y@HTZP42?8J!<)&[5I2^ZBW,KJ\?/LRIMG@0?*5+1U?>;^4E*HU-&I-G0.
MN#R2M.^GG`(?J5!JA(@`#ZY#AY-N;ZK;'<T<CBP-;(>C#<!L:-/NP(+GV!9\
M[+%U:+=0H;=L*95-#47[$'4IN(FHZTE:KZEZ/,H2>&#RICD%-7O<I3U]/8VS
MHT)E6U%+]^GJ:0[^ZJ,O.KA=,8?JTE!)3?%TKJTI_GTJL3F5V#Q#!IQ*;*H;
M?OP2FV;+V)TTZN,6W.3LJU;>U(>@IQJ<FZYCZZ&T[DO(6\OH70=BVD=7A7#'
MG38@$7\\53;_R5CTW%8^QW$+"0V3N#Z^X?6=[M/,>WW*<CKSZ67]F"Z=GL^E
M]HE^32@*:*Z[\@7;V.ZFPH/&#_?NB0#L&=<DW-7+.[`)?&X&X3G=H9\H^+!&
M89\JA$/=^Y2OE_Y*\`TYPO`#W0F9(Z.O]T==K0=_UVR[-]6&1L_0G.FTJP\&
MCC7L]1MQK_Y70K>,.0&(%\VZ2"\`SQ2\HKS/GB%K8T^.G(UB!F834RK_<S#X
M*$&6Q"B]1(`S+\5XT:7[S5,PIL6`Z&R9(P\P0!X#]-$UNAP&21=JA*F$N*2E
MX;<E9,&SG]2E"XCA8J!!&!'FO3(YFA$'$?$L7Q<\(PK5*VN\J(M]3TX2BT)U
MU?(2>JY@MKE)Q./V<DCA<B4!`VV*%_+,BHAF=$>+U&,8^W5K[7L(6-<BW&&:
M0Z[,4E3>H6)VB_MXB1@K[L01!P`AJO*)CL7<;,202[S`(RQM6<,@L'X6\":>
M0>H+,-I\*76OQWMRQKJAL@.&&4"@!H97S"'N8?6B(@$1[Y2O?ZFYV4=^%C52
M-)!9SMGSP^LHN&89D*1$G(/BNO7LI]*%:SM'\U8@)=OY`#\QRR\'T#Q3L5&I
M2D`,:=Y4T!L:M:SJRFKP@X)>/8+G85S`>C6<?V1@,J%<IU*J/^<B/<X/P8-?
MK@]L9S0V3$,S1]9`LR>]CN:,C9'6G?1'(]T<3QSG\0N4S!I%:IRW5!J*X@E$
M5<FGTPQ%`4_#=.QHO72'<+01E-!=>1G.CFFWWH:S\];K*H[,1DW-^#?&E"Q]
MB!^H?N@-8<"T+OQH!=9[Z<[H-312FH_6(IIEC%-U]I,R*81@/]R5&!>:XGAZ
M1*UQ+[!BA(&778(+2CQ2F00+A>-/4=^$\$D:CUHZQ>5ZH,`CB+'*!!*L<''C
M*S>(%EY(0-H(H49S;,3:!.XQH9K@JF1EVB5H-7K=V98"I,3#,0$UKVR]&_X_
MS='-3O&RLQ(F2NW[!/(H,&&%15&2$)4E$,X4(@**R<NDGL9>@`#*A(;V899&
MB.!CP"'%6H\OH%03A-^D9_"W:`KH5D)>`2'_E;DX+%.@WRO#>*@"2L*6P>M`
M2MWX6[LU`B\5MA7Z+J,$IN);7/`6A0B52*JU(0!7'\+=&&5J&5:"R*X%9!A/
M=<.VRS,51S$?O(0(=5D\NP+NU7Y+XF;QZ+95[%^C*5T%<)1XZ@A.B;J\C+U+
M_/UE3*@W:,!Q.C`\Z6>S>^[@O(8`C<[93^+P^`F5A^6(?'`D?^Z<Z_*#^#ZJ
MR\-#YEVD!=(:+D*9KN'B/&WE>T'D*K-+A`/FXPB(U(L%H!J9T24-K/&B+`G6
M!:K;YOZB;:0_^TD0GRT\GE$D4DX*Q`#*"2$@"26/B"[.N8/.C5BXN\!QKW,/
M3R<!@^<K`/<$Z>P)'[&H?HS0DQ"(SV)(!+@=["L2;A3.EBB]5PQ<VRD=B'='
M\_>"8J1.,0`&B/6ST3WOY^M&U"-D4/2=7`RQ40%_2#X8J$[\!&+MR?.^4?17
MEF%<"^$3%\*Q0S2WB3,^9>NWI&^>N($$ED>D,(E#+9$-*]+0)G$O<998>6YN
MXR,^97].*GR<9C%#JA%KWN/$X!+A3+/N\*MBWBJ?!(Y+>+H35I+N>?`KU.7C
M=_.W$I64DI`E8FRA9"_7%24.13,Q48;(\7<W!)6_5JC1Y]K1MJ`_@[\GJ8)9
M5V<]SLH@H!*G%(N2-?A!X]+B6&#HGE?JJQ=>+$A2JSJ8,_5:+!]O@2<23QN&
M68MB/Z4%KZ+D-Z5`JZJ7JZ>59;?^E(I)AF7PRH88N2^56N)\B!"-Y:@KE`Y1
MTR)06ZEBFN(IQ0L`YW?&4]WQAY68*EX!O!3H?:A*=P%>ED];OD*7J]7QS6>E
M<8`HTV"?C$(]A#14?%ZV=NA089TV36TKOD[:?*^5(&"M&VX,5B<H9%J$U7$*
M<3C/?6\ND$\$,&)&XQ`PG*7O;YTTEH\D0BZE$BB:?64<Y[86U>.;$_9(7LNS
MI?:)(!\Z2BS'H-5FF0/UO'0GEC&V1R/-M#M]S78L1^OWNWUMTNN.)^/QT#&Z
MS<C-G7"H3SC4)QSJ$P[U"8?ZA$-]PJ$^X5"?<*A/.-0G'.K]F]=..-3/ILLC
MCXE..-2G)KGGSX!3DUQUPR<<ZOWUYQY.Q0F'NFE%Y2<<ZJ/O&#KA4)]PJ%^.
MM)]PJ$\XU'L]X81#?<*A/K5,-K&_Z/G0[X1#?4>7]81#O6=;[`F'^F7W+YXH
M^+`Z>H\.T!OJP2HHRB$VDWUQ?QRH:FQ@#WH=?6!JMM$;:W:_-]2<KC'6ACU]
M.NPYG5%W.FY$U1@3H@64:&0WIZQ:RE(_\/\M4'+S]C99"H#%[CGT.`,ET[;@
M(2EN3"U9R@LKYC)J@H](K&.U><[W9"O*W$N]>.F'7#W$)47<$.@1IO*%EW['
MWM)2%Z?H[Q15PV=<;8ROXFY-7/*6=V+#9^S!.EVL?A1E)F=8XNHR*C(\),Z;
M3P.7KJE=K!4/`H0*QEY";C]%C&AQU:RNUZ7K:!5C&:L[$,RY:!&D@JWOU!M+
M)2(%P"L^TZ<B*ZIY"?QOV%Y`(,N((\SMK[`2X((L)G>)B%5R\X(%M'3LN<C@
M^<LI.%`D]C+SN0T913<+19=6BJ7*0I)9CC'4YXH7*BV1F,U<DW@%?[NB_@OL
MCV7AX?Z%5)3DM>"KU+^JE+^I\EH\K/H(+-P!MDF@;1`X]YL7<B^?*DD7GO@+
M5DNRH'II%H>RV`6[92^\T%OX::+T&LO^^[;XDGP/]_9>>%LD37P_@0^Y=#JS
M%4$2NW!668A+]:/8H,8ES$L@0JKT&LOWG9<[!5#BL?89FS,21,CFLB\N`\J9
M@E4]R(UP304V\N-<WH0/6L'!#>AH<['-A0*7C(5T6"-REC<#R79PI06<"[N`
M]W#T$JPL$:]_C44B;ZB_`<C#R,MA5"P83V#^[BVK+Y;"M6%246W4)-U8D;07
MOO<6LULVSB-UL_R5]U[Z80'?N__,!S^);-/H??WK\U@=_*!9&S9\`H^:CJ8#
M;3RRIIH]'1E:WQJ,M:ZI3W3;G@[M7A=LN-%Y]8=FZ'H7_D\OMKIC$^7=PF_Y
MSUB\/;AV_0!=G2\19[L_*T6Q7#G=0`H8@@)FB0*WW%BEPQQ/Q?LHS#M(^%$3
M<4B:1P0':&#WP.E32;![%U67%'N\\,3SA][*8]R\O79?_6&4>;UM\1M>-[6I
MC#W^[]N0"/1!4H?Q_1]SPX8]<4S'Z6KC\6"HV<-)7QM.^V/-&ALV<',RZ76&
M*.$XW,4P*EO>9S,U4EVC&4HG!$SE9S=0YL4,\GK-)JM!()&Q*?P/L-D*"<M'
MB3I>FD<-&[1!QS`JVF!SZ3>=CX\(5^//GT#M[7LR3&![9T,;[-Y'==>L*S["
M!QJX0TM'P>Y7-E@L^286#ABP17[E$PUR0=''AJWF;1>-N7D3.W?M:8=WT\"#
MVK_9=:F,+H.M>]3$N,3P_M^B@W$L)AHEW-NX]+-E4AC%)MJT'CHL9;&^V][V
M-W%--E_V;<Q7O6G:/"<CT;96')"DH:<>E%S'N>'4U^^F3(./[IJ$`NSZIV@M
M8L]#[7<S[ZI/[<%HTA]HP^ZXH]EVIZ/U>U9?&W7Z/;L_-'H#>\SF6=EIW9KK
M=_4E&LP(%>YCC"Y]NOX8X-C#<#Z!WW*7=?-X:P)OK;)^VW\_93I,73_^7YPU
M5GAI'Q9Y+6+SM@Y!F=US[-+>=^ZAPG8!<H&#&M\*R(</Y*]^6$P8;JUY>S9!
MN$U;KS#\QIU45)G\S(+B=)`(22%TV!E9,_D0CP+77S:1\4B#LC:[S88J(^56
MB%T03[U'U62..1H84WVB@0"#W3*F76W@C'O:9#2>C(<]TW*&';Y!JD09RG++
M^Q`#!F#K@])X@>;F5""V,#MTT5AL[X9=;'B?(S>Y`NG'/O'Y</U7@E[K5#9>
M#V;P5?^@-NH>![E3<Y#WWU%%B&MA<!NX:]ATSRAK[/JU5W+&0!20"?S/I,!Y
M8$#?JB?3P%V;7?#&3;U3]L=OLZDM69(_">#O$WQ/')"#^I^=S9'!?:L_&CN.
MUNET=<T>]"RMW^U;FND8YJ0WL#K3_I35F%DYZ#NWL&?0_:=RK]H\IN/-@6/I
M-WC=FUNI3Y\T5XU#I&E4G+#*HO=@)P6@X+?*\N>F\1(\#JNW1]Y$W<=>QHHC
M[<8;*[#5G8Z^CZVJV5"9$'+`%ZB^<8%?U5SYQHQ9M^*%[=S#[6Y%&J[$X'1;
MM[H8V:K)Z,:D&`$]`K-_^:@^=\^T!_I@,-$L>V*`XVUTM/Y@"#]U[,%T..YV
M]%&7C96:-*M==7EG8V\5PWO);X&?`T^@H*EYM@;RUJJR=I]];`^A,=R$#[]S
M4[SK67]8O".`1M2$Q?U/`\E@&I@<VQY0[[6ORAR)L*AZ^>+^&(J:F*(^0M9M
MP',?R\!OGH?IM-MW[(FM&9VNHP&Q>IHS&%F:88YT9^R,1M.:\W"/K=VD%XMK
MEW6#+U"Z:`YNT(B;.]GBOT\D:&/SS!YHA^U7G'+=O*W9>NF228ROO3F%<\F'
MA5(',HUBF:#Y0D4B#UV/:PR[CM/K3[2!Z6`][J`//_4F6M^>#GJ.95C68/04
M@P&V5@@.J.QK5\T5"%,5=6X+*C/B$<:"^`H<G)NE5U&,Q[1UD:4H*(PS78$$
MQB)!PD9*FH-"M`<`00-`B.S;@Q#M^,I#_?[)7GWT2"VWPR-1J^P/#8+S9!NK
M54(/N[>C%YL3P,]S`/AIMHS=_01OGTG?6)UT[S??J97RF)$C2L@I$H[T3DV!
M)ZB@)]EXSS;;/?,H\%.:(O.B0`.G1X2$Q[H*W"/$"T*@#[VMVR].Z#N]7MOL
M'WB\]'/KH7\^&!TG^C4!XZ2Y+LT70N6N26O='PTQ.!Z@$;/M])UVQSJPFGP.
MA+),,*.F<;(G+Q51Y$3!A[4I.S!9[GS?4[HN(E0*^OSG5>"G!X)JL1V][TQ,
M71N875NS!_I(&W;ZCC;1X0\]9S#4;?VQKX;T&J0608\6$:1%%"&B/SI@BUS9
M;<;;+OQ`3(Y=,IH`8Z+@%2BA$B#D!0U(%S/@B^G#6!E1F8%SMF58\L;\F;!R
MF85SBP3822M!`L*3:#R4H2VB6.OUSSL\'^H\1^B@UQ"J3`Z4H2`S\"["*/7R
M8;%UGVNW+C$`C;T4Q]%0,"H06O(Q6*5E\7C>(!"3<ACW`]-W-?`H&X=N]ZE1
M#EA]6>T3E%E9?7W8[PXGFC%UX`3V.H8VT)V!ID]L9ZK;_>[(T;D:7%8&W[Q^
M99]*_97H>VE>0Y)%)11;EJOLI=R8)YKQ/H1'4DC310X6#+S%9A02_.G/D,$#
M.2-WC*/Q'L@6[,DM;+KH@XG0NYHE-U.W+&75Y1IN62HT)CB?U;W*OZKS*O5I
M5Q\-QMJ0*ATZ6.30-0W-&$X@3##L*?R#M]#76W-WG2!,3.`EB=C'C0M5-<CL
MRIMGV$,TNG+#2R]Y&^;=5<I03Z7@[S#5';9IVWW#Z&I.OSN!/4\<K3\RIMIH
M.!ITQU-K8H^,)S#AMYLWY3&:?WK%(V&I-';=2K+ETHW7<B0ZCQ_#F@RT-3.F
MNH0,6@#M"<'+VWLJ\9^H;%K6F0H$Y8=)&F=LX%[3HZ,L`4N7O&E.`<B1C*'J
MW[X"I/=T%2`'?_4+NV;-77?1:EAQUP]]O_J`&X!X[;L;GT9GE;][Z#H':3?7
M#1"<0^]58@L\NH@==1)\Z`:$&^E2T+R](O1.N:;[9,9^OEN6MMNVNT\]&N6P
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M>?/!M1?#!]]GF([]L*#Y%H@$Y`=9FA?$96F2NB'>.=Y_ZUS^O+L495\TH]ZK
M/_I.S^HZ/4&`.^Y*+110AGUP7\[[*/4D`N>'^!.^($&<Z2#"H4,/7B$P[?1&
MHZ$UUO2I.=1L:]33!J9E:-;`F?;'76ML668CYK'9Y[)9C^O\_J$VZSUZJ=_6
M"H:W8>OO;IAA90)2O8UI)F!5Z,VHEN6[GU*E'ET^R"@]O*P"4V!Y7>#15"*<
M>`2'J5K`SY5PEY>Q=XEE/BN!NH,?^]DZU^$92S\(Y,@J<"SER#$:]98"Z1*7
MEE0N1V2DBS.L>KCVM+7GQGE7));D@2*972%0I&'J;0?4<7UW00LGG85G.+H)
M=(.?X/I\SE7_W#GO=;!\C[]ZWAIG'CY9C/;"C5S["8[2:I<K&G&N6NP1)C/-
M:A)3PN3$KF*9`JP#MHS3U8J1>+"F(M]WCHS"NH:"!`B]MJ2:R_P[9S^ITZ$J
M;RFMAD97T9/G^"+/G5W1E^6D.ZY7;.%8LX#?YL:!#U3@45L%H<2_Y7O:\!2<
M8,<5GCX.IRK-^9.C[6)O%KA)XB]\6@]\*U$TBUH-VO)(S;2QNLG[L?)%)6GE
MO>>M`=:`^O*680Y$:&_6TO!(+&HX$=]4UT80*059F4P_Z^=V+ILTP:_EMB[\
M,%IBM@J(G8*DP/<BJJE*-)0<_-`RFGO!C56>=]:G:D4:5L-<B!);4./5`K9#
MJN/AH#LR!_V^-AR`/;*GI@D6>=313#3#7=L:#W2K"377'=3&"IE(RPA"M0I*
M-4\Y#[+++$D+/]#4]6Z[-0*^#]UUB^[?053]$#5,BR"4O4M_AC7'/AT$5.#P
MI`]Q>A5I[V;O/3]HPW-GYSBB+\DN$G_NH_*'L_'WZ"I,!&G$S^<(7R0T\1F7
MJLDGM]%N)(D7MCZ"8ERZ,R]+:2;?^_]M4^';8@''"G4]?;6\@$L4;SYB<BLN
M#OR;!1G-Q?L>Q<'\NS_W4)_$[+9I%Z"#\&0%@FWPY7?#_Z<YNMGA"G&ADN4<
MOH\?!Y]J0V;)E\__]V[XX4\B]KP<+N?D1L,&:AL,U6O6[H5J&OWV$"_X&$?S
M;)8J*F_\VYO"[%(,C92/F&;(,K%_4:CNQW/BD,^_6+K?@#49D`=)DGB@;I.,
ME/M#KE;,814B@4-5Y1!&L/'B,!52"A:XM<A@):ATXB@H>@80X=P7ZC>Z]M@R
MQ@)Q$R>[YA74M!UP'@1,.%F`,QK6^*`;HT?.J]82R3F'55[B0KP%%G<2L6$_
M^"VJ\!=4=G,HU//\@.#^R2^*`J^ZZV*`YPHG*_'>VMAF06X6N!>)-\OXETN<
M)>J%XAJ=YU+B--8P\8KSN8(CAP:?1`A?QMT);`P?5@;4_;FYJ-)M3IRDK="[
MC%)?;?PHR0<24!YEET5XE@7N0YU<L<S6(HZ6Z)4)6105MB!8H1AQF^O2`"A%
M;$T\[QL.,,W/%KNXW,;BT6]"V(WTY&KEE5BWC)AQP*A?:,0J.IWH.+F!Q`H%
M:J'D'.)TELZFU-XY]27S?!P+FOII($<(XT@8KY6MR&D-6\Y_2`7<BM!%#KV4
M''PZ\`^[ZO?@L(MY)JWO.`EUZ<X]<2+#2"R#QJ_B'\5*Y[ELP4Z*[?$05'&T
M'F0(ZI.@!V)XEH6>:O\-?8O]3[]'&QI3'#`D8N[DL&JHM]X).P>MU^+/;]H4
ME=SH*+116A99C*97+H+U$XZ<NB93`7QB1]3#F<0I^&*P.OP`0?FGB+8+B[Z,
M<!1$DI^N-/;<5%P3PT.^F.-W]."(7^4G5,:="/L@1,(%6?4TBC_"*(R]!;P;
MTUDH"S@\.`JBRS6&9%X";_*\:MA4$.N\T!SPCB#!4,4#2^!C.?O&>?G9-)T\
M6.!(&L,I7'TNV31D6/HJ57X5"H)5%,_XANC,]ZXY2/R.)ITBE>(\8*`N/:;R
M`5VIAXL43;Z.*_<:Z7&!`\_QH.'Z,6RJTQX5HK15U8_!=\6XW]ZTDSM0,NX\
M<5DL7WZ<^PU!E^9R!;]!#2\.^C:Q2O:UZNQJ5>VZ:M4;I1=:V+U4SHA40H+<
MPN::440$8]^%:%`>=_[7&SX'I#BC@OC(61!6_/65&T3@<&!TC>%VBNH4W%(_
M`JE-D*NQ?TU37!(Y-AN^<,G>LUS+/'_RF_,S[J'97.6*L>83MM&\/'JBNE<X
M&_"`?T8^:H?O(:H!%!R<6;\H.4/X1?ZYY:Y6`;:GTO1S$J%B6/;&`L7\=`A=
MYLIQ0D+@?'=*!@B_+P\4VLHA+8<DK6]A]%V[BKXS-:3XOOWX!L,L]`#SE%<-
M1<I<+C2=$C;!(PHU(![0%JU&E+<@[T8R7IR`\E(X%Z,J<-5E\>JIQ$VV.5-8
M2<:>F.6>AS'D6F476AZ_E=Y\K@J":J^D^*&/^;/9QDL53,>1-<_)A#I<H;M+
M"Z"C+EU-#(SR#!JHUUP/HJ%1M!'Y\*1N\\[@W`'*OT/&;UVH64D2<N,E43YF
M,6:C9&]P'4L+43W;U@I]@P07A@L7'BOGDTYGAA)`W^5E4>H#+`J=F6!-IV9>
M5@GG\K15/$-AX?3SPL))&[W(THR.HJK5\226UJ/RIV7^1Y6J2%2P7>AM5*V7
MJH'49Y)54]\I&80G03J0TN6_@Q/8KG,^T6ZRU<1!N+G5O"G3=Y<L72G)EV,N
MB.Q@WE1R(#@%4Q^,.L.1C;=KIF9WG:[F3.RI9EEFIS\UIR/'Z3;BIJ7NFJ6U
MK>7FJ5-Z_ZBD_<G;4&XB1"Z8G7>44OCY8EVY;F'/\I]9N/.2AH^`DF<G7RU0
MAI"(DU&"1[@0M3W)E>>E;,T*3W!!42PH;&^Y4M/P%((%]/V$6[W7_/8H2Q.T
M1CLTG/`;6?_G]Q4RQ$/O?EZ^"\%0@DROYY-9Q04,`W?V3?L\`_*AZN#%E5+Q
M%)!?%!<EW\5=*%XJ0.#OH=,*6BSD3Z-]5]+\X@ES;^7Q/2^%PJ)S%[N=P(M(
M((!*-N\EOM3=09"%*]_-:$OP5[.XN(]1:F(W[F6(X^+JK6@=5EYSX>&GB_D-
MK'3)20F%<I9I4I_F.;1>>XRW\*96*M`C9J.O@&900!;QH`"T1<)=*.;LMD"?
MU7C,&YIQ7]56:</'9O>)N(BJHM+(<Y8_JH$H"I8E1BTI'?NWVI-"CV(LYB8Y
MDR\1CVJ*XB:"25CFJS]LVRKHL.]>E.U/_1_>G`;X)/F@M:>8N+'OEG'2E%/L
M>-?RE5V^C\(9R(BDSRA*:!Q+AE`Y.-6Y$);<!C1P[S:PNZ.P^_:[.@R(R->^
M:?0[]@_#-`S'ZF\"<DQLW;:&CM;M]TW$E](U![:D#9Q^;^!,IA.GT_]JZ+H8
M@@@ON@6LB*S%44!CZIS$A]I:SM[\T;M+CO;?.TJV9.Q^>]H^9RH?XOU)AKOW
MW7[7-FWK+O`_(\NV!F-[H!F6,]%LO0O";9AC31\-!M;`-B>=Z8BAC;;,EMK8
MB\)\.<7['80KE'RKTJCQ^S8*V*,;-U-?NG#M#5#!7^:'X\/BP;=?V5N_,S;,
M"58-]H=]S9Y:0\TQS:G6!W&>H'=J#Z;*@8;3K#N:96P&=+O6?OC"R<HVX9]=
MV^K]Z)L6?.)6597[,5L01#_7G5L55AY\&#OLW.KUC1\&V!NK:]YIS.UX.+3[
M(W.HC2:VH=EFIZL-C#%0Q.D-A^:D.QAW)[FBL[C(]_;3V5F`,#++)]:+6I\O
M$&<]U/;OO#7P2S]V_D_*^;9E;G`5(@$0`@@?4<WC=DGE_Y5XBRSXTU_<PRZ7
M!+I:#3L8Z*9NPP$>.3T-!'B@#2936YN.]&'/F.B#0:\P31][_U?BUDU+?O0]
M6F:_4S/(;9\]FN)@?K3NL\<'G2\.V^KI1@=8UW&L?0[D73$%!7L[74>_[<#Q
M`VW8Z7?W,+AWW;#DM6%W;[WAO.[_'6<<4!K^X:=7?X71!0*]XD7IVW"5I>BJ
M@&].95SPE$^8V<';$JP7!P\]!Q<;Y2FFMR$MH%30B'KP/K:M9Q@&"E#70M/6
M[_5U^%??@1#J3D'*=#P9C?21UC6[E-4<:$X?S/JX;X`_JX-^U/OLS\B0]$G)
M]J2<*UJTCXU]16+EZ4EWTRS4<7YG>O_YT$]%;PA[0%-MC(;?:ZN5T=%AZL^Q
M#P4^5*"&3GX07.(<_2I4;%DJL$8G;HRW0@FXGL2$P9**[.].O4[?1'IU#7MG
M4\[;]]--[WGL3$!U3[3)R.QHMJ,/M+YI6IK3=9!,0]L8#7+OV7!L^)^>,GWZ
M(3;>0%I:>K<4>3X@+4UA]?MZM]?O'I241V8SE6/_%5Q*R^JR4&]UP7XD_J^A
M'_SM%:S/NYL6,($5K5^.WV#=FG;W5Z`F&JPG]C>>SF(]"<'!8AGZW<V5V"R]
M_($V2P^&1U/-Q5K\"_[MS_$W"VR^2F97P*&_O;I*T]6OO_SR_?OW\\2;G5]&
MU[^,WO[WJS_@K89NFWK/_OV7XFO%HQ+ODE)2O_^XB(.Y_ZOW`RM)_/0=H0VV
MYOX2[^VB\&^O-H1PN,Y__"]X)A9.K`ES>/##3U[]L?%YEDSZA,6/__V7VK?>
M8C&;0DLB75D!(YQ*&,KDAI?_(FDBJ/]+B?R_\WVK0L'4C3EUCUS5=`/^%YZ1
M_S;_H!?.E8]9E#:4OY.O4A[^^R]"HNXI7JK-;:1`?9;7QX*!\D:ZPD7EUN<E
M,I`=T&-FH$@7OC#F;8V]&LG*1BEW93%Y?4.->I=E`.^CE#T6=H.P=.*%R9J2
M9FRD=+VENJ)<7?P9<<EJF9V?1$,`HD\4M\2B].%%,I02Y<?+T/_T0E`@`?!S
M,%_ZH>CHN/9>)$O5*YU&LO037EJ7&?@.F+;,EB^147R_>#2,<G^\/$:5+K@;
MR:G:ZW+F'&,P26R/\(4IPQTU*HUBY-SS?_W3NW2#":U&81UA6+R;A9X?@"U\
M*,?W=+1K2K6>HT0\3WYQ0>F1\$NT+5=ZWE\6ZP[.J^.DCE7-H9I&IZ$NQIXI
MN$_>W/.6F!\91>$USN6%'S_*T;J'SJU:^S'6>GS&GI+CQ\W`4W+\.)EW2E@^
M2X:>$I;/AZ6G&.R(^-4L1[X!U+&Z'2*/81XQ>0SS8.0QRH>]:_6[<-A-S*5^
M[5OP%^<'G'_#;%@X+S7UV+M(BW(V10-,(P2>D_U6#Y67^S,*+Q'U`E_[9;WR
ME!<.DL&2$&0.JVVLISY/VP5&/VJ!^8+(GB=Y.8B\Z'V]5Z-@CDQ";J52[L$V
MO:_IO9O9QA\[*-N<FF/><8Z-;0@\_`A<<_8Z;/RQPRIG0V^BKX/8%_OX.OJA
M35>=*CIJT_5<?9T]E"!_[/$%YN3KG.1EB[R0!CXIF,8+C+E?]$T?>WR!.2F8
MD[QLRHM(]?7A!Q00<-#[/PRCVW&Z#6TG0(B1]^Y2Y97H9@T1%LB_]O`37[Y'
M7ZZB+''#^2"<H_"DGA<>UECT]S,6?4)K.SPOU=JWE\[99I?)-4UVFA;G-8,Z
M>(#DR2IR%\=F1S]C%_>^AO2>R8L]V,8?.Q3;*OJ0N::;0.LCX]K4G5&KVI^1
M&^:8?X?62*;SI&>NS#P;"`WFR^@:71O_217Z>J<+U*^P%O[I=$T'_JH[IM%I
M)J='L3?W4\G64N%^$'Q.@</IWR%$"MW@8PS?_@3$?2@3]Z!"MO=;W[G_C&+T
ML1-$:KV0('&(""&A4S:TU)<8=-35@VT\+]'X#.Z$"P*JOE#\"KR+EW.L&FCG
MFT`<`RQ[\XAC&)JI[Y'LAH^9!R6.[K`U[=DV5DG:3D-5[$<>5_HEDB`=F1LH
M`+IE)_]/Q&(IP*(/J@.`17IW+TXB].T!.&DZ?(-JFLY&DJB9O'R0M-`]+U#-
M_2Y03=)AA^!:K]&Z>\^RK(/I;ETIRD+,(]W6?_0=W;$:ZNOS?`G\4B7SN#F-
MXF'EVH=S!`\MU8')WQV:'SV[TU0,JJW\J,E!/0.&F'VGV_G1[]I]O==,AFS%
ME!ZN*QSZF,6S*T0C_APMTN]N_,"&X"GY8YFFV3UB_N2X.Q#+^CB^#SXX]7_@
M3P_L9#TEETR<5O<,N$1>,$+?O5WB9-1#^,)/R":(ZSI.KV$=![?7=A\6"W^&
MYXCA9;TX_^BSX-0)N?*8D2N?1FA.B'C/!Q'O"23HR6/IQ]RSV;P]FX?>LUYH
M"M';W6MJ`=2>O=V?@3)>,CDDSH+"(/W0#,KQ7BQ0VSJ&/;U>0_,V.8,$!!=1
MOHXYPT=B3@Y:\@C,.275&LB/4U*M,0QYT45VQ\"A4]KS*/AS2GL>`Y=.:<]C
M8-,I[7D,G#JE/9])VO-IA.;EBLDQ<:KC=)XQI\SGQ*F>U5#_\R$X93P'3ITN
M?9[EI<]C2Y"A6TZG8YY$Z&%%2)U"D?_]N0E-X\7D17&FV^]T,75D=?I'9L@'
M2>*E-?KW711ZZW=N_,U+IUDXOREH.?D0]Q"9ER(DQ\,7`WR[7N_8PJ<JF\3U
M8[R*8C?U1.LC?6CHSKYY\Z+_L4FG^UG$<JH4O5RY.0I6G2:N-8PAI[E+36)(
MDZKU#K[G$QK5O>MF19OEP3E4#[R!-'8:IC6."?V"\(7W`[\X.B%Y`5)Q%#PA
M`)T^&'G'.4;\G&,XQD\&8G-(%_01153$!&97MQJ*$+]O3/#@J$)/P)`FN:"/
ML.?&N=W6@=WN$[SA_LPH4`L/Q8QBO(D<)VKK#<UAW:IC:?0X33'%))/#,^@T
M?^;)F='5NV:S3)3>U>!_S4-I"*/?=_1NH\PR+@GW?$BM>)H>=!L+=>C,I-TH
M^>/,I'U8M[`AT)#E?G%&?#S<GILQ^ZF\9_VP/?+Y_`S%^SJ&\1D/,-#BJ/V^
M8E;&X47C-(NG8;-5GEP,CD)%//<).X\H!0J$[BE*OV-@R'"YAV?0">/XX7F1
MA3XS8I7%7D[4I><F\.\_\)>__R+_Q5_';U2^ZR>1;1J]KW]]'G^%5WU-L)LO
MR9\V]Z^!O,6*\7OO@4*QFT8%N977BN?]"L\KOYUW4_]]>NS8"Z.E'VY[,"]L
MVS,WO_S[+\K::[=>V>JN%]U$NHV';"7#7DP0%Q<-Y()ZK_*@O/C7(MT@8I;&
MO^(?]J!@?M>X\1`V=O+/6Q[%!QI^^/]02P,$%`````@`47NO1,EE2O'^#@``
M9\P``!4`'`!C>6UA+3(P,30P,S,Q7V-A;"YX;6Q55`D``^H4=5/J%'53=7@+
M``$$)0X```0Y`0``Y5UM;^,V$OY>H/]!YP*'.^`<Q]GN7C?8M'"<I`B0K`W;
MV^O=ET*1QC&ODN@C*2?>7W^D9+W8%O5B2Z:8_;(;VWQYGB$UG!D.J4^_O+J.
ML0)"$?:N.OVS\XX!GH5MY#U?=;Y,NX/I\/Z^\\O/WW_WZ2_=KC&9&#?8\\!Q
M8&W\;H$#Q&1@S,Q7[&%W;0Q-Q_(=D_'6C`?D_?ED4OB'(?ZU#?[5[]>3!^/B
MK&\8"\:6E[W>R\O+&2%VU.29A=V>T>U&W?T6`KLT/IQ=<&RI7R;8]VS^?>JK
M(8&P8YM#NC0NSOL_=L_?=_OO9_V?+B]^NGS_X3_ITGBY)NAYP8R_67_GA7E)
M7N.=,3F;G*4X_M688H_RTN[2]-;&P'&,B:A%C0E0("NPSS:-.ANZ!I>H1Z\Z
M*8:O3\0YP^2YQ[MYUXL*=K[_S@@+7[Y2M%7AY5U4O-_[_?%A:BW`-;O(H\ST
MK*V*HK&LJOV/'S_V@E_#TA1=TJ"5!VP%4BH!T)"6$)^Z4;&N^*K;O^B^ZY^]
M4KOSL^CP$\$.3&!N!!@NV7H)5QV*W*4#G<UW"P+SJXZUYLS$6)V_"^O_<(,M
MWP6/4[5O/8;8^MZ;8^(&J#N&:/?+Y#Z&CUQ@!+V>@?ULDB[V>-,03".VF9,]
M4:.7VVCO6,@37O./*>/S3O0QFM\ACP\4,ITQIDAT,71,2M$<@7TP@Y+-GY++
MV"1P^)!4Z(,M@"'+=.IG=\^5G0MU<-BT5#O"H4D7=PY^H?>>C0A8K`ZP^XT>
MC?L&4<O!U"<P(L^FA[X&S];`LV^`6@0MQ:?1_-JG'!RE`]L.!MIT:GFZ:^B[
M1@%,?=<UR7HTGZ)GC\]BR_38P++XDL7XNCK&#K(0-":"8WH_N1#$TF;[#G`=
M8"+RF^GX,*`4&.6#]X#,)^1PE$`?P11MVB-O`I9/"&_AVJ2(GDQ<Q^)4*-CA
MPO2>@3_I,?+1_%\F(;Q:A'RM0(ZE8+7CH>RK?2K["L3`/]T@QV=H!5,QDX/9
M??MJ.;X-]AW![FP!PBCVF1DJUZ`TV)^!/6!*QT"F"[YRGTYP=0&N4=1#(,Q$
MWK7I"*M]N@!@]WP!IF."E_RG-5<=M__ST5(LR34(JE)W)Z#)!XGXD-:.#9+,
MZ*Q.BMAUL3=EV/ISHZ(:6[U+=U4K/<<QGS")K*8'9(%'8?!,(+`7&R1[4,<U
M4K^!)]84.WG;-4]-Q$)A>?80!UH1O"8-S,I=GH;NG<]X@4?D(==W'[@A!F-S
M'91LEG-.OW6NVT(C++!C`Z%"C7-]WI3_4+*G1LE%T;5@4::C^<!G"TS05["O
M??;%0Y1R;9_2E8WPK@RB;I&,^2HGYEOPX5I$484)PU5DJ#";G`"'='U:^HEA
MF/GS[:OXLQ8+M#8L-0IH`H[)@O`86\^XF4!-2_34F-*OUE\]4;#/F`&=X3@Z
M&`>P:#K,PY4QY5Z`'1D18_ZLBDAO:.9G5$Y(S>"573O'J(\30M1-II%KIH%L
M8ZA-RSC7AVUR-I;LN!W\9^:3T\B\J=1]X[+PE[R18%/*2?NSR?QL=D94Z;Y-
MLFAN=E0'T;A<]FQ2438*#(Q(N!=]F@7M<"Q-2ZDPC'`:`1T$HVG9B"#$:>C+
M>FI^]*6N^:G&O1*`=LFC,6UZ$`PU^E2E_E0Q0THC:6ZIK8B@<2V9)!#,TX[[
MQNL=8LHQBRA0X-I'\;U&M>F1B%HNL<9F5CVXFI:>+)IR&DU4I?>-)*PDL5/D
M=6Y)A)<%SQ:I;>&WHO=:\_-""+T=#*<!5C+M+@##X7"9;4%P1+HE)MO398,@
MR*F<F_0I2*ST:??9-)<]D87:`X?1Z)L@+[5[WM_D5_ZP^?J/C0=+^1P6DW;H
M$Q)L)(<]<4L4G*M.0>&>0MP3L`"M!)K/P,JASZRBB,/.=G,A`4EY1>A]UP]T
MP(@M@`@]26#!525:09C'*'(BN(Q'\YGY*N=4J14E3./H]-A$]KTW-)>(>_<R
M1I+22I`'V64RH.&/ZG`5S/:M,BI0BOQ6X77P_X1YN3*=P`]A0Y.0-?=#@GPS
M"?IR=96P2K8:<PGL%E.!]=YC0("R4JN3I+!*W,E24P[Z?GD5Z+>2K3+Q[F=(
M*4,8[:9N^8'%L+.K*>:2/TE:LNX_B/1W[A81X.M<$>*,HDHP8^]Y!L05@"(\
M,LQ9155@?C3)G\"$+DA24?/%G5=#!8/`H"NSU&<45(SW,_:LLI!3996A3NF&
M<M"S*ZC`/^9M`>_>+C1)LDHJ0KSDIOTF'R=_:F>758,ZS.`6.4@LG<;-?2LI
M^)PJ*CA,0.1M@WUK$H\;T33E/=[`'%E2K5ZBH@H^^R8(=WD=WPX2"DBP`\@8
M04]^H-5G6#RJV&,$.QS*<V0U2CC7U+@*N<1)ZYX=;@B/?":.+0OL$K:Y56(.
MJ4#?@&S3,8D5-<W_W(KR[9]=WI3H49&R)UKK(@9N5'].L+OG9T>=89F+:V#"
MARHX/__/\_..\0*"1_"9?UH2A/F2OK[J7'0,GW)P>!F&&=K*+E_A)&1_>@MD
M);9#PO*C;BQWUK4TV9*!D81\_PV1S[7+$\H7;XAR?K`]X?SN#7'.">$DA']\
M0X0E5FU"]OT;(IOEFB9,/^C#-"-6E^:9%5R*>?8U&M$BGID!GH3IVQG1/'<_
MX:N1`5DVEBN9UFG6&EF2A["NRUN,!7:AT?HE#Y-G62J[&T;)'#E_@Y1E600)
M:XT,\'*L\R,$"7&-S/!RQ+.W7Q+"&MG@Y0C+]H`3RAIIL7H#?COF^WX8/9&1
M1N&'YF2TG_J0+(4:K0O-"4B:Z93(2:.5I$$Y5<U]2^2GT8+4G/S*[.,D(CMD
M26MUHN_V=90MP;NY>E)-1MKNTU.0-9I70\5^U:_@`3$=;HP.;!=YB#)Q?F\%
M\?41F2R*:JG,7,M'OEM*#=(51R#F;C@!"G9#I<558.>3-5DE)("WRRA'.5B9
MR`GU?,J,VJP.XGI*JPR/$JTHR:%9BBO(^4JTF="R,=DOIQ1MX1S**JDL1TEB
M),53X@Z3J9G>51O8__7#1[9@.:BM^;;)Y@C>ZCEQ<Q!OS[_\1:6@DII\(PK<
M8EX$ET"OP,%!_D(^C?PZ*EC,P%UB8I+UYB(VRR(@+,H9GH#-?Q-_AY<1QT^$
MA-LA+2EU84J8EFF_I/**IV5<N:)0*GJX.H5<,^VP+>Y92ZV6^_^%5.7VM)8I
M`"7X[G@ZDOW_KN8\B]9B+;,.#W1-I+I>TWS$&L1PD'$@26ML^:,B]?*V0Y.Y
M)I^6.8VEB!?&L+3,;<SQE3/7^41"DK3&ML_Q"MYD62.OFH=^7-*!^CCX_EN-
M%%T-$:CA@2MV6KYN+B(5=ZL$^2WA%:4N\EV:V&W2@_Z'-5;-5=V_O49\\\=V
MEYMN1EY6$O4.^LK5VW-%P!CX-+?Y`T3$1>XW$/XOV\NHTH0*CC?`E8*%@C'@
M?SOA5.++1&IL)-Q*557!*7G_4JS!XA<'R1ZC_#IJMD"VI\>]MY/_)MT+*:K7
M&C8BM6T_%5]^9+%B(ZWB67SO0JFJ[>`D[FHDII62-ZTR:I+J[>"VDY)6A5=&
MU79P"@S`V`S.O3BH9.4V\CKD$9.WT`Z&VP=W2M/:J::$"Z6^N"![\\8+;AA$
MRZGP-("LD`5T1(:.B5SI>%5J0]$VNC#NQ@2O$'=3KM=?J%B.-OE!_'&QN)N=
M-R4K--`B?J$K<02_K`9:Q"]1=P?RRVI`>9I':Y-1XDM6\<#B;A(!Z?%R"84*
M#2BZGL,"L*EXRV2LTX)PRVB>>ZE5B8JJ^0@P7,"/)A.^^GHT+^'^']Z.DHL\
MXLN`T]<%2RA)"JO=$SX@D+&SFU):26IY++,A`66NDEH>VVA(0)EFDI;'$:K;
M@3NWJ12N#UJ>9JEN/FZ)I8)9(#D>W?(=G2/E4WT9UO(\=74CO50N@/[JI:0$
MR@7YM=P"/DXP%6,46EZ&<YR$9+:OKFER!XBB^E:GKCEU1\R30_>TM<W+.T)6
M!?N3NN;L':.'2^\P23+YWO1\J;IWJF<"7]TRVMTYD63S?V-2R=X)E*1U?6.R
MV<NOT/780Q.Z1G(KUS=C")=+%-#RWIIF=8QDXAQB&2O*'TV],##U5OD@AYQ:
M!"U#4_?:I^+V)II<L]*6%]0E^*=B-I`U=W?S7G.N/X.IM0#;%]'3Q-8.EKK@
MG<OQ?'SD\Y6W:8^\B?#>"&]!'*6@FG(=+DSO&;A_%9..W8J(]%HK:ID3L:\7
M!?[I!CF^.&R1A`AN7\55.V"+P.UL`2*TXK/89>:EP>9*6<0KQT""$$Q+2`^!
MB,M]KDU'A,VF"P!VS]<5&@7FMV+R:E+KD[N&BH.>5=,,:FN^5>\(^97(<T,*
M*K6*Q['O.E%A>Y4A4^J]"YM!U#*(7U4(]3WE1YX#:ZT^SG#::CGP$S8;G:/+
M?CM27LEOZ4V\^3*,+3*^X@-!J^`XIG`J*2-^UH&OBI452IH_;W/N"`4/RAV4
M%+>LD@H>M^[2P6N`S5O02\^<XGKJWGQ7\2$HJ*3V!1!%7-)K18FQU#(CH)00
M<I6VEJ9"I;$OTD=:[N=7'O@R*XV6V_F5YD*1%CQNSUZ](9A<"A+?GM_B,-X0
M.WS!P22*I#X@2RBGP3.!X*1^J\'?P!-K,SXQ%U"88"%R=G$0D`*O[:'='-AW
M/N,%'I&'7-]]$+L,46JHBB!3LK4AD&R#BW#=2%]T6[:VTLM'\[$5F([5&FDQ
M3Y&_O8)_@TD*[V`MWU"[^6*?U,,W;JC5?&>\UWH&.-52NQF_X'KX1NVTXP:H
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M@K1\;(YDU>H1D[DME9Z<3SV![(FSYQ_^#U!+`P04````"`!1>Z]$&7T$&H0;
M``#GN@$`%0`<`&-Y;6$M,C`Q-#`S,S%?9&5F+GAM;%54"0`#ZA1U4^H4=5-U
M>`L``00E#@``!#D!``#M/6MOXSB2WQ?8_^#+`H<[X))TDNG9F<;T+O*<RR*)
M#2<]N[@O#4:B;=W(HH^4TO'\^B/UL*2(I$B9,BEW]L-..B'%JF*Q6&_^\O?7
M93AZ@9@$*/I\<'+TX6`$(P_Y033_?/#E\?#\\?+V]N#O?_OSGW[YM\/#T70Z
MND)1!,,0KD?_\F`(,8CAZ`F\H@@MUZ,K.`NB(*8?&]T%T>_/@,#_&K'_]T?T
M5_^ZF-Z-3H].1J-%'*\^'1]_^_;M"&._^.*1AY;'H\/#8K7?,K@^C7X\.J6@
M5?XR14GDT]]7?G6)(4@7]BE$GT:G'TY^./SP\?#DX]/)3Y].?_KT\<?_J8Y&
MJS4.YHMX]!_>?]+!="2=<3::'DV/*BC^^^@1182.7JY`M!Z=A^%HRF:1T102
MB%^@?Y1_-,S1'5&"1N3S007#UV<<'B$\/Z;+G!T7`P_^_*=1-OC3*PEJ$[Z=
M%<-/CO]U?_?H+>`2'`81B4'DU2:RC_&FGOS\\\_'Z5^KHRD<?KP97@7KXW'V
MQVPT"3Z1=,T[Y*4T54!G)!S!_G58##MDOSH\.3T\.SEZ)?[!W]B"OV`4PBF<
MC5*(/\7K%?Q\0(+E*H0'^>\6&,X^'WAK2@>VLQ_.LOE_N4)>LH01)8Q_'<5!
MO+Z-9@@O4Z@/1NR[7Z:W&_"#)8QQ\'H$_3G`ARBBGX8IT\4Y`Q^S&<?2CQYO
M"_*4SOSZ&%,N96N,9S=!1+<U`.$$D?3H7(:`D&`60+\S!HJ?WR4N$X!A]RW1
M6"->P#CP0&@>NULJ&9?0!`[YEXQ#>`G(XB9$W\AMY`<8>K$)8)L?W1KNJX!X
M(2()AF,\!U'P1WJVSB/_"A(/!ROVK_'L(B$4.$+.?3_=:!`:.=T&UC9(@,=D
MN01X/9X]!O.(<K$'HOC<\^@%%]-+>(+"P`M@;R389O6=$X%=A'X20BH#0(!_
M`V$"SPF!,:&;=Q>`YR"D4$)R#P'[IC^.IM!+,*9?N``D(#LCU[9P6B3LY0)$
M<TA/^@;R\>R?`&,ZK8!\;8&.2F"Y<2A/[)[*$PMDH/^Z"L(D#E[@(^/DE+NO
M7[TP\:%_@]'R:0&9"IW$(!.NZ6CH/\#X#A$R@?AQ06_NW1'.%,`&27T)<0R"
MZ`*$3,=_7$`8W](+F$PP6M$_K:GHN/Z_)%BQ*]D`H;26VP&:=)-P`JO2L4<D
M.8N91!$MERAZC)'W>RZB>KN]E9<RBEX8@F>$"ZWI+O!@1.#Y',-47^P1V4X+
M&T3]"C['?6$G_K9AU@SBC%B1?XE2J0BC/A5,[25W@^Y-$M,!]T$4+)/E'57$
MX`2LTY']XBQ9U^2]S23"`H4^Q(2)<2K/^[(?%%?J%;G"%Y=>RF0\.T_B!<+!
M']"_2.(O44`(E?856=D+WMI`F";)A-YRC-_2?UPPGRM38:B(S`1FGPS09>G=
MHE\JAMP_7[^R'XUHH,9@,4B@*0Q!G+K'XO4351,(\-A*O0E]O?7,>,$>4`S)
M$]IX!S<.+%)U\U!A3*@5X!=*Q(2>5>;IS=1\SN02J2?X&E^$VXB/'8(X-)H6
MIMD`:+L!M6\:2VW8/KE1<6$W\'\"SV$O?*.U?.^T2%;T(VE0*JS:LR5_]LL1
M.LN[1(O^N$,?B-[ITM!)V=C",3#&6>1Z-Q=:=UCZIE*K&V$W!.H$1M^T84Z(
MW:`O6JG_W1>:YKO:=RT`W*)';]*T$QAVY*E-^6F#0Y0AZ>^JU82@=RE9)A#,
MJH9[;O5>(D)A9EZ@U+0O_'N]2M,M(7*<8KUQEAFX^J:>R)NR&TFDLWI."8`]
M56((L@:+?$26+O@QI1$(PX-1_N$J?IM9010?^\'R.!]SS";T"`]=BG(+)<2A
M#V<@"6,]Z)K3=P,K6H(@Z@QJ-KM/2-,5#I=P^0RQ)IBUJ3W"N*"?P%[R#`\W
ME-&#E/>!'%Y_DS]]1R&KP4P/&8Q\EA.:_99]RFAB:P;!<1V$G8"EF*WJ.H#U
M[%,GH,WS3)V`I9E&:@\L$SF@+D"_3?KF<.#?-I\R18JB1764&BXA*V]`F'L/
MI-)[!LAS*L(3<C@'8'7,:D2.81B3XC=IU<CAAY.\GN$O^:^_9O!MP"TQ+A8+
MP3,,/Q^TCS_6@KZI7++??+U$>,5\35F:2>2GRUT`[W?HEPEP]_FM6P-0>[H>
MO&:HK<L6=,`#BG"-2RBGPS0[3+!#9M<8*I52DZ='"F7?=X`Z(F'R)4+/+-&#
MP7D;K9*8_AE1A2`,4JEZL4ZGITK!5:YLJQ#+W'+OM.N\W-=3N]2K0G3^&K1*
MHL9XR]!O?OSO`&)J[2S6=_`%AFJHR"9;QFM38J"Q,YPY5K%(#P!)27K"O>A5
M9KB"P:DV!J>.87"FC<&9"Q@H:-NM4K=^,M0$?6_K6J5FCDKJ9FV*/S7**'W#
M!I:5+5,W@UHFV<#C'D5P?0_P[S"^22*?;R6U##9BP[VM=Q.;:X*1&RA*\_X<
MU^&A3%-\,/=6JCG:\SDSC)9]64P%G*@/@V.$L`_QYX.3#Q^./M#_T=52K^\G
MQGG0_WP0XP26OT11#%_CZRS_Y_,!@?.L+&N%`T2-X?7G@].#44(H\=`J<[ST
M1?PW#G,KVR#Q=11D/?KPD1'U^Z1/FR0LB?2C'2)Q(QI]D:KF0>">YA9#HB37
MAW=R<:W&G$*G[Q2267`YE<ZL44E?-AEWK%3))5)TRO/VU^^:3OJ.]))R/UFB
M7#-)04H]D0-*HG09)+5UP=[,DW"66E]/AT@O!0<AEWAJAO+PZ"%V+'+)T)_W
MQ3[I-&1\WTZHC;`76=PEM7YPGUHZ3B8NU_$\QR4%3KXO"IPV*7#Z?5'@K$F!
M,R4*#"S51*GEU'N\[3W>)L(B31ROE2UH!#S:IN\Q;K:C\,./TMU&),9)5EBU
MR4Z]C9I4[Z@^78+02\*L4@*%X0W"WP#VVZED!:J]WHF&W]D6\>_<R&SK&TVE
M]+?=`/&>![`W>0#[1DW;-_A>YU7L'$N'=O.?0;QH<"2ILV2=?Y5E\2WKS]9Z
MC>X4EN^`ZH\PCK,L"D=(7P5HN/3/W17*6/=*>VU@K-`]LQ98YPD,O%B>Y248
M;`/NV\C#K(OH%<S^>QM=01R\`-;:NM9,F8N(ZFP;F`E\!!)OD&R&#0R*;D</
M*,[$2G9>6!VDE+W:YSD3+GX/Z.V.'JZ%?!59Y#W&.?3PL!N,IQ'N4O1/UX@H
MN/_MI_!HX&W7[]LFV':AQ@XJ*KMOVZ5M:^M&D-]W2T_G'U2>BCOTM>D#L5XP
MT5[-L_.8EB`C92>1GN^A+NC[V%#1^6_L\!#*)78:Y_Q.BG2LT53JZ1I@+8\+
MS#GX@I]=)#EK."H'5034<[JKK91G-=>;@M]<<&9:G";61;J:_ZPG_+LXP0:1
M\2QX1=9&IP7PRE[%DS=8J(VQT@\B>[M/#F5MC`THBW=<V4MD<?4QU[:,086)
M3N'SA<!9$MX%,U%:GLI,&QA-67F!))I9_MT:=%(>KXZP$A_>5&H(=UB6K:D\
M?==^%O636[,AE*FQQQZ-;J13$BTN:7\2Y:<A5*J(ULZT?6VN?3\Y0JC6L*!^
M$P\A]M.&45T#LAX?4;;]=85Q@RV[>8V&H6#3?UT%8<+",V6/B.M7+TPH)#>4
MCD\+]F0T-3GS=RC3T=!_@/$=(F0"<6J96&EC36'WI;#7`+\&.**8;T`^7S):
M"&Y@,]^VH7IL"7F;"F[L\S9H4WGA6JH^-L?9@#8W\RDY441EE#1IGC_6BG(.
M?0B73)Y>HNB%2MN`_CBA"T",H=].>_7Y=A7[+0^"FOIO9!$K="J>UGC#F-(4
M6>D<BTFR*@FQEMI8FI;V?+/-#*_OL7'7YS884G.&D&\CO?$X02%WPA\&<>,H
M*4.P'I7QTU`0AFACFM0+:M)8?J/:=YFH!<!4]((JV@*V&I@Q?DG9G,)=?8L]
ME?>%0Z+JB[!B2GM>LDS2MS2OX`I#+XO2TY]#F#)(Y--[A![5["TRH1]%9#2:
M^KR5ZKN$GM"8;B*%Y"9X93^U5."))UCI=<_2<%GD^':YPN@ERSR0(B";8:1;
M_'@V"SR8/J;-1"'$FQT6]XUOG>-4Y.]B_437EA@[*C.=PNA7C(@V,MDDI_#8
MMQCS`Q1)7>D4IW!@'"]U;ZG,W#N,M'M;"*3M),'>@KT1_HAF\3>J8XJ%K&CH
M>PR]KXPXC1M$*2Y<9;R!V`3]D<")XM#W9`KGDRERW<9Z?5-OF)NS[ZR_![-[
M[D@UK"'DF&MH(YLVXNVFV!"<JUTP%ZI%0_"V:B*LXLNP[FSM#VVI"\1Z8&0G
MB4Q*2M:>>%7I;4=5F^IK30=.@%L&=HJB)FY]@PT'<%I,LNDA/\;38+Z()>XK
M\7@K>3T\:*3FMVS&X#&PU!23"]'U*Y5M`8$33-6,S1])_E<M]FK[E#,XM[D8
M6R8Y@\=#PF[(\:P,8UY28Q;Z%^MMME'CJ\Y00N9HDDPPXK[C?Q_B)<^!)QYL
M@Y;<UB\/*&*%PN)H8=LL2XY>#T*?L/@]ZQ#$%(XQ?@1,&9.V*568:/(!9C*.
M).[=YB"[SL]6K:.6%R.[(JU[^=1<G:80=L*QJ6"O*:@U;Q\TJW*P=6>3T'>K
M=N^W[N;^>VH-$4I'%1F"PTJ?+"HWT!`\5X88HM6N&(([2YT6;9J@=2=6+SO?
MJC]:C]@H^^[:S8I6EA^FCPZ%5`-EKU)G8:8[>EPC`L_G&&9N6`,N,)'A5%V:
M\-86&>K:T\T8>JT+\LQ0K:FFX7R!YXQ#Y^D:5R!F^<_%DBUP2J<:@C,M=:7?
MFX!U2H0I]&"0MJ2Z8(&?<73%NBBAU`]^_<)YZ*/[=XQ@4/ELOC0//LZH[B8R
M@=[1'+U0H1%DUC']X:U13'_U]9K2).8_Y-/XLU/0F,JJ^@>("('19`&HS/)@
M$@<>",EMY(G-[[8I_=/I#LY!F%&#X]SGC3!"J[?2B!UW'H&XXXQ"P.+<U0MI
M(Q\GB-YZ<0#"XHS?(%PY6/=!"$F,HL9K)::_;J5K5,^]K01[<D_EZB)<Y\2[
M@7S:<D896;VP*"O;P+LW>2"I3C63*X_C!;KW(AB$4N'"'6?%55JR^!2M02AY
MXH<[U$S.:_[E>^##+U2;Q6]WAYO]VCK)MNMY0Z5,`X&B=VWE<]X[B@VOHY@6
MA*9TG(QUUA-JXE+N!_-"W7V`,7,\<85CZYQ=N6J[VH"ENT75'MM#]ZU)XLF-
M1)>]M5M3H?T`N>RRW1I]A5O893?M-O@KWMXN^VVWWGZ^V6?=9]LGRLI6A?70
M9K_"OXOGS>44^ZU)PC-V77Z_S=CA-^%Q*0GU\_X1BN?DW2!\XEYNAY%;D>LC
M*+&VI`JV1O.ZQ&D8WES?J_4$GM[0Y1C]UI^*D7"T*()0%DEQ?7`EN[JGNK>B
MU!J^*+&SI9G*<P@EX8SBQ-4)8/VXR5,$-?%Q(P-0+<US2(V_C78R=V.3>NO\
M?:)FLEO.0+F"SW%_22:ULFE(2?'6)2\:9<1!>T[.ERFIQ'&AMT.<J:EXKRY[
MK\QRIZ+I&GB+^E@=`FA]UPHU,*02\`9XZ9-[LJ/7'&@?7OEAXPT=(,R6JC;9
M]9@U8F5J3]Z2E3V)6;R3F;8E)>FSZ/Z)`!_-C]C"LX1'<@(X`^W#F[ZI^;C"
M$/CCZ#>``V9R3T$,93NB--T^;I4VP"4/I5>)&G*R^2Y@]P(C*OVO(/%PD&K&
MBE@UY]G'YC:*(3W(,>.=M)>O7\8VE="2?L`^?@VOI129.ZLUVW58[D',5(\U
M)[=288)]^!_`4MXQ43A\P+!;O/-+<#*#-/!RISPK*"(75'U%5(KFOT(7<`("
M4;99Y\_9QUU6V,\;^5Y%__V]:+0UU)9.^?4K"\(G`5DP_F4Y"<^Q]-$SR00C
MWJK"WKE#H(P#BSU7LN%FX`DPB8M:6@D<G&'FUG_"]+.+MN7KH\RLCA(<+Q30
MYXVSP<^%ZGC]NF+Q1\:=`D;FC;32>I_JA^-9W=AG7<""F+'R#82MRK/.%US!
M,`\77"",T3<J4"[!BOY%V"%%ZQ-6<$31G&DQC(TJF9R0FM'1_"9X97Z.TJ@1
M8:GW$5MXQCF(;QLO<[!I#'4!9NGE+!@\4+@M:17WX'\19E"07$'(>DG&Z]+W
M+6$<U=F.8B;=)O7Y>XV=);ZL)EI7/((2+4$VPS8&Q77!+D=2W(X*>/#G&=$7
M'^F=16\K).TPUAQD=.VG;ZA][7*0G6<K,BB^1&0%O6`60%]ZKL3C!PV]J1(T
M*EU0Y+=;*=QQ!B%H-=-XPZSL(,0L_*SQXK)LACT,KK4QX,^P@L%>O'Z\@:@X
MY"K0U\8:.7]/BP`K"`#>,$.=-</P,<80QO]`"8Y`.,'!,@V>RAIMMLPQVO-3
M>BLV!^U%!\QA)%9VZ7]9V<T-BJ>V2N44^[@*LXMJN\G-C[&_C6I\VQG%H20!
MR]*7*DS:)@Q+GG6S;H`?W1-MJ#C.:W]+E?AV.S2=X%UA$]Z6U`TQ@OO;MZ$#
M:?1<^"ZW:^B`O-1KY')OAJW/0#U?R.4V#%NC*D]:<[D%P]:H2W,K7>[$T`%S
M;GS8Y3X+'7"4Y72XW#^A(R/K)*:[W$UARYM)$`UPN2V"!L;".CJ7NR!L+9EU
MLBZM-T;H]XKB),B[7%O?1<?63"'1+;%U''WU6A;[70=ZMZV$"6`E[GNACADH
MP"PILA?*VY8/F9SLB5JG^J;'R5#TN&;YQT:MX:88ER[2H>@U$@SY`?H2Q:&<
M7`F*W`CD!L.S/=A$?BYXB>)0U$X9BK+B@Q)32^JF\CM"DO(EL<8UE'YCFDBV
MI%E8;SEF&E]^@G:.YMG>H"G(.\GQ_&%O\%3.I,XQ_[@WF/."Z3F2/^X/DJUO
MN/W5Y70`:=5C[;C*TO5*9=Y=%Z4FIH+4RE+CM66FJ>4]R*I\9)?-P/(>MD/3
MB;P'!=:5EQ&5SO6W;>)*9K6EV:LQJV:QD>;M.C"6W@4QAL+XVM5,;_P5;]+Y
MR_/@KK^].\J\.O,28W>];*W%*.6F-FN32@3=C2#I(\A-#K:E6JG)<*5BB%J.
M`U\?LR^6E*2T&73=D,.:&\RK$ZGISV)V=PE7E<WMC&J7C;7^A'<1L"3I:Q[Y
MVRX>TS?ZZZN,(1C/QK-9X,''%?"X[\4V!UGI^PE600S".P@('#^'P3Q[*>$-
MP&VCC50$W=)=7T:4W3R0,48687O;>D,^UDH_!$:.\D4):;4??ZPUJ*]?5T'V
M.,:5I!\G=ZB1/4^_3`43%C^K7!]AAU*$0,@`H;*C\AP@&:\@HT@T3X$D+$EF
M/&,R!@-/5/#>\6-V^GP04I.8=RT-)B43G(!?UC!/,-@&W&\X8<KTL2PM^`&*
MV$H^QTI'"'ID&1E1P<,)""O\+JG'59GI($92N:\V=R^QJG93V%%Q5;ODJKM1
M^7)BCTNL]`C4(I"&4%:ER1$=;_PA%%VI48*KG0VAT$IWHWE*\!"JJC2VD6..
M#J%Z2F\GA8;L$(JH-#93;"5;+Z%23D*0*^;UMS85E$B7_&\R7Z.&1JQ!@X$]
M/]<G$=QP/+<?=RV5NW%=-3U-NM6#[OID;Y*8#KBG<"R398IM\=KN@0N0ITDS
M"Q12<I,L]&'`B6STR;`40I7WW:H#+3YQU@5>2TTZJX"T><+X8ZU`30\;BE)`
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MR@1J4TB'$&/KCNP;*V((831E9&7JU!`":ELA6M.[AA!6T^!AB1=B".&U+IB*
M/4A#B+)UW]OF>76WG4TKECKZUA#Z$JHAK&&P#Z$UH3(O=^Y$Z7#?0F7DE3J.
M.MR74./NU61M6ZT)E7,$%'P$W+X;37/6?D18LQ1)9)%S&C34S$J7$%6I0^J&
MYP"+D)IAXRDD$+]053G3DF>E\GB1Q%^B()7&E?O8=D2Y(7R&$._,4\(R&A<4
MOT$X2S(HQ&1[U$WQ.T;\8)5E<Q5-_#J2<*P12#)&O8U8B\_@A5TBD1@4\6`;
M/'!+E1R2)IB\[9[1>&N[,=`^O)=4/,Z9,$AS2:1.986)>X:/I=R/GB(6[V[:
M@>G9'6X7^YY;-?53+#3K[U2T'^V!Z*&F$!Y*UJFZ5-XX3<3:R!!<]!T0EB@]
MUGWU?9G.O',P1`.+;19+*,Z0!B0UH%B56KKA_75[X/#,TS?TM$`)`9%/`6(M
MF&,(]=1GZ2=LJ$#YLVI2_:T^QDK*#"4=:Z0L*R^N#K$)HS3M^<V@@<!I23V?
MLM()R9:7?[<&G?3<5$=8-F^8.ML4GI42V(MU.28OSCC_!K"O:`QM^7TKU&'P
M/$M@SD%^?@MR65A:O`K%IXZQ[QMQ_+1ND6B'Z/V%6<G.;50WBJKOQ#3OOCZ7
ML\8M7?!I\[$:^+!=_MB\GY/E2[R`(&1GFMK,OS+3(N/A8E>O8/9?HRS3#8)!
M<=$X5<Q)_C(/PRY#VC13"=>Q7&/+T?]J@=(W.HU]PUVM:E8+K:%X)/@*ILP8
MEQM6]M.NE#:SH:U6=[*F+`YA$SG:;;U[<\ULM)XGUL6+8D8GYIU71S(4W"!*
MY5Q8?_Y&&$LQI]X)`B_;TG6/PS1F:6]%F;4?#=HUF7NPHH<0?'")5U4,<^OA
M#;N,:=;4TJUT<#]\\I@LEP"OBY#2VS_G[0!MI*E=+U<A6D/X2%F:-3CC[V:8
M0I!6'$VAA^81R[7+Y,DE(G%K:UO3J]CP*?P*(XA!2/?XW%]2SB(Q3M^RS3=/
MZJ%6FVLGV8BR-MPDE=[E.R#-^A+/<`@#:=A%/F<OL+`52Z*7([V3%I35K^`+
M#-%J6?8[E4=Q%&;:C>Z8D6)JD1Z3:[GC@=5RH_;I;R]N7&7W>#%AUP9S3_<S
MWWHVRN![;$GO8E,$YV<(%G"/Y%$YTO;M6]64T5;5JYYH)M40K'M!5=-&S2$]
ME$"-DFY7<^6J*%%#<#EH8ZYH9%GOA=#!Y=^#]JAP4@:9D#J%(6N2P!K]KMGC
ME01XJ:](DH5J!>('%+,^Q#=!!"(O`.&&^F2,YR#*DZ4O*>0H#/QL/R)_@NGQ
MCN)\ESF32T(\42@OPDT%XYXC.:$?8&V,G43V,9AG?>.C^-SS6!%\$,T+B-W>
M)S704\GB*.V3U2JS#$!X`4)6&?2X@#`N><CU'=!`P.5]:%1BL[%%,Y0QG@;S
MQ7#$UR4*J=V/<"&R[NBM'%4;Q`\%$=:78RBP2KK7[R<*@SO.0]D&9>@=WH$2
MVK1_U,8,R!7@5.-O1$\=O^NVQ,GAW1*9)3HGYI=C!AC+TJ#_^']02P,$%```
M``@`47NO1((^BFB!6@``@NP$`!4`'`!C>6UA+3(P,30P,S,Q7VQA8BYX;6Q5
M5`D``^H4=5/J%'53=7@+``$$)0X```0Y`0``[;WK<N0ZDB;X?\SF';!GVJ9G
MS)290<;]3%>/*96I7LTJ4[),G:J>/;9VC(I`2*R*(*-)AC)53[^X\$X`!"\!
MAVKW1]512J3#/Z=_#L?-\2__\^=ACUYP%/MA\*=?G/>37Q`.-N'6#Y[^],MO
MW]]=?K^ZN?GE?_[K?_Y/__)_O'N'OGU#G\(@P/L]?D7_OL%[''D)1@_>SS`(
M#Z_HUGO$^QC=^L'?'KT87R#Z_UL4!NC?/WZ[1>Y[!Z'G)#G^^N'#CQ\_WD?1
M-I/V?A,>/J!W[[*6_LQU^A4MWKM$K=)?OH6G8$M^7_K5582]A#R-MD2;7Y$[
M<6;O)O-WSOS!6?WJKGZ=+_[O\M/A\37RGYX3]-\V_YT\3)XD;TS1M_??WI?@
M_5?T/0QB\O3AZ`6OZ'*_1]_H6S'ZAF,<O>#M^U3H/H6+B#&#^$^_E!#^?(SV
M[\/HZ0-I9OHA>_"7__R?$'_XUY^Q7WGAQS1[W/GP[U]NOV^>\<%[YP=QX@6;
MRHM4F.A59[U>?V!_Y4_'_J\QDW(;;IB5-!1$TB?HO]YEC[VCOWKGN.^FSON?
M\?:7?Z4-_DL4[O$WO$-,AU^3UR/^TR^Q?SCN\2_I[YXCO!-KL8^B#_3]#P%^
M(M]R2UM8TQ:<!6WAOZ2_9G[V"Z)/_O;M1@IH79'%7_K`E=S3?U`_K:B)?R8X
MV.)MIBA]76$N)IU9F@FE8L--1>">VCR,A,"9K)T7/S*!I_C=D^<=/U!7_(#W
M29S]ACGGNXF3&OF_I+_^XW*S(4Q("%/OP[V_\7%\^1@GD;=)LM88QC_]HO'"
MAUQ_^DH%083C\!1M<">3\,_348L_]H_TI<.>O$+##P[>_?;]%^1O__2+O_UC
MNEHL5L[JC[6[6B]7?SA_.+_\:R$+9<+0[YFX_^=?N![C0DM(7,*WY\?G]L-W
M&57]SXLVF9[DQQ:`Z1,?-B$)-<?D7>4S[J+PH.5+6?NAMDT^P+$GOO=>O<<]
MOCI%$0Y:F%-_V#QK:AIH>M1TNES.*XR)42H(I9)`N3($E5M!=>2"+&"&Q+$$
MK!"AAV3$-[S!_@O5Z"M.]'@A?`6`'2(]=+UIM9Q,:APIQ"$BSPZJ#(;("',5
M!BS\HB@7%]M`&I7OB:@CM080@2),$^S+0Q@E_M]9LGVW^^3'7-G+8'L?X8-_
M.L0WP0N.DP/1-I9_[S["S)*NAX:ZOCI?3I8Y'7D[J-P0NMNAO"E$VD)98ZC4
MVKA<%0TGX&PSH\;Y&@;O-E[\C/R`A!`B"'EQ'&Y\JB#ZX2?/:(L?$[1-&T9>
MIA@PVP<0I18'^MJY6X38O))1.)U7F$Q3UM/?L/9/>/OYYQ$',8[%O:7JR9'Y
MN@TW)PJ1V4%?#4W'6Q#X[A_3C)1$#LH$G;5S%$6AL=`XQM%(N_JQ(+EE2,<(
MO]N05OR-MT<>"9/Y/Y+()_^/TX8@XH$&A2C9V^P"U=<3=6Y][]'?^XDOXW[[
M\X9[;*$2VB,NQYE6&5.2!9X?CX"M0IU](>L\F,+$VY\?TX)B>J!ML=Y?`YG)
M/$!)HGI7+S?&F+UYUL0K221P1(87B?^";X*;($ZBDRAG[_@R4)_?KIF>6SF3
M^72^GE3S@%PXR\MS\2071Z4&0+*#L7$+XQ\`;JT\8FSP+$!>A]$/+R*I1#J+
M`)T[Z!.VGDYHF@<PP[B/PAV.Z5*HM[_&FFF&["7SN89$$^T.;%V>!:"$*PM$
M5*(5:<<8,&MI>PGF#EO13[>XHJ"S5ID%B%.GPVE/)T<^83(RHO,D1#GR\Y[/
M(@3;\D0"4?^(H^3UGGR]A/SM\W^<_.-!R;YQQ)OEZ2@Z:[OZ;+G.&9VUC,I-
MH[QM-JU7F?3+FD>L??;W7`/`N3X`"[+9OUM"+IK4YW;<ENU(1_M>J67@$#(J
M\VK!9KP/`!R6[I)G'-$M1Q%^QD',LI%->,"W81Q_Q<G=[L'[V>Z'6E)@@HR.
M:KI,F+GNM!E+6`NHT@3B;2#:"%O*(\DZ:0<L93B;,=RZ,4)FC$W%&#YKPY)H
MT,7A):37MB((M[=;/V$)T+WG;V^"*^_H)Y[4-R1/F^2J6`7]31DY)W-!B$JB
M0^)4%A#O1@#FUH`=B:1W?H`V<F#&.*5VM`IW%):`X<A?3^G2W$/X#5.P/EO1
M+WC\$%YY\3/INE_\+=Y^?/TMQD3QNR/=?^P'3Y<;,G!GDX)M>R#/T911=HZO
MO^Z^Q+4[R_9=%EJ@AQ#E>K"^M=S7DC]295"F#?KXBJ@^-!CD&J%")?C=F]#V
M=>OV34*Z22>U;T#LNZ>&);^E/[.E_Q,U*`E"86Y0+]?A5]B0=#Y>5^/9F3Y:
M_V`8X\W[I_#EPQ;[/`Z2'^KAC_SJCTNB]99J?KWWGFH^V?R[@4#3:%37>YWU
M+)NJRUY']'VS/!ZFOJNG_KGY(W4,ZO1BA..L?U4VT:0;9^Z"+U[T-YS037;?
M\>84,9H(EQPZO&Y\#4Q?-]T%$<=9KE?I*EAM8UHJ']T%J&@!%4T87@<[%W;'
M&NPM:V'G,H#;,$"XHSMNF`'(OPZ%`6*E`<RLEG6G=[%>UM&$H\>C>QSYX;;M
MZZ9/0487KH*F'SF+Q70V%001+@4N3O1!T0P'9T2AS_@^4/@RM[?A2_O[T`LN
M2CMLRQ"/4HC&.5VEB)"Z)5N`#/2#Q-_Z^Q-=92\"QN>?F_V)9.77!!:=QCLE
M:9CY[$4!2<YCHO7W9R_"!,E)OO@VBFR30_DQ%-:=O2)^G?77I69+W3+*&D:T
M951JFG;J6>.4T8@UCWC[0*-TXZ9S,].]RVU7].@(9[:CS$3),V8S[IG]2$[`
M7J(;[^C8G80,%%,]0,?F8U*Q,A@?[=N\P0AUZP?X)L$'Z:F>L<2_G3B5ZZP[
M$I_.5NZXH>IWJ@-B2D!-*T+8T-6RX:YNP["7#=](W&H0=,305?U*XXR`(NS=
M[>YV.W^#OQ^]PBLKR6[C(>/CG[H&FGZZG,S==3KZ(2(H?;D0Q*08'OX,`N$8
M!=$R^AF$Q,V1D$@0<B2Q#(F908Z,!<481XAX'`K&;+85;[_@PR..A/:N/6*<
M?M7V-;_V?.;DY(M1*@']SF6<IY^4<V\``L<D@A;B#8#A=H!AAG5BQR\X)P`+
MDK+',4YN#D?/CRA+KDA7_-18H&AYV&0Z+=1`=S"Z7LZ=S.-CNMB>"T*I)*`$
M=S@J1H`2'CI6!M[WKO2L2N8HAP]&"24%S+N\MC.0_U^47!SJ[&5WG<L'+:6:
M&_5=N:]"^V;;-JWJ0\9]M7/)MME\4O99^'U,_6&X:NJ9=6#EMI\F1CB';CF7
M5WG&N#MW/(ZV=&K>?-8C=GJ1N`^$4D#>\->M"<RJLW,-O.!>K16MZ\]">7G7
MH+=P9G.1MUL2PX>@XK7>*JX/NR%4Y512#E@2X:])<O]G;W_"M+H4&9R<HOIL
M;/OSQCDA4$(_IUW/*KR@LA`3A@IID-08"LZM)^SH@#TJ98N\!.THW!<J'IXR
M"M]KTD9F%@CJ?/1B/[[;U0H`O_+_?\`_DX^D\;])OK+FRP9)I:>1KA-.)HLT
MSV)RZ<I!O>+S:_:?WZETQ,0#=4=GP.X6V$.V<S3.IKDA*=?-9\O\ZV`B$#*>
M8C_`<7P5'A[]@-FY;2"N?,4D\11ZZ+J<.U^E>Z`R::@L#CS?&PVCVQ>C,89I
M.&*%5VV6@6!3>FKREJ0,^.YQ[S]QO20?5_:T00Y)5-!UK05IA-,G%828)%02
M!<.;,7!5BN_X`=O#]^CMZ9TK*'[&-#>,,#]2GX3D@2T^!/[.WZ1;9M0F,$6K
M%H\L,TIE,Q@RQ<^7P9;^A];C(&DW/<UWF5QY4?1*.E*6STJ_O\Z[1HFFH9#V
M2,5=Y;2+GUG)&_9#23*Z3%`FFP_0SD)$OM7]<Z"LAC,^]EF.G96OI3_@$G8R
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M+Z'1]?43CC>1?Y3M[6]_R?1I@U:-=&MHK-?K97H`H48[E$E%);%F3R2,C-(!
M1:D^M3`R5/6H_0(=,M1;-6HCAQRT.9D?>]"SUF@!8X_C^/-/'&W\&-_MKL+#
M(0R^)R1SN0ZCOWA1Y!&;YK<8R+YN-R$0`:63AIK^Z,X7Z]FD"#"T#90U0F?+
M>#.(M8-(0RAKJ;C6PWS0.:,E'+$E[N`LT1Z8SF@.?N`DCD]LE8?XPX9;(696
M.!U#/H/!C/6#-X5PJ@IHP.H5$RH!K+M50<9(>R^.[W9,L4_AP?/KX4/QH,GQ
M3*/U#JOUZ18[)H,RD5/P=RX':MIA&""W`!3J`#(VJI"Z4V6L(`8/[?^W+95%
MQ,\"L>"V:[V*^6(B(<(M=.F.X;B$?&C!!<&)AHO):'$[H-#%J,Q(NZJ[Z)O_
M])Q<_O1;V"%XWCQ#FDIH5W59KIT:2U)AZ"Y"3!SZG0J$I<I`@%6Z9`##=H"&
M.2-W/@%O)#:QACLZZ97P#6C^=,I/W-4ZVW&M8)`-N==@D&TLLB<?4SEB*Y/L
MR-"J.F4#J_O(W^#\CW'ZUTY=5)LH:/:UZ*<];%C/Z^E?@Y;Y=`5KJ_1(G#\#
MM?_TW)9A7,[Q'ZG$LR!]P=%C"(S5$8"MS\U8%[0T&=\:S70,:4V8TQR1REZ"
M#EU=QW)39Y9OQ)7G#K8,5\?`VI9"V#6$;7'.5NY9.JC]>J+%M<C`.]^,<^7M
M]_0*F\_>YKGZ;!>7Z"07FJM=E-7-DI=S=]E&9]XNFXTJ*J?RINE-5K3QQDL6
MT?YL9F.1(4^__#@^89`2^*,SIS5*=#;I&P@D0P8H':3:&T1Z)JSN?+(:&D*L
M'L.<R6+YNBLQP8\,?Q*B(T'U3+>.6YWK=^?1@*!B]PC@@6X3[N)0_`7H0,"T
MT)Y,F\Y:.?X[DVA3PM\=8ENR+X<(RL:*"[82K3#+./NSA&W@Z"#<S")]V/A^
M*YDFNG<DN<Y\.4OW54E)004:WCTU#JX6LI\-5\M>J''`E3-WE$B@F-G(U$:>
M8L.2$OHX3`[W1,\P8IRY#+:W_@8',;Y\BC!F]\H6I91DQZ?ZRS'._QY*ZNZL
M<U:KY3P-#>5FV.&*M"%4M%0J)';^XU;RP'%V@SA6&J0EXIS=*F[3*I[0*G!!
M:D!<*.)77T..']IB4?.RB?S.KX,&,K5N'78&3Q>"^!7+^'KV&7^]J#4F^F:P
M@D/?(42-:8)F9.IM`O-Q2H_DXO"D841#44DTN=#I5?NB48=1N>-.9[/ULE,D
M.N,LQ(`@U`-TEP`$,?5R/N1=X@[<C$P?!G<(-V//TA0-ON!+.H9\8NU\\A)\
MM\N;;?G&RE<!0XU*+]VI@8F[GJT;H>:%N%LA&E'9K$)M)ATLT(P'N1YH0"!K
MAYGQ</,]5NP^<UKM,`F1AS;5<9@*LNGXHD-;47QI-1C(2DIX./@)"W2TY$#(
MZ@3C8.-+[RQ3O6%R+46NAG:IS>*83R&,U]THBP-:2!D)GUO'QX[!M^$SMHK2
M[GZ59906HUC&H&(FI:6N=3<9=K"LJ9A^L?69H\&[RN0C<#'L\]E!R,^>=K"`
MM7*7U^2QQ)S6,KNU?ETW(;9QNW-=M^EZ/>E*;OC*=N<S13N_K6>RNJY==]-!
M<3DM*I$6&__^[!%?^H9C'+W@[74879\2HFI6@4/A*=WD&&9T)^6T-\JM\J)1
MY=(L6>5]W@K*FF$E6WA#*&L)CM?G,TCIPJ8H@QYS4]AT1*BOY]=9WMV0P$2O
MWA0N=XWT.1BB=KJ;?3I9S*8"(L)<,C\.&K>$AM<Z"H_I[3"`=\ZWNI.$'<"W
MSY<TN?>BN^A[0B\)867<[W'$.-O^$:5OPC!$IH[VZ;%E>;B9<X:(I=OHN.#T
M(D$BFG=FX$0:!72#6A?HZ%EPBV`'+Y703&D>8.+QGO'RE#R'D?]WO&W_V(TW
M8(A65T,_C"\7`H*E66$A#YQ4@P`*R)0F>YX2(0"I9!XH(9/0+%:0B!_+T?VP
MZ=.0Y.$J:(\BE@M1-I<2YT9ZD!&`-#V`-1.[E"]QN#\/+)V*$6-\,7DHL.#P
MJ9I#RA!0LH45]+\[)7'B!5L_>-+]G.57(`-!20_MZ<+\0E!1-"@)M"0D](4H
M9T^HQ@A&(8$?*GE4MPPPF92W%=8?@R%-I]O8YHO57$"4\UTUV(4;W9$(^/!/
MD_>3R<0I1FN_(F<RN9CP_S7SSO_AD#\L9A>S]9RM+ZPO9O,Y_4VU7V)_*Y$,
M>6RF\@OAQC.:.A>(;E=C#WW"&S:1D?UV>D&G.(]X0[>Q[(75MP'8*;_73O0]
M1MJ^ETM.3X#EA:G5]UEU?=O\)CY=U73WD+JN,\_.999YFIWWR^4;N^%*%(S.
M"KX9I.#`MVWL.X\%W'8+`.[IZ\KETK:^3N8Z4^@1+G"HGX4/*YV6"%:3U505
M0\ZZ\-$A7/0`)8\-,*LYXR%CG"_EP-6;+/(:*Y#+.UJ$4K`=?IGG&.%G',0D
M';L)B'WQ5YS<[1Z\G_(,5?J&V91?IH9NSCR=EI9`"V&(2T/TUM>['2("@>ZT
M'0GAHHEP'\;0FX7:O*Z6A"LM80EQ>'^M>1FM[NNPE!+JI%\4J]0Y-?F5IJO@
M6>M9X;M-^+?VD4_IN2U,E-L(AI8$?Y#PTS[?_/AO5Q'>^@G]2?K9Y6\8)9]4
M#>W%Q>4TWUM7$H:H#,3%L9^AZ#4.0+<)D%YYIX9GCENM[E>ED]HF(XWVTIVT
MR;WW>N`7Q&ZP_T)/HW[T8KR]"S[A%[P/C_2/GU_H$^*,OH<<\Z/$[DKJ7@-*
M+SW*CY-FS:"L'50TA%A+Z"Y`I;80;\ST^/+<YG`L-$?;R/3<-G%K-CGR=A#>
M^T\^-4@2HHBUB1$)7]N25?B9NL.!ULOW]@A+C61H7-L_=)3&O#WM#90_O!#O
M(=$EO1/L\A">@H2O9SORKDWUDMDL0J&)]G'/R=K-B9W**ZZNXR+3327(`<LF
MQ@+JUH"2;(+DN#L<T4/D?*:)\-6>3?@Z#EI+,MI,9073RCM'M)E6?0F2:15-
M=,>(Z_E\*6=:9?N6-4SK#U3G8N(*#PD#,3ZP'(+_(6'=9XV>5M%1Z,5*.C;M
M.5+:'QUIM0C\"3\FE\'V,HYQ\M';_`UOBWK<JG4?_=?-)_G:NNF71ULNLRO5
M,^F(BF<'3ED#B+=0KG</M6AT)OB.3?#;DO@SV<"MVF!+;4"3<H_9X)';(-:S
M@:$<O3//2ZEY-RN"Y`EL2N3:V[`U<=5=N,T'3>8#C=9UN\;9S,VHQR>Q,B&P
M=]X.P^-VPV.LNY8Z4Z6+%F.']W[U;;:B1\$8T.UJU]EB/I=P`/;6VJ&8Q#RP
MX9):A6/)N3#*M;2D]WS_%+Y\V&*?$X'\4/=_\JL_KDXDQP^2:S_>>/O_C;WH
M<["EU<YJWTKYJ`'_5[6OZRNDA6RIE$M"7!2BLM!GNH^62#/+@=%PN7UPG9L'
M.@Y&>=!J!8A>@:9KQ3B2_Y3@[4T0)Q$;.NG,I7048K`GZ::9]NKA;)8>+F4#
MF]*$2]X"*IJP8_+EC)9@K+P-O0#MLGX)_Z03]2<_?F;E,\F_-\^TS*1-14CZ
MN7ZY1^MA4RB.:Y?]DSQLF+.]"]BYJ[RR`N.F1?7Z1L#E=L=EDDUZA?84=H!G
M1]MN.]G38/SHOIEL/9M("`*^<6X,:#E'[&&#<B.<"C,4'XH>3#%+)GC0,`NJ
MK>MZR6*Z+F=OI40-<I9L(!ZW&QZ3/!`[4YT"`NSPWO_1B_WX^S'"WO8N^+,7
M^70!\1L9KZE&0EJO@S%%KI-^)I)MQJ[[&Y.-N'"Z22L3CZA\R('/Z/`9W?)9
MN#T9^UR@8^0?,&)K/<?]"71C=E<OEI.QQ5[P%+TJ5O.+H=A]Y&\T.:IZ'XRD
M"J6T<Z'9="EF:4EX>>J"B;>#I&/!K^_'.E(1]O!2PW7EQ&RSD0W,?,&!%R2?
M<+R)_*-@"X;^>X!,;"BC?\;`D3*0"T4EJ7;P;AA84:^X\XE$M@-YDTJWJ&=4
MN*B*>6(KC;+7JMK4M>='K%C(E1=%KW[PQ/XAF<'K_K[IW59=E-.^%6[E3-+M
M5G6:T0;2(JI9$^D_SSP5*-UO=3X#".,,F`'4.Z[.9P7A*+BO%8SLN>K#]WS3
M56=#PB<%-^Q*M3BA0PA>*_<>1_3DFO<D*P?600!8FJ#22GN7QW3NBGF<2>?C
MZ+0Z=-&`#:G#:`80YQ`_^2U\W`H1T$)_?X^6)Q.M=H.G[*WD\O.VI\'(>-OM
M1FOB>&O7D<P(WT+=WCTF-/'D<`LT&#8UG$U.G=L!=VZ?@R=?O(3N<WX5;"S3
M>`&,+64M])<<9I*N*I,&L,ML9'B,-#F<+>UYPQW;Q6\/6T0N)R=,PQ3PG/GJ
M';!R*[+T<3"^%#IHWWOANI(!&I4%O"]Y%'"B#N:B'1T,:9H^)Z=,S1[PA"'9
MH1]N_4UZ`/X!1X?XH[??AV&0_2K\B.\]7W9#06]Q8(33UU'_L/94DN]E;67%
M)Q!K#:7-%;\-T4>,:),VD/9,!I+-YNZ+D5A:CL(>;G>GAYS['<T*'QL>Z-JL
MEL?P)\$8S9K7'L$X66W%Q@B&R;&BW^R.B+'K^^89;T][EEG>AL'3.]+L`=5P
MQBJ@,#2K>)J<08558,AQC/#&9ZL1Y.<]IC_0HZF',$K\OXM6*3J]:I0^[?KH
MQO;U<IUW?H54E(OEY[1+@J'X-3)DMP&9'<9N`6J.7_K.6B6<IIE@&!CY+QZ]
MGB&K1.[C^"LQ!C\%)?WRZK>,\DZIBOZ5&I.\"\L$HI)$5(B$(MMX.-.TT4]O
M":%=6UI>&^T+X5!W;8WZ1=.#3\$38OUV'2;HE22:W*O&DG;;C+3)(2_2EF;2
MXF7BQE/F-RS45=!TD/5\MIQENQ**FGSW\O'2.3<=#`+AF`31MG%@$!*WC@1P
M^-K"@](2OQ`R2&^>'U*YV]'JS3B(>;59O*?KEE=AG,3LP.,C+<6856AL.VXX
M3*C)7&"0IOK7NN:;!HN#67<[5&X1I4TBUB8J&BU*IH*?=31G++=FK%!EK`MN
MK7>=S&6LRQZ%8)4>??AGL#K2?"RKW7IT<Z!4&V.-6%7MJR^=Q:)/L$G+,!?T
M@3\X:M!@?.:.%9J\)X_';!Z!_?L=MTM9@3<13]0TZA50%'8>9PB1INZ7P?9S
MD)"QUDVP"Z,#4T:Y/UKG/>/##`VE-%UT[KB393KP2*6R"3TN%Y4$PVV"'ANM
M8P':EH'+V)#=X9#-C'`ZT+08\^A:Z_R%PS)5>,$FOB)X37Y7WPNI?M90Z3"I
M`OHUMIQUC4UID2TN##%IYFN'C0/,[0/,1/&P5B?+JH>I[6":#;1\F1X7BB=!
MF)`WK^LNSCJ?]ZJY"RLV9P4+^H$2<D`-RCP#&HXE]O^J!<QY/^>=O(*D^#G#
MGE]I7-]%5O7XG\9'N+J1PP&Y70&9]'BA,]7]O8G=G+<_$+&*S\+^;-BW:9L=
M/*`>RNGK<'[<67E72WF3/EMVB;JKYO`@Y@T_>U'@!T\QX0N;A&A9>Y`^;G"F
M3Z:#]FTH*R<M=YU)HA$NG::#7@48!9S;"YRI.;8VERM/GBG-80-?:+&?#1EU
M?_+WIP3+=I"WO07(GIHJVG[F9OO!!7[&9+(IEE2J'5P:`I51BN.B<]=;+@(%
M.&'W>:,C`9]5Z:5MV40PB8^J>"8RE0UTT[O?N^TM0+KUN\YZZJS62RG=K+G$
M>TRPC'!?";WHC=T,[!6GUW?;Z*5Q<[>.84#H=3CNPU>,T[6HTAZV*^5^T_;W
M3%*L31E=OYO-EEEBF(K,5W++.T^O(+>=C@N6D>QRLXEHE?V-)6NPVDY989B6
M72`Y]AU'+_X&%TN]Y<7@RSW3@-U+^`UOPJ?`_SNK:^&'?(7XMJ6BQ-BM`/!W
M)-5U">"NEXL:VU,-*CLV*AL["BWHGH]"CVR*C&_X@*^``6E25V[2=`]968F+
MLDW#_C8U'9Q&9K,HE(WY\<X_^<F7G:](I(V\_4VPQ3__+_PJF-03/V=H.E38
MN/[48IZ#\XT#J1S$!"$BR?P4Z7!`;E=`)J9-E<Z4S9_*L1OS=C8B*=TC?'=*
MXL0+MB37EW\LU4MF>:#01'^;0%;6)O.A=)16OD.[)!>,(F-A=258+S3!&J2/
MAG?6N-1F)%/$$M:W:?S9*%FZ73_IK+,;G5-7@:E8,TA]5U-]<Q[=+$$C!&C*
M2Z_]/8ZNR'#S*8SDJ4[U*:,^6VE:_]MGM\&FWYY)09D8*`?NC\7MA,6<-PO=
MI^K43="F?/L;?O+I4ANOYR3]*K7'C'IWM6U]EYA6L_A"#*N^!>7?`]"XW="8
M\W"Q$U5=7(`;9);N/T[TMO&6W0_5ATS.D55:UIZ/F2XR7V?OP^]NZ`_#U89A
M;"I(Z#*5F9PF7#C?IK-'84!&R\KBD>)GC7MZ30'=<+B<NO.*P^=R@$M&#D?E
M=D9EE@<2]VK2062$4<ZW<?$W`2T%[K]@>M#P"SX\XJCV35H>-GV23:J)IGLL
M9W/'Y<?74O?(9;'#ENAW+L[PD;5Q8#E`L-1GT\;!5F:TGV,[LO.Q*G!&3J&U
MDBD_>J8VQKF8_?`C?'@.3[$7;"^#[<.S'R48=^.[4H0%44"EG^8=+\YBOEHX
MJN!`&D%9*VS'7M:./6%C/#LHH@F0'3K'F?&,P<(/S1A1]_@*%8)T6*\*3*W6
M`TG/?R9^\'3RXV<:(>YVM"#HY2$\R7=?R5\PF:A+M=`=URW7TRQ;K\BB>RM8
M05<N#BAC'P<>WV'%WLON0D`;C_CD?H^WZ$0R8>3'\8G^AOX]VT+,5L_81F*P
MLG]C?=^TXA^)*+NT,/8%"HMU)7K#:+#QC]Z>%Q=--Z/E];)CG"1[\0YR8P.<
M5H)61CEJNXV2$&4EQJE9+Y\BC-E=%=+D1_6XZ41'H8ONQ743UYFDE0+S6NO,
MP7)Y0,G+:-@<,&SJA&0T@&Y?@$8R#PUZY5E&FTD@,HK\6L/+[5]/<<+CT%]X
MJ579!E+U.P;S"J4BVEW/)-NK5;K*LA!(,XQ,)$QZ,1Y*?F/W,WD0DUZ3=+*J
M,L*@]76UW++<E;8;"99=,4E.8C*0*.TV_X(]6NIK>Q=\P[0(,$D%R`-?PR#*
M_DF/5K5NYQZW#1#VCJ"X[@3YRLD&]V6V,P786+Y\>B/3`=W1.GUIL^RILA[L
M"*,-.[GA[.E6[7F1&=23&30L&]3K9U#SH6A$#HM#UUC?[:V&.M45.^/)?V,A
MKLOE-U/7F4[/$]X@;P.",6,MJF7V8C4W+U3QRX(+A49GX]@!"_;RHAH"@<Y,
MR=^"\#'&T0O5]28XGA)Z?":@@S@V9_'QE;U^M??B6+E3XFS-P86RT3!H4W*9
MW=_>C&SB2,8#5UDAQ#1"5970QU<N!S&M@'=_6&%F/A.M:1.@D#8Z9Q41;MRO
M`!KPRCI=_O1;!Y6-YR%"3ET)[9NFU_-%(V;4Z4X%0I-]$,`F6Z60C'-5YFY"
ML@FM`,R6_,?_T\<1L<#SZRV],T:/.JJ787BDT$B[QM%R/1&1JO2O7#ABTFWA
MV%C@&],=!5ZKJ*?ANQ(>MED*F)39<..U0S<F>`>&@DU%M#?W.DYS[I(P+Y=H
M5Y<V$"C?#*`-#8!?<C>4T$IB$6`VL?.[S^%^2[YMNN]:?T3;]CH,QY0Z:0^%
M)O/FPB"A6UEXMB'.JJ'CF/CKDV"/5?S_K&\``()J>;:$J^TF!*5M<550VQV`
MRE<@Z"G00_M*NM5DU:!D21[XJ;710-9YIP_2.,\4KBCDELPTH'QBTS<QRW(=
MX>XXG3<@V-140S?+FB^GS=D1+BX=MSE`&\C&!LE320U(QKDC=SLA=21VL(4Y
M;F?FN'8PQ^WH5*MY<R!688YK(7/Z@"PQ1PT)DCEN-^:X%C)GVIDY4SN8,^WF
M5.O5M(4Y4PN9TP=DB3EJ2)#,F79CSM0>YI"\D1T>B-FHS-_Y>'L3-,=L/5?N
MKKS]YK3G=Z^&^_UU&/WP(MF-#=!:P40`"*C:(ZCY>B:(,KG*J-"9_%HXH3-L
M2T%)??0[!8!2!/!!S?KOUEA=D7PX/Q#/1(DWF3+E+]H_W47';P<0O2%#GZ2'
M`'.J?^A>Z%9WY[\Y1?X1^YK;KGO>%\M)<P7<9/=BT5D#.S\.;!]BW]$%XY$*
MI)^XM><0Q+FA:IV4,*/$/V*7T.6P@+M<N,UU8J/=@15G,^S[)M"]@$7'0(S&
M(Y#@;\F!$O5)&+U=X]5M0GK[<,[6+D1X/Q<8[>@Q%R3X[4?G.APX:>QKLV/G
MD!6&%VPYZF(NX['UW)07AM.S?BG0"%HZ9LGOOM2[R%7_?8B(UJ:4+D%FDWGS
M?&])>';!JS7WO)['`O40$>[0M1]XQ+G9E51YIF%%?-!U:"'/M<QF"U_CYKD!
MO>Q%2P8P;Z6*::]N3-?-S8OE!L1':"Q)#4:W1)W#>H@AV=OJWFT,5AO.%A;_
MQ4^>&[E#7$T>JIF&]MCN)HY/N'4YPZ@NP%'E[`!U.3E=SIICGG)F0345#&[B
M^NBF/A[J-A/&E;8GUMGU?5C,O"D5@=WE68^?-VM;V#063]K"KYEO^?^!,/Z=
M%=IE#]I!I;)"_[@!O812-VJL%Y.U!5&]I/FXH7W-/U*`G[P$;RT*[KV_U8Q^
MK.+M_S_(BZ(-8*2O?]BW&^Z9A+N=-O*S$JNS,F\NS'=%J!LV%E/!,>4Q0CR7
M=+?K%NO/DKH?<>2'V\^!@0A_UL_$@OM';\_2=R^FP?T+G09`4^<"T=K]9[3>
M]\2+DC=NOWG3?I_PAAU*R$PX??L]8]_`/'ZOV.MCCG-MA1_%23;255Q7(7C,
M^#4531UT;SAP9]/Y*KV>@DI!^=@>Z%:*H5`<TU!:+J$8BL?MB,?,G1-R;A1W
M34B0CT?.AXB(?F[C9O4I$&I65-"]^&PR<U?K,C-3*9#$'`#$,0Q$@Y8#T+C=
MT)@CI9`354XV88]$R9]XRZN5W@27_&:LSS^/.(@;ZRWMSYNGJ5P9W7B]F+GN
M(B,L$9?5!O8#E$I$F4C3U!T+G-,`=V,(7!N=QT+H%@B]_/-E][QA!4)#%&_G
M6(GL+48!F3CB1^>NPH"5W8G550?$#YN<>!%JH'T,?Y'="IW*0;D@Z!H#PW&Y
M(EQVU!E0^EAEC"HWPSA](OERR;/&(%+TG/$^4*!$A['*(KW7G8L!'T<.!N,8
M!]/2QPU&Y'9%9*9/4W"DZ,MDX$'ZL%,4^,DIPI?!EG2R]*>6?DS^@LF^3*J%
M=CW.(@?,9+';>C)IT)W:.`#=*D!ZN<Y.!Z"Q[JW5_2I=G-HH$/SY-QS@R-L3
MA2ZW!S_P:05&>NEYFIQ*OF[;6P:9U***]HV8LZR6:"J0D:DJ,AM5P3!J3*!N
M&2B[/;LB$I)1F@Y9II6.92SDEK*;TGO7'IYUK28X=779!MR1C8^[A7Q6]&N=
M7+<#%X%[NYO#T?,C=AUP],F/CV'L[>]VMV'P=$MT3"=H]$Z8]1)ED*]]]-/M
M0YS\]K6B%707H:P=NDV$MH184]GTI#6GT,YN&K=FFI";XUW9')#L'D*#,ME[
M&Q*$^\$F/.#OB9>P[0\M=?)E3YMDL%@%[=/3JWEZA(,+0KDD\+KX8R!S>R`S
MQB^UJU4HI#"%!2RYI2WY8:"X54GU!AQ;RFIH^]7$F4L8DXD#O4UI+(ABZFA`
M!.*/R`D5'&K8Q2(>*0]`J]^!YU*W8[W.>N*TL@GT-/-X,-L89<$19BV'U&`5
M\!%EKM6#]U-SE"9[W#B;FCIH3X3/EXL*D8@HBP938Z!SJ^A@=G7HNEB3)!+T
M0/R(L!?C3YC_E^TV"4\!&8=YKXHRD>WOF66,6AE=YUJM5\N<.DP4RF2FNZ68
M5)2*!6/0B&CY_<\9L*,<F$$ZZ7EDC5<:-K&&8'0[UTU`OC2.:5TM[+,3%5^Q
M8G:ABQ!HZDDUT_7,>;Z)0\9#MJ<O:P,5C2#2"M0AX7/:8I;2E.'V,]Q1+M`Z
MQK:Z>"M]U9:SBLNE>GI=?:/\J@V\+>FCWX\X"PVVEB1;U'$.P>R62;E7PP,G
MH\!'M2A8-XX=Q,NV?1:!(>[2?4I>!R6@6"?M$ZZS[`"=D(3Y)M^2=+OZRC'@
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MJGTK];.FRTG(%-$MM.5,YUE)B9JHXC(VLS4EQD'DF$>D+BPQ#BQ7!`NX0]4B
M3UYC0FD'F$Z2STBU]8G5IXQV@96F]=>]W;S'2V<2P7NW`4!F%218CL1<9R;T
MFVK?U01L@8M_PH_R*<WFDW"N3IOO,(&^$KL[HF*@1E/#\+B6.WW9DQ2.G^.&
M=/Y[DC.V?";V"("[TW:U-QFZ\W7-S^GKL/[=&0"?2O?B9\0&)[LPRM>[;'#O
MLJ^(_#K'"^O0;`GMZA1%9(30^H4J#X,X>5D#_>L`ED[#W?FZ;RH)VO-[H[)X
MM5?E8&(^-*P`R8QBQY4>.9K/`_"CH81VIK!R)C6*E';96\&28=C$1+%E1WV+
MRXGH(C8'#&->B#YTAHF?=\LTE'Y/R>-&^2+607MN=#;+Z9))0ND)Q1M%#F*"
M+2,@JPX9?"8(EB!J#ZOR0V$`6'H\D*:4I3(:#X)0(FM=^XSN1$`&*@2X',8@
M/&XW/.:94'<F,0<JV.&]_\I+\%,8^7]G\[;*$H<:+X*Q0Z2-MG?EMZS6O:LJ
M%;BPX<B`:W2*+2EZH>N;<G))+3/.<F):1OMN=Q4>#F'P/0DW?_N+%T4>L>%#
MR%4)(^&M+=KO&E]NU%1,MV3Z?.E,T]M<RM>=;YAP%%/IZ$<J'B4AR6?2!@RO
M29X%ME.!?;=#7#ABTE$F'CV$Z.:LL%L6+L^"O7'#O?"3PRUG=B1OL;S9Q5H@
MG7JN(%/M,MAFVEV'T7<<O?@;'-]%5WO//TBSW4XR3';U7133KJOM..LF5SE)
M:7'CG*BD#90U0HNF\F:`<H"S68(Q]VL8O,.'XSY\Q9AS]MVC%^,MI3%=\N%I
MD`T+5GW<O9(R=#;D*-G#__*".,;!_;,7';P-/B7^QMO'9%@LO]ZF[173N4*+
M/KK]A>.LIND-C:E$5!-Y0:=OW@-=@3,J2D>!DH*$O!EG5*#NL,]I)`?0I&#>
M]>L8"*+'OZ7;)B^?(LRJ_:GOT!$_:[`'%RJ@?6/:;)6>?V%B4"$'>$0^'!7O
M=?$/5$-FQ9T"2@\K=Z9R.X`1X_//HQ_Q^I=>@AW5!ZP_:IH6M?:U_6>YJ+"B
M$(.H'.0`<F(()+>`A`M(6R('G`L2IVI0000?C`G/X7Y[<SA&X8MN1R%YPS0O
MQ&KH^M)TZI;I086ALC0;NHX1$+I5A+XN0J.\4;M@@SX*LX"Q2*]ZL?!1T[SI
M6==W,L^*R/'@:TW!XL&@&$<^X1V.(KQ%WR3;9HPR0J-2L13V*!,13/KWQ(L2
MVD6)!H:U)TQ/,U2;U[ZK=4++`DX++XZI!)8]O#<[@3!$_Q(+F026T`',#0S!
MX(J^`=B@7^SN^1A?`+1_3Q/CS?NG\.7#%ON\DR$_U/L6\BO2Z).W_QPD?O(J
MV((B>L)`3R)H5C<?<=;S6>:Z1`#B$D!VG`Q%X79`<6[_5;@*]5\95)A,*8XQ
MIF2BU2SH=/H3S^"*X_.4:/$#C@YT)2U0E6'J*<QHMM5'0^W:1,MY/H"A[:"T
M(51NJ5QC@K6%:&-\T9DW!Y6SG=TTO/1$#G_/X1/-#K#9W1`*5/._WB8$X7YK
M=1B@ZB\]2ILL'#==M#E[X98P\?9*(O74?D&U?Z#2H<^1*QRDXNX6%%8IZ7`9
M;-G",)V+(,'N\W^<FB4CM%^#\7:A+MK'^9;9N=N21+8OHBP3<:'@U!@.5<P7
M5@0P+DG^9X2EB`&(I/12";ODMK*1<BVU.K5?MXB"G8M43E?Z5`0OTGD6]&X=
M_5ODI:I$9R>K`?-4??A2\"`,]SJ>W9VYV>V793\[ZS'+#AU<'S"E+FW#7[<P
M%50<JY3`M\/[]?NE^@N@;.@:?=?+[#X^`2MLZFN&X.-5*YH4`2WYW.YR:J[8
MU&-<>W[T9WKCQ"<_WNS#^!3)ZG&UO`3#'8$FVF/QN2O(W:A`Q"2B0B0XA8;"
M=,5#J`/VJ*@M\A)+[A[1\TP)O616&F=5UM_0G?7Y5CKIVJSH.>,KM`(E--<(
M)ZO);#I+UVFYF-+>Q[.M=LH7:P=#<0Q#:5FX'8S'+>/Q<CRPB[@*=A1+N3+H
MHQ(TV%Z%>Z)GR+?Y%7M?[\.$_,?W]O?>*_O%=1A]PB]X'Q[I/[_X>WI0+&A,
MDH\M'2H8#%==UT\7B\FR'D*"+:HT7]XJGBN`,@W8R:Z2#JA0`B;\F#:>\X:,
MIQ?P3%N0A<G".+M30O(!M"V9Y9BV!QXUQPM9C5@[DM5A1BD!/=1+\E,_N?8V
MK&8Q/>+KLW("UQC?8^*H)/`]R8<L^A*,CE^TU=+>3#F=3[.8$?"3[4P\RN2C
MH@%$6D!%$U"#F_/8@+$^![W#P*.9SAY<'=ITLY$M)/WB_?0/I\/',(K"'_PF
M*_(7Q1IM!Q'`-)7II;V@.7%;>)JV@/(F4-:&/40=Q0J,J1G:QQSMYIQH7W#T
M&`+A=1C@/Q.^\CSD,4$[/_""#=LB%7I!:2SG'<(3\%;X'KQNBUU*,T(%KSC3
MLFWM3/"HX6!4;U_7_:;+B5L$G;@4=4!+E0Z&5.WK*86@&2-SICHSA+!A&/`?
M)Y_H\5I,F;8>I%*]8I01<CUTUYCF>:WK7%IIVM^&`U9C@70K(&%YTNYR5;ZT
MF`"$-V'P1'?WTGL6BBS\(_8BTJ]=^S_Q-J\\W%PGZ"G$)+<Z::9=V]!=9@>H
MB'R^'9ZV4!J,HK0-Q!HI;A[_9GRRWH`IFOW7!4D)?U9*;D.?K>_EYQ7Z=K<?
M%*&35,V6RL/"1PV3L]Z^KM\YT\FJH&"2,Q"\`/%@4&X&ZEV.ZL*6.L0JYZIS
M16@$&QC!2]!J?K[T84!6<`VT<Z1UN6NJ\T)1?=<\,WH`4W##@L+":D=3\:-D
M"L@DL#S7T9)%5!X%2.C*[6O/7CFS:3UMJ\Y>PF9FO3&)\J\]CN-\3^XQC.BB
M&30Y9#XF2K,:QH`A1AS34X\DP\/!QL<QU>HFP=+RMHH7C))$IH7VB8C)*IMI
M([)011CZG9&&R0/K2D8!Z/8$:(XS;>Y798[2*%;PYX'>7*3[4?G#D+QA&FC7
MREI.5W+.,%&VT*4[+BE5Y+C`6%)Q,B5#"CM`L..+]]<PHNE??+>CF>!EL.4G
ML;YCTG'S@UKRT;ONVP;YHZF2KN.M%MG&=B:8)?ILT8>-:.A>LO0\8B$>=.A_
M#OAN'7Z8PO<ZPC?%QHY.7:9G%_M9RE?EW(+^^W9QMMM`?;6:+SJS%G1BXCPF
MZ,I<"R8P.CMX1_8"3W-\\:*_X81V^85*ZLT2JC>,<E2JAO;IJ?5BF;$R$U9V
M/]`-%&/A<VOXXEP:+*M:W:[*([4Q8)C#-CPIRSI7GS'*CE+#VH,:)[N],MNY
M!UNKN3\(5Q>$.7\7.$O5P^M807S:#]I]NO*,29\N-ZR]%K_.]LZGKT/[=&\0
MKBX(8SXM<I:*3S>P@OAT&.!7WH%<GX*MN@Z_Y&&37B[40-M3IO.T@AZ3@[@@
MQ"1!>_YP8&X![,"![5J!&6.#TLTJM)`;8I2SLD1^\KQ_30^)76/QF5?!4Z;/
MKC95T"YU/9O.)_P,:BH$9<<IJ1BSITB'PG",PE"?YQR*Q2UCV:=8=A(L1HYA
MRMF0'Z>4@(;HK+[BY,J+G^^C\,7?XNW'U]]BNH?N.CM+<KE)_!=5L=<.`@QV
M:OI::=^=.<OR.B(;4>$HDXX^OB(J']T$*&\!%4W`%!4[DPD6F0DVU`3'S`2/
MKZ7S1YX2NJD.LKMKESO-CN:SF[LM1<QZ"+*2RYU+3BXFDYZ<!B^)=F:K\-U,
M;Y;1JA)J/2UG$</Y+>0#>F>1`'A&"[32[9K6[MK58'+>@JV]\U`3R'MG/X=N
M-9<5KJW!89GY[.9NO]Y9)<A*+G?NAV;9Q8Z=.6UK[SR655CO?/-F&=VC=VZS
MG$4,SZ]MZ=L[BP3`,UJ@E?Y6C*E.[US<\7/NWKDG?8>:@-<?IO!W^_!'C"A_
M4)BC5M,8+"<9BKJ:DYQB=B)5&S9P]%*062-JR4QG=[3JEX^H!%D9O3KVO-/)
M>K+N&<5LS4?&LDKMBK:WQN@>^4B;Y8`8?A-LP@.F6^SECE!ZQBPOBX:U#]8M
MIHN"<OQ]1`6`L:@G!C?#L#^;\AJ]>T_E%V=77J.2V@#_J1@?/"8U*5H+-S68
MX)'D\L7S]W0KY$-(ZT6&0?G6HH]>[&]T/IF&%*AHU*Z:?B$Q=RF,5RAO`SV$
MB+=2O=6+M6-!9!C9&)78@;PDB?S'$]\8G(1HPPU1ON#+&G;JN[V4OYJV'&43
M#FF8Y"@;C+?Q-0%U$\<GCP"^V]U'_HN7X/N]MV'E($6[,/1?-KUE1ULS3:]<
M+I>S%=_(0[TRDXVH<)1)IP=E4ODH;\#L'I_SX'9LP:W>%'0>\'D:<,S`L_D7
M/P,?[A#M#HM]#*93G7-^>`WPQ_3+'U5?WL@6JLZQ+-]9U<UZXP1>`H8,$+.F
MKL(XB4D70`^+D'%B*>[G"\S"S]Y=BO%0W%E%W:U\BYGK9D&9-U*$)-8,RMJA
M,X?E[*G8FV$X/)_9%HZ.+6Z,VJ(E9)_9(&[9('G4VC"#^"7G*&>4ZDAN)I+U
M#@Y%2.MG69!A8QCDT_H\"_[\\\@N#FF946Y]S^30L$T9W<6/Y6R]R(E<+'>D
MH\)4*/S,\*AP^41P\HPCRDJ*\[]A+NZ_@UZRJ>V9E;&<EFG&22).]$@&/;.=
MWYES&6SK5YP)SU7HOFH\7=#3JT,W,'/2'(%)YM4,BON7:%&#QKU\AD]FG`6S
M8P7FEN[_',#=$G`R/BE?MD7+-^SKEQ;"G?GH2-^B;^]@ME'BS-UN1X2S>[P.
MQQ/YIK0Z!+^B2W1*4>\=TY&E32%-+W/<^6HYY2&%BV1NE0E%N=3SGF.4!I-Q
M83HEF)<`,-7Q8URL;NV3;C*L6`NKD9"AR\0\5FB9""+KSY?"T^Q(MO3<?,Y@
M5M]H7#.MG4T6JXP\>0J?R8!9KAD&95%<WEV,2;`"D*D47>I&Y91<C-T*KV\9
MX\J?AV1!YT%>O@>JR0;PH>PXZ&I[F3)J@`Y?6YU-R1'PC4EWU5&T8GN2Z$D(
M?G3?:C++*^[=U:=ZSK=A2;NKZ(EGD1><+6]5#@,[.@KU3AH9=E`"W&*/$/*:
MW1Z=5JO);DS^=)+59-9]&X(H:I7TMXID!P0*\G#)B(M&61VB_%9R(AV84R-"
M+R5EZ<WBAQ0OY*WB/;U72$(-8UE,3'6!RHY"[*-IUS*/BU4C"6QG*VQURS-:
M@B6,=*KM#7!44?*RAX4L9BP]S_^"_S?VHM944U^0?<PM::=_??3"Z<%>5@?C
M!2/6EM4<[FN3C,>K-\!C@7OWX'+=4G;SF3C4.'S.!5G)YTP[[8':9+GLR6?2
MU-O@<R^;9'Q>O@T^U]V['Y\KEK*:SP^DU7$ZZ)(D&QE=J*>=5CI]NVC6UIO@
M=$^K9*1>O`E2-WV\%ZMKMK*;UC_"<4B=R;&2TJERVI,\;E9VM3.A?X1O@\Y]
M+)*1>?XVR%SS['Y4+MO)`B)_(YJEZT1?L>8$5^T=.()6%=%UO=5R+IN^H@+S
MG;E$I!6D&X"2$8R!LFJ%7^5Z"E8)#`'"H.C)"_R_LX6PJS"(P[V_9?^X#+;W
MQ"&RK6MWNW1'OK?_3G[#M_*U[1(81;9)1HZAL/;Z_"JK"%=N%E7:99O;RBW3
M/;-YVZAH''Z[@G'3N7737=1LY]5M%_:RG;&`,B83*X%GM$_SY@+4)S_>[,.8
MI"\/^&?RD:CYMW/XKZB9MQ*V!+KK]LK.:KX:+X(5BJ#?J2J(Z?(6P]E0DS8B
M&PMEGW"\B?QC%LD^GF(_P.*].&\B9"FX.5KTDGV)<8X?1,ES^&438']_$VP4
M1PY$SQD_9B!0HLL!ENQH`16#OFR^$CET1QC4:8+!:)PRFL`(FI9#`X,AN3FD
M=\4'>F_!X0`%3XH#`3+X(#D'/?-YN=E$)[R]];U'?Z]QLVO+2R;S`:4FVI-:
M"S?;`\J.P*8"44DB\"Z8\6"63OIZ5*"WA^U7M?ROTDNVVP*.2'&,$RWR5!XT
M3IARZ]KW%*QGLPI)F!`;>-$;38D+&_XZ\I@P>$:('*G)@@9R8,^G-2]TG;_T
M+(S_%PIH7Z0U7XLH4`@"9T%/3.5.P28"-/U)PH$:;C`:T#.>$7[&0>R_8$%!
MP>LP^NZ5+R>_W/[U%"=T//,5)W>[!^^GZB./(=XTV4;067O[T'(Q+_.STK2D
MK"=I'M'V4:$`*C2@BTET&H<H`<AMTR9DX>"W(,+>WO\[R8.?/%KX/TCOTF5F
MB_.VP$/%B)QK1)>Q+&];0!H0;&P+)%T]?+YREGI!XMS<;SVQ-#;J12G?K:#F
M-9]L97)?EKX)!M[CR`^WY/<172O_A/E_VY:;APNVC+UJ;;572]U99VXCWC3*
MVD99X_`+S6;MYLJB`RT!_H&'"-C3]*/1J6L$T;`R6'PIS8'I#;_%+YB.!T(M
MM+/4^6):YGEYHM:*T?AP="4V[@MAX/13>EN#5G(S@-%%6AQ2]3GE+YFFC503
M_2,VJTH7J:AQ"LB?<6"6.)3NH[Q`@7AWJ%$2M?I@@TAJ>T"0Z=Z+**WI#1D!
MZP5/'C%B1#X*VX]P^=.7'270>=,@K334T4VC%LMLB205RB^-R<6BDER271+)
M0)GEV)C=,N:D#V93_.O@MF42ZAK,0B8*=^MT>]<>-G;9++)VYQ-GKL]'D`TQ
MY\.MS<E/X<'S`YM9V=Q(T]UL,,SD)XBNP^A;^.KM%5=*"Q\URKMF^]H'/&?9
M:"P_!4=757(Y4(P:B(@?PF&OOF;UG&!)(O>F*B<DP$?9"II)_^)M\6_!EH[Q
MJE6O13O^VE\RO4FT52/-#8F3J;-RUGS':.[]5"AB4IM5WLWN'AT9I@,+4[VM
M=&2L;@7K@6(],:R>"J.1;:;:',SWG.K9!K*/?`@O-_]Q\B-\']&1;O)Z3SX2
MK:J?E\MNB?,:`@#ZTW:MM/NDN3.K$9!DLZETE(E'3#X[BI*W,"X7UQQ\@)^\
M!&]U>N"Q;3!C1B`*/[/#O^P*O!0]/3V"5;A-=];Z;BWJPC4M!\);HLE7[X!5
M$SWE1TQRK]2NKF=-5EF!;/HVHJ_#SM#TQ>#J8C#&!(&C5'R]CA32F_E8N.6;
MI`\!>#1O6?N$'?FQX=.*T;XYK^Z!H^[7-LQ:")U&Y-LEO"#>361A>N\@NV_P
MWHON(G9P</MG;W_"]SCZ_NQ%L@4PS9=-LD%+(UWO<N?9=7^YW/1>3B(9W47\
MX.X6,>%TLPABXH$(-#YTMPJ=W<!Y@8X$^PN5"4JP3GY;(9Z^G>`)R72)+T_)
M<QC1_;9:W[[Q$A@!ZYKHSE*OY[.)F'A<(BI$VD"V03#%)(LY3D^)$X9L,I^4
MDTQH'UO(16_A[42L]`5@4G$MM,/Y>CI3$HJ+LX=,/>`Q(EV%P0L9#?OT(,*Q
M2BIVQ_29,)(V'T,C*!UEO)!#A(P558JUQ8F246R)$7>G)$Z\8%NZS%OCZY;?
M`HX6)56T=V\X,U<9,DHRS\*I8QC[B?_2F51]L4Z5S`K/C+97E.P+M354GAMM
MSWC9VXU%G[8-)&3$%`2<MK!9MPU\[&0#*JVORY\$BY&L>>U2&9/Y7!P7_RP;
M%)L.#MWQB$/?/TW>3R83IQCQ_XJ<R07Y%?U?<XCR/U`05A,1MNAB)<TJOBFG
M5F%)(#H=/7^;[N=5UPX1/VN64DT%M$L-+"?+G%143%ZR%[2(R'!,;AF3#15[
ME3Y5(X($.PP5P@W&V_B:@"DE+I_PHYP0\C>,TD*JAO8ESWF-W$P8HM)0.8&C
M\J`X,@Y`QI2O86+)*+;5W:I<4=L`FC%T2.T1T'>[^\A_\1)\O_<VHBUY'5\&
MXI%<(^W8O)H**95)I@>`4]DH%P[/KY&`,ZK]6T0/.Q\S^.PV8#^#'^[H0=]#
M&*1#)9K'_?#H[NF$T#-`'GF16^=X5NMHC1/'=PP>BW"B,`]E'=KQ8JO0B6T7
MHLO"5HOIQMD@K-4>.UE]C7%,-S.E&5/MVP^59GQ+<6]5=8N?SF>KK#KM?<5G
M;TH^VXAH6:T#VBC?&*C(4,\2WHV:IVO`-VN>EBW,AFS4#'W>CFB&MGA[VK"3
MP'G$1]X3_?\=M0[;71DG_H%MB`AW9`Q-GX4<\8P4<HJ-TL.^@#4Y("M+=;>C
M^T23URZ=:O5%Z-ROHHUV]^XX2W482$N^$=9SR18E??T1N\U^02O58V?BZ1/Y
MTYLP%I>`!$OU!OB!P"PQ_?@UDUB7W`D9W)K8-0T%'9)NZ=T-=[NK"&]]G9%H
M]7F@`%110KNF\-(1IA],&`TV7!Q\L.F/CI'I<DM>(TFPMZ\-G5Y(UT@O-=GB
MQ\2^89/0$66$:IH(G$=A\/2`H^Y\$KX'Q2N1,OH>Z*Z$_")"$95J(=,&XV6,
MN_8VM(S2*]J'7G"!MI'W(["&5BJ_E-)+:A=HFN5'IK_A#?9?%)L&5>\`T:NA
MB+:KS=?"E#D7B#*)\)P:!K)TJI_"BA2P(-@D=3\9D\36@&81S4+)V/B+E]"Z
MR*]WNR]YZ>BB5K+&M]:3`\0V+>6TE\>F$^%B!1NHTFFIK!G:O14-E<J6PS-S
M?(-(!F_LT*]UU<A[$T#&;7U[`O%=?":YI7AQ^WMF^:Q61G<+XFJUR#??RX_B
M@]<4'A>O6\9[D0+V.@`V2$T]7ZU14<-65E'OX^L#:5MU)E_C31OH5ZBC?<YJ
MM9AK$/#C*Z*280_WCXRZG887;:#!B=CT7"TJUBQF%1G9YHNN+L!?LH&"3!/=
ML=5J-==A'Y-I&>FZXZSPK5ISY@(]R2""4ZSBCUKL*DQC%;'HK-%-@@^=R56\
M:`/!<FVTZWI.EVN='),*1DRR;1U</\@Z:68+9G#R-7Q6BX!5>UE%PJ^X\P"/
MOF(#\8@>^KN6%XX&Y;Z*J\H#,JTK1F6?)BF:/QQ>VQ58H\%;](`''C-*%-.*
M%IE1K(H3]^'>W[P^X)_)1]+\W[I^Z/KK-L2/FD[:4R8+9Z412[AT]#N5CU@#
MMO7B0_`WXXRR3B4X!R7NJ\5'D9VLXF9O5MK%Q\Z>.)\MECJ)M+T4[`?YK9&O
M'^UL)AQI65UC4N--*RB7JZ-=G70VTYDAXO.4L%4J1P:M/SUK0U%+?=?5(V/5
M9E:Q\;<8[T[[6W\G+V#1_J8-;"S4T<[%9EK+E5PPHI(MXV)/R,IA;G&VY<1Q
M[_T7\"T%NJZKQ<::U<8Y\)=68M]>L>WTK*0&:;/TK[^D)PVNR']?_>!)5#-F
MD"CC1_WZZ:E[2&LQFTXFZ3F_K*7F^8W*+_)SNYNT05[+Y;WA,WXF[.)4[<*%
MI]5Y:/2J_")K#V4-0A3P,6>;K!+)%A-E#GY`['.,?,$!H&-NOUT8Y=X#=X)O
M6`PICN\-,/*XP?![N$N(6;'P^CWEHV#!K*J'9K>ZF*TGRWJLRB2=]U*]]C`T
M`)$#@4@S@@R`Y59AQ3JPS$8`,7&:#!<8`6)P\8W>-:C8<%7\W>!`(6]4NX#B
M;)JZ/'L5='=4/^5='>5-I>T-IR@GYU5\8#ZKO!>V_(1IO^T4U::35;:HDGY\
MT&M<^P(H>Z\%DT`"!VEX,'3<)3DN/M"M\*5:7-6ZCFH/UW[?I/_K*J5=3=R9
MI_6="]&5DG+U\J;`]#D+?K>&?Z.HB0R9!_5V[0HW.YD0AKE[.L=&KVY^?2!C
ML=C;T*%)W')LI/4UHSQ5ZZ(]);E<3#)Z,HF(B41EF>!'1D8%ZPX":XZ!>BY:
M)9Z&F6SBVR<_WNS#^!3AMFT`7218P$*!6MK)V'+NM!*RD&_!#H%S&:%,U'=-
M(]C(3H5#ZQ!59C$8SL:86.3Y,MA^PB]X'[+5F[34F-035.\8Y:5"$>W#^K-L
M$BX3QR;W2P*S0GU0O!L+I%L!25=VMH5`6)YI.&&566TVL8Y++6/$]C=MX56G
M<9&[6B^F>NP"'Q&.BUE)-DM&?]KNJLT]\!&?0C>^2;;/YT_?M(6!7!W]@[O+
MA28#N6`+^=<#<9-_`L3`V:6VLVKSKV2H45:9:6/1"]ZFET+M2NO;UV&4%8-\
MH+-`LK%=?SFFUZ?[**GID_/U;)8N7F>MY!??[:H;24A310%9UMCY!W_2!>ZS
MF\2QU23J%?*SV\45V27<E:XJ1H^G!/T6I%=CE>T%MK0^)%KDZ^Z]30N4<"21
MOR&C_"LOIB&9_H=N@GSQ]B342-?JVUXSFVHH==$N6#`IY1FI1$1E\;UR](>2
M5+`D8SRL;@WKAL@"SB>T?+&63+0;!(98B4=W%7[VHL`/GN++#>F\3VP^[1/>
M^1MI15J-%XV2JTT;79>;SXH)8RX394)122I*Q4+Q:U2XO`AT"=Q6#LX<RW0=
ML\HS+<.,E+._T._$+W,][OV6@]%Z[YC/Q=4*:?K1<CU9K;.\FTG,;IVF,HV=
M@%;DUR/"=*!AMN7,(V)U)5@!<U\]UI7R7`USC!,06.7>UWM,/B>AW!/^2+>U
MW@5?<4(+?PJOPVI]QWA`:%%(\_B",YW,W%D:$;A(5,A$3"BZ"]A=34RNX7@P
M*DH'%F5+.!@5*M]N7D`D0^4H!9Y5WD9D?$POH(EE@,W$"4TR%G%"QTZCQ(GO
MI`$O\L.[0'&8I/F0Z4C0T$"SXUC/9ZL59WXF@G``ZNC(,!2.611J)@^#XE:@
MA`&^2/=-QN3[HT<O]F/X0R-2:N0T%1MA5%X^_`C;>5D\!,7+7`/-"#Z9+R;+
M68V81`@P,7O"<,S"T&-F3RQ5:B8M6(P2L<&%!A&KF"'FL#)-?@OB(][X.Y\,
M]E4E6>3/&YRQDBJA?\QD[=184)(%7'%E''057EQHPS,U1=7J=^69*;5%8&CS
MC+<G>KG@Y683G?#VUO<>Z:U4/HZ5*\T]!!@EEJY6VL<1U]-UQC0NFZZ<IM)1
M23SXFNF9;9#-$]=QPY*PJQ=76=G)4,`T#1)_Z^]/"1EE%]?%?/ZYV9^V>$OO
ME[D*#\<3SQSO=MD<.!G1LC5>AJ?=8<9H!(;N(VBNO?70=2>"D%#2H'2/$\IT
MX!=`E;1@%Q9GJTM$$;X!@000J@M\[#!M4+=BT%##H+NZ0<.N!@6(4R/26!++
MQOIP;SO>Z:<O8S7T)N->Y\*CRXESSMAG4?($85F>9)&6WWUJC7S),ZY'/_82
M^3M=<K@-XQ@=,]/^8T0_S6QNS"\WTN1BIMO5,ZVV$-\$UYX?L6I5=[MK?K>V
MM]<=@XTCT_S4Y3"%==>JG-4JJV%5CE%IH^@F0+197CF._B%O&6(TIY@A-6FM
M1D2WTUIM$[$F3=;(5S.3^163A663W01Q$C&6P*V-CA6+2G/!(Y@=-MG\?#CN
MPU=,>HOHQ=]@U@U\3`L/TB,?+*9=[IDNK,_XAC?A4T!WB)->PP_)<W$2ZXVQ
MQVP+).4<$8!V;K28N,T8E2F"4DW2)/)C5D@T5P85VM#W"GT05P@QC6P9>4/9
MMQ'0Q/9]]]BP[T79P&$O`YO/1<_`>7$Z.O;W_(<(E=K#\[';>\LALVOI#V?E
M+$R$37L&[9"&YO'S=#AXT2N-@FS3Z3N!6165+MYL&-0;F9_C\\"&PSS3O8QC
MG,2707D1Z0OV:`&:[5WPC4Y#1'[P])%NM>JXP#I&&R!A;P3%=3.8V7HE&,66
MQF%<!79,KCQPS;2@&W5S/1!3!'Q0"V_01DK8-*@G,VC8,*@=`6]$QHJ#W%@?
M"3BPG1*BYQ<_\`^GPRW1&M][KVSFXCJ,KKRC3^_ZI+_N',WZ"H8)83VUU:;9
M9+(2Q"W6*DJ;1:P!E#7,3NJG3?,_61FJ3!B.Q2>EL2R).0/))`DT0TP,&UWD
M%XQIS:&UO`X2*=0Z:8\DG)E@;TG+O9963%N-B%_GAGB;II+TO%E,8@VSP5)5
M,DBC]^X\819M/KX6SZ01Z/*'%VWUN#Q4/@C9!RJMO1%ZOA1D!_+YFE+[Z.-K
MY<%4!\24L"5FF#1C8RPCF\VNFO'QM?*@MAG-1Z&1B"H.4V-\*>`X1J?C/KY>
M[;U8<Z6N^09,K*FKH5^B;RV*'NP</XD.3*`UD6`0R":W&<A'#9``/)4YHH1Y
M0LN,LRT)$\6W6;4OQ;%'T7/&MP\)E-"]3M&=3>=IA1(NIJAT!W3^<3`8QSB8
MELTW@Q&Y71&9V2ZCX$BQ!48&?D2:TN+V)"BTL;3Z&`Q)*SKHGH:=K%QG7N%H
M*@:4H@.@.*:AZ!!T`!ZW(QZ#]!1RH\;.)G*0?!1'/HX_=KC:3/6&R7Q4KH;V
M]5W+_.@^$X8^6G9AV5@8W3+&=TX)I0TEZ35<L)*)MA@%CD57G5DD?L,XBX1J
M:$]FS+);TU,/N[*21<,QEEET92F+E"[89)'<*'`L^MR91>(WC+-(J(;VM,'2
M75=8]-E*%@W'6&;19TM9I'3!)HOD1@%AD7!F5/95Q0^;Y(Y0`^V:W+-E=OQ3
ML@@!Q);AJ!A1\KVQ["XA/\(;XC7\,MET`6!37BG`9[RS[`5'C^'943L\/O0`
M:"Q$*/E5B0YR<X`%AD?%DDFZ8O)87S'Y_//H1^QAONE5]?5'D6\Z_(RAM';M
MFOE\4HI8ZN6^?-%4M-A7:)#N?P<,=<8MZ!8Q7Q`FO)()'U]17'KNF-K0HRI<
MT("2&?$H-:+1T#(F0QO1:+3O-,Y$<MLBKFP-]R;81'0CV4W`+XS)KH\IZN4*
M9QS/V)SQB>WS8=%=)9E,%[-I.D&NL0-$O0$D4XL>\$XO/LHO0BI4,SSC;HN-
ME0GNF[!QRU*`+8;6[U6.1=5Q/S.K'Z0]392J`;<*<?[`6JQFG/GCV3.&UL!T
MZP?X)L$'V1U@(P@&'YMWT58[IYOE6X,&A[G?:>N(-0\U5V;6;D74:MD]V+)Y
ML,5NL`/L/N1K'XQW_B:P>>_7$YU:3'<_QI<OGK^G.["NP^C?R+L)S\^SN/H)
M\_^.VN/VT^#-9,>]X.EN6W"FTY4S5L+,-<VW7\<H5Y:=QV+J9N?B\\0OT_B-
MY-$&OL9(?8Y]7^-,&;>!3\*ZLTS$-L^J8^3E-MT1F_KI[K:WEV0/BN+#\^[^
MG_!-I>)W1_I@_/DG&4[X,47(@8^=LTG;>0N)NDQY[5.OT^ERK!B:ZH)*RJ1Q
M]8UE\:,857\J(N!]3[A#Z;7@(6__3>;P;:P=):57?J`S9OAIH1W]#CE[P8[\
M.=5&]Z*OZ3H_XR"+#8K*0Z;3T3[@U('OG.#Z9'=]$%J[&J_/LI:$J6P5>_(;
M'J$N`YJ'$:+Z+YB>QX[Y;;&=^BNU)/`<1:F>;H<Y7;<NDO!V6*6"O"5VD#].
M+TJV*<<8SR@E_NIMC8)-$+3<OCT%:+<?&-.?P_V6.`6MJI#P,Y27/WWE:H'D
M#=/,%:NA?0QA.EV4&)H*0UQ:=BB6"H2<L1\!HEN'^,^Z&(T23^V%#8(I##-2
MMAQ&R0..#C?!"XX3FII>A4$2>9ODY.V_>`F],J'>[75YTWS^K*.6[K388CE9
M9'<84\&(2D:%:%22C3+AIG/J\0$[%@!NR[/'1^WFJ-\E%/6F!/7`)0)=<M>#
MJJ7<6]M2(%VS_Q3X.W]#2QYM-N&)Y`S!$TL7Z.T`;:4$]5XVV6%K::1=`FNR
MRH:ZA5Q4"$:99!OJ_8V/O%%&66T$T+Z]DQM7NGE]NX'P\Q@&<1A=8RQ-E4M/
MF&1:T:RN4RW=5;8!G+^,Z-M`=.FI/K\6;/OBDY=?T0YC=/3\+4I"%.&]E[!M
MUI&X2S;&A:;+5!R^AAS$JTD"R>:I64J=5M91#0>ESYOT>)D2VN.D=>[_F:AT
M<)07@P(="8Z"CQ&$HPK;41GC1)O#51BB-`0H7]*!:'@@)*:EWG0X(WP'@C<B
M173G]);SM5OG3C:_D`NT@SZ#8?+SCQW`&6>1R@V%3)+:!)1-=[LK+WZ^WH<_
MXLO'F(W)VCZNZ!4(+@GTT"^,,E_4J43O&23R$!-(/"T5"4VEH2C=*LJP`TKC
MG%(XHY!2,ML`,RJ_9?`^C'VV&*'-+/FK,`R3ZJ.]G66QG@J85MQ"F0FVB7'C
MH&XRKS-J``:V.J^$B6J;@3+R^P8'7N2'.IEBY5D(SI45T':WY=JIDRR38T="
MV!M56DRW%8MQIHB<2DB-!G08+I#Q6V4EK[5/DKY@E!4R+;0O$W56>:97R,K&
M3?!]SBCXW#J^?T:82?L5EBIM/E?EB](4=I#F)MCL3ULV.QZQ/BY)(O_QE+`;
M;<*OQ"9T72O<$U6>;@+R^7&L3[!>PD')V$=CW<'+;#Z9RHF;MXS2IE&Y;?00
MHFKK*&O^/#P/Z>5&=IEN04WW0!7C%:-JD<&NP#"$5^H@TMO.=@2<KV&"/_GQ
M9A_2B_I:%Z.UWP<-&Q*EM"<('7<ICPQ4."JDV[`L?18#"/K\SQ8RN\6!U>15
MV<D>?K+??C_N?;JKY87\B829;W1WF-/)(11BP-DJUTU[-\72G;>0EB^4L590
MT0QB[2#')NZ.9`Y&X6^8"L"\DT8Q%6H?@]M=O)W(+48;9R^IL.6_L`-S27P7
M??.?GI.XO4,=*,SXCM.^FFKN3G36,V>]3#>ARNB;-8?N(L0;--H-BX*:2>.H
M8QNP<5IVLIJQ$-\6$1X.)*CS6)\U`;>A=6B\*/:X#K+A>,'OAIT"_G2B=WGS
MP_R7![JCCUW"2XRQW_-#,KM/^+$^-=%7"DBXZZ2B=B$X9S%Q2W$.\580;R:K
MX<$;2F^^+IJBZUJT,8#P=D9C.!8:0R.<G=$BO$0)MT5:G"3<T;.Q-+#Q-,X/
MT*9L#/+WK<08YN)<K]!0#7#=K0HR3#L=CWNV]N+M/WI[JMCW9XR3(OJV;^OO
M(L+D\*R#7MIEY-QU=A-223I*Q2,FOY2M6+'3_UQFX#D*CA*/4+AJ`58&#G1H
MUL.M*\.RKD:#YFZVN><FV(71P=/92:/Y-A!C%2KI7T8T<P1DS?=TH9)L^.7-
M,V!W&]BWQ4"*]L/4$CMJ";]HR1;::GBTC+%M]H,@ZP,^',/(BU[3!=O-)L)4
ML8?P&]Z2O]&?_^SM3_AR^]<3/_@G\90^D@R2N(=Z^A>?9.4K\D:RF8.\&;J>
M632$6$NH:&I<<J^Y.0+\1,_RJ.A]=JO,V$FCW`KLA%%NA1=F!<)X^CM\8.N^
M&S:SF/CTYV-^MQ3+R2%#P`">E,-!7WO#A(8TDVCIL9O/&:5UK7'MZ7LW&QD7
MJ3!X;SL,C=L)C3GF2-RHR@L1\%'FU!Z>_4CC3GK18Z9GQ00Z=+CR?#'ATUY,
M"O2%](.A.*:AJ&>D!N-Q.^(Q,JFDX$8^:R1#WK]+BO'F_5/X\F&+?=X;D1_J
MG1#YU1\/D4>W_7Q_/3R&]8_2_+N!3J?1J.[$A+/.]KNDKR/^OEE''J:^JZ?^
MN?U6ZAC48<4((9*GWX((;\*GP/\[WCYX/S_B`._\)+X)-N$!DU_<X\#;TTHP
MK,H9W[0F+B\ZAD2#"=D`-37=D?3OJS1U*S>&B'"4-8=X>^QW>8MI]4#>)DQY
M3]-62FNQIY##"!US8V25'LB0S.?&2KR?L/5/1B!-.:D<:F20N!'CN]WG./$/
MY./(CCK5'C+)[DK+VJ.3U3S=.4;>I\N*N00@]O5'X68HPA84QC@C=)@*#9IH
M1QE8_<7;[[\G$<;)_R*?B%#I/O(/^!MI1#[*:GW'])"K32'=_3'.PEG,^/B+
MBD1<)DJ%(B:5[H.$&H^-B].!QJD>K(T+UAT(ULA(3I>,^;!.RT8CQ0FV@^K6
M]Q[]O9^\JJ*#\$GS,4&DAFX9R"GI)MPL$C!!*)<$1O[A@!P`0&TL'X[*+:/:
M:Z$R1&<59THDEIH`(GE-U1$27/R,P=2UTK#NS,=ZX<RJK@_C\,-!E#T]9A=P
M5;:[07J\TGW*F6P3/:"7TU$CWQ)\=TKBQ`OHK)/ZLXE?,<\!H1ZZPZ"YNYQ6
M*,'G5=(M\26!H`P9#E'<-5C`#Z7C">@B-P4D>[Z&R7><)'M,5_UO`KHW1J??
M4+P'P".I,MJU'Q;3.IF(3%0(I7>]LYUA5O0[(P%VN^>2ICG6ZIXBHJFM,^9@
M*KX+E+,L]8>`AE"%!KI#[MELNJB.GDB?$L#-F@R"X9B%H35<ZHNEDC]>9)<\
MTCU:_H;-AO[3_/URCHXXXB<JK!E#-:E2'S[53#(J3Q_">_(9GSTZ!\L/SO%#
MM.S0B>HSJ5^$XK-2*]VAM[M<N9,:QQ]"E$EF93S+9PRY=!CFCPC8L0&P7HP8
M$75UW)F$Z)BAEA^\HJDCVO%JA.)QA-$`HL7A1E!IM^&X@>9'V)X0%`^!!9!,
M`]W>QUU,IJMZL/@1`B<$/6$X9F%HDKT?%IV$8#*Q,2%H4*7)W8I)QN$IID-P
MO+U\P9'WA+-+W#]ZL;\A`_1/_OY$_LJC@WQ":9`HXYSOIZ>N&R[7$W>11H:T
M)90VE=X[3CM6UAJ;H4K;2WO7L\]4R6.(";,XMIJE)2:9L(U;L8V7VB9+0M*L
MI!".3C'?)K7Q]IL3W31%;W0GUB-_1MO4>@%.T#Z,8Q;ORJ+@HMVP@%/$Q`&?
MA$><U`2W1"SY-_D7^8'>1DW^\?\"4$L#!!0````(`%%[KT2'Q@UN]"T``+])
M`P`5`!P`8WEM82TR,#$T,#,S,5]P<F4N>&UL550)``/J%'53ZA1U4W5X"P`!
M!"4.```$.0$``.U];7/C.)+F]XW8_^"KC;BXB[BJ:E=-STUW=.^&+=MSWK,M
MA>R:F;TO'3`)2=BF2"U`NJS^]0>0HDA*>"5!@8+TI=ME`V#B`9#(3.3++__V
MOHPNWB`F*(E__7#YZ8</%S`.DA#%\U\_?'O^>/4\NK__\&__^L__],M_^_CQ
M8CJ]N$GB&$817%_\(X`1Q""%%R_@/8F3Y?IB@B&!<0I2.MS%`XI_?P4$_J\+
M]M_P@O[J']?3AXLOGRXO+A9INOKY\^?OW[]_PC@LQ_P4),O/%Q\_EM_[6T'9
MSQ=__O2%$E?[RS3)XI#^OO:K$8;%AT-*T\\77WZX_-/''W[\>/GCR^5??O[R
MEY]__//_J[=.5FN,YHOTXG\$_Y,VIBUICZ\7TT_33[5)_O>+YR0FM/5R!>+U
MQ54474Q9+W(QI5/%;S#\M!DTVDSW@D(:DU\_U&;X_HJC3PF>?Z:?^?JY;/CA
MG__IHFC\\SM!C0[?OY;-+S__X_'A.5C`)?B(8I*".&AT9(/QNE[^]--/G_._
M%JT)^IGDHSPD08Z2!H$7PA;L7Q_+9A_9KSY>?OGX]?+3.PD__"O[X"\XB>`4
MSBYR&GY.UROXZP>"EJL(?MC\;H'A[-</P9K.C*W5#U^+_O]RDP39DNVB.+R-
M4Y2N[^-9@I<YU1\NV+C?IO=;\M$2IAB]?X+A'."/24R'AODV2C>;\C/K\5DZ
MZ.>N)$]IS]^>Z;Z'[!OCV1V*Z4(A$$T2@M@G1A$@!,T0#%O/0'/X0\YE`C!L
MOR0&WT@7,$4!B.S/[IYRNR6T,8?-2-8I'`&RN(N2[^0^#A&&06J#V/U!.]-]
M@T@0)23#<(SG($9_Y&?K*@YO(`DP6K%_C6?7&:'$$7(5AOE"@\C*Z;;P;8L`
M/&?+)<#K\>P9S6.ZBP,0IU=!0*^LE%ZLDR1"`8*]0=#EZP<'@5UM819!R@,`
MPG\#40:O"($IH8OW@,`KBBB5D#Q"P,8,Q_$4!AG&=(1K0!`Y&%Q=Z70([&@!
MXCFD)WU+^7CV=X`Q[592OG:`HQ99PSB4EVY/Y:4#&.B_;E"4I>@-/K.=G._N
MV_<@RD(8WN%D^;*`3"C."F%_/,M;P_`)I@\)(1.(GQ?TYCX<<+8(M@CU".(4
MH/@:1$QJ?UY`F-[3"YA,<+*B?UI3UG'[7QE:L2O9`E!&GSO`-.DBX0S6N6./
MD^1\S.84D^4RB9_3)/A]PZ)ZN[VU/V5U>E$$7A-<2DT/*(`Q@5=S#'-YL<?)
MMOJPQ:G?P->TK]F)Q[:\-5%:@!6'HR3GBC#N4\`T_N1AIGN7I;3!(XK1,EL^
M4$$,3L`Z;]GOG"7?M7EO,XZP2*(08L+8..7G?>D/FE_J=7*E=2V_E,EX=I6E
MBP2C/V!XG:7?8D0(Y?8U7MG+O(V)L`W)A-YR;+_E_[AF5E0FPE`663#,/C=`
MFT\?=OJ58,C]\^T[^]&*!&J-%HL`36$$TMP\EJY?J)A`0,"^U!O3-_N>'2O8
M4Y)"\I)LK8-;`Q:IFWDH,R94"PA+(:+^"%$S+5:=JTF]P/?T.NK"/@Y(XK%A
M6JIF1X#MEM2^,9;JL'WN1LT/#V/^+^`UZF7?&'V^=RRR%1TD?Y2*ZOILM3_[
MW1$FGQ\2%OWM#G,B>L=E3R9E;4O#P!@7;]&'N=#:T](W2DHSPF$`:D5&W]@P
M(\1AIB_Z4O^K+U3-#[7N1@0,"X_>N&DK,MSP4Y?\T\4.T::DOZO6D(+>N63E
M0#"K*^X;K7>4$$HSLP+EJGUIW^N5FW:D:."(];:S[-#5-WHB:\IA.)')US=(
MK&I:-7/L;$!"&\,X9+YMQ6_9YZTZZ.4T4"HH18T/1\R9,<'-Q=A\-_=8)##X
M-$_>/H<0?6;NG>R'W,_SXP^7&W_%?Z&_^NV*?CIDG[^+P+P<C@IS,/KUP_[?
M/_=.SRC#S.WMCBX(B/X#`GP;AS=TS3BD"9N:4;F_A=EO?BN7Y8JS+%>O),6`
M.:0UB-+OUS^.)1D%.A.(41+>T=\1#I#BMH>FDZVB'I55R\/16"`CWI#\=H>C
M[X4.*R$K_W/_U!2[?D0_B)EI/(3O_Q>N.63QVQV,ONKQ:O/(E:7,R9P%`(B)
ME74Z%.5W*()X1'?6/,%B7)NM#D7;%,X18W%Q^@26O+W(;=8_=?2N9VOTO%Z^
M)A&'K.;?M_34[_XKW*0-X*`<B/[8N/CWPP8V+3ZO<I_NC\$"15N988:3I<G=
M45*1<$[W18*I8I''LUS^\,.'"SJ!&:2W9/A0S%5(8$Y=2G42F+=D/5&"*06_
M?OCRX2(C='+)JGCM.BYX=N2;"I\O9WPD=UN%T]<S3E(YI4+J3V>D%))GA=6/
M9ZPX]U*%SY_/^(BEB@JF_WV&22)R5SC]Y8R3W+A00?73&2JAKK%%B0J79Y0T
M=<D*M+Y%\E\^[QHK#V3"U(S0;:WFS0!YS8')R,<Y`*M"UX-12LK?["I]FU__
MMG%V(1.P9O;M#0/8T0`5C=NKI]WIGL(`HC=&S1-,]:CG=G$TAYW(%.4$!.T=
M49\ML_RY8)PN*!=,EO0<+6!,T!LL0IY9^!3%>#Q[`>_B.1F-XF2F6T?6"4#A
M?3P"*Y2"73.)JK43RO-`5!&AQ1_=T25X)1`T<D>GXE0VVCBG4@O4W;8NJ&:)
M!IC[!_T?>^=_`U'N$)*.`,9K*ACD@;^"6>CU=3(KL6^+:"Z2'JYFL!'6I$NP
MV\P%K?<QE?\@2;6D%T%CEW17HH@>Z?OM75#?B-OETKL?;.N,PC(PI^%2I":;
MWVV(<U$P?.WNCN<F/P`#D7GWR=!'?PAW[@/+<C.>C:AVC13:$K>I$YJ3>/X"
M\9(15-(CHIG7U`7-CP#_#E/&IZN,$W*X93U<S"!7QG3$7TY#Q_0^)7&@2W*M
MK3.J:SQ"CW1^!Q?T3TI;G5)<Y+5T1/&*JN6;L%OYUN:W=4-UD:B%A1JG]6PM
M3U!,O*2+BSE,(4O/`L-;@&.JX9":Y><&SE`@Y.H:'5W,1V;354@%6EW=S,E0
MNAR8/+E/SGW,\CSEL9PXAS=-,7K-\IOV)6'LDRK<.(DH*?-2R]*>:ZO!7>"R
MS1<4AT4LGMB93ZN+BS<HN>V0/3@I[&';=Z8O?CUAZ@,COT:V^'SUZ_%2'Q^!
M$%D!XY?/H.F)JB/1QCLP24%T#$@(5/LZ()K&Z^IIVR\O06.\I`IQA9)?'H+&
M*,D?M2N8_'(.-(9)8CVO,/++0=`8(X&>6^'CEV>@,3X\^U8%CE_N@.9\2(1+
M&\%Y^+>^Z0M+'2K9BT"E</@I4'?"C6O5KQ#S4]+N@IC,5ESAYE?4CN436@>J
MC4#N-RN3NJY4P/DIHW<!3M:ZPLU/H=W2R11X:53HM1'GC^JX&JB'N]Y.OL:T
MMD9)Y%7M:W!K.Z#DCP*^!KBVP^J!ZSCC:VAK.XQ$SIB^!K6VW4DRON3G-6?R
M5+YOA^`)4WY:K]KBI"^$50CZ:>(R$T"Y[DN^!D^W@V@_&L#7H.EV^`ACPWP-
MF&X)DVFPH*^1U.W@T_&=.UP8]3$@9LL3K$*U;X^'@0>G-ZLMNXU+H[2,<4YV
MF%]*54W)XK/B4#5A3\>1=D5:A*J*E'HF>ST&,8/[O/"5+O6;UH.@7.T1V5-R
M0UO>]X:'0K.S^WEI'@U%IZ',0WI`)!V&0K_ZF*AZ>>VK?T1&`UWNX?OK@AW\
M]KF4[X\--G$KN6*G1X<WB%^34T)-\%[3XBUBE5/PYBEV6IJ#[Z\4%L"3\3@_
MW6VM@;;/X%H8E[UF<)HY`GLW.@_!#%,81!T967;MLHH$;K(>+D3]TD1:<O9K
M0%!P%8<W*,I2H>:EZN5B)G^%,<0@HE1<A4L4YQE^V26]+5_-G8FJEYMT1VQ;
M;#>X0N,2M7:9J$F.^6XK-Y2^40H88`5^BF!F87,7M%.&4;T!"0ANMG%.Y=4;
M0%'Q=%"[N38/#CGWT)F'QBA.9DJOI15D?(,]A3!B-SM;<7+5_9PD62E)VA`C
MVF'[[09!K0)S<7NGU"O/,Z^ELQ0\@N?H[?&\2_`SJ,>N7H7_F17L4R$>61M^
M:-ATF/?@YU34Y*"_QQ`0>`.+_ZL.8O>!G>$A9-RRN8H[N4DO1"#54EE4_@U\
M@U&2)[:03T/>Q\4L7N!RE6"`UQL/AX#N$*9QOB13&-*_L9]SPU7%(01S:S.2
ME;J0?X?,F1R&5V]T;\SA4[9\A7@\V]&H5*])G89R:?]0Z#J-B#[Q5>^[$V(;
ME.HB13=[T/`]I@WPT1#6??=%-$"K%8-MYXSX4X%?#.?LN<$;!(W5X&Z.B5Z=
M51O"9S>/1*\.L]1:W2WWDE?;3FD3]ST#DP96W617WW,S:5L$FP&!(I.T[\&E
M+>':>6MHY])Q3&)'*YQ4%@O?/3E:@;;SQ.)[Q*G2BMZ,KI&:CGS/*6>$E?)1
MVO<,<T9H<9Z>NB69.X*39\V^KJLXF;W2^.[.?'C\>=B>0K`<2_Y[%R7?R3U5
M`C"DP#FJ(9H;L*Z6+*SQCWSFX]D-(D6N(,JH)Q@N4;8DE3@NK`C9;C`W-3G+
MHTV8Z2Y(X@#EZ7*K??F2L!6:X.0-T46_7G\CD.[Y+4N^"NB]5;`)1<G$/CYE
MY:FEN4R;I1G'O&3+O.<5D^[G"I%',ZO?O@QH7ORKQFAZ@B&LG"#VJ0@2<OL.
M<8`(2T5:F;&I/%'FR"HSK.Q6#FPYB(OUN8'T<@Q0?MKISU'!Z*D<7^,"@G71
MZNIB3G<`X9W7FO&LA%LP&7D?*[OJ#KW#L$A>=!]O\M$)G,_4[1TY[#8.6TY5
M/?>@V'57T6\PLV$8[R>2%]?3,AQD4/-4%VS5ZCJ,.;'$M$R$JO`F)JLFZ#Z,
MN>VDT#.9%Z?K,.:TE8(WJ9'4WO^Z`PQD?DPUKD3]3:4<W;GQ.@]Q7FU8B'B$
M8<QPTJB1H3VMG6YNZYXC4413HXD5J8;%,((X:(JWI>#TDA06@01S)1SMOD[0
MW!*7DT4%VY(R9E&$^`T%D(SQ*`)H*=S]1F,X"E_A&2DV09IU(X4X<D5W@&'/
M3Q7%8C[0@.9;'*4.Z\D;8-CS:[>>LH$&-%^.$=%LGKP!ACV_=NMIS]IZ'$&-
M@EN:)3*DZ)3WT2@AS*B05XIAZ4EKAJF2G_'NZQ:C.,E0!=8;N_Q5\%\9PE!8
MX52P``8#.*K['4`8DCN<++<21O[(.9Z5-3+X\U)W=#T?1@P%^!&D[(UA/9YI
M/%NT'\=)UK&-KR4,V<LI519D-E9!8\?9TK9OG/I9TO:[.)E#MEI%.44@*BFZ
MCV<)7@*=I&^:O9U6\^OQ!;3^]*_W;N![ON9#H6VHB_J>]/E0L(M8M>_!%GWC
M:^ZFX'W)[`/MZ+:.0>U"08[)Z?Q0*Z!XG/8]9,3\):@9#*'[[M>N.O$Q;5C;
M2,I?O]M5+3YE/'??D=I5,3YE!/EOJ.VJ&I\RCGM>.MWJ'9_>)<-SF/&]]+%M
M#'E.++Z70>Z7(0JVHY_A:.W?<9OYTM66<]_+2=I!TL1OH%MYR>$'M[5_DV[L
M38-7JW;!I\<D`UG"U/QER?=(53O`FKB9^![;VMZ%H;=0_*/=AJ;FS%Z,=KZG
MV;.#O8EPZWMU8&LL0-O7JUORON$S51UO@W;8\<J>^YD`T1*&4M%@B^%7/U_X
M+6$HU:XJ#/U\KC?%T"QFN$*O[_02QXS>7B1Y!5L+&_`J7PM*&4Y/$+S?OM3A
M:U-8+X?O-AZX#FX*GK9W706>GW9?0S=#7KJ_(H;+][1$+8#2"*7WOL9J2]3T
M0_5\S\39%L$6B4$Z56#U&,HV$2F'R^'I+),8\\2+$I)A.,9S$&\\]/(<E"3`
M:%7XZUUGA'8GY"H,44%W#7(7"<<H%NPPT+5`Z1T(\KW_"-[1,EM>)Q@GWPNK
M$/V+,#C%:(AAAZH=;2B>D]`TF'*?96<33.7O%$XB$$!.L)9A9R=5E&I'>)3$
M)(E06)[G28V3U(KB;F5N984W*V.[#O?27FW#SE9VIMZW\D27=Q`RWVE9.J<.
MH[E>)<::2<F;-1:FV=Y-W:\44"+"LL8!U1&R91:Q=^\;.$.!<!H:':WLK5RT
M*>I_WV28?JDP;UTMF:<>E21';'M$4>F?#U^Y[*_%*$ZST-KDATJ_'@Y+\5V?
M/@C`.]S`=VV[-TS-9.9.*OD;Q*_)R0'=^1+W77?O!W$#@;Z30G_"F[J-]."[
M1U%O?%KHF=7".^@T]VPW!Q<_789Z`UE']3E<Z<\!&%*?L^42X/5X]HSF,:((
M,'?J(B2*<4X*?)!7!1F(*95#FJ(2@;B#DQH,[%GN?KD""+.].EH`/!>:1`6-
MK65QKQ[Q2[_OFAV=IU&K.[DQQFP.:'[QJZIDZ_:R8R3+<+#8I,@HGVR8!\7^
M"Z.LE$&GH1P5EJ=<**!,E>\R(C0O*;K9,2XM$IR^0+RL<CB4<?(9B,I-S34H
MZ?5TDW^JJB%<Q&H])2DLMO:*ZLZ43BI=$7I$IXQW7PI6P'@8%W/]%F,8)/2V
M^@.&+^#]&L;TYL[?1ZD8FI=JHO=4[D08AWL%(KG3[C*BT[0<RMNPX8%DO$=\
MMPCJX=>-D_MN`33`4$/F\-VWQ@`MW7O*=SN<&9-3BQZ^U[HUPTNDD/AN$#-#
MJ9/(X7O$G!F42FVMDVW+T(1X-`:8YV`!PXQE8JA2I.4>OG3#U5)=/$+`Q@S'
M\91%;3/C]S4@B#@QU>3T;<FM9BRS=G#;VS%X)'B58)!"9O!GN5C9YZY!\#O=
MB=L(]T>X?(5XAT#C[E;H9=^YC^DYRAA?WL+2D"X%MB_S_FX+T>EM9-K@*6%\
MN+:OV2OQ?0J%)4;L?N-847J1E)^S-_X`T!&QOV]Q\DH@SA/VW<>K+"VCX8L4
MS=?KO/LH`H3<)$N`1`G'>_N<4^SJ]%R](^59VFOOF/KMC_\'04S%EL7Z`;[!
M2&\JLLZ.Y[6-DS!8&4X?I[/(MS_)(;WD7JXZ/88R@R_&,_@RL!E\-9[!UR',
M0$/"5?+<YLG08_.]?=<IFINIY&_E^^Q/#QFM,5S,LK9D^JJ'HI.+>3PF,5P7
M2;CNLCCD:R:*QE;TD(U9>[N-Q2J2H*4+TT1K#8J?C+RSZ%W9-/Q,!-*++K=G
MIN2?:-_MN;UCJV*9OIN"K:O87":BT%-*D'\XLXAN*._JLB6P9][;$5B>.EJ"
M^^4,;A=P[7#V+0LY%1YBW=Q77QR1`.[[:]XA,#9_D/'=X5UIC)7P#8M+=#)Z
MBI;5F(NYGO7DA(`4FZFY^/5GRSL9S/LVAVY9M,CVX[O+62M3*7>W\]X_?/>J
M[06]+_OH^>E/VPMZ7_?1Z]N_]@A=JT8+$,\AN8^W$&Z+3U8YZ\YOW>>W;M$L
M<F_&1H2%P6.CJKO3N56'2A5P*>UR?@?O.(/R-8OD.X/R-!8BOK]O6HJ%(Q`%
M69$889I$T5V"OP,<JE%R0I77*['W8.,*_(=A>#_V/4TM%\G#$''VM#E[VAR#
MIPV/PK^C=+&W3J2Y4,U5U3Y3>4(?)3L\*"TG@/HS3-,B@?5`H*\3=+SX;Y1+
M[5GWBKTQ,6?<G1#SVQ<WR!?R=AE[+/=$%#1V0?=^";X;F.?80V]U<4,P$=W>
M3I)]\.T$$JN)K(>+&92Y$IZ2M&#HQ8EAL=K2[:7N-PC3[?EU\?RZ>,28:YDQ
M&_`+KHB3\=J0F$<%3S,',6><S)YU:QA5<?)#R*F=GD6/IF*AMPMN;`;Q/5'2
M`%=:6Z%HYQ[S4[$V,9RS;+3GU1GV.6P8QMJ%()T7?``+WL((TRT@ZDC*V[I[
MZ70B,(NVW0G%5!STB?4<(C?(I9!:%D\GDFX(1^&TP^W<K\`![[T3NF0.$;I@
M\,AP,L%\/3N3^QG(H/'.)F#>"@OZX>RR1^.%SZTP<^G"VWY395"><*?1QDE^
M(!2KJ6RT<50GE^J[Z7H2L46/0W865HP)*9S(U?T&-1N5MZY&QT'-YQN!LRQZ
M0#.12ZQ.3R>%9U@`C\0/HOJ[,^JD)[;>PHEGR3862KC",D]I[>XN;W5MGM10
MC+6!\?W-59\)[I1(5K,:W^7)/>[4*%Q19PZ^;R(.)VSD7FD*-[Z'_*K0:`JD
MOK_\FMY!>X?H1*S%77#28>*'M$H=CYI*_W6#HHR]^5=9BF[?@RBCE+"*WB\+
M.$J6JZPL4)NWAN$33%F%Y`G$N6W`24$.2GLHI;U!>%DBMR2YJ)\MD/SLC.VD
M(FLWRE6JG[7A76!3JVXG55OVV[F@=F]3R6T,PN9.:"^,A'0K)#%E>-+00'Y;
M-W5>0PB7[)(I:D>FB/[8+/`D5W>U^[M5ACL>8CV5V<I'W-2>W51>W]F8TH`4
M:1^'(2DZX2<#"#6Q?6LU<FW;D1-\3Q*FNF[XYB,[K,1W^X#T.N2\\9[*BZ0V
M+AS)S7<KBC8V!E++Z=A:;(HXS:+C4N'@A*PT?2%L3Q3PWP])2U2M@RM@*B?E
MP#&B+)+.^AI$(`[@\P+"--\PI1&Q;C]T8M<*@FS)G+=A>`,I+D'A*$9_CF"^
MM^*0RJ24S?^1_UYH^Q19<&P-[R1Y0T9/>TH7D5)RA][93XH$#N(.3LIYL4`K
MYDAUOUSAY*UP8)-.0-;#2D&L\6R&`@9/P58AWJZPN#26LL^@W#_\<LZY7K_0
M;TML$3H]!S6CO^*$&$^FZ#2H>:ALY\?F-O4$C8\,ZS*H.;`=+[4^Z_2TPF<G
M&0X6E)>'S\DL_4Y%.S%[%34]NU"=7:@&J(487%5:C_;U,WNRV$E-VJJKU/<:
MDNU0LZ=8M8N8/J8`><O[,A<END4G)2F(CA2S?2%D6Y)&K7WY_@;0!C6A+.7[
MHX`A6#IF$]_?!%I")K74^/X6W(LO9ET:/*%WDK,W:X\V>RK2X0S6Z\R:6>P%
MNOIFV-OW%8P))*,,XWV#NJRE$\_//2SX=*O;6[%W[`R_'L^J]&+W<2T=@016
MC<X.D:;G=`8)R8_*'=2$6]3)B9?F<A4E:PBG,%>*M'>.NI^+V8S3!<2FAT#1
MR:G_X7AVAV+*[Q"()@G)P\D53QE:70?Q8*TQM\:[M7JG^JXGF4(GO<A\UY/:
M[C,59_==6>JRR71N>N\5IY;[3G5W^6[0[7A>Y9"UR&II9&T<@GY4^<>6::*X
M&6A<^#/EJ8*VE6?'>(KFBU3BOR!N[R1FC$>-]$59UF,P,[A]ASA`!$XP"JJR
MP&3S5Z.E40TUF#GO/5WHS.[!;<0BCZ2GC%DAQ[/*.W8$H@B&U^LNRV@PZF"0
MD'D>2#I8L6_PQX=XR;-GB!N[P)*;Y_TIB0.IJJSJY2[.5!49VVSDR#\I@#`D
MS'V=E3Q@5LPQ?@;,0"PMS:;1T<INWI[Q6.*7M-_(I<RHE"L:`42R:]QW)Q,-
M&6:KS'$V0C=)^DCAD?HY=+Z6?3=6F4.JPR$[6:W>('Y-_,.MG73?R8[E&9(J
M:<YWFY7YGE/*C[Z;J]3*B/*(GH@?A`6D'DXIHI.OT"@Q.KBG^2!LGA%53A(,
M-KZ[#_2NBPF\FF-8>&L-Q@)ZG1$Z&4)&R?(5Q3D9>W4U=_0^:1<[]HLZ?(2'
MG\A>9MS]0/3RK$%&76W3^0:OV"&=Y]^X`2F+FB\_J:!3VM42G7DF0#K>!*QS
M$*8P@"BO4W'-?&O'\0TKCY#DKF>W;R)7G5;C6)E!;=C-IWGT<5JUMP`1&'R:
M)V^?0XB*XT]_V#WU]%>_W5),TC7WF6#OSU:P^'<0$\IX)PM`^5P`LQ0%("+W
M<2"VYJBZ](_2`YR#J,""\Q[$:V$%J]W3SXX7#R!N.ZL4,+?_^B6VY4>3A-Z4
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MJ1`[215C[W6=:VKWUO.@+4H<TU")T:FJ^WL8F9]9?STV1,]\56HGKJF\8DY^
M*?%*.)0OE!4R?NF9DI?.DCLW@?/5R"@TOI_KQII52KWLVX8U`.^N&_B:6G#@
M$B6GJ>=YA!2.W:<K42L[J7'(U3*'2OQ^NMMD,"%WY\#=<^#N<`)>;T&P:+8U
M`<!H7"=H4.Z.TCL0Y'DU9$=OOZ%[>N6'C=?433#L:UH4SF+Y7C8EM&!8I2W)
MRPH1%I,$PTO!;`P'<37/ZGI5N!\+&KNBN\)1<@8X#=W3>PT((L]4;@+A./X;
MP(BIU%.00ME.TNKN?FZU<G/5WL\O$[W)R?H/879O,*;\_P:2`*-</M:<U7X_
M][.YCZD"`$G*]DZ>;">L'`VTIB4=P/W\]LS$TLD\.$WJT:3E$:1,^%ASO)`U
M.KBG_PDLY156A,W=TUXH=2C8O".P>$]R347`A/*AS:^2:S@!2.39V'HX]W.7
MY4[AM3PG*NF>J$10S76'?GY;)U2_,W^##)%%D9LM-\ILZF'S21=WL&(Y*?6%
MAP143\]B*XJLN1UZ$"9IF:Y`0@>GF;WOOU`U-5BH/M]L9>?K28;3A<;T>>U<
M[.=2B-GD0V6[4["1>2V=%(RDDLIXUE266;(_E+*M?`>A4HPS&6$H,]P8OJ\3
MC)/OE*&,P(K^19@DR6@()W-,XCF3!M@VJCGX0JK0Q?,[],XL!95X+9JEV2"N
MYIEN2-PM_<69S5[3(=`LO9H%C=V$R?UG@AD-9'/-%H4BTG5ES93`K]M[H#.3
M+I)^?]<!5#4+B.0NDO5P/8.2*3$63$H>K#$/?C\K4LDSY8R4)R;25';[C:Q^
M^^5[HOYVU<A-8<^"BF\Q6<$`S1`,I:=*W-X.<C!(XE`M2W+;6:1`*4SSFCE9
M/ZKE0C*:E%X`>?)G:="@K(>[&=P:SX#?PVFICAV577;SROLXG45YQ'6H;[2U
M<OY>%@AK,`!>,TLI4*/H.<40IO].]=481!.,EOECBRPCJJ*/U>2LTEMEO]'@
M\GZ=D[/J(J5(SEK;"%MXOO@5;B;Q;.#M(*[C@?=;1^)N4=LS*K96;2&_'&_U
M/!^:B2TY+R2^[R*Q@X48FOJCWVGA\R"+1S*S9?J:"J$%<%*CB*]Y#UK@)',=
M\#7%06>8Y+XOOJ8WZ`R;U+W+URP'+5#C/BKZFL.@!3XR)X).N0F.(@^]X?$S
M\43V-5=!1_E!\"3A:](!`[2$H4^^YACH?`>:.`CZFG;`@B#!\:3V-0ZZC=9H
MZ!URN#C0P4.G'VSA:W2Y)2N%T*>LPNWD!7T+L8D5FB>O%G0L7'7I5S*S5KQ/
MMPK390O]X`B5J_U(E*W0R_73KMX]3D'JE:##][VIX#D%7B6!A^N8L$7GZXEO
M'GX00`7/*2A#,GAD$2L52J>@!`E3KO%>(+W-3V>(C<+%S-L4=88P\2,/2G2^
MG#@Z`@^_$IZO)PZ/=BA%"=B?3APPGE-6B<V/IXZ-NMKKGT\<(J&2ZV^VT.UC
MJ"P.O,&R9<[QE6;OYUN6(4J"((A*@?735B2+MI3)1J?BN">/[*P>1'>S,5;[
MQD_=U3!RU%!2.I7=91RENF-NVPDTJS:=GX]Z[>'BY;BHT/+3]449G%EMIOUH
MUPH</ZU*YN!PXV7\%)VT0A(;[GE\6<MW]BT->FR(F.+==CB,!I"0N_(0('D1
MH$TIJH!)"_WEZ<80C&?CV0P%\'D%`FZ=[OU&3G+?@A5*0?0``8'CUPC-B_H8
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MQ`;;AZ.P^QXJ;+:#A&8"WR.&#3:16+/WM9:YG@K2+'VL(2Y[[T2ICY=L^_GO
M=F*@7!ELLE,ITVFDR.V)"_N6OL,%[@_[W>`N2VF#1Q2S!$DY5F5!=[/'@],P
M@_=B+&HL08G^32:R>NGV'O#,1M+:,8:##'B>]_$=>H/_`0$6V<U:##3L^289
MMC/?[4"#GN\+_:J=!:Z--.P9?T_LS+<<YZ@-J*8,SW=;X:$`K>]#WRV'!\2T
MQLU\-SH>#M7:G>B[E?*`H%:"E>_&S4.!VM7^F3";ZO$HQ7F<RB*)Z)1)X8!I
MP8?.DAI<Q*_E%,HKN.\W=.*]5B-CSZ0L(?G!J:\).U=)G!,R`7B,B[RT?P-1
MQK(OY8D>)28&54_',RKR5%YEZ8(>Q#^J,R.>R5Z/0<R@R+2I2_VFM1O*RZRA
MF\U=Y%?=9@H53$#::1#SV,EXJC>/9B=7E99-,KERYV4XB+NJQ@J;Z$ZC<QWC
M)?CM":;UE+5E]ISQ;)+G](*3"`3YFP'/Q56_LYOJ@/587`U&*NDP%/K'64I2
M$(=T3QA,HM[+=9U&[1UFV-E-Y<(%#+,(;MC]]3H7ZV3.NK(>[BK?7?/#UODS
MD/1P6C.N+E+KU(W;:V^W0EHRR7"P8+XULST!C<=+]3H.H#X81Q_;3X0@V%&^
M)PR6JH`-YRN%?.F]A;PU4#L*A?=F;UV@9-*.]U;L+B`U1"KO3=/ZYTYB1/'>
MUMP");'QS'=_VO9[:I\_^>E,JT3(1'3TO=B.'E@&=@O?Z^UHG[_699T\+<:C
M#9Q6X3!/B^T8R%:&Q[%-O9VC*`;`-T8W4[E(#$>^.[%K6,VX*8/W#3S>1Y48
M0B4XJ_Y'E2B-@"*43C*!TK[/QY1^&[]1M;C0B&>5LG>=I=]BE$L$-5G4M3O(
MWD5T#.X5FX#+`N,2\;L$%YY(Y96I?N37',>*.;OVV8UZPGT<D+?U\T%8@%@Q
MYGW,ZI:A-R;XQ&+(Q(U=8'9/%0*2N]CM)O'=P8W3T#V](WH%S!G3REFH]`U+
MHZ-'SXE#5AI:L$??GT;.VH,4'C&3:I9"5[.&TT)*QAZW5C7Q=>_[.UL+L"0W
MO>\/;H9Z*>_,GG7WP>GN0U%-V4EB01X%;H#DJB?+-%8LWU#B$RJJ\W>:+8%3
M&+%7P%%"4I)+,Z]L"F6(B4(EZ3AH7RK,R_?D99%D!,0A71A6AS*%T$RQD0[A
M0MQ^!.\L]D>J*33;./&=I-"QJHZRM)/U)BYIE$;I[#1R0>>4)4J1`%G]W1EU
MTMU8;^%8064L:)\UUQ(=7J^K-ALV=?4=X%!3G>TXOA-TMFQ90/.&Y-==DJLT
M?A-([VB1>[J]\:W<$LHE$JT0O14P"\&\CYNZ/B6.71=@SDVGW>?GG.V6-O-1
MV;XM#.QV?SQEC,%M>`"Y>@,H8F?Z+L%_91IIL8?+5;V!Q?^M;IEV%!S5+AKG
MHC^Y?:>G`!$VNV+2MC>5\#M.JT-:D=P%)KFN-Z/O9BF>0-OP(]D1)D\%#T'E
M*&-ES'?GW#TAOKYY&C*T[SN'HS`T2R0V]%O?W9"M*R<\IG1ZMDO[6-8.<`FD
MMT>T5R!MJ!`GX!MF3=&JJCD>6+7Q_<G;[A+U8(_Q_?5S2&=$QSSD_?MJ?P?"
MKK'@</&2Q_$X^9PMEP"ORS??W3]O"B:=7RL=9N!9KJ)D#>$S92JL-`S_3$0Y
M!7G4^10&R3QFOM#%;9!/2F6$M?T5%TC]%<80@XCN]:MPB6+$%HV9(#:;6/I2
MI=?7C=,H/>)P&S#PL%D!J;>KN,>`9B!]?)7W<?+:2=DVO1`7=(O<P#<8)2M&
MF,[>TNGI]G74SNG7>RFU^:WAO&`8/4/T^5Y5WMC:STME!U_?-ZSN;=\MM#T)
M&VJAOJ/-X#C";/L#5X<A^&X3T!"4FCZ^4JG$]Y.N)90UK.`Z\H_O=@YCU#1U
M$M_3./4J:FJ<ZI-[!NL99NM7V8F%#6P$6U8><?V"`04LR"V6@XD5$!(HMZ\I
MNSG1V%:4@@3?P;U$IKP63ATD-%%OR-/UV1WNX<W9(7I*4E90]`[%(`X0B+:\
MGHSQ',2;$+@1`R5"8;%Z<3BID36><3I79_.%4GD=.4H:<14$+$T3BN<32CXK
M%J,X<9(.3@K2V5X#_JRM?\;EJ5>O>:,LD'6$STS#(ISE$IZ9ASG]5()$+)E/
MDZIU\5\52]#L["2G#B!,;6;_8]ZQ;R!BFT=O6GI]AS.K*:0;"`7,:BNAW&BR
MFD/VE#_H`8%7%%&N)E\OT]Z.<CM13KN@^AEZ@X6F;'+"M+L[*H#$O&T*-Z@I
M(K^/Z`V&4O:3<#KB'DX>^@&.*=LB92)FO451]7(QDSN`<)Y3^A$"=CFRN])D
MH^GW=_*<O5Q1^O+$JI@*`*N$@&@\>TCB^0,]%^$5(5"7N;<:RMT3_@MXUYR7
MJ+D+VO/RF7IT<YLZH1G1ZXTRH[6^2B3MXJB(T@IB>O-%]!ZDMS:[L5?545;-
M1[O[X)Q!I"*.3D\KDLP4LKS9A0_@\XJ*(!KRB[+/<!PN"A=/BF(CTDPN7K89
MR<6,O[%,^K<D14NJ:(ILECN-CL>`(>=MOH<.F&&EJQ'[_K9OAMKN^?']55H/
M'<U;P?>G:+.M9*#*^![';`:<ILW+]R!?&Z#IFM1\KTIDB*7,(.1[32(SJ/0U
M-=]+$YGAULX2Y'N5(D-M@&N=\;U(D8'$9O(BT:E4D3>P&1EI?*_P:P99*UM+
M!>%98Y"9RBN<S@J"R6-DA=M91]!X)JS@ZEL-&*`[SS.:QVB&`B;([L%Z]NSK
M8H;70U9@>=?K?#RG4!>-D_:MTP,I#S(X^\MU"N"^HD2%*,J8;/8,@XSN%$K<
M[7L0971U6853=MUFI2OC[AVB/+[V/V0G!'I+UVC!<L*0^WAKL*TY;)8*$]MU
M;+-)WT`[C^EV)VQI+:P/5&BO4;HQ8H?C>,K6#M.ER5^8I*CT\XTC8O5VL3T_
M<%8!RYV/[_G=D[]3[=T'AWL[':(`DZU64?XCB*Y!Q.KY/2\@3"O/!;<Z1:?@
M!86L8V=L)Y>AR:H)[CJ3(5PR"*L[H,%+C$`\;37'`"IWRLZ95Q@YJ;9V3QV*
M(D!%!YS!4%?W:3&`EWQ/9T/X+L+W=ZD8[,[#B?9#O%+8<^\BB2@$I"BHP=IN
MWG_)&$_1?&$A9EUD5FG]=9X]I?5@+OCG]NN*&V^_G<L#*Z2Z4K7;+^E)RW:C
M)*(KG^"2_3V@@'D/7,TQM)0W0AB(VN+#G./7:ISSR;-W\MHMY$D?NAOXF@XD
M'TN3%%5V<7YC%Z=)!*$.X<.0\.7(UZ5*X5Q/^A`QOT&4%B)Y'%(QGEF18<QL
MR`,Y6UH4*HZ<V1B.DBZ8K$.':0[CW+9:U1W',"/`SJ=<&RQWUL?3..NUI^(L
MI<0\HIA5-"Q\W#=9R^\2/`(KE((H_[7QVWO;@8^:)]@`]J3Y!%__'X@@4!"D
M./T[C9P<;VT0!:=8N[_3-/7<U6B<1GT<SH=.!R=W]W+_1T^8GJ2HDE?4S,O+
M?I1A3I21WQ.2L7=4M;M>JW&&>;PZX'+2QTR[>DR]3J!;QYUS<3M#D@5+UQ$(
MP:A^E4+JC/&9N;1'S]W-?F8QNZJCI9H8VJJZ[>_YQ99Z7)>39EBB&A(#T?5]
M*BQB`K79M(9F$VA3F,0('<=']I?/C'S&N^@__C]02P,$%`````@`47NO1%7?
MBDA9#P``E9L``!$`'`!C>6UA+3(P,30P,S,Q+GAS9%54"0`#ZA1U4^H4=5-U
M>`L``00E#@``!#D!``#M75MOXS86?B_0_\#UP^X4J.-Q,C/;"28M<ID4+I*Q
M87O:8E\*6J)M8232):DD[J_?0TJ4:4N6)=E)9$`OB27RW'@^W@XO^O3+4^"C
M!\*%Q^A%JWORMH4(=9CKT=E%Z^NH?3FZ[O5:O_S\_7>?_M5NH^$0W3!*B>^3
M)?K3(3[A6!(TQD^,LF")1LZ<!/A'-,&"N(A1].?5\`Z=GG01FDNY..]T'A\?
M3SAW#9,3AP4=U&X;`;]'JIRC#R>GH(V5,F0A=>&]]>J:$RPA-W)!B7-T^K;[
MKOWV?;O[?MS]Z?STI_/W'_YGYV:+)?=F<XG>.#]`9L@)%&=H>#(\L:SZ-QHQ
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M'5(2(M`:!83*6\:#&S+%H0_Z_AUBWYMZQ&TA+(''))1D+4-(5UE^5EP^84J9
MU.V*?E9O%@N/3EG\""]4Y3GGS"=CP`U2/[X.>[NUE7$SV5$4G1OFA$I?3-W/
M5'IRV0,9/-"26\AS+UJY.1)MC#XNF7K4TWIWWW91&QER^R>P0A$O9#'[U-GD
ML,D\A/:\3W_6OQWL.Z&O">_@.2:.<^01+CBTH%16H%QIMITN?FO<<F!OC4!M
M#:_^]-:CT#I[V!\PH76Z]K$0,<J4WX9`\%=!@GPWGH'O$D9(]6'4)53UK5?8
M5UT$&LT)D:)QX($<.,#0U,HYD1X44FEO:NH=+GU7T*7HS9HN/S0N+N/B'@QB
M`Y+MP#@MWTWOM[HI>2L0FZ+^0@V!/35D5&VK&C9R,H><W@-!=TPT5;.4WZZQ
MF-_Z[%'TJ.MQXLAL%Z:SY7OS0T%O*KY(,V[<MM-M7Y@D8LR2]G!5E'T^P]3[
M1UL%12V8[[GZX9*Z`\MBJS%=$=]XPO&9"#D9DR=YY3/GFP6"%Q2:#ZG_JF%5
M0@4/MGS=%MP0X7!OH9\!6U>A@')L&H2]D#7R9A2Z6@=3>>GH.95'9P-PM>,!
M12F\%&25CX*?-E$P"H,`\Z5RN"4`K20@(Z+!P3XX"!>+:+J'_7C<I(=-*U^4
M14,9AOF8^+B)B6O")?;H^@`/]4!R`X*]0"#!&7/FNX2+SW^',*E5>?_`G&/=
M'T1QNZK]277NN?#HODW!@P4!=!%:'C+\&V#L`8QKYOMXPKCI_N\\1XWV+F><
M[#?&J,0X'P[=-!PL&7H@$4M!*S$-.O9`QPV9R*H`V$:;[^/331\K-HT/]ZKA
M0>!)_1.J(0SWU="*4#6NJEZW2[',]_A95B,?<X\#!1;_!@H''P4<MM<O#X!W
MJ8F!Q?@_*&+=^'V?9CPIW?Y4A=V@B]06#@F4$8$*+,";<\S)E5J,'N"EIBK9
MW.\I(Q\C[S,Q@@8P2X@:"?W<UKR1+;[!S1ZXB7TWP%PNQS#6%MC1\=NJ+489
M?OEX^+")AYAU6_-&-O,&`34*3YJ(SJN$*1/A^=BJ'*Y$;XR$9@GJ^2.78SSQ
M"P*I%,-\<.P1Q41O(@D-.%XJG%D&(N79Y@.E3&BS0<;+3W1+8*,2XUQTG&9&
M-K=.>AM\O.CLMTRS49)G/BI2`<ZLF7`#AAI,B4M`Y#"2\H&3BIH6G1XW8"JQ
M"W7E2&M"`#V"-1WH3\UDX-)UM;;83V]6/0"C?#RD8JJ%IS!MM))G[WM%;VX(
M#%^:S76E@!)/#OK3W!E((:CLPRH?+.GX:_$I30.7EX>+.B3CACYT)[?8X[]C
M/R270A`].+WS\,3SP1PB[@E6/,&.(5'G(H`#M/^>J`:L?87F0S`=WBT#0:.;
MRJVT0UH]%.D7+PLG&B*CHCISE2B)M)8-:E\"M==S#!,;T:,)DOK3>"^'\=-R
M7Y`6DI&/R52(N3(F8V403/XM>$)"K%$"SV4#P!?N9;L'[&:[.P"5BBL?HI_M
M-I!Y1LC`TXWGA])[("/55>@>Y/.3XX<N<6\Y"\9SHJ93H5F(T+F)^X5(=:!A
M0+B>V54$V:&DY\-RGX@VP!+>M(V6:*4F,GJB*2B*Y)P@2U7%.U86@;;Z]`=:
M$(ZTP@VDJT`ZCB_;P6L=7!YP!B4KES!04P&DA0HO;`*R%&T^G$K%O=O(2(B.
M6QH9#0(.B0"HN3PD]C"]J/\S*'.]?Y:.:^=Z/^:_-CYO7%_%]7ICM([RF6W1
MA:(*A>GRW9ZQ,S=CHW83+3BPSW?LL"Z(@$I<\O&0BD<7V:G=P..@\%`;IPLA
M8'O&?">G@LR*4>/$@[?K6Y:>"[?OI>CS79X*%><O6S=8>"$LW(82,MR#JD$8
MW!$LB%E'+`&('";YJ$A%;W>A(I*$8E%(RT)&6`..2@&-U$:$8JM*!<GR`9`.
ME6;M6VA:@^=UN+ET3<=01']Z&<HYX]X_Q+T*Y5?J"1&J[0;)@'\W%DISS(=)
M.@":#1,C-HH&Z=LF5I+1))3(R%Z?9S0XJHHCO5$$^@/]H'>)V)M$BK<D5?CD
M8R8=G2RZLZ5I;EX8)JNH=F;RYR?U,QT+/QCC?""EXI(E@&1'Q+?EBK5HT%4%
M7=L.!A5J><H1YZ+D72I^N?U<4=/`P&OU1]VF.B13I"]*/5?W@UZTA!<L?*CK
MT3O,'46??\5J9Q$M!<`4H6/8&@8IZO4[736:-LHOULIPF',RO6BIVU3;YB;,
MOX#BY"GP31;I227E>L4'*4;B1X1]O]6IK^7K;BQ@.!!D&'Z3L#D2NWT\(7Y!
MDR%OALEWBL.16+M9S0L8#2091MM'Y[)L_]2Q;W&%I_5;7C^!Z8Q+1%-WS^9<
MSXRB&Z#OF*,9Y9"HI[:A:ZM7[>YI^ZQ[\B3<6,4R&JQ*NIP&AJZL!ID7'Q>5
M;0B4T/>%Q.7>(KU-K!:9>6UUA_A2)+S:*U[E2S]U5W2A0MBD4B7Q415_]\,^
M*EC77)=4@]$OU33)NQ9\#\>H-V7]LNMV[5QULNC,PWZ*9-S574P3FS!Y:J_8
ME-=EXP+P0FH8&O5CKX+8O$J\D/2$2/_:2W[Z4O)"&EAD\>^]M-B\Y+R0#@F1
M_M5>D=ORX\O.M0(7K7C+03Q=$]<:/O&&&-5[_K4M0]3QZP\2G`>,PA"?+]4^
M!C4J;B$\$9+#S."B-<6^[MAU1NCP/>:.-6G4J4F3-(EV1(!43F`:T4+44VND
MJH>6H``40`@\/1DJ\W_E+%P8Z1Y(S34NV4_:G]Z``@]8;<[JT1XHP$-K6<"V
MMPC-411!`&"+3[KTIS#6";PPZ--[S+^!OL![M4?-+H0R5'L7@QOR>":[40XN
MF3Q#,0RTZ"W6FD3;**-?1:,.H3XGN#_M3Z>>0T:JT;"U3Z=%RD,7#T-Q@E]1
M;7$)3RYQ[TDP(=Q6>C,E5EE_I>/<90'V,HL[4N69U59W.:OH^P/VX>4]E@KJ
M2^N(F&5(@;PVE,`.C\Y>SR-*79\(\?F)<,<3T1E,LUYQR[C9F[1Q\B`QM23M
M\S4-!VPB]2W\R7F(^'K.,>&!;?OV//5J*:I?8!G968E\K?)*\[XFA2"RS(!Y
M/M&[+K?9OHNJ6*5^F>9JI][Z4',I2V.*%[;2E>=SH.1..-'EO-/>!W*I*N1,
M)]]@"6U28D.VO?D4:W49$E\3PIL[49-F51\W6&;7WN)$]:NSF[JG!@W;L]1J
M]&!V]TBSA6=('`(#!&"K%\KZ](8\$)_IK?V?'S;F']7(GVTJ<K@A^#7C"U4%
MHPV6U-7G4:^P\XVXJ]E$AL]+4-4)!DK?U6PQ.7=Y#<!=@G^C(\.Q2I:]Y<AJ
MU`M9H(R!NV95.O$8IHWFZV>7&=]1RW)>H>PU<EJTQZ@'I495UZA6_U,U,"=/
MG>I;AIKC1S:>LU!@:#:H.YY[7!)2R,!\RCJ9?8L=W;_?,4R3@4S*Q-Q<M3+'
MXT+VA`A534Z;D95:._75K@AGOD7[C<1Z*?]$HOY5].A&V'?-C+QL1S'COV4A
ME_/M,,M,KI.K>M0E0704.5K_3D=KMF<YAK"U*?RU&),),(U93R^P,&[CLCC)
M,8P\?L,4JA@=S#&,'QP2ZD\Y0H5S4FC=F;-.P-5G&T90X'KN;5FQF5"?F?AF
M;&13\<SD^JFO3K?8L;TDU#-@4@U\L&_FF[>,6^/U>\]7]8:N]0&'9'H$4]=[
MF)//_65L]2U9*XNLQ&-H8K\0.>#,(<05ZO*,5?,YT,N=:ASL;`;22M`<0R/[
MA5$'BZ2GUW=/0L.IEKC='K57-Z)[+.G,+HL*Q$=1**'J-M2R=U)=LR+$=DD4
MI;#-]Z@D,\)?KV&,5DQU$Z8N8B$\N6XCU<7NSEJG/K8/@U=V[U#B^5GCA>SD
M.AE@^HQ[[)*O,(SEFU"RK"F0]Q@J7;%6%9K?_E3U,"K`E)Z9[</D*`HIY,X\
M/NYB&M>H4FX.]]?"I78)5>5P#!UZ8MR(3>4CYNF)[=8<=:K]FZ<LUS<9&%SK
M!<JL-;!JY'5;#1M"5\I%=!ILM(!Y^_9%O]U9:V<<6V)?+@>$JY`KGIEU+6B9
M1MA?:])V9UWM=5I$F5[/KA&(Q\"[3]-5+R.M3I7.J#=^9%M5M]+JI7K>+:?)
M#?36G5I;VX[]6=6MJHV(PZB[-=*9G5PK[VH-MX74,U-KI7[R)8.UD]^K+2A7
MR]3'#BZA9X89)(P,X&6/1AV9Z=96+:%=#,\I9;\&-AGWO&9AF@EJ9.3E`_:T
M*C`>^%4-]J(]OZ8L;DCT_Q#E6U'PV@JQ)GW%%B33]K73ZSEEE.0[AOG%:,ZX
MWM09K16H%+4;1RD68M_L[5VSN1C!6C2XRA;1@]:BRE^GMPROSJ-V/:0RI:>O
M3[D)U6:,J%)>!NI,%U34:X4RWX^/0JCM.9OE4)+X*%9(U9:'[<.&S-0Z=;M_
M8-\?24Z(_(V%G&)_P+V`#+%,V[([:[T,6]_6F6%.=H8:&B&RYDD9:754?<Q,
M+&4MPA#U\QGF[,B_9X=_R.XAT3AC)IB15BOG$-7M$/?R@7`8NIK!E_J6B:,^
M)Q7=L!X'AD*IRLQ=7].IS.$51VR?.M'14/CY?U!+`0(>`Q0````(`%%[KT1;
M];:-8)@``,%:!0`1`!@```````$```"D@0````!C>6UA+3(P,30P,S,Q+GAM
M;%54!0`#ZA1U4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%%[KT3)94KQ
M_@X``&?,```5`!@```````$```"D@:N8``!C>6UA+3(P,30P,S,Q7V-A;"YX
M;6Q55`4``^H4=5-U>`L``00E#@``!#D!``!02P$"'@,4````"`!1>Z]$&7T$
M&H0;``#GN@$`%0`8```````!````I('XIP``8WEM82TR,#$T,#,S,5]D968N
M>&UL550%``/J%'53=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`47NO1((^
MBFB!6@``@NP$`!4`&````````0```*2!R\,``&-Y;6$M,C`Q-#`S,S%?;&%B
M+GAM;%54!0`#ZA1U4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%%[KT2'
MQ@UN]"T``+])`P`5`!@```````$```"D@9L>`0!C>6UA+3(P,30P,S,Q7W!R
M92YX;6Q55`4``^H4=5-U>`L``00E#@``!#D!``!02P$"'@,4````"`!1>Z]$
M5=^*2%D/``"5FP``$0`8```````!````I('>3`$`8WEM82TR,#$T,#,S,2YX
M<V155`4``^H4=5-U>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``@EP!
#````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 08, 2013

</div>
          <div>New Lease Agreement [Member]

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expenses</a></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating leases term</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_LeaseStartDate', window );">Lease start date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 16,
				 2014<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">Apr. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
				 2018<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_AreaOfOfficeSpace', window );">Area of office space</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,894<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Accrued in the balance sheets related to indemnification obligations</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_IndemnificationLiability', window );">Indemnification liabilities</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_AreaOfOfficeSpace">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area Of Office Space</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_AreaOfOfficeSpace</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_IndemnificationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indemnification Liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_IndemnificationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_LeaseStartDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease start date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_LeaseStartDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LossContingenciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesRentExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Warrant Liability (Detail) (Level 3 [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant Liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity', window );">Balance as of December 31, 2013</a></td>
        <td class="nump">$ 6,466<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues', window );">Issuance of financial instrument</a></td>
        <td class="nump">443<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
        <td class="nump">4,784<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements', window );">Settlement of financial instrument</a></td>
        <td class="num">(55)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity', window );">Balance as of March 31, 2014</a></td>
        <td class="nump">11,638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Forward Contract [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity', window );">Balance as of December 31, 2013</a></td>
        <td class="nump">453<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues', window );">Issuance of financial instrument</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
        <td class="num">(10)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements', window );">Settlement of financial instrument</a></td>
        <td class="num">(443)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity', window );">Balance as of March 31, 2014</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInstrumentsClassifiedInShareholdersEquityMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of issuances of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of settlements of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquitySettlements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified in shareholders' equity measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisValueOfInstrumentsClassifiedInShareholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Additional Information (Detail) (2013 Equity Incentive Plan [Member])<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease', window );">Increased in shares available for issuance</a></td>
        <td class="nump">472,753<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage', window );">Share based compensation arrangement percentage increase in share reserved</a></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share based compensation arrangement number of issued options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">830,647<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation arrangement by share based payment award, expiration period</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Reserved Percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Period Increase Decrease</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>4. Common Stock Warrants</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In January 2014, in connection with the 2013 financing, the Company
 completed the sale of common stock for aggregate proceeds of $3.0
 million and as part of this transaction, the Company issued
 five-year warrants to purchase 120,800 shares of common stock at an
 exercise price of $5.75 per share. Due to certain provisions, the
 Company is required to account for the warrants issued as a
 liability at fair value. In addition, the estimated liability
 related to the warrants is required to be revalued at each
 reporting period until the earlier of the exercise of the warrants,
 at which time the liability will be reclassified to
 stockholders&#x2019; equity, or expiration of the warrants. At
 issuance date, the fair value of the total warrant liability was
 estimated to be $0.4 million using a binomial lattice
 options-pricing model.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stockholders Equity Note Warrants Or Rights Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S
M93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Y
M,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T)A
M;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]N9&5N<V5D7T)A;&%N8V5?4VAE971S7U!A<F5N/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7U-T871E
M;65N='-?;V9?3W!E<F%T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N9&5N<V5D7U-T871E;65N='-?;V9?0V%S:%]&/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N
M7V%N9%]$97-C<FEP=&EO;E]O/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V5R=&%I;E]"
M86QA;F-E7U-H965T7TET96US/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]M;6]N7U-T;V-K7U=A<G)A;G1S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L;&%B;W)A=&EO;E]A;F1?
M3&EC96YS95]!9W)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^1&5B=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET
M>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M7U!L86YS7V%N9%]3=&]C:T)A<V5D7T-O;3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961087)T>5]4<F%N<V%C=&EO;G,\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ
M871I;VY?86YD7T1E<V-R:7!T:6]N7V\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O
M=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-E
M<G1A:6Y?0F%L86YC95]3:&5E=%])=&5M<U]483PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG
M96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T;V-K:&]L9&5R<U]%<75I='E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?4&QA;G-?86YD7U-T;V-K0F%S
M961?0V]M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D]R9V%N:7IA=&EO;E]A;F1?1&5S8W)I<'1I;VY?;S(\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC
M86YT7T%C8V]U;G0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG
M;FEF:6-A;G1?06-C;W5N=#0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0U/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O
M9E]3:6=N:69I8V%N=%]!8V-O=6YT-CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-E<G1A:6Y?0F%L86YC95]3:&5E=%])=&5M<U]0
M<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-E<G1A
M:6Y?0F%L86YC95]3:&5E=%])=&5M<U]!8SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-O;6UO;E]3=&]C:U]787)R86YT<U]!9&1I
M=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;&QA8F]R871I;VY?86YD7TQI8V5N<V5?06=R93$\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S$N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$96)T7T%D9&ET:6]N86Q?26YF;W)M
M871I;VY?1&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O
M;G1I;F=E;F-I97-?,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?061D:71I;VYA;#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='E?4F5S97)V961?4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K7U!L86YS7V%N9%]3=&]C:T)A<V5D7T-O;3(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]0;&%N
M<U]A;F1?4W1O8VM"87-E9%]#;VTS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4F5L871E9%!A<G1Y7U1R86YS86-T:6]N<U]!9&1I
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(
M4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53
M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E
M/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD
M;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB
M;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*
M("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O
M9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?
M,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X
M.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S
M+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q0T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M
M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"U1/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q+`T*"0DR,#$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3
M>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=#64U!/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)T-Y;6%"87D@5&AE<F%P975T:6-S+"!);F,N/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG,#`P,3`T,C`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<M+3$R+3,Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#
M;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`V-"PX,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X
M-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H
M965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44E!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#;VYD96YS960@0F%L86YC92!3:&5E=',@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(L,S0R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M-"PT,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#@T,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W0@<F5C96EV86)L
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!I;G1E<F5S="!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@W-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8W5R<F5N="!A
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,"PY,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,BPR,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$L,3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PP-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EA8FEL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0V
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%C:6QI='D@;&]A;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#4R
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDL-#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86-I;&ET>2!L;V%N+"!L97-S(&-U<G)E;G0@<&]R=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP.3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0P-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H
M97(@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DL.#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,L.3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N
M=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S
M)R!E<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP,#`Q('!A<B!V86QU93H@
M,3`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9#L@;F\@<VAA<F5S(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M("0P+C`P,#$@<&%R('9A;'5E.B`Q,#`L,#`P+#`P,"!S:&%R97,@875T:&]R
M:7IE9#LQ,"PP-C0L-#DU(&%N9"`Y+#0U-2PP-C0@<VAA<F5S(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<@87,@;V8@36%R8V@@,S$L(#(P,30@86YD($1E8V5M
M8F5R(#,Q+"`R,#$S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<P+#(W-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-RPT,S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F
M:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4X+#DP-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-#@L.#0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PS-S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PU.38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L
M:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S$L,3DV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,BPU,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R
M83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P
M-C$O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D%!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0F%L86YC92!3:&5E=',@
M*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N
M="!/9B!&:6YA;F-I86P@4&]S:71I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A
M=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S
M=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"PP-C0L-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT-34L,#8T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L,#8T+#0Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL-#4U+#`V-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W
M,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE
M971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:44%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-O;F1E;G-E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@
M86YD($-O;7!R96AE;G-I=F4@3&]S<R`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPV,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M-#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@
M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPT,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-2PQ,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,BPT,34I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN
M8V]M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,3(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!E>'!E
M;G-E+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-S<U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P+#`V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#8R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W)E=&EO;B!T;R!R961E;7!T:6]N('9A;'5E
M(&]F(')E9&5E;6%B;&4@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ,#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO
M<W,@871T<FEB=71A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#`V,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#<S-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3W1H97(@8V]M<')E:&5N<VEV92!L;W-S+VEN8V]M93H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E86QI>F5D
M(&=A:6X@;VX@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-O;7!R96AE;G-I=F4@:6YC
M;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!R
M96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q,"PP-C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@U+#<S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S
M('!E<B!C;VUM;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,2XP,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#DX-2XP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9R!U<V5D('1O(&-A;&-U;&%T92!B87-I8R!A
M;F0@9&EL=71E9"!N970@;&]S<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#@W,RPV.#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#@R-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A
M.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V
M,2]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!4D%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!3=&%T96UE;G1S(&]F($-A
M<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!A8W1I=FET:65S/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`L,#8R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPV
M,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S
M<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUE;7!L;WEE92!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E(&%N9"!D:7)E8W1O<B!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!P<F5M:75M(&]N(&UA<FME
M=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.;VXM8V%S:"!I;G1E<F5S="!A<W-O8VEA=&5D('=I=&@@9&5B
M="!D:7-C;W5N="!A8V-R971I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F('=A<G)A;G0@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<X
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!A<W-E=',@86YD(&QI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G1R86-T(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0@<F5C96EV86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E
M>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,3(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,C$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I
M;G1E<F5S="!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PP
M,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPQ-3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&EN9R!A8W1I=FET:65S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA
M<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L97,@;V8@
M;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@:6YV97-T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',L(&YE="!O
M9B!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPT,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#`R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!D96-R96%S92!I;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`U.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G:6YN:6YG(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L-#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW
M,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@96YD(&]F('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L,S0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F4@;V8@8V%S:"!F;&]W
M(&EN9F]R;6%T:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEX960@87-S971S(&EN(&%C
M8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@=7!O;B!C87-H;&5S<R!W87)R86YT(&5X97)C:7-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;F-A<V@@:7-S
M=6%N8V4@8V]S=',@:6YC=7)R960@:6X@8V]M;6]N('-T;V-K(&9I;F%N8VEN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S
M,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S
M,#8Q+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@1&5S8W)I<'1I
M;VX@;V8@0G5S:6YE<W,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]R9V%N:7IA=&EO;B!A;F0@1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-
M"B`\8CXQ+B!/<F=A;FEZ871I;VX@86YD($1E<V-R:7!T:6]N(&]F($)U<VEN
M97-S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($-Y;6%"
M87D@5&AE<F%P975T:6-S+"!);F,N("AT:&4@)B-X,C`Q0SM#;VUP86YY)B-X
M,C`Q1#L@;W(-"B`F(W@R,#%#.T-Y;6%"87DF(W@R,#%$.RD@:7,@82!B:6]P
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M:&4-"B!#;VUP86YY)B-X,C`Q.3MS('-E8V]N9"!P<F]D=6-T(&-A;F1I9&%T
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M;B!O;F4@<V5G;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@3VX@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('1H92!#;VUP86YY('-O
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M<')I=F%T92!P;&%C96UE;G0@;VX@4V5P=&5M8F5R)B-X03`[,S`L#0H@,C`Q
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M.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>0T*('-O;&0@861D:71I;VYA;"!S:&%R
M97,@;V8@:71S(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA
M<V4-"B!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:RP@=VAI8V@@<V%L97,@
M87)E(&%L<V\@<&%R="!O9B!T:&4-"B!P<FEV871E('!L86-E;65N="P@9F]R
M(&YE="!P<F]C965D<R!O9B`D,BXR(&UI;&QI;VX@869T97(@9&5D=6-T:6YG
M#0H@<&QA8V5M96YT(&%G96YT(&9E97,@86YD(&5S=&EM871E9"!O9F9E<FEN
M9R!E>'!E;G-E<RX@1G5R=&AE<BP@;VX-"B!.;W9E;6)E<B8C>$$P.S(R+"`R
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M8V@@<V%L97,@;V-C=7)R960@;VX-"B!*86YU87)Y)B-X03`[,CDL(#(P,30L
M(&%F=&5R('1H92!L:7-T:6YG(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@
M8V]M;6]N('-T;V-K(&]N('1H92!O=F5R+71H92UC;W5N=&5R(&UA<FME="X@
M5&AE($-O;7!A;GD@<F5F97)S('1O#0H@=&AE('!R:79A=&4@<&QA8V5M96YT
M+"!T:&4@=F5N='5R92!D96)T(&9I;F%N8VEN9R!A;F0@=&AE(&ES<W5A;F-E
M#0H@;V8F(WA!,#MT:&4@0V]M<&%N>2=S)B-X03`[8V]M;6]N('-T;V-K(&EN
M(&-A;F-E;&QA=&EO;B!O9B!T:&4-"B`D,38N.2!M:6QL:6]N(&]F(&1E8G0@
M87,@=&AE(#(P,3,@9FEN86YC:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!H87,@:6YC=7)R960@;F5T(&]P97)A
M=&EN9R!L;W-S97,@86YD(&YE9V%T:79E(&-A<V@-"B!F;&]W<R!F<F]M(&]P
M97)A=&EO;G,@<VEN8V4@:71S(&EN8V5P=&EO;BX@1'5R:6YG('1H92!T:')E
M92!M;VYT:',-"B!E;F1E9"!-87)C:"8C>$$P.S,Q+"`R,#$T+"!T:&4@0V]M
M<&%N>2!I;F-U<G)E9"!A(&QO<W,@9G)O;0T*(&]P97)A=&EO;G,@;V8@)#$P
M+C$@;6EL;&EO;B!A;F0@=7-E9"`D-2XP(&UI;&QI;VX@;V8@8V%S:"!I;@T*
M(&]P97)A=&EO;G,N($%T($UA<F-H)B-X03`[,S$L(#(P,30L('1H92!#;VUP
M86YY(&AA9"!A;B!A8V-U;75L871E9`T*(&1E9FEC:70@;V8@)#,U."XY(&UI
M;&QI;VXN($-Y;6%"87D@97AP96-T<R!T;R!I;F-U<B!I;F-R96%S960-"B!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@87,@:70@8V]N=&EN
M=65S('1O('-T=61Y(&ET<PT*('!R;V1U8W0@8V%N9&ED871E<R!I;B!C;&EN
M:6-A;"!T<FEA;',N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?
M,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X
M.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S
M+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/C(N(%-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P="<^#0H@/&(^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M;F-E(%4N4RX@1T%!4"`H)B-X,C`Q0SM'04%0)B-X,C`Q1#LI(&%N9"!F;VQL
M;W=I;F<-"B!T:&4@<F5Q=6ER96UE;G1S(&]F('1H92!5;FET960@4W1A=&5S
M(%-E8W5R:71I97,@86YD($5X8VAA;F=E#0H@0V]M;6ES<VEO;B`H)B-X,C`Q
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M)B-X,C`Q.3MS(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!A8V-O;7!A;GEI
M;F<@;F]T97,@9F]R('1H90T*(&9I<V-A;"!Y96%R(&5N9&5D($1E8V5M8F5R
M)B-X03`[,S$L(#(P,3,L('=H:6-H(&ES(&-O;G1A:6YE9"!I;B!T:&4-"B!#
M;VUP86YY)B-X,C`Q.3MS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&%S
M(&9I;&5D('=I=&@@=&AE(%-%0R!O;@T*($UA<F-H)B-X03`[,S$L(#(P,30N
M(%1H92!R97-U;'1S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D#0H@36%R
M8V@F(WA!,#LS,2P@,C`Q-"P@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T
M:79E(&]F(')E<W5L=',@=&\-"B!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@
M;W(@9F]R(&%N>2!O=&AE<B!P97)I;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY5
M<V4@;V8@17-T:6UA=&5S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
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M<F5P;W)T960@:6X@=&AE(&9I;F%N8VEA;`T*('-T871E;65N=',@86YD(&%C
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M=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;BP@86-C<G5E9"!L:6%B:6QI=&EE
M<RP@86YD(&5Q=6ET>2!A;F0@;&EA8FEL:71Y#0H@:6YS=')U;65N="!V86QU
M871I;VYS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[
M($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`F(WA!,#L\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#!P="<^#0H@/&(^4F5V97)S92!3=&]C:R!3<&QI=#PO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P="<^#0H@3VX@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('1H92!#
M;VUP86YY(&9I;&5D(&%N(&%M96YD960@86YD#0H@<F5S=&%T960@8V5R=&EF
M:6-A=&4@;V8@:6YC;W)P;W)A=&EO;B!U;F1E<B!W:&EC:"!T:&4-"B!#;VUP
M86YY)B-X,C`Q.3MS('!R969E<G)E9"!S=&]C:R!A;F0@8V]M;6]N('-T;V-K
M('=A<R!R979E<G-E('-P;&ET#0H@;VX@82`Q+69O<BTW.2XU(&)A<VES+B!4
M:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9`T*(&YO
M=&5S('1O('1H92!F:6YA;F-I86P@<W1A=&5M96YT<RP@9VEV92!R971R;V%C
M=&EV92!E9F9E8W0@=&\@=&AE#0H@<F5V97)S92!S<&QI="!F;W(@86QL('!E
M<FEO9',@<')E<V5N=&5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^1F%I<B!686QU
M92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@9FEN86YC
M:6%L(&EN<W1R=6UE;G1S(&-O;G-I<W0@;V8@8V%S:"!A;F0@8V%S:`T*(&5Q
M=6EV86QE;G1S+"!S:&]R="UT97)M(&UA<FME=&%B;&4@<V5C=7)I=&EE<RP@
M86-C;W5N=',@<&%Y86)L92P-"B!A8V-R=65D(&5X<&5N<V5S+"!W87)R86YT
M(&QI86)I;&ET:65S(&%N9"!C;VYV97)T:6)L92!N;W1E<RX@1F%I<@T*('9A
M;'5E(&5S=&EM871E<R!O9B!T:&5S92!I;G-T<G5M96YT<R!A<F4@;6%D92!A
M="!A('-P96-I9FEC('!O:6YT#0H@:6X@=&EM92P@8F%S960@;VX@<F5L979A
M;G0@;6%R:V5T(&EN9F]R;6%T:6]N+B!4:&5S92!E<W1I;6%T97,@;6%Y#0H@
M8F4@<W5B:F5C=&EV92!I;B!N871U<F4@86YD(&EN=F]L=F4@=6YC97)T86EN
M=&EE<R!A;F0@;6%T=&5R<R!O9@T*('-I9VYI9FEC86YT(&IU9&=M96YT(&%N
M9"!T:&5R969O<F4@8V%N;F]T(&)E(&1E=&5R;6EN960@=VET:`T*('!R96-I
M<VEO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1F%I<B!V
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M=F%B;&4@:6YP=71S(&%N9"!I<R!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#0E.R!-
M05)'24XM5$]0.B`V<'0G/@T*($QE=F5L(#$F(W@R,#$T.U%U;W1E9"!P<FEC
M97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',-"B!O
M<B!L:6%B:6QI=&EE<R!T:&%T('1H92!#;VUP86YY(&AA<R!T:&4@86)I;&ET
M>2!T;R!A8V-E<W,@870@=&AE#0H@;65A<W5R96UE;G0@9&%T92X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`T)3L@34%21TE.+51/4#H@-G!T)SX-"B!,979E;"`R)B-X,C`Q-#M);G!U
M=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S
M#0H@=&AA="!A<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T(&]R(&QI86)I
M;&ET>2P@96ET:&5R(&1I<F5C=&QY(&]R#0H@:6YD:7)E8W1L>2X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`T)3L@34%21TE.+51/4#H@-G!T)SX-"B!,979E;"`S)B-X,C`Q-#M);G!U
M=',@=&AA="!A<F4@=6YO8G-E<G9A8FQE(&9O<B!T:&4@87-S970@;W(-"B!L
M:6%B:6QI='DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H
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M<G5M96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Y,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-CDE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T
M(&%L:6=N/3-$8V5N=&5R/CQB/D%S(&]F($UA<F-H)B-X03`[,S$L(#(P,30\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9#L@5TE$5$@Z(#,Y+C5P="<^#0H@/&(^1&5S
M8W)I<'1I;VX\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9A
M:7(F(WA!,#M686QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@36]N
M97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q
M+#<S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$L-S,W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!#;W)P;W)A=&4@9&5B="!A;F0@87-S970@
M8F%C:V5D('-E8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L,3DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-BPQ.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&%S<V5T<R!M96%S=7)E9"!A="!F
M86ER('9A;'5E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$L-S,W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8L,3DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L.3(X/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=A<G)A
M;G0@;&EA8FEL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$Q+#8S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,2PV,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(%1O=&%L(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A
M:7(@=F%L=64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3$L-C,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#8S
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M,2!O<B!,979E;"`R+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!!<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H96QD
M(&$@3&5V96P@,R!L:6%B:6QI='D-"B!A<W-O8VEA=&5D('=I=&@@=V%R<F%N
M=',L(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE#0H@0V]M<&%N>28C
M>#(P,3D[<R`R,#$S(&9I;F%N8VEN9RX@5&AE('=A<G)A;G1S(&%R92!C;VYS
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M('1H92!#;VUP86YY)B-X,C`Q.3MS('!E97)S(&%N9"!T:&4@<FES:RUF<F5E
M(')A=&4-"B!C;W)R97-P;VYD:6YG('1O('1H92!E>'!E8W1E9"!T97)M(&]F
M('1H92!W87)R86YT<RX@07,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S
M+"!T:&4@0V]M<&%N>2!A;'-O(&AE;&0@82!,979E;"`S(&QI86)I;&ET>0T*
M(&%S<V]C:6%T960@=VET:"!A(&9O<G=A<F0@8V]N=')A8W0@=VAI8V@@87)O
M<V4@:6X@8V]N;F5C=&EO;B!W:71H#0H@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M3F]V96UB97(F(WA!,#LR,BP@,C`Q,R!E>&5C=71I;VX@;V8@86X@97%U:71Y
M#0H@<'5R8VAA<V4@86=R965M96YT('=I=&@@8V5R=&%I;B!I;G9E<W1O<G,N
M(%1H92!A9W)E96UE;G0@<F5Q=6ER960-"B!T:&4@0V]M<&%N>2!T;R!I<W-U
M92!A(&9I>&5D(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%N
M9`T*('=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!A="!A('!R
M961E=&5R;6EN960@<')I8V4@;V8@)#,N,`T*(&UI;&QI;VX@<')O=FED960@
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M;V-C=7)R960@;VX@2F%N=6%R>28C>$$P.S(Y+`T*(#(P,30N(%1H92!F86ER
M('9A;'5E(&]F('1H92!U;F1E<FQY:6YG(&-O;6UO;B!S=&]C:R!A;F0@=V%R
M<F%N=',-"B!W97)E('9A;'5E9"!U<VEN9R!A;B!O<'1I;VXM<')I8VEN9R!M
M;V1E;"P@=&AE(&EN<'5T<R!O9B!W:&EC:"!A<F4-"B!S:6UI;&%R('1O('1H
M;W-E('5S960@:6X@=&AE('9A;'5A=&EO;B!O9B!T:&4@0V]M<&%N>28C>#(P
M,3D[<PT*(&QI86)I;&ET>2!C;&%S<VEF:65D('=A<G)A;G1S+B!#:&%N9V5S
M('1O(&%N>2!O9B!T:&4@:6YP=71S('1O('1H90T*(&]P=&EO;BUP<FEC:6YG
M(&UO9&5L<R!U<V5D(&)Y('1H92!#;VUP86YY(&-A;B!H879E(&$@<VEG;FEF
M:6-A;G0-"B!I;7!A8W0@=&\@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F
M('1H92!W87)R86YT<R!A;F0@9F]R=V%R9`T*(&-O;G1R86-T(&QI86)I;&ET
M:65S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/
M3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA!,#L\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A
M8FQE('-E=',@9F]R=&@@86X@86-T:79I='D@<W5M;6%R>2!W:&EC:"!I;F-L
M=61E<PT*('1H92!C:&%N9V5S(&EN('1H92!F86ER('9A;'5E(&]F)B-X03`[
M=&AE($-O;7!A;GDG<R8C>$$P.TQE=F5L(#,-"B!F:6YA;F-I86P@:6YS=')U
M;65N=',@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P
M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^
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M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^5V%R<F%N=#PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY&;W)W87)D/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQI86)I
M;&ET>3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^0V]N
M=')A8W0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@87,@
M;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XV+#0V-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#4S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!)<W-U86YC92!O9B!F:6YA;F-I
M86P@:6YS=')U;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!#:&%N9V4@:6X@9F%I<B!V86QU93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C0L-S@T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-E='1L96UE;G0@;V8@9FEN
M86YC:6%L(&EN<W1R=6UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH-34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T-#,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@0F%L86YC92!A<R!O9B!-87)C:"8C>$$P
M.S,Q+"`R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L-C,X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&=A:6YS(&%N9"!L
M;W-S97,@9G)O;2!R96UE87-U<F5M96YT(&]F($QE=F5L(#,@9FEN86YC:6%L
M#0H@;&EA8FEL:71I97,@87)E(')E8V]R9&5D('1H<F]U9V@@;W1H97(@97AP
M96YS92P@;F5T(&]N('1H90T*(&%C8V]M<&%N>6EN9R!S=&%T96UE;G1S(&]F
M(&]P97)A=&EO;G,@86YD(&-O;7!R96AE;G-I=F4@;&]S<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X
M<'0G/@T*(#QB/D-A<V@L($-A<V@@17%U:79A;&5N=',L(&%N9"!-87)K971A
M8FQE(%-E8W5R:71I97,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@;&EQ=6ED
M(&EN=F5S=&UE;G1S('=I=&@@80T*(')E;6%I;FEN9R!M871U<FET>2!O9B`Y
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M96-U<FET:65S(&%N9`T*(&%R92!C;&%S<VEF:65D(&%S("8C>#(P,4,[879A
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5A;&EZ960@9V%I
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M=F5R>2!I;B!M87)K970-"B!V86QU92X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/E)E
M<W1R:6-T960@0V%S:#PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!M86EN=&%I;B!C;VUP
M96YS871I;F<@8V%S:"!B86QA;F-E<R!W:71H#0H@9FEN86YC:6%L(&EN<W1I
M='5T:6]N<R!T:&%T('!R;W9I9&4@=&AE($-O;7!A;GD@=VET:"!I=',@8V]R
M<&]R871E#0H@8W)E9&ET(&-A<F1S+B!!<R!O9B!-87)C:"8C>$$P.S,Q+"`R
M,#$T(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+`T*(&-A<V@@<F5S=')I
M8W1E9"!U;F1E<B!T:&5S92!A<G)A;F=E;65N=',@=V%S("0Q,#`L,#`P(&%N
M9"`D,34U+#`P,"P-"B!R97-P96-T:79E;'DN(%1H97-E(&%M;W5N=',@87)E
M('!R97-E;G1E9"!I;B!O=&AE<B!A<W-E=',@;VX@=&AE#0H@86-C;VUP86YY
M:6YG(&)A;&%N8V4@<VAE971S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^0V]N8V5N
M=')A=&EO;B!O9B!#<F5D:70@4FES:SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
M3D1%3E0Z(#0E)SX-"B!#87-H+"!C87-H(&5Q=6EV86QE;G1S+"!A;F0@;6%R
M:V5T86)L92!S96-U<FET:65S(&-O;G-I<W0@;V8-"B!F:6YA;F-I86P@:6YS
M=')U;65N=',@=&AA="!P;W1E;G1I86QL>2!S=6)J96-T('1H92!#;VUP86YY
M('1O(&$-"B!C;VYC96YT<F%T:6]N(&]F(&-R961I="!R:7-K('1O('1H92!E
M>'1E;G0@;V8@=&AE(&9A:7(@=F%L=64-"B!R96-O<F1E9"!I;B!T:&4@8F%L
M86YC92!S:&5E="X@5&AE($-O;7!A;GD@:6YV97-T<R!C87-H('1H870@:7,@
M;F]T#0H@<F5Q=6ER960@9F]R(&EM;65D:6%T92!O<&5R871I;F<@;F5E9',@
M<')I;6%R:6QY(&EN(&AI9VAL>2!L:7%U:60-"B!I;G-T<G5M96YT<R!T:&%T
M(&)E87(@;6EN:6UA;"!R:7-K+B!4:&4@0V]M<&%N>2!H87,@97-T86)L:7-H
M960-"B!G=6ED96QI;F5S(')E;&%T:6YG('1O('1H92!Q=6%L:71Y+"!D:79E
M<G-I9FEC871I;VXL(&%N9"!M871U<FET:65S#0H@;V8@<V5C=7)I=&EE<R!T
M;R!E;F%B;&4@=&AE($-O;7!A;GD@=&\@;6%N86=E(&ET<R!C<F5D:70@<FES
M:RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$X<'0G/@T*(#QB/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4')O<&5R='D@
M86YD(&5Q=6EP;65N="!I<R!S=&%T960@870@8V]S="P@;&5S<R!A8V-U;75L
M871E9`T*(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N+B!$97!R96-I
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M;F0-"B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD@87,@:6YC=7)R960N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q.'!T)SX-"B`\8CY);7!A:7)M96YT(&]F($QO;F<M3&EV960@
M07-S971S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C>$$P.S,Q
M+`T*(#(P,3,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+51/4#H@,'!T)SX-"B`\8CY$969E<G)E9"!296YT/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY#;VUM;VX@4W1O8VL@5V%R<F%N="!,
M:6%B:6QI='D\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M5V%R<F%N=',@:7-S=65D('1O(&-O;6UO;B!S=&]C:R!H;VQD97)S(&%N9"!L
M96YD97)S(&)Y('1H92!#;VUP86YY#0H@:6X@8V]N:G5N8W1I;VX@=VET:"!T
M:&4@,C`Q,R!F:6YA;F-I;F<@=V5R92!C;&%S<VEF:65D(&%S#0H@;&EA8FEL
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M<F%T:6]N<R!A;F0@8V]M<')E:&5N<VEV92!L;W-S+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^
M#0H@/&(^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M8V]M<&5N<V%T:6]N.R!C;VYT<F%C=`T*(')E<V5A<F-H(&]R9V%N:7IA=&EO
M;G,@86YD(&]T:&5R('1H:7)D('!A<G1I97,@=&AA="!A<W-I<W0@:6X-"B!M
M86YA9VEN9RP@;6]N:71O<FEN9RP@86YD(&%N86QY>FEN9R!C;&EN:6-A;"!T
M<FEA;',[(&EN=F5S=&EG871O<@T*(&%N9"!S:71E(&9E97,[(&QA8F]R871O
M<GD@<V5R=FEC97,[(&-O;G-U;'1A;G1S.R!C;VYT<F%C=`T*(&UA;G5F86-T
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M(&1E=F5L;W!M96YT(&-O<W1S(&%R92!E>'!E;G-E9`T*(&%S(&EN8W5R<F5D
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M86=R965M96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
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M86-T:79I='D@:6YC=7)R960@=6YD97(@96%C:`T*(&-O;G1R86-T(&%S(&EN
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M<R!U;F1E<B!T:&5S92!C;&EN:6-A;`T*('1R:6%L(&%R<F%N9V5M96YT<R!I
M;B!A9'9A;F-E(&]F('1H92!R96-E:7!T(&]F('1H92!R96QA=&5D#0H@<V5R
M=FEC97,@87)E(')E8V]R9&5D(&%S('!R97!A:60@87-S971S+"!D97!E;F1I
M;F<@;VX@=&AE('1E<FUS(&]F#0H@=&AE(&%G<F5E;65N="P@=6YT:6P@=&AE
M('-E<G9I8V5S(&%R92!R96YD97)E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/E-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)
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M=6%T:6]N(&UO9&5L(&%N9`T*('1H92!S:6YG;&4M;W!T:6]N(&%P<')O86-H
M(&%N9"!R96-O9VYI>F5S(&5X<&5N<V4@=7-I;F<@=&AE#0H@<W1R86EG:'0M
M;&EN92!A='1R:6)U=&EO;B!M971H;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
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M86YD#0H@86UO<G1I>F5D('1O(&5X<&5N<V4@87,@96%R;F5D+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,3AP="<^#0H@/&(^26YC;VUE(%1A>&5S/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M;F-E<R!B971W965N('1H92!F:6YA;F-I86P@<F5P;W)T:6YG(&%N9`T*('1H
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M="!W:6QL(&YO="!B92!R96%L:7IE9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@
M,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@5&AE(&%C8V]U;G1I;F<@9W5I9&%N8V4@9F]R('5N8V5R=&%I;G1Y(&EN
M(&EN8V]M92!T87AE<R!P<F5S8W)I8F5S#0H@82!R96-O9VYI=&EO;B!T:')E
M<VAO;&0@86YD(&UE87-U<F5M96YT(&%T=')I8G5T92!C<FET97)I82!F;W(@
M=&AE#0H@9FEN86YC:6%L(')E8V]G;FET:6]N(&%N9"!M96%S=7)E;65N="!O
M9B!T87@@<&]S:71I;VYS('1A:V5N(&]R#0H@97AP96-T960@=&\@8F4@=&%K
M96X@:6X@82!T87@@<F5T=7)N+B!&;W(@=&AO<V4@8F5N969I=',@=&\@8F4-
M"B!R96-O9VYI>F5D+"!A('1A>"!P;W-I=&EO;B!M=7-T(&)E(&UO<F4@;&EK
M96QY('1H86X@;F]T('1O(&)E#0H@<W5S=&%I;F5D('5P;VX@97AA;6EN871I
M;VX@8F%S960@;VX@=&AE('1E8VAN:6-A;"!M97)I=',@;V8@=&AE#0H@<&]S
M:71I;VXN5&AE($-O;7!A;GD@<F5C;W)D<R!I;G1E<F5S="!R96QA=&5D('1O
M(&EN8V]M92!T87AE<RP@:68-"B!A;GDL(&%S(&EN=&5R97-T+"!A;F0@86YY
M('!E;F%L=&EE<R!W;W5L9"!B92!R96-O<F1E9"!A<R!O=&AE<@T*(&5X<&5N
M<V4@:6X@=&AE('-T871E;65N=',@;V8@8V]M<')E:&5N<VEV92!I;F-O;64@
M*&QO<W,I+B!4:&5R92!W87,-"B!N;R!I;G1E<F5S="!O<B!P96YA;'1I97,@
M<F5L871E9"!T;R!I;F-O;64@=&%X97,@<F5C;W)D960@9'5R:6YG#0H@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C>$$P.S,Q+"`R,#$T(&%N9"`R
M,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3AP="<^#0H@/&(^0V]M<')E:&5N<VEV92!,;W-S/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M8V]M92`H;&]S<RD-"B!I<R!D:7-C;&]S960@:6X@=&AE('-T871E;65N=',@
M;V8@<F5D965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960-"B!S=&]C:R!A
M;F0@<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U:71Y("AD969I8VET*2P@86YD
M(&ES('-T871E9"!N970-"B!O9B!R96QA=&5D('1A>"!E9F9E8W1S+"!I9B!A
M;GDN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY.970@3&]S<R!097(@0V]M;6]N(%-H
M87)E/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
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M9R!T:&4@<&5R:6]D+B!0<FEO<B!T;R!T:&4@,C`Q,R!F:6YA;F-I;F<L(&EN
M(&%D9&ET:6]N('1O#0H@8V]M;6]N('-T;V-K+"!T:&4@0V]M<&%N>2!H860@
M<')E9F5R<F5D('-T;V-K(&]U='-T86YD:6YG('1H870-"B!C;VYT<F%C='5A
M;&QY(&5N=&ET;&5D('1H92!H;VQD97(@=&\@<&%R=&EC:7!A=&4@:6X@9&EV
M:61E;F1S(&%N9`T*(&5A<FYI;F=S(&]F('1H92!#;VUP86YY+B!!8V-O<F1I
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M96UB97(F(WA!,#LS,"P@,C`Q,RP@:6X@8V]N;F5C=&EO;B!W:71H('1H92`R
M,#$S(&9I;F%N8VEN9RP@86QL#0H@;W5T<W1A;F1I;F<@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B-X,C`Q.3MS('!R969E<G)E9"!S=&]C:R!W97)E#0H@8V]N
M=F5R=&5D(&EN=&\@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O
M;6UO;B!S=&]C:RX-"B!!8V-O<F1I;F=L>2P@;F\@<')E9F5R<F5D('-T;V-K
M('=A<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('1H<F5E#0H@;6]N=&AS(&5N
M9&5D($UA<F-H)B-X03`[,S$L(#(P,30N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4G/@T*($1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&]F(&-O
M;6UO;B!S=&]C:R!I<R!C86QC=6QA=&5D('5S:6YG('1H90T*(&UO<F4@9&EL
M=71I=F4@;V8@=&AE('1W;R!A<'!R;V%C:&5S.B!O;F4L#0H@)B-X,C`Q0SMA
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M>#(P,4,[='=O+6-L87-S)B-X,C`Q1#L@;65T:&]D(&%S(&1E<V-R:6)E9"!A
M8F]V92X@56YD97(-"B!E:71H97(@87!P<F]A8V@L('1H92!W96EG:'1E9"!A
M=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;W5T<W1A;F1I;F<-"B!I<R!A;'-O
M(&%D:G5S=&5D('1O(&EN8VQU9&4@=&AE(&%S<W5M960@97AE<F-I<V5S(&]F
M('-T;V-K(&]P=&EO;G,-"B!A;F0@=V%R<F%N=',L(&EF(&1I;'5T:79E+B!&
M;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9`T*($UA<F-H)B-X03`[,S$L(#(P
M,30@86YD(#(P,3,L(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&ES('1H
M90T*('-A;64@87,@8F%S:6,L(&%S(&%N>2!A9&IU<W1M96YT<R!W;W5L9"!H
M879E(&)E96X-"B!A;G1I+61I;'5T:79E+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0
M.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-H;W=S('1H92!T;W1A;"!O=71S
M=&%N9&EN9R!S96-U<FET:65S#0H@8V]N<VED97)E9"!A;G1I+61I;'5T:79E
M(&%N9"!T:&5R969O<F4@97AC;'5D960@9G)O;2!T:&4-"B!C;VUP=71A=&EO
M;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@
M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S@E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\8CY4:')E92!-;VYT:',-"B!%
M;F1E9#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A
M;&EG;CTS1&-E;G1E<CX\8CY-87)C:"8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#%P=#L@1D].5"U3
M25I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#!P="<@86QI9VX],T1C96YT97(^*'5N875D:71E9"D\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=A<G)A;G1S(&9O<B!C;VUM;VX@
M<W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@T."PT
M.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C@L,C$P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#;VUM;VX@<W1O8VL@;W!T
M:6]N<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP-BPW.38\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3<L-C@W/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!2
M961E96UA8FQE(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C8Q+#`U.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR+#<U-2PR.#,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XW.#8L.34V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A
M8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?
M-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,#@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#97)T86EN
M($)A;&%N8V4@4VAE970@271E;7,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@0V]N<V]L:61A
M=&EO;B!!;F0@4')E<V5N=&%T:6]N($]F($9I;F%N8VEA;"!3=&%T96UE;G1S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-E<G1A:6X@0F%L86YC92!3:&5E="!)=&5M<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/C,N($-E<G1A:6X@0F%L86YC92!3:&5E="!)=&5M<SPO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT
M(&-O;G-I<W1S(&]F('1H92!F;VQL;W=I;F<@*&EN#0H@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-S0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB
M/DUA<F-H)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/@T*(#QB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P
M,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX-"B`\8CXH=6YA=61I=&5D*3PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3V9F:6-E(&%N
M9"!C;VUP=71E<B!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-34V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-38\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%!U<F-H87-E9"!S;V9T=V%R93PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V-CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($9U<FYI='5R92!A;F0@9FEX='5R97,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XT,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C,T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#4S-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$Q-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C,L,CDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,
M97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PP-30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#,L,CDU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;W!E
M<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@36%R8V@@,C`Q-"P@
M=&AE($-O;7!A;GD@8V5A<V5D('5S92!O9B!A('-U8G-T86YT:6%L('!O<G1I
M;VX@;V8-"B!I=',@;&5A<V5D(&9A8VEL:71Y(&EN($AA>7=A<F0L($-A;&EF
M;W)N:6$N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4-"B!C;&]S=7)E(&]F('1H
M:7,@9F%C:6QI='DL('1H92!#;VUP86YY(&1I<W!O<V5D(&]F(&-E<G1A:6X@
M9G5L;'D-"B!D97!R96-I871E9"!L96%S96AO;&0@:6UP<F]V96UE;G1S+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!8V-R=65D(&QI86)I
M;&ET:65S(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9R`H:6X@=&AO=7-A;F1S
M*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*
M(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@
M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-S0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\
M8CY-87)C:"8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX-"B`\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^*'5N875D:71E9"D\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
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M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-3$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R=65D('!R
M92UC;&EN:6-A;"!A;F0@8VQI;FEC86P@=')I86P@97AP96YS97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(S,SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,3@\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W)U960@<')O9F5S<VEO
M;F%L(&9E97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,#$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@R/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&;W)W87)D(&-O;G1R86-T/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-3,\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R(&%C8W)U
M86QS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@5&]T86P@86-C<G5E9"!L:6%B:6QI=&EE<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L,S8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,C4Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?
M,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P
M,S`V,2]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM;VX@4W1O8VL@5V%R<F%N=',\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY4
M97AT($)L;V-K(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!787)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*
M(#QB/C0N($-O;6UO;B!3=&]C:R!787)R86YT<SPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!);B!*86YU87)Y(#(P,30L(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@,C`Q,R!F:6YA;F-I;F<L('1H92!#;VUP86YY#0H@
M8V]M<&QE=&5D('1H92!S86QE(&]F(&-O;6UO;B!S=&]C:R!F;W(@86=G<F5G
M871E('!R;V-E961S(&]F("0S+C`-"B!M:6QL:6]N(&%N9"!A<R!P87)T(&]F
M('1H:7,@=')A;G-A8W1I;VXL('1H92!#;VUP86YY(&ES<W5E9`T*(&9I=F4M
M>65A<B!W87)R86YT<R!T;R!P=7)C:&%S92`Q,C`L.#`P('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870@86X-"B!E>&5R8VES92!P<FEC92!O9B`D-2XW-2!P
M97(@<VAA<F4N($1U92!T;R!C97)T86EN('!R;W9I<VEO;G,L('1H90T*($-O
M;7!A;GD@:7,@<F5Q=6ER960@=&\@86-C;W5N="!F;W(@=&AE('=A<G)A;G1S
M(&ES<W5E9"!A<R!A#0H@;&EA8FEL:71Y(&%T(&9A:7(@=F%L=64N($EN(&%D
M9&ET:6]N+"!T:&4@97-T:6UA=&5D(&QI86)I;&ET>0T*(')E;&%T960@=&\@
M=&AE('=A<G)A;G1S(&ES(')E<75I<F5D('1O(&)E(')E=F%L=65D(&%T(&5A
M8V@-"B!R97!O<G1I;F<@<&5R:6]D('5N=&EL('1H92!E87)L:65R(&]F('1H
M92!E>&5R8VES92!O9B!T:&4@=V%R<F%N=',L#0H@870@=VAI8V@@=&EM92!T
M:&4@;&EA8FEL:71Y('=I;&P@8F4@<F5C;&%S<VEF:65D('1O#0H@<W1O8VMH
M;VQD97)S)B-X,C`Q.3L@97%U:71Y+"!O<B!E>'!I<F%T:6]N(&]F('1H92!W
M87)R86YT<RX@070-"B!I<W-U86YC92!D871E+"!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@=&]T86P@=V%R<F%N="!L:6%B:6QI='D@=V%S#0H@97-T:6UA=&5D
M('1O(&)E("0P+C0@;6EL;&EO;B!U<VEN9R!A(&)I;F]M:6%L(&QA='1I8V4-
M"B!O<'1I;VYS+7!R:6-I;F<@;6]D96PN/"]P/@T*(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A
M.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V
M,2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E($%G
M<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY497AT($)L;V-K(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I;VX@
M86YD($QI8V5N<V4@06=R965M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^-2X@0V]L;&%B;W)A=&EO
M;B!A;F0@3&EC96YS92!!9W)E96UE;G1S/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M+`T*(')O>6%L='DM8F5A<FEN9R!L:6-E;G-E('1O($U"6"TX,#(U(&%N9"!C
M97)T86EN(&]T:&5R#0H@4%!!4CQF;VYT/F0\+V9O;G0^)B-X03`[8V]M<&]U
M;F1S("AT:&4-"B`F(W@R,#%#.U!005(\9F]N=#YD/"]F;VYT/B8C>$$P.U!R
M;V1U8W1S)B-X,C`Q1#LI('=I=&@@=&AE(')I9VAT#0H@=&\@9W)A;G0@<W5B
M;&EC96YS97,@=&\@=&AI<F0@<&%R=&EE<R!T;R!M86ME+"!U<V4@86YD('-E
M;&P@<W5C:`T*(%!005(\9F]N=#YD/"]F;VYT/B8C>$$P.U!R;V1U8W1S+B!5
M;F1E<@T*('1H92!T97)M<R!O9B!T:&4@86=R965M96YT+"!#>6UA0F%Y(&AA
M<R!F=6QL(&-O;G1R;VP@86YD#0H@<F5S<&]N<VEB:6QI='D@;W9E<B!T:&4@
M<F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9"!R96=I<W1R871I;VX@;V8-"B!A
M;GD@4%!!4CQF;VYT/F0\+V9O;G0^)B-X03`[4')O9'5C=',-"B!A;F0@:7,@
M<F5Q=6ER960@=&\@=7-E(&1I;&EG96YT(&5F9F]R=',@=&\@8V]N9'5C="!A
M;&P@<W5C:`T*(&%C=&EV:71I97,N($IA;G-S96X@:&%S('1H92!S;VQE(')E
M<W!O;G-I8FEL:71Y(&9O<B!T:&4-"B!P<F5P87)A=&EO;BP@9FEL:6YG+"!P
M<F]S96-U=&EO;BP@;6%I;G1E;F%N8V4@;V8L(&%N9"!D969E;G-E(&]F#0H@
M=&AE('!A=&5N=',@=VET:"!R97-P96-T('1O+"!T:&4@4%!!4CQF;VYT/F0\
M+V9O;G0^)B-X03`[4')O9'5C=',N($IA;G-S96X@:&%S(&$@<FEG:'0-"B!O
M9B!F:7)S="!N96=O=&EA=&EO;B!U;F1E<B!T:&4@86=R965M96YT('1O(&QI
M8V5N<V4@82!P87)T:6-U;&%R#0H@4%!!4CQF;VYT/F0\+V9O;G0^)B-X03`[
M4')O9'5C="!F<F]M#0H@0WEM84)A>2!I;B!T:&4@979E;G0@=&AA="!#>6UA
M0F%Y(&5L96-T<R!T;R!S965K(&$@=&AI<F0@<&%R='D-"B!C;W)P;W)A=&4@
M<&%R=&YE<B!F;W(@=&AE(')E<V5A<F-H+"!D979E;&]P;65N="P@<')O;6]T
M:6]N+"!A;F0O;W(-"B!C;VUM97)C:6%L:7IA=&EO;B!O9B!S=6-H(%!005(\
M9F]N=#YD/"]F;VYT/B8C>$$P.U!R;V1U8W1S+B!5;F1E<B!T:&4@=&5R;7,@
M;V8-"B!T:&4@86=R965M96YT($IA;G-S96X@:7,@96YT:71L960@=&\@<F5C
M96EV92!U<"!T;R!A;B`X)2!R;WEA;'1Y(&]N#0H@;F5T('-A;&5S(&]F(%!0
M05(\9F]N=#YD/"]F;VYT/B8C>$$P.U!R;V1U8W1S+B!.;R!P87EM96YT<R!W
M97)E(&UA9&4-"B!A;F0@;F\@<F]Y86QT:65S('=E<F4@<F5C96EV960@=6YD
M97(@=&AI<R!A9W)E96UE;G0@9'5R:6YG('1H90T*('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"8C>$$P.S,Q+"`R,#$T(&%N9"`R,#$S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!*=6YE)B-X03`[,C`Q,"P@0WEM
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M($-Y;6%"87D@:7,@86QS;PT*(&5L:6=I8FQE('1O(')E8V5I=F4@=7`@=&\@
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M<VEB:6QI='D@;W9E<B!T:&4@<F5S96%R8V@L(&1E=F5L;W!M96YT(&%N9`T*
M(')E9VES=')A=&EO;B!O9B!A;GD@<')O9'5C=',@9&5V96QO<&5D(&%N9"]O
M<B!D:7-C;W9E<F5D(&9R;VT@=&AE#0H@;65T86)O;&EC(&1I<V5A<V4@=&%R
M9V5T<R!A;F0@:7,@<F5Q=6ER960@=&\@=7-E(&1I;&EG96YT(&5F9F]R=',-
M"B!T;R!C;VYD=6-T(&%L;"!S=6-H(&%C=&EV:71I97,N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($IU;F4@,3DY."P@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@;&EC96YS92!A9W)E96UE;G0@=VET:`T*($1I
M851E>"P@26YC+B`H1&EA5&5X*2!R96QA=&EN9R!T;R!P<F]D=6-T<R!C;VYT
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M=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=&AE(&QI8V5N<V5D('!R;V1U8W1S
M+B!4:&4@0V]M<&%N>2!A;'-O#0H@<F5T86EN960@=&AE(')I9VAT('1O('-U
M8BUL:6-E;G-E('1H92!C;W9E<F5D($E0+B!4:&4@;&EC96YS90T*(&%G<F5E
M;65N="!C;VYT86EN<R!A("0R+#`P,"!P97(@;6]N=&@@;&EC96YS92!F964@
M87,@=V5L;"!A<R!A#0H@<F5Q=6ER96UE;G0@=&\@;6%K92!A9&1I=&EO;F%L
M('!A>6UE;G1S(&9O<B!D979E;&]P;65N=`T*(&%C:&EE=F5M96YT<R!A;F0@
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M"B!$:6%497@N($1I851E>"!I<R!E;G1I=&QE9"!T;R!U<"!T;R`D,"XX(&UI
M;&QI;VX@9F]R('1H92!F=71U<F4-"B!D979E;&]P;65N="!O9B!A<FAA;&]F
M96YA=&4L(&%S('=E;&P@87,@82`R)2!R;WEA;'1Y('!A>6UE;G0@;VX@;F5T
M#0H@<V%L97,@;V8@<')O9'5C=',@8V]N=&%I;FEN9R!A<FAA;&]F96YA=&4N
M($YO(&1E=F5L;W!M96YT('!A>6UE;G1S#0H@=V5R92!M861E(&EN('1H92!T
M:')E92!M;VYT:',@96YD960@36%R8V@F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q
M,RP-"B!A;F0@;F\@<F]Y86QT:65S(&AA=F4@8F5E;B!P86ED('1O(&1A=&4N
M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?
M-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,3$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$96)T/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5B="!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/C8N($1E8G0\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T
M=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($]N($IU;F4F(WA!,#LR,"P@
M,C`P-B!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!E<75I='D@86YD(&QO
M86X-"B!F86-I;&ET>2!W:71H('1H92!*;VAN<V]N(&%N9"!*;VAN<V]N($1E
M=F5L;W!M96YT($-O<G!O<F%T:6]N#0H@*"8C>#(P,4,[2DI$0R8C>#(P,40[
M*2!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!C;W5L9"!D<F%W;B!D
M;W=N#0H@=7`@=&\@86X@86=G<F5G871E(&]F("0S,"!M:6QL:6]N(&EN(&QO
M86YS(&EN('1H92!F;W)M(&]F#0H@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K('!R;VUI<W-O<GD@;F]T97,N($EN($UA<F-H(&%N9`T*(%-E<'1E;6)E
M<B`R,#`X+"!T:&4@0V]M<&%N>2!I<W-U960@;F]T97,@:6X@=&AE(&%G9W)E
M9V%T92!A;6]U;G0@;V8-"B`D,RXU(&UI;&QI;VX@86YD("0Q,"XU(&UI;&QI
M;VXL(')E<W!E8W1I=F5L>2X@5&AE(&YO=&5S('=E<F4@9'5E(&]N#0H@36%R
M8V@F(WA!,#LQ-R!A;F0@4V5P=&5M8F5R)B-X03`[,3<L(#(P,3$L(&EN8VQU
M9&EN9R!I;G1E<F5S="!T:&%T#0H@86-C<G5E9"!A="`W+C4W)28C>$$P.W!E
M<B!A;FYU;2X@26X@1&5C96UB97(@,C`Q,"P@=&AE(&%G9W)E9V%T90T*('!R
M:6YC:7!A;"!A;6]U;G0@86YD(&%L;"!A8V-R=65D(&EN=&5R97-T('5N9&5R
M('1H92!N;W1E<R!I<W-U960@:6X-"B!-87)C:"!A;F0@4V5P=&5M8F5R(#(P
M,#@@=V5R92!C;VYV97)T960@:6YT;R!T:&4@0V]M<&%N>28C>#(P,3D[<PT*
M(%-E<FEE<R!%+3,@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K("A397)I
M97,@12TS(%!R969E<G)E9"D@870-"B`D,C,R+CDS)B-X03`[<&5R('-H87)E
M+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB
M;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@1F5B<G5A<GD@86YD
M($IU;'D@,C`P.2P@=&AE($-O;7!A;GD@:7-S=65D(&YO=&5S(&EN('1H90T*
M(&%G9W)E9V%T92!A;6]U;G0@;V8@)#<N,"!M:6QL:6]N(&%N9"`D-BXW(&UI
M;&QI;VXL(')E<W!E8W1I=F5L>2P-"B!W:&EC:"!R97!R97-E;G1E9"!T:&4@
M<F5M86EN:6YG(&%M;W5N="!A=F%I;&%B;&4@=&\@=&AE($-O;7!A;GDL(&EN
M#0H@86-C;W)D86YC92!W:71H('1H92!T97)M<R!O9B!T:&4@97%U:71Y(&%N
M9"!L;V%N(&9A8VEL:71Y('=I=&@-"B!*2D1#+B!4:&4@;F]T97,@=V5R92!D
M=64@:6X@1F5B<G5A<GD@,C`Q,B!A;F0@2G5L>2`R,#$R+"!I;F-L=61I;F<-
M"B!I;G1E<F5S="!T:&%T(&%C8W)U960@870@-"XT,B4F(WA!,#MP97(@86YN
M=6T@86YD(#0N.38P)28C>$$P.W!E<@T*(&%N;G5M+"!R97-P96-T:79E;'DN
M($EN($IA;G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@86UE;F1E9"!T:&4-"B!M
M871U<FET>2!D871E<R!O9B!T:&4@;W5T<W1A;F1I;F<@)#<N,"!M:6QL:6]N
M(&%N9"`D-BXW(&UI;&QI;VX-"B!C;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO
M=&5S('1O(&5X=&5N9"!T:&4@;6%T=7)I='D@9&%T92!T;PT*($UA<F-H)B-X
M03`[,2P@,C`Q,RP@86YD(&EN=&5R97-T(')A=&5S('=E<F4@:6YC<F5A<V5D
M('1O(#0N.3$Y)2!A;F0-"B`U+C0V)28C>$$P.W!E<B!A;FYU;2P@<F5S<&5C
M=&EV96QY+B!);B!A9&1I=&EO;BP@=&AE(&-O;G9E<G-I;VX-"B!P<FEC92!O
M9B!T:&4@;F]T97,@=&\@8V]N=F5R="!I;G1O('-H87)E<R!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<PT*(%-E<FEE<R!#+3$@4')E9F5R<F5D(%-T;V-K('=A
M<R!D96-R96%S960@9G)O;2`D-#,X+C@T('!E<B!S:&%R92!T;PT*("0R.3(N
M-38@<&5R('-H87)E+B!!;&P@;V8@=&AE<V4@;F]T97,@=V5R92!F=7)T:&5R
M(&%M96YD960@:6X@36%R8V@-"B`R,#$S+"!T;R!E>'1E;F0@=&AE(&UA='5R
M:71Y(&1A=&4@;VX@=&AE(&YO=&5S('1O($%U9W5S="8C>$$P.S$L#0H@,C`Q
M,RP@86YD('1O(&UA:V4@=&AE(&YO=&5S('-U8F]R9&EN871E('1O(')E<&%Y
M;65N="!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('-E=F5R86YC92!O8FQI
M9V%T:6]N<R!T;R!A;&P@96UP;&]Y965S('5N=&EL#0H@2F%N=6%R>28C>$$P
M.S$L(#(P,30N($]N($IU;'DF(WA!,#LS,2P@,C`Q,RP@=&AE(&UA='5R:71Y
M(&1A=&4@=V%S#0H@97AT96YD960@=&\@1&5C96UB97(F(WA!,#LS,2P@,C`Q
M,RX@5&AE<F4@87)E(&YO(&9I;F%N8VEA;`T*(&-O=F5N86YT<R!A<W-O8VEA
M=&5D('=I=&@@=&AE(&YO=&5S+B!&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9`T*($UA<F-H)B-X03`[,S$L(#(P,3,L('1H92!#;VUP86YY(')E8V]G;FEZ
M960@)#`N,B!M:6QL:6]N(&]F#0H@:6YT97)E<W0@97AP96YS92!R96QA=&5D
M('1O('1H92!C;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&5S+B!/;@T*(%-E
M<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@;W5T<W1A;F1I;F<@<')I;F-I
M<&%L(&%N9"!A8V-R=65D#0H@:6YT97)E<W0@;V8@)#$V+CD@;6EL;&EO;B!U
M;F1E<B!T:&4@97%U:71Y(&%N9"!L;V%N(&9A8VEL:71Y('=I=&@-"B!*2D1#
M('=A<R!E>'1I;F=U:7-H960@:6X@97AC:&%N9V4@9F]R(#8R-"PY-#0@<VAA
M<F5S(&]F(&-O;6UO;@T*('-T;V-K(&%S(&%N(&EN=&5G<F%L('!A<G0@;V8@
M=&AE(#(P,3,@9FEN86YC:6YG+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ
M93HQ<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/@T*("8C
M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R9VEN
M+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#QB/D9A8VEL:71Y($QO86X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@
M=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*($]N(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!F86-I;&ET>0T*(&QO86X@
M86=R965M96YT('=I=&@@4VEL:6-O;B!686QL97D@0F%N:R!A;F0@3WAF;W)D
M($9I;F%N8V4@9F]R(&$-"B!T;W1A;"!L;V%N(&%M;W5N="!O9B`D,3`N,"!M
M:6QL:6]N(&]F('=H:6-H('1H92!F:7)S="!T<F%N8VAE(&]F#0H@)#4N,"!M
M:6QL:6]N('=A<R!D<F%W;B!A<R!P87)T(&]F)B-X03`[=&AE(#(P,3,@9FEN
M86YC:6YG+B8C>$$P.U1H90T*(&QO86X@:&%S(&$@9FEX960@:6YT97)E<W0@
M<F%T92!O9B`X+C<U)2!P87EA8FQE('1W96QV92!M;VYT:',-"B!I;G1E<F5S
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M=&@@;VYE(&]F('1W;R!F:6YA;F-I86P@8V]V96YA;G1S(&%T(&%L;`T*('1I
M;65S.B`H,2DF(WA!,#MM86EN=&%I;B`Q+C,@=&EM97,@8V%S:"!T;R!O=71S
M=&%N9&EN9R!D96)T(&]R#0H@*#(I)B-X03`[;6%I;G1A:6X@<W5F9FEC:65N
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M=&AE(&=R96%T97(@;V8@*&DI)B-X03`[."XW-24F(WA!,#MP97(@86YN=6T@
M86YD("AI:2DF(WA!,#MT:&4-"B!S=6T@;V8@=&AE(%=A;&P@4W1R965T($IO
M=7)N86P@<')I;64@<F%T92!P;'5S(#0N,C4E)B-X03`[<&5R#0H@86YN=6TN
M(%=E('=E<F4@86QS;R!R97%U:7)E9"!T;R!P87D@82!F86-I;&ET>2!F964@
M;V8@,2XP,"4@;VX@=&AE#0H@=&5R;2!L;V%N(&9A8VEL:71Y(&-O;6UI=&UE
M;G0N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN
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M<V4@<')I8V4@;V8@)#4N,#`@<&5R('-H87)E+B8C>$$P.T%S(&$@<F5S=6QT
M(&]F('1H:7,-"B!I<W-U86YC92P@82!W87)R86YT(&QI86)I;&ET>2!O9B`D
M,"XU(&UI;&QI;VX@=V%S(')E8V]R9&5D(&EN('1H90T*(&%C8V]M<&%N>6EN
M9R!B86QA;F-E('-H965T<R!W:&EC:"!I<R!R97%U:7)E9"!T;R!B92!R979A
M;'5E9"!A=`T*(&5A8V@@8F%L86YC92!S:&5E="!D871E+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X
M.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S
M93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,3AP="<^#0H@/&(^-RX@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A
M;GD@;&5A<V5D(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C92!I;B!A('-I
M;F=L92!B=6EL9&EN9PT*(&EN($AA>7=A<F0L($-A;&EF;W)N:6$N(%1H92!F
M86-I;&ET>2!L96%S92P@87,@86UE;F1E9"!O;@T*($IU;'DF(WA!,#LQ-2P@
M,C`Q,"P@:&%D(&$@=&5R;2!O9B!F;W5R('EE87)S(&%N9"!E>'!I<F5D(&]N
M#0H@07!R:6PF(WA!,#LS,"P@,C`Q-"X@3VX@3F]V96UB97(F(WA!,#LX+"`R
M,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D#0H@:6YT;R!A(&YE=R!L96%S92!C
M;VUM96YC:6YG($IA;G5A<GDF(WA!,#LQ-BP@,C`Q-"P@86YD(&5X<&ER:6YG
M(&]N#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q."P@9F]R(#@L.#DT('-Q=6%R
M92!F965T(&]F(&]F9FEC92!S<&%C92!I;@T*($YE=V%R:RP@0V%L:69O<FYI
M82X@4F5N="!E>'!E;G-E('=A<R`D,"XR(&UI;&QI;VX@86YD("0P+C$@;6EL
M;&EO;@T*(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H)B-X03`[
M,S$L(#(P,30@86YD(#(P,3,L#0H@<F5S<&5C=&EV96QY+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&=71U<F4@;6EN:6UU;2!L96%S92!P
M87EM96YT<R!A<F4@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R
M<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C
M96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#@E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CY,96%S93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY087EM96YT<SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@665A<B!E;F1I;F<@1&5C96UB97(F(WA!,#LS,3H\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%
M3E0Z("TQ96TG/@T*(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`R,#$U/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$V/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B`R,#$W/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,C(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B`R,#$X/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C(X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!F=71U<F4@
M;6EN:6UU;2!P87EM96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#8S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY);F1E;6YI9FEC
M871I;VX\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@
M=&AE(&YO<FUA;"!C;W5R<V4@;V8@8G5S:6YE<W,L('1H92!#;VUP86YY(&5N
M=&5R<R!I;G1O(&-O;G1R86-T<PT*(&%N9"!A9W)E96UE;G1S('1H870@8V]N
M=&%I;B!A('9A<FEE='D@;V8@<F5P<F5S96YT871I;VYS(&%N9`T*('=A<G)A
M;G1I97,@86YD('!R;W9I9&4@9F]R(&=E;F5R86P@:6YD96UN:69I8V%T:6]N
M+"!I;F-L=61I;F<-"B!I;F1E;6YI9FEC871I;VX@87-S;V-I871E9"!W:71H
M('!R;V1U8W0@;&EA8FEL:71Y(&]R(&EN9G)I;F=E;65N=`T*(&]F(&EN=&5L
M;&5C='5A;"!P<F]P97)T>2!R:6=H=',N(%1H92!#;VUP86YY)B-X,C`Q.3MS
M(&5X<&]S=7)E('5N9&5R#0H@=&AE<V4@86=R965M96YT<R!I<R!U;FMN;W=N
M(&)E8V%U<V4@:70@:6YV;VQV97,@9G5T=7)E(&-L86EM<R!T:&%T#0H@;6%Y
M(&)E(&UA9&4@86=A:6YS="!T:&4@0V]M<&%N>2!T:&%T(&UA>2!B92P@8G5T
M(&AA=F4@;F]T('EE="!B965N+`T*(&UA9&4N(%1O(&1A=&4L('1H92!#;VUP
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!#
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M=&AE<V4-"B!O8FQI9V%T:6]N<R!A<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T
M(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+@T*($YO(&%S<W5R86YC97,@
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M8V%T:6]N(&]B;&EG871I;VYS+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?-#4T
M-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R
M:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VMH;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXX+B!3=&]C:VAO
M;&1E<G,F(W@R,#$Y.R!%<75I='D\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@57!O;B!T:&4@8VQO<VEN9R8C>$$P.VEN('1H92`R,#$S
M(&9I;F%N8VEN9R!O;B!397!T96UB97(F(WA!,#LS,"P-"B`R,#$S+"!A;&P@
M;V8@=&AE(&]U='-T86YD:6YG('-H87)E<R!O9B!R961E96UA8FQE(&-O;G9E
M<G1I8FQE#0H@<')E9F5R<F5D('-T;V-K('=E<F4@8V]N=F5R=&5D(&EN=&\@
M,BPW.3,L,C@Q('-H87)E<R!O9B!C;VUM;VX-"B!S=&]C:RP@86YD('1H92!R
M96QA=&5D(&-A<G)Y:6YG('9A;'5E(&]F("0S,C`N,"!M:6QL:6]N('=A<PT*
M(')E8VQA<W-I9FEE9"!T;R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"X@
M07,@;V8@36%R8V@F(WA!,#LS,2P-"B`R,#$T+"!N;R!S:&%R97,@;V8@<F5D
M965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@=V5R90T*(&ES
M<W5E9"!O<B!O=71S=&%N9&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>#L@34%21TE.+51/4#H@,3)P
M>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@
M5&AE($-O;7!A;GD@=V%S(&%U=&AO<FEZ960@=&\@:7-S=64@,3`P+#`P,"PP
M,#`@<VAA<F5S(&]F(&-O;6UO;@T*('-T;V-K('=I=&@@82!P87(@=F%L=64@
M;V8@)#`N,#`P,2!P97(@<VAA<F4@87,@;V8@36%R8V@F(WA!,#LS,2P-"B`R
M,#$T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@<V]L9"`U+#,V-BPV
M-CD@<VAA<F5S(&]F#0H@8V]M;6]N('-T;V-K(&%N9"`Q+#`W,RPS,S@@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO;@T*('-T;V-K(&EN
M('1H92`R,#$S(&9I;F%N8VEN9R!F;W(@;F5T('!R;V-E961S('1O('1H92!#
M;VUP86YY(&]F#0H@)#(R+C@@;6EL;&EO;B!A9G1E<B!D961U8W1I;F<@<&QA
M8V5M96YT(&%G96YT(&9E97,@86YD(&5S=&EM871E9`T*(&]F9F5R:6YG(&5X
M<&5N<V5S+B!!;'-O(&]N('1H870@9&%T92P@=&AE($-O;7!A;GD@:7-S=65D
M(#8R-"PY-#0-"B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN(&-A;F-E;&QA
M=&EO;B!O9B!A<'!R;WAI;6%T96QY("0Q-BXY#0H@;6EL;&EO;B!O9B!D96)T
M(&]W960@=&\@2DI$0RP@=&AE(&AO;&1E<B!O9B!T:&%T(&1E8G0@*$YO=&4@
M-BDN($]N#0H@3V-T;V)E<B8C>$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!S
M;VQD(&%N(&%D9&ET:6]N86P@-C8T+#,P,`T*('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@86YD('=A<G)A;G1S('1O('!U<F-H87-E(#$S,BPX-C`@<VAA<F5S
M(&]F#0H@8V]M;6]N('-T;V-K+"!W:&EC:"!S86QE<R!W97)E(&%L<V\@<&%R
M="!O9B!T:&4@,C`Q,R!F:6YA;F-I;F<L(&9O<@T*(&YE="!P<F]C965D<R!T
M;R!#>6UA0F%Y(&]F("0R+C(@;6EL;&EO;B!A9G1E<B!D961U8W1I;F<@<&QA
M8V5M96YT#0H@86=E;G0@9F5E<R!A;F0@97-T:6UA=&5D(&]F9F5R:6YG(&5X
M<&5N<V5S+B!/;B!.;W9E;6)E<B8C>$$P.S(R+`T*(#(P,3,L('1H92!#;VUP
M86YY(&5N=&5R960@:6YT;R!A;B!A9W)E96UE;G0@=VET:"!I;G9E<W1O<G,@
M=&\-"B!P=7)C:&%S92`V,#0L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M86YD(#$R,"PX,#`@=V%R<F%N=',@=&\-"B!P=7)C:&%S92!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&%S('!A<G0@;V8@=&AE(#(P,3,@9FEN86YC:6YG(&9O
M<@T*(&YE="!P<F]C965D<R!O9B`D,BXW(&UI;&QI;VXL('=H:6-H('-A;&5S
M('=E<F4@<V5T('1O(&]C8W5R('-H;W)T;'D-"B!A9G1E<B!T:&4@;&ES=&EN
M9R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@;VX@=&AE
M#0H@;W9E<BUT:&4M8V]U;G1E<B!M87)K970N(%1H92!#;VUP86YY(&)E9V%N
M('1R861I;F<@;VX@=&AE#0H@;W9E<BUT:&4M8V]U;G1E<B!M87)K970@;VX@
M2F%N=6%R>28C>$$P.S(T+"`R,#$T(&5N86)L:6YG('1H:7,-"B!P;W)T:6]N
M(&]F('1H92`R,#$S9FEN86YC:6YG('1O(&)E(&-O;7!L971E9"!I;B!L871E
M($IA;G5A<GD-"B`R,#$T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M)SX-"B!!<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$S+"!T:&4@0V]M<&%N>0T*(&AA9"!R97-E<G9E9"!S:&%R
M97,@;V8@875T:&]R:7IE9"!B=70@=6YI<W-U960@8V]M;6]N('-T;V-K(&%S
M#0H@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X
M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0W-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/@T*(#QB/DUA<F-H)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/D1E8V5M8F5R)B-X03`[,S$L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\8CXH=6YA=61I
M=&5D*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0V]M;6]N('-T;V-K('=A<G)A;G1S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX-#@L-#@W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-S0R+#<R-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@17%U:71Y(&EN8V5N=&EV92!P;&%N<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#4P+#`T-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-S<L,CDT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@<F5S97)V
M960@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPX.3@L-3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,BPS,C`L,#(Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U
M7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!0;&%N<R!A;F0@
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!/9B!#;VUP
M96YS871I;VX@4F5L871E9"!#;W-T<R!3:&%R96)A<V5D(%!A>6UE;G1S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(%!L86YS(&%N9"!3=&]C:RU"87-E9"!#;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q
M.'!T)SX-"B`\8CXY+B!3=&]C:R!0;&%N<R!A;F0@4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B`\8CY3=&]C:R!0;&%N<SPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<W1O8VMH
M;VQD97)S#0H@87!P<F]V960@=&AE(#(P,3,@17%U:71Y($EN8V5N=&EV92!0
M;&%N+"!O<B`R,#$S(%!L86XL('5N9&5R('=H:6-H#0H@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A<F4@<F5S97)V960@
M9F]R#0H@:7-S=6%N8V4@<'5R<W5A;G0@=&\@<W1O8VL@87=A<F1S+"!I;F-L
M=61I;F<L(&)U="!N;W0@;&EM:71E9"!T;RP-"B!I;F-E;G1I=F4@<W1O8VL@
M;W!T:6]N<RP@;F]N<W1A='5T;W)Y('-T;V-K(&]P=&EO;G,L('-T;V-K#0H@
M87!P<F5C:6%T:6]N(')I9VAT<RP@<F5S=')I8W1E9"!S=&]C:R!A=V%R9',L
M(')E<W1R:6-T960@<W1O8VL@=6YI=`T*(&%W87)D<RP@<&5R9F]R;6%N8V4@
M<W1O8VL@87=A<F1S+"!A;F0@<&5R9F]R;6%N8V4@8V%S:"!A=V%R9',N($EN
M#0H@861D:71I;VXL('1H92!S:&%R92!R97-E<G9E(&%U=&]M871I8V%L;'D@
M:6YC<F5A<V5D(&)Y(#0W,BPW-3,-"B!S:&%R97,@;VX@2F%N=6%R>28C>$$P
M.S$L(#(P,30L(&%N9"!W:6QL(&-O;G1I;G5E('1O(&%U=&]M871I8V%L;'D-
M"B!I;F-R96%S92!O;B!*86YU87)Y)B-X03`[,3QS=7`@<W1Y;&4],T0G1D].
M5"U325I%.B`X-24[(%9%4E1)0T%,+4%,24=..B!T;W`G/G-T/"]S=7`^(&]F
M(&5A8V@@>65A<BP@9F]R(&$-"B!P97)I;V0@;V8@;F]T(&UO<F4@=&AA;B!T
M96X@>65A<G,L(&EN(&%N(&%M;W5N="!E<75A;"!T;R`U)2!O9B!T:&4-"B!T
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M($9R;VT@<&QA;B!I;F-E<'1I;VX@=&AR;W5G:"!-87)C:"8C>$$P.S,Q+"`R
M,#$T+"!T:&4@0V]M<&%N>0T*(&AA9"!I<W-U960@;W!T:6]N<R!F;W(@86X@
M86=G<F5G871E(&]F(#@S,"PV-#<F(WA!,#MS:&%R97,@;V8@=&AE#0H@0V]M
M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@=6YD97(@=&AE(#(P,3,@4&QA
M;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$X<'0G/@T*(#QB/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;B!%>'!E;G-E/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B`\:3Y%;7!L;WEE92!A;F0@
M1&ER96-T;W(@17AP96YS93PO:3X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P="<^#0H@16UP;&]Y964@
M86YD(&1I<F5C=&]R('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M(')E8V]R9&5D('=A<PT*(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX]
M,T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#,E
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY4:')E
M928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DUA<F-H)B-X
M03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/BAU;F%U9&ET960I/"]B/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-"B`\
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M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V
M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y
M7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#$U+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5L871E
M9"U087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T
M:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296QA=&5D+5!A<G1Y(%1R86YS86-T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*
M(#QB/C$P+B!296QA=&5D+5!A<G1Y(%1R86YS86-T:6]N<SPO8CX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!P86ED(&$@
M9F]R;65R(&UE;6)E<B!O9B!I=',@0F]A<F0@;V8@1&ER96-T;W)S+"!W:&\@
M:7,-"B!A;'-O(&$@;65M8F5R(&]F(&ET<R!38VEE;G1I9FEC(&%N9"!#;&EN
M:6-A;"!!9'9I<V]R>2!";V%R9',L(&$-"B!T;W1A;"!O9B`D-#4L,#`P(&EN
M('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD#0H@
M)#$U+#`P,"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C>$$P
M.S,Q+"`R,#$T+"!I;B!M;VYT:&QY#0H@8V%S:"!R971A:6YE<G,N(%1H92!#
M;VUP86YY(&%L<V\@:7-S=65D(&]P=&EO;G,@=&\@<'5R8VAA<V4@<VAA<F5S
M#0H@;V8@8V]M;6]N('-T;V-K(&%N9"!I;F-E;G1I=F4@87=A<F1S('1O('1H
M:7,@:6YD:79I9'5A;"!I;B!H:7,-"B!C87!A8VET>2!A<R!A(&UE;6)E<B!O
M9B!I=',@4V-I96YT:69I8R!!9'9I<V]R>2!";V%R9"X\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS
M,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W
M.69A8S`S,#8Q+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135$
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!$
M97-C<FEP=&EO;B!O9B!"=7-I;F5S<R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN
M9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:7%U:61I='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%1H92!#;VUP86YY(&AA<R!I;F-U<G)E9"!N970@;W!E<F%T:6YG
M(&QO<W-E<R!A;F0@;F5G871I=F4@8V%S:`T*(&9L;W=S(&9R;VT@;W!E<F%T
M:6]N<R!S:6YC92!I=',@:6YC97!T:6]N+B!$=7)I;F<@=&AE('1H<F5E(&UO
M;G1H<PT*(&5N9&5D($UA<F-H)B-X03`[,S$L(#(P,30L('1H92!#;VUP86YY
M(&EN8W5R<F5D(&$@;&]S<R!F<F]M#0H@;W!E<F%T:6]N<R!O9B`D,3`N,2!M
M:6QL:6]N(&%N9"!U<V5D("0U+C`@;6EL;&EO;B!O9B!C87-H(&EN#0H@;W!E
M<F%T:6]N<RX@070@36%R8V@F(WA!,#LS,2P@,C`Q-"P@=&AE($-O;7!A;GD@
M:&%D(&%N(&%C8W5M=6QA=&5D#0H@9&5F:6-I="!O9B`D,S4X+CD@;6EL;&EO
M;BX@0WEM84)A>2!E>'!E8W1S('1O(&EN8W5R(&EN8W)E87-E9`T*(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!A<R!I="!C;VYT:6YU97,@
M=&\@<W1U9'D@:71S#0H@<')O9'5C="!C86YD:61A=&5S(&EN(&-L:6YI8V%L
M('1R:6%L<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G
M/@T*(#QB/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@86-C;VUP86YY:6YG(&EN=&5R:6T@
M8V]N9&5N<V5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%R90T*('5N875D:71E
M9"X@5&AE<V4@=6YA=61I=&5D(&EN=&5R:6T@9FEN86YC:6%L('-T871E;65N
M=',@:&%V92!B965N#0H@<')E<&%R960@:6X@86-C;W)D86YC92!5+E,N($=!
M05`@*"8C>#(P,4,[1T%!4"8C>#(P,40[*2!A;F0@9F]L;&]W:6YG#0H@=&AE
M(')E<75I<F5M96YT<R!O9B!T:&4@56YI=&5D(%-T871E<R!396-U<FET:65S
M(&%N9"!%>&-H86YG90T*($-O;6UI<W-I;VX@*"8C>#(P,4,[4T5#)B-X,C`Q
M1#LI(&9O<B!I;G1E<FEM(')E<&]R=&EN9RX@07,@<&5R;6ET=&5D#0H@=6YD
M97(@=&AO<V4@<G5L97,L(&-E<G1A:6X@9F]O=&YO=&5S(&]R(&]T:&5R(&9I
M;F%N8VEA;"!I;F9O<FUA=&EO;@T*('1H870@87)E(&YO<FUA;&QY(')E<75I
M<F5D(&)Y($=!05`@8V%N(&)E(&-O;F1E;G-E9"!O<B!O;6ET=&5D+B!);@T*
M(&UA;F%G96UE;G0F(W@R,#$Y.W,@;W!I;FEO;BP@=&AE('5N875D:71E9"!I
M;G1E<FEM(&9I;F%N8VEA;`T*('-T871E;65N=',@:&%V92!B965N('!R97!A
M<F5D(&]N('1H92!S86UE(&)A<VES(&%S('1H92!A=61I=&5D#0H@9FEN86YC
M:6%L('-T871E;65N=',@86YD(&EN8VQU9&4@86QL(&%D:G5S=&UE;G1S+"!W
M:&EC:"!I;F-L=61E#0H@;VYL>2!N;W)M86P@<F5C=7)R:6YG(&%D:G5S=&UE
M;G1S+"!N96-E<W-A<GD@9F]R('1H92!F86ER#0H@<')E<V5N=&%T:6]N(&]F
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;"!P;W-I=&EO;B!A;F0@
M:71S#0H@<F5S=6QT<R!O9B!O<&5R871I;VYS(&%N9"!C;VUP<F5H96YS:79E
M(&QO<W,@86YD(&ET<R!C87-H(&9L;W=S(&9O<@T*('!E<FEO9',@<')E<V5N
M=&5D+B!4:&5S92!S=&%T96UE;G1S(&1O(&YO="!I;F-L=61E(&%L;"!D:7-C
M;&]S=7)E<PT*(')E<75I<F5D(&)Y($=!05`@86YD('-H;W5L9"!B92!R96%D
M(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!F
M:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@86-C;VUP86YY:6YG(&YO=&5S(&9O
M<B!T:&4-"B!F:7-C86P@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S+"!W:&EC:"!I<R!C;VYT86EN960@:6X@=&AE#0H@0V]M<&%N>28C>#(P
M,3D[<R!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!A<R!F:6QE9"!W:71H
M('1H92!314,@;VX-"B!-87)C:"8C>$$P.S,Q+"`R,#$T+B!4:&4@<F5S=6QT
M<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9`T*($UA<F-H)B-X03`[,S$L
M(#(P,30L(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!R97-U
M;'1S('1O#0H@8F4@97AP96-T960@9F]R('1H92!Y96%R(&]R(&9O<B!A;GD@
M;W1H97(@<&5R:6]D+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T
M)SX-"B`\8CY5<V4@;V8@17-T:6UA=&5S/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
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M8VQO<W5R97,@<F5P;W)T960@:6X@=&AE(&9I;F%N8VEA;`T*('-T871E;65N
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M:6UA=&EN9R!S=&]C:RUB87-E9`T*(&-O;7!E;G-A=&EO;BP@86-C<G5E9"!L
M:6%B:6QI=&EE<RP@86YD(&5Q=6ET>2!A;F0@;&EA8FEL:71Y#0H@:6YS=')U
M;65N="!V86QU871I;VYS+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5R<V4@4W1O8VL@
M4W!L:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`P<'0G/@T*(#QB/E)E=F5R<V4@4W1O8VL@4W!L:70\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V
M<'0G/@T*($]N(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@0V]M<&%N
M>2!F:6QE9"!A;B!A;65N9&5D(&%N9`T*(')E<W1A=&5D(&-E<G1I9FEC871E
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&:6YA
M;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY&86ER(%9A;'5E(&]F($9I;F%N
M8VEA;"!);G-T<G5M96YT<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!4:&4@0V]M<&%N>28C>#(P,3D[<R!F:6YA;F-I86P@:6YS=')U
M;65N=',@8V]N<VES="!O9B!C87-H(&%N9"!C87-H#0H@97%U:79A;&5N=',L
M('-H;W)T+71E<FT@;6%R:V5T86)L92!S96-U<FET:65S+"!A8V-O=6YT<R!P
M87EA8FQE+`T*(&%C8W)U960@97AP96YS97,L('=A<G)A;G0@;&EA8FEL:71I
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M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!&86ER('9A;'5E(&ES(&1E
M9FEN960@87,@=&AE(&5X8VAA;F=E('!R:6-E('1H870@=V]U;&0@8F4@<F5C
M96EV960-"B!F;W(@86X@87-S970@;W(@<&%I9"!T;R!T<F%N<V9E<B!A(&QI
M86)I;&ET>2`H86X@97AI="!P<FEC92D@:6X@=&AE#0H@<')I;F-I<&%L(&]R
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M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-"4[($U!4D=)3BU43U`Z
M(#9P="<^#0H@3&5V96P@,28C>#(P,30[475O=&5D('!R:6-E<R!I;B!A8W1I
M=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<PT*(&]R(&QI86)I;&ET
M:65S('1H870@=&AE($-O;7!A;GD@:&%S('1H92!A8FEL:71Y('1O(&%C8V5S
M<R!A="!T:&4-"B!M96%S=7)E;65N="!D871E+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#0E.R!-05)'
M24XM5$]0.B`V<'0G/@T*($QE=F5L(#(F(W@R,#$T.TEN<'5T<R!O=&AE<B!T
M:&%N('%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',-"B!T:&%T(&%R
M92!O8G-E<G9A8FQE(&9O<B!T:&4@87-S970@;W(@;&EA8FEL:71Y+"!E:71H
M97(@9&ER96-T;'D@;W(-"B!I;F1I<F5C=&QY+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#0E.R!-05)'
M24XM5$]0.B`V<'0G/@T*($QE=F5L(#,F(W@R,#$T.TEN<'5T<R!T:&%T(&%R
M92!U;F]B<V5R=F%B;&4@9F]R('1H92!A<W-E="!O<@T*(&QI86)I;&ET>2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&-A<G)Y:6YG
M(&%M;W5N=',@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G1S('-U8V@@87,@8V%S
M:"!A;F0@8V%S:`T*(&5Q=6EV86QE;G1S+"!A8V-O=6YT<R!P87EA8FQE+"!C
M;VYV97)T:6)L92!N;W1E<RP@86YD(&%C8W)U960-"B!E>'!E;G-E<R!A<'!R
M;WAI;6%T92!T:&4@<F5L871E9"!F86ER('9A;'5E<R!D=64@=&\@=&AE('-H
M;W)T+71E<FT-"B!M871U<FET:65S(&]F('1H97-E(&EN<W1R=6UE;G1S+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M<B!,979E;"`R+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!
M<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H96QD(&$@
M3&5V96P@,R!L:6%B:6QI='D-"B!A<W-O8VEA=&5D('=I=&@@=V%R<F%N=',L
M(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE#0H@0V]M<&%N>28C>#(P
M,3D[<R`R,#$S(&9I;F%N8VEN9RX@5&AE('=A<G)A;G1S(&%R92!C;VYS:61E
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M92!#;VUP86YY)B-X,C`Q.3MS('!E97)S(&%N9"!T:&4@<FES:RUF<F5E(')A
M=&4-"B!C;W)R97-P;VYD:6YG('1O('1H92!E>'!E8W1E9"!T97)M(&]F('1H
M92!W87)R86YT<RX@07,@;V8-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!T
M:&4@0V]M<&%N>2!A;'-O(&AE;&0@82!,979E;"`S(&QI86)I;&ET>0T*(&%S
M<V]C:6%T960@=VET:"!A(&9O<G=A<F0@8V]N=')A8W0@=VAI8V@@87)O<V4@
M:6X@8V]N;F5C=&EO;B!W:71H#0H@=&AE($-O;7!A;GDF(W@R,#$Y.W,@3F]V
M96UB97(F(WA!,#LR,BP@,C`Q,R!E>&5C=71I;VX@;V8@86X@97%U:71Y#0H@
M<'5R8VAA<V4@86=R965M96YT('=I=&@@8V5R=&%I;B!I;G9E<W1O<G,N(%1H
M92!A9W)E96UE;G0@<F5Q=6ER960-"B!T:&4@0V]M<&%N>2!T;R!I<W-U92!A
M(&9I>&5D(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%N9`T*
M('=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!A="!A('!R961E
M=&5R;6EN960@<')I8V4@;V8@)#,N,`T*(&UI;&QI;VX@<')O=FED960@=&AE
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M=7)R960@;VX@2F%N=6%R>28C>$$P.S(Y+`T*(#(P,30N(%1H92!F86ER('9A
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M92!W87)R86YT<R!A;F0@9F]R=V%R9`T*(&-O;G1R86-T(&QI86)I;&ET:65S
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&=A:6YS(&%N9"!L;W-S
M97,@9G)O;2!R96UE87-U<F5M96YT(&]F($QE=F5L(#,@9FEN86YC:6%L#0H@
M;&EA8FEL:71I97,@87)E(')E8V]R9&5D('1H<F]U9V@@;W1H97(@97AP96YS
M92P@;F5T(&]N('1H90T*(&%C8V]M<&%N>6EN9R!S=&%T96UE;G1S(&]F(&]P
M97)A=&EO;G,@86YD(&-O;7!R96AE;G-I=F4@;&]S<RX\+W`^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87-H+"!#87-H($5Q=6EV86QE;G1S+"!A;F0@36%R:V5T86)L92!396-U
M<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3AP="<^#0H@/&(^0V%S:"P@0V%S:"!%<75I=F%L96YT<RP@86YD($UA
M<FME=&%B;&4@4V5C=7)I=&EE<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%
M3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!C;VYS:61E<G,@86QL(&AI9VAL>2!L
M:7%U:60@:6YV97-T;65N=',@=VET:"!A#0H@<F5M86EN:6YG(&UA='5R:71Y
M(&]F(#DP(&1A>7,@;W(@;&5S<R!A="!T:&4@=&EM92!O9B!P=7)C:&%S92!T
M;R!B90T*(&-A<V@@97%U:79A;&5N=',N($-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',@8V]N<VES="!O9B!D97!O<VET<PT*('=I=&@@8V]M;65R8VEA;"!B
M86YK<R!I;B!C:&5C:VEN9RP@:6YT97)E<W0M8F5A<FEN9RP@86YD(&1E;6%N
M9`T*(&UO;F5Y(&UA<FME="!A8V-O=6YT<RX@5&AE($-O;7!A;GD@:6YV97-T
M<R!E>&-E<W,@8V%S:"!I;@T*(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!W:71H
M(&AI9V@@8W)E9&ET(')A=&EN9W,N(%1H97-E('-E8W5R:71I97,-"B!C;VYS
M:7-T('!R:6UA<FEL>2!O9B!C;W)P;W)A=&4@9&5B="!A;F0@87-S970M8F%C
M:V5D('-E8W5R:71I97,@86YD#0H@87)E(&-L87-S:69I960@87,@)B-X,C`Q
M0SMA=F%I;&%B;&4M9F]R+7-A;&4N)B-X,C`Q1#L@36%N86=E;65N="!M87D-
M"B!L:7%U:61A=&4@86YY(&]F('1H97-E(&EN=F5S=&UE;G1S(&EN(&]R9&5R
M('1O(&UE970@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!L:7%U:61I='D@;F5E
M9',@:6X@=&AE(&YE>'0@>65A<BX@06-C;W)D:6YG;'DL(&%N>0T*(&EN=F5S
M=&UE;G1S('=I=&@@8V]N=')A8W1U86P@;6%T=7)I=&EE<R!G<F5A=&5R('1H
M86X@;VYE('EE87(@9G)O;0T*('1H92!B86QA;F-E('-H965T(&1A=&4@87)E
M(&-L87-S:69I960@87,@<VAO<G0M=&5R;2!I;B!T:&4@8F%L86YC90T*('-H
M965T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!296%L:7IE
M9"!G86EN<R!A;F0@;&]S<V5S(&9R;VT@=&AE('-A;&4@;V8@;6%R:V5T86)L
M92!S96-U<FET:65S+`T*(&EF(&%N>2P@87)E(&-A;&-U;&%T960@=7-I;F<@
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M<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDL(&EN#0H@=&AE(&)A;&%N
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M+"!I;F-L=61I;F<@=&AE(&-A=7-E+"!D=7)A=&EO;B!O9B!T:6UE(&%N9`T*
M('-E=F5R:71Y(&]F('1H92!I;7!A:7)M96YT+"!A;GD@861V97)S92!C:&%N
M9V5S(&EN('1H90T*(&EN=F5S=&5E<R8C>#(P,3D[(&9I;F%N8VEA;"!C;VYD
M:71I;VXL(&%N9"!T:&4@0V]M<&%N>28C>#(P,3D[<PT*(&EN=&5N="!A;F0@
M86)I;&ET>2!T;R!H;VQD('1H92!S96-U<FET>2!F;W(@82!P97)I;V0@;V8@
M=&EM90T*('-U9F9I8VEE;G0@=&\@86QL;W<@9F]R(&%N(&%N=&EC:7!A=&5D
M(')E8V]V97)Y(&EN(&UA<FME=`T*('9A;'5E+CPO<#X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<W1R:6-T960@0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$X<'0G/@T*(#QB/E)E<W1R:6-T960@0V%S:#PO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!I<R!R
M97%U:7)E9"!T;R!M86EN=&%I;B!C;VUP96YS871I;F<@8V%S:"!B86QA;F-E
M<R!W:71H#0H@9FEN86YC:6%L(&EN<W1I='5T:6]N<R!T:&%T('!R;W9I9&4@
M=&AE($-O;7!A;GD@=VET:"!I=',@8V]R<&]R871E#0H@8W)E9&ET(&-A<F1S
M+B!!<R!O9B!-87)C:"8C>$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S+`T*(&-A<V@@<F5S=')I8W1E9"!U;F1E<B!T:&5S92!A<G)A
M;F=E;65N=',@=V%S("0Q,#`L,#`P(&%N9"`D,34U+#`P,"P-"B!R97-P96-T
M:79E;'DN(%1H97-E(&%M;W5N=',@87)E('!R97-E;G1E9"!I;B!O=&AE<B!A
M<W-E=',@;VX@=&AE#0H@86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE971S+CPO
M<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;F-E;G1R871I;VX@;V8@0W)E9&ET(%)I<VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-
M"B`\8CY#;VYC96YT<F%T:6]N(&]F($-R961I="!2:7-K/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M=&EN9R!N965D<R!P<FEM87)I;'D@:6X@:&EG:&QY(&QI<75I9`T*(&EN<W1R
M=6UE;G1S('1H870@8F5A<B!M:6YI;6%L(')I<VLN(%1H92!#;VUP86YY(&AA
M<R!E<W1A8FQI<VAE9`T*(&=U:61E;&EN97,@<F5L871I;F<@=&\@=&AE('%U
M86QI='DL(&1I=F5R<VEF:6-A=&EO;BP@86YD(&UA='5R:71I97,-"B!O9B!S
M96-U<FET:65S('1O(&5N86)L92!T:&4@0V]M<&%N>2!T;R!M86YA9V4@:71S
M(&-R961I="!R:7-K+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CY0<F]P97)T>2!A;F0@17%U:7!M96YT/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
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M8W1I=F4@87-S971S+`T*(&=E;F5R86QL>2!T:')E92!T;R!S979E;B!Y96%R
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M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I(&%S(&EN8W5R<F5D+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\
M8CY);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M+"`R,#$T(&%N9"!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3,N/"]P/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@4F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#!P="<^#0H@/&(^1&5F97)R960@4F5N=#PO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@0V]M<&%N>2!R
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M;F-E('-H965T+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!787)R86YT
M($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$X<'0G/@T*(#QB/D-O;6UO;B!3=&]C:R!787)R86YT($QI86)I
M;&ET>3PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!787)R
M86YT<R!I<W-U960@=&\@8V]M;6]N('-T;V-K(&AO;&1E<G,@86YD(&QE;F1E
M<G,@8GD@=&AE($-O;7!A;GD-"B!I;B!C;VYJ=6YC=&EO;B!W:71H('1H92`R
M,#$S(&9I;F%N8VEN9R!W97)E(&-L87-S:69I960@87,-"B!L:6%B:6QI=&EE
M<R!I;B!T:&4@86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE971S+"!A<R!T:&4@
M=&5R;7,@9F]R#0H@<F5D96UP=&EO;B!O9B!T:&4@=6YD97)L>6EN9R!S96-U
M<FET>2!W97)E(&]U='-I9&4@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;VYT
M<F]L+B!4:&4@=V%R<F%N=',@=V5R92!R96-O<F1E9"!A="!F86ER('9A;'5E
M#0H@=7-I;F<@96ET:&5R('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC
M:6YG(&UO9&5L+"!P<F]B86)I;&ET>0T*('=E:6=H=&5D(&5X<&5C=&5D(')E
M='5R;B!M;V1E;"!O<B!A(&)I;F]M:6%L(&UO9&5L+"!D97!E;F1I;F<@;VX-
M"B!T:&4@8VAA<F%C=&5R:7-T:6-S(&]F('1H92!W87)R86YT<RX@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE<V4-"B!W87)R86YT<R!I<R!R92UM96%S=7)E9"!A
M="!E86-H(&9I;F%N8VEA;"!R97!O<G1I;F<@<&5R:6]D('=I=&@@86YY#0H@
M8VAA;F=E<R!I;B!F86ER('9A;'5E(&)E:6YG(')E8V]G;FEZ960@87,@82!C
M;VUP;VYE;G0@;V8@;W1H97(-"B!I;F-O;64@*&5X<&5N<V4I(&EN('1H92!A
M8V-O;7!A;GEI;F<@8V]N9&5N<V5D('-T871E;65N=',@;V8-"B!O<&5R871I
M;VYS(&%N9"!C;VUP<F5H96YS:79E(&QO<W,N/"]P/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^4F5S96%R
M8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]B/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
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M.R!C;VYT<F%C=`T*(')E<V5A<F-H(&]R9V%N:7IA=&EO;G,@86YD(&]T:&5R
M('1H:7)D('!A<G1I97,@=&AA="!A<W-I<W0@:6X-"B!M86YA9VEN9RP@;6]N
M:71O<FEN9RP@86YD(&%N86QY>FEN9R!C;&EN:6-A;"!T<FEA;',[(&EN=F5S
M=&EG871O<@T*(&%N9"!S:71E(&9E97,[(&QA8F]R871O<GD@<V5R=FEC97,[
M(&-O;G-U;'1A;G1S.R!C;VYT<F%C=`T*(&UA;G5F86-T=7)I;F<@<V5R=FEC
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M(&-O<W1S(&%R92!E>'!E;G-E9`T*(&%S(&EN8W5R<F5D+"!I;F-L=61I;F<@
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&5X<&5N<V5S
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M=7)R960@=6YD97(@96%C:`T*(&-O;G1R86-T(&%S(&EN9&EC871E9"!B>2!S
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M92!C;&EN:6-A;`T*('1R:6%L(&%R<F%N9V5M96YT<R!I;B!A9'9A;F-E(&]F
M('1H92!R96-E:7!T(&]F('1H92!R96QA=&5D#0H@<V5R=FEC97,@87)E(')E
M8V]R9&5D(&%S('!R97!A:60@87-S971S+"!D97!E;F1I;F<@;VX@=&AE('1E
M<FUS(&]F#0H@=&AE(&%G<F5E;65N="P@=6YT:6P@=&AE('-E<G9I8V5S(&%R
M92!R96YD97)E9"X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@16UP;&]Y964@86YD(&1I
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M92!B87-E9`T*(&UE87-U<F5M96YT<R!O9B!O<'1I;VYS('5S:6YG('1H92!"
M;&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E;"!A;F0-"B!T:&4@<VEN9VQE
M+6]P=&EO;B!A<'!R;V%C:"!A;F0@<F5C;V=N:7IE<R!E>'!E;G-E('5S:6YG
M('1H90T*('-T<F%I9VAT+6QI;F4@871T<FEB=71I;VX@;65T:&]D+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!%<75I='D@87=A<F1S(&=R
M86YT960@=&\@;F]N+65M<&QO>65E<R!A<F4@86-C;W5N=&5D(&9O<B!U<VEN
M9R!T:&4-"B!";&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E;"!T;R!D971E
M<FUI;F4@=&AE(&9A:7(@=F%L=64@;V8@<W5C:`T*(&EN<W1R=6UE;G1S+B!4
M:&4@9F%I<B!V86QU92!O9B!E<75I='D@87=A<F1S(&=R86YT960@=&\-"B!N
M;VXM96UP;&]Y965S(&%R92!R92UM96%S=7)E9"!O=F5R('1H92!R96QA=&5D
M('9E<W1I;F<@<&5R:6]D(&%N9`T*(&%M;W)T:7IE9"!T;R!E>'!E;G-E(&%S
M(&5A<FYE9"X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY)
M;F-O;64@5&%X97,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^
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M(')E86QI>F5D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
M<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA!
M,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@86-C;W5N
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M=&5M96YT<R!O9B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RDN(%1H97)E
M('=A<PT*(&YO(&EN=&5R97-T(&]R('!E;F%L=&EE<R!R96QA=&5D('1O(&EN
M8V]M92!T87AE<R!R96-O<F1E9"!D=7)I;F<-"B!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H)B-X03`[,S$L(#(P,30@86YD(#(P,3,N/"]P/@T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<')E:&5N<VEV92!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^0V]M<')E:&5N<VEV
M92!,;W-S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M96YS:79E(&EN8V]M92`H;&]S<RD-"B!I<R!D:7-C;&]S960@:6X@=&AE('-T
M871E;65N=',@;V8@<F5D965M86)L92!C;VYV97)T:6)L92!P<F5F97)R960-
M"B!S=&]C:R!A;F0@<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U:71Y("AD969I
M8VET*2P@86YD(&ES('-T871E9"!N970-"B!O9B!R96QA=&5D('1A>"!E9F9E
M8W1S+"!I9B!A;GDN/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@4&5R($-O;6UO
M;B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$X<'0G/@T*(#QB/DYE="!,;W-S(%!E<B!#;VUM;VX@4VAA<F4\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@0F%S:6,@;F5T(&QO
M<W,@<&5R('-H87)E(&]F(&-O;6UO;B!S=&]C:R!I<R!B87-E9"!O;B!T:&4@
M=V5I9VAT960-"B!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&]U='-T86YD:6YG(&5Q=6EV86QE;G1S#0H@9'5R:6YG('1H92!P
M97)I;V0N(%!R:6]R('1O('1H92`R,#$S(&9I;F%N8VEN9RP@:6X@861D:71I
M;VX@=&\-"B!C;VUM;VX@<W1O8VLL('1H92!#;VUP86YY(&AA9"!P<F5F97)R
M960@<W1O8VL@;W5T<W1A;F1I;F<@=&AA=`T*(&-O;G1R86-T=6%L;'D@96YT
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M>$$P.S,P+"`R,#$S+"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(#(P,3,@9FEN
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M8V@F(WA!,#LS,2P@,C`Q-"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@1&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4@;V8@8V]M;6]N('-T
M;V-K(&ES(&-A;&-U;&%T960@=7-I;F<@=&AE#0H@;6]R92!D:6QU=&EV92!O
M9B!T:&4@='=O(&%P<')O86-H97,Z(&]N92P-"B`F(W@R,#%#.V%S+6-O;G9E
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M;V8@=&AE('!E<FEO9"P@86YD('1H90T*(&]T:&5R+"!T:&4@)B-X,C`Q0SMT
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M=&AR964@;6]N=&AS(&5N9&5D#0H@36%R8V@F(WA!,#LS,2P@,C`Q-"!A;F0@
M,C`Q,RP@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4@:7,@=&AE#0H@<V%M
M92!A<R!B87-I8RP@87,@86YY(&%D:G5S=&UE;G1S('=O=6QD(&AA=F4@8F5E
M;@T*(&%N=&DM9&EL=71I=F4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G
M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P
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M;'5T960@;F5T(&QO<W,@<&5R('-H87)E.CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/
M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(]
M,T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W."4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H<F5E($UO;G1H<PT*($5N9&5D/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$
M8V5N=&5R/CQB/DUA<F-H)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CXH=6YA=61I=&5D*3PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@5V%R<F%N=',@9F]R(&-O;6UO;B!S=&]C:SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#0X+#0X-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."PR,3`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;6UO;B!S=&]C:R!O<'1I;VYS/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3`V+#<Y-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-RPV.#<\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XV-C$L,#4Y/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L-S4U+#(X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C<X-BPY-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W
M,C5?,V4W.69A8S`S,#8Q+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U
M;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@1F%I<B!686QU
M92!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN
M9R!"87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-CDE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$
M8V5N=&5R/CQB/D%S(&]F($UA<F-H)B-X03`[,S$L(#(P,30\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9#L@5TE$5$@Z(#,Y+C5P="<^#0H@/&(^1&5S8W)I<'1I;VX\
M+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9A:7(F(WA!,#M6
M86QU93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@36]N97D@;6%R:V5T
M(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#<S-SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$L-S,W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!#;W)P;W)A=&4@9&5B="!A;F0@87-S970@8F%C:V5D('-E
M8W5R:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L
M,3DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPQ
M.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%1O=&%L(&%S<V5T<R!M96%S=7)E9"!A="!F86ER('9A;'5E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$L-S,W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L,3DQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<L.3(X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=A<G)A;G0@;&EA8FEL
M:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT
M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$Q+#8S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PV,S@\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(%1O=&%L(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3$L-C,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#8S.#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-C:&5D=6QE(&]F($-H86YG97,@:6X@1F%I<B!686QU92!O9B!&
M:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
M(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H(&%N(&%C=&EV:71Y('-U;6UA
M<GD@=VAI8V@@:6YC;'5D97,-"B!T:&4@8VAA;F=E<R!I;B!T:&4@9F%I<B!V
M86QU92!O9B8C>$$P.W1H92!#;VUP86YY)W,F(WA!,#M,979E;"`S#0H@9FEN
M86YC:6%L(&EN<W1R=6UE;G1S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@
M34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E
M<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W.24^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=A<G)A;G0\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^1F]R=V%R9#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY,:6%B:6QI='D\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/D-O;G1R86-T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!"86QA;F-E(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPT-C8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C0U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@27-S=6%N
M8V4@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@
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M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@0VAA;F=E(&EN(&9A:7(@=F%L=64\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<X-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3971T
M;&5M96YT(&]F(&9I;F%N8VEA;"!I;G-T<G5M96YT/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#4U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XH-#0S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@87,@
M;V8@36%R8V@F(WA!,#LS,2P@,C`Q-#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q
M+#8S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT:2U$:6QU=&EV92!396-U<FET
M:65S($5X8VQU9&5D(&9R;VT@=&AE($-O;7!U=&%T:6]N(&]F($1I;'5T960@
M3F5T($QO<W,@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F
M;VQL;W=I;F<@=&%B;&4@<VAO=W,@=&AE('1O=&%L(&]U='-T86YD:6YG('-E
M8W5R:71I97,-"B!C;VYS:61E<F5D(&%N=&DM9&EL=71I=F4@86YD('1H97)E
M9F]R92!E>&-L=61E9"!F<F]M('1H90T*(&-O;7!U=&%T:6]N(&]F(&1I;'5T
M960@;F5T(&QO<W,@<&5R('-H87)E.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W."4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V
M(&%L:6=N/3-$8V5N=&5R/CQB/E1H<F5E($UO;G1H<PT*($5N9&5D/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N
M=&5R/CQB/DUA<F-H)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T
M)R!A;&EG;CTS1&-E;G1E<CXH=6YA=61I=&5D*3PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@5V%R<F%N=',@9F]R(&-O;6UO;B!S=&]C:SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#0X+#0X-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."PR,3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($-O;6UO;B!S=&]C:R!O<'1I;VYS/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3`V+#<Y-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-RPV.#<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
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M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV-C$L,#4Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(L-S4U+#(X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<X-BPY-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P
M.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?
M,V4W.69A8S`S,#8Q+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-E<G1A:6X@0F%L86YC92!3
M:&5E="!)=&5M<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!#;VYS;VQI9&%T
M:6]N($%N9"!0<F5S96YT871I;VX@3V8@1FEN86YC:6%L(%-T871E;65N=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1S(&]F('1H
M92!F;VQL;W=I;F<@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)
M3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S0E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DUA<F-H)B-X03`[,S$L
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/D1E
M8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\
M8CXH=6YA=61I=&5D*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@3V9F:6-E(&%N9"!C;VUP=71E<B!E<75I
M<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-34V/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(%!U<F-H87-E9"!S;V9T=V%R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$V-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($9U<FYI='5R92!A;F0@9FEX='5R97,\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XT,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@3&5A<V5H;VQD(&EM
M<')O=F5M96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,T
M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#4S-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,CDX
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!,97-S(&%C8W5M=6QA=&5D
M(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,2PP-30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#,L,CDU/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R
M=65D($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!8V-R=65D
M(&QI86)I;&ET:65S(&-O;G-I<W0@;V8@=&AE(&9O;&QO=VEN9R`H:6X@=&AO
M=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0W-B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$-S0E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX-"B`\8CY-87)C:"8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY$96-E;6)E<B8C>$$P.S,Q+#PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CXR,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^*'5N875D:71E
M9"D\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
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M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-3$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!!8V-R
M=65D('!R92UC;&EN:6-A;"!A;F0@8VQI;FEC86P@=')I86P@97AP96YS97,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(S,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,3@\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8W)U960@<')O
M9F5S<VEO;F%L(&9E97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU,#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S@R
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!&;W)W87)D(&-O;G1R86-T
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-3,\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R
M(&%C8W)U86QS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$U
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@5&]T86P@86-C<G5E9"!L:6%B:6QI=&EE<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C(L,S8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L,C4Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y
M,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E
M-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N
M=&EN9V5N8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG
M96YC:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E($UI;FEM=6T@3&5A
M<V4@4&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9U='5R92!M:6YI
M;75M(&QE87-E('!A>6UE;G1S(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N
M9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0X."4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/DQE87-E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E!A>6UE;G1S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!996%R(&5N9&EN9R!$96-E;6)E
M<B8C>$$P.S,Q.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@,C`Q-#PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(#(P,34\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR,#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,38\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,38\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#(P,3<\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,C(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*(#(P,3@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR,C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O
M=&%L(&9U='5R92!M:6YI;75M('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PP-C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S
M,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S
M,#8Q+U=O<FMS:&5E=',O4VAE970R,"YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5R=F5D(%-H87)E<R!O9B!!=71H
M;W)I>F5D(&)U="!5;FES<W5E9"!#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4G/@T*($%S(&]F($UA<F-H)B-X03`[,S$L(#(P,30@86YD($1E8V5M
M8F5R)B-X03`[,S$L(#(P,3,L('1H92!#;VUP86YY#0H@:&%D(')E<V5R=F5D
M('-H87)E<R!O9B!A=71H;W)I>F5D(&)U="!U;FES<W5E9"!C;VUM;VX@<W1O
M8VL@87,-"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R
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M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^#0H@/&(^36%R8V@F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^1&5C96UB97(F(WA!
M,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/BAU
M;F%U9&ET960I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#;VUM;VX@<W1O8VL@=V%R<F%N=',\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@T."PT.#<\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PW-#(L-S(W/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%<75I='D@:6YC96YT:79E('!L
M86YS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-3`L,#0W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4W-RPR.30\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!R
M97-E<G9E9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR+#@Y."PU,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#,R,"PP,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V
M7S@W,C5?,V4W.69A8S`S,#8Q+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K(%!L86YS
M(&%N9"!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%1A8FQE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C
M;&]S=7)E($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S(%-H87)E8F%S
M960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU43U`Z(#9P="<^#0H@16UP;&]Y964@86YD(&1I<F5C=&]R
M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E8V]R9&5D('=A
M<PT*(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'
M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(@8F]R
M9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.#,E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY4:')E928C>$$P.TUO;G1H
M<R8C>$$P.T5N9&5D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DUA<F-H)B-X03`[,S$L/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`Q<'0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQB/BAU;F%U9&ET960I/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A
M;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X
M.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S
M93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M4DA!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD
M($1E<V-R:7!T:6]N(&]F($)U<VEN97-S("T@061D:71I;VYA;"!);F9O<FUA
M=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#(R+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,C`L(#(P,#8\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W)G86YI>F%T:6]N($-O;G-O;&ED871I;VX@06YD(%!R97-E
M;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1W)O<W,@<')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@86YD('=A<G)A;G1S(&EN(&$@<')I=F%T92!P;&%C96UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPW,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-BPX,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!R;V-E961S(&9R;VT@=F5N='5R92!D
M96)T(&9I;F%N8VEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5F5N='5R92!D96)T(&9I;F%N8VEN9R!L;V%N
M(&%G<F5E;65N="!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M<')O8V5E9',@869T97(@9&5D=6-T:6YG('!L86-E;65N="!A9V5N="!F965S
M(&%N9"!E<W1I;6%T960@;V9F97)I;F<@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR."PX,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!P<FEV871E('!L86-E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPX,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=65D('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:6X@8V%N
M8V5L;&%T:6]N(&]F(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-BPY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,#8R+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#8R."PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,#$Q+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$U
M.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#,U."PY,#0L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,T."PX-#(L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R
M-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%2TM!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!!9&1I=&EO;F%L($EN
M9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5V97)S92!S=&]C:R!S<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XP,3(U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9&5T97)M:6YE9"!P<FEC92!O9B!C;VUM
M;VX@<W1O8VL@<'5R8VAA<V5D(&9O<B!W87)R86YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',L(&UA='5R:71Y(&1E<V-R:7!T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SDP(&1A>7,@;W(@;&5S<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&]R="UT97)M(&-O;G1R86-T=6%L(&UA='5R:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26UP86ER;65N="!L;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&]R('!E;F%L=&EE<R!R96QA=&5D
M('1O(&EN8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!O=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V
M7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K
M<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$573T%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`M(%-C:&5D=6QE(&]F($9A:7(@5F%L=64@07-S971S(&%N
M9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@0F%S:7,@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI
M86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R
M:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C<L.3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G0@;&EA8FEL:71Y(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@
M3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U
M<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!M96%S
M=7)E9"!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,2PV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F=6YD<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R
M<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M87-S971S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q+#<S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]R<&]R871E(&1E8G0@86YD(&%S
M<V5T(&)A8VME9"!S96-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T
M<R!A;F0@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.
M;VYR96-U<G)I;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',@;65A
M<W5R960@870@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S
M(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO
M;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!M96%S
M=7)E9"!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,2PW,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE=F5L(#$@6TUE;6)E<ET@?"!-;VYE>2!M87)K970@
M9G5N9',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE
M<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!M96%S=7)E9"!A="!F86ER('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PW,S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE
M<R!-96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<R!M96%S=7)E9"!A="!F86ER('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V
M96P@,B!;365M8F5R72!\($-O<G!O<F%T92!D96)T(&%N9"!A<W-E="!B86-K
M960@<V5C=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI
M86)I;&ET:65S($UE87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R
M:6YG($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,979E;"`S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA
M8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I
M;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!M96%S=7)E
M9"!A="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,2PV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE=F5L(#,@6TUE;6)E<ET@?"!787)R86YT(&QI86)I;&ET
M>2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE
M87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PV,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P
M,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y
M9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0T9!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!38VAE9'5L92!O9B!#:&%N9V5S
M(&EN($9A:7(@5F%L=64@;V8@5V%R<F%N="!,:6%B:6QI='D@*$1E=&%I;"D@
M*$QE=F5L(#,@6TUE;6)E<ETL(%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N="!,:6%B:6QI='D@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!6
M86QU92P@26YS=')U;65N=',@0VQA<W-I9FEE9"!I;B!3:&%R96AO;&1E<G,G
M($5Q=6ET>2!-96%S=7)E9"!O;B!296-U<G)I;F<@0F%S:7,L(%5N;V)S97)V
M86)L92!);G!U="!296-O;F-I;&EA=&EO;BP@0V%L8W5L871I;VX@6U)O;&P@
M1F]R=V%R9%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A;&%N8V4@87,@;V8@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPT-C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&9I;F%N8VEA;"!I;G-T<G5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5T=&QE;65N="!O9B!F:6YA
M;F-I86P@:6YS=')U;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"86QA;F-E(&%S(&]F($UA<F-H(#,Q+"`R,#$T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV,S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<G=A<F0@0V]N=')A
M8W0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@26YS=')U;65N=',@0VQA<W-I9FEE9"!I
M;B!3:&%R96AO;&1E<G,G($5Q=6ET>2!-96%S=7)E9"!O;B!296-U<G)I;F<@
M0F%S:7,L(%5N;V)S97)V86)L92!);G!U="!296-O;F-I;&EA=&EO;BP@0V%L
M8W5L871I;VX@6U)O;&P@1F]R=V%R9%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@87,@;V8@1&5C96UB97(@
M,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F
M86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E='1L96UE;G0@;V8@9FEN86YC:6%L(&EN<W1R=6UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0T,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@87,@;V8@36%R
M8V@@,S$L(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U
M-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#(V+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%1T9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y
M(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@+2!!9&1I=&EO
M;F%L($EN9F]R;6%T:6]N(#$@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@
M4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0L(&5S=&EM871E9"!U<V5F=6P@;&EV97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R
M;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R
M='D@86YD(&5Q=6EP;65N="P@97-T:6UA=&5D('5S969U;"!L:79E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?
M-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O
M5V]R:W-H965T<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$M!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@+2!!;G1I+41I;'5T:79E(%-E8W5R:71I97,@17AC
M;'5D960@9G)O;2!T:&4@0V]M<'5T871I;VX@;V8@1&EL=71E9"!.970@3&]S
M<R!P97(@4VAA<F4@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET
M:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R
M(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<R!E
M>&-L=61E9"!F<F]M('1H92!C;VUP=71A=&EO;B!O9B!D:6QU=&5D(&QO<W,@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<U
M-2PR.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW.#8L.34V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT<R!F;W(@8V]M;6]N('-T;V-K(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U
M=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I
M+61I;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O;2!T:&4@8V]M<'5T
M871I;VX@;V8@9&EL=71E9"!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PX-#@L-#@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L,C$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@;W!T:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC
M;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06YT:2UD:6QU=&EV92!S96-U<FET:65S(&5X8VQU9&5D
M(&9R;VT@=&AE(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@;&]S<R!P97(@<VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP-BPW.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-RPV
M.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E9&5E;6%B;&4@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O
M;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;G1I+61I;'5T:79E('-E8W5R:71I97,@97AC;'5D960@9G)O;2!T:&4@8V]M
M<'5T871I;VX@;V8@9&EL=71E9"!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V,2PP-3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X
M-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H
M965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5%=!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#97)T86EN($)A;&%N8V4@4VAE970@271E;7,@+2!0<F]P
M97)T>2!A;F0@17%U:7!M96YT("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2!A;F0@97%U:7!M96YT+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@86-C=6UU;&%T960@
M9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L,#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,CDU*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/9F9I8V4@86YD(&-O;7!U=&5R(&5Q=6EP;65N="!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O
M<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R
M='D@86YD(&5Q=6EP;65N="P@9W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5D('-O9G1W87)E(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2!A;F0@97%U:7!M96YT+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U<F4@86YD(&9I>'1U<F5S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!G<F]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD(&EM<')O=F5M96YT
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@9W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#4S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T
M-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7
M;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V24%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/D-E<G1A:6X@0F%L86YC92!3:&5E="!)=&5M<R`M
M($%C8W)U960@3&EA8FEL:71I97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-T871E;65N="!/9B!&:6YA;F-I86P@4&]S:71I;VX@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D('!R92UC;&EN:6-A;"!A;F0@8VQI
M;FEC86P@=')I86P@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D('!R;V9E<W-I;VYA;"!F965S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<G=A<F0@
M8V]N=')A8W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R(&%C8W)U86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPS-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,C4Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S,F$Y
M7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q
M+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%-04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]M;6]N(%-T;V-K(%=A<G)A;G1S("T@061D
M:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@
M;V8@5V%R<F%N="!O<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M<V%L92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,BPT,#(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G0@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S+"!%>&5R8VES92!P<FEC92!O9B`D-2XW-2!P97(@<VAA
M<F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,"PX,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G0@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U
M-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%-4Q!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O
M<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',@+2!!9&1I=&EO;F%L($EN
M9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#$Y.3@\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]L;&%B;W)A=&EO;G,@
M06YD($QI8V5N<V4@06=R965M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G
M92!O9B!R;WEA;'1Y(')E8V5I=F5D(&]N(&YE="!S86QE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE
M;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2G5N(#,P
M+`T*"0DQ.3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUO;G1H;'D@;&EC96YS92!F965S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!F=71U
M<F4@9&5V96QO<&UE;G0@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5V96QO<&UE;G0@<&%Y;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y('!A>6UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)T:&\M
M36-.96EL($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VQL86)O<F%T:6]N<R!!;F0@3&EC96YS
M92!!9W)E96UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1E<F5D(&EN=&\@82!C;VQL
M86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^075G(#,Q+`T*"0DR,#`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&UA9&4@=6YD97(@
M86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)O>6%L=&EE<R!R96-E:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<G1H;RU-8TYE:6P@26YC+B!;365M8F5R72!\($UA>&EM
M=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VQL86)O<F%T:6]N<R!!;F0@3&EC96YS92!!9W)E96UE
M;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(')O>6%L='D@<F5C96EV
M960@;VX@;F5T('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y*86YS<V5N(%!H87)M86-E=71I8V%L<RP@26YC+B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;&QA8F]R871I;VYS($%N9"!,:6-E;G-E($%G<F5E;65N=',@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQI8V5N<V4@86=R965M96YT(&1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DIU;B`S,"P-"@D),C`Q,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@9&5V96QO<&UE;G0@86YD(&QI8V5N<V4@86=R965M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT('!A>6UE
M;G0@96QI9VEB;&4@=&\@<F5C96EV92!O;B!D979E;&]P;65N="!A;F0@8V]M
M;65R8VEA;"!E=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C(X+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S
M,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R
M83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,S(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5/0D-+/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E
M8G0@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\
M8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q,#XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#(P+"`R,#`V/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^5V%R<F%N=',L($5X97)C:7-E('!R:6-E(&]F("0U
M+C`P('!E<B!S:&%R92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/E-E<FEE<R!%+3$@4')E9F5R
M<F5D(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;"X@,S$L(#(P,#D\8G(^4V5R:65S($,M,2!0<F5F97)R960@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@
M,C`P.3QB<CY397)I97,@0RTQ(%!R969E<G)E9"!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/E-E
M<FEE<R!#+3$@4')E9F5R<F5D(%M-96UB97)=/&)R/D%S($%M96YD960@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`P.#QB<CY&:7)S="!)<W-U86YC92!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#`X/&)R/E-E8V]N
M9"!)<W-U86YC92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y&96(N(#(X+"`R,#`Y/&)R/E1H:7)D($ES<W5A;F-E(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L
M(#(P,3,\8G(^5&AI<F0@27-S=6%N8V4@6TUE;6)E<ET\8G(^07,@06UE;F1E
M9"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$S/&)R/E1H:7)D($ES<W5A;F-E(%M-96UB97)=/&)R/D%S
M($%M96YD960@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2F%N+B`S,2P@,C`Q,CQB<CY4:&ER9"!)<W-U86YC92!;365M8F5R
M73QB<CY!<R!!;65N9&5D(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,#D\8G(^1F]U<G1H($ES<W5A;F-E
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,S$L(#(P,3,\8G(^1F]U<G1H($ES<W5A;F-E(%M-96UB97)=/&)R/D%S
M($%M96YD960@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CY&;W5R=&@@27-S=6%N8V4@6TUE;6)E
M<ET\8G(^07,@06UE;F1E9"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$R/&)R/D9O=7)T:"!)<W-U86YC
M92!;365M8F5R73QB<CY!<R!!;65N9&5D(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1F%C:6QI
M='D@3&]A;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY&86-I;&ET>2!,;V%N
M($%G<F5E;65N="!;365M8F5R73QB<CY&:7)S="!4<F%N8VAE(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^1F%C:6QI='D@3&]A;B!!9W)E96UE;G0@6TUE;6)E<ET\8G(^4V-E
M;F%R:6\@;VYE+"!C;VYV97)S:6]N(&)A<VES(%M-96UB97)=/&)R/E-E8V]N
M9"!4<F%N8VAE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1F%C:6QI='D@3&]A;B!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^4V-E;F%R:6\@='=O(%M-96UB97)=/&)R/E-E8V]N
M9"!4<F%N8VAE(%M-96UB97)=/&)R/E=A;&P@4W1R965T($IO=7)N86P@4')I
M;64@4F%T92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@8F]R<F]W:6YG(&-A<&%C
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BXW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%T=7)I='D@9&%T92!O9B!D96)T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#$W+`T*"0DR
M,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^4V5P(#$W+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^1F5B(#(X+`T*"0DR,#$R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR
M,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^075G(#$L#0H)"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y-87(@,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;"`S,2P-"@D),C`Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D1E8R`S,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/D%U9R`Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#$L#0H)"3(P,3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86-I;&ET>2!L;V%N+"!F:7AE9"!I;G1E<F5S="!R871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RXU-R4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C4W
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0N-#(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+CDR)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0N.38E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+C0V)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."XW-24\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N
M('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]A;B!F86-I;&ET>2P@;W5T<W1A;F1I
M;F<@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T('-E='1L960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BXY/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]A;B!F86-I;&ET>2!E>'1I;F=U:7-H960@:6X@
M97AC:&%N9V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,C0L.30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C(T+#DT-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A8VEL:71Y(&QO86XL(&1R87=N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A8VEL:71Y
M(&QO86XL(&EN=&5R97-T(&%M;W)T:7IA=&EO;B!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,V
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%C:6QI='D@;&]A;BP@9FEN86P@:6YT97)E<W0@<&%Y
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A8VEL:71Y(&QO86XL(&9I;F%N8VEA;"!C
M;W9E;F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)U5N=&EL('!O<VET:79E("!0:&%S92`R8B!D871A
M(&ES(&%C:&EE=F5D+"!T:&4@0V]M<&%N>2!M=7-T(&)E(&EN(&-O;7!L:6%N
M8V4@=VET:"!O;F4@;V8@='=O("!F:6YA;F-I86P@8V]V96YA;G1S(&%T(&%L
M;"!T:6UE<R`H,2D@;6%I;G1A:6X@,2XS('1I;65S(&-A<V@@=&\@;W5T<W1A
M;F1I;F<@(&1E8G0@;W(@*#(I(&UA:6YT86EN('-U9F9I8VEE;G0@8V%S:"!O
M;B!H86YD('1O('-U<'!O<G0@96EG:'0@;6]N=&AS(&]F("!O<&5R871I;VYS
M(&)A<V5D(&]N(&$@=')A:6QI;F<@879E<F%G92!M;VYT:&QY(&-A<V@@8G5R
M;BX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A8VEL:71Y(&QO86XL(&9I>&5D(&EN=&5R97-T(')A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@N-S4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9A8VEL:71Y(&QO86XL('!R:6UE(')A=&4@<&QU<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+C(U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%C:6QI='D@9F5E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(Q+#<S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]N9R!T97)M('=A<G)A;G0@;&EA8FEL:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S
M,#8Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R
M83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,S,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5'2$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`P."P@,C`Q,SQB<CY.
M97<@3&5A<V4@06=R965M96YT(%M-96UB97)=/&)R/G-Q9G0\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]S<R!#;VYT
M:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N="!E>'!E;G-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P97)A=&EN9R!L96%S97,@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E('-T87)T(&1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIA;B`Q-BP-"@D),C`Q-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&5A<V4@97AP:7)A=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y!<'(@,S`L#0H)"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07)E
M82!O9B!O9F9I8V4@<W!A8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN('1H92!B86QA;F-E('-H965T<R!R
M96QA=&5D('1O(&EN9&5M;FEF:6-A=&EO;B!O8FQI9V%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YD96UN:69I8V%T:6]N
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X
M-S(U7S-E-SEF86,P,S`V,2]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4U1$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S("T@1G5T=7)E($UI;FEM=6T@3&5A<V4@4&%Y
M;65N=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@
M0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,30\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!F=71U<F4@;6EN:6UU;2!P87EM96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#@Y,S`S,&1?
M,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P
M,S`V,2]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%4T)'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@
M061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN
M($UI;&QI;VYS+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3F]V+B`R,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O
M9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!U<&]N(&-O;G9E<G-I;VX@;V8@<F5D965M86)L92!C;VYV97)T:6)L
M92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#<Y,RPR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!P<F5F97)R960@
M<W1O8VL@=&\@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K(&]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S
M:&%R97,@<V]L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`T
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,S8V+#8V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8V-"PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#,V-BPV-CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,V-BPV-CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP-C0L
M-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PT-34L,#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&EN(#(P,3,@9FEN86YC:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,C`L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S,L,S,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,R+#@V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#<S
M+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#<S+#,S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!I<W-U86YC92!O
M9B`R,#$S(&9I;F%N8VEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,BXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,;V%N(&9A8VEL:71Y(&5X=&EN9W5I<VAE9"!I
M;B!E>&-H86YG92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,C0L.30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-"PY-#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!O9B!D
M96)T(&-A;F-E;&QE9"!U<&]N(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BXY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!P<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(#(P,3,@9FEN
M86YC:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C8N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y397)I97,@0BTQ(%!R969E<G)E9"!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`X
M.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S
M93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#,V+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5$)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q
M=6ET>2`M(%)E<V5R=F5D(%-H87)E<R!O9B!!=71H;W)I>F5D(&)U="!5;FES
M<W5E9"!#;VUM;VX@4W1O8VL@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S
M(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E<V5R=F5D('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L.#DX+#4S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S(P+#`R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K
M('=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!R97-E<G9E9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@T."PT.#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<T,BPW,C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q
M=6ET>2!I;F-E;G1I=F4@<&QA;G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(')E<V5R=F5D('-H87)E<R!O9B!C;VUM;VX@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4P+#`T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W
M-RPR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E-SEF86,P,S`V,0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R
M-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3:&5E=#,W+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%5$Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!0;&%N<R!A
M;F0@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H,C`Q,R!%<75I='D@26YC96YT:79E(%!L86X@
M6TUE;6)E<ETI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-R96%S960@:6X@<VAA<F5S(&%V86EL86)L92!F;W(@:7-S=6%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W,BPW-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B
M87-E9"!C;VUP96YS871I;VX@87)R86YG96UE;G0@<&5R8V5N=&%G92!I;F-R
M96%S92!I;B!S:&%R92!R97-E<G9E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B87-E9"!C;VUP96YS871I;VX@87)R
M86YG96UE;G0@;G5M8F5R(&]F(&ES<W5E9"!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#,P+#8T-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E
M+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@8F%S960@
M8V]M<&5N<V%T:6]N(&%R<F%N9V5M96YT(&)Y('-H87)E(&)A<V5D('!A>6UE
M;G0@87=A<F0L(&5X<&ER871I;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R-5\S
M93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Y
M,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q+U=O<FMS:&5E=',O
M4VAE970S."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)$044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VL@4&QA;G,@86YD(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;B`M(%-U;6UA<GD@;V8@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R
M:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E
M<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E
M(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N
M(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?-#4T-E\X-S(U7S-E
M-SEF86,P,S`V,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P.#DS
M,#,P9%\S,F$Y7S0U-#9?.#<R-5\S93<Y9F%C,#,P-C$O5V]R:W-H965T<R]3
M:&5E=#,Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%1T@^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4F5L871E9"U087)T>2!4<F%N<V%C=&EO;G,@+2!!9&1I=&EO;F%L($EN
M9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E
M;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9'9I<V]R>2!F
M964@<&%I9"!T;R!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#DS,#,P9%\S,F$Y7S0U-#9?.#<R
M-5\S93<Y9F%C,#,P-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,#@Y,S`S,&1?,S)A.5\T-30V7S@W,C5?,V4W.69A8S`S,#8Q+U=O<FMS:&5E
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M1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M
M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S`X.3,P,S!D7S,R83E?
:-#4T-E\X-S(U7S-E-SEF86,P,S`V,2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="nump">$ 419<span></span></td>
        <td class="nump">$ 518<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_AccruedExpensesCurrent', window );">Accrued pre-clinical and clinical trial expenses</a></td>
        <td class="nump">1,233<span></span></td>
        <td class="nump">418<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
        <td class="nump">501<span></span></td>
        <td class="nump">782<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_AccruedLiabilityOfDerivativeInInstruments', window );">Forward contract</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">453<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accruals</a></td>
        <td class="nump">215<span></span></td>
        <td class="nump">80<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
        <td class="nump">$ 2,368<span></span></td>
        <td class="nump">$ 2,251<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_AccruedExpensesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Expenses Current</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_AccruedExpensesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_AccruedLiabilityOfDerivativeInInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Liability Of Derivative In Instruments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_AccruedLiabilityOfDerivativeInInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">$ 1,114<span></span></td>
        <td class="nump">$ 3,298<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
        <td class="num">(1,054)<span></span></td>
        <td class="num">(3,295)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">60<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office and computer equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">556<span></span></td>
        <td class="nump">556<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Purchased software [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">166<span></span></td>
        <td class="nump">166<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and fixtures [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">42<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">$ 349<span></span></td>
        <td class="nump">$ 2,534<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock</a></td>
        <td class="nump">$ 2,402,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Fair value of warrant liabilities</a></td>
        <td class="nump">400,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants, Exercise price of $5.75 per share [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrants to purchase common stock</a></td>
        <td class="nump">120,800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock</a></td>
        <td class="nump">$ 3,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of common stock</a></td>
        <td class="nump">5.75<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ClassOfWarrantOrRightTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ClassOfWarrantOrRightTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5LAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 1998</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborationsAndLicenseAgreementsLineItems', window );"><strong>Collaborations And License Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_RoyaltyPercentageBasedOnNetSales', window );">Percentage of royalty received on net sales</a></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_LicenseAgreementDate', window );">License agreement date</a></td>
        <td class="text">Jun. 30,
				 1998<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_MonthlyLicenseFees', window );">Monthly license fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones', window );">Potential future development payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_DevelopmentPayment', window );">Development payment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ortho-McNeil Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborationsAndLicenseAgreementsLineItems', window );"><strong>Collaborations And License Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborativeArrangementDateOfAgreement', window );">Entered into a collaboration agreement</a></td>
        <td class="text">Aug. 31,
				 2006<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_PaymentsMadeUnderLicenseAgreement', window );">Payments made under agreement</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Royalties received</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Ortho-McNeil Inc. [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborationsAndLicenseAgreementsLineItems', window );"><strong>Collaborations And License Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_RoyaltyPercentageBasedOnNetSales', window );">Percentage of royalty received on net sales</a></td>
        <td class="nump">8.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Janssen Pharmaceuticals, Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborationsAndLicenseAgreementsLineItems', window );"><strong>Collaborations And License Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_LicenseAgreementDate', window );">License agreement date</a></td>
        <td class="text">Jun. 30,
				 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_NumberOfDevelopmentAndLicenseAgreements', window );">Number of development and license agreements</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payment eligible to receive on development and commercial events</a></td>
        <td class="nump">$ 228,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CollaborationsAndLicenseAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CollaborationsAndLicenseAgreementsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CollaborativeArrangementDateOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative Arrangement Date Of Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CollaborativeArrangementDateOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent Payments Receivable Based On Development Events</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ContingentPaymentsReceivableBasedOnDevelopmentEvents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_DevelopmentPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development Payment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_DevelopmentPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_LicenseAgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License Agreement Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_LicenseAgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License And Collaboration Agreements Potential Payments For Development Milestones</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_MonthlyLicenseFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Monthly License Fees</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_MonthlyLicenseFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_NumberOfDevelopmentAndLicenseAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Development And License Agreements</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_NumberOfDevelopmentAndLicenseAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_PaymentsMadeUnderLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payments Made Under License Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_PaymentsMadeUnderLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_RoyaltyPercentageBasedOnNetSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty Percentage Based On Net Sales</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_RoyaltyPercentageBasedOnNetSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for royalties during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRoyalties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received for royalties during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRoyaltiesReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>3. Certain Balance Sheet Items</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment consists of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Office and computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Purchased software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">349</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,054</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,295</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In March 2014, the Company ceased use of a substantial portion of
 its leased facility in Hayward, California. In connection with the
 closure of this facility, the Company disposed of certain fully
 depreciated leasehold improvements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Accrued liabilities consist of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">518</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued pre-clinical and clinical trial expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">418</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">501</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forward contract</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">215</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOBCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="10">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2006</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants, Exercise price of $5.00 per share [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010

</div>
          <div>Series E-1 Preferred [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2009

</div>
          <div>Series C-1 Preferred [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2009

</div>
          <div>Series C-1 Preferred [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Series C-1 Preferred [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2008

</div>
          <div>First Issuance [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2008

</div>
          <div>Second Issuance [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2009

</div>
          <div>Third Issuance [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>Third Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Third Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Third Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2009

</div>
          <div>Fourth Issuance [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>Fourth Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Fourth Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Fourth Issuance [Member]

</div>
          <div>As Amended [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Facility Loan Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Facility Loan Agreement [Member]

</div>
          <div>First Tranche [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Facility Loan Agreement [Member]

</div>
          <div>Scenario one, conversion basis [Member]

</div>
          <div>Second Tranche [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Facility Loan Agreement [Member]

</div>
          <div>Scenario two [Member]

</div>
          <div>Second Tranche [Member]

</div>
          <div>Wall Street Journal Prime Rate [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
        <td class="nump">$ 10.0<span></span></td>
        <td class="nump">$ 10.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 30.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Notes issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.5<span></span></td>
        <td class="nump">10.5<span></span></td>
        <td class="nump">7.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Mar. 17,
				 2011<span></span></td>
        <td class="text">Sep. 17,
				 2011<span></span></td>
        <td class="text">Feb. 28,
				 2012<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">Aug.
				01,
				 2013<span></span></td>
        <td class="text">Mar.
				01,
				 2013<span></span></td>
        <td class="text">Jul. 31,
				 2012<span></span></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">Aug.
				01,
				 2013<span></span></td>
        <td class="text">Mar.
				01,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Facility loan, fixed interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.57%<span></span></td>
        <td class="nump">7.57%<span></span></td>
        <td class="nump">4.42%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.919%<span></span></td>
        <td class="nump">4.96%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.46%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.75%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 233<span></span></td>
        <td class="nump">$ 439<span></span></td>
        <td class="nump">$ 439<span></span></td>
        <td class="nump">$ 293<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Loan facility, outstanding principal and accrued interest settled</a></td>
        <td class="nump">16.9<span></span></td>
        <td class="nump">16.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Loan facility extinguished in exchange of common stock</a></td>
        <td class="nump">624,944<span></span></td>
        <td class="nump">624,944<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Facility loan, drawn</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_AmortizationPeriod', window );">Facility loan, interest amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">36 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Facility loan, final interest payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Facility loan, financial covenants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Until positive  Phase 2b data is achieved, the Company must be in compliance with one of two  financial covenants at all times (1) maintain 1.3 times cash to outstanding  debt or (2) maintain sufficient cash on hand to support eight months of  operations based on a trailing average monthly cash burn.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Facility loan, fixed interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.75%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Facility loan, prime rate plus</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.25%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long term warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_AmortizationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortization Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_AmortizationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentCovenantDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of debt extinguished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ExtinguishmentOfDebtAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityCommitmentFeePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtPercentageBearingFixedInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLongTermLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 22,342<span></span></td>
        <td class="nump">$ 24,401<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">6,191<span></span></td>
        <td class="nump">6,843<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Contract receivables</a></td>
        <td class="nump">168<span></span></td>
        <td class="nump">110<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
        <td class="nump">90<span></span></td>
        <td class="nump">68<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">1,876<span></span></td>
        <td class="nump">364<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">266<span></span></td>
        <td class="nump">453<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">30,933<span></span></td>
        <td class="nump">32,239<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">60<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">203<span></span></td>
        <td class="nump">258<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">31,196<span></span></td>
        <td class="nump">32,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,069<span></span></td>
        <td class="nump">697<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">2,368<span></span></td>
        <td class="nump">2,251<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
        <td class="nump">11,638<span></span></td>
        <td class="nump">6,466<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Facility loan</a></td>
        <td class="nump">410<span></span></td>
        <td class="nump">38<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
        <td class="nump">36<span></span></td>
        <td class="nump">36<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">15,521<span></span></td>
        <td class="nump">9,488<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Facility loan, less current portion</a></td>
        <td class="nump">4,099<span></span></td>
        <td class="nump">4,407<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
        <td class="nump">200<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">19,820<span></span></td>
        <td class="nump">13,904<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 100,000,000 shares authorized;10,064,495 and 9,455,064 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">370,276<span></span></td>
        <td class="nump">367,435<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(358,904)<span></span></td>
        <td class="num">(348,842)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
        <td class="nump">11,376<span></span></td>
        <td class="nump">18,596<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 31,196<span></span></td>
        <td class="nump">$ 32,500<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Line-of-Credit Arrangement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6517033<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LinesOfCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Line-of-Credit Arrangement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6517033<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361426&amp;loc=d3e1314-112600<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361426&amp;loc=d3e1336-112600<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermLineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <b>1. Organization and Description of Business</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 CymaBay Therapeutics, Inc. (the &#x201C;Company&#x201D; or
 &#x201C;CymaBay&#x201D;) is a biopharmaceutical company focused on
 developing therapies to treat metabolic and rare diseases with high
 unmet need. The Company&#x2019;s lead product candidate,
 arhalofenate, is being developed for the treatment of gout. The
 Company&#x2019;s second product candidate, MBX-8025, is being
 considered for the treatment of certain orphan diseases. The
 Company was incorporated in Delaware in October 1988 as Transtech
 Corporation. The Company&#x2019;s headquarters and operations are
 located in Newark, California and it operates in one segment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On September&#xA0;30, 2013, the Company sold shares of its common
 stock and warrants to purchase shares of its common stock in a
 private placement for aggregate gross proceeds of $26.8 million,
 and raised an additional $5.0 million in venture debt financing
 pursuant to a $10.0 million loan agreement which it entered into
 simultaneously with the private placement on September&#xA0;30,
 2013, resulting in aggregate net proceeds to the Company of $28.8
 million after deducting placement agent fees and estimated offering
 expenses. At the same time the Company issued shares of its common
 stock in cancellation of approximately $16.9 million of debt owed
 to the holder of that debt. On October&#xA0;31, 2013, the Company
 sold additional shares of its common stock and warrants to purchase
 shares of its common stock, which sales are also part of the
 private placement, for net proceeds of $2.2 million after deducting
 placement agent fees and estimated offering expenses. Further, on
 November&#xA0;22, 2013, the Company entered into an agreement with
 investors to purchase shares of its common stock and warrants to
 purchase shares of its common stock as part of the private
 placement for net proceeds of $2.7 million, which sales occurred on
 January&#xA0;29, 2014, after the listing of the Company&#x2019;s
 common stock on the over-the-counter market. The Company refers to
 the private placement, the venture debt financing and the issuance
 of&#xA0;the Company's&#xA0;common stock in cancellation of the
 $16.9 million of debt as the 2013 financing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has incurred net operating losses and negative cash
 flows from operations since its inception. During the three months
 ended March&#xA0;31, 2014, the Company incurred a loss from
 operations of $10.1 million and used $5.0 million of cash in
 operations. At March&#xA0;31, 2014, the Company had an accumulated
 deficit of $358.9 million. CymaBay expects to incur increased
 research and development expenses as it continues to study its
 product candidates in clinical trials.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EESBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Nov. 22, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of common stock upon conversion of redeemable convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,793,281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred stock to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 320.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares sold</a></td>
        <td class="nump">604,000<span></span></td>
        <td class="nump">5,366,669<span></span></td>
        <td class="nump">664,300<span></span></td>
        <td class="nump">5,366,669<span></span></td>
        <td class="nump">5,366,669<span></span></td>
        <td class="nump">10,064,495<span></span></td>
        <td class="nump">9,455,064<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase shares of common stock in 2013 financing</a></td>
        <td class="nump">120,800<span></span></td>
        <td class="nump">1,073,338<span></span></td>
        <td class="nump">132,860<span></span></td>
        <td class="nump">1,073,338<span></span></td>
        <td class="nump">1,073,338<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of 2013 financing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.2<span></span></td>
        <td class="nump">22.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Loan facility extinguished in exchange of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">624,944<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">624,944<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Amount of debt cancelled upon issuance of common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of 2013 financing</a></td>
        <td class="nump">$ 2.7<span></span></td>
        <td class="nump">$ 26.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B-1 Preferred [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_NetProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Proceeds From Issuance Of Private Placement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_NetProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_WarrantsToPurchaseOfCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants To Purchase Of Common Stock Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_WarrantsToPurchaseOfCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockAmountIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of debt extinguished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ExtinguishmentOfDebtAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Nov. 22, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2006</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from issuance of common stock and warrants in a private placement</a></td>
        <td class="nump">$ 2,700,000<span></span></td>
        <td class="nump">$ 26,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Additional proceeds from venture debt financing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Venture debt financing loan agreement amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses', window );">Net proceeds after deducting placement agent fees and estimated offering expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of private placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">22,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt', window );">Issued shares of common stock in cancellation of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(10,062,000)<span></span></td>
        <td class="num">(2,628,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,011,000)<span></span></td>
        <td class="num">(2,159,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (358,904,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (348,842,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_NetProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Proceeds From Issuance Of Private Placement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_NetProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from Issuance of Private Placement Net Of Fees And Expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ProceedsFromIssuanceOfPrivatePlacementNetOfFeesAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Amount For Cancellation Of Debt</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_StockIssuedDuringPeriodAmountForCancellationOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Stockholders' Equity - Reserved Shares of Authorized but Unissued Common Stock (Detail)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
        <td class="nump">2,898,534<span></span></td>
        <td class="nump">2,320,021<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Outstanding common stock warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
        <td class="nump">1,848,487<span></span></td>
        <td class="nump">1,742,727<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity incentive plans [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
        <td class="nump">1,050,047<span></span></td>
        <td class="nump">577,294<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">$ 27,928<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
        <td class="nump">11,638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
        <td class="nump">11,638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money market funds [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">21,737<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate debt and asset backed securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">6,191<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">21,737<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member] | Money market funds [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">21,737<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">6,191<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member] | Corporate debt and asset backed securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
        <td class="nump">6,191<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
        <td class="nump">11,638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member] | Warrant liability [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
        <td class="nump">$ 11,638<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial and nonfinancial obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>2. Summary of Significant Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Basis of Presentation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The accompanying interim condensed financial statements are
 unaudited. These unaudited interim financial statements have been
 prepared in accordance U.S. GAAP (&#x201C;GAAP&#x201D;) and following
 the requirements of the United States Securities and Exchange
 Commission (&#x201C;SEC&#x201D;) for interim reporting. As permitted
 under those rules, certain footnotes or other financial information
 that are normally required by GAAP can be condensed or omitted. In
 management&#x2019;s opinion, the unaudited interim financial
 statements have been prepared on the same basis as the audited
 financial statements and include all adjustments, which include
 only normal recurring adjustments, necessary for the fair
 presentation of the Company&#x2019;s financial position and its
 results of operations and comprehensive loss and its cash flows for
 periods presented. These statements do not include all disclosures
 required by GAAP and should be read in conjunction with the
 Company&#x2019;s financial statements and accompanying notes for the
 fiscal year ended December&#xA0;31, 2013, which is contained in the
 Company&#x2019;s Annual Report on Form 10-K as filed with the SEC on
 March&#xA0;31, 2014. The results for the three months ended
 March&#xA0;31, 2014, are not necessarily indicative of results to
 be expected for the year or for any other period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The financial statements have been prepared in accordance with
 GAAP, which requires management to make estimates and assumptions
 that affect the amounts and disclosures reported in the financial
 statements and accompanying notes. Management bases its estimates
 on historical experience and on assumptions believed to be
 reasonable under the circumstances. The estimation process often
 may yield a range of potentially reasonable estimates of the
 ultimate future outcomes, and management must select an amount that
 falls within that range of reasonable estimates. Actual results
 could differ materially from those estimates. The Company believes
 significant judgment is involved in estimating stock-based
 compensation, accrued liabilities, and equity and liability
 instrument valuations.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Reverse Stock Split</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On September&#xA0;30, 2013, the Company filed an amended and
 restated certificate of incorporation under which the
 Company&#x2019;s preferred stock and common stock was reverse split
 on a 1-for-79.5 basis. The accompanying financial statements and
 notes to the financial statements, give retroactive effect to the
 reverse split for all periods presented.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Fair Value of Financial Instruments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s financial instruments consist of cash and cash
 equivalents, short-term marketable securities, accounts payable,
 accrued expenses, warrant liabilities and convertible notes. Fair
 value estimates of these instruments are made at a specific point
 in time, based on relevant market information. These estimates may
 be subjective in nature and involve uncertainties and matters of
 significant judgment and therefore cannot be determined with
 precision.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants at the
 measurement date. Assets and liabilities that are measured at fair
 value are reported using a three-level fair value hierarchy that
 prioritizes the inputs used to measure fair value. This hierarchy
 maximizes the use of observable inputs and maximizes the use of
 unobservable inputs and is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 1&#x2014;Quoted prices in active markets for identical assets
 or liabilities that the Company has the ability to access at the
 measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 2&#x2014;Inputs other than quoted prices in active markets
 that are observable for the asset or liability, either directly or
 indirectly.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 3&#x2014;Inputs that are unobservable for the asset or
 liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The carrying amounts of financial instruments such as cash and cash
 equivalents, accounts payable, convertible notes, and accrued
 expenses approximate the related fair values due to the short-term
 maturities of these instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>As of March&#xA0;31, 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate debt and asset backed securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total assets measured at fair value</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,928</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total liabilities measured at fair value</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Marketable securities consist of available-for-sale securities that
 are reported at fair value, with the related unrealized gains and
 losses included in accumulated other comprehensive income (loss), a
 component of stockholders&#x2019; equity. The Company values cash
 equivalents and marketable securities using quoted market prices or
 alternative pricing sources and models utilizing observable market
 inputs and, as such, classifies cash equivalents and marketable
 securities within Level 1 or Level 2.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of March&#xA0;31, 2014, the Company held a Level 3 liability
 associated with warrants, issued in connection with the
 Company&#x2019;s 2013 financing. The warrants are considered a
 liability and are valued using an option-pricing model, the inputs
 for which include exercise price of the warrants, market price of
 the underlying common shares, expected term, volatility based on a
 group of the Company&#x2019;s peers and the risk-free rate
 corresponding to the expected term of the warrants. As of
 December&#xA0;31, 2013, the Company also held a Level 3 liability
 associated with a forward contract which arose in connection with
 the Company&#x2019;s November&#xA0;22, 2013 execution of an equity
 purchase agreement with certain investors. The agreement required
 the Company to issue a fixed number of shares of common stock and
 warrants to purchase common stock at a predetermined price of $3.0
 million provided the Company completes the listing of its common
 stock on a public stock exchange. The forward contract&#x2019;s fair
 value was determined upon execution as the difference between the
 present value of the equity proceeds to be received under the
 agreement less the fair value of the underlying securities. The
 forward contract liability is presented in the balance sheet as a
 component of accrued liabilities and is revalued at each reporting
 period until contract settlement which occurred on January&#xA0;29,
 2014. The fair value of the underlying common stock and warrants
 were valued using an option-pricing model, the inputs of which are
 similar to those used in the valuation of the Company&#x2019;s
 liability classified warrants. Changes to any of the inputs to the
 option-pricing models used by the Company can have a significant
 impact to the estimated fair value of the warrants and forward
 contract liabilities.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table sets forth an activity summary which includes
 the changes in the fair value of&#xA0;the Company's&#xA0;Level 3
 financial instruments (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Warrant</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Forward</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Liability</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Contract</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance as of December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,466</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Issuance of financial instrument</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">443</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Change in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Settlement of financial instrument</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(443</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance as of March&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The gains and losses from remeasurement of Level 3 financial
 liabilities are recorded through other expense, net on the
 accompanying statements of operations and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Cash, Cash Equivalents, and Marketable Securities</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all highly liquid investments with a
 remaining maturity of 90 days or less at the time of purchase to be
 cash equivalents. Cash and cash equivalents consist of deposits
 with commercial banks in checking, interest-bearing, and demand
 money market accounts. The Company invests excess cash in
 marketable securities with high credit ratings. These securities
 consist primarily of corporate debt and asset-backed securities and
 are classified as &#x201C;available-for-sale.&#x201D; Management may
 liquidate any of these investments in order to meet the
 Company&#x2019;s liquidity needs in the next year. Accordingly, any
 investments with contractual maturities greater than one year from
 the balance sheet date are classified as short-term in the balance
 sheet.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Realized gains and losses from the sale of marketable securities,
 if any, are calculated using the specific identification method.
 Realized gains and losses and declines in value judged to be
 other-than-temporary are included in interest income or expense in
 the statements of operations. Unrealized holding gains and losses
 are reported in accumulated other comprehensive income (loss), in
 the balance sheet. To date, the Company has not recorded any
 impairment charges on its marketable securities related to
 other-than-temporary declines in market value. In determining
 whether a decline in market value is other-than-temporary, various
 factors are considered, including the cause, duration of time and
 severity of the impairment, any adverse changes in the
 investees&#x2019; financial condition, and the Company&#x2019;s
 intent and ability to hold the security for a period of time
 sufficient to allow for an anticipated recovery in market
 value.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Restricted Cash</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain compensating cash balances with
 financial institutions that provide the Company with its corporate
 credit cards. As of March&#xA0;31, 2014 and December&#xA0;31, 2013,
 cash restricted under these arrangements was $100,000 and $155,000,
 respectively. These amounts are presented in other assets on the
 accompanying balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Concentration of Credit Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Cash, cash equivalents, and marketable securities consist of
 financial instruments that potentially subject the Company to a
 concentration of credit risk to the extent of the fair value
 recorded in the balance sheet. The Company invests cash that is not
 required for immediate operating needs primarily in highly liquid
 instruments that bear minimal risk. The Company has established
 guidelines relating to the quality, diversification, and maturities
 of securities to enable the Company to manage its credit risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Property and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment is stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization is
 calculated using the straight-line method, and the cost is
 amortized over the estimated useful lives of the respective assets,
 generally three to seven years. Leasehold improvements are
 amortized over the shorter of the useful lives or the
 non-cancelable term of the related lease. Maintenance and repair
 costs are charged as expense in the statements of operations and
 comprehensive income (loss) as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Impairment of Long-Lived Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company reviews long-lived assets for impairment whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. An
 impairment loss is recognized if the estimated undiscounted future
 cash flow expected to result from the use and eventual disposition
 of an asset is less than the carrying amount. While the
 Company&#x2019;s current and historical operating losses and cash
 flows are indicators of impairment, the Company believes the future
 cash flows to be received support the carrying value of its
 long-lived assets. Accordingly, the Company has not recognized any
 impairment losses as of March&#xA0;31, 2014 and December&#xA0;31,
 2013.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Deferred Rent</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company records its costs under facility operating lease
 agreements as rent expense. Rent expense is recognized on a
 straight-line basis over the non-cancelable term of the operating
 lease. The difference between the actual amounts paid and amounts
 recorded as rent expense is recorded to deferred rent in the
 balance sheet.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Common Stock Warrant Liability</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Warrants issued to common stock holders and lenders by the Company
 in conjunction with the 2013 financing were classified as
 liabilities in the accompanying balance sheets, as the terms for
 redemption of the underlying security were outside the
 Company&#x2019;s control. The warrants were recorded at fair value
 using either the Black-Scholes option pricing model, probability
 weighted expected return model or a binomial model, depending on
 the characteristics of the warrants. The fair value of these
 warrants is re-measured at each financial reporting period with any
 changes in fair value being recognized as a component of other
 income (expense) in the accompanying condensed statements of
 operations and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Research and Development Expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenses consist of costs incurred in
 identifying, developing, and testing product candidates. These
 expenses consist primarily of costs for research and development
 personnel, including: related stock-based compensation; contract
 research organizations and other third parties that assist in
 managing, monitoring, and analyzing clinical trials; investigator
 and site fees; laboratory services; consultants; contract
 manufacturing services; non-clinical studies, including materials;
 and allocated expenses, such as depreciation of assets, and
 facilities and information technology that support research and
 development activities. Research and development costs are expensed
 as incurred, including expenses that may or may not be reimbursed
 under research and development funding arrangements. Research and
 development expenses under collaboration agreements approximate the
 revenue recognized under such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The expenses related to clinical trials are based upon estimates of
 the services received and efforts expended pursuant to contracts
 with multiple research institutions and clinical research
 organizations (CROs) that conduct and manage clinical trials on
 behalf of the Company. Expenses related to clinical trials are
 accrued based upon the level of activity incurred under each
 contract as indicated by such factors as progress made against
 specified milestones or targets in each period, patient enrollment
 levels, and other trial activities as reported by CROs.
 Accordingly, the Company&#x2019;s clinical trial accrual is
 dependent upon the timely and accurate reporting of expenses by
 clinical research organizations and other third-party
 vendors.&#xA0;Payments made to third parties under these clinical
 trial arrangements in advance of the receipt of the related
 services are recorded as prepaid assets, depending on the terms of
 the agreement, until the services are rendered.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Employee and director stock-based compensation is measured at the
 grant date, based on the fair-value based measurements of the stock
 awards, and the portion that is ultimately expected to vest is
 recognized as an expense over the related vesting periods, net of
 estimated forfeitures. The Company calculates the fair-value based
 measurements of options using the Black-Scholes valuation model and
 the single-option approach and recognizes expense using the
 straight-line attribution method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Equity awards granted to non-employees are accounted for using the
 Black-Scholes valuation model to determine the fair value of such
 instruments. The fair value of equity awards granted to
 non-employees are re-measured over the related vesting period and
 amortized to expense as earned.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company utilizes the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on differences between the financial reporting and
 the tax bases of assets and liabilities and are measured using
 enacted tax rates and laws that will be in effect when the
 differences are expected to reverse. A valuation allowance is
 recorded when it is more likely than not that all or part of a
 deferred tax asset will not be realized.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The accounting guidance for uncertainty in income taxes prescribes
 a recognition threshold and measurement attribute criteria for the
 financial recognition and measurement of tax positions taken or
 expected to be taken in a tax return. For those benefits to be
 recognized, a tax position must be more likely than not to be
 sustained upon examination based on the technical merits of the
 position.The Company records interest related to income taxes, if
 any, as interest, and any penalties would be recorded as other
 expense in the statements of comprehensive income (loss). There was
 no interest or penalties related to income taxes recorded during
 the three months ended March&#xA0;31, 2014 and 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Comprehensive Loss</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive loss includes net loss and net unrealized gains and
 losses on marketable securities, which are presented in a single
 continuous statement. Accumulated other comprehensive income (loss)
 is disclosed in the statements of redeemable convertible preferred
 stock and stockholders&#x2019; equity (deficit), and is stated net
 of related tax effects, if any.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Net Loss Per Common Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic net loss per share of common stock is based on the weighted
 average number of shares of common stock outstanding equivalents
 during the period. Prior to the 2013 financing, in addition to
 common stock, the Company had preferred stock outstanding that
 contractually entitled the holder to participate in dividends and
 earnings of the Company. Accordingly, the Company applied the
 two-class method for calculating net loss per share. Under this
 method, all undistributed earnings are allocated first to the
 preferred stockholders based on their contractual right to
 dividends. This right is calculated on a pro rated basis for the
 portion of the period the preferred shares were outstanding. On
 September&#xA0;30, 2013, in connection with the 2013 financing, all
 outstanding shares of the Company&#x2019;s preferred stock were
 converted into shares of the Company&#x2019;s common stock.
 Accordingly, no preferred stock was outstanding during the three
 months ended March&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Diluted net loss per share of common stock is calculated using the
 more dilutive of the two approaches: one,
 &#x201C;as-converted&#x201D; method, under which the weighted average
 number of common stock shares outstanding during the period is
 adjusted to include the assumed conversion of redeemable
 convertible preferred stock at the beginning of the period, and the
 other, the &#x201C;two-class&#x201D; method as described above. Under
 either approach, the weighted average number of shares outstanding
 is also adjusted to include the assumed exercises of stock options
 and warrants, if dilutive. For the three months ended
 March&#xA0;31, 2014 and 2013, diluted net loss per share is the
 same as basic, as any adjustments would have been
 anti-dilutive.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three Months
 Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">(unaudited)</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants for common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,848,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">906,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Redeemable convertible preferred stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">661,059</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,755,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">786,956</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">10,064,495<span></span></td>
        <td class="nump">9,455,064<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">10,064,495<span></span></td>
        <td class="nump">9,455,064<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="69%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>As of March&#xA0;31, 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 39.5pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate debt and asset backed securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total assets measured at fair value</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,191</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,928</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total liabilities measured at fair value</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock', window );">Schedule of Changes in Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table sets forth an activity summary which includes
 the changes in the fair value of&#xA0;the Company's&#xA0;Level 3
 financial instruments (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Warrant</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Forward</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Liability</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Contract</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance as of December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,466</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Issuance of financial instrument</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">443</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Change in fair value</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Settlement of financial instrument</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(55</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(443</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance as of March&#xA0;31, 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three Months
 Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">(unaudited)</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants for common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,848,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">906,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Redeemable convertible preferred stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">661,059</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,755,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">786,956</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Changes In Fair Value Of Financial Liabilities Table [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ScheduleOfChangesInFairValueOfFinancialLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">CYMA<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CymaBay Therapeutics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001042074<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,064,826<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment consists of the following (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Office and computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Purchased software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">349</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,298</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,054</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,295</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Accrued liabilities consist of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">518</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued pre-clinical and clinical trial expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,233</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">418</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued professional fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">501</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forward contract</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">215</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total accrued liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,251</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 2,615<span></span></td>
        <td class="nump">$ 1,490<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">2,500<span></span></td>
        <td class="nump">925<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">5,115<span></span></td>
        <td class="nump">2,415<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(5,115)<span></span></td>
        <td class="num">(2,415)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">12<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(184)<span></span></td>
        <td class="num">(212)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
        <td class="num">(4,775)<span></span></td>
        <td class="num">(2)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(10,062)<span></span></td>
        <td class="num">(2,628)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion to redemption value of redeemable convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,109)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
        <td class="num">(10,062)<span></span></td>
        <td class="num">(5,737)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss/income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (10,061)<span></span></td>
        <td class="num">$ (5,737)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share</a></td>
        <td class="num">$ (1.02)<span></span></td>
        <td class="num">$ (985.06)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding', window );">Weighted average common shares outstanding used to calculate basic and diluted net loss per common share</a></td>
        <td class="nump">9,873,687<span></span></td>
        <td class="nump">5,824<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number Of Basic And Diluted Shares Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_WeightedAverageNumberOfBasicAndDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669619-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>7. Commitments and Contingencies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company leased office and laboratory space in a single building
 in Hayward, California. The facility lease, as amended on
 July&#xA0;15, 2010, had a term of four years and expired on
 April&#xA0;30, 2014. On November&#xA0;8, 2013, the Company entered
 into a new lease commencing January&#xA0;16, 2014, and expiring on
 December&#xA0;31, 2018, for 8,894 square feet of office space in
 Newark, California. Rent expense was $0.2 million and $0.1 million
 for the three months ended March&#xA0;31, 2014 and 2013,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future minimum lease payments are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Lease</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Payments</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Year ending December&#xA0;31:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">222</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total future minimum payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,063</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Indemnification</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In the normal course of business, the Company enters into contracts
 and agreements that contain a variety of representations and
 warranties and provide for general indemnification, including
 indemnification associated with product liability or infringement
 of intellectual property rights. The Company&#x2019;s exposure under
 these agreements is unknown because it involves future claims that
 may be made against the Company that may be, but have not yet been,
 made. To date, the Company has not paid any claims or been required
 to defend any action related to these indemnification obligations,
 and no amounts have been accrued in the accompanying balance sheets
 related to these indemnification obligations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has agreed to indemnify its executive officers and
 directors for losses and costs incurred in connection with certain
 events or occurrences, including advancing money to cover certain
 costs, subject to certain limitations. The maximum potential amount
 of future payments the Company could be required to make under this
 indemnification is unlimited; however, the Company maintains
 insurance policies that may limit its exposure and may enable it to
 recover a portion of any future amounts paid. Assuming the
 applicability of coverage, the willingness of the insurer to assume
 coverage, and subject to certain retention, loss limits, and other
 policy provisions, the Company believes the fair value of these
 indemnification obligations is not material. Accordingly, the
 Company has not recognized any liabilities relating to these
 obligations as of March&#xA0;31, 2014 and December&#xA0;31, 2013.
 No assurances can be given that the covering insurers will not
 attempt to dispute the validity, applicability, or amount of
 coverage without expensive litigation against these insurers, in
 which case the Company may incur substantial liabilities as a
 result of these indemnification obligations.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>6. Debt</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On June&#xA0;20, 2006 the Company entered into a equity and loan
 facility with the Johnson and Johnson Development Corporation
 (&#x201C;JJDC&#x201D;) pursuant to which the Company could drawn down
 up to an aggregate of $30 million in loans in the form of
 convertible preferred stock promissory notes. In March and
 September 2008, the Company issued notes in the aggregate amount of
 $3.5 million and $10.5 million, respectively. The notes were due on
 March&#xA0;17 and September&#xA0;17, 2011, including interest that
 accrued at 7.57%&#xA0;per annum. In December 2010, the aggregate
 principal amount and all accrued interest under the notes issued in
 March and September 2008 were converted into the Company&#x2019;s
 Series E-3 convertible preferred stock (Series E-3 Preferred) at
 $232.93&#xA0;per share.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In February and July 2009, the Company issued notes in the
 aggregate amount of $7.0 million and $6.7 million, respectively,
 which represented the remaining amount available to the Company, in
 accordance with the terms of the equity and loan facility with
 JJDC. The notes were due in February 2012 and July 2012, including
 interest that accrued at 4.42%&#xA0;per annum and 4.960%&#xA0;per
 annum, respectively. In January 2012, the Company amended the
 maturity dates of the outstanding $7.0 million and $6.7 million
 convertible promissory notes to extend the maturity date to
 March&#xA0;1, 2013, and interest rates were increased to 4.919% and
 5.46%&#xA0;per annum, respectively. In addition, the conversion
 price of the notes to convert into shares of the Company&#x2019;s
 Series C-1 Preferred Stock was decreased from $438.84 per share to
 $292.56 per share. All of these notes were further amended in March
 2013, to extend the maturity date on the notes to August&#xA0;1,
 2013, and to make the notes subordinate to repayment of the
 Company&#x2019;s severance obligations to all employees until
 January&#xA0;1, 2014. On July&#xA0;31, 2013, the maturity date was
 extended to December&#xA0;31, 2013. There are no financial
 covenants associated with the notes. For the three months ended
 March&#xA0;31, 2013, the Company recognized $0.2 million of
 interest expense related to the convertible promissory notes. On
 September&#xA0;30, 2013, the outstanding principal and accrued
 interest of $16.9 million under the equity and loan facility with
 JJDC was extinguished in exchange for 624,944 shares of common
 stock as an integral part of the 2013 financing.</p>
 <p style="font-size:1px;margin-top:18px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Facility Loan</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 On September&#xA0;30, 2013, the Company entered into a facility
 loan agreement with Silicon Valley Bank and Oxford Finance for a
 total loan amount of $10.0 million of which the first tranche of
 $5.0 million was drawn as part of&#xA0;the 2013 financing.&#xA0;The
 loan has a fixed interest rate of 8.75% payable twelve months
 interest only and thirty-six months amortization thereafter, with a
 final interest payment of&#xA0;$0.3 million at the end of the loan
 period.&#xA0;Until positive Phase 2b data is achieved, the Company
 must be in compliance with one of two financial covenants at all
 times: (1)&#xA0;maintain 1.3 times cash to outstanding debt or
 (2)&#xA0;maintain sufficient cash on hand to support eight months
 of operations based on a trailing average monthly cash burn. The
 first tranche loans under the term loan facility bear interest at a
 rate equal 8.75%&#xA0;per annum. Loans under the second tranche
 will bear interest at a rate fixed at the time of borrowing equal
 to the greater of (i)&#xA0;8.75%&#xA0;per annum and (ii)&#xA0;the
 sum of the Wall Street Journal prime rate plus 4.25%&#xA0;per
 annum. We were also required to pay a facility fee of 1.00% on the
 term loan facility commitment.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At the time of the facility loan drawdown, the
 Company&#xA0;issued&#xA0;warrants exercisable for a total of
 121,739 shares of the Company&#x2019;s common stock to the lenders
 at an exercise price of $5.00 per share.&#xA0;As a result of this
 issuance, a warrant liability of $0.5 million was recorded in the
 accompanying balance sheets which is required to be revalued at
 each balance sheet date.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
        <td class="nump">0.01258<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue', window );">Predetermined price of common stock purchased for warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CashEquivalentMaturityDescription', window );">Cash and cash equivalents, maturity description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ShortTermInvestmentContractualMaturity', window );">Short-term contractual maturities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">155,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties related to income taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CashEquivalentMaturityDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash Equivalent Maturity Description</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CashEquivalentMaturityDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchased common stock and common stock warrants carrying value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_PurchasedCommonStockAndCommonStockWarrantsCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ShortTermInvestmentContractualMaturity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Short Term Investment Contractual Maturity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ShortTermInvestmentContractualMaturity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future Minimum Lease Payments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Future minimum lease payments are as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="88%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>Lease</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Payments</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Year ending December&#xA0;31:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">209</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">216</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">222</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">228</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total future minimum payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,063</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>10. Related-Party Transactions</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company paid a former member of its Board of Directors, who is
 also a member of its Scientific and Clinical Advisory Boards, a
 total of $45,000 in the year ended December&#xA0;31, 2013 and
 $15,000 for the three months ended March&#xA0;31, 2014, in monthly
 cash retainers. The Company also issued options to purchase shares
 of common stock and incentive awards to this individual in his
 capacity as a member of its Scientific Advisory Board.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>8. Stockholders&#x2019; Equity</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Upon the closing&#xA0;in the 2013 financing on September&#xA0;30,
 2013, all of the outstanding shares of redeemable convertible
 preferred stock were converted into 2,793,281 shares of common
 stock, and the related carrying value of $320.0 million was
 reclassified to additional paid-in capital. As of March&#xA0;31,
 2014, no shares of redeemable convertible preferred stock were
 issued or outstanding.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The Company was authorized to issue 100,000,000 shares of common
 stock with a par value of $0.0001 per share as of March&#xA0;31,
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On September&#xA0;30, 2013, the Company sold 5,366,669 shares of
 common stock and 1,073,338 warrants to purchase shares of common
 stock in the 2013 financing for net proceeds to the Company of
 $22.8 million after deducting placement agent fees and estimated
 offering expenses. Also on that date, the Company issued 624,944
 shares of common stock in cancellation of approximately $16.9
 million of debt owed to JJDC, the holder of that debt (Note 6). On
 October&#xA0;31, 2013, the Company sold an additional 664,300
 shares of common stock and warrants to purchase 132,860 shares of
 common stock, which sales were also part of the 2013 financing, for
 net proceeds to CymaBay of $2.2 million after deducting placement
 agent fees and estimated offering expenses. On November&#xA0;22,
 2013, the Company entered into an agreement with investors to
 purchase 604,000 shares of common stock and 120,800 warrants to
 purchase shares of common stock as part of the 2013 financing for
 net proceeds of $2.7 million, which sales were set to occur shortly
 after the listing of the Company&#x2019;s common stock on the
 over-the-counter market. The Company began trading on the
 over-the-counter market on January&#xA0;24, 2014 enabling this
 portion of the 2013financing to be completed in late January
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of March&#xA0;31, 2014 and December&#xA0;31, 2013, the Company
 had reserved shares of authorized but unissued common stock as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,848,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,742,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity incentive plans</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,050,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">577,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total reserved shares of common stock</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,898,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,320,021</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans and Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>9. Stock Plans and Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Stock Plans</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On September&#xA0;30, 2013, the Company&#x2019;s stockholders
 approved the 2013 Equity Incentive Plan, or 2013 Plan, under which
 shares of the Company&#x2019;s common stock are reserved for
 issuance pursuant to stock awards, including, but not limited to,
 incentive stock options, nonstatutory stock options, stock
 appreciation rights, restricted stock awards, restricted stock unit
 awards, performance stock awards, and performance cash awards. In
 addition, the share reserve automatically increased by 472,753
 shares on January&#xA0;1, 2014, and will continue to automatically
 increase on January&#xA0;1<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup> of each year, for a
 period of not more than ten years, in an amount equal to 5% of the
 total number of shares of capital stock outstanding on
 December&#xA0;31<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup> of the preceding
 calendar year, unless the Board determines otherwise prior to
 December&#xA0;31<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">st</sup> of such calendar
 year. From plan inception through March&#xA0;31, 2014, the Company
 had issued options for an aggregate of 830,647&#xA0;shares of the
 Company&#x2019;s common stock under the 2013 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Stock-Based Compensation Expense</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>Employee and Director Expense</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Employee and director stock-based compensation expense recorded was
 as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>(unaudited)</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">568</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">714</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5DAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Description of Business (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has incurred net operating losses and negative cash
 flows from operations since its inception. During the three months
 ended March&#xA0;31, 2014, the Company incurred a loss from
 operations of $10.1 million and used $5.0 million of cash in
 operations. At March&#xA0;31, 2014, the Company had an accumulated
 deficit of $358.9 million. CymaBay expects to incur increased
 research and development expenses as it continues to study its
 product candidates in clinical trials.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Basis of Presentation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The accompanying interim condensed financial statements are
 unaudited. These unaudited interim financial statements have been
 prepared in accordance U.S. GAAP (&#x201C;GAAP&#x201D;) and following
 the requirements of the United States Securities and Exchange
 Commission (&#x201C;SEC&#x201D;) for interim reporting. As permitted
 under those rules, certain footnotes or other financial information
 that are normally required by GAAP can be condensed or omitted. In
 management&#x2019;s opinion, the unaudited interim financial
 statements have been prepared on the same basis as the audited
 financial statements and include all adjustments, which include
 only normal recurring adjustments, necessary for the fair
 presentation of the Company&#x2019;s financial position and its
 results of operations and comprehensive loss and its cash flows for
 periods presented. These statements do not include all disclosures
 required by GAAP and should be read in conjunction with the
 Company&#x2019;s financial statements and accompanying notes for the
 fiscal year ended December&#xA0;31, 2013, which is contained in the
 Company&#x2019;s Annual Report on Form 10-K as filed with the SEC on
 March&#xA0;31, 2014. The results for the three months ended
 March&#xA0;31, 2014, are not necessarily indicative of results to
 be expected for the year or for any other period.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The financial statements have been prepared in accordance with
 GAAP, which requires management to make estimates and assumptions
 that affect the amounts and disclosures reported in the financial
 statements and accompanying notes. Management bases its estimates
 on historical experience and on assumptions believed to be
 reasonable under the circumstances. The estimation process often
 may yield a range of potentially reasonable estimates of the
 ultimate future outcomes, and management must select an amount that
 falls within that range of reasonable estimates. Actual results
 could differ materially from those estimates. The Company believes
 significant judgment is involved in estimating stock-based
 compensation, accrued liabilities, and equity and liability
 instrument valuations.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Reverse Stock Split</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On September&#xA0;30, 2013, the Company filed an amended and
 restated certificates of incorporation under which the
 Company&#x2019;s preferred stock and common stock was reverse split
 on a 1-for-79.5 basis. The accompanying financial statements and
 notes to the financial statements, give retroactive effect to the
 reverse split for all periods presented.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Fair Value of Financial Instruments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company&#x2019;s financial instruments consist of cash and cash
 equivalents, short-term marketable securities, accounts payable,
 accrued expenses, warrant liabilities and convertible notes. Fair
 value estimates of these instruments are made at a specific point
 in time, based on relevant market information. These estimates may
 be subjective in nature and involve uncertainties and matters of
 significant judgment and therefore cannot be determined with
 precision.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants at the
 measurement date. Assets and liabilities that are measured at fair
 value are reported using a three-level fair value hierarchy that
 prioritizes the inputs used to measure fair value. This hierarchy
 maximizes the use of observable inputs and maximizes the use of
 unobservable inputs and is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 1&#x2014;Quoted prices in active markets for identical assets
 or liabilities that the Company has the ability to access at the
 measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 2&#x2014;Inputs other than quoted prices in active markets
 that are observable for the asset or liability, either directly or
 indirectly.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Level 3&#x2014;Inputs that are unobservable for the asset or
 liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The carrying amounts of financial instruments such as cash and cash
 equivalents, accounts payable, convertible notes, and accrued
 expenses approximate the related fair values due to the short-term
 maturities of these instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Marketable securities consist of available-for-sale securities that
 are reported at fair value, with the related unrealized gains and
 losses included in accumulated other comprehensive income (loss), a
 component of stockholders&#x2019; equity. The Company values cash
 equivalents and marketable securities using quoted market prices or
 alternative pricing sources and models utilizing observable market
 inputs and, as such, classifies cash equivalents and marketable
 securities within Level 1 or Level 2.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of March&#xA0;31, 2014, the Company held a Level 3 liability
 associated with warrants, issued in connection with the
 Company&#x2019;s 2013 financing. The warrants are considered a
 liability and are valued using an option-pricing model, the inputs
 for which include exercise price of the warrants, market price of
 the underlying common shares, expected term, volatility based on a
 group of the Company&#x2019;s peers and the risk-free rate
 corresponding to the expected term of the warrants. As of
 December&#xA0;31, 2013, the Company also held a Level 3 liability
 associated with a forward contract which arose in connection with
 the Company&#x2019;s November&#xA0;22, 2013 execution of an equity
 purchase agreement with certain investors. The agreement required
 the Company to issue a fixed number of shares of common stock and
 warrants to purchase common stock at a predetermined price of $3.0
 million provided the Company completes the listing of its common
 stock on a public stock exchange. The forward contract&#x2019;s fair
 value was determined upon execution as the difference between the
 present value of the equity proceeds to be received under the
 agreement less the fair value of the underlying securities. The
 forward contract liability is presented in the balance sheet as a
 component of accrued liabilities and is revalued at each reporting
 period until contract settlement which occurred on January&#xA0;29,
 2014. The fair value of the underlying common stock and warrants
 were valued using an option-pricing model, the inputs of which are
 similar to those used in the valuation of the Company&#x2019;s
 liability classified warrants. Changes to any of the inputs to the
 option-pricing models used by the Company can have a significant
 impact to the estimated fair value of the warrants and forward
 contract liabilities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The gains and losses from remeasurement of Level 3 financial
 liabilities are recorded through other expense, net on the
 accompanying statements of operations and comprehensive loss.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Cash, Cash Equivalents, and Marketable Securities</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all highly liquid investments with a
 remaining maturity of 90 days or less at the time of purchase to be
 cash equivalents. Cash and cash equivalents consist of deposits
 with commercial banks in checking, interest-bearing, and demand
 money market accounts. The Company invests excess cash in
 marketable securities with high credit ratings. These securities
 consist primarily of corporate debt and asset-backed securities and
 are classified as &#x201C;available-for-sale.&#x201D; Management may
 liquidate any of these investments in order to meet the
 Company&#x2019;s liquidity needs in the next year. Accordingly, any
 investments with contractual maturities greater than one year from
 the balance sheet date are classified as short-term in the balance
 sheet.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Realized gains and losses from the sale of marketable securities,
 if any, are calculated using the specific identification method.
 Realized gains and losses and declines in value judged to be
 other-than-temporary are included in interest income or expense in
 the statements of operations. Unrealized holding gains and losses
 are reported in accumulated other comprehensive income (loss), in
 the balance sheet. To date, the Company has not recorded any
 impairment charges on its marketable securities related to
 other-than-temporary declines in market value. In determining
 whether a decline in market value is other-than-temporary, various
 factors are considered, including the cause, duration of time and
 severity of the impairment, any adverse changes in the
 investees&#x2019; financial condition, and the Company&#x2019;s
 intent and ability to hold the security for a period of time
 sufficient to allow for an anticipated recovery in market
 value.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Restricted Cash</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company is required to maintain compensating cash balances with
 financial institutions that provide the Company with its corporate
 credit cards. As of March&#xA0;31, 2014 and December&#xA0;31, 2013,
 cash restricted under these arrangements was $100,000 and $155,000,
 respectively. These amounts are presented in other assets on the
 accompanying balance sheets.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Concentration of Credit Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Cash, cash equivalents, and marketable securities consist of
 financial instruments that potentially subject the Company to a
 concentration of credit risk to the extent of the fair value
 recorded in the balance sheet. The Company invests cash that is not
 required for immediate operating needs primarily in highly liquid
 instruments that bear minimal risk. The Company has established
 guidelines relating to the quality, diversification, and maturities
 of securities to enable the Company to manage its credit risk.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Property and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment is stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization is
 calculated using the straight-line method, and the cost is
 amortized over the estimated useful lives of the respective assets,
 generally three to seven years. Leasehold improvements are
 amortized over the shorter of the useful lives or the
 non-cancelable term of the related lease. Maintenance and repair
 costs are charged as expense in the statements of operations and
 comprehensive income (loss) as incurred.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Impairment of Long-Lived Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company reviews long-lived assets for impairment whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. An
 impairment loss is recognized if the estimated undiscounted future
 cash flow expected to result from the use and eventual disposition
 of an asset is less than the carrying amount. While the
 Company&#x2019;s current and historical operating losses and cash
 flows are indicators of impairment, the Company believes the future
 cash flows to be received support the carrying value of its
 long-lived assets. Accordingly, the Company has not recognized any
 impairment losses as of March&#xA0;31, 2014 and December&#xA0;31,
 2013.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Deferred Rent</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Deferred Rent</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company records its costs under facility operating lease
 agreements as rent expense. Rent expense is recognized on a
 straight-line basis over the non-cancelable term of the operating
 lease. The difference between the actual amounts paid and amounts
 recorded as rent expense is recorded to deferred rent in the
 balance sheet.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CommonStockWarrantLiabilityPolicyTextBlock', window );">Common Stock Warrant Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Common Stock Warrant Liability</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Warrants issued to common stock holders and lenders by the Company
 in conjunction with the 2013 financing were classified as
 liabilities in the accompanying balance sheets, as the terms for
 redemption of the underlying security were outside the
 Company&#x2019;s control. The warrants were recorded at fair value
 using either the Black-Scholes option pricing model, probability
 weighted expected return model or a binomial model, depending on
 the characteristics of the warrants. The fair value of these
 warrants is re-measured at each financial reporting period with any
 changes in fair value being recognized as a component of other
 income (expense) in the accompanying condensed statements of
 operations and comprehensive loss.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Research and Development Expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenses consist of costs incurred in
 identifying, developing, and testing product candidates. These
 expenses consist primarily of costs for research and development
 personnel, including: related stock-based compensation; contract
 research organizations and other third parties that assist in
 managing, monitoring, and analyzing clinical trials; investigator
 and site fees; laboratory services; consultants; contract
 manufacturing services; non-clinical studies, including materials;
 and allocated expenses, such as depreciation of assets, and
 facilities and information technology that support research and
 development activities. Research and development costs are expensed
 as incurred, including expenses that may or may not be reimbursed
 under research and development funding arrangements. Research and
 development expenses under collaboration agreements approximate the
 revenue recognized under such agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The expenses related to clinical trials are based upon estimates of
 the services received and efforts expended pursuant to contracts
 with multiple research institutions and clinical research
 organizations (CROs) that conduct and manage clinical trials on
 behalf of the Company. Expenses related to clinical trials are
 accrued based upon the level of activity incurred under each
 contract as indicated by such factors as progress made against
 specified milestones or targets in each period, patient enrollment
 levels, and other trial activities as reported by CROs.
 Accordingly, the Company&#x2019;s clinical trial accrual is
 dependent upon the timely and accurate reporting of expenses by
 clinical research organizations and other third-party
 vendors.&#xA0;Payments made to third parties under these clinical
 trial arrangements in advance of the receipt of the related
 services are recorded as prepaid assets, depending on the terms of
 the agreement, until the services are rendered.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Employee and director stock-based compensation is measured at the
 grant date, based on the fair-value based measurements of the stock
 awards, and the portion that is ultimately expected to vest is
 recognized as an expense over the related vesting periods, net of
 estimated forfeitures. The Company calculates the fair-value based
 measurements of options using the Black-Scholes valuation model and
 the single-option approach and recognizes expense using the
 straight-line attribution method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Equity awards granted to non-employees are accounted for using the
 Black-Scholes valuation model to determine the fair value of such
 instruments. The fair value of equity awards granted to
 non-employees are re-measured over the related vesting period and
 amortized to expense as earned.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company utilizes the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on differences between the financial reporting and
 the tax bases of assets and liabilities and are measured using
 enacted tax rates and laws that will be in effect when the
 differences are expected to reverse. A valuation allowance is
 recorded when it is more likely than not that all or part of a
 deferred tax asset will not be realized.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The accounting guidance for uncertainty in income taxes prescribes
 a recognition threshold and measurement attribute criteria for the
 financial recognition and measurement of tax positions taken or
 expected to be taken in a tax return. For those benefits to be
 recognized, a tax position must be more likely than not to be
 sustained upon examination based on the technical merits of the
 position.The Company records interest related to income taxes, if
 any, as interest, and any penalties would be recorded as other
 expense in the statements of comprehensive income (loss). There was
 no interest or penalties related to income taxes recorded during
 the three months ended March&#xA0;31, 2014 and 2013.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Comprehensive Loss</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive loss includes net loss and net unrealized gains and
 losses on marketable securities, which are presented in a single
 continuous statement. Accumulated other comprehensive income (loss)
 is disclosed in the statements of redeemable convertible preferred
 stock and stockholders&#x2019; equity (deficit), and is stated net
 of related tax effects, if any.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Net Loss Per Common Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic net loss per share of common stock is based on the weighted
 average number of shares of common stock outstanding equivalents
 during the period. Prior to the 2013 financing, in addition to
 common stock, the Company had preferred stock outstanding that
 contractually entitled the holder to participate in dividends and
 earnings of the Company. Accordingly, the Company applied the
 two-class method for calculating net loss per share. Under this
 method, all undistributed earnings are allocated first to the
 preferred stockholders based on their contractual right to
 dividends. This right is calculated on a pro rated basis for the
 portion of the period the preferred shares were outstanding. On
 September&#xA0;30, 2013, in connection with the 2013 financing, all
 outstanding shares of the Company&#x2019;s preferred stock were
 converted into shares of the Company&#x2019;s common stock.
 Accordingly, no preferred stock was outstanding during the three
 months ended March&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Diluted net loss per share of common stock is calculated using the
 more dilutive of the two approaches: one,
 &#x201C;as-converted&#x201D; method, under which the weighted average
 number of common stock shares outstanding during the period is
 adjusted to include the assumed conversion of redeemable
 convertible preferred stock at the beginning of the period, and the
 other, the &#x201C;two-class&#x201D; method as described above. Under
 either approach, the weighted average number of shares outstanding
 is also adjusted to include the assumed exercises of stock options
 and warrants, if dilutive. For the three months ended
 March&#xA0;31, 2014 and 2013, diluted net loss per share is the
 same as basic, as any adjustments would have been
 anti-dilutive.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table shows the total outstanding securities
 considered anti-dilutive and therefore excluded from the
 computation of diluted net loss per share:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three Months
 Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">(unaudited)</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Warrants for common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,848,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">906,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Redeemable convertible preferred stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">661,059</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,755,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">786,956</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CommonStockWarrantLiabilityPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock Warrant Liability Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CommonStockWarrantLiabilityPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ReverseStockSplitPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reverse Stock Split Policy [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ReverseStockSplitPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 40<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209073<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209026<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2208979<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeasePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Lease Payments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 188<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">209<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">216<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">222<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">228<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum payments</a></td>
        <td class="nump">$ 1,063<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Employee and director stock-based compensation expense recorded was
 as follows (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>(unaudited)</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">568</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">714</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information 1 (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
        <td class="text">7 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EARAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (10,062)<span></span></td>
        <td class="num">$ (2,628)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-employee stock-based compensation expense</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Employee and director stock-based compensation expense</a></td>
        <td class="nump">714<span></span></td>
        <td class="nump">18<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_AmortizationOfPremiumOnMarketableSecurities', window );">Amortization of premium on marketable securities</a></td>
        <td class="nump">71<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Non-cash interest associated with debt discount accretion</a></td>
        <td class="nump">49<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">4,784<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractReceivablesNet', window );">Contract receivables</a></td>
        <td class="num">(58)<span></span></td>
        <td class="num">(11)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest receivable</a></td>
        <td class="num">(22)<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num">(1,512)<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(211)<span></span></td>
        <td class="num">(55)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">372<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">830<span></span></td>
        <td class="nump">228<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
        <td class="nump">26<span></span></td>
        <td class="nump">204<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(5,011)<span></span></td>
        <td class="num">(2,159)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(32)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable securities</a></td>
        <td class="nump">582<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
        <td class="nump">550<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
        <td class="nump">2,402<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">2,402<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
        <td class="num">(2,059)<span></span></td>
        <td class="num">(2,159)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">24,401<span></span></td>
        <td class="nump">7,726<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">22,342<span></span></td>
        <td class="nump">5,567<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">109<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_FixedAssetsInAccruedExpenses', window );">Fixed assets in accrued expenses</a></td>
        <td class="nump">28<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_IssuanceOfCommonStockWarrantsToInvestors', window );">Issuance of common stock warrants</a></td>
        <td class="nump">443<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CashlessExerciseOfCommonStockForWarrantsLiability', window );">Issuance of common stock upon cashless warrant exercise</a></td>
        <td class="nump">55<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing', window );">Noncash issuance costs incurred in common stock financing</a></td>
        <td class="nump">$ 453<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_AmortizationOfPremiumOnMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortization Of Premium On Marketable Securities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_AmortizationOfPremiumOnMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CashlessExerciseOfCommonStockForWarrantsLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless Exercise of Common Stock For Warrants Liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CashlessExerciseOfCommonStockForWarrantsLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_FixedAssetsInAccruedExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fixed Assets in Accrued Expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_FixedAssetsInAccruedExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_IssuanceOfCommonStockWarrantsToInvestors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock warrants to investors</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_IssuanceOfCommonStockWarrantsToInvestors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Noncash Issuance Costs Incurred in Common Stock Financing</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_NoncashIssuanceCostsIncurredInCommonStockFinancing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractReceivablesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in receivables arising from the contracting of goods and services, net for uncollectible accounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInContractReceivablesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInterestPayableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>5. Collaboration and License Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In August&#xA0;2006, CymaBay entered into a strategic alliance with
 Ortho-McNeil, Inc., a subsidiary of Johnson and Johnson. As part of
 the alliance, Janssen Pharmaceutical NV, an affiliate of
 Ortho-McNeil, granted to CymaBay an exclusive worldwide,
 royalty-bearing license to MBX-8025 and certain other
 PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;compounds (the
 &#x201C;PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products&#x201D;) with the right
 to grant sublicenses to third parties to make, use and sell such
 PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products. Under
 the terms of the agreement, CymaBay has full control and
 responsibility over the research, development and registration of
 any PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products
 and is required to use diligent efforts to conduct all such
 activities. Janssen has the sole responsibility for the
 preparation, filing, prosecution, maintenance of, and defense of
 the patents with respect to, the PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products. Janssen has a right
 of first negotiation under the agreement to license a particular
 PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Product from
 CymaBay in the event that CymaBay elects to seek a third party
 corporate partner for the research, development, promotion, and/or
 commercialization of such PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products. Under the terms of
 the agreement Janssen is entitled to receive up to an 8% royalty on
 net sales of PPAR<font style="FONT-FAMILY: SYMBOL">d</font>&#xA0;Products. No payments were made
 and no royalties were received under this agreement during the
 three months ended March&#xA0;31, 2014 and 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In June&#xA0;2010, CymaBay entered into two development and license
 agreements with Janssen Pharmaceuticals, Inc. (Janssen), a
 subsidiary of Johnson and Johnson, to further develop and discover
 undisclosed metabolic disease target agonists for the treatment of
 T2DM and other disorders and received a one-time nonrefundable
 technology access fee related to the agreements. CymaBay is also
 eligible to receive up to $228 million in contingent payments if
 certain development and commercial events are achieved as well as
 royalties on worldwide net sales of products. No such payments have
 been made to date. Under the terms of the agreements, Janssen has
 full control and responsibility over the research, development and
 registration of any products developed and/or discovered from the
 metabolic disease targets and is required to use diligent efforts
 to conduct all such activities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In June 1998, the Company entered into a license agreement with
 DiaTex, Inc. (DiaTex) relating to products containing halofenate,
 its enantiomers, derivatives, and analogs (the licensed products).
 The license agreement provides that DiaTex and the Company are
 joint owners of all of the patents and patent applications covering
 the licensed products and methods of producing or using such
 compounds, as well as certain other know-how (the covered IP). As
 part of the license agreement, the Company received an exclusive
 worldwide license, including as to DiaTex, to use the covered IP to
 develop and commercialize the licensed products. The Company also
 retained the right to sub-license the covered IP. The license
 agreement contains a $2,000 per month license fee as well as a
 requirement to make additional payments for development
 achievements and royalty payments on any sales of licensed
 products. Pursuant to the license agreement, all of the
 Company&#x2019;s patents and patent applications related to
 arhalofenate, its use, and production are jointly owned with
 DiaTex. DiaTex is entitled to up to $0.8 million for the future
 development of arhalofenate, as well as a 2% royalty payment on net
 sales of products containing arhalofenate. No development payments
 were made in the three months ended March&#xA0;31, 2014 and 2013,
 and no royalties have been paid to date.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration And License Agreements Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_CollaborationAndLicenseAgreementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
        <td class="nump">2,755,283<span></span></td>
        <td class="nump">786,956<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants for common stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
        <td class="nump">1,848,487<span></span></td>
        <td class="nump">28,210<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
        <td class="nump">906,796<span></span></td>
        <td class="nump">97,687<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Redeemable convertible preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">661,059<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Organization and Description of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlock</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock</Role>
      <ShortName>Common Stock Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Stock Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock Plans and Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related-Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Organization and Description of Business (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies</Role>
      <ShortName>Organization and Description of Business (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsSupplementalBalanceSheetDisclosuresTextBlockTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Stock Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock Plans and Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Organization and Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformation</Role>
      <ShortName>Organization and Description of Business - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasis</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfWarrantLiability</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Warrant Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information 1 (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsPropertyAndEquipment</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Certain Balance Sheet Items - Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCertainBalanceSheetItemsAccruedLiabilities</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Common Stock Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation</Role>
      <ShortName>Common Stock Warrants - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureDebtAdditionalInformation</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePayments</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Lease Payments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Stockholders' Equity - Reserved Shares of Authorized but Unissued Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockholdersEquityReservedSharesOfAuthorizedButUnissuedCommonStock</Role>
      <ShortName>Stockholders' Equity - Reserved Shares of Authorized but Unissued Common Stock (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Stock Plans and Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureStockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpense</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Related-Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related-Party Transactions - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOrSaleOfEquity had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '123 - Disclosure - Organization and Description of Business - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '124 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '131 - Disclosure - Common Stock Warrants - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '134 - Disclosure - Commitments and Contingencies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Condensed Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Condensed Balance Sheets (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Nov. 22, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Oct. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Condensed Statements of Operations and Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Condensed Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>cyma-20140331.xml</File>
    <File>cyma-20140331.xsd</File>
    <File>cyma-20140331_cal.xml</File>
    <File>cyma-20140331_def.xml</File>
    <File>cyma-20140331_lab.xml</File>
    <File>cyma-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2DAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 714<span></span></td>
        <td class="nump">$ 18<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">714<span></span></td>
        <td class="nump">18<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">146<span></span></td>
        <td class="nump">6<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 568<span></span></td>
        <td class="nump">$ 12<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock', window );">Reserved Shares of Authorized but Unissued Common Stock</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of March&#xA0;31, 2014 and December&#xA0;31, 2013, the Company
 had reserved shares of authorized but unissued common stock as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>March&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(unaudited)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,848,487</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,742,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Equity incentive plans</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,050,047</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">577,294</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total reserved shares of common stock</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,898,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,320,021</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reserved Shares Of Common Stock For Issuance Table [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>cyma_ReservedSharesOfCommonStockForIssuanceTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>cyma_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
